site,doi,date,link,title,authors,affiliations,abstract,category,match_type,author_similarity,affiliation_similarity
medRxiv,10.1101/2021.01.25.21250356,2021-01-26,https://medrxiv.org/cgi/content/short/2021.01.25.21250356,"Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY.",Brian MacKenna; Helen J Curtis; Caroline E Morton; Peter Inglesby; Alex J Walker; Jessica Morley; Amir Mehrkar; Sebastian CJ Bacon; George Hickman; Christopher Bates; Richard Croker; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth J Williamson; William J Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background On December 8th 2020, NHS England administered the first COVID-19 vaccination as part of an ambitious vaccination programme during a global health emergency. Aims To develop a framework for detailed near-real-time monitoring of COVID-19 vaccine roll-out; to describe trends and variation in coverage by geographic area, and between key clinical and demographic patient groups. Methods Working on behalf of NHS England we used routine clinical data from 23.4 million adults to conduct a retrospective cohort study of comprehensive electronic health record data in NHS England, using the OpenSAFELY-TPP platform which covers approximately 40% of the general population in England with weekly data updates. We developed algorithms to identify key demographic and clinical sub-groups within this population and generated descriptive statistics on proportion of eligible patients receiving the vaccine among key Joint Committee on Vaccination and Immunisation (JCVI) target groups. Results Between December 8th and January 13th 961,580 people out of 23.4m in our dataset received a COVID-19 vaccine. Of 1,160,062 patients aged 80 or over and not living in a care home (currently targeted by JCVI) 476,375 had been vaccinated in total (41.1%). We observed a substantial divergence in vaccination by ethnicity within this group (White 42.5% vaccinated, Black 20.5%) and across rankings of deprivation (least deprived 44.7%, most deprived 37.9%). Patients with pre-existing medical conditions were equally likely, or more likely, to have received a vaccine across most co-morbidity groups with two exceptions: severe mental illness (30.3% vaccinated) and learning disability (28.1%). We identify substantial variation in vaccination among the over-80s between Sustainability and Transformation Partnerships (STPs; Range 12%-74%); lower vaccination rates among ethnic minority and deprived groups was observed in most but not all STPs. In the 70-79 age cohort 74,108 people (3.6%) had been vaccinated. 378,921 vaccine recipients under 70 and not identifiably resident in a care home were presumed to be health or social care workers; 32,174 recipients were identified as older aged care home residents (33.2% coverage). Of all those vaccinated, 169,472 had received a second dose (17.6%). Conclusions The NHS in England has rapidly delivered mass vaccination. We were able to deploy a data monitoring framework across small clinical subgroups using linked patient-level NHS data on 23.4 million people with very short delays from vaccine administration to completed analysis. Targeted activity may be needed to address lower vaccination rates observed among certain key groups: ethnic minorities, people living in areas of higher deprivation, and those with severe mental illness or learning disabilities. However we note that this data is only from the first preliminary weeks of the vaccination programme. Variation in vaccination coverage between groups and regions will have many complex drivers, the figures presented in this manuscript require thoughtful interpretation to support a rapidly evolving NHS vaccination campaign; we are sharing local level data with national and regional NHS teams on request. Keywords: Vaccination, COVID-19, SARS-CoV-2, NHS England",public and global health,exact,100,100
medRxiv,10.1101/2021.01.22.21250321,2021-01-26,https://medrxiv.org/cgi/content/short/2021.01.22.21250321,Factors influencing nursing students' intention to accept COVID-19 vaccination - A pooled analysis of seven countries,Evridiki Patelarou; Petros Galanis; Enkeleint A Mechili; Agathi Argyriadi; Alexandros Argyriadis; Evanthia Asimakopoulou; Stiliana Brokaj; Jorgjia Bucaj; Juan Manuel Carmona-Torres; Ana Isabel Cobo-Cuenca; Jakub Dolezel; Stefano Finotto; Darja Jarosov; Athina Kalokairinou; Daniela Mecugni; Velide Pulomenaj; Aurela Saliaj; Idriz Sopjani; Majlinda Zahaj; Athina Patelarou; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,Hellenic Mediterranean University; National and Kapodistrian University of Athens; University of Vlora; Frederick University; Frederick University; Frederick University; University of Vlora; University of Vlora; University of Castilla-La Mancha; University of Castilla-La Mancha; University of Ostrava; University of Modena and Reggio Emilia; University of Ostrava; National and Kapodistrian University of Athens; University of Modena and Reggio Emilia; AAB College; University of Vlora; AAB College; University of Vlora; Hellenic Mediterranean University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Experiencing the second wave of COVID-19 pandemic, high vaccination coverage by a safe and effective vaccine globally would be a great achievement. Acceptance of vaccination by healthcare students is an important issue as they have a key role as future professionals in educating patients, informing and guiding them to the right clinical decision. The aim of this study was to explore the intention of nursing students to get vaccinated for SARS-CoV-2 infection and the factors acting either as motivators or barriers towards vaccination. A multicenter cross-sectional study was conducted in 7 countries (Greece, Albania, Cyprus, Spain, Italy, Czech Republic and Kosovo) through a web survey. In total 2249 undergraduate nursing students participated. Forty three point eight percent of students agreed to accept a safe and effective COVID-19 vaccine, while the acceptance was higher among Italian students. The factors for intention to get vaccinated were male gender (p=0.008), no working experience in healthcare facilities during the pandemic (p=0.001), vaccination for influenza in 2019 and 2020 (p<0.001), trust in doctors (p<0.001), governments and experts (p=0.012), high level of knowledge (p<0.001) and fear of COVID-19 (p<0.001). Understanding of factors that influence students' decision to accept COVID-19 vaccination could increase the acceptance rate contributing to a management of the pandemic.",public and global health,exact,100,100
medRxiv,10.1101/2021.01.23.21250370,2021-01-26,https://medrxiv.org/cgi/content/short/2021.01.23.21250370,Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) have increased levels of plasma inflammatory mediators upregulated in severe COVID-19,Nathalie Acevedo; Jose Miguel Escamilla-Gil; Hector Espinoza; Ronald Regino; Jonathan Ramirez; Lucila Florez De Arco; Rodolfo Dennis; Carlos Torres-Duque; Luis Caraballo; Ana Isabel Cobo-Cuenca; Jakub Dolezel; Stefano Finotto; Darja Jarosov; Athina Kalokairinou; Daniela Mecugni; Velide Pulomenaj; Aurela Saliaj; Idriz Sopjani; Majlinda Zahaj; Athina Patelarou; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,"Instituto de Investigaciones Inmunologicas, Universidad de Cartagena; Instituto de Investigaciones Inmunologicas, Universidad de Cartagena; Universidad de Cartagena, Facultad de Ingenieria; Instituto de Investigaciones Inmunologicas, Universidad de Cartagena; Instituto de Investigaciones Inmunologicas, Universidad de Cartagena; Clinica Respitaroria y de Alergias; Fundacion Cardioinfantil; Fundacion Neumologica Colombiana; Instituto de Investigaciones Inmunologicas, Universidad de Cartagena; University of Castilla-La Mancha; University of Ostrava; University of Modena and Reggio Emilia; University of Ostrava; National and Kapodistrian University of Athens; University of Modena and Reggio Emilia; AAB College; University of Vlora; AAB College; University of Vlora; Hellenic Mediterranean University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background: Respiratory diseases such as chronic obstructive pulmonary disease (COPD) have been associated with increased risk of severe SARS-CoV-2 infection, but the mechanisms and putative immune pathways are unclear. Besides, increased levels of several immune mediators in patients with severe coronavirus disease 19 (COVID-19) have been reported. Objective: To perform an immunoproteomic profiling of dysregulated plasma proteins in patients with asthma and COPD and to evaluate their relationship with biomarkers of severe COVID-19. Methods: 92 protein biomarkers were quantified in 315 plasma samples from adult subjects (age 40-90 years) including 118 asthmatics, 99 COPD patients and 98 healthy controls, that have been recruited in two reference pneumology clinics in Colombia before the beginning of the COVID-19 pandemic. Results: Forty-one plasma proteins showed differences between patients and controls. Asthmatic patients have increased levels in IL-6 and CCL3 while COPD patients have a broader systemic inflammatory dysregulation driven by HGF, OPG, and several chemokines (CXCL9, CXCL10, CXCL11, CX3CL1, CXCL1, MCP-3, MCP-4, CCL3, CCL4 and CCL11). Functional annotation revealed their enrichment in chemokine signaling pathways related with response to viral infections. Some of these proteins were found up-regulated upon SARS-Cov-2 infection of Calu-3 cells. Also, HPG, CXCL9, CXCL10, IL-6, MCP-3, TNF and EN-RAGE have been found increased in patients with severe COVID-19. HGF, the most significant protein in this study as well as its correlated proteins could be associated with the increased risk of severe COVID-19 in COPD patients. Conclusions: Asthma and COPD patients have altered plasma levels of proteins that have been found associated with increased risk of severe COVID-19. The reasons for sharing these profiles with this infection are unknown, but our study suggest that adult patients with asthma and COPD have a systemic dysregulation in chemokine networks that could make them more susceptible to severe COVID-19.",respiratory medicine,exact,100,100
medRxiv,10.1101/2021.01.25.21250233,2021-01-26,https://medrxiv.org/cgi/content/short/2021.01.25.21250233,Contamination of air and surfaces in workplaces with SARS-CoV-2 virus: a systematic review,John Cherrie; Mark Cherrie; Alice Davis; David Holmes; Sean Semple; Susanne Steinle; Ewan MacDonald; Ginny Moore; Miranda Loh; Ana Isabel Cobo-Cuenca; Jakub Dolezel; Stefano Finotto; Darja Jarosov; Athina Kalokairinou; Daniela Mecugni; Velide Pulomenaj; Aurela Saliaj; Idriz Sopjani; Majlinda Zahaj; Athina Patelarou; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,Institute of Occupational Medicine; Institute of Occupational Medicine; Institute of Occupational Medicine; Institute of Occupational Medicine; University of Stirling; Institute of Occupational Medicine; University of Glasgow; Public Health England; Institute of Occupational Medicine; University of Castilla-La Mancha; University of Ostrava; University of Modena and Reggio Emilia; University of Ostrava; National and Kapodistrian University of Athens; University of Modena and Reggio Emilia; AAB College; University of Vlora; AAB College; University of Vlora; Hellenic Mediterranean University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Objectives This systematic review aimed to evaluate the evidence for air and surface contamination of workplace environments with SARS-CoV-2 RNA and the quality of the methods used to identify actions necessary to improve the quality of the data. Methods We searched Web of Science and Google Scholar until 24th December 2020 for relevant articles and extracted data on methodology and results. Results The vast majority of data come from healthcare settings, with typically around 6 % of samples having detectable concentrations of SARS-CoV-2 RNA and almost none of the samples collected had viable virus. There were a wide variety of methods used to measure airborne virus, although surface sampling was generally undertaken using nylon flocked swabs. Overall, the quality of the measurements was poor. Only a small number of studies reported the airborne concentration of SARS-CoV-2 virus RNA, mostly just reporting the detectable concentration values without reference to the detection limit. Imputing the geometric mean air concentration assuming the limit of detection was the lowest reported value, suggests typical concentrations in health care settings may be around 0.01 SARS-CoV-2 virus RNA copies/m3. Data on surface virus loading per unit area were mostly unavailable. Conclusion The reliability of the reported data is uncertain. The methods used for measuring SARS-CoV-2 and other respiratory viruses in work environments should be standardised to facilitate more consistent interpretation of contamination and to help reliably estimate worker exposure.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2021.01.25.20248984,2021-01-26,https://medrxiv.org/cgi/content/short/2021.01.25.20248984,Impulse dispersion of aerosols during playing wind instruments,Sophia Gantner; Matthias Echternach; Reinhard Veltrup; Caroline Westphalen; Marie Christine Koeberlein; Liudmila Kuranova; Gregor Peters; Bernhard Jakubass; Tobias Benthaus; Michael Doellinger; Stefan Kniesburges; Stefano Finotto; Darja Jarosov; Athina Kalokairinou; Daniela Mecugni; Velide Pulomenaj; Aurela Saliaj; Idriz Sopjani; Majlinda Zahaj; Athina Patelarou; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,LMU Munich; LMU Munich; University Erlangen; LMU Munich; LMU Munich; LMU Munich; University Erlangen; University Erlangen; LMU Munich; University Erlangen; Erlangen University; University of Modena and Reggio Emilia; University of Ostrava; National and Kapodistrian University of Athens; University of Modena and Reggio Emilia; AAB College; University of Vlora; AAB College; University of Vlora; Hellenic Mediterranean University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Musical activities especially singing and playing wind instruments have been singled out as potentially high-risk activities for transmission of SARS CoV-2, because of a higher rate of aerosol production and emission. Playing wind instruments can produce condensation water, droplets of saliva, and aerosol particles, which hover and convectional spread in the environmental air and can be potentially infectious. The aim of this study is to investigate the primary impulse dispersion of aerosols during playing different wind instruments in comparison to breathing and speaking. Nine professional musicians (3 trumpeters, 3 cross flutists and 3 clarinetists) of the Bavarian Symphony Orchestra performed the main theme of Ludwig van Beethoven' 9th symphony, 4th movement in different pitches and loudness. Thereby, the inhaled air volume was marked with small aerosol particles produced with a commercial e-cigarette. The expelled aerosol cloud was recorded by cameras from different perspectives. Afterwards, the dimensions and dynamics of the aerosol cloud was measured by segmenting the video footage at every time point. Overall, the flutes produced the largest dispersion at the end of task of up to maximum distances of 1.88 m in front direction. Thereby it was observed an expulsion of aerosol in different directions: upwards and downwards at the mouthpiece, at the end of the instrument and along the flute at the key plane. In comparison, the maximum impulse dispersion generated by the trumpets and clarinets were lower in frontal and lateral direction (1.2 m and 1.0 m in front- direction). The expulsion to the sides was also lower. Consequently, a distance of 3 m to the front and to the sides of 2 m for the flutes in an orchestral formation is proposed, for trumpets and clarinets a safety distance of 2 m to the front and 1.5 m between instrumentalists are recommendable.",otolaryngology,exact,100,100
medRxiv,10.1101/2021.01.22.21250304,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.22.21250304,Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform,John Tazare; Alex J Walker; Laurie Tomlinson; George Hickman; Christopher T Rentsch; Elizabeth J Williamson; Krishnan Bhaskaran; David Evans; Kevin Wing; Rohini Mathur; Angel YS Wong; Anna Schultze; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background Patients with COVID-19 are thought to be at higher risk of cardiometabolic and pulmonary complications, but quantification of that risk is limited. We aimed to describe the overall burden of these complications in survivors of severe COVID-19. Methods Working on behalf of NHS England we used data from the OpenSAFELY platform linking primary care records to death certificate and hospital data. We constructed two cohorts: a COVID-19 cohort consisting of patients discharged following hospitalisation with COVID-19, and a comparison population of patients discharged following hospitalisation with pneumonia in 2019. Outcomes included DVT, PE, ischaemic stroke, MI, heart failure, AKI and new type 2 diabetes diagnosis. Outcome rates from hospital discharge were measured in each cohort, stratified by patient demographics and 30-day period. We fitted Cox regression models to estimate crude and age/sex adjusted hazard ratios comparing outcome rates between the two cohorts. Results Amongst the population of 31,569 patients discharged following hospitalisation with COVID-19, the highest rates were observed for heart failure (199.3; 95% CI: 191.8 - 207.1) and AKI (154.5; 95% CI: 147.9 - 161.4). Rates of DVT, heart failure, ischaemic stroke, MI, PE and diabetes were high over the four months post discharge, especially in the first month. Patterns were broadly similar to those seen in patients discharged with pneumonia but somewhat higher in the COVID-19 population for stroke (adj-HR 1.78; 95% CI: 1.53 - 2.08), PE (adj-HR 1.38; 95% CI: 1.21 - 1.58), MI (adj-HR 1.46; 95% CI: 1.20 - 1.76), AKI (adj-HR 1.27; 95% CI: 1.19 - 1.36) and T2DM (adj-HR 1.28; 95% CI: 1.08 - 1.50). Conclusions In this descriptive study of survivors of severe COVID-19, rates of the measured outcomes are at least as high, though in some cases slightly higher, than in patients discharged after hospitalisation with pneumonia. Further work is needed to identify what characteristics of COVID-19 patients put them at highest risk of adverse events.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.22.21249308,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.22.21249308,Using Non-Pharmaceutical Interventions and High Isolation of Asymptomatic Carriers to Contain the Spread of SARS-CoV-2 in Nursing Homes,Alec J Schmidt; Yury Garcia; Diego Pinheiro; Tom Reichert; Miriam Nuno; Elizabeth J Williamson; Krishnan Bhaskaran; David Evans; Kevin Wing; Rohini Mathur; Angel YS Wong; Anna Schultze; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,University of California Davis; Universidad de Costa Rica; University of California Davis; Entropy Research Institute; University of California Davis; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Objective. Using a pandemic influenza model modified for COVID-19, this study investigated the degree of control over pre-symptomatic transmission that common non-pharmaceutical interventions (NPIs) would require to reduce the spread in long-term care facilities. Methods. We created a stochastic compartmental SEIR model with Poisson-distributed transition states that compared the effect of R0, common NPIs, and isolation rates of pre-symptomatic carriers primarily on attack rate, peak cases, and timing in a 200-resident nursing home. Model sensitivity was assessed with 1st order Sobol' indices. Results. The most rigorous NPIs decreased the peak number of infections by 4.3 and delayed the peak by 9.7 days in the absence of pre-symptomatic controls. Reductions in attack rate were not likely, even with rigorous application of all defined NPIs, unless pre-symptomatic carriers were identified and isolated at rates exceeding 76%. Attack rate was most sensitive to the pre-symptomatic isolation rate (Sobol' index > 0.7) and secondarily to R0. Conclusions. Common NPIs delayed and reduced epidemic peaks. Reducing attack rates ultimately required efficient isolation of pre-symptomatic cases, including rapid antigen tests on a nearly daily basis. This must be accounted for in testing and contact tracing plans for group living settings.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.25.21250437,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.25.21250437,Tracking the mental health of home-carers during the first COVID-19 national lockdown: evidence from a nationally representative UK survey,Elise Whitley; Kelly Reeve; Michaela Benzeval; Tom Reichert; Miriam Nuno; Elizabeth J Williamson; Krishnan Bhaskaran; David Evans; Kevin Wing; Rohini Mathur; Angel YS Wong; Anna Schultze; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,University of Glasgow; Universityof Essex; University of Essex; Entropy Research Institute; University of California Davis; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background: Unpaid carers who look after another member of their household (home-carers) have poorer mental health than the general population. The first COVID-19 national lockdown led to an increasing reliance on home-carers and we investigate the short and longer-term impact of lockdown on their mental health. Methods: Data from 9,737 adult participants (aged 16+) from the UK Household Longitudinal Study (Understanding Society) were used to explore changes in 12-item General Health Questionnaire (GHQ-12) score between (a) pre-pandemic (2019) and early lockdown (April 2020) and (b) early and later (July 2020) lockdown. Results: GHQ-12 scores among home-carers were higher pre-lockdown and increased more than for non-carers from 2019 to April 2020 with further increases for home-carers compared with non-carers between April and July. Compared with respondents caring for a spouse/partner, those caring for a child under 18 had a particularly marked increase in GHQ-12 score between 2019 and April, as did those caring for someone with learning difficulties. Home-carers of children under 18 improved from April to July while those caring for adult children saw a marked worsening of their mental health. Home-carers with greater care burden saw larger increases in GHQ-12 score from 2019 to April and from April to July, and increases through both periods were greater for home-carers who had formal help prior to lockdown but then lost it. Conclusions: The mental health of home-carers deteriorated more during lockdown than non-carers. Policies that reinstate support for them and their care-recipients will benefit the health of both vulnerable groups.",public and global health,exact,100,100
medRxiv,10.1101/2021.01.22.21249968,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.22.21249968,An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: national validation cohort study in England,Vahe Nafilyan; Ben Humberstone; Nisha Metha; Ian Diamond; Luke Lorenzi; Piotr Pawelek; Ryan Schofield; Jasper Morgan; Paul Brown; Ronan Lyons; Aziz Sheikh; Julia Hippisley-Cox; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,Office for National Statistics; Office for National Statistics; Office of the Chief Medical Officer; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Swansea University; University of Edinburgh; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background: To externally validate a risk prediction algorithm (QCovid) to estimate mortality outcomes from COVID-19 in adults in England. Methods: Population-based cohort study using the ONS Public Health Linked Data Asset, a cohort based on the 2011 Census linked to Hospital Episode Statistics, the General Practice Extraction Service Data for pandemic planning and research, radiotherapy and systemic chemotherapy records. The primary outcome was time to COVID-19 death, defined as confirmed or suspected COVID-19 death as per death certification. Two time periods were used: (a) 24thJanuary to 30thApril 2020; and (b) 1st May to 28th July 2020. We evaluated the performance of the QCovid algorithms using measures of discrimination and calibration for each validation time period. Findings: The study comprises 34,897,648 adults aged 19-100 years resident in England There were 26,985 COVID-19 deaths during the first time-period and 13,177 during the second. The algorithms had good calibration in the validation cohort in both time periods with close correspondence of observed and predicted risks. They explained 77.1% (95% CI: 76.9% to 77.4%) of the variation in time to death in men in the first time-period (R2); the D statistic was 3.76 (95% CI: 3.73 to 3.79); Harrell's C was 0.935 (0.933 to 0.937) Similar results were obtained for women, and in the second time-period In the top 5% of patients with the highest predicted risks of death, the sensitivity for identifying deaths in the first time period was 65.9% for men and 71.7% for women. People in the top 20% of predicted risks of death accounted for 90.8% of all COVID-19 deaths for men and 93.0% for women. Interpretation: The QCovid population-based risk algorithm performed well, showing very high levels of discrimination for COVID-19 deaths in men and women for both time periods. It has the potential to be dynamically updated as the pandemic evolves and therefore, has potential use in guiding national policy. Funding: National Institute of Health Research",public and global health,exact,100,100
medRxiv,10.1101/2021.01.24.21250397,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.24.21250397,Using an Ecological and Biological Framing for an Anti-racist Covid-19 Approach,Araceli Camargo; Elahi Hossain; Sarah Aliko; Daniel Akinola-Odusola; Josh Artus; Ilan Kelman; Ryan Schofield; Jasper Morgan; Paul Brown; Ronan Lyons; Aziz Sheikh; Julia Hippisley-Cox; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,"The Centric Lab; Interaction Centre,  University College London; Experimental Psychology, University College London, UK; The Centric Lab; The Centric Lab; Institute for Risk & Disaster Reduction, University College London; Office for National Statistics; Office for National Statistics; Office for National Statistics; Swansea University; University of Edinburgh; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","In the United States and the United Kingdom COVID-19 has disportionately affected Black, Indigenous and People of Colour (BIPOC) and Black, Asian and Minority Ethnic (BAME) people respectively. Multiple studies identify environmental factors such as overcrowded housing and poor workplace conditions as contributing factors for the disproportionate COVID-19 rates amongst BAME and BIPOC communities. This paper will show that to fully understand the phenomenon, both an ecological and biological approach is needed. An ecological approach highlights how a person's habitat and the experiences within it mediate their susceptibility to disease. Moreover, to understand how this mediation works, this paper will use allostatic load as a biological pathway to link a person to their habitat and the poor health outcomes that contributed to COVID-19 susceptibility. In introducing this new approach, the paper will serve as an anti-racist framework for understanding how COVID-19 affected BAME and BIPOC communities. It is anti-racist by centering poor health outcomes on the habitats people are forced to live in due to structural racism rather than the physiology of a person's race or ethnicity. This is important in order to avoid similar crises in the future and to improve the health of marginalised communities.",public and global health,exact,100,100
medRxiv,10.1101/2021.01.20.21249656,2021-01-22,https://medrxiv.org/cgi/content/short/2021.01.20.21249656,Clinical prediction rule for SARS-CoV-2 infection from 116 U.S. emergency departments,Jeffrey Kline; - RECOVER Network; John Paul Jeans; Alexandra Monkhouse; Georgia Chisnall; Cecilia Vindrola-Padros; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Ira Madan; Sally Marlow; Isabel McMullen; Anne Marie Rafferty; Martin Parsons; Catherine Polling; Danai Serfioti; Helen Gaunt; Peter Aitken; Joanna Morris-Bone; Chloe Simela; Veronica French; Rachel Harris; Sharon A.M. Stevelink; Simon Wessely,"IUSOM; ; 33N Ltd., London, UK; 33N Ltd., London, UK; Rapid Research, Evaluation and Appraisal Lab (RREAL), University College London, UK; Rapid Research, Evaluation and Appraisal Lab (RREAL), University College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Guy's and St Thomas' NHS Foundation Trust, London; Institute of Psychiatry, Psychology and Neuroscience, King's College London; Department of Psychological Medicine, King's College Hospital, South London and Maudsley NHS Foundation Trust; Adult Nursing, King's College London; Mental Health Liaison Team, King's College Hospital; Institute of Psychiatry, Psychology and Neuroscience, King's College London; King's Centre for Military Health Research, King's College London, Room 307, Weston Education Centre, 10 Cutcombe Road, London SE5 9RJ; University Hospital of Leciester NHS Trust. Groby Road Leciester LE4 9QP; Devon Partnership NHS Trust, Trust HQ, R&D, Dryden Road, Exeter, Devon, EX2 5AF; Avon & Wiltshire Mental Health Partnership NHS Trust, R&D, Fromeside, Blackberry Hill Hospital, Bristol, BS16 1EG; Guy's and St Thomas' NHS Foundation Trust, London; Nottinghamshire Healthcare NHS Foundation Trust; Cornwall Partnership Foundation NHS Trust/ Research and Innovation Team; King's Centre for Military Health Research, Department of Psychological Medicine, King's College London, London, UK. AND Department of Psychological Medicine, K; Department of Psychological Medicine, King's College London, Weston Education, Denmark Hill, London, SE5 9JR","ObjectivesAccurate and reliable criteria to rapidly estimate the probability of infection with the novel coronavirus-2 that causes the severe acute respiratory syndrome (SARS-CoV-2) and associated disease (COVID-19) remain an urgent unmet need, especially in emergency care. The objective was to derive and validate a clinical prediction rule for SARS-CoV-2 infection that uses simple criteria widely available at the point of care.

MethodsData came from the Registry data from the national REgistry of suspected COVID-19 in EmeRgency care (RECOVER network) comprising 116 hospitals from 25 states in the US. Clinical predictors and 30-day outcomes were abstracted from medical records of 19,850 emergency department (ED) patients tested for SARS-CoV-2. The criterion standard for diagnosis of SARS-CoV-2 required a positive molecular test from a swabbed sample or positive antibody testing within 30 days. The prediction rule was derived from a 50% random sample (n=9,925) using unadjusted analysis of 107 candidate variables as a screening step, followed by stepwise forward logistic regression on 72 variables.

ResultsMultivariable regression yielded a 13-variable score, which was simplified to 13-point rule: +1 point each for age>50 years, measured temperature>37.5{degrees}C, oxygen saturation<95%, Black race, Hispanic or Latino ethnicity, household contact with known or suspected COVID-19, patient reported history of dry cough, anosmia/dysgeusia, myalgias or fever; and -1 point each for White race, no direct contact with infected person, or smoking. In the validation sample (n=9,975), the score produced an area under the receiver operating character curve of 0.80 (95% CI: 0.79-0.81), and this level of accuracy was retained across patients enrolled from the early spring to summer of 2020. In the simplified rule, a score of zero produced a sensitivity of 95.6% (94.8-96.3%), specificity of 20.0% (19.0-21.0%), likelihood ratio negative of 0.22 (0.19-0.26). Increasing points on the simplified rule predicted higher probability of infection (e.g., >75% probability with +5 or more points).

ConclusionCriteria that are available at the point of care can accurately predict the probability of SARS-CoV-2 infection. These criteria could assist with decision about isolation and testing at high throughput checkpoints.

Key pointsO_ST_ABSQuestionC_ST_ABSCan clinical criteria, derived solely from interview and vital signs accurately estimate the probability of infection from the novel coronavirus (SARS-CoV-2) that causes COVID-19?

FindingsFrom derivation sample (n=9,925), we derived a set of 13 clinical criteria that produced an area under the receiver operating characteristic curve of 0.80 (0.79-0.81) in a validation sample (n=9,925). At a score of zero, the simplified version of the criteria produced sensitivity of 95.6% (94.8 to 96.3%), and specificity of 20.0% (19.0 to 21.0%).

MeaningClinical criteria can estimate the probability of SARS-CoV-2 infection.",emergency medicine,exact,100,100
medRxiv,10.1101/2021.01.15.21249756,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.15.21249756,Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,Krishnan Bhaskaran; Sebastian CJ Bacon; Stephen JW Evans; Chris J Bates; Christopher T Rentsch; MacKenna Brian; Laurie Tomlinson; Alex J Walker; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundMortality from COVID-19 shows a strong relationship with age and pre-existing medical conditions, as does mortality from other causes. However it is unclear how specific factors are differentially associated with COVID-19 mortality as compared to mortality from other causes.

MethodsWorking on behalf of NHS England, we carried out a cohort study within the OpenSAFELY platform. Primary care data from England were linked to national death registrations. We included all adults (aged [&ge;]18 years) in the database on 1st February 2020 and with >1 year of continuous prior registration, the cut-off date for deaths was 9th November 2020. Associations between individual-level characteristics and COVID-19 and non-COVID deaths were estimated by fitting age- and sex-adjusted logistic models for these two outcomes.

Results17,456,515 individuals were included. 17,063 died from COVID-19 and 134,316 from other causes. Most factors associated with COVID-19 death were similarly associated with non-COVID death, but the magnitudes of association differed. Older age was more strongly associated with COVID-19 death than non-COVID death (e.g. ORs 40.7 [95% CI 37.7-43.8] and 29.6 [28.9-30.3] respectively for [&ge;]80 vs 50-59 years), as was male sex, deprivation, obesity, and some comorbidities. Smoking, history of cancer and chronic liver disease had stronger associations with non-COVID than COVID-19 death. All non-white ethnic groups had higher odds than white of COVID-19 death (OR for Black: 2.20 [1.96-2.47], South Asian: 2.33 [2.16-2.52]), but lower odds than white of non-COVID death (Black: 0.88 [0.83-0.94], South Asian: 0.78 [0.75-0.81]).

InterpretationSimilar associations of most individual-level factors with COVID-19 and non-COVID death suggest that COVID-19 largely multiplies existing risks faced by patients, with some notable exceptions. Identifying the unique factors contributing to the excess COVID-19 mortality risk among non-white groups is a priority to inform efforts to reduce deaths from COVID-19.

FundingWellcome, Royal Society, National Institute for Health Research, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, Health Data Research UK.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.18.21249463,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.18.21249463,Viral dispersion in open air,Gabriella Trombini Machado; Claudia Ramos de Carvalho Pinto; Luisa Andrea Villanueva da Fonseca; Taissa Cristina dos Santos Ramos; Tuanny Fernanda Pereira Paggi; Beny Spira; Laurie Tomlinson; Alex J Walker; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","The SARS-CoV-2 pandemic has revived the debate about the routes of virus transmission and their likelihoods. It is of utmost importance to assess the risks of contamination of susceptible people by infectious individuals and to evaluate the level of viral transmission in the community. Most countries have imposed non-pharmaceutical measures to contain SARS-CoV-2 transmission, including social distancing and mask wearing. Here we evaluated the spreading of viruses in open air using harmless Escherichia coli bacteriophages as a surrogate. Phages were sprayed towards Petri dishes seeded with bacteria at different lengths and angles. Median droplets size was 127 {micro}m, similar to those produced by sneeze. Our results showed that the transmission rate decreased exponentially with distance. The highest recorded transmission rate was 9 x 10-6 PFU/plate when phages were sprayed from a 1 m distance, suggesting that the probability of transmission of a single virus at a 1 m distance is 1:100,000. These results agree with the WHO recommendation that face mask protection in an uncrowded well-ventilated space is not required.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.16.21249937,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.16.21249937,Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic,Chandrakumar Shanmugam; Michael Behring; Vishwas Luthra; Sixto M. Leal Jr.; Sooryanarayana Varambally; George J. Netto; Upender Manne; Alex J Walker; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"RVM Institute of Medical Sciences & Research Center (KNR University of Health Sciences), Laxmakkapally, Mulugu, Telangana, India 502279; University of Alabama at Birmingham; Sri Guru Ram Das Institute of Medical Sciences and Research, Mehta Road, Vallah, Amritsar, Punjab, India 143501; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundAccurate detection of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is necessary to mitigate the coronavirus disease-19 (COVID-19) pandemic. However, the test reagents and assay platforms are varied and may not be sufficiently robust to diagnose COVID-19.

MethodsWe reviewed 85 studies (21,530 patients), published from five regions of the world, to highlight issues involved in the diagnosis of COVID-19 in the early phase of the pandemic, following the standards outlined in the PRISMA statement. All relevant articles, published up to May 31, 2020, in PubMed, BioRiXv, MedRiXv, and Google Scholar, were included. We evaluated the qualitative (9749 patients) and quantitative (10,355 patients) performance of RT-PCR and serologic diagnostic tests for real-world samples, and assessed the concordance (5,538 patients) between methods in meta-analyses.

ResultsThe RT-PCR tests exhibited heterogeneity in the primers and reagents used. Of 1,957 positive RT-PCR COVID-19 participants, 1,585 had positive serum antibody (IgM +/- IgG) tests (sensitivity 0.81, 95%CI 0.66-.90). While 3,509 of 3581 participants RT-PCR negative for COVID-19 were found negative by serology testing (specificity 0.98, 95%CI 0.94-0.99). The chemiluminescent immunoassay exhibited the highest sensitivity, followed by ELISA and lateral flow immunoassays. Serology tests had higher sensitivity and specificity for laboratory-approval than for real-world reporting data.

ConclusionsThe robustness of the assays/platforms is influenced by variability in sampling and reagents. Serological testing complements and may minimize false negative RT-PCR results. Lack of standardized assay protocols in the early phase of pandemic might have contributed to the spread of COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.15.21249891,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.15.21249891,Inactivation of SARS-CoV-2 virus in saliva using a guanidium based transport medium suitable for RT-PCR diagnostic assays,Sukalyani Banik; Kaheerman Saibire; Shraddha Suryavanshi; Glenn Johns; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"Rutgers Biomedical and Health Sciences; Rutgers Biomedical and Health Sciences; Rutgers Biomedical and Health Sciences; Cepheid; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundUpper respiratory samples used to test for SARS-CoV-2 virus may be infectious and present a hazard during transport and testing. A buffer with the ability to inactivate SARS-CoV-2 at the time of sample collection could simplify and expand testing for COVID-19 to non-conventional settings.

MethodsWe evaluated a guanidium thiocyanate-based buffer, eNAT (Copan) as a possible transport and inactivation medium for downstream RT-PCR testing to detect SARS-CoV-2. Inactivation of SARS-CoV-2 USA-WA1/2020 in eNAT and in diluted saliva was studied at different incubation times. The stability of viral RNA in eNAT was also evaluated for up to 7 days at room temperature (28{degrees}C), refrigerated conditions (4{degrees}C) and at 35{degrees}C.

ResultsSARS-COV-2 virus spiked directly in eNAT could be inactivated at >5.6 log10 PFU/ml within a minute of incubation. When saliva was diluted 1:1 in eNAT, no cytopathic effect (CPE) on vero-E6 cell lines was observed, although SARS-CoV-2 RNA could be detected even after 30 min incubation and after two cell culture passages. A 1:2 (saliva:eNAT) dilution abrogated both CPE and detectable viral RNA after as little as 5 min incubation in eNAT. SARS-CoV-2 RNA from virus spiked at 5X the limit of detection remained positive up to 7 days of incubation in all tested conditions.

ConclusioneNAT and similar guanidinium thiocyanate-based media may be of value for transport, preservation, and processing of clinical samples for RT-PCR based SARS-CoV-2 detection.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.19.21250092,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.19.21250092,The Impact of U.S. County-Level Factors on COVID-19 Morbidity and Mortality,Nevo Itzhak; Tomer Shahar; Robert Moskovitch; Yuval Shahar; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundThe effect of socioeconomic factors, ethnicity, and other variables, on the frequency of COVID-19 cases [morbidity] and induced deaths [mortality] at sub-population, rather than at individual levels, is only partially understood.

ObjectiveTo determine which county-level features best predict COVID-19 morbidity and mortality for a given county in the U.S.

DesignA Machine-Learning model that predicts COVID-19 mortality and morbidity using county-level features, followed by a SHAP-values-based importance analysis of the predictive features.

SettingPublicly available data from various American government and news websites.

Participants3,071 U.S. counties, from which 53 county-level features, as well as morbidity and mortality numbers, were collected.

MeasurementsFor each county: Ethnicity, socioeconomic factors, educational attainment, mask usage, population density, age distribution, COVID-19 morbidity and mortality, air quality indicators, presidential election results, ICU beds.

ResultsA Random Forest classifier produced an AUROC of 0.863 for morbidity prediction and an AUROC of 0.812 for mortality prediction. A SHAP-values-based analysis indicated that poverty rate, obesity rate, mean commute time to work, and proportion of people that wear masks significantly affected morbidity rates, while ethnicity, median income, poverty rate, and education levels, heavily influenced mortality rates. The correlation between several of these factors and COVID-19 morbidity and mortality, from 4/2020 to 11/2020 shifted, probably due to COVID-19 being initially associated with more urbanized areas, then with less urbanized ones.

LimitationsData are still coming in.

ConclusionsEthnicity, education, and economic disparity measures are major factors in predicting the COVID-19 mortality rate in a county. Between-counties low-variance factors (e.g., age), are not meaningful predictors.

Differing correlations can be explained by the COVID-19 spread from metropolitan to less metropolitan areas.

Primary Funding SourceNone.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.18.21250053,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.18.21250053,Forecasting the Spread of the COVID-19 Epidemic in Lombardy: A Dynamic Model Averaging Approach,Lisa Gianmoena; Vicente Rios; Robert Moskovitch; Yuval Shahar; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"University of Pisa; University of Milan; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","Forecasting with accuracy the evolution of COVID-19 daily incidence curves is one of the most important exercises in the field of epidemic modeling. We examine the forecastability of daily COVID-19 cases in the Italian region of Lombardy using Dynamic Model Averaging and Dynamic Model Selection methods. To investigate the predictive accuracy of this approach, we compute forecast performance metrics of sequential out-of-sample real-time forecasts in a back-testing exercise ranging from March 1 to December 10 of 2020. We find that (i) Dynamic Model Averaging leads to a consistent and substantial predictive improvements over alternative epidemiological models and machine learning approaches when producing short-run forecasts. Using estimated posterior inclusion probabilities we also provide evidence on which set of predictors are relevant for forecasting in each period. Our findings also suggest that (ii) future incidences can be forecasted by exploiting information on the epidemic dynamics of neighboring regions, human mobility patterns, pollution and temperatures levels.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.19.21249816,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.19.21249816,Modelling the COVID-19 Fatality Rate in England and its Regions,Nigel Saunders; Vicente Rios; Robert Moskovitch; Yuval Shahar; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"Thermotech Ltd., Surrey Technology Centre, The Surrey Research Park,  Guildford, Surrey GU2 7YG, U.K.; University of Milan; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","A model to account for the fatality rate in England and its regions is proposed. It follows the clear observation that, rather than two connected waves, there have been many waves of infections and fatalities in the regions of England of various magnitudes, usually overlapping. The waves are self-limiting, in that clear peaks are seen, particularly in reported positive test rates. The present model considers fatalities as the data reported are more reliable than positive test rates, particularly so during the first wave when so little testing was done.

The model considers the observed waves are essentially similar in form and can be modelled using a single wave form whose final state is only dependent on its peak height and the start date of the particular wave. The basic wave form was modelled using the observed fatality rates for London, which unlike the other regions, exhibited almost completely as a single wave in the ""first wave"". Its form matches rather well with the ""Do Nothing"" model reported by Imperial College on 16th March 2020, but reduced substantially from its expected peak.

There are, essentially, only two adjustable parameters used in the model, the start date of the relevant wave and its height. The modelled fatalities for each wave are summated per day and a cumulative curve is matched to that reported. The minimal number of adjustable parameters, alongside the fact that the waves invariably overlap, provides highly stringent conditions on the fitting process.

Results are presented for each region for both the ""first"" and ""second waves. High levels of accuracy are obtained with R2 values approaching 100% against the ideal fit for both waves. It can also be seen there are fundamental differences between the underlying behaviour of the ""first"" and ""second"" waves.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.18.21250012,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.18.21250012,Studying the course of Covid-19 by a recursive delay approach,Erhard Scholz; Matthias Kreck; Robert Moskovitch; Yuval Shahar; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"University of Wuppertal; University of Bonn; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","AO_SCPLOWBSTRACTC_SCPLOWIn an earlier paper we proposed a recursive model for epidemics; in the present paper we generalize this model to include the asymptomatic or unrecorded symptomatic people, which we call dark people (dark sector). We call this the SEPARd-model. A delay differential equation version of the model is added; it allows a better comparison to other models. We carry this out by a comparison with the classical SIR model and indicate why we believe that the SEPARd model may work better for Covid-19 than other approaches.

In the second part of the paper we explain how to deal with the data provided by the JHU, in particular we explain how to derive central model parameters from the data. Other parameters, like the size of the dark sector, are less accessible and have to be estimated more roughly, at best by results of representative serological studies which are accessible, however, only for a few countries. We start our country studies with Switzerland where such data are available. Then we apply the model to a collection of other countries, three European ones (Germany, France, Sweden), the three most stricken countries from three other continents (USA, Brazil, India). Finally we show that even the aggregated world data can be well represented by our approach.

At the end of the paper we discuss the use of the model. Perhaps the most striking application is that it allows a quantitative analysis of the influence of the time until people are sent to quarantine or hospital. This suggests that imposing means to shorten this time is a powerful tool to flatten the curves.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.18.21249998,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.18.21249998,The Association between Early Country-level Testing Capacity and Later COVID-19 Mortality Outcomes,Sneha Kannoth; Sasikiran Kandula; Jeffrey Shaman; Yuval Shahar; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"Columbia University, Mailman School of Public Health; Columbia University, Mailman School of Public Health; Columbia University, Mailman School of Public Health; Ben-Gurion University of the Negev; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundThe COVID-19 pandemic has overrun hospital systems while exacerbating economic hardship and food insecurity on a global scale. In an effort to understand how early action to find and control the virus is associated with cumulative outcomes, we explored how country-level testing capacity affects later COVID-19 mortality.

MethodsWe used the Our World in Data database to explore testing and mortality records in 27 countries from December 31, 2019 to September 30, 2020; we applied ordinary-least squares regression with clustering on country to determine the association between early COVID-19 testing capacity (cumulative tests per case) and later COVID-19 mortality (time to specified mortality thresholds), adjusting for country-level confounders, including median age, GDP, hospital bed capacity, population density, and non-pharmaceutical interventions.

ResultsHigher early testing implementation, as indicated by more cumulative tests per case when mortality was still low, was associated with longer accrual time for higher per capita deaths. For instance, a higher cumulative number of tests administered per case at the time of 6 deaths per million persons was positively predictive of a longer time to reach 15 deaths per million, after adjustment for all confounders ({beta}=0.659; P=0.001).

ConclusionsCountries that developed stronger COVID-19 testing capacity at early timepoints, as measured by tests administered per case identified, experienced a slower increase of deaths per capita. Thus, this study operationalizes the value of testing and provides empirical evidence that stronger testing capacity at early timepoints is associated with reduced mortality and better pandemic control.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.17.21249837,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.17.21249837,Modeling and Simulation: A study on predicting the outbreak of COVID- 19 in Saudi Arabia,Ahmed Hussein Msmali; Zico Meetei Mutum; Idir Mechai; Abdullah A Ahmadini; Soumitesh Chakravorty; Robert Kwiatkawoski; David Alland; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"Jazan University, Saudi Arabia; Jazan University, Saudi Arabia; Jazan University, Saudi Arabia; Jazan University, Saudi Arabia; Cepheid; Cepheid (United States); Rutgers New Jersey Medical School; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","The novel coronavirus (Covid-19) infection has resulted in an ongoing pandemic affecting health system and economy of more than 200 countries around the world. Mathematical models are used to predict the biological and epidemiological trends of an epidemic and develop methods for controlling it. In this work, we use mathematical model perspective to study the role of behavior change in slowing the spread of the COVID-19 disease in Saudi Arabia. The real-time updated data from 1st May 2020 to 8th January 2021 is collected from Saudi Ministry of Health, aiming to provide dynamic behaviors of the pandemic in Saudi Arabia. During this period, it has infected 297,205 people, resulting in 6124 deaths with the mortality rate 2.06 %. There is weak positive relationship between the spread of the infection and mortality (R2 =0.412). We use Susceptible-Exposed-Infection-Recovered (SEIR) mode, the logistic growth model and with special focus on the exposed, infection and recovery individuals to simulate the final phase of the outbreak. The results indicate that social distancing, good hygienic conditions, and travel limitation are the crucial measures to prevent further spreading of the epidemic.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.18.21250071,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.18.21250071,"The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US",Xutong Wang; Zhanwei Du; Kaitlyn Johnson; Spencer Fox; Michael Lachmann; Jason S McLellan; Lauren Ancel Meyers; Padmapriya P. Banada; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; Santa Fe Institute; University of Texas at Austin; The University of Texas at Austin; Rutgers Biomedical and Health Sciences; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","As COVID-19 vaccination begins worldwide, policymakers face critical trade-offs. Using a mathematical model of COVID-19 transmission, we find that timing of the rollout is expected to have a substantially greater impact on mortality than risk-based prioritization and adherence and that prioritizing first doses over second doses may be life saving.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.18.21250032,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.18.21250032,"Remote care for mental health: qualitative study with service users, carers and staff during the COVID-19 pandemic",Elisa Liberati; Natalie Richards; Jennie Parker; Janet Willars; David Scott; Nicola Boydell; Vanessa Pinfold; Graham Martin; Mary Dixon-Woods; Peter B Jones; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"THIS Institute (The Healthcare Improvement Studies Institute), Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; THIS Institute (The Healthcare Improvement Studies Institute), Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; McPin Foundation, London, SE1 4YR, UK; Department of Health Sciences, University of Leicester, Leicester, UK; Population Health and Genomics, University of Dundee, Dundee, UK; Centre for Biomedicine Self and Society, Usher Institute, University of Edinburgh, Edinburgh, UK; McPin Foundation, London, SE1 4YR, UK; THIS Institute (The Healthcare Improvement Studies Institute), Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; THIS Institute (The Healthcare Improvement Studies Institute), Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Department of Psychiatry, University of Cambridge; Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, CB2 0SZ, UK; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","ObjectivesTo explore the experiences of service users, carers and staff seeking or providing secondary mental health services during the COVID-19 pandemic.

DesignQualitative interview study, co-designed with mental health service users and carers.

MethodsWe conducted semi-structured, telephone or online interviews with a purposively constructed sample; a peer researcher with lived experience conducted and analysed interviews with service users. Analysis was based on the constant comparison method.

SettingNHS secondary mental health services in England between June and August 2020.

ParticipantsOf 65 participants, 20 had either accessed or needed to access English secondary mental healthcare during the pandemic; 10 were carers of people with mental health difficulties; 35 were members of staff working in NHS secondary mental health services during the pandemic.

ResultsExperiences of remote care were mixed. Some service users valued the convenience of remote methods in the context of maintaining contact with familiar clinicians. Most participants commented that a lack of non-verbal cues and the loss of a therapeutic  safe space challenged therapeutic relationship building, assessments, and identification of deteriorating mental wellbeing. Some carers felt excluded from remote meetings and concerned that assessments were incomplete without their input. Like service users, remote methods posed challenges for clinicians who reported uncertainty about technical options and a lack of training. All groups expressed concern about intersectionality exacerbating inequalities and the exclusion of some service user groups if alternatives to remote care are lost.

ConclusionsWhilst remote mental healthcare is likely to become increasingly widespread in secondary mental health services, our findings highlight the continued importance of a tailored, personal approach to decisions about remote mental healthcare. Further research should focus on which types of consultations best suit face-to-face interaction, and for whom and why, and which can be provided remotely and by which medium.

ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIStrengths include its qualitative approach in speaking to a large sample of participants with varied mental health difficulties, carers, and a diverse range of mental healthcare staff.
C_LIO_LIIts novelty lies in a deep exploration of the views and experiences of remote mental healthcare during a pandemic.
C_LIO_LIThe methods are strengthened by the involvement of experts-by-experience and the use of peer research methods.
C_LIO_LIWe did not adopt a narrative method; the interviews were one-off conversations so we could not explore change as the pandemic progressed and people may have become accustomed to remote care.
C_LIO_LIThe study used remote methods to comply with UK lockdown regulations; this will have excluded some groups without the ability to engage remotely.
C_LI",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2021.01.14.21249801,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.14.21249801,Factor V is an immune inhibitor that is expressed at increased levels in leukocytes of patients with severe Covid-19,Jun Wang; Prasanti Kotagiri; Paul Lyons; Federica Mescia; Laura Bergamaschi; Lorinda Turner; Rafia Al-Lamki; Michael D Morgan; Fernando J Calero-Nieto; Karsten Bach; Nicole Mende; Nicola K Wilson; Emily R Watts; - Cambridge Institute of Therapeutic Immunology and Infectious Disease - NIHR Covid BioResource; Patrick Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen Stirrups; Neil Walker; Ravindra K Gupta; Mark Toshner; Michael Weekes; James A Nathan; Sarah Walmsley; Willem Hendrik Ouwehand; Mary Kasanicki; Berthold Gottgens; John C Marioni; Smith GC Smith; Jordan S Pober; John R Bradley; Robert H. Vonderheide; Lynn M Schuchter; Anurag Verma; Ivan Maillard; Ronac Mamtani; Scott E. Hensley; Robert Gross; E. Paul Wileyto; Alexander C. Huang; Kara N. Maxwell; Angela DeMichele; Devendra Singh Parihar; Anas Saifi; Jasleen Kaur; Virendra Kumar; Avinash Mishra; Iranna Gogeri; Geetha Vani Rayasam; Praveen Singh; Rahul Chakraborty; Gaura Chaturvedi; Pinreddy Karunakar; Rohit Yadav; Sunanda Singhmar; Dayanidhi Singh; Sharmistha Sarkar; Purbasha Bhattacharya; Sundaram Acharya; Vandana Singh; Shweta Verma; Drishti Soni; Surabhi Seth; Firdaus Fatima; Shakshi Vashisht; Sarita Thakran; Akash Pratap Singh; Akanksha Sharma; Babita Sharma; Manikandan Subramanian; Yogendra Padwad; Vipin Hallan; Vikram Patial; Damanpreet Singh; Narendra Vijay Tirpude; Partha Chakrabarti; Sujay Krishna Maity; Dipyaman Ganguly; Jit Sarkar; Sistla Ramakrishna; Balthu Narender Kumar; Kiran A Kumar; Sumit G. Gandhi; Piyush Singh Jamwal; Rekha Chouhan; Vijay Lakshmi Jamwal; Nitika Kapoor; Debashish Ghosh; Ghanshyam Thakkar; Umakanta Subudhi; Pradip Sen; Saumya Raychaudhri; Amit Tuli; Pawan Gupta; Rashmi Kumar; Deepak Sharma; Rajesh P. Ringe; Amarnarayan D; Mahesh Kulkarni; Dhanasekaran Shanmugam; Mahesh Dharne; Syed G Dastager; Rakesh Joshi; Amita P. Patil; Sachin N Mahajan; Abu Junaid Khan; Vasudev Wagh; Rakeshkumar Yadav; Ajinkya Khilari; Mayuri Bhadange; Arvindkumar H. Chaurasiya; Shabda E Kulsange; Krishna khairnar; Shilpa Paranjape; Jatin Kalita; G.Narahari Sastry; Tridip Phukan; Prasenjit Manna; Wahengbam Romi; Pankaj Bharali; Dibyajyoti Ozah; Ravi Kumar Sahu; Elapaval VSSK Babu; Rajeev K Sukumaran; Aishwarya R Nair; Anoop Puthiyamadam; Prajeesh Kooloth Valappil; Adarsh Velayudhanpillai; Kalpana Chodankar; Samir Damare; Yennapu Madhavi; Ved Varun Agrawal; Sumit Dahiya; Anurag Agrawal; Debasis Dash; Shantanu Sengupta,"University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Edinburgh; ; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; University of Cambridge; University of Edinburgh; Prof; Cambridge University Hospitals; University of Cambridge; EMBL-EBI; University of Cambridge; Yale University; University of Cambridge; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Salt Marine Chemicals Research Institute, Bhavnagar-364002, Gujarat, India; CSIR Fourth Paradigm Institute, Bengaluru-560037, India; CSIR- Headquarters, Rafi Marg, New Delhi-110011, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, Telangana, India; CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, Telangana, India; CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, Telangana, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Petroleum, Dehradun-248005, Uttarakhand, India; CSIR-Indian Institute of Petroleum, Dehradun-248005, Uttarakhand, India; CSIR-Institute of Minerals and Materials Technology, Bhubaneswar-751013, Odisha, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR- National Aerospace Laboratories, Bengaluru-560017, Karnataka, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Environmental Engineering Research Institute, Nagpur-440020, Maharashtra, India; CSIR-National Environmental Engineering Research Institute, Nagpur-440020, Maharashtra, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-National Geophysical Research Institute, Hyderabad- 500007, Telangana, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute of Oceanography, Goa-403004, India; CSIR-National Institute of Oceanography, Goa-403004, India; CSIR-National Institute of Science, Technology and Development Studies, New Delhi-110012, India; CSIR-National Physical Laboratory, New Delhi-110012, India; CSIR-National Physical Laboratory, New Delhi-110012, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India","Severe Covid-19 is associated with elevated plasma Factor V (FV) and increased risk of thromboembolism. We report that neutrophils, T regulatory cells (Tregs), and monocytes from patients with severe Covid-19 express FV, and expression correlates with T cell lymphopenia. In vitro full length FV, but not FV activated by thrombin cleavage, suppresses T cell proliferation. Increased and prolonged FV expression by cells of the innate and adaptive immune systems may contribute to lymphopenia in severe Covid-19. Activation by thrombin destroys the immunosuppressive properties of FV. Anticoagulation in Covid-19 patients may have the unintended consequence of suppressing the adaptive immune system.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.15.21249879,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.15.21249879,"Anticipating the curve: can online symptom-based data reflect COVID-19 case activity in Ontario, Canada?",Arjuna S Maharaj; Jennifer Parker; Jessica P Hopkins; Effie Gournis; Isaac Bogoch; Benjamin Rader; Christina M Astley; Noah M Ivers; Jared B Hawkins; Liza Lee; Ashleigh Tuite; David N Fisman; John S Brownstein; Lauren Lapointe-Shaw; Patrick Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen Stirrups; Neil Walker; Ravindra K Gupta; Mark Toshner; Michael Weekes; James A Nathan; Sarah Walmsley; Willem Hendrik Ouwehand; Mary Kasanicki; Berthold Gottgens; John C Marioni; Smith GC Smith; Jordan S Pober; John R Bradley; Robert H. Vonderheide; Lynn M Schuchter; Anurag Verma; Ivan Maillard; Ronac Mamtani; Scott E. Hensley; Robert Gross; E. Paul Wileyto; Alexander C. Huang; Kara N. Maxwell; Angela DeMichele; Devendra Singh Parihar; Anas Saifi; Jasleen Kaur; Virendra Kumar; Avinash Mishra; Iranna Gogeri; Geetha Vani Rayasam; Praveen Singh; Rahul Chakraborty; Gaura Chaturvedi; Pinreddy Karunakar; Rohit Yadav; Sunanda Singhmar; Dayanidhi Singh; Sharmistha Sarkar; Purbasha Bhattacharya; Sundaram Acharya; Vandana Singh; Shweta Verma; Drishti Soni; Surabhi Seth; Firdaus Fatima; Shakshi Vashisht; Sarita Thakran; Akash Pratap Singh; Akanksha Sharma; Babita Sharma; Manikandan Subramanian; Yogendra Padwad; Vipin Hallan; Vikram Patial; Damanpreet Singh; Narendra Vijay Tirpude; Partha Chakrabarti; Sujay Krishna Maity; Dipyaman Ganguly; Jit Sarkar; Sistla Ramakrishna; Balthu Narender Kumar; Kiran A Kumar; Sumit G. Gandhi; Piyush Singh Jamwal; Rekha Chouhan; Vijay Lakshmi Jamwal; Nitika Kapoor; Debashish Ghosh; Ghanshyam Thakkar; Umakanta Subudhi; Pradip Sen; Saumya Raychaudhri; Amit Tuli; Pawan Gupta; Rashmi Kumar; Deepak Sharma; Rajesh P. Ringe; Amarnarayan D; Mahesh Kulkarni; Dhanasekaran Shanmugam; Mahesh Dharne; Syed G Dastager; Rakesh Joshi; Amita P. Patil; Sachin N Mahajan; Abu Junaid Khan; Vasudev Wagh; Rakeshkumar Yadav; Ajinkya Khilari; Mayuri Bhadange; Arvindkumar H. Chaurasiya; Shabda E Kulsange; Krishna khairnar; Shilpa Paranjape; Jatin Kalita; G.Narahari Sastry; Tridip Phukan; Prasenjit Manna; Wahengbam Romi; Pankaj Bharali; Dibyajyoti Ozah; Ravi Kumar Sahu; Elapaval VSSK Babu; Rajeev K Sukumaran; Aishwarya R Nair; Anoop Puthiyamadam; Prajeesh Kooloth Valappil; Adarsh Velayudhanpillai; Kalpana Chodankar; Samir Damare; Yennapu Madhavi; Ved Varun Agrawal; Sumit Dahiya; Anurag Agrawal; Debasis Dash; Shantanu Sengupta,"University of Toronto; University of Toronto; Public Health Ontario; Dalla Lana School of Public Health, University of Toronto; University of Toronto; Boston University; Harvard Medical School; University of Toronto; Boston University; Public Health Agency of Canada; University of Toronto; University of Toronto; Boston University; University of Toronto; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; University of Cambridge; University of Edinburgh; Prof; Cambridge University Hospitals; University of Cambridge; EMBL-EBI; University of Cambridge; Yale University; University of Cambridge; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Scientific Instruments Organization, Chandigarh-160030, India; CSIR-Central Salt Marine Chemicals Research Institute, Bhavnagar-364002, Gujarat, India; CSIR Fourth Paradigm Institute, Bengaluru-560037, India; CSIR- Headquarters, Rafi Marg, New Delhi-110011, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Institute of Himalayan Bioresource Technology, Palampur-176061, Himachal Pradesh, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Biology, Kolkata-700032, West Bengal, India; CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, Telangana, India; CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, Telangana, India; CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, Telangana, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Integrative Medicine, Jammu-180001, Jammu and Kashmir, India; CSIR-Indian Institute of Petroleum, Dehradun-248005, Uttarakhand, India; CSIR-Indian Institute of Petroleum, Dehradun-248005, Uttarakhand, India; CSIR-Institute of Minerals and Materials Technology, Bhubaneswar-751013, Odisha, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR-Institute of Microbial Technology, Chandigarh-160036, India; CSIR- National Aerospace Laboratories, Bengaluru-560017, Karnataka, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Chemical Laboratory, Pune-411008, Maharashtra, India; CSIR-National Environmental Engineering Research Institute, Nagpur-440020, Maharashtra, India; CSIR-National Environmental Engineering Research Institute, Nagpur-440020, Maharashtra, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-North - East Institute of Science and Technology, Jorhat-785006, Assam, India; CSIR-National Geophysical Research Institute, Hyderabad- 500007, Telangana, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram- 695019, Kerala, India; CSIR-National Institute of Oceanography, Goa-403004, India; CSIR-National Institute of Oceanography, Goa-403004, India; CSIR-National Institute of Science, Technology and Development Studies, New Delhi-110012, India; CSIR-National Physical Laboratory, New Delhi-110012, India; CSIR-National Physical Laboratory, New Delhi-110012, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India; CSIR-Institute of Genomics and Integrative Biology, New Delhi-110025, India","BackgroundLimitations in laboratory diagnostic capacity and reporting delays have hampered efforts to mitigate and control the ongoing COVID-19 pandemic globally. Syndromic surveillance of COVID-19 is an important public health tool that can help detect outbreaks, mobilize a rapid response, and thereby reduce morbidity and mortality. The primary objective of this study was to determine whether syndromic surveillance through self-reported COVID-19 symptoms could be a timely proxy for laboratory-confirmed case trends in the Canadian province of Ontario.

MethodsWe retrospectively analyzed self-reported symptoms data collected using an online tool - Outbreaks Near Me (ONM) - from April 20th to Oct 11th, 2020 in Ontario, Canada. We estimated the correlation coefficient between the weekly proportion of respondents reporting a COVID-like illness (CLI) to both the weekly number of PCR-confirmed COVID-19 cases and the percent positivity in the same period for the same week and with a one-week lag.

ResultsThere were 314,686 responses from 188,783 unique respondents to the ONM symptom survey. Respondents were more likely to be female and be in the 40-59 age demographic compared to the Ontario general population. There was a strong positive correlation between the weekly number of reported cases in Ontario and the percent of respondents reporting CLI each week (r = 0.89, p <0.01) and with a one-week lag (r = 0.89, p <0.01).

InterpretationWe demonstrate a strong positive and significant correlation (r = 0.89, p <0.01) between percent of self-reported COVID-like illness and the subsequent weeks COVID-19 cases reported, highlighting that a rise in CLI may precede official statistics by at least 1 week. This demonstrates the utility of syndromic surveillance in predicting near-future disease activity. Digital surveillance systems are low-cost tools that may help measure the burden of COVID-19 in a community if there is under-detection of cases through conventional laboratory diagnostic testing. This additional information can be used to guide a healthcare response and policy decisions.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.15.21249885,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.15.21249885,Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study,Daniel Ayoubkhani; Kamlesh Khunti; Vahe Nafilyan; Thomas Maddox; Ben Humberstone; Ian Diamond; Amitava Banerjee; Leticia Fontan Garcia-Rodrigo; Lorena Vega Piris; Marta Chicot Llano; David Arribas Mendez; Begona Gonzalez de Marcos; Julia Hernando Santos; Ana Sanchez Azofra; Elena Avalos Perez-Urria; Pablo Rodriguez-Cortes; Laura Esparcia; Ana Marcos-Jimenez; Santiago Sanchez-Alonso; Irene Llorente; Joan B. Soriano; Carmen Suarez Fernandez; Rosario Garcia-Vicuna; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,Office for National Statistics; University of Leicester; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University College London; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa,"ObjectivesThe epidemiology of post-COVID syndrome (PCS) is currently undefined. We quantified rates of organ-specific impairment following recovery from COVID-19 hospitalisation compared with those in a matched control group, and how the rate ratio (RR) varies by age, sex, and ethnicity.

DesignObservational, retrospective, matched cohort study.

SettingNHS hospitals in England.

Participants47,780 individuals (mean age 65 years, 55% male) in hospital with COVID-19 and discharged alive by 31 August 2020, matched to controls on demographic and clinical characteristics.

Outcome measuresRates of hospital readmission, all-cause mortality, and diagnoses of respiratory, cardiovascular, metabolic, kidney and liver diseases until 30 September 2020.

ResultsMean follow-up time was 140 days for COVID-19 cases and 153 days for controls. 766 (95% confidence interval: 753 to 779) readmissions and 320 (312 to 328) deaths per 1,000 person-years were observed in COVID-19 cases, 3.5 (3.4 to 3.6) and 7.7 (7.2 to 8.3) times greater, respectively, than in controls. Rates of respiratory, diabetes and cardiovascular events were also significantly elevated in COVID-19 cases, at 770 (758 to 783), 127 (122 to 132) and 126 (121 to 131) events per 1,000 person-years, respectively. RRs were greater for individuals aged <70 than [&ge;] 70 years, and in ethnic minority groups than the White population, with the biggest differences observed for respiratory disease: 10.5 [9.7 to 11.4] for <70 years versus 4.6 [4.3 to 4.8] for [&ge;] 70 years, and 11.4 (9.8 to 13.3) for Non-White versus 5.2 (5.0 to 5.5) for White.

ConclusionsIndividuals discharged from hospital following COVID-19 face elevated rates of multi-organ dysfunction compared with background levels, and the increase in risk is neither confined to the elderly nor uniform across ethnicities. The diagnosis, treatment and prevention of PCS require integrated rather than organ- or disease-specific approaches. Urgent research is required to establish risk factors for PCS.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.14.21249854,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.14.21249854,An Estimation of Reproduction Number of SARS-CoV-2 by Age Class for Age Classes in Japan,Junko Kurita; Takahide Hata; Tamie Sugawara; Yasushi Ohkusa; Atsuko Hata; Ian Diamond; Amitava Banerjee; Leticia Fontan Garcia-Rodrigo; Lorena Vega Piris; Marta Chicot Llano; David Arribas Mendez; Begona Gonzalez de Marcos; Julia Hernando Santos; Ana Sanchez Azofra; Elena Avalos Perez-Urria; Pablo Rodriguez-Cortes; Laura Esparcia; Ana Marcos-Jimenez; Santiago Sanchez-Alonso; Irene Llorente; Joan B. Soriano; Carmen Suarez Fernandez; Rosario Garcia-Vicuna; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"Tokiwa University, Ibaraki, Japan; Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan; National Institute of Infectious Diseases, Tokyo, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Kitano hospital, The Tazuke Kofukai Medical Research Institute; Office for National Statistics; University College London; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","BackgroundInfectiousness of COVID-19 by age class inferred from the infection source and by infected people might be different. However, studies of such infectiousness have not been reported.

ObjectThe object of this study was estimation of reproduction numbers by age class of the source of infection and the infected persons. To do so, after examining a new procedure for reproduction number estimation, we checked infected places by age class of the source of infection and the infected persons.

MethodWe ignore patients who infected no one because their reliability might be lower than that of patients who infected more than one person. We estimated the reproduction number from the histogram of the number of the infected people by the same patient, assuming that the histogram follows an exponential distribution.

Discussion and ConclusionThe obtained results demonstrated that the effective reproduction numbers for infection from children were very low. They were higher among adult and elderly people than among the same age class. Moreover, although the highest and second-highest infected places were  other and  at home with some exceptions, the data for infection at hospitals were remarkable among adults and elderly people. Among elderly people, infection at facilities for elderly was also high. Infections at nursing schools, schools, restaurants, and entertainment venues at night were negligible.",public and global health,exact,100,100
medRxiv,10.1101/2021.01.15.21249724,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.15.21249724,Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments,Caroline Cake; Emma Ogburn; Heather Pinches; Garry Coleman; David Seymour; Fran Woodard; Sinduja Manohar; Marjia Monsur; Martin Landray; Gaynor Dalton; Andrew D Morris; Patrick F Chinnery; - UK COVID-19 National Core Studies Consortium; F D Richard Hobbs; Christopher Butler; Jia Li; Laura Esparcia; Ana Marcos-Jimenez; Santiago Sanchez-Alonso; Irene Llorente; Joan B. Soriano; Carmen Suarez Fernandez; Rosario Garcia-Vicuna; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"Health Data Research UK; University of Oxford; NHS DigiTrials; NHS Digital; Health Data Research UK; NHS Digital; Health Data Research UK; Department for Health and Social Care; University of Oxford; NHS Digital; Health Data Research UK; University of Cambridge; ; University of Oxford; University of Oxford; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chin; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","BackgroundThe COVID-19 pandemic has presented unique challenges for rapidly designing, initiating, and delivering therapeutic clinical trials. PRINCIPLE is the UK national platform investigating repurposed therapies for COVID-19 treatment of older people in the community at high risk of complications. Standard methods of patient recruitment were failing to meet the required pace and scale of enrolment.

This paper describes the development and appraisal of a near real-time, data-driven, ethical approach for enhancing recruitment in community care by contacting people with a recent COVID-19 positive test result from the central NHS Test and Trace service within 24-48 hours of their test result.

MethodsA multi-disciplinary team was formed to solve the technical, ethical, public perception, logistical and information governance issues required to provide a near-real time (within 24-48 hours of receiving a positive test) feed of potential trial participants from test result data to the research team. PRINCIPLE was also given unique access to the Summary Care Record (SCR) to ensure safe prescribing, and to enable the trial team to quickly and safely bring consented patients into the trial. A survey of the public was used to understand public perceptions of the use of test data for this proposed methodology.

ResultsPrior to establishing the data service, PRINCIPLE registered on average 87 participants per week. This increased by up to 87 additional people registered per week from the test data, contributing to an increase from 1,013 recruits to PRINCIPLE at the start of October 2020 to 2,802 recruits by 20th December 2020.

While procedural caveats were identified by the public consultation, out of 2,639 people contacted by PRINCIPLE following a positive test result, no one raised a concern about being approached.

ConclusionsThis paper describes a novel approach to using near-real time NHS operational data to recruit community-based patients within a few days of presentation with acute illness.

This approach increased recruitment, and reduced time between positive test and randomisation, allowing more rapid evaluation of treatments and increased safety for participants. End-to-end public and patient involvement in the design of the approach provided evidence to inform information governance decisions.

Trial registrationPRINCIPLE is funded by UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research.

EudraCT number: 2020-001209-22

ISRCTN registry: ISRCTN86534580

REC number: 20/SC/058

IRAS number: 281958",primary care research,exact,100,100
medRxiv,10.1101/2021.01.13.21249721,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.13.21249721,"Increased infections, but not viral burden, with a new SARS-CoV-2 variant",Ann Sarah Walker; Karina Doris Vihta; Owen Gethings; Emma Pritchard; Joel Jones; Thomas House; Iain Bell; John Bell; John Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team; Roberto Bertollini; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"University of Oxford; University of Oxford; Office for National Statistics; University of Oxford; Office for National Statistics; University of Manchester; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Glasgow; Public Health England; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Ministry of Public Health, Doha, Qatar; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","BackgroundA new variant of SARS-CoV-2, B.1.1.7/VOC202012/01, was identified in the UK in December-2020. Direct estimates of its potential to enhance transmission are limited.

MethodsNose and throat swabs from 28-September-2020 to 2-January-2021 in the UKs nationally representative surveillance study were tested by RT-PCR for three genes (N, S and ORF1ab). Those positive only on ORF1ab+N, S-gene target failures (SGTF), are compatible with B.1.1.7/VOC202012/01. We investigated cycle threshold (Ct) values (a proxy for viral load), percentage of positives, population positivity and growth rates in SGTF vs non-SGTF positives.

Results15,166(0.98%) of 1,553,687 swabs were PCR-positive, 8,545(56%) with three genes detected and 3,531(23%) SGTF. SGTF comprised an increasing, and triple-gene positives a decreasing, percentage of infections from late-November in most UK regions/countries, e.g. from 15% to 38% to 81% over 1.5 months in London. SGTF Ct values correspondingly declined substantially to similar levels to triple-gene positives. Population-level SGTF positivity remained low (<0.25%) in all regions/countries until late-November, when marked increases with and without self-reported symptoms occurred in southern England (to 1.5-3%), despite stable rates of non-SGTF cases. SGTF positivity rates increased on average 6% more rapidly than rates of non-SGTF positives (95% CI 4-9%) supporting addition rather than replacement with B.1.1.7/VOC202012/01. Excess growth rates for SGTF vs non-SGTF positives were similar in those up to high school age (5% (1-8%)) and older individuals (6% (4-9%)).

ConclusionsDirect population-representative estimates show that the B.1.1.7/VOC202012/01 SARS-CoV-2 variant leads to higher infection rates, but does not seem particularly adapted to any age group.",infectious diseases,exact,100,100
bioRxiv,10.1101/2021.01.15.426787,2021-01-15,https://biorxiv.org/cgi/content/short/2021.01.15.426787,Correlation of Computerized Tomography (CT) Severity Score for COVID-19 pneumonia with Clinical Outcomes,Kiran Hilal; Jehanzeb Shahid; Abdullah Aameen; Russell Seth Martins; Avinash Nankani; Ainan Arshad; Haq Tu; John Bell; John Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team; Roberto Bertollini; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"Aga Khan University Hospital; Aga Khan University Hospital; Aga Khan University Hospital; Aga Khan University Medical College Pakistan; Dow University of Health Sciences; Aga Khan University Hospital; Aga Khan University Hospital; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Glasgow; Public Health England; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Ministry of Public Health, Doha, Qatar; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","IntroductionVarious CT severity scores have already been described in literature since the start of this pandemic. One pertinent issue with all of the previously described severity scores is their relative challenging calculation and variance in inter-observer agreement. The severity score proposed in our study is relatively simpler, easier to calculate and apart from a trained radiologist, can easily be calculated even by physicians with good inter-observer agreement. Therefore, a rapid CT severity score calculation can give a clue to physician about possible clinical outcome without being dependent on radiologist who may not be readily available especially in third world countries.

ObjectiveThe objective of this study is to develop a simple CT severity score (CT-SS) with good inter-observer agreement and access its correlation with clinical outcome.

MethodsThis retrospective study was conducted by the Department of Radiology and Internal Medicine, at the Aga Khan University Hospital Karachi, from April 2020 to August 2020. Non-probability consecutive sampling was used to include all patients who were positive for COVID-19 on PCR, and underwent CT chest examination at AKUH. Severity of disease was calculated in each lobe on the basis of following proposed CT severity scoring system (CT-SS). For each lobe the percentage of involvement by disease was scored - 0% involvement was scored 0, <50% involvement was scored 1 and >50% involvement was scored 2. Maximum score for one lobe was 2 and hence total maximum overall score for all lobes was 10. Continuous data was represented using mean and standard deviation, and compared using independent sample t-tests. Categorical data was represented using frequencies and percentages, and compared using Chi-squared tests. Inter-observer reliability between radiologist and COVID intensivist for the 10 point CT-SS rated on 0-10 was assessed using the Kappa statistic. A p-value < 0.05 was considered significant for all analyses.

ResultsA total of 73 patients were included, the majority male (58.9%) with mean age 55.8 {+/-} 13.93 years. The CT-SS rated on 0-10 showed substantial inter-observer reliability between radiologist and intensivist with a Kappa statistic of 0.78. Patients with CT-SS 8-10 had a significantly higher ICU admission & intubation rate (53.8% vs. 23.5%) and mortality rate (35.9% vs. 11.8%; p = 0.017), as compared to those with CT-SS 0-7.

ConclusionWe conclude that the described CT severity score (CT-SS) is a quick, effective and easily reproducible tool for prediction of adverse clinical outcome in patients with COVID 19 pneumonia. The tool shows good inter-observer agreement when calculated by radiologist and physician independently.",pathology,exact,100,100
bioRxiv,10.1101/2021.01.12.426407,2021-01-15,https://biorxiv.org/cgi/content/short/2021.01.12.426407,Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y in Clinical Samples in Columbus Ohio,Huolin Tu; Matthew R Avenarius; Laura Kubatko; Matthew Hunt; Xiaokang Pan; Peng Ru; Jason Garee; Keelie Thomas; Peter Mohler; Preeti Pancholi; Dan Jones; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team; Roberto Bertollini; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"James Molecular Laboratory, The Ohio State University Wexner Medical Center; Department of Pathology, The Ohio State University Wexner Medical Center; The Ohio State University; The James Molecular Laboratory, The Ohio State University Wexner Medical Center; James Molecular Laboratory, The Ohio State University Wexner Medical Center; The Ohio State University Comprehensive Cancer Center; The Ohio State University Wexner Medical Center; Department of Pathology, The Ohio State University Wexner Medical Center; Departments of Physiology and Internal Medicine and Davis Heart and Lung Research Institute, he College of Medicine and Ohio State University Wexner Medical Cen; Department of Pathology, The Ohio State University Wexner Medical Center,; Department of Pathology, The Ohio State University Wexner Medical Center,; Office for National Statistics; Office for National Statistics; University of Glasgow; Public Health England; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Ministry of Public Health, Doha, Qatar; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","Following the worldwide emergence of the p.Asp614Gly shift in the Spike (S) gene of SARS-CoV-2, there have been few recurring pathogenic shifts occurring during 2020, as assessed by genomic sequencing. This situation has evolved in the last several months with the emergence of several distinct variants (first identified in the United Kingdom and South Africa) that manifest multiple changes in the S gene, particularly p.Asn501Tyr (N501Y), that likely have clinical impact. We report here the emergence in Columbus, Ohio in December 2020 of two novel SARS-CoV-2 clade 20G variants. One variant, that has become the predominant virus found in nasopharyngeal swabs in the December 2020-January 2021 period, harbors S p.Gln677His (Q677H), affecting a consensus QTQTN domain near the S1/S2 furin cleavage site, nucleocapsid (N) p.Asp377Tyr (D377Y) and membrane glycoprotein (M) p.Ala85Ser (A85S) mutations, with additional S mutations in subsets. The other variant present in two samples, contains S N501Y, which is a marker of the UK-B.1.1.7 (clade 20I/501Y.V1) strain, but lacks all other mutations from that virus. The Ohio variant is from a different clade and shares multiple mutations with the clade 20G viruses circulating in the area prior to December 2020. These two SARS-CoV-2 viruses, which we show are also present and evolving currently in several other parts of North America, add to the diversity of S gene shifts occurring worldwide. These and other shifts in this period of the pandemic support multiple independent acquisition of functionally significant and potentially complementing mutations affecting the S QTQTN site (Q675H or Q677H) and certain receptor binding domain mutations (e.g., E484K and N501Y).",genomics,exact,100,100
medRxiv,10.1101/2021.01.10.21249370,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.10.21249370,Dynamic Prediction of SARS-CoV-2 RT-PCR status on Chest Radiographs using Deep Learning Enabled Radiogenomics,Wan Hang Keith Chiu; Dmytro Poplavskiy; Sailong Zhang; Philip Leong Ho Yu; Michael D Kuo; Peng Ru; Jason Garee; Keelie Thomas; Peter Mohler; Preeti Pancholi; Dan Jones; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team; Roberto Bertollini; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"Department of Diagnostic Radiology, The University of Hong Kong; Medical Artificial Intelligence Laboratory Program, Department of Diagnostic Radiology, The Uni; Ensemblehealth.ai, Scottsdale, AZ, USA; Department of Diagnostic Radiology, The University of Hong Kong; Department of Mathematics and Information Technology, The Education University of Hong Kong SAR; Ensemblehealth.ai, Scottsdale, AZ, USA; Medical Artificial Intelligence Laboratory Program, Department of Diagnostic Radiology, The University of Hong Kong, Hon; The Ohio State University Comprehensive Cancer Center; The Ohio State University Wexner Medical Center; Department of Pathology, The Ohio State University Wexner Medical Center; Departments of Physiology and Internal Medicine and Davis Heart and Lung Research Institute, he College of Medicine and Ohio State University Wexner Medical Cen; Department of Pathology, The Ohio State University Wexner Medical Center,; Department of Pathology, The Ohio State University Wexner Medical Center,; Office for National Statistics; Office for National Statistics; University of Glasgow; Public Health England; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Ministry of Public Health, Doha, Qatar; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is the gold standard for diagnosis of SARS-CoV-2 infection, but requires specialized equipment and reagents and suffers from long turnaround times. While valuable, chest imaging currently only detects COVID-19 pneumonia, but if it can predict actual RT-PCR SARS-CoV-2 status is unknown. Radiogenomics may provide an effective and accurate RT-PCR-based surrogate. We describe a deep learning radiogenomics (DLR) model (RadGen) that predicts a patient's RT-PCR SARS-CoV-2 status solely from their frontal chest radiograph (CXR).",radiology and imaging,exact,100,100
medRxiv,10.1101/2021.01.11.21249265,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.11.21249265,A Viral Fragmentation Signature for SARS-CoV-2 in Clinical Samples Correlating with Contagiousness,Yukti Choudhury; Chae Yin Cher; Zi Yi Wan; Chao Xie; Jing Shan Lim; Ramandeep Kaur Virk; Min Han Tan; Alvin Kuo Jing Teo; Li Yang Hsu; Preeti Pancholi; Dan Jones; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team; Roberto Bertollini; Julio Ancochea; Jesus Sanz; Cecilia Munoz-Calleja; Rafael de la Camara; Alfonso Canabal Berlanga; Isidoro Gonzalez-Alvaro; Laura Cardenoso,"Lucence Diagnostics; Lucence Diagnostics; Lucence Diagnostics; Lucence Diagnostics; Lucence Diagnostics; Lucence Diagnostics; Lucence Health; Saw Swee Hock School of Public Health; Saw Swee Hock School of Public Health; Department of Pathology, The Ohio State University Wexner Medical Center,; Department of Pathology, The Ohio State University Wexner Medical Center,; Office for National Statistics; Office for National Statistics; University of Glasgow; Public Health England; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Ministry of Public Health, Doha, Qatar; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa; Hospital Universitario de La Princesa","The viral load of SARS-CoV-2 in clinical samples as measured by the primary diagnostic tool of RT-PCR is an imperfect readout for infection potential as most targeted assays designed for sensitivity, indiscriminately detect short and long RNA fragments, although infectivity is embodied only in the whole virus and its intact genome. Here, we used next-generation sequencing (NGS) to characterize 155 clinical samples and show sensitive and quantitative detection of viral RNA which confirmed subgenomic RNA in 57.6% of samples and provided a novel method to determine relative integrity of viral RNA in samples. The relative abundance of long fragments quantified as a viral fragmentation score was positively associated with viral load and inversely related to time from disease onset. An empirically determined score cut-off for presence of substantially fragmented RNA was able to identify 100% of samples collected after 8 days of illness with poor infection potential in line with current clinical understanding of infectiousness of SARS-CoV-2. The quantification of longer fragments in addition to existing short targets in an NGS or RT-PCR-based assay could provide a valuable readout of infection potential simultaneous to the detection of any fragments of SARS-CoV-2 RNA in test samples.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2021.01.11.20248765,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.11.20248765,Early immune pathology and persistent dysregulation characterise severe COVID-19,Laura Bergamaschi; Federica Mescia; Lorinda Turner; Aimee Hanson; Prasanti Kotagiri; Benjamin J. Dunmore; Helene Ruffieux; Aloka DeSa; Oisin Huhn; Mark R. Wills; Stephen Baker; Rainer Doffinger; Gordon Dougan; Anne Elmer; Ian G Goodfellow; Ravindra K. Gupta; Myra Hosmillo; Kelvin Hunter; Nathalie Kingston; Paul J. Lehner; Nicholas J. Matheson; Jeremy K. Nicholson; Anna M. Petrunkina; Sylvia Richardson; Caroline Saunders; James E.D. Thaventhiran; Erik J.M. Toonen; Michael P. Weekes; - CambridgeInstituteofTherapeuticImmunologyandInfectiousDisease-NationalInstituteofHealthResearch(CITI; Mark Toshner; Christoph Hess; John R. Bradley; Paul A. Lyons; Kenneth G.C. Smith,"Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 ; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; The Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Murdoch, Western Australia WA 6150, Australia; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 ; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; ; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK","In a study of 207 SARS-CoV2-infected individuals with a range of severities followed over 12 weeks from symptom onset, we demonstrate that an early robust immune response, without systemic inflammation, is characteristic of asymptomatic or mild disease. Those presenting to hospital had delayed adaptive responses and systemic inflammation already evident at around symptom onset. Such early evidence of inflammation suggests immunopathology may be inevitable in some individuals, or that preventative intervention might be needed before symptom onset. Viral load does not correlate with the development of this pathological response, but does with its subsequent severity. Immune recovery is complex, with profound persistent cellular abnormalities correlating with a change in the nature of the inflammatory response, where signatures characteristic of increased oxidative phosphorylation and reactive-oxygen species-associated inflammation replace those driven by TNF and IL-6. These late immunometabolic inflammatory changes and unresolved immune cell defects, if persistent, may contribute to ""long COVID"".",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.11.20248882,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.11.20248882,Modelling the effect of lockdown,Hideto Kamei; Akihiro Sato; Lorinda Turner; Aimee Hanson; Prasanti Kotagiri; Benjamin J. Dunmore; Helene Ruffieux; Aloka DeSa; Oisin Huhn; Mark R. Wills; Stephen Baker; Rainer Doffinger; Gordon Dougan; Anne Elmer; Ian G Goodfellow; Ravindra K. Gupta; Myra Hosmillo; Kelvin Hunter; Nathalie Kingston; Paul J. Lehner; Nicholas J. Matheson; Jeremy K. Nicholson; Anna M. Petrunkina; Sylvia Richardson; Caroline Saunders; James E.D. Thaventhiran; Erik J.M. Toonen; Michael P. Weekes; - CambridgeInstituteofTherapeuticImmunologyandInfectiousDisease-NationalInstituteofHealthResearch(CITI; Mark Toshner; Christoph Hess; John R. Bradley; Paul A. Lyons; Kenneth G.C. Smith,"-; Yokohama City University; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 ; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; The Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Murdoch, Western Australia WA 6150, Australia; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 ; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; ; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK","1This note models the effect of the lockdown during the first wave of COVID-19. We use SEIR type of model with a certain time lag between infection and becoming infectious. Firstly we compare the timing of the change of the coefficient of infection, growth rate of confirmed cases corresponds to the change of mobility index, and secondly we assume the change of the coefficient of infection, activity index {beta} (analogous to R0) and fit the parameter to reproduce the actual number of confirmed cases. Finally, we assume that the activity index {beta} is proportional to the square of the mobility and fit the parameters. The curves in various cuontries fits reasonably well in any cases, but estimating {beta} from various parameters (including temperature) remains as an important task.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.11.21249461,2021-01-13,https://medrxiv.org/cgi/content/short/2021.01.11.21249461,A national retrospective cohort study of mechanical ventilator availability and its association with mortality risk in intensive care patients with COVID-19,Harrison Wilde; Thomas A Mellan; Iwona Hawryluk; John Dennis; Spiros Denaxas; Christina Pagel; Andrew Duncan; Samir Bhatt; Seth Flaxman; Bilal A Mateen; Sebastian Vollmer; Qi Ouyang; Fangting Li; William A Petri Jr.; David Camerini; Elaine L. Hill; Stephanie S. Hong; Hunter Jimenez; Ramakanth Kavuluru; Kristin Kostka; Harold P. Lehmann; Eli Levitt; Sandeep K. Mallipattu; Amin Manna; Julie A. McMurry; Michele Morris; John Muschelli; Andrew J. Neumann; Matvey B. Palchuk; Emily R. Pfaff; Zhenglong Qian; Nabeel Qureshi; Seth Russell; Heidi Spratt; Anita Walden; Andrew E. Williams; Jacob T. Wooldridge; Yun Jae Yoo; Xiaohan Tanner Zhang; Richard L. Zhu; Christopher P. Austin; Joel H. Saltz; Kenneth R. Gersing; Melissa Haendel; Christopher G. Chute; - National Covid Cohort Collaborative,"University of Warwick; Imperial College; Imperial College London; University of Exeter; University College London; University College London; Imperial College London; Imperial College London; Imperial College London; The Alan Turing Institute; University of Warwick; School of Physics, Center for Quantitative Biology, Peking University, Beijing 100871, China; School of Physics, Center for Quantitative Biology, Peking University, Beijing 100871, China; University of Virginia Health System; Antigen Discovery Inc.; University of Rochester Medical Center, Rochester, NY, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA; Stony Brook University, Stony Brook, NY, USA; University of Kentucky, Lexington, KY, USA; Real World Solutions, IQVIA, Cambridge, MA, USA; Observational Health Data Sciences and Informatics, New York, NY, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA; University of Alabama at Birmingham, Birmingham, AL, USA; Stony Brook University, Stony Brook, NY, USA; Palantir Technologies, Denver, CO, USA; Translational and Integrative Sciences Center, Oregon State University, Corvallis, OR, USA; Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA; Translational and Integrative Sciences Center, Oregon State University, Corvallis, OR, USA; TriNetX, Cambridge, MA, USA; North Carolina Translational and Clinical Sciences Institute (NC TraCS), University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Auburn University, Auburn, AL; Palantir Technologies, Denver, CO, USA; Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, University of Colorado, Aurora, CO, USA; University of Texas Medical Branch, Galveston, TX, USA; Oregon Clinical and Translational Research Institute, Oregon Health & Science University, Portland, OR, USA; Sage Bionetworks, Seattle, WA, USA; Tufts Medical Center Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA, USA; Stony Brook University, Stony Brook, NY, USA; Stony Brook University, Stony Brook, NY, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA; Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA; Oregon Health & Science University; Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, MD, USA; ","ObjectivesTo determine if there is an association between survival rates in intensive care units (ICU) and occupancy of the unit on the day of admission.

DesignNational retrospective observational cohort study spanning the first wave of the Englands COVID-19 pandemic.

Setting114 hospital trusts (groups of hospitals functioning as single operational units).

Participants4,032 adults admitted to an ICU in England between 2nd April and 1st June, 2020, with presumed or confirmed COVID-19, for whom data was submitted to the national surveillance programme and met study inclusion criteria.

InterventionsN/A

Main Outcomes and MeasuresA Bayesian hierarchical approach was used to model the association between hospital trust level (mechanical ventilation compatible) bed occupancy, and in-hospital all-cause mortality. Results were adjusted for unit characteristics (pre-pandemic size), individual patient-level demographic characteristics (age, sex, ethnicity, time-to-ICU admission), and recorded chronic comorbidities (obesity, diabetes, respiratory disease, liver disease, heart disease, hypertension, immunosuppression, neurological disease, renal disease).

Results79,793 patient-days were observed, with a mortality rate of 19.4 per 1,000 patient days. Adjusting for patient-level factors, mortality was higher for admissions during periods of high occupancy (>85% occupancy versus the baseline of 45 to 85%) [OR 1.19 (95% posterior credible interval (PCI): 1.00 to 1.44)]. In contrast, mortality was decreased for admissions during periods of low occupancy (<45% relative to the baseline) [OR 0.75 (95% PCI: 0.62 to 0.89)].

Conclusion and RelevanceIncreasing occupancy of beds compatible with mechanical ventilation, a proxy for operational strain, is associated with a higher mortality risk for individuals admitted to ICU. Public health interventions (such as expeditious vaccination programmes and non-pharmaceutical interventions) to control both incidence and prevalence of COVID-19, and therefore keep ICU occupancy low in the context of the pandemic, are necessary to mitigate the impact of this type of resource saturation.

Trial RegistrationN/A

O_TEXTBOXSummary Box

What is already known on this topicPre-pandemic, higher occupancy of intensive care units was shown to be associated with increased mortality risk. However, there is limited data on the extent to which occupancy levels impacted patient outcomes during the first wave of COVID-19, especially in light of the mobilisation of significant additional resources. A recent study from Belgium reported a 42% higher mortality during periods of ICU surge capacity deployment, although in the analysis surge capacity was evaluated only as a binary variable. Although, this contradicts earlier results from smaller studies in Australia and Wales, where no association between ICU occupancy and mortality was identified.

What this study addsThe results of this study suggest that survival rates for patients with COVID-19 in intensive care settings appears to deteriorate as the occupancy of (surge capacity) beds compatible with mechanical ventilation (a proxy for operational pressure), increases. Moreover, this risk doesnt occur above a specific threshold, but rather appears linear; whereby going from 0% occupancy to 100% occupancy increases risk of mortality by 92% (after adjusting for relevant individual-level factors). Furthermore, risk of mortality based on occupancy on the date of recorded outcome is even higher; OR 4.74 (95% posterior credible interval: 3.54 - 6.34). As such, this national-level cohort study of England provides compelling evidence for a relationship between occupancy and critical care mortality, and highlights the needs for decisive action to control the incidence and prevalence of COVID-19.

C_TEXTBOX",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2021.01.06.21249352,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249352,OpenSAFELY NHS Service Restoration Observatory 1: describing trends and variation in primary care clinical activity for 23.3 million patients in England during the first wave of COVID-19,Helen J Curtis; Brian MacKenna; Richard Croker; Alex J Walker; Peter Inglesby; Jessica Morley; Amir Mehrkar; Caroline E Morton; Seb Bacon; George Hickman; Chris Bates; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan T. Bhaskaran; Anna Schultze; Christopher T. Rentsch; Elizabeth J Williamson; Will Hulme; Helen I McDonald; Laurie Tomlinson; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; LSHTM; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; London School of Medicine and Tropical Medicine; LSHTM; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","BackgroundThe COVID-19 pandemic has disrupted healthcare activity globally. The NHS in England stopped most non-urgent work by March 2020, but later recommended that services should be restored to near-normal levels before winter where possible. The authors are developing the OpenSAFELY NHS Service Restoration Observatory, using data to describe changes in service activity during COVID-19, and reviewing signals for action with commissioners, researchers and clinicians. Here we report phase one: generating, managing, and describing the data.

ObjectiveTo describe the volume and variation of coded clinical activity in English primary care across 23.8 million patients records, taking respiratory disease and laboratory procedures as key examples.

MethodsWorking on behalf of NHS England we developed an open source software framework for data management and analysis to describe trends and variation in clinical activity across primary care EHR data on 23.8 million patients; and conducted a population cohort-based study to describe activity using CTV3 coding hierarchy and keyword searches from January 2019-September 2020.

ResultsMuch activity recorded in general practice declined to some extent during the pandemic, but largely recovered by September 2020, with some exceptions. There was a large drop in coded activity for commonly used laboratory tests, with broad recovery to pre-pandemic levels by September. One exception was blood coagulation tests such as International Normalised Ratio (INR), with a smaller reduction (median tests per 1000 patients in 2020: February 8.0; April 6.2; September 7.0). The overall pattern of recording for respiratory symptoms was less affected, following an expected seasonal pattern and classified as ""no change"" from the previous year. Respiratory tract infections exhibited a sustained drop compared with pre-pandemic levels, not returning to pre-pandemic levels by September 2020. Various COVID-19 codes increased through the period. We observed a small decline associated with high level codes for long-term respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Asthma annual reviews experienced a small drop but since recovered, while COPD annual reviews remain below baseline.

ConclusionsWe successfully delivered an open source software framework to describe trends and variation in clinical activity across an unprecedented scale of primary care data. The COVD-19 pandemic led to a substantial change in healthcare activity. Most laboratory tests showed substantial reduction, largely recovering to near-normal levels by September 2020, with some important tests less affected. Records of respiratory infections decreased with the exception of codes related to COVID-19, whilst activity of other respiratory disease codes was mixed. We are expanding the NHS Service Restoration Observatory in collaboration with clinicians, commissioners and researchers and welcome feedback.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2021.01.06.21249345,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249345,Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection,Sudeb C. Dalai; Jennifer N. Dines; Thomas M. Snyder; Rachel M. Gittelman; Tera Eerkes; Pashmi Vaney; Sally Howard; Kipp Akers; Lynell Skewis; Anthony Monteforte; Pam Witte; Cristina Wolf; Hans Nesse; Megan Herndon; Jia Qadeer; Sarah Duffy; Emily Svejnoha; Caroline Taromino; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Adaptive Biotechnologies, Seattle, WA, USA;  Stanford University School of Medicine, Stanford, CA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","BackgroundWhile diagnostic, therapeutic, and vaccine development in the COVID-19 pandemic has proceeded at unprecedented speed and scale, critical gaps remain in our understanding of the immune response to SARS-CoV-2. Current diagnostic strategies, including serology, have numerous limitations in addressing these gaps. Here we describe clinical performance of T- Detect COVID, the first reported assay to determine recent or prior SARS-CoV-2 infection based on T-cell receptor (TCR) sequencing and immune repertoire profiling from whole blood samples.

MethodsMethods for high-throughput immunosequencing of the TCR{beta} gene from blood specimens have been described1. We developed a statistical classifier showing high specificity for identifying prior SARS-CoV-2 infection2, utilizing >4,000 SARS-CoV-2-associated TCR sequences from 784 cases and 2,447 controls across 5 independent cohorts. The T-Detect COVID Assay comprises immunosequencing and classifier application to yield a qualitative positive or negative result. Several retrospective and prospective cohorts were enrolled to assess assay performance including primary and secondary Positive Percent Agreement (PPA; N=205, N=77); primary and secondary Negative Percent Agreement (NPA; N=87, N=79); PPA compared to serology (N=55); and pathogen cross-reactivity (N=38).

ResultsT-Detect COVID demonstrated high PPA in subjects with prior PCR-confirmed SARS-CoV-2 infection (97.1% 15+ days from diagnosis; 94.5% 15+ days from symptom onset), high NPA ([~]100%) in presumed or confirmed SARS-CoV-2 negative cases, equivalent or higher PPA than two commercial EUA serology tests, and no evidence of pathogen cross-reactivity.

ConclusionT-Detect COVID is a novel T-cell immunosequencing assay demonstrating high clinical performance to identify recent or prior SARS-CoV-2 infection from standard blood samples. This assay can provide critical insights on the SARS-CoV-2 immune response, with potential implications for clinical management, risk stratification, surveillance, assessing protective immunity, and understanding long-term sequelae.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.06.20249009,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.20249009,SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing,Andreas K. Lindner; Olga Nikolai; Chiara Rohardt; Franka Kausch; Mia Wintel; Maximilian Gertler; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","BackgroundAntigen-detecting rapid diagnostic tests (Ag-RDTs) have been widely recommended as a complement to RT-PCR. Considering the possibility of nasal self-sampling and the ease-of-use in performing the test, self-testing may be an option.

Methods and FindingsWe performed a manufacturer-independent, prospective diagnostic accuracy study of nasal mid-turbinate self-sampling and self-testing when using a WHO-listed SARS-CoV-2 Ag-RDT. Symptomatic participants suspected to have COVID-19 received written and illustrated instructions. Procedures were observed without intervention. For comparison, Ag-RDTs with nasopharyngeal sampling were professionally performed. Estimates of agreement, sensitivity, and specificity relative to RT-PCR on a combined oro-/nasopharyngeal sample were calculated. Feasibility was evaluated by observer and participant questionnaires.

Among 146 symptomatic adults, 40 (27.4%) were RT-PCR-positive for SARS-CoV-2. Sensitivity with self-testing was 82.5% (33/40 RT-PCR positives detected; 95% CI 68.1-91.3), and 85.0% (34/40; 95% CI 70.9-92.9) with professional testing. The positive percent agreement between self-testing and professional testing on Ag-RDT was 91.4% (95% CI 77.6-97.0), and negative percent agreement 99.1% (95% CI 95.0-100). At high viral load (>7.0 log10 SARS-CoV-2 RNA copies/ml), sensitivity was 96.6% (28/29; 95% CI 82.8-99.8) for both self- and professional testing. Deviations in sampling and testing (incomplete self-sampling or extraction procedure, or imprecise volume applied on the test device) were observed in 25 out of the 40 PCR-positives. Participants were rather young (mean age 35 years) and educated (59.6% with higher education degree). Most participants (80.9%) considered the Ag-RDT as rather easy to perform.

ConclusionsAmbulatory participants suspected for SARS-CoV-2 infection were able to reliably perform the Ag-RDT and test themselves. Procedural errors might be reduced by refinement of the Ag-RDTs for self-testing, such as modified instructions for use or product design/procedures. Self-testing may result in more wide-spread and more frequent testing. Paired with the appropriate information and education of the general public about the benefits and risks, self-testing may therefore have significant impact on the pandemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.07.21249353,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.07.21249353,Inherent random fluctuations in COVID-19 outbreaks may explain rapid growth of new mutated virus variants,Kenneth Bodin; Joacim Rocklov; Chiara Rohardt; Franka Kausch; Mia Wintel; Maximilian Gertler; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Umea University; Umea University; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","A new virus variant of SARS-COV-2 has had a profound impact on society while governments have taken action to limit its impacts by enforcing lockdowns and limiting spread from the UK to other countries. Variants with mutations in the virus genome are likely to occur, but do not always associate to significant changes in the biology of the virus, or the disease. For the variant VOC 202012/01 (also referred to as B.1.1.7), however, preliminary reports indicate it may be more transmissible. Here we use a simulation model calibrated to the inherent random fluctuating transmission pattern of COVID-19 to investigate what the probability may be for detecting more transmissible virus variants post facto. We find that post facto identification of successful virus variants of SARS-COV-2 are likely to exhibit growth rates that are substantially larger than the average growth rate. This finding has implications for interpreting growth rate and transmissibility of new virus variants.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.06.21249365,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249365,"Modeling the effect of vaccination strategies in an Excel spreadsheet: The rate of vaccination, and not only the vaccination coverage, is a determinant for containing COVID-19 in urban areas",Mario Moises Alvarez; Sergio Bravo-Gonzalez; Grissel Trujillo-de Santiago; Franka Kausch; Mia Wintel; Maximilian Gertler; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Tecnologico de Monterrey; Tecnologico de Monterrey; Tecnologico de Monterrey; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","We have investigated the importance of the rate of vaccination to contain COVID-19 in urban areas. We used an extremely simple epidemiological model that is amenable to implementation in an Excel spreadsheet and includes the demographics of social distancing, efficacy of massive testing and quarantine, and coverage and rate of vaccination as the main parameters to model the progression of COVID-19 pandemics in densely populated urban areas. Our model predicts that effective containment of pandemic progression in densely populated cities would be more effectively achieved by vaccination campaigns that consider the fast distribution and application of vaccines (i.e., 50% coverage in 6 months) while social distancing measures are still in place. Our results suggest that the rate of vaccination is more important than the overall vaccination coverage for containing COVID-19. In addition, our modeling indicates that widespread testing and quarantining of infected subjects would greatly benefit the success of vaccination campaigns. We envision this simple model as a friendly, readily accessible, and cost-effective tool for assisting health officials and local governments in the rational design/planning of vaccination strategies.",epidemiology,exact,100,100
medRxiv,10.1101/2021.01.06.21249368,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249368,Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs,James A Watson; Stephen Kissler; Nicholas PJ Day; Yonatan H. Grad; Nicholas J White; Maximilian Gertler; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"University of Oxford; Harvard T. H. Chan School of Public Health; Mahidol Oxford Tropical Medicine Research Unit; Harvard TH Chan School of Public Health; University of Oxford; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","There is no agreed methodology for pharmacometric assessment of candidate antiviral drugs in COVID-19. The most widely used measure of virological response in clinical trials so far is the time to viral clearance assessed by qPCR of viral nucleic acid in eluates from serial nasopharyngeal swabs. We posited that the rate of viral clearance would have better discriminatory value. Using a pharmacodynamic model fit to individual SARS-CoV-2 virus clearance data from 46 uncomplicated COVID-19 infections in a cohort of prospectively followed adults, we simulated qPCR viral load data to compare type 2 errors when using time to clearance and rate of clearance under varying antiviral effects, sample sizes, sampling frequencies and durations of follow-up. The rate of viral clearance is a uniformly superior endpoint as compared to time to clearance with respect to type 2 error, and it is not dependent on initial viral load or assay sensitivity. For greatest efficiency pharmacometric assessments should be conducted in early illness and daily qPCR samples should be taken over 7 to 10 days in each patient studied. Adaptive randomisation and early stopping for success permits more rapid identification of active interventions.",pharmacology and therapeutics,exact,100,100
medRxiv,10.1101/2021.01.06.21249354,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249354,Blood omega-3 fatty acids and death from COVID-19: A Pilot Study,Arash Asher; Nathan L Tintle; Michael Myers; Laura Lockshon; Heribert Bacareza; William S Harris; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, CA.; Fatty Acid Research Institute, Sioux Falls, SD USA; Los Alamitos Medical Center, Los Alamitos, CA; Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, CA.; Department of Medical Affairs, Cedars-Sinai Medical Center, Los Angeles, CA; Fatty Acid Research Institute; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","Very-long chain omega-3 fatty acids (EPA and DHA) have anti-inflammatory properties that may help reduce morbidity and mortality from COVID-19 infection. We conducted a pilot study in 100 patients to test the hypothesis that RBC EPA+DHA levels (the Omega-3 Index, O3I) would be inversely associated with risk for death by analyzing the O3I in banked blood samples drawn at hospital admission. To have adequate power (>80%) in this pilot study, we pre-specified a significance level of 0.10. Fourteen patients died, one of 25 in quartile 4 (Q4) (O3I [&ge;]5.7%) and 13 of 75 in Q1-3. After adjusting for age and sex, the odds ratio for death in patients with an O3I in Q4 vs Q1-3 was 0.25, p=0.07. Thus, we have suggestive evidence that the risk for death from COVID-19 was lower in those with the highest O3I levels. These preliminary findings need to be confirmed in larger studies.",nutrition,exact,100,100
medRxiv,10.1101/2021.01.06.21249118,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249118,"Knowledge, attitude, and practices regarding COVID-19: A study on workers from a food industry in Bangladesh.",Md. Fahad Jubayer; Md. Shahidullah Kayshar; Md. Faizul Kabir; Md. Tariqul Islam Limon; Md. Al-Emran; Md. Nasir Uddin; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Sylhet Agricultural University; Sylhet Agricultural University; Bangladesh Bank (central bank of Bangladesh); Coxs Bazar Medical College and Hospital, Bangladesh.; Bangladesh Agricultural University; Bangladesh Agricultural University; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","While people around the world are terrified of the global pandemic coronavirus disease 2019 (COVID-19) and no registered vaccine is out yet, undertaking preventive safety measures are said to be the only way to stay away from it. Peoples adherence to these measures is broadly dependent on their knowledge, attitude, and practices (KAP). The present study was designed to evaluate workers knowledge, attitude, and practices from a food industry in Dhaka, Bangladesh, towards COVID-19. A number of 155 respondents took part in this online-based study. The information was acquired online from the participants through a questionnaire prepared in Google form. With a correct response rate of about 90% on average (knowledge 89.7%, attitude 93%, practices 88.2%), the participants showed a good level of KAP regarding COVID-19. However, education and working experiences had a significant association with the total KAP scores (p < 0.05). Further KAP studies in different generic food industries in Bangladesh should be carried out to bring a more precise picture for ensuring the level of workplace and workers safety.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2021.01.06.21249303,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249303,Socioeconomic Disparities in the Effects of Pollution on Spread of Covid-19: Evidence from US Counties,Osvalso Allen; Ava Brown; Ersong Wang; Md. Tariqul Islam Limon; Md. Al-Emran; Md. Nasir Uddin; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Austin Peay State University; Austin Peay state University; Austin Peay state University; Coxs Bazar Medical College and Hospital, Bangladesh.; Bangladesh Agricultural University; Bangladesh Agricultural University; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","This paper explores disparities in the effect of pollution on confirmed cases of Covid-19 based on counties socioeconomic and demographic characteristics. Using data on all US counties on a daily basis over the year 2020 and applying a rich panel data fixed effect model, we document that: 1) there are discernible social and demographic disparities in the spread of Covid-19. Blacks, low educated, and poorer people are at higher risks of being infected by the new disease. 2) The criteria pollutants including Ozone, CO, PM10, and PM2.5 have the potential to accelerate the outbreak of the novel coronavirus. 3) The disadvantaged population is more vulnerable to the effects of pollution on the spread of coronavirus. Specifically, the effects of pollution on confirmed cases become larger for blacks, low educated, and counties with lower average wages in 2019.",health economics,exact,100,100
medRxiv,10.1101/2021.01.07.21249366,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.07.21249366,Quarantine fatigue thins fat-tailed coronavirus impacts in U.S. cities by making epidemics inevitable,Marc N Conte; Matthew Gordon; Charles Sims; Md. Tariqul Islam Limon; Md. Al-Emran; Md. Nasir Uddin; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Fordham University; Yale University; University of Tennessee, Knoxville; Coxs Bazar Medical College and Hospital, Bangladesh.; Bangladesh Agricultural University; Bangladesh Agricultural University; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","We use detailed location data to show that contacts between individuals in most U.S. cities and counties are fat tailed, suggesting that the fat tails documented in a small number of superspreading clusters are widespread. We integrate these results into a stochastic compartmental model to show that COVID-19 cases were also fat tailed for many U.S. cities for several weeks in the spring and summer. Due to epidemiological thresholds, fat-tailed cases would have been more prevalent if not for the gradual increase in contact rates throughout the summer that made outbreaks more certain.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.06.20248960,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.20248960,Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes,Winston A. Haynes; Kathy Kamath; Carolina Lucas; John Shon; Akiko Iwasaki; Md. Nasir Uddin; Susen Burock; Merle Hrig; Julian Bernhard; Frank Tobian; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Serimmune, Inc.; Serimmune, Inc.; Yale University School of Medicine; Serimmune, Inc.; Yale University School of Medicine; Bangladesh Agricultural University; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Charit Comp; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","In 579 COVID patients samples collected between March and July of 2020, we examined the effects of non-synonymous mutations harbored by the circulating B.1.1.7 strain on linear antibody epitope signal for spike glycoprotein and nucleoprotein. At the antigen level, the mutations only substantially reduced signal in 0.5% of the population. Although some epitope mutations reduce measured signal in up to 6% of the population, these are not the dominant epitopes for their antigens. Given dominant epitope patterns observed, our data suggest that the mutations would not result in immune evasion of linear epitopes for a large majority of these COVID patients.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.06.20249091,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.20249091,"Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study.",Sergey Yegorov; Maiya Goremykina; Raifa Ivanova; Sara V Good; Dmitriy Babenko; Alexandr Shevtsov; - the COVID-19 Genomics Research Group; Kelly S. MacDonald; Yersin Zhunussov; - the Semey COVID-19 Epidemiology Research Group; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan; Department of Rheumatology and Non-Infectious Diseases, Semey Medical University, Semey, Kazakhstan; Department of Rheumatology and Non-Infectious Diseases, Semey Medical University, Semey, Kazakhstan; Department of Biology, University of Winnipeg, Winnipeg, Canada; Department of Biology, University of Winnipeg, Winnipeg, Canada; National Centre for Biotechnology, Nur-Sultan, Kazakhstan; ; Departments of Medicine, Microbiology & Immunology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada; Department of Public Health, Semey Medical University, Semey, Kazakhstan; ; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","BackgroundThe earliest coronavirus disease-2019 (COVID-19) cases in Central Asia were announced in March 2020 by Kazakhstan. Despite the implementation of aggressive measures to curb infection spread, gaps remain in the understanding of the clinical and epidemiologic features of the regional pandemic.

MethodsWe did a retrospective, observational cohort study of patients with laboratory-confirmed COVID-19 in Kazakhstan between February and April 2020. We compared demographic, clinical, laboratory and radiological data of patients with different COVID-19 severities on admission. Univariable and multivariable logistic regression was used to assess factors associated with disease severity and death. Whole-genome SARS-CoV-2 analysis was performed in 53 patients without a recent history of international travel.

FindingsOf the 1072 patients with laboratory-confirmed COVID-19 in March-April 2020, the median age was 36 years (IQR 24-50) and 484 (45%) were male. On admission, 683 (64%) participants had mild, 341 (32%) moderate, and 47 (4%) severe-to-critical COVID-19 manifestation; 20 deaths (1.87%) were reported at study exit. Multivariable regression indicated increasing odds of severe disease associated with older age (odds ratio 1.05, 95% CI 1.03-1.07, per year increase; p<0.001), the presence of comorbidities (2.13, 95% CI 1.07-4.23; p<0.031) and elevated white blood cell count (WBC, 1.14, 95% CI 1.01-1.28; p<0.032) on admission, while older age (1.09, 95% CI 1.06-1.12, per year increase; p<0.001) and male sex (5.97, 95% CI 1.95-18.32; p<0.002) were associated with increased odds of death. The Kazakhstan SARS-CoV-2 isolates grouped into seven distinct lineages O/B.4.1, S/A.2, S/B.1.1, G/B.1, GH/B.1.255, GH/B.1.3 and GR/B.1.1.10.

InterpretationOlder age, comorbidities, increased WBC count, and male sex were risk factors for COVID-19 disease severity and mortality in Kazakhstan. The broad SARS-CoV-2 diversity suggests multiple importations and community-level amplification, likely predating the declaration of state emergency. Continuous epidemiologic and genomic surveillance may be critical for a better understanding of the regional COVID-19 dynamics.",infectious diseases,exact,100,100
medRxiv,10.1101/2021.01.07.21249116,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.07.21249116,Multi-organ complement deposition in COVID-19 patients,Paolo Macor; Paolo Durigutto; Alessandro Mangogna; Rossana Bussani; Stefano D'Errico; Martina Zanon; Nicola Pozzi; Pier Luigi Meroni; Francesco Tedesco; - the Semey COVID-19 Epidemiology Research Group; Mary Gaeddert; Federica Lainati; Victor M. Corman; Terry C. Jones; Jilian A. Sacks; Joachim Seybold; Claudia M. Denkinger; Frank P. Mockenhaupt; Ian M. Kaplan; John Alsobrook; Thomas Manley; Lance Baldo; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"Department of Life Sciences, University of Trieste, Trieste, Italy; Istituto Auxologico Italiano, IRCCS, Laboratory of Immuno-Rheumatology, Milan, Italy; Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO, US; Istituto Auxologico Italiano, IRCCS, Laboratory of Immuno-Rheumatology, Milan, Italy; Istituto Auxologico Italiano, IRCCS, Laboratory of Immuno-Rheumatology, Milan, Italy; ; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Medical Dire; Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany.; Charit - Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health; Institute of; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; Adaptive Biotechnologies, Seattle, WA, USA; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","BackgroundIncreased levels of circulating complement activation products have been reported in COVID-19 patients, but only limited information is available on complement involvement at tissue level. The mechanisms and pathways of local complement activation remain unclear.

MethodsWe performed immunofluorescence analyses of autopsy specimens of lungs, kidney and liver from nine COVID-19 patients who died of acute respiratory failure. Snap-frozen samples embedded in OCT were stained with antibodies against complement components and activation products, IgG and spike protein of SARS-CoV-2.

FindingsLung deposits of C1q, C4, C3 and C5b-9 were localized in the capillaries of the interalveolar septa and on alveolar cells. IgG displayed a similar even distribution, suggesting classical pathway activation. The spike protein is a potential target of IgG, but its uneven distribution suggests that other viral and tissue molecules may be targeted by IgG. Factor B deposits were also seen in COVID-19 lungs and are consistent with activation of the alternative pathway, whereas MBL and MASP-2 were hardly detectable. Analysis of kidney and liver specimens mirrored findings observed in the lung. Complement deposits were seen on tubules and vessels of the kidney with only mild C5b-9 staining in glomeruli, and on hepatic artery and portal vein of the liver.

InterpretationComplement deposits in different organs of deceased COVID-19 patients caused by activation of the classical and alternative pathways support the multi-organ nature of the disease.

FundingGrants from the Italian Ministry of Health (COVID-2020-12371808) to PLM and National Institutes of Health HL150146 to NP are gratefully acknowledged.",allergy and immunology,exact,100,100
medRxiv,10.1101/2020.12.30.20248603,2021-01-01,https://medrxiv.org/cgi/content/short/2020.12.30.20248603,SARS-CoV-2 positivity in asymptomatic-screened dental patients,David I Conway; Shauna Culshaw; Maura Edwards; Claire Clark; Chris Watling; Chris Robertson; Raymond Braid; Emma O'Keefe; Niall McGoldrick; Jacky Burns; Stacey Provan; Harper VanSteenhouse; Jodie Hay; Rory Gunson; - Dental COVID-19 Surveillance Survey Group; Brenda Eskenazi,"University of Glasgow and Public Health Scotland; University of Glasgow; NHS Ayrshire and Arran; Public Health Scotland; Public Health Scotland; Strathclyde University and Public Health Scotland; Public Health Scotland; NHS Fife; NHS Fife; NHS Fife; NHS Greater Glasgow & Clyde; BioClavis Ltd; University of Glasgow; NHS Greater Glasgow & Clyde; ; University of California, Berkeley","Enhanced community surveillance is a key pillar of the public health response to COVID-19. Asymptomatic carriage of SARS-CoV-2 is a potentially significant source of transmission, yet remains relatively poorly understood. Disruption of dental services continues with significantly reduced capacity. Ongoing precautions include pre- and/or at appointment COVID-19 symptom screening and use of enhanced personal protective equipment (PPE). This study aimed to investigate SARS-CoV-2 infection in dental patients to inform community surveillance and improve understanding of risks in the dental setting. Thirty-one dental care centres across Scotland invited asymptomatic screened patients over 5-years-old to participate. Following verbal consent and completion of sociodemographic and symptom history questionnaire, trained dental teams took a combined oropharyngeal and nasal swab sample using standardised VTM-containing testkits. Samples were processed by the Lighthouse Lab and patients informed of their results by SMS/e-mail with appropriate self-isolation guidance in the event of a positive test. Over a 13-week period (from 3August to 31October2020) n=4,032 patients, largely representative of the population, were tested. Of these n=22 (0.5%; 95%CI 0.5%, 0.8%) tested positive for SARS-CoV-2. The positivity rate increased over the period, commensurate with uptick in community prevalence identified across all national testing monitoring data streams. All positive cases were successfully followed up by the national contact tracing program. To the best of our knowledge this is the first report of a COVID-19 testing survey in asymptomatic-screened patients presenting in a dental setting. The positivity rate in this patient group reflects the underlying prevalence in community at the time. These data are a salient reminder, particularly when community infection levels are rising, of the importance of appropriate ongoing Infection Prevention Control and PPE vigilance, which is relevant as healthcare team fatigue increases as the pandemic continues. Dental settings are a valuable location for public health surveillance.",dentistry and oral medicine,exact,100,100
medRxiv,10.1101/2020.12.25.20248859,2020-12-31,https://medrxiv.org/cgi/content/short/2020.12.25.20248859,Factors influencing intention to adhere to precautionary behavior in times of COVID- 19 pandemic in Sudan: an application of the Health Belief Model,Azzaa A Mehanna; Yasir Ahmed Mohammed Elhadi; Don Eliseo Lucero-Prisno III; Claire Clark; Chris Watling; Chris Robertson; Raymond Braid; Emma O'Keefe; Niall McGoldrick; Jacky Burns; Stacey Provan; Harper VanSteenhouse; Jodie Hay; Rory Gunson; - Dental COVID-19 Surveillance Survey Group; Brenda Eskenazi,"Health Administration and Behavioral Sciences Department, High Institute of Public Health, Alexandria University, Egypt.; Health Administration and Behavioral Sciences Department, High Institute of Public Health, Alexandria University, Egypt.; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom; Public Health Scotland; Public Health Scotland; Strathclyde University and Public Health Scotland; Public Health Scotland; NHS Fife; NHS Fife; NHS Fife; NHS Greater Glasgow & Clyde; BioClavis Ltd; University of Glasgow; NHS Greater Glasgow & Clyde; ; University of California, Berkeley","BackgroundCorona virus disease (covid-19) is an emerging highly infectious disease caused by novel corona virus (SARS-CoV-2). Several public health and social protective measures that may prevent or slow down the transmission of the COVID-19 were introduced. However, these measures are unfortunately neglected or deliberately ignored by some individuals.

ObjectiveTo identify the factors influencing intention to adhere to precautionary measures againstCOVID-19 in Sudan.

Methods and DesignCross sectional online based survey using virtual convenience sampling technique.

Variables MeasuredPerceived threat of corona virus (perceived severity and perceived susceptibility), perceived benefits, perceived barriers, self-efficacy and intention to adhere to precautionary behavior towards COVID-19

ResultsThe significant predictors of intention to adhere to the precautionary behavior against COVID-19 were: gender ({beta} =3.34, P <0.001), self-efficacy ({beta}= 0.476, P<0.001), perceived benefits ({beta}= 0.349, P<0.001) and perceived severity ({beta}= 0.113, P=0.005). These factors explained 43% of the variance in participants intention to adhere to the protective measures. Participants who were female, confident in their ability to adhere to the protective measures when available, believing in the benefits of the protective measures against COVID-19 and perceiving that the disease could have serious consequences were more likely to be willing to adhere to the protective measures.

ConclusionHealth Belief model is a useful framework for addressing factors influencing intention to adhere to precautionary behavior during COVID pandemic.",public and global health,exact,100,100
bioRxiv,10.1101/2020.12.29.424739,2020-12-30,https://biorxiv.org/cgi/content/short/2020.12.29.424739,Meta-analysis of virus-induced host gene expression reveals unique signatures of immune dysregulation induced by SARS-CoV-2,Srikeerthana Kuchi; Quan Gu; Massimo Palmarini; Sam J Wilson; David L Robertson; Chris Robertson; Raymond Braid; Emma O'Keefe; Niall McGoldrick; Jacky Burns; Stacey Provan; Harper VanSteenhouse; Jodie Hay; Rory Gunson; - Dental COVID-19 Surveillance Survey Group; Brenda Eskenazi,"University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; Strathclyde University and Public Health Scotland; Public Health Scotland; NHS Fife; NHS Fife; NHS Fife; NHS Greater Glasgow & Clyde; BioClavis Ltd; University of Glasgow; NHS Greater Glasgow & Clyde; ; University of California, Berkeley","The clinical outcome of COVID-19 has an extreme age, genetic and comorbidity bias that is thought to be driven by an impaired immune response to SARS-CoV-2, the causative agent of the disease. The unprecedented impact of COVID-19 on global health has resulted in multiple studies generating a variety of large gene expression datasets in a relatively short period of time. In order to better understand the immune dysregulation induced by SARS-CoV-2, we carried out a meta-analysis of these transcriptomics data available in the published literature. Datasets included both those available from SARS-CoV-2 infected cell lines in vitro and those from patient samples. We focused our analysis on the identification of viral perturbed host functions as captured by co-expressed gene module analysis. Transcriptomics data from lung biopsies and nasopharyngeal samples, as opposed to those available from other clinical samples and infected cell lines, provided key signatures on the role of the hosts immune response on COVID-19 pathogenesis. For example, severity of infection and patients age are linked to the absence of stimulation of the RIG-I-like receptor signaling pathway, a known critical immediate line of defense against RNA viral infections that triggers type-I interferon responses. In addition, co-expression analysis of age-stratified transcriptional data provided evidence that signatures of key immune response pathways are perturbed in older COVID-19 patients. In particular, dysregulation of antigen-presenting components, down-regulation of cell cycle mechanisms and signatures of hyper-enriched monocytes were strongly correlated with the age of older individuals infected with SARS-CoV-2. Collectively, our meta-analysis highlights the ability of transcriptomics and gene-module analysis of aggregated datasets to aid our improved understanding of the host-specific disease mechanisms underpinning COVID-19.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.12.23.424229,2020-12-25,https://biorxiv.org/cgi/content/short/2020.12.23.424229,Patterns of within-host genetic diversity in SARS-CoV-2,Gerry Tonkin-Hill; Inigo Martincorena; Roberto Amato; Andrew R J Lawson; Moritz Gerstung; Ian Johnston; David K Jackson; Naomi R Park; Stefanie V Lensing; Michael A Quail; Snia Gonalves; Cristina Ariani; Michael Spencer Chapman; William L Hamilton; Luke W Meredith; Grant Hall; Aminu S Jahun; Yasmin Chaudhry; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","Monitoring the spread of SARS-CoV-2 and reconstructing transmission chains has become a major public health focus for many governments around the world. The modest mutation rate and rapid transmission of SARS-CoV-2 prevents the reconstruction of transmission chains from consensus genome sequences, but within-host genetic diversity could theoretically help identify close contacts. Here we describe the patterns of within-host diversity in 1,181 SARS-CoV-2 samples sequenced to high depth in duplicate. 95% of samples show within-host mutations at detectable allele frequencies. Analyses of the mutational spectra revealed strong strand asymmetries suggestive of damage or RNA editing of the plus strand, rather than replication errors, dominating the accumulation of mutations during the SARS-CoV-2 pandemic. Within and between host diversity show strong purifying selection, particularly against nonsense mutations. Recurrent within-host mutations, many of which coincide with known phylogenetic homoplasies, display a spectrum and patterns of purifying selection more suggestive of mutational hotspots than recombination or convergent evolution. While allele frequencies suggest that most samples result from infection by a single lineage, we identify multiple putative examples of co-infection. Integrating these results into an epidemiological inference framework, we find that while sharing of within-host variants between samples could help the reconstruction of transmission chains, mutational hotspots and rare cases of superinfection can confound these analyses.",genomics,exact,100,100
bioRxiv,10.1101/2020.12.23.424171,2020-12-25,https://biorxiv.org/cgi/content/short/2020.12.23.424171,A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism,Anton Schmitz; Anna Weber; Mehtap Bayin; Stefan Breuers; Michael Famulok; Gunter Mayer; David K Jackson; Naomi R Park; Stefanie V Lensing; Michael A Quail; Snia Gonalves; Cristina Ariani; Michael Spencer Chapman; William L Hamilton; Luke W Meredith; Grant Hall; Aminu S Jahun; Yasmin Chaudhry; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"University of Bonn; University of Bonn; University of Bonn; University of Bonn; University of Bonn; University of Bonn; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","The receptor binding domain (RBD) of the spike glycoprotein of the coronavirus SARS-CoV-2 (CoV2-S) binds to the human angiotensin converting enzyme 2 (ACE2) representing the initial contact point for leveraging the infection cascade. We used an automated selection process and identified an aptamer that specifically interacts with CoV2-S. The aptamer does not bind to the RBD of CoV2-S and does not block the interaction of CoV2-S with ACE2. Notwithstanding, infection studies revealed potent and specific inhibition of pseudoviral infection by the aptamer. The present study opens up new vistas in developing SARS-CoV2 infection inhibitors, independent of blocking the ACE2 interaction of the virus and harnesses aptamers as potential drug candidates and tools to disentangle hitherto inaccessible infection modalities, which is of particular interest in light of the increasing number of escape mutants that are currently being reported.",biochemistry,exact,100,100
bioRxiv,10.1101/2020.12.23.424111,2020-12-25,https://biorxiv.org/cgi/content/short/2020.12.23.424111,Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L,Anneliese Ashhurst; Arthur Tang; Pavla Fajtova; Michael Yoon; Anupriya Aggarwal; Alexander Stoye; Mark Larance; Laura Beretta; Aleksandra Drelich; Danielle Skinner; Linfeng Li; Thomas Meek; James McKerrow; Vivian Hook; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"The University of Sydney; The University of Sydney; University of California, San Diego; University of California, San Diego; Kirby Institute; The University of Sydney; The University of Sydney; University of California, San Diego; University of Texas Medical Branch at Galveston; University of California, San Diego; Texas A&M University; Texas A&M University; University of California, San Diego; University of California, San Diego; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","The emergence of SARS-CoV-2 in late 2019, and the subsequent COVID-19 pandemic, has led to substantial mortality, together with mass global disruption. There is an urgent need for novel antiviral drugs for therapeutic or prophylactic application. Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is recognized as a promising drug target. The marine natural product, gallinamide A and several synthetic analogues, were identified as potent inhibitors of cathepsin L activity with IC50 values in the picomolar range. Lead molecules possessed selectivity over cathepsin B and other related human cathepsin proteases and did not exhibit inhibitory activity against viral proteases Mpro and PLpro. We demonstrate that gallinamide A and two lead analogues potently inhibit SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range, thus further highlighting the potential of cathepsin L as a COVID-19 antiviral drug target.",biochemistry,exact,100,100
bioRxiv,10.1101/2020.12.24.422670,2020-12-24,https://biorxiv.org/cgi/content/short/2020.12.24.422670,Detection and molecular characterisation of SARS-CoV-2 in farmed mink (Neovision vision) in Poland,Lukasz Rabalski; Maciej Kosinski; Teemu Smura; Kirsi Aaltonen; Ravi Kant; Tarja Sironen; Boguslaw Szewczyk; Maciej Grzybek; Aleksandra Drelich; Danielle Skinner; Linfeng Li; Thomas Meek; James McKerrow; Vivian Hook; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"University of Gdansk; University of Gdansk; University of Helsinki; University of Helsinki; University of Helsinki; Haartman Institute, University of Helsinki; University of Gdansk; Medical University of Gdansk; University of Texas Medical Branch at Galveston; University of California, San Diego; Texas A&M University; Texas A&M University; University of California, San Diego; University of California, San Diego; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","SARS-CoV-2 is the aetiological agent of COVID-19 disease and has been spreading worldwide since December 2019. The virus has been shown to infect different animal species under experimental conditions. Also, minks have been found to be susceptible to SARS-CoV-2 infection in fur farms in Europe and the USA. Here we investigated 91 individual minks from a farm located in Northern Poland. Using RT-PCR, antigen detection and NGS, we confirmed 15 animals positive for SARS-CoV-2. The result was verified by sequencing of full viral genomes, confirming SARS-CoV-2 infection in Polish mink. Country-scale monitoring conducted by veterinary inspection so far has not detected the presence of SARS-CoV-2 on other mink farms. Taking into consideration that Poland has a high level of positive diagnostic tests among its population, there is a high risk that more Polish mink farms become a source for SARS-CoV-2. Findings reported here and from other fur producing countries urge the assessment of SARS-CoV-2 prevalence in animals bred in Polish fur farms.",microbiology,exact,100,100
bioRxiv,10.1101/2020.12.24.424203,2020-12-24,https://biorxiv.org/cgi/content/short/2020.12.24.424203,Experimental SARS-CoV-2 infection of bank voles - general susceptibility but lack of direct transmission,Lorenz Ulrich; Anna Michelitsch; Nico Halwe; Kerstin Wernike; Donata Hoffmann; Martin Beer; Boguslaw Szewczyk; Maciej Grzybek; Aleksandra Drelich; Danielle Skinner; Linfeng Li; Thomas Meek; James McKerrow; Vivian Hook; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"Friedrich-Loeffler-Institut; Friedrich-Loeffler-Institut; Friedrich-Loeffler-Institut; Friedrich-Loeffler-Institut; Friedrich-Loeffler-Institut; Friedrich-Loeffler-Institut; University of Gdansk; Medical University of Gdansk; University of Texas Medical Branch at Galveston; University of California, San Diego; Texas A&M University; Texas A&M University; University of California, San Diego; University of California, San Diego; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","After experimental inoculation, SARS-CoV-2 infection was proven for bank voles by seroconversion within eight days and detection of viral RNA in nasal tissue for up to 21 days. However, transmission to contact animals was not detected. Therefore, bank voles are unlikely to establish effective SARS-CoV-2 transmission cycles in nature.

Article Summary LineBank voles show low-level viral replication and seroconversion upon infection with SARS-CoV-2, but lack transmission to contact animals.",microbiology,exact,100,100
bioRxiv,10.1101/2020.12.24.424271,2020-12-24,https://biorxiv.org/cgi/content/short/2020.12.24.424271,Real-time monitoring epidemic trends and key mutations in SARS-CoV-2 evolution by an automated tool,Binbin Xi; Dawei Jiang; Shuhua Li; Jerome R Lon; Yunmeng Bai; Shudai Lin; Meiling Hu; Yuhuan Meng; Yimo Qu; Yuting Huang; Wei Liu; Hongli Du; James McKerrow; Vivian Hook; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006; University of California, San Diego; University of California, San Diego; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","With the global epidemic of SARS-CoV-2, it is important to monitor the variation, haplotype subgroup epidemic trends and key mutations of SARS-CoV-2 over time effectively, which is of great significance to the development of new vaccines, the update of therapeutic drugs, and the improvement of detection reagents. The AutoVEM tool developed in the present study could complete all mutations detections, haplotypes classification, haplotype subgroup epidemic trends and key mutations analysis for 131,576 SARS-CoV-2 genome sequences in 18 hours on a 1 core CPU and 2G internal storage computer. Through haplotype subgroup epidemic trends analysis of 131,576 genome sequences, the great significance of the previous 4 specific sites (C241T, C3037T, C14408T and A23403G) was further revealed, and 6 new mutation sites of highly linked (T445C, C6286T, C22227T, G25563T, C26801G and G29645T) were discovered for the first time that might be related to the infectivity, pathogenicity or host adaptability of SARS-CoV-2. In brief, we proposed an integrative method and developed an efficient automated tool to monitor haplotype subgroup epidemic trends and screen out the key mutations in the evolution of SARS-CoV-2 over time for the first time, and all data could be updated quickly to track the prevalence of previous key mutations and new key mutations because of high efficiency of the tool. In addition, the idea of combinatorial analysis in the present study can also provide a reference for the mutation monitoring of other viruses.",genomics,exact,100,100
bioRxiv,10.1101/2020.12.23.424254,2020-12-24,https://biorxiv.org/cgi/content/short/2020.12.23.424254,Cell-type apoptosis in lung during SARS-CoV-2 infection,Yakun Liu; Tania M. Garron; Qing Chang; Zhengchen Su; Changcheng Zhou; Eric C. Gong; Junying Zheng; Whitney Yin; Thomas Ksiazek; Trevor Brasel; Yang Jin; Paul Boor; Jason Edward Comer; Bin Gong; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"University of Texas Medical Branch at Galveston; University of Texas Medical Branch at Galveston; University of Texas Medical Branch at Galveston; University of Texas Medical Branch at Galveston; University of Texas Medical Branch at Galveston; University of Texas Medical Branch at Galveston; The University of Texas Medical Branch; University of Texas Medical Branch, Galveston; University of Texas Medical Branch at Galveston; University of Texas Medical Branch; Boston University Medical Campus; University of Texas Medical Branch; UTMB; University of Texas Medical Branch; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","The SARS-CoV-2 pandemic has inspired renewed interest in understanding the fundamental pathology of acute respiratory distress syndrome (ARDS) following infection because fatal COVID-19 cases are commonly linked to respiratory failure due to ARDS. The pathologic alteration known as diffuse alveolar damage in endothelial and epithelial cells is a critical feature of acute lung injury in ARDS. However, the pathogenesis of ARDS following SRAS-CoV-2 infection remains largely unknown.

In the present study, we examined apoptosis in post-mortem lung sections from COVID-19 patients and lung tissues from a non-human primate model of SARS-CoV-2 infection, in a cell-type manner, including type 1 and 2 alveolar cells and vascular endothelial cells (ECs), macrophages, and T cells. Multiple-target immunofluorescence (IF) assays and western blotting suggest both intrinsic and extrinsic apoptotic pathways are activated during SARS-CoV-2 infection. Furthermore, we observed that SARS-CoV-2 fails to induce apoptosis in human bronchial epithelial cells (i.e., BEAS2B cells) and primary human umbilical vein endothelial cells (HUVECs), which are refractory to SARS-CoV-2 infection. However, infection of co-cultured Vero cells and HUVECs or Vero cells and BEAS2B cells with SARS-CoV-2 induced apoptosis in both Vero cells and HUVECs/BEAS2B cells, but did not alter the permissiveness of HUVECs or BEAS2B cells to the virus. Post-exposure treatment of the co-culture of Vero cells and HUVECs with an EPAC1-specific activator ameliorated apoptosis in HUVECs. These findings may help to delineate a novel insight into the pathogenesis of ARDS following SARS-CoV-2 infection.",pathology,exact,100,100
bioRxiv,10.1101/2020.12.23.424189,2020-12-24,https://biorxiv.org/cgi/content/short/2020.12.23.424189,Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro,Finny S. Varghese; Esther van Woudenbergh; Gijs J. Overheul; Marc J. Eleveld; Lisa Kurver; Niels van Heerbeek; Arjan van Laarhoven; Pascal Miesen; Gerco den Hartog; Marien I. de Jonge; Ronald P. van Rij; Paul Boor; Jason Edward Comer; Bin Gong; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Section Paediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijm; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Otolaryngology, Head and Neck Surgery, Radboudumc, Nijmegen, The Netherlands; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Section Paediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijm; Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; University of Texas Medical Branch; UTMB; University of Texas Medical Branch; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a new human pathogen in late 2019 and has infected an estimated 10% of the global population in less than a year. There is a clear need for effective antiviral drugs to complement current preventive measures including vaccines. In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2. Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations. Time-of-addition studies indicated that berberine acts on the late stage of the viral life cycle. In agreement, berberine mildly affected viral RNA synthesis, but strongly reduced infectious viral titers, leading to an increase in the particle-to-pfu ratio. In contrast, obatoclax acted at the early stage of the infection, in line with its activity to neutralize the acidic environment in endosomes. We assessed infection of primary human nasal epithelial cells cultured on an air-liquid interface and found that SARS-CoV-2 infection induced and repressed expression of a specific set of cytokines and chemokines. Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells. We propose berberine and obatoclax as potential antiviral drugs against SARS-CoV-2 that could be considered for further efficacy testing.",microbiology,exact,100,100
bioRxiv,10.1101/2020.12.23.424199,2020-12-24,https://biorxiv.org/cgi/content/short/2020.12.23.424199,Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods,Christophe Dumet; Yann Jullian; Astrid Musnier; Philippe Rivire; Nicolas Poirier; Herv Watier; Thomas Bourquard; Anne Poupon; Gerco den Hartog; Marien I. de Jonge; Ronald P. van Rij; Paul Boor; Jason Edward Comer; Bin Gong; Chien-Te Tseng; Stuart Grant Turville; William Gerwick; Richard J Payne; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"MAbSilico; MAbSilico; MAbSilico; Visionscarto; OSE Immunotherapeutics; Universit de Tours; MAbSilico; MAbSilico; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Section Paediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijm; Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; University of Texas Medical Branch; UTMB; University of Texas Medical Branch; University of Texas Medical Branch; Kirby Institute; University of California, San Diego; The University of Sydney; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","Since the beginning of the COVID19 pandemics, an unprecedented research effort has been conducted to analyze the antibody responses in patients, and many trials based on passive immunotherapy -- notably monoclonal antibodies -- are ongoing. Twenty-one antibodies have entered clinical trials, 6 having reached phase 2/3, phase 3 or having received emergency authorization. These represent only the tip of the iceberg, since many more antibodies have been discovered and represent opportunities either for diagnosis purposes or as drug candidates. The main problem facing laboratories willing to develop such antibodies is the huge task of analyzing them and choosing the best candidate for exhaustive experimental validation. In this work we show how artificial intelligence-based methods can help in analyzing large sets of antibodies in order to determine in a few hours the best candidates in few hours. The MAbCluster method, which only requires knowledge of the amino acid sequences of the antibodies, allows to group the antibodies having the same epitope, considering only their amino acid sequences and their 3D structures (actual or predicted), and to infer some of their functional properties. We then use MAbTope to predict the epitopes for all antibodies for which they are not already known. This allows an exhaustive comparison of the available epitopes, but also gives a synthetic view of the possible combinations. Finally, we show how these results can be used to predict which antibodies might be affected by the different mutations arising in the circulating strains of the virus, such as the N501Y mutation that has started to spread in Great-Britain.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.12.22.20248691,2020-12-24,https://medrxiv.org/cgi/content/short/2020.12.22.20248691,Automated processing of thermal imaging to detect COVID-19,Rafael Y. Brzezinski; Neta Rabin; Nir Lewis; Racheli Peled; Ariel Kerpel; Avishai M. Tsur; Omer Gendelman; Nili Naftali-Shani; Irina Gringauz; Howard Amital; Avshalom Leibowitz; Haim Mayan; Ilan Ben-Zvi; Eyal Heler; Liran Shechtman; Ori Rogovski; Shani Shenhar-Tsarfaty; Eli Konen; Edith M. Marom; Avinoah Ironi; Galia Rahav; Yair Zimmer; Ehud Grossman; Zehava Ovadia-Blechman; Jonathan Leor; Oshrit Hoffer; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"Sheba Medical Center and Tel Aviv University; Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Tel Aviv Sourasky Medical Center and Tel Aviv University; Tel Aviv Sourasky Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Afeka Tel Aviv Academic College of Engineering; Sheba Medical Center and Tel Aviv University; Afeka Tel Aviv Academic College of Engineering; Sheba Medical Center and Tel Aviv University; Afeka Tel Aviv Academic College of Engineering; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","Rapid and sensitive screening tools for SARS-CoV-2 infection are essential to limit the spread of COVID-19 and to properly allocate national resources. Here, we developed a new point-of-care, non-contact thermal imaging tool to detect COVID-19, based on image-processing algorithms and machine learning analysis. We captured thermal images of the back of individuals with and without COVID-19 using a portable thermal camera that connects directly to smartphones. Our novel image processing algorithms automatically extracted multiple texture and shape features of the thermal images and achieved an area under the curve (AUC) of 0.85 in detecting COVID-19 with up to 92% sensitivity. Thermal imaging scores were inversely correlated with clinical variables associated with COVID-19 disease progression. We show, for the first time, that a hand-held thermal imaging device can be used to detect COVID-19. Non-invasive thermal imaging could be used to screen for COVID-19 in out-of-hospital settings, especially in low-income regions with limited imaging resources.

HIGHLIGHTSO_LIAutomated processing of thermal images of the back can be used to detect COVID-19 with up to 92% sensitivity.
C_LIO_LIThe extracted texture features of the thermal image are associated with COVID-19 disease progression and lung injury.
C_LIO_LIA portable thermal camera that connects directly to smartphones can be used to detect COVID-19.
C_LIO_LINon-invasive thermal imaging could be used to screen for COVID-19 in out-of-hospital settings and regions with limited imaging resources.
C_LI

GRAPHICAL ABSTRACT

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=68 SRC=""FIGDIR/small/20248691v2_ufig1.gif"" ALT=""Figure 1"">
View larger version (15K):
org.highwire.dtl.DTLVardef@13f95fborg.highwire.dtl.DTLVardef@18f9b9corg.highwire.dtl.DTLVardef@1313936org.highwire.dtl.DTLVardef@a31525_HPS_FORMAT_FIGEXP  M_FIG C_FIG",radiology and imaging,exact,100,100
medRxiv,10.1101/2020.12.22.20248501,2020-12-24,https://medrxiv.org/cgi/content/short/2020.12.22.20248501,Prevalence of bacterial pathogens and potential role in COVID-19 severity in patients admitted to intensive care units in Brazil,Fabiola Marques Carvalho; Leandro Nascimento Lemos; Luciane Prioli Ciapina; Rennan Garcias Moreira; Alexandra Gerber; Ana Paula Guimaraes; Tatiani Fereguetti; Virginia Antunes de Andrade Zambelli; Renata Avila; Tailah Bernardo de Almeida; Jheimson Silva Lima; Shana Priscila Coutinho Barroso; Mauro Martins Teixeira; Renan Pedra Souza; Cynthia Chester Cardoso; Renato Santana Aguiar; Ana Tereza Ribeiro Vasconcelos; Eli Konen; Edith M. Marom; Avinoah Ironi; Galia Rahav; Yair Zimmer; Ehud Grossman; Zehava Ovadia-Blechman; Jonathan Leor; Oshrit Hoffer; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"Laboratorio Nacional de Computacao Cientifica; Laboratorio Nacional de Computacao Cientifica; Laboratorio Nacional de Computacao Cientifica; Universidade Federal de Minas Gerais; Laboratorio Nacional de Computacao Cientifica; Laboratorio Nacional de Computacao Cientifica; Hospital Eduardo de Menezes; Hospital Eduardo de Menezes; Hospital Eduardo de Menezes; Instituto de Estudos do mar Almirante Paulo Moreira; Hospital Naval Marcilio Dias; Hospital Naval Marcilio Dias; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal do Rio de Janeiro; Universidade Federal de Minas Gerais; Laboratorio Nacional de Computacao Cientifica; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Sheba Medical Center and Tel Aviv University; Afeka Tel Aviv Academic College of Engineering; Sheba Medical Center and Tel Aviv University; Afeka Tel Aviv Academic College of Engineering; Sheba Medical Center and Tel Aviv University; Afeka Tel Aviv Academic College of Engineering; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","Secondary bacterial and fungal infections are associated with respiratory viral infections and invasive mechanical ventilation. In Coronavirus disease 2019 (COVID-19), lung injury by SARS-CoV-2 and impaired immune response can provide a favorable environment for microorganism growth and colonization in hospitalized individuals. Recent studies suggest that secondary bacterial pneumonia is a risk factor associated with COVID-19. In Brazil, knowledge about microbiota present in COVID-19 patients is incipient. This work describes the microbiota of 21 COVID-19 patients admitted to intensive care units from two Brazilian centers. We identified respiratory, nosocomial and bacterial pathogens as prevalent microorganisms. Other bacterial opportunistic and commensal species are also represented. Virulence factors of these pathogenic species, metabolic pathways used to evade and modulate immunological processes and the interconnection between bacterial presence and virulence in COVID-19 progression are discussed.

Article Summary LineWe identified respiratory, nosocomial and bacterial pathogens as prevalent microorganisms in 21 Brazilian COVID-19 patients admitted to Intensive Care Units. Pathogen virulence factors and immune response evasion metabolic pathways are correlated to COVID-19 severity.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.12.18.20248477,2020-12-20,https://medrxiv.org/cgi/content/short/2020.12.18.20248477,Face covering adherence is positively associated with better mental health and wellbeing: a longitudinal analysis of the CovidLife surveys,Drew M Altschul; Chloe Fawns-Ritchie; Alex Kwong; Louise Hartley; Clifford Nangle; Rachel Edwards; Rebecca Dawson; Christie Levein; Archie Campbell; Robin Flaig; Andrew McIntosh; Ian Deary; Riccardo Marioni; Caroline Hayward; Cathie Sudlow; Elaine Douglas; David Bell; David Porteous; Dhwani Batra; Jan Pohl; Justin Lee; Shivaprakash Gangappa; Suryaprakash Sambhara; Michelle Gadush; Nianshuang Wang; Maria D Person; Brent L Iverson; Jimmy D Gollihar; John Dye; Andrew Herbert; Ralph S Baric; Jason S McLellan; George Georgiou; Jason J Lavinder; Gregory C Ippolito; Fergus Gleeson; Yper Hall; Simon G. P. Funnell; Sally Sharpe; Francisco Javier Salguero; Andrew R Gorringe; Miles Carroll,"The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; University of Stirling; University of Stirling; The University of Edinburgh; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; U.S. Army Medical Research Institute of Infectious Diseases; U.S. Army Medical Research Institute of Infectious Diseases; University of North Carolina at Chapel Hill; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; Oxford Departments of Radiology and Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust.; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down","Face masks or coverings are effective at reducing airborne infection rates, yet pandemic mitigation measures, including wearing face coverings, have been suggested to contribute to reductions in quality of life and poorer mental health. Longitudinal analyses of more than 11,000 participants across the UK found no association between lower adherence to face covering guidelines and poorer mental health. The opposite appears to be true. Even after controlling for behavioral, social, and psychological confounds, including measures of pre-pandemic mental health, individuals who wore face coverings ""most of the time"" or ""always"" had better mental health and wellbeing than those who did not. These results suggest that wearing face coverings more often will not negatively impact mental health.",psychiatry and clinical psychology,exact,100,100
bioRxiv,10.1101/2020.12.19.423592,2020-12-20,https://biorxiv.org/cgi/content/short/2020.12.19.423592,The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to Type I IFN and IFITM2,Drew M Altschul; Chloe Fawns-Ritchie; Alex Kwong; Louise Hartley; Clifford Nangle; Rachel Edwards; Rebecca Dawson; Christie Levein; Archie Campbell; Robin Flaig; Andrew McIntosh; Ian Deary; Riccardo Marioni; Caroline Hayward; Cathie Sudlow; Elaine Douglas; David Bell; David Porteous; Dhwani Batra; Jan Pohl; Justin Lee; Shivaprakash Gangappa; Suryaprakash Sambhara; Michelle Gadush; Nianshuang Wang; Maria D Person; Brent L Iverson; Jimmy D Gollihar; John Dye; Andrew Herbert; Ralph S Baric; Jason S McLellan; George Georgiou; Jason J Lavinder; Gregory C Ippolito; Fergus Gleeson; Yper Hall; Simon G. P. Funnell; Sally Sharpe; Francisco Javier Salguero; Andrew R Gorringe; Miles Carroll,"The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; University of Stirling; University of Stirling; The University of Edinburgh; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; U.S. Army Medical Research Institute of Infectious Diseases; U.S. Army Medical Research Institute of Infectious Diseases; University of North Carolina at Chapel Hill; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; Oxford Departments of Radiology and Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust.; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down; Public Health England, Porton Down","The cellular entry of severe acute respiratory syndrome-associated coronaviruses types 1 and 2 (SARS-CoV-1 and -2) requires sequential protease processing of the viral spike glycoprotein (S). The presence of a polybasic cleavage site in SARS-CoV-2 S at the S1/S2 boundary has been suggested to be a factor in the increased transmissibility of SARS-CoV-2 compared to SARS-CoV-1 by facilitating maturation of the S precursor by furin-like proteases in the producer cells rather than endosomal cathepsins in the target. We investigate the relevance of the polybasic cleavage site in the route of entry of SARS-CoV-2 and the consequences this has for sensitivity to interferons, and more specifically, the IFN-induced transmembrane (IFITM) protein family that inhibit entry of diverse enveloped viruses. We found that SARS-CoV-2 is restricted predominantly by IFITM2 and the degree of this restriction is governed by route of viral entry. Removal of the cleavage site in the spike protein renders SARS-CoV-2 entry highly pH- and cathepsin-dependent in late endosomes where, like SARS-CoV-1 S, it is more sensitive to IFITM2 restriction. Furthermore, we find that potent inhibition of SARS-CoV-2 replication by type I but not type II IFNs is alleviated by targeted depletion of IFITM2 expression. We propose that the polybasic cleavage site allows SARS-CoV-2 to mediate viral entry in a pH-independent manner, in part to mitigate against IFITM-mediated restriction and promote replication and transmission. This suggests therapeutic strategies that target furin-mediated cleavage of SARS-CoV-2 S may reduce viral replication through the activity of type I IFNs.

IMPORTANCEThe furin cleavage site in the S protein is a distinguishing feature of SARS-CoV-2 and has been proposed to be a determinant for the higher transmissibility between individuals compared to SARS-CoV-1. One explanation for this is that it permits more efficient activation of fusion at or near the cell surface rather than requiring processing in the endosome of the target cell. Here we show that SARS-CoV-2 is inhibited by antiviral membrane protein IFITM2, and that the sensitivity is exacerbated by deletion of the furin cleavage site which restricts viral entry to low pH compartments. Furthermore, we find that IFITM2 is a significant effector of the antiviral activity of type I interferons against SARS-CoV-2 replication. We suggest one role of the furin cleavage site is to reduce SARS-CoV-2 sensitivity to innate immune restriction, and thus may represent a potential therapeutic target for COVID-19 treatment development.",immunology,exact,100,100
medRxiv,10.1101/2020.12.15.20248244,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.15.20248244,REACT-1 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-CoV-2 infection during the second national COVID-19 lockdown in England,Steven Riley; Caroline E. Walters; Haowei Wang; Oliver Eales; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Liana F. Lareau; Jennifer A. Doudna; David F. Savage; Patrick D. Hsu; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Department of Bioengineering, University of California, Berkeley, CA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California, Berkeley, California, USA; Department of Bioengineering, University of California, Berkeley, CA; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital","BackgroundEngland exited a four-week second national lockdown on 2nd December 2020 initiated in response to the COVID-19 pandemic. Prior results showed that prevalence dropped during the first half of lockdown, with greater reductions in higher-prevalence northern regions.

MethodsREACT-1 is a series of community surveys of SARS-CoV-2 RT-PCR swab-positivity in England, designed to monitor the spread of the epidemic and thus increase situational awareness. Round 7 of REACT-1 commenced swab-collection on 13th November 2020. A prior interim report included data from 13th to 24th November 2020 for 105,122 participants. Here, we report data for the entire round with swab results obtained up to 3rd December 2020.

ResultsBetween 13th November and 3rd December (round 7) there were 1,299 positive swabs out of 168,181 giving a weighted prevalence of 0.94% (95% CI 0.87%, 1.01%) or 94 per 10,000 people infected in the community in England. This compares with a prevalence of 1.30% (1.21%, 1.39%) from 16th October to 2nd November 2020 (round 6), a decline of 28%. Prevalence during the latter half of round 7 was 0.91% (95% CI, 0.81%, 1.03%) compared with 0.96% (0.87%, 1.05%) in the first half. The national R number in round 7 was estimated at 0.96 (0.88, 1.03) with a decline in prevalence observed during the first half of this period no longer apparent during the second half at the end of lockdown. During round 7 there was a marked fall in prevalence in West Midlands, a levelling off in some regions and a rise in London. R numbers at regional level ranged from 0.60 (0.41, 0.80) in West Midlands up to 1.27 (1.04, 1.54) in London, where prevalence was highest in the east and south-east of the city. Nationally, between 13th November and 3rd December, the highest prevalence was in school-aged children especially at ages 13-17 years at 2.04% (1.69%, 2.46%), or approximately 1 in 50.

ConclusionBetween the previous round and round 7 (during lockdown), there was a fall in prevalence of SARS-CoV-2 swab-positivity nationally, but it did not fall uniformly over time or by geography. Continued vigilance is required to reduce rates of infection until effective immunity at the population level can be achieved through the vaccination programme.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.15.20248173,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.15.20248173,The Covid-19 containment effects of public health measures - A spatial difference-in-differences approach,Reinhold Kosfeld; Timo Mitze; Johannes Rode; Klaus Waelde; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Liana F. Lareau; Jennifer A. Doudna; David F. Savage; Patrick D. Hsu; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,"University of Kassel; Southern University of Denkmark; Technical University of Darmstadt; Johannes Gutenberg University Mainz; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Department of Bioengineering, University of California, Berkeley, CA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California, Berkeley, California, USA; Department of Bioengineering, University of California, Berkeley, CA; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital","Since mid-March 2020 the Federal and state governments in Germany agreed on comprehensive public health measures to contain the spread of Covid-19. We study the effects of the policy actions on the progression of the pandemic in the first containment period in spring 2020 before easing of measures have started to work by the end of April. To exploit both the time and spatial dimension in the dissemination of the virus, we conduct a spatial data panel analysis for German NUTS-3 regions. Specifically, we employ a spatial difference-in-differences approach to identify the effects of individual public health measures. We find that contact restrictions and closure of schools substantially contributed to flattening the infection curve. Additionally, a strong treatment effect of wearing face masks is established in the few treated regions during the containment phase. No incremental effect is evidenced for closure of establishments and shutdown of shopping malls and other stores. These findings prove to be highly robust to changes in model specification. By contrast, the dampening effect of restaurant closure is sensitive to model variation.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.14.20248203,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.14.20248203,Socioeconomic inequalities associated with mortality for COVID-19 in Colombia: A cohort nation-wide study,Myriam Patricia Cifuentes; Laura Andrea Rodriguez-Villamizar; Maylen Liseth Rojas-Botero; Carlos Arturo Alvarez-Moreno; Julian Alfredo Fernandez-Nino; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Liana F. Lareau; Jennifer A. Doudna; David F. Savage; Patrick D. Hsu; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,"Ministry of Health and Social Protection of Colombia; Universidad Industrial de Santander; Ministry of Health and Social Protection of Colombia; Universidad Nacional de Colombia; Ministry of Health and Social Protection of Colombia; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Department of Bioengineering, University of California, Berkeley, CA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California, Berkeley, California, USA; Department of Bioengineering, University of California, Berkeley, CA; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital","BackgroundAfter eight months of the COVID-19 pandemic, Latin American countries have some of the highest rates in COVID-19 mortality. Despite being one of the most unequal regions of the world, there is a scarce report of the effect of socioeconomic conditions on COVID-19 mortality in their countries. We aimed to identify the effect of some socioeconomic inequality-related factors on COVID-19 mortality in Colombia.

MethodsWe conducted a survival analysis in a nation-wide retrospective cohort study of confirmed cases of COVID-19 in Colombia from March 2nd to October 26th, 2020. We calculated the time to death or recovery for each confirmed case in the cohort. We used an extended multivariable time-dependent Cox regression model to estimate the hazard risk ratio (HR) by age groups, sex, ethnicity, type of health insurance, area of residence, and socioeconomic strata.

ResultsThere were 1 033 218 confirmed cases and 30 565 deaths for COVID-19 in Colombia between March 2nd and October 26th. The risk of dying for COVID-19 among confirmed cases was higher in males (HR=1.68 95% CI: 1.64-1.72), in people older than 60 years (HR=296.58 95% CI: 199.22-441.51), in indigenous people (HR=1.20 95% CI: 1.08-1.33), in people with subsidized health insurance regime (HR=1.89 95% CI: 1.83-1.96), and in people living in the very low socioeconomic strata (HR=1.44 95% CI: 1.24-1.68).

ConclusionOur study provides evidence of socioeconomic inequalities in COVID-19 mortality in terms of age groups, sex, ethnicity, type of health insurance regime, and socioeconomic status.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.15.20248271,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.15.20248271,Social distancing and preventive practices of government employees in response to COVID-19 in Ethiopia,Wakgari Deressa; Alemayehu Worku; Workeabeba Abebe; Sefonias Getachew; Wondwosson Amogne; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Liana F. Lareau; Jennifer A. Doudna; David F. Savage; Patrick D. Hsu; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,"Department of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Department of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Department of Pediatrics and Child Health, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Department of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Department of Bioengineering, University of California, Berkeley, CA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California, Berkeley, California, USA; Department of Bioengineering, University of California, Berkeley, CA; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital","BackgroundPublic health measures are critical to mitigate the spread of the novel coronavirus disease 2019 (COVID-19) pandemic. Ethiopia has implemented a variety of essential public health measures in response to the spread of the virus. This study aimed to assess social distancing and preventive practices of government employees in response to COVID-19.

MethodsA cross-sectional study was conducted among 1573 government employees selected from 46 public institutions (16 National, 18 from Addis Ababa City Administration, and 12 from Oromia Regional State) located in Addis Ababa. Data were collected from 8th to 19th June 2020 using a paper-based self-administered questionnaire and analyzed using SPSS version 23.0. ANOVA and t-tests were applied to assess the difference between groups. Bivariate and multivariable logistic regression analyses were used to identify factors associated with outcome variables.

ResultsThe majority of the participants reported wearing of facemask (96%), avoiding close contact with people including handshaking (94.5%), frequent had washing (94.1%), maintaining physical distancing (89.5%), avoiding mass gatherings (88.1%), and restricting movement and travelling (84.1%). More than 80% of the participants perceived that consistently wearing a facemask is highly effective in preventing the transmission of coronavirus. Participants from Oromia reported statistically significantly lower odds of perceived effectiveness of facemask in preventing coronavirus infection (adjusted OR=0.27, 95% CI:0.17-0.45). About 19% of the respondents reported that they had ever tested for COVID-19. Participants within the age groups of 18-29 were more likely to test for coronavirus than the older age groups. Whilst, respondents from Oromia were less likely to test for coronavirus than those from national level (adjusted OR=0.31, 95% CI:0.16-0.60). About one-third (31.3%) of the respondents strongly agreed that the policy responses that the Government had taken to contain the spread of coronavirus were reasonable, and 38.5% agreed with the policy responses.

ConclusionsThe findings showed higher social distancing and preventive practices among the government employees in response to COVID-19. People should properly apply social distancing measures, wearing facemasks, and washing hands frequently with water and soap as a comprehensive package of SARS-CoV-2 prevention and control strategies. Rules and regulations imposed by the Government should be properly enforced in order to control the pandemic.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.14.20245266,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.14.20245266,Efficacy and Safety of Indomethacin in Covid -19 patients,Rajan Ravichandran; Prassana Purna; Sivakumar Vijayaragavan; Ravi Teja Kalavakollu; Shilpa Gaidhane; Ramarathnam Krishna Kumar; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Liana F. Lareau; Jennifer A. Doudna; David F. Savage; Patrick D. Hsu; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,"Department of Nephrology, MIOT International, Chennai; Department of Pulmonology, Narayana Medical College, Nellore, Andhra Pradesh, India; Narayana Translational Research Centre, Narayana Medical College, Nellore, Andhra Pradesh, India; Department of Pulmonology, Narayana Medical College, Nellore, Andhra Pradesh, India; Department of Medicine, Datta Meghe Institute of Medical Science, Wardha, Maharashtra, India; Department of Engineering Design, Indian Institute of Technology Madras, Chennai, India; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Department of Bioengineering, University of California, Berkeley, CA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California, Berkeley, California, USA; Department of Bioengineering, University of California, Berkeley, CA; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital","BackgroundIndomethacin, a well-known non-steroidal anti-inflammatory drug (NSAID), has in addition broad spectrum anti-viral activity in the laboratory including on SARS-Cov-2 virus. This trial is to observe the likelihood of efficacy and safety of Indomethacin in treating RT-PCR positive Covid patients

Materials and MethodsThe study was done in two groups. In the first group of the study, where mild and moderate patients were involved, Propensity Score Matching was used as a methodology to compare Indomethacin and paracetamol based treatments in addition to the standard protocol for treating covid-19 patients.. Blood chemistry was collected before and after the treatment. The patients were monitored every day for clinical parameters. In this part, a patient developing hypoxia was the end point. In the second group, severe patients admitted with hypoxia were treated with Indomethacin in addition to Remdesivir, and the end point was the requirement of mechanical ventilation/admission to ICU.

ResultsIt was observed that patients treated with Indomethacin had a reduction in the number of days to become afebrile, reduction in cough and myalgia by half compared to the paracetamol set. Only one out of 72 patients in the Indomethacin arm of the first group required supplementary oxygen while 28 of the 72 patients required supplementary oxygen in the paracetamol arm. No one in the second group deteriorated enough to require mechanical ventilation. There wea no evidence of adverse reaction to indomethacin or deterioration of renal or liver function.

ConclusionIndomethacin, along with standard care, seems to provide faster symptomatic relief and prevent progression of pneumonia in Covid-19 patients. It should be considered to replace paracetamol when there is no contraindication for its use.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.14.20248184,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.14.20248184,Uncertainty reduction in logistic regressions: a COVID-19 case-study using surrogate locations' asymptotic values,Bruno Hebling Vieira; Nathalia Hanna Hiar; George Cunha Cardoso; Ravi Teja Kalavakollu; Shilpa Gaidhane; Ramarathnam Krishna Kumar; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Liana F. Lareau; Jennifer A. Doudna; David F. Savage; Patrick D. Hsu; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,"Department of Physics, FFCLRP, University of S&atildeo Paulo; Department of Biology, FFCLRP, University of S&atildeo Paulo; Department of Physics, FFCLRP, University of S&atildeo Paulo; Department of Pulmonology, Narayana Medical College, Nellore, Andhra Pradesh, India; Department of Medicine, Datta Meghe Institute of Medical Science, Wardha, Maharashtra, India; Department of Engineering Design, Indian Institute of Technology Madras, Chennai, India; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Department of Bioengineering, University of California, Berkeley, CA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California, Berkeley, California, USA; Department of Bioengineering, University of California, Berkeley, CA; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital","Logistic regressions are subject to high uncertainty when the data are not past the inflection point. For example, for logistic regressions estimated with data up to or before inflection point, uncertainties in the upper asymptotic value K can be of the same order of magnitude of the population under analysis. This paper presents a method for uncertainty reduction in logistic regression using data from a surrogate logistic process. We illustrate the procedure using the Richards growth function (Generalized Logistic Function) to make predictions for COVID-19 evolution in Brazilian cities at stages before and during their epidemic inflection points. We constrain the logistic function regression with K calculated from selected surrogate international cities where the epidemic is clearly past its inflection point. Information gained with this constraint stabilizes the logistic regression, reducing the uncertainty in the curves parameters, including the rate of growth at the inflection point. The uncertainty is reduced even when the actual surrogate K is used just as an anchor to simulate different epidemic scenarios. Results predicted for COVID-19 trajectories within Brazil agree with actual data. These results suggest that in the absence of big data, a simple logistic regression may provide low uncertainty if surrogate cities have been identified for estimates of K, even if the specifics of the evolution in the surrogate cities are different. The method may be used for other logistic models and for other logistic processes in other areas such as economics and biology, if surrogate processes can be identified.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.10.20247155,2020-12-14,https://medrxiv.org/cgi/content/short/2020.12.10.20247155,Self-harm presentations to Emergency Departments and Place of Safety during the first wave of the UK COVID-19 pandemic: South London and Maudsley data on service use from February to June 2020.,Eleanor Nuzum; Evangelia Martin; Gemma Morgan; Rina Dutta; Christoph Mueller; Catherine Polling; Megan Pritchard; Sumithra Velupillai; Robert Stewart,South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London,"The lockdown and social distancing policy imposed due to the COVID-19 pandemic has had a substantial impact on both mental health service delivery, and the ways in which people are accessing these services. Previous reports from the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for around 1.2m residents in South London) have highlighted increased use of virtual contacts by mental health teams, with dropping numbers of face-to-face contacts over the first wave of the pandemic. There has been concern that the impact of the COVID-19 pandemic would lead to higher mental health emergencies, particularly instances of self-harm. However, with people advised to stay at home during the  first wave lockdown, it is as yet unclear whether this impacted mental health service presentations. Taking advantage of SLaMs Clinical Records Interactive Search (CRIS) data resource with daily updates of information from its electronic mental health records, this paper describes overall presentations to Emergency Department (ED) mental health liaison teams, and those with self-harm. The paper focussed on three periods: i) a pre-lockdown period 1st February to 15th March, ii) a lockdown period 16th March to 10th May and iii) a post-lockdown period 11th May to 28th June. In summary, all attendances to EDs for mental health support decreased during the lockdown period, including those with self-harm. All types of self-harm decreased during lockdown, with self-poisoning remaining the most common. Attendances to EDs for mental health support increased post-lockdown, although were only just approaching pre-lockdown levels by the end of June 2020.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.12.07.20245183,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.07.20245183,"Indicators of COVID-19 status in a cohort study of university staff and post-graduate research students, including results from home antibody testing",Katrina A S Davis; Ewan Carr; Daniel Leightley; Valentina Vitiello; Gabriella Bergin Cartwright; Grace Lavelle; Alice Wickersham; Michael H Malim; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"KCL Institute of Psychiatry, Psychology and Neuroscience; KCL Institute of Psychiatry Psychology and Neuroscience; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","BackgroundCohort studies of people with a history of COVID-19 infection and controls will be essential to understand the epidemiology of long-term effects. However, clinical diagnosis requires resources that are frequently restricted to the severely ill. Cohort studies may have to rely on surrogate indicators of COVID-19 illness. We describe the prevalence and overlap of five potential indicators: self-reported suspicion, self-reported core symptoms, symptom algorithm, self-reported routine test results, and home antibody testing.

MethodsAn occupational cohort of staff and postgraduate students at a large London university who participated in surveys and antibody testing. Self-report items cover March to June 2020 and antibody test results from  lateral flow IgG/IgM antibody test cassettes sent to participants in June 2020.

ResultsValid antibody test results were returned for 1882 participants. Of the COVID-19 indicators, the highest prevalence was core symptoms (770 participants positive, 41%), followed by participant suspicion of infection (n=509, 27%), a symptom algorithm (n=297, 16%), study antibody positive test (n=124, 6.6%) and self-report of a positive external test (n=39, 2.1%). Study antibody positive result was rare in people who had no suspicion they had experienced COVID-19 (n=4, 0.7%) or did not experience core symptoms (n=10, 1.6%). When study antibody test results were compared with earlier external antibody results in those who had reported them, the study antibody results agreed in 88% cases (kappa= 0.636), with a lower proportion testing positive on this occasion (proportion with antibodies detected 15% in study test vs 24% in external testing).

DiscussionOur results demonstrate that there is some agreement between different COVID indicators, but that they a more complete story when used together. Antibody testing may provide greater certainty and be one of the only ways to detect asymptomatic cases, but is likely to under-ascertain due to weak antibody responses to mild infection, which wane over time. Cohort studies will need to review how they deal with different and sometimes conflicting indicators of COVID-19 illness in order to study the long-term outcomes of COVID-19 infection and related impacts.

What is already known on this subject?Research into the effects of COVID-19 in the community is needed to respond to the pandemic. Objective testing has not been widely available and accuracy may not be high when carried out in retrospect. Many cohort studies are considering how best to measure COVID-19 infection status.

What this study adds?Antibody testing is feasible, but it is possible that sensitivity may be poor. Each indicator included added different aspects to the ascertainment of COVID-19 exposure. Using combinations of self-reported and objectively measured variables, it may be possible to tailor COVID-19 indicators to the situation.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.05.20244376,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.05.20244376,Rt2: computing and visualising COVID-19 epidemics temporal reproduction number,Bastien Reyn; Gonch Danesh; Samuel Alizon; Mircea T. Sofonea; Gabriella Bergin Cartwright; Grace Lavelle; Alice Wickersham; Michael H Malim; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"Universit de Montpellier; Universit de Montpellier; CNRS; Universit de Montpellier; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","Analysing the spread of COVID-19 epidemics in a timely manner is essential for public health authorities. However, raw numbers may be misleading because of spatial and temporal variations. We introduce Rt2, an R-program with a shiny interface, which uses incidence data, i.e. number of new cases per day, to compute variations in the temporal reproduction number ([R]t), which corresponds to the average number of secondary infections caused by an infected person. This number is computed with the R0 package, which better captures past variations, and the EpiEstim package, which provides a more accurate estimate of current values. [R]t can be computed in different countries using either the daily number of new cases or of deaths. For France, these numbers can also be computed at the regional and departmental level using also daily numbers of hospital and ICU admissions. Finally, in addition to [R]t, we represent the incidence using a one-week sliding window to buffer daily variations. Overall, Rt2 provides an accurate and timely overview of the state and speed of spread of COVID-19 epidemics at different scales, using different metrics.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.06.20244780,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.06.20244780,Seasonality and Progression of COVID-19 among Countries With or Without Lock-downs.,Dr. Jose-Luis Sagripanti; Gonch Danesh; Samuel Alizon; Mircea T. Sofonea; Gabriella Bergin Cartwright; Grace Lavelle; Alice Wickersham; Michael H Malim; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"Department of Defense; Universit de Montpellier; CNRS; Universit de Montpellier; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","Early predictions by computer simulation of 7 billion infections and 40 million deaths by COVID-19 during 2020 alone if lock-downs and other confining measures were not enforced may have justified restrictive policies mandated by governments of 165 countries. A main objective of the present study was to determine differences between the infection and death rate in countries that established early, nation-wide curfews, state-at-home orders, or lock-downs versus countries that did not mandate lock-downs to deal with the COVID-19 crisis.

The analyzed epidemiological data indicates that lock-downs, and other confining measures had no effect on the chances of healthy individuals becoming infected with- or dying of SARS-CoV-2.

The highest incidence of COVID-19 infection progressed from countries in northern latitudes, where it was winter at the beginning of the pandemic, to countries in the southern hemisphere in July 21, 2020 were winter was starting. This trend reversed again during the last quarter of 2020. A considerable (4-fold) increase in COVID-19 infection rate is observed between fall and beginning of winter in countries in the southern hemisphere. This seasonal progression correlates with the variation in the germicidal solar flux received by these countries, suggesting that infectious virus in the environment plays a role in the evolution of COVID-19. In addition, hypotheses are presented that could explain the recurrent new spikes of COVID-19 as well as the mortality of SARS-Co V-2 observed in some developed countries higher than the mortality rate reported in several developing countries.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.06.20244731,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.06.20244731,Epidemic Progression and Vaccination in a Heterogeneous Population. Application to the Covid-19 epidemic,Vitaly Volpert; Malay Banerjee; Swarnali Sharma; Mircea T. Sofonea; Gabriella Bergin Cartwright; Grace Lavelle; Alice Wickersham; Michael H Malim; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"CNRS, University Lyon 1; IIT Kanpur; Vijaygarh Jyotish Ray College; Universit de Montpellier; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","The paper is devoted to a compartmental epidemiological model of infection progression in a heterogeneous population which consists of two groups with high disease transmission (HT) and low disease transmission (LT) potentials. Final size and duration of epidemic, the total and current maximal number of infected individuals are estimated depending on the structure of the population. It is shown that with the same basic reproduction number R0 in the beginning of epidemic, its further progression depends on the ratio between the two groups. Therefore, fitting the data in the beginning of epidemic and the determination of R0 are not sufficient to predict its long time behaviour. Available data on the Covid-19 epidemic allows the estimation of the proportion of the HT and LT groups. Estimated structure of the population is used for the investigation of the influence of vaccination on further epidemic development. The result of vaccination strongly depends on the proportion of vaccinated individuals between the two groups. Vaccination of the HT group acts to stop the epidemic and essentially decreases the total number of infected individuals at the end of epidemic and the current maximal number of infected individuals while vaccination of the LT group only acts to protect vaccinated individuals from further infection.",epidemiology,exact,100,100
medRxiv,10.1101/2020.12.04.20244129,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.04.20244129,Self-harm and the COVID-19 pandemic: a study of factors contributing to self-harm during lockdown restrictions,Keith Hawton; Karen Lascelles; Fiona Brand; Deborah Casey; Elizabeth Bale; Jennifer Ness; Samantha Kelly; Keith Waters; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; Univeristy of Oxford; Derbyshire Healthcare NHS Foundation Trust; Derbyshire Healthcare NHS Foundation Trust; Derbyshire Helathcare NHS Foundation Trust; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","IntroductionThe COVID-19 pandemic and resulting public health measures may have major impacts on mental health, including on self-harm. We have investigated what factors related to the pandemic influenced hospital presentations following self-harm during lockdown in England.

MethodMental health clinicians assessing individuals aged 18 years and over presenting to hospitals in Oxford and Derby following self-harm during the period March 23rd to 17th May 2020 recorded whether the self-harm was related to the impact of COVID- 19 and, if so, what specific factors were relevant. These factors were organized into a classification scheme. Information was also collected on patients demographic characteristics, method of self-harm and suicide intent.

ResultsOf 228 patients assessed, in 46.9% (N=107) COVID-19 and lockdown restrictions were identified as influencing self-harm. This applied more to females than males (53.5%, N=68/127 v 38.6%, N=39/101, {chi}2 = 5.03, p=0.025), but there were no differences in age, methods of self-harm or suicide intent between the two groups. The most frequent COVID-related factors were mental health issues, including new and worsening disorders, and cessation or reduction of services (including absence of face-to-face support), isolation and loneliness, reduced contact with key individuals, disruption to normal routine, and entrapment. Multiple, often inter- connected COVID-related factors were identified in many patients.

ConclusionsCOVID-related factors were identified as influences in nearly half of individuals presenting to hospitals following self-harm in the period following introduction of lockdown restrictions. Females were particularly affected. The fact that mental health problems, including issues with delivery of care, predominated has implications for organisation of services during such periods. The contribution of isolation, loneliness and sense of entrapment highlight the need for relatives, friends and neighbours to be encouraged to reach out to others, especially those living alone. The classification of COVID-related factors can be used as an aide-memoire for clinicians.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.12.05.20244590,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.05.20244590,Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis,Benedicto Crespo-Facorro; Miguel Ruiz-Veguilla; Javier Vazquez-Bourgon; Ana C. Sanchez-Hidalgo; Nathalia Garrido-Torres; Jose M. Cisneros; Carlos Prieto; Jesus Sainz; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio - IBIS - CIBERSAM. Sevilla, Spain.; Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio. IBIS. CIBERSAM Sevilla, Spain; Department of Psychiatry, University Hospital Marques de Valdecilla - Instituto de Investigacion Marques de Valdecilla (IDIVAL), Santander, Spain.; Seville Biomedical Research Centre (IBiS), Sevilla, Spain; University Hospital Virgen del Rocio. IBiS. Sevilla, Spain; Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, University o; Bioinformatics Service, Nucleus, University of Salamanca, Salamanca, Spain.; Spanish National Research Council (CSIC), Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), Santander, Spain; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","BackgroundAntipsychotics suppress expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the potential effects of aripiprazole (an FDA approved phenylpiperazine) on COVID19-related immunological parameters.

MethodsDifferential gene expression profiles of non-COVID versus COVID RNA-Seq samples (CRA002390 project in GSA database) and drug-naive patients with psychosis at baseline and after three months of aripiprazole treatment was identified. An integrative analysis between COVID and aripiprazole immunomodulatory antagonist effects was performed.

Findings82 out the 377 genes (21.7%) with expression significantly altered by aripiprazole have also their expression altered in COVID-19 patients and in 93.9% of these genes their expression is reverted by aripiprazole. The number of common genes with expression altered in both analyses is significantly higher than expected (Fishers Exact Test, two tail; P value=3.2e-11). 11 KEGG pathways were significantly enriched with genes with altered expression both in COVID-19 patients and aripiprazole medicated schizophrenia patients (P adj<0.05). The most significant pathways were associated to the immune system such as the ""inflammatory bowel disease (IBD)"" (the most significant pathway with a P adj of 0.00021), ""Th1 and Th2 cell differentiation"" and ""B cell receptor signaling pathway"", all three related to the defense against infections.

InterpretationThis exploratory investigation may provide further support to the notion that protective effect is exerted by phenylpiperazine by modulating the immunological dysregulation associated to COVID-19. Along with many ongoing studies and clinical trials, repurposing available medications could be of use in countering SARS-CoV-2 infection, but require further studies and trials.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.12.05.20244566,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.05.20244566,Does higher BMI increase COVID-19 severity?: a systematic review and meta-analysis,Akibul Islam Chowdhury; Md. Fazley Rabbi; Tanjina Rahman; Sompa Reza; Mohammad Rahanur Alam; Jose M. Cisneros; Carlos Prieto; Jesus Sainz; Carolin Oetzmann; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"Department of Food Technology and Nutrition Science, Noakhali Science and Technology University, Bangladesh; Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Bangladesh; Department of Food Technology and Nutrition Science, Noakhali Science and Technology University, Bangladesh; Institute of Nutrition and Food Science, University of Dhaka, Bangladesh; Department of Food Technology and Nutrition Science, Noakhali Science and Technology University, Bangladesh; Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, University o; Bioinformatics Service, Nucleus, University of Salamanca, Salamanca, Spain.; Spanish National Research Council (CSIC), Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), Santander, Spain; King's College London; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","IntroductionCOVID-19 pandemic has caused havoc worldwide, and different comorbidities have been seen to exacerbate the condition. Obesity is one of the leading comorbidities, which is associated with many other diseases. In this paper, we present a systematic review and meta-analysis estimating the effects of overweight and obesity on COVID-19 disease severity.

MethodologyTwo electronic databases (Medline and Cochrane library) and one grey literature database (Grey Literature Report) were searched using the following keywords: overweight, obesity, body mass index, respiratory disease, coronavirus, COVID-19. The risks of bias of the selected studies were assessed by using the Navigation Guide method for human data. Both random and fixed effect meta-analysis were determined using Review Manager (RevMan) software version 5.4.

ResultsAfter initial screening, 12 studies (7 cohort studies, four case-control studies, and one cross-sectional study) were fulfilled the eligibility criteria, comprising a total of 405359 patients and included in the systematic review. The pooled risk of disease severity was 1.31 times higher based on both fixed and random effect model among those overweight patients, I2 0% and 2.09 and 2.41 times higher based on fixed and random effect respectively among obese patients, I2 42% compared to healthy individuals.

ConclusionOverweight and obesity are common risk factors for disease severity of COVID-19 patients. However, further assessment of metabolic parameters included BMI, waist-hip ratio, and insulin levels, are required to estimate the risk factors of COVID-19 patients and understanding the mechanism between COVID-19 and body mass index.",public and global health,exact,100,100
medRxiv,10.1101/2020.12.04.20234450,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.04.20234450,A two-pronged approach for rapid and high-throughput SARS-CoV-2 nucleic acid testing,Neeru Gandotra; Irina Tikhonova; Nagarjuna R Cheermarla; James Knight; Ellen Foxman; Antonio Giraldez; Peidong Shen; Kaya Bilguvar; Curt Scharfe; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Center for Genome Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.; Yale Center for Genome Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Yale University School of Medicine; Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94305, USA.; Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA.; Yale University School of Medicine; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","Improved molecular screening and diagnostic tools are needed to substantially increase SARS-CoV-2 testing capacity and throughput while reducing the time to receive test results. Here we developed multiplex reverse transcriptase polymerase chain reaction (m-RT-PCR) for detection of SARS-CoV-2 using rapid DNA electrophoresis and alternatively using multiplex viral sequencing (mVseq). For RNA specimens extracted from nasopharyngeal (NP) swabs in viral transport media (VTM), our assays achieved a sensitivity for SARS-CoV-2 detection corresponding to cycle threshold (Ct) of 37.2 based on testing of these specimens using quantitative reverse transcription PCR (RT-qPCR). For NP swab-VTM specimens without prior RNA extraction, sensitivity was reduced to Ct of 31.6, which was due to lower concentration of SARS-CoV-2 genome copies in VTM compared to RNA-extracted samples. Assay turnaround time was 60 minutes using rapid gel electrophoresis, 90 minutes using Agilent Bioanalyzer, and 24-48 hours using Illumina sequencing, the latter of which required a second PCR to produce a sequence-ready library using m-RT-PCR products as the template. Our assays can be employed for high-throughput sequencing-based detection of SARS-CoV-2 directly from a clinical specimen without RNA isolation, while ease-of-use and low cost of the electrophoresis-based readout enables screening, particularly in resource-constrained settings.",public and global health,exact,100,100
bioRxiv,10.1101/2020.12.06.413682,2020-12-07,https://biorxiv.org/cgi/content/short/2020.12.06.413682,"Scientific publications and COVID-19 ""research pivots"" during the pandemic: An initial bibliometric analysis",Philip Shapira; Irina Tikhonova; Nagarjuna R Cheermarla; James Knight; Ellen Foxman; Antonio Giraldez; Peidong Shen; Kaya Bilguvar; Curt Scharfe; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"University of Manchester; Yale Center for Genome Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.; Yale Center for Genome Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Yale University School of Medicine; Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94305, USA.; Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA.; Yale University School of Medicine; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","An examination is presented of scientific research publication trends during the global coronavirus (COVID-19) pandemic in 2020. After reviewing the timing of the emergence of the pandemic in 2020 and the growth of governmental responses, available secondary and sources are used to highlight impacts of COVID-19 on scientific research. A bibliometric analysis is then undertaken to analyze developments in COVID-19 related scientific publications through to October of 2020 by broad trends, fields, countries, and organizations. Two publication data sources are used: PubMed and the Web of Science.

While there has been a massive absolute increase in PubMed and Web of Science papers directly focused on COVID-19 topics, especially in medical, biological science, and public health fields, this is still a relatively small proportion of publication outputs across all fields of science. Using Web of Science publication data, the paper examines the extent to which researchers across all fields of science have pivoted their research outputs to focus on topics related to COVID-19. A COVID-19 research pivot is defined as the extent to which the proportion of output in a particular research field has shifted to a focus on COVID-19 topics in 2020 (to date) compared with 2019. Significant variations are found by specific fields (identified by Web of Science Subject Categories). In a top quintile of fields, not only in medical specialties, biomedical sciences, and public health but also in subjects in social sciences and arts and humanities, there are relatively high to medium research pivots. In lower quintiles, including other subjects in science, social science, and arts and humanities, low to zero COVID-19 research pivoting is identified.

Version NoteThis working paper is Version 1, completed on December 6, 2020. As further data becomes available, it may be updated.",scientific communication and education,exact,100,100
bioRxiv,10.1101/2020.12.07.414631,2020-12-07,https://biorxiv.org/cgi/content/short/2020.12.07.414631,Identification of potential coagulation pathway abnormalities in SARS-Cov-2 infection; insights from bioinformatics analysis,Sareh Arjmand; Nazanin Hosseinkhan; Nagarjuna R Cheermarla; James Knight; Ellen Foxman; Antonio Giraldez; Peidong Shen; Kaya Bilguvar; Curt Scharfe; Catherine Polling; Sharon A.M. Stevelink; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"Shahid Beheshti University; Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.; Yale Center for Genome Analysis, Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Yale University School of Medicine; Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA; Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94305, USA.; Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA.; Yale University School of Medicine; King's College London; King's College London; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","Abnormal coagulation parameters have been explored in a significant number of severe COVID-19 patients, linked to poor prognosis and increased risk of organ failure. Here, to uncover the potential abnormalities in coagulation pathways, we analyzed the RNA-seq data (GEO147507) obtained from the treatment of three pulmonary epithelial cell lines with SARS-CoV-2. The significant differentially expressed genes (DEGs) were subjected to Enrichr database for KEGG pathway enrichment analysis and gene ontology (GO) functional annotation. The STRING database was used to generate PPI networks for identified DEGs. We found three upregulated procoagulant genes (SERPINE1, SERPINA5, and SERPINB2) belong to the serine protease inhibitor (serpin) superfamily that inhibit tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) in the fibrinolysis process. In conclusion, we suggest the fibrinolysis process, especially the blockage of t-PA and u-PA inhibitors, a potential target for more study in treating coagulopathy in severe COVID-19 cases.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.12.07.414706,2020-12-07,https://biorxiv.org/cgi/content/short/2020.12.07.414706,Spike Protein of SARS-CoV-2 Activates Macrophages and Contributes to Induction of Acute Lung Inflammations in Mice,Xiaoling Cao; Yan Tian; Vi Nguyen; Yuping Zhang; Chao Gao; Rong Yin; Wayne Carver; Daping Fan; Helmut Albrecht; Taixing Cui; Wenbin Tan; Reza Razavi; Matthew Hotopf; - KCL-CHECK research team; Kirk C Hansen; Tellen D Bennett; Elena W.Y. Hsieh; Joaquin M Espinosa; Cindy Bethel; Scott Matushek; Kathleen Beavis; Nishant Agrawal; Jeremy Segal; Savas Tay; Evgeny Izumchenko,"University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina School of Medicine; University of South Carolina, School of Medicine; King's College London; King's College London; ; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus.; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus; Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO; UNIVERSITY OF CHICAGO","BackgroundCoronavirus disease 2019 (COVID-19) patients exhibit multiple organ malfunctions with a primary manifestation of acute and diffuse lung injuries. The Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial to mediate viral entry into host cells; however, whether it can be cellularly pathogenic and contribute to pulmonary hyper-inflammations in COVID-19 is not well known.

Methods and FindingsIn this study, we developed a Spike protein-pseudotyped (Spp) lentivirus with the proper tropism of SARS-CoV-2 Spike protein on the surface and tracked down the fate of Spp in wild type C57BL/6J mice receiving intravenous injection of the virus. A lentivirus with vesicular stomatitis virus glycoprotein (VSV-G) was used as the control. Two hours post-infection (hpi), Spp showed more than 27-75 times more viral burden in the lungs than other organs; it also exhibited about 3-5 times more viral burden than VSV-G lentivirus in the lungs, liver, kidney and spleen. Acute pneumonia was evident in animals 24 hpi. Spp lentivirus was mainly found in LDLR+ macrophages and pneumocytes in the lungs, but not in MARC1+ macrophages. IL6, IL10, CD80 and PPAR-{gamma} were quickly upregulated in response to infection of Spp lentivirus in the lungs in vivo as well as in macrophage-like RAW264.7 cells in vitro. We further confirmed that forced expression of the Spike protein in RAW264.7 cells could significantly increase the mRNA levels of the same panel of inflammatory factors.

ConclusionsOur results demonstrate that the Spike protein of SARS-CoV-2 alone can induce cellular pathology, e.g. activating macrophages and contributing to induction of acute inflammatory responses.",pathology,exact,100,100
medRxiv,10.1101/2020.12.03.20243535,2020-12-04,https://medrxiv.org/cgi/content/short/2020.12.03.20243535,OpenSAFELY: impact of national guidance on switching from warfarin to direct oral anticoagulants (DOACs) in early phase of COVID-19 pandemic in England,Helen J Curtis; Brian MacKenna; Alex J Walker; Richard Croker; Amir Mehrkar; Caroline E Morton; Seb Bacon; George Hickman; Peter Inglesby; Chris Bates; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth Williamson; William Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundEarly in the COVID-19 pandemic the NHS recommended that appropriate patients anticoagulated with warfarin should be switched to direct acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued regarding patients being inappropriately co-prescribed two anticoagulants following a medication change, and associated monitoring.

ObjectiveTo describe which people were switched from warfarin to DOACs; identify potentially unsafe co-prescribing of anticoagulants; and assess whether abnormal clotting results have become more frequent during the pandemic.

MethodsWorking on behalf of NHS England we conducted a population cohort based study using routine clinical data from >17 million adults in England.

Results20,000 of 164,000 warfarin patients (12.2%) switched to DOACs between March and May 2020, most commonly to edoxaban and apixaban. Factors associated with switching included: older age, recent renal function test, higher number of recent INR tests recorded, atrial fibrillation diagnosis and care home residency. There was a sharp rise in co-prescribing of warfarin and DOACs from typically 50-100 per month to 246 in April 2020, 0.06% of all people receiving a DOAC or warfarin. INR testing fell by 14% to 506.8 patients tested per 1000 warfarin patients each month. We observed a very small increase in elevated INRs (n=470) during April compared with January (n=420).

ConclusionsIncreased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people co-prescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic.",cardiovascular medicine,exact,100,100
bioRxiv,10.1101/2020.12.04.410340,2020-12-04,https://biorxiv.org/cgi/content/short/2020.12.04.410340,First-described recently discovered non-toxic vegetal-derived furocoumarin preclinical efficacy against SARS-CoV-2: a promising antiviral herbal drug.,Ivan Jose Galindo-Cardiel; Adriana Toledo Nunez; Maria Celaya Fernandez; Ariel Ramirez Labrada; Iratxe Uranga-Murillo; Maykel Arias Cabrero; Julian Pardo; Ezio Panzeri; Peter Inglesby; Chris Bates; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth Williamson; William Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre,"WorldPathol Global United S.A.; WorldPathol Global United S.A.; WorldPathol Global United S.A.; Unidad de Nanotoxicologa e Inmunotoxicologa (UNATI), Instituto de Investigacin Sanitaria de Aragn (IISA); Immunotherapy, Inflammation and Cancer, Instituto de Investigacin Sanitaria Aragn (IISA); Instituto de Carboqumica; Universidad de Zaragoza/ARAID; ICE-P Life Ltd.; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiology of coronavirus disease 2019 (COVID19) pandemic. ICEP4 purified compound (ICEP4) is a recently discovered furocoumarin-related purified compound derived from the roots and seeds of Angelica archangelica (herbal drug). ICEP4-related herbal preparations have been extensively used as active herbal ingredients in traditional medicine treatments in several European countries. Extraction method of patent pending ICEP4 (patent application no. GB2017123.7) has previously shown strong manufacturing robustness, long-lasting stability, and repeated chemical consistency. Here we show that ICEP4 presents a significant in vitro cytoprotective effect in highly virulent-SARS-CoV-2 challenged Vero E6 cellular cultures, using doses of 34.5 and 69 M. No dose-related ICEP4 toxicity was observed in Vero E6 cells, M0 macrophages, B, CD4+ T and CD8+ T lymphocytes, Natural Killer (NK) or Natural Killer T (NKT) cells. No dose-related ICEP4 inflammatory response was observed in M0 macrophages quantified by IL6 and TNF release in cell supernatant. No decrease in survival rate was observed after either 24 hr acute or 21-day chronic exposure in in vivo toxicity studies performed in C. elegans. Therefore, ICEP4 toxicological profile has demonstrated marked differences compared to others vegetal furocoumarins. Successful ICEP4 doses against SARS-CoV-2-challenged cells are within the maximum threshold of toxicity concern (TTC) of furocoumarins as herbal preparation, stated by European Medicines Agency (EMA). The characteristic chemical compounding of ICEP4, along with its safe TTC, allow us to assume that the first-observation of a natural antiviral compound has occurred. The potential druggability of a new synthetic ICEP4-related compound remains to be elucidated. However, well-established historical use of ICEP4-related compounds as herbal preparations may point towards an already-safe, widely extended remedy, which may be ready-to-go for large-scale clinical trials under the EMA emergency regulatory pathway. To the best of the authors knowledge, ICEP4-related herbal drug can be postulated as a promising therapeutic treatment for COVID19.",pharmacology and toxicology,exact,100,100
medRxiv,10.1101/2020.12.03.20243196,2020-12-04,https://medrxiv.org/cgi/content/short/2020.12.03.20243196,Mental health problems in the general population during and after the first lockdown phase due to the SARS-Cov-2 pandemic: Rapid review of multi-wave studies,Dirk Richter; Steffi Riedel-Heller; Simeon Zuercher; Ariel Ramirez Labrada; Iratxe Uranga-Murillo; Maykel Arias Cabrero; Julian Pardo; Ezio Panzeri; Peter Inglesby; Chris Bates; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth Williamson; William Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre,"Bern University Hospital for Mental Health; University of Leipzig, Institute of Social Medicine, Occupational Health and Public Health (ISAP), Leipzig, Germany; Bern University Hospital for Mental Health, Bern, Switzerland; Unidad de Nanotoxicologa e Inmunotoxicologa (UNATI), Instituto de Investigacin Sanitaria de Aragn (IISA); Immunotherapy, Inflammation and Cancer, Instituto de Investigacin Sanitaria Aragn (IISA); Instituto de Carboqumica; Universidad de Zaragoza/ARAID; ICE-P Life Ltd.; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundThe SARS-Cov-2 pandemic and the lockdown response have increased mental health problems in general populations compared to pre-pandemic times. The course of mental health problems during and after the first lockdown phase has not yet been reviewed.

MethodsWe conducted a rapid review of multi-wave studies in general populations with time points during and after the first lockdown phase. Repeated cross-sectional and longitudinal studies were included. The main outcome assessed was whether indicators of mental health problems have changed during and after the first lockdown phase. The study was registered with PROSPERO No. CRD42020218640

Findings23 studies with 56 indicators were included in the qualitative review. Studies that reported data from pre-pandemic assessments through lockdown indicated an increase in mental health problems. During lockdown no uniform trend could be identified. After lockdown mental health problems decreased slightly.

InterpretationAs mental health care utilization indicators and data on suicides do not suggest an increase in demand during the first lockdown phase, we regard the increase in mental health problems as general distress that is to be expected during a global health crisis. Several methodological, pandemic-related, response-related and health policy-related factors need to be considered when trying to gain a broader perspective on the impact of the first wave of the pandemic and the first phase of lockdown on general populations mental health.",psychiatry and clinical psychology,exact,100,100
bioRxiv,10.1101/2020.12.04.411389,2020-12-04,https://biorxiv.org/cgi/content/short/2020.12.04.411389,Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of the induction of IFN-mediated innate immune defences,Vanessa Herder; Kieran Dee; Joanna Wojtus; Daniel Goldfarb; Christoforos Rozario; Quan Gu; Ruth Jarrett; Ilaria Epifano; Andrew Stevenson; Steven McFarlane; Meredith Stewart; Agnieszka Szemiel; Rute Pinto; Andreu Masdefiol Garriga; Sheila Graham; Pablo Murcia; Chris Boutell; Elizabeth Williamson; William Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre,MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; MRC-University of Glasgow Centre for Virus Research; University of Glasgow; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"The pandemic spread of SARS-CoV-2, the etiological agent of COVID-19, represents a significant and ongoing international health crisis. A key symptom of SARS-CoV-2 infection is the onset of fever, with a hyperthermic temperature range of 38 to 41{degrees}C. Fever is an evolutionarily conserved host response to microbial infection and inflammation that can influence the outcome of viral pathogenicity and regulation of host innate and adaptive immune responses. However, it remains to be determined what effect elevated temperature has on SARS-CoV-2 tropism and replication. Utilizing a 3D air-liquid interface (ALI) model that closely mimics the natural tissue physiology and cellular tropism of SARS-CoV-2 infection in the respiratory airway, we identify tissue temperature to play an important role in the regulation of SARS-CoV-2 infection. We show that temperature elevation induces wide-spread transcriptome changes that impact upon the regulation of multiple pathways, including epigenetic regulation and lncRNA expression, without disruption of general cellular transcription or the induction of interferon (IFN)-mediated antiviral immune defences. Respiratory tissue incubated at temperatures >37{degrees}C remained permissive to SARS-CoV-2 infection but severely restricted the initiation of viral transcription, leading to significantly reduced levels of intraepithelial viral RNA accumulation and apical shedding of infectious virus. To our knowledge, we present the first evidence that febrile temperatures associated with COVID-19 inhibit SARS-CoV-2 replication. Our data identify an important role for temperature elevation in the epithelial restriction of SARS-CoV-2 that occurs independently of the induction of canonical IFN-mediated antiviral immune defences and interferon-stimulated gene (ISG) expression.",microbiology,exact,100,100
medRxiv,10.1101/2020.12.01.20241729,2020-12-03,https://medrxiv.org/cgi/content/short/2020.12.01.20241729,International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples,Eric Robinson; Andrew Jones; India Lesser; Michael Daly; Aliu Mohammed; Abdul-Aziz Seidu; Daisy Fancourt; Angelos Angelakas Dr; Theingi Aung Dr; Kathryn Banfill Dr; Mark Baxter Dr; Talvinder Bhogal Dr; Hayley Boyce Dr; Ellen Copson Dr; Elena Dickens Dr; Leonie Eastlake Dr; Hannah Frost Ms; Fabio Gomes Dr; Donna Graham Dr; Christina Hague Dr; Michelle Harrison Dr; Laura Horsley Dr; Prerana Huddar Dr; Zoe Hudson Dr; Sam Khan Dr; Umair T Khan Dr; Alec Maynard Dr; Hayley McKenzie Dr; Tim Robinson Dr; Michael Rowe Dr; Anne Thomas Prof; Lance Turtle; Roseleen Sheehan Dr; Alexander Stockdale; Jamie Weaver Dr; Sophie Williams Dr; Caroline Wilson Dr; Richard Hoskins Dr; Julie Stevenson Dr; Paul Fitzpartick Dr; Carlo Palmieri Prof; Donal Landers Dr; Tim Cooksley Dr; Caroline Dive Prof; Andre Freitas Dr; Anne C Armstrong Dr,"University of Liverpool; University of Liverpool; University of Liverpool; Maynooth University; University of Cape Coast; University of Cape Coast; University College London; University Hospitals of Morecambe Bay, Kendal LA9 7RG; Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS foundation Trust, Sheffield S10 2JF; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; The University of Manchester, Oxford road, M13 9PL; University of Dundee, Dundee DD1 4HN; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS foundation Trust, Sheffield S10 2JF; Cancer Sciences Academic Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD; Oncology Department, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW; University Hospitals Plymouth NHS Trust, Plymouth, PL6 8DH; . Digital experimental cancer medicine and Bioinformatics and Biostatistics teams, Cancer Research UK Manchester Institute Cancer Biomarker Centre, The Universi; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; Ninewells Hospital, Dundee DD2 1SG; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT; Bristol Haematology and Oncology Centre, Bristol BS2 8ED; Oncology Department, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW; Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 ; Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, L7 8YA; The University of Liverpool, Liverpool, L69 3BX; Sheffield Teaching Hospitals NHS foundation Trust, Sheffield S10 2JF; Cancer Sciences Academic Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD; Bristol Haematology and Oncology Centre, Bristol BS2 8ED; Sunrise Centre, Royal Cornwall Hospital, Truro, Cornwall, TR1 3LJ; Oncology Department, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW; Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 ; Institute of Infection, Ecological and Veterinary Sciences, University of Liverpool and Tropical and Infectious Diseases Unit, Liverpool University Hospitals; Sheffield Teaching Hospitals NHS foundation Trust, Sheffield S10 2JF; Institute of Infection, Ecological and Veterinary Sciences, University of Liverpool and Tropical and Infectious Diseases Unit, Liverpool University Hospitals; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; Sheffield Teaching Hospitals NHS foundation Trust, Sheffield S10 2JF; Sheffield Teaching Hospitals NHS foundation Trust, Sheffield S10 2JF; The University of Manchester, Oxford road, M13 9PL; . Digital experimental cancer medicine and Bioinformatics and Biostatistics teams, Cancer Research UK Manchester Institute Cancer Biomarker Centre, The Universi; . Digital experimental cancer medicine and Bioinformatics and Biostatistics teams, Cancer Research UK Manchester Institute Cancer Biomarker Centre, The Universi; Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, L7 8YA; . Digital experimental cancer medicine and Bioinformatics and Biostatistics teams, Cancer Research UK Manchester Institute Cancer Biomarker Centre, The Universi; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; Cancer Research UK Manchester Institute Cancer Biomarker Centre, Alderley Park, SK10 4TG; The University of Manchester, Oxford road, M13 9PL; Digital experimental cancer medicine team, Manchester Centre for Cancer Biomarker Sciences, Alderley Park, S; The Christie NHS Foundation Trust, Wilmslow road, M20 4BX; The University of Manchester, Oxford road, M13 9PL","BackgroundWidespread uptake of COVID-19 vaccines will be essential to extinguishing the COVID-19 pandemic. Vaccines have been developed in unprecedented time and hesitancy towards vaccination among the general population is unclear.

MethodsSystematic review and meta-analysis of studies using large nationally representative samples (n[&ge;]1000) to examine the percentage of the population intending to vaccinate, unsure, or intending to refuse a COVID-19 vaccine when available. Generic inverse meta-analysis and meta-regression were used to pool estimates and examine time trends. PubMed, Scopus and pre-printer servers were searched from January-November, 2020. Registered on PROSPERO (CRD42020223132).

FindingsTwenty-eight nationally representative samples (n = 58,656) from 13 countries indicate that as the pandemic has progressed, the percentage of people intending to vaccinate and refuse vaccination have been decreasing and increasing respectively. Pooled data from surveys conducted during June-October suggest that 60% (95% CI: 49% to 69%) intend to vaccinate and 20% (95% CI: 13% to 29%) intend to refuse vaccination, although intentions vary substantially between samples and countries (I2 > 90%). Being female, younger, of lower income or education level and belonging to an ethnic minority group were consistently associated with being less likely to intend to vaccinate. Findings were consistent across higher vs. lower quality studies.

InterpretationIntentions to be vaccinated when a COVID-19 vaccine becomes available have been declining globally and there is an urgent need to address social inequalities in vaccine hesitancy and promote widespread uptake of vaccines as they become available.

FundingN/A

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, Scopus and pre-print servers for manuscripts from January to November, 2020, reporting on studies examining intentions to be vaccinated against COVID-19 in large nationally representative samples (N[&ge;]1000). No language restrictions were applied. Search terms were [(COVID OR coronavirus OR SARS-COV-2) AND (Vaccine OR Vaccination) AND (Inten* OR willing* OR attitud* OR hypothetical)]. From 792 articles, we identified 20 eligible articles reporting on 28 nationally representative samples.

Added value of this studyThis is the first systematic study and meta-analysis to estimate the proportion of the global population willing to be vaccinated against vs. intending to refuse a vaccine when COVID-19 vaccines become available and how this trend has changed over time, using large and nationally representative samples. Results indicate that COVID-19 vaccination intentions vary substantially across countries, the percentage of the population intending to be vaccinated has declined across countries as the pandemic has progressed (March-May estimate: 79%, June-October estimate: 60%) and a growing number report intending to refuse a vaccine, when available (March-May estimate: 12%, June-October estimate: 20%). There is consistent socio-demographic patterning of vaccination intentions; being female, younger, of lower income or education level and belonging to an ethnic minority group are associated with a reduced likelihood of intending to be vaccinated when a vaccine become available.

Implications of all the available evidenceIntentions to vaccinate against COVID-19 among the general public when a vaccine becomes available have been declining and this will limit the effectiveness of COVID-19 vaccination programmes. Findings highlight the need to improve public acceptability, trust and concern over the safety and benefit of COVID-19 vaccines and target vaccine uptake in disadvantaged groups who have already been disproportionately affected by the pandemic.",public and global health,exact,100,100
medRxiv,10.1101/2020.11.27.20238147,2020-12-02,https://medrxiv.org/cgi/content/short/2020.11.27.20238147,"Ethnicity, Household Composition and COVID-19 Mortality: A National Linked Data Study",Vahe Nafilyan; Nazrul Islam; Daniel Ayoubkhani; Clare Gilles; Srinivasa Vittal Katikireddi; Rohini Mathur; Annabel Summerfield; Karen Tingay; Miqdad Asaria; Ann John; Peter Goldblatt; Amitava Banerjee; Myer Glickman; Kamlesh Khunti; Dorina Schckermann; Janin Korn; Allan Koch; Susanne Zock-Emmenthal; Marlies Becker; Margitta Scholz; Gustavo Maral Schmidt Garcia Moreira; Esther Veronika Wenzel; Giulio Russo; Hendrikus S.P. Garritsen; Sebastian Casu; Andreas Gerstner; Gnter Roth; Andreas Hermann; Thomas Schirrmann; Stefan Dbel; Andr Frenzel; Joop Van den Heuvel; Luka Cicin-Sain; Maren Schubert; Michael Hust,"Office for National Statistics; Nuffield Department of Population Health, Big Data Institute, University of Oxford; Office for National Statistics; Diabetes Research Centre, University of Leicester; University of Glasgow; London School of Hygiene and Tropical Medicine; Office for National Statistics; Office for National Statistics; London School of Economics and Political Sciences; Swansea University; UCL Institute of Health Equity, University College London; University College London; Office for National Statistics; Diabetes Research Centre, University of Leicester; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; Stdtisches Klinikum Braunschweig; Helios Klinikum Salzgitter; Stdtisches Klinikum Braunschweig; BioCopy GmbH; CORAT Therapeutics GmbH; YUMAB GmbH; TU Braunschweig; YUMAB GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; TU Braunschweig; TU Braunschweig","BackgroundEthnic minorities have experienced disproportionate COVID-19 mortality rates. We estimated associations between household composition and COVID-19 mortality in older adults ([&ge;] 65 years) using a newly linked census-based dataset, and investigated whether living in a multi-generational household explained some of the elevated COVID-19 mortality amongst ethnic minority groups.

MethodsUsing retrospective data from the 2011 Census linked to Hospital Episode Statistics (2017-2019) and death registration data (up to 27th July 2020), we followed adults aged 65 years or over living in private households in England from 2 March 2020 until 27 July 2020 (n=10,078,568). We estimated hazard ratios (HRs) for COVID-19 death for people living in a multi-generational household compared with people living with another older adult, adjusting for geographical factors, socio-economic characteristics and pre-pandemic health. We conducted a causal mediation analysis to estimate the proportion of ethnic inequalities explained by living in a multi-generational household.

ResultsLiving in a multi-generational household was associated with an increased risk of COVID-19 death. After adjusting for confounding factors, the HRs for living in a multi-generational household with dependent children were 1.13 [95% confidence interval 1.01-1.27] and 1.17 [1.01-1.35] for older males and females. The HRs for living in a multi-generational household without dependent children were 1.03 [0.97 - 1.09] for older males and 1.22 [1.12 - 1.32] for older females. Living in a multi-generational household explained between 10% and 15% of the elevated risk of COVID-19 death among older females from South Asian background, but very little for South Asian males or people in other ethnic minority groups.

ConclusionOlder adults living with younger people are at increased risk of COVID-19 mortality, and this is a notable contributing factor to the excess risk experienced by older South Asian females compared to White females. Relevant public health interventions should be directed at communities where such multi-generational households are highly prevalent.

FundingThis research was funded by the Office for National Statistics.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.26.20192823,2020-12-02,https://medrxiv.org/cgi/content/short/2020.11.26.20192823,"Protection of health care workers from exhaled air of patients operated under local, regional, spinal or epidural anaesthesia during COVID 19 pandemic",Kuldeep Atodaria; Mayank Singh; Vimalkumar S Prajapati; Kush Shaileshkumar Shahkush; Pradipkumar Raghuvirsinh Atodaria; Rohini Mathur; Annabel Summerfield; Karen Tingay; Miqdad Asaria; Ann John; Peter Goldblatt; Amitava Banerjee; Myer Glickman; Kamlesh Khunti; Dorina Schckermann; Janin Korn; Allan Koch; Susanne Zock-Emmenthal; Marlies Becker; Margitta Scholz; Gustavo Maral Schmidt Garcia Moreira; Esther Veronika Wenzel; Giulio Russo; Hendrikus S.P. Garritsen; Sebastian Casu; Andreas Gerstner; Gnter Roth; Andreas Hermann; Thomas Schirrmann; Stefan Dbel; Andr Frenzel; Joop Van den Heuvel; Luka Cicin-Sain; Maren Schubert; Michael Hust,"Harsiddhi Cosmetic and Plastic Surgery Hospital, Surat-395007; Radiance Cosmetic Centre, Greater Kailash, New Delhi; Aspee Shakilam Biotechnology Institute, Surat-395007; Resident in Onco Surgery, Bharat Cancer Hospital, Sutrat; Chief Consultant, Harsiddhi Cosmetic and Plastic Surgery Hospital, Sagrampura  Gujarat, India-395002; London School of Hygiene and Tropical Medicine; Office for National Statistics; Office for National Statistics; London School of Economics and Political Sciences; Swansea University; UCL Institute of Health Equity, University College London; University College London; Office for National Statistics; Diabetes Research Centre, University of Leicester; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; Stdtisches Klinikum Braunschweig; Helios Klinikum Salzgitter; Stdtisches Klinikum Braunschweig; BioCopy GmbH; CORAT Therapeutics GmbH; YUMAB GmbH; TU Braunschweig; YUMAB GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; TU Braunschweig; TU Braunschweig","The SARS-CoV-2 (COVID-19) pandemic mandates the use of N-95/FFP-2 masks for healthcare workers, especially in operation room (OR) for surgical or aerosol producing procedures. During pandemic, surgical interventions such as limb trauma, limb amputations, and limb malignancies continued to flow into the hospitals and are normally performed under local, regional or spinal anaesthesia. N-95/FFP-2 masks normally do not prevent escape of exhaled air to surrounding and to avoid the escape of exhaled unfiltered air, sealing masks by taping its edges to face possibly serves the purpose, but causes significant discomfort to patients. HEPA filters, high vacuum suction apparatus, and negative pressure operating-room may protect partially against the-risk of infection if patients exhaled air is infected. In order to reduce risk of transmission from patients exhaled air to the healthcare workers, a technique has been designed to divert the patients exhaled air to outside the-OR using a suction machine. This technique is easy, simple and cost-effective and trial has been performed with four-volunteers to see feasibility to breathe through N-95 mask sealed by sticking its edges to face using tape. The trial reflected reduction in SpO2, causing increased respiratory-rate, tachycardia and hypertension, in-addition an un-acclimatized volunteers had difficulty in breathing through sealed N-95 masks, which was relieved by supplying oxygen to them. Attaching suction system to remove the-exhaled air aids to comfort levels. Treating exhaled-air with sodium-hypochlorite and diverting it externally to an open-space outside the-OR added to safety for the patients, surgical team and the hospital surroundings.",surgery,exact,100,100
medRxiv,10.1101/2020.11.27.20239913,2020-12-02,https://medrxiv.org/cgi/content/short/2020.11.27.20239913,Wearing masks and establishing COVID-19 areas reduces secondary attack risk in nursing homes,Bastien Reyn; Christian Selinger; Mircea T. Sofonea; Stphanie Miot; Amandine Pisoni; Edouard TUAILLON; Jean J Bousquet; Hubert Blain; Samuel Alizon; Ann John; Peter Goldblatt; Amitava Banerjee; Myer Glickman; Kamlesh Khunti; Dorina Schckermann; Janin Korn; Allan Koch; Susanne Zock-Emmenthal; Marlies Becker; Margitta Scholz; Gustavo Maral Schmidt Garcia Moreira; Esther Veronika Wenzel; Giulio Russo; Hendrikus S.P. Garritsen; Sebastian Casu; Andreas Gerstner; Gnter Roth; Andreas Hermann; Thomas Schirrmann; Stefan Dbel; Andr Frenzel; Joop Van den Heuvel; Luka Cicin-Sain; Maren Schubert; Michael Hust,"Montpellier University; IRD; Univ. Montpellier; CHU de Montpellier; CHU de Montpellier; Montpellier University; CHU; CHU de Montpellier; CNRS; Swansea University; UCL Institute of Health Equity, University College London; University College London; Office for National Statistics; Diabetes Research Centre, University of Leicester; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; Stdtisches Klinikum Braunschweig; Helios Klinikum Salzgitter; Stdtisches Klinikum Braunschweig; BioCopy GmbH; CORAT Therapeutics GmbH; YUMAB GmbH; TU Braunschweig; YUMAB GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; TU Braunschweig; TU Braunschweig","BackgroundCOVID-19 is spreading rapidly in nursing homes (NHs). It is urgent to evaluate the effect of infection prevention and control (IPC) measures to reduce COVID spreading.

MethodsWe analysed COVID-19 outbreaks in 12 NH using rRT-PCR for SARS-CoV-2. We estimated secondary attack risks (SARs) and identified cofactors associated with the proportion of infected residents.

ResultsThe SAR was below 5%, suggesting a high efficiency of IPC measures. Mask-wearing or establishment of COVID-19 zones for infected residents were associated with lower SAR.

ConclusionsWearing masks and isolating potentially infected residents appear to limit SARS-CoV-2 spread in nursing homes.",geriatric medicine,exact,100,100
medRxiv,10.1101/2020.11.23.20237404,2020-12-02,https://medrxiv.org/cgi/content/short/2020.11.23.20237404,A COVID-19 transmission model informing medication development and supply chain needs,Annabelle Lemenuel-Diot; Barry Clinch; Aeron C. Hurt; Paul Boutry; Johann Laurent; Mathias Leddin; Stefan Frings; Jean Eric Charoin; Samuel Alizon; Ann John; Peter Goldblatt; Amitava Banerjee; Myer Glickman; Kamlesh Khunti; Dorina Schckermann; Janin Korn; Allan Koch; Susanne Zock-Emmenthal; Marlies Becker; Margitta Scholz; Gustavo Maral Schmidt Garcia Moreira; Esther Veronika Wenzel; Giulio Russo; Hendrikus S.P. Garritsen; Sebastian Casu; Andreas Gerstner; Gnter Roth; Andreas Hermann; Thomas Schirrmann; Stefan Dbel; Andr Frenzel; Joop Van den Heuvel; Luka Cicin-Sain; Maren Schubert; Michael Hust,"Roche Innovation Center; Roche Products Ltd; F. Hoffmann-La Roche Ltd; F. Hoffmann-La Roche Ltd; Roche Innovation Center; Roche Innovation Center; F. Hoffmann-La Roche Ltd; F. Hoffmann-La Roche Ltd; CNRS; Swansea University; UCL Institute of Health Equity, University College London; University College London; Office for National Statistics; Diabetes Research Centre, University of Leicester; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; Stdtisches Klinikum Braunschweig; Helios Klinikum Salzgitter; Stdtisches Klinikum Braunschweig; BioCopy GmbH; CORAT Therapeutics GmbH; YUMAB GmbH; TU Braunschweig; YUMAB GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; TU Braunschweig; TU Braunschweig","Accurate prediction of COVID-19 cases can optimize clinical trial recruitment, inform mitigation strategies and facilitate rapid medication development. Here we present a country-specific, modified Susceptible, Exposed, Infectious, Removed (SEIR) model of SARS-CoV-2 transmission using data from the Johns Hopkins University COVID-19 Dashboard. Inter-country differences in initial exposure, cultural/environmental factors, reporting requirements and stringency of mitigation strategies were incorporated. Asymptomatic patients and super-spreaders were also factored into our model. Using these data, our model estimated 65.8% of cases as asymptomatic; symptomatic and asymptomatic people were estimated to infect 2.12 and 5.83 other people, respectively. An estimated 9.55% of cases were super-spreaders with a 2.11-fold higher transmission rate than average. Our model estimated a mean maximum infection rate of 0.927 cases/day (inter-country range, 0.63-1.41) without mitigation strategies. Mitigation strategies with a stringency index value of [&ge;]60% were estimated to be required to reduce the reproduction ratio below 1. It was predicted that cases over the next 2 months would differ between countries, with certain countries likely to experience an accelerated accumulation of cases. Together, results from our model can guide distribution of diagnostic tests, impact clinical trial development, support medication development and distribution and inform mitigation strategies to reduce COVID-19 spread.

Key FindingsO_LIPredicting COVID-19 cases can inform medication development and mitigation strategies
C_LIO_LIWe created a modified SEIR model of SARS-CoV-2 transmission
C_LIO_LIWe integrated asymptomatic cases, super-spreaders and hotspots that drive viral spread
C_LIO_LIMitigation strategies with a stringency index of [&ge;]60% are required to reduce the RR below 1
C_LIO_LISome countries may experience an accelerated accumulation of cases in the coming months
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.29.20235218,2020-12-02,https://medrxiv.org/cgi/content/short/2020.11.29.20235218,Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.,David M Wiseman; Pierre Kory; Samir A Saidi; Dan Mazzucco; Johann Laurent; Mathias Leddin; Stefan Frings; Jean Eric Charoin; Samuel Alizon; Ann John; Peter Goldblatt; Amitava Banerjee; Myer Glickman; Kamlesh Khunti; Dorina Schckermann; Janin Korn; Allan Koch; Susanne Zock-Emmenthal; Marlies Becker; Margitta Scholz; Gustavo Maral Schmidt Garcia Moreira; Esther Veronika Wenzel; Giulio Russo; Hendrikus S.P. Garritsen; Sebastian Casu; Andreas Gerstner; Gnter Roth; Andreas Hermann; Thomas Schirrmann; Stefan Dbel; Andr Frenzel; Joop Van den Heuvel; Luka Cicin-Sain; Maren Schubert; Michael Hust,"Synechion, Inc., Dallas, TX, USA; Aurora St. Lukes Medical Center, Milwaukee, WI; Central Clinic School, University of Sydney, Australia; Third Eye Associates, Cherry Hill, NJ; Roche Innovation Center; Roche Innovation Center; F. Hoffmann-La Roche Ltd; F. Hoffmann-La Roche Ltd; CNRS; Swansea University; UCL Institute of Health Equity, University College London; University College London; Office for National Statistics; Diabetes Research Centre, University of Leicester; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; TU Braunschweig; Stdtisches Klinikum Braunschweig; Helios Klinikum Salzgitter; Stdtisches Klinikum Braunschweig; BioCopy GmbH; CORAT Therapeutics GmbH; YUMAB GmbH; TU Braunschweig; YUMAB GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; Helmholtz-Zentrum fur Infektionsforschung GmbH; TU Braunschweig; TU Braunschweig","BACKGROUNDA recent trial (NCT04308668) found that post-exposure prophylaxis with hydroxychloroquine (HCQ) was associated with a reduced incidence of Covid-19 by 17% overall; 36% in younger subjects, 31% in household contacts and 49% given within one day. To understand these trends, we re-analyzed the released dataset.

METHODSOur protocol conformed to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). We compared the incidence of Covid-19 after HCQ or placebo, stratifying by intervention lag, age, and gender.

RESULTSRequesting additional data, we found that 52% of subjects received medication 1-2 days after the intended overnight delivery; 19% of them outside the intended four-day intervention lag. After re-analysis, there was a reduced incidence of Covid-19 associated with HCQ compared with placebo (9.6% vs. 16.5%) when received Early (up to 3 days) after exposure (RR 0.58, 95%CI 0.35 - 0.97; p=0.044; NNT 14.5) but not Late (RR 1.22, 95%CI 0.72 - 2.04).

We found a significant HCQ-associated Covid-19 reduction in subjects 18 to 45 years old with Early (RR 0.54, 95%CI 0.29-0.97; p=0.0448, NNT 11.5) but not Late (RR 1.02, 95%CI 0.55-1.89) prophylaxis, attenuated in older subjects (RR 0.75, 95%CI 0-27-2.05) and by co-morbidities. There were reductions associated with Early prophylaxis in household contacts (RR 0.35, 95%CI 0.13-0.89; p=0.025, NNT 5.7) and Health Care Workers (RR 0.74, 95%CI 0.4-1.38). We did not detect effects of gender, folate, zinc, or ascorbic acid.

CONCLUSIONSUsing novel data with a prospective post hoc re-analysis, hydroxychloroquine, in an age-dependent manner, was associated with reduced illness compatible with Covid-19 or confirmed infection when supplied for post-exposure prophylaxis between 1 and 3 days after high-risk or moderate-risk exposure, at higher loading and maintenance doses than in similar studies. This finding warrants prospective confirmation.

Registered with the Open Science Framework (last revised September 27, 2020, osf.io/fqtnw).

Short SummaryA prospective re-analysis of a public dataset integrated with novel data found an HCQ-associated reduction of illness compatible with Covid-19 when received between 1 and 3 days after a high-risk or moderate-risk exposure (RR 0.58, 95% CI 0.35-0.97, p=0.044, NNT14.5).

Plain Language SummaryA recent clinical trial examined the ability of hydroxychloroquine (HCQ) to prevent Covid-19 just after an exposure to a person confirmed to have Covid-19. There was an HCQ-associated reduction of Covid-19 by an overall 17%; 36% in younger subjects, and 49% in subjects given HCQ within one day of being exposed. Likely because the study had too few patients to find what may have been a medically and economically meaningful, reduction, this effect was not statistically significant.

Studying the trial data, we discovered an unintended and variable delay in the delivery of study drug which may have masked any drug effect. The investigators provided further information at our request that confirmed our theory. About half of the participants received drugs one or two days later than intended, about a fifth beyond the four days the investigators thought the drug might work.

When we factored in this new information, we found that if HCQ was given early (up to three days after exposure), it was associated with a statistically significant 42% reduction of Covid-19. Giving HCQ later had no effect. There was a greater effect in younger (less than 45 years) rather than older subjects (47% vs. 25%). Gender did not seem to affect the results, but there was a greater HCQ-associated reduction (65%) when it was given early to people exposed to Covid-19 in a household environment rather than to health care workers (26%). The effects associated with HCQ were better in people without co-existing conditions.

These re-calculations are important because the study, as originally analyzed, was the only randomized study that dealt with preventing Covid-19 cited by FDA to support a key public health decision made in June 2020 regarding HCQ. Although other studies have shown that the drug is not effective to treat established cases of Covid-19, our research suggests that that it is effective for prevention. Other prevention studies have failed to show a benefit of HCQ, possibly because they have used lower doses or have estimated the timing of dosing differently. Our research paves the way for our result to be confirmed under clinical trial conditions and for a re-examination of public health policy regarding this drug. Even with the introduction of vaccination, there remains a need for approaches like this to prevent Covid-19 while individual and community immunity develops, especially in subjects given a lower priority for vaccination.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.23.20237313,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.23.20237313,"Identifying optimal combinations of symptoms to trigger diagnostic work-up of suspected COVID-19 cases in vaccine trials: analysis from a community-based, prospective, observational cohort",Michela Antonelli; Joan Capdevila; Amol Chaudhari; Julia Granerod; Liane Canas; Mark Graham; Kerstin Klaser; Marc Modat; Erica Moldeni; Ben Murray; Carole Sudre; Richard Davies; Anna May; Long Nguyen; David Drew; Amit Joshi; Andrew Chan; Jakob Cramer; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,King's College London; Zoe Global; Coalition for Epidemic Preparedness Innovations; Coalition for Epidemic Preparedness Innovations; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; University College London; Zoe Global; Zoe Global; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Coalition for Epidemic Preparedness Innovations; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute,"BackgroundDiagnostic work-up of participants following any COVID-19 associated symptom for example, in vaccine efficacy trials will lead to extensive testing, potentially overwhelming laboratory capacity whilst primarily yielding negative results. We aimed to identify an efficient symptom combination to capture most cases using the lowest possible number of tests.

MethodsUK and US users of the COVID-19 Symptom Study app who reported new-onset symptoms between March-September 2020 and an RT-PCR test within seven days of symptom onset were included. Sensitivity, specificity, and number of RT-PCR tests needed to identify one RT-PCR positive case were calculated for individual symptoms and symptom combinations. A multi-objective evolutionary algorithm was applied to generate symptom combinations with good trade-offs between sensitivity and specificity.

FindingsThe UK cohort included 122,305 individuals (1,202 RT-PCR positive). Findings were replicated in the US cohort which included 3,162 individuals (79 RT-PCR positive). Within three days of symptom onset, the COVID-19 specific symptom combination (cough, dyspnoea, fever, anosmia/ageusia) identified 69% of cases requiring 47 RT-PCR tests per case (TPC). The symptom combination with highest sensitivity at three days was fatigue, anosmia, cough, diarrhoea, headache, sore throat, identifying 96% of cases and requiring 96 TPC.

InterpretationWe confirm the significance of COVID-19 specific symptoms widely recommended for triggering RT-PCR. By using the data-driven optimization technique we identified additional symptoms (fatigue, sore throat, headache, diarrhoea) that enabled many more positive cases to be captured efficiently. By providing a set of solutions with optimal trade-offs between sensitivity and specificity, we produced a selection of symptom combinations that maximise the capture of cases given different laboratory capacities. This may be of use for COVID-19 vaccine developers across a range of resource settings and have more far-reaching public health implications for detection of symptomatic SARS CoV2 infection.

FundingZoe Global Limited, Department of Health, Wellcome Trust, Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health Research (NIHR), Medical Research Council (MRC), Alzheimers Society, Massachusetts Consortium for Pathogen Readiness (MassCPR), Coalition for Epidemic Preparedness Innovations (CEPI)

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed up to November 16, 2020, with the terms ""COVID-19"" OR ""SARS-CoV-2"" AND ""symptom"" AND ""community-based"", with no date or language restrictions, to find information about symptoms associated with COVID-19 from the community setting. The search retrieved 68 articles; however, most were not relevant as related to specific subgroups (e.g. pregnant women, cancer patients) or aspects (e.g. mental health, diagnostic testing). Fever, cough, dyspnoea, tachypnoea, anosmia, and ageusia are the symptoms most commonly identified in COVID-19 patients and typically included in guidelines from the WHO and similar bodies. These data however come primarily from hospital-based studies. An assessment of the value of symptom combinations for predicting COVID-19 in the community is lacking.

Added value of this studyWe present data from the largest, prospective community-based cohort study to date and quantify the contribution of COVID-19 symptoms and symptom combinations to COVID-19 case-finding. Our study is unique in that it simulates PCR testing in a clinical trial. Using RT-PCR as the gold standard for detecting COVID-19, we assessed the sensitivity and specificity of symptoms occurring within three days of symptom onset. An analysis of symptoms occurring within seven days of symptom onset aimed to capture delayed symptom triggers. We confirm the significance of fever, cough, and anosmia/ageusia, widely used to trigger RT-PCR testing and identified fatigue, headache, sore throat, and diarrhoea as additional symptoms for efficient COVID-19 case finding.

Implications of all the available evidenceThe applied methodology enables the selection of symptom combinations to maximise the capture of cases while taking account of specific laboratory capacity. Our findings not only have important implications for COVID-19 vaccine developers to optimise the choice of triggering symptoms for diagnostic work-up COVID-19 vaccine efficacy trials, but also have wider public health implications for early detection of symptomatic SARS-CoV-2 infection.",health informatics,exact,100,100
medRxiv,10.1101/2020.11.23.20236703,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.23.20236703,Evidence of the effectiveness of travel-related measures during the early phase of the COVID-19 pandemic: a rapid systematic review,Karen Ann Grepin; Tsi-Lok Ho; Zhihan Liu; Summer Marion; Julianne Piper; Catherin Z Worsnop; Kelley Lee; Marc Modat; Erica Moldeni; Ben Murray; Carole Sudre; Richard Davies; Anna May; Long Nguyen; David Drew; Amit Joshi; Andrew Chan; Jakob Cramer; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Maryland; Simon Fraser University; University of Maryland; Simon Fraser University; King's College London; King's College London; King's College London; University College London; Zoe Global; Zoe Global; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Coalition for Epidemic Preparedness Innovations; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute,"ObjectiveTo review evidence of the effectiveness of travel measures implemented during the early stages of the COVID-19 pandemic in order to recommend change on how evidence is incorporated in the International Health Regulations (2005) (IHR).

DesignWe used an abbreviated preferred reporting items for systematic reviews and meta-analysis protocol (PRISMA-P) and a search strategy aimed to identify studies that investigated the effectiveness of travel-related measures (advice, entry and exit screening, medical examination or vaccination requirements, isolation or quarantine, the refusal of entry, and entry restrictions), pre-printed or published by June 1, 2020.

ResultsWe identified 29 studies, of which 26 were modelled (vs. observational). Thirteen studies investigated international measures while 17 investigated domestic measures (one investigated both), including suspended transportation (24 studies), border restrictions (21), and screening (5). There was a high level of agreement that the adoption of travel measures led to important changes in the dynamics of the early phases of the COVID-19 pandemic. However, most of the identified studies investigated the initial export of cases out of Wuhan, which was found to be highly effective, but few studies investigated the effectiveness of measures implemented in other contexts. Early implementation was identified as a determinant of effectiveness. Most studies of international travel measures failed to account for domestic travel measures, and thus likely led to biased estimates. Poor data and other factors contributed to the low quality of the studies identified.

ConclusionTravel measures, especially those implemented in Wuhan, played a key role in shaping the early transmission dynamics of the COVID-19 pandemic, however, the effectiveness of these measures was short-lived. There is an urgent need to address important evidence gaps, but also a need to review the way in which evidence is incorporated in the IHR in the early phases of a novel infectious disease outbreak.

What is already known on this subject?O_LIPrevious reviews of the evidence from outbreaks of influenza and other infectious disease have generally found that there is limited evidence that travel-measures are effective at containing outbreaks.
C_LIO_LIHowever, it is unclear if the lessons from other infectious disease outbreaks would be relevant in the context of COVID-19.
C_LIO_LIBased on evidence at the time, WHO did not recommend any travel restrictions when it declared COVID-19 a Public Health Emergency of International Concern.
C_LI

What does this study add?O_LIThis study rapidly reviews the evidence on the effectiveness of travel measures implemented in the early phase of the pandemic on epidemiological countries.
C_LIO_LIThe study investigated both international and domestic travel measures and a wide range of travel measures.
C_LIO_LIThe study finds that the domestic travel measures implemented in Wuhan were effective at reducing the importation of cases internationally and within China. The study also finds that travel measures are more effective when implemented earlier in the outbreak.
C_LIO_LIThe findings generate recommendations on how to incorporate evidence into the International Health Regulations and highlights important research gaps that remain.
C_LI

How might this affect future outbreaks?O_LIThe findings of this study suggest the need to decouple recommendations of travel measures from the declaration of a public health emergency of international concern.
C_LIO_LIHighlights the need to evaluate the potential effectiveness of travel measures for each outbreak, and not just assume effectiveness based on past outbreak scnearios.
C_LI",health policy,exact,100,100
medRxiv,10.1101/2020.11.23.20237198,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.23.20237198,The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing,Pavel Drevinek; Jakub Hurych; Zdenek Kepka; Ales Briksi; Michal Kulich; Miroslav Zajac; Petr Hubacek; Marc Modat; Erica Moldeni; Ben Murray; Carole Sudre; Richard Davies; Anna May; Long Nguyen; David Drew; Amit Joshi; Andrew Chan; Jakob Cramer; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,"2nd Faculty of Medicine, Charles University and Motol University Hospital; 2nd Faculty of Medicine, Charles University and Motol University Hospital; Motol University Hospital; Motol University Hospital; Faculty of Mathematics and Physics, Charles University; Motol University Hospital; 2nd Faculty of Medicine, Charles University and Motol University Hospital; King's College London; King's College London; King's College London; University College London; Zoe Global; Zoe Global; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Coalition for Epidemic Preparedness Innovations; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute","ObjectivesAntigen tests have recently emerged as an interesting alternative to SARS-CoV-2 diagnostic PCR, thought to be valuable especially for the screening of bigger communities. To check appropriateness of the antigen based testing, we determined sensitivity of two point-of-care antigen tests when applied to a cohort of COVID-19 symptomatic, COVID-19 asymptomatic and healthy persons.

MethodsWe examined nasopharyngeal swabs with antigen test 1 (Panbio Covid-19 Ag Rapid Test, Abbott) and antigen test 2 (Standard F Covid-19 Ag FIA, SD Biosensor). An additional nasopharyngeal and oropharyngeal swab of the same individual was checked with PCR (Allplex SARS-nCoV-2, Seegene). Within a 4-day period in October 2020, we collected specimens from 591 subjects. Of them, 290 had COVID-19 associated symptoms.

ResultsWhile PCR positivity was detected in 223 cases, antigen test 1 and antigen test 2 were found positive in 148 (sensitivity 0.664, 95% CI 0.599 - 0.722) and 141 (sensitivity 0.623, 95% CI 0.558 - 0.684) patients, respectively. When only symptomatic patients were analysed, sensitivity increased to 0.738 (95% CI 0.667 - 0.799) for the antigen test 1 and to 0.685 (95% CI 0.611 - 0.750) for the antigen test 2. The substantial drop in sensitivity to 12.9% (95% CI 0.067 - 0.234) was observed for samples with the PCR threshold cycle above > 30.

ConclusionsLow sensitivity of antigen tests leads to the considerable risk of false negativity. It is advisable to implement repeated testing with high enough frequency if the antigen test is used as a frontline screening tool.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.24.20237560,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.24.20237560,"Demography, social contact patterns and the COVID-19 burden in different settings of Ethiopia: a modeling study",Filippo Trentini; Giorgio Guzzetta; Margherita Galli; Agnese Zardini; Fabio Manenti; Giovanni Putoto; Valentina Marziano; Worku Gamshie Nigussa; Ademe Tsegaye; Alessandro Greblo; Alessia Melegaro; Marco Ajelli; Stefano Merler; Piero Poletti; David Drew; Amit Joshi; Andrew Chan; Jakob Cramer; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,Bruno Kessler Foundation; Bruno Kessler Foundation; Bruno Kessler Foundation; Bruno Kessler Foundation; Doctors with Africa CUAMM; Doctors with Africa CUAMM; Bruno Kessler Foundation; Doctors with Africa CUAMM; Doctors with Africa CUAMM; Doctors with Africa CUAMM; Bocconi University; Indiana University School of Public Health; Bruno Kessler Foundation; Bruno Kessler Foundation; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Coalition for Epidemic Preparedness Innovations; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute,"BackgroundCOVID-19 spread may have a dramatic impact in countries with vulnerable economies and limited availability of, and access to, healthcare resources and infrastructures. However, in sub-Saharan Africa a low prevalence and mortality have been observed so far.

MethodsWe collected data on individuals social contacts in Ethiopia across geographical contexts characterized by heterogeneous population density, work and travel opportunities, and access to primary care. We assessed how socio-demographic factors and observed mixing patterns can influence the COVID-19 disease burden, by simulating SARS-CoV-2 transmission in remote settlements, rural villages, and urban neighborhoods, under the current school closure mandate.

ResultsFrom national surveillance data, we estimated a net reproduction number of 1.62 (95%CI 1.55-1.70). We found that, at the end of an epidemic mitigated by school closure alone, 10-15% of the overall population would have been symptomatic and 0.3-0.4% of the population would require mechanical ventilation and/or possibly result in a fatal outcome. Higher infection attack rates are expected in more urbanized areas, but the highest incidence of critical disease is expected in remote subsistence farming settlements.

ConclusionsThe relatively low burden of COVID-19 in Ethiopia can be explained by the estimated mixing patterns, underlying demography and the enacted school closures. Socio-demographic factors can also determine marked heterogeneities across different geographical contexts within the same country. Our findings can contribute to understand why sub-Saharan Africa is experiencing a relatively lower attack rate of severe cases compared to high income countries.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.24.20235952,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.24.20235952,Severity of COVID-19 is inversely correlated with increased number counts of non-synonymous mutations in Tokyo,Kodai Abe; Yasuaki Kabe; Susumu Uchiyama; Yuka Iwasaki W.; Hirotsugu Ishizu; Yoshifumi Uwamino; Toshiki Takenouchi; Shunsuke Uno; Makoto Ishii; Mitsuru Murata; Naoki Hasegawa; Hideyuki Saya; Yuko Kitagawa; Koichi Fukunaga; Masayuki Amagai; Haruhiko Siomi; Makoto Suematsu; Kenjiro Kosaki; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,"Keio University, School of Medicine; Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan; Department of Biotechnology, Graduate School of Engineering, Osaka University School of Medicine, Osaka, Japan/ Exploratory Research Center on Life and Living S; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan; Division of Infection Diseases and Infection Control, Keio University Hospital, Tokyo, Japan: Department of Infectious Diseases, Keio University School of Medic; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan; Division of Infection Diseases and Infection Control, Keio University Hospital, Tokyo, Japan: Department of Infectious Diseases, Keio University School of Medic; Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Infection Diseases and Infection Control, Keio University Hospital, Tokyo, Japan: Department of Infectious Diseases, Keio University School of Medic; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan; Department of Surgery, Keio University School of Medicine, Tokyo, Japan; Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan; Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan; Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute","BackgroundSARS-CoV-2 genome accumulates point mutations in a constant manner. Whether the accumulation of point mutations is correlated with milder manifestations of COVID-19 remains unknown.

MethodsWe performed SARS-CoV-2 genome sequencing in 90 patients with COVID-19 infection treated at a tertiary medical center in Tokyo between March and August 2020. The possible association between disease severity and viral haplotype was then assessed by counting the number of mutations in addition to performing phylogenic tree analysis, comparative amino acid sequence analysis among {beta}-coronaviruses, and mathematical prediction of the functional relevance of amino acid substitutions.

ResultsThe number of non-synonymous mutations was inversely correlated with COVID-19 severity, as defined by requiring oxygen supplementation. Phylogenic tree analysis identified two predominant groups which were separated by a set of 6 single nucleotide substitutions, including four leading to non-synonymous amino acid substitutions. Among those four, Pro108Ser in 3 chymotrypsin-like protease (3CLpro) and Pro151Leu in nucleocapsid protein occurred at conserved locations and were predicted to be deleterious. Patients with Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein had a lower odds ratio for developing hypoxia requiring supplemental oxygen (odds ratio of 0.24 [95% confidence interval of 0.07-0.88, P-value = 0.032]) after adjustments for age and sex, compared with patients lacking this haplotype in Clade 20B.

ConclusionViral genome sequencing in 90 patients treated in the Tokyo Metropolitan area showed that the accumulation of point mutations, including Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein, was inversely correlated with COVID-19 severity. Further in vitro research is awaited.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.23.20237057,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.23.20237057,"Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial",Jean-Marc Schwob; Alix Miauton; Dusan Petrovic; Jean Perdrix; Nicolas Senn; Katia Jaton; Onya Opota; Alain Maillard; Gianni Minghelli; Jacques Cornuz; Gilbert Greub; Blaise Genton; Valerie D'Acremont; Koichi Fukunaga; Masayuki Amagai; Haruhiko Siomi; Makoto Suematsu; Kenjiro Kosaki; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,"Center for primary care and public health, University of Lausanne (Unisante); Center for primary care and public health, University of Lausanne (Unisante); Center for primary care and public health, University of Lausanne (Unisante); Center for primary care and public health, University of Lausanne (Unisante); Center for primary care and public health, University of Lausanne (Unisante); Institute of microbiology, University hospital of Lausanne; Institute of microbiology, University hospital of Lausanne; Vidy-Med; Vidy-Med; Centre for primary care and public health, University of Lausanne (Unisante); Institute of microbiology, University hospital of Lausanne; Centre for primary care and public health, University of Lausanne (Unisante); Centre for primary care and public health, University of Lausanne (Unisante); Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan; Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan; Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute","BackgroundNasopharyngeal antigen Rapid Diagnostic Tests (RDTs) and saliva RT-PCR have shown variable performance to detect SARS-CoV-2.

MethodsIn October 2020, we conducted a prospective trial involving patients presenting at testing centers with symptoms of COVID-19. We compared detection rates and performance of RDT, saliva PCR and nasopharyngeal (NP) PCR.

ResultsOut of 949 patients enrolled, 928 patients had all three tests. Detection rates were 35.2% (95%CI 32.2-38.4%) by RDT, 39.8% (36.6-43.0%) by saliva PCR, 40.1% (36.9-43.3%) by NP PCR, and 41.5% (38.3-44.7%) by any test. For those with viral loads (VL) [&ge;]106 copies/ml, detection rates were 30.3% (27.3-33.3), 31.4% (28.4-34.5), 31.5% (28.5-34.6), and 31.6% (28.6-34.7%) respectively.

Sensitivity of RDT compared to NP PCR was 87.4% (83.6-90.6%) for all positive patients and 96.5% (93.6-98.3%) for those with VL[&ge;]106. Sensitivity of STANDARD-Q(R), Panbio and COVID-VIRO(R) Ag tests were 92.9% (86.4-96.9%), 86.1% (78.6-91.7%) and 84.1% (76.9-89.7%), respectively. For those with VL[&ge;]106, sensitivities were 96.6% (90.5-99.3%), 97.8% (92.1-99.7%) and 95.3% (89.4-98.5%) respectively. Specificity of RDT was 100% (99.3-100%) compared to any PCR. RDT sensitivity was similar <4 days (87.8%) and [&ge;]4 days (85.7%) after symptoms onset (p=0.6). Sensitivities of saliva and NP PCR were 95.7% (93.1-97.5%) and 96.5% (94.1-98.1%), respectively, compared to the other PCR.

ConclusionsThe high performance of RDTs allows rapid identification of COVID cases with immediate isolation of the vast majority of contagious individuals. RDT could be a game changer in primary care practices, and even more so in resource-constrained settings. PCR on saliva can replace NP PCR.

ClinicalTrial.gov Identifier: NCT04613310",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.23.20236901,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.23.20236901,SalivaSTAT: Direct-PCR and pooling of saliva samples collected in healthcare and community setting for SARS-CoV-2 mass surveillance.,Nikhil Shri Shri Sahajpal; Ashis K Mondal; Sudha Ananth; Allan Njau; Pankaj Ahluwalia; Gary Newnam; Adriana Lozoya-Colinas; Nicholas V Hud; Vamsi Kota; Ted M Ross; Michelle D Reid; Sadanand Fulzele; Alka Chaubey; Madhuri Hegde; Amyn M Rojiani; Ravindra Kolhe; Makoto Suematsu; Kenjiro Kosaki; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Alfred E Loeliger; Alex Sigal,"Augusta University; Augusta University; Augusta University; Aga Khan University Hospital; Augusta University; Georgia Institute of Technology; Georgia Institute of Technology; Georgia Institute of Technology; Augusta University; University System of Georgia; Emory University; Augusta University; Augusta University; PerkinElmer; Augusta University; Augusta University; Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan; Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations; Africa Health Research Institute","BackgroundThe limitations of widespread current COVID-19 diagnostic testing lie at both pre-analytical and analytical stages. Collection of nasopharyngeal swabs is invasive and is associated with exposure risk, high cost, and supply-chain constraints. Additionally, the RNA extraction in the analytical stage is the most significant rate-limiting step in the entire testing process. To alleviate these limitations, we developed a universal saliva processing protocol (SalivaSTAT) that would enable an extraction free RT-PCR test using any of the commercially available RT-PCR kits.

MethodsWe optimized saliva collection devices, heat-shock treatment and homogenization. The effect of homogenization on saliva samples for extraction-free RT-PCR assay was determined by evaluating samples with and without homogenization and preforming viscosity measurements. Saliva samples (872) previously tested using the FDA-EUA method were reevaluated with the optimized SalivaSTAT protocol using two widely available commercial RT-PCR kits. Further, a five-sample pooling strategy was evaluated as per FDA guidelines using the SalivaSTAT protocol.

ResultsThe saliva collection (done without any media) performed comparable to the FDA-EUA method. The SalivaSTAT protocol was optimized by incubating saliva samples at 95{degrees}C for 30-minutes and homogenization, followed by RT-PCR assay. The clinical sample evaluation of 630 saliva samples using the SalivaSTAT protocol with PerkinElmer (600-samples) and CDC (30-samples) RT-PCR assay achieved positive (PPA) and negative percent agreement (NPA) of 95.8% and 100%, respectively. The LoD was established as [~]20-60 copies/ml by absolute quantification. Further, a five-sample pooling evaluation using 250 saliva samples achieved a PPA and NPA of 92% and 100%, respectively.

ConclusionWe have optimized an extraction-free direct RT-PCR assay for saliva samples that demonstrated comparable performance to FDA-EUA assay (Extraction and RT-PCR). The SalivaSTAT protocol is a rapid, sensitive, and cost-effective method that can be adopted globally, and has the potential to meet testing needs and may play a significant role in management of the current pandemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.19.20234120,2020-11-23,https://medrxiv.org/cgi/content/short/2020.11.19.20234120,Actionable druggable genome-wide Mendelian randomization identifies repurposingopportunities for COVID-19,Liam Gaziano; Claudia Giambartolomei; Alexandre C Pereira; Anna Gaulton; Daniel C Posner; Sonja A Swanson; Yuk Lam Ho; Sudha K Iyengar; Nicole M Kosik; Marijana Vujkovic; David R Gagnon; A Patricia Bento; Pedro Beltrao; Inigo Barrio Hernandez; Lars Ronnblom; Niklas Hagberg; Christian Lundtoft; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"VA Boston Healthcare System, University of Cambridge; Instituto Italiano di Tecnologia, University of California Los Angeles; University of Sao Paulo, Harvard University; European Molecular Biology Laboratory, European Bioinformatics Institute; VA Boston Healthcare System; Erasmus Medical Center; VA Boston Healthcare System; Case Western Reserve University and Louis Stoke Cleveland VAMC; VA Boston Healthcare System; The Corporal Michael J. Crescenz VA Medical Center, the University of Pennsylvania Perelman School of Medicine; Boston University, VA Boston Healthcare System; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; Uppsala University; Uppsala University; Uppsala University; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization (MR) analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2: P=1.6x10-6, IFNAR2: P=9.8x10-11, and IL-10RB: P=1.9x10-14) using cis-eQTL genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared eQTL signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.20.20235903,2020-11-23,https://medrxiv.org/cgi/content/short/2020.11.20.20235903,Modeling the spread of Covid-19 under active management,Ivan Cherednik; Claudia Giambartolomei; Alexandre C Pereira; Anna Gaulton; Daniel C Posner; Sonja A Swanson; Yuk Lam Ho; Sudha K Iyengar; Nicole M Kosik; Marijana Vujkovic; David R Gagnon; A Patricia Bento; Pedro Beltrao; Inigo Barrio Hernandez; Lars Ronnblom; Niklas Hagberg; Christian Lundtoft; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"UNC at Chapel Hill; Instituto Italiano di Tecnologia, University of California Los Angeles; University of Sao Paulo, Harvard University; European Molecular Biology Laboratory, European Bioinformatics Institute; VA Boston Healthcare System; Erasmus Medical Center; VA Boston Healthcare System; Case Western Reserve University and Louis Stoke Cleveland VAMC; VA Boston Healthcare System; The Corporal Michael J. Crescenz VA Medical Center, the University of Pennsylvania Perelman School of Medicine; Boston University, VA Boston Healthcare System; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; Uppsala University; Uppsala University; Uppsala University; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","AO_SCPLOWBSTRACTC_SCPLOWThe challenges with modeling the spread of Covid-19 are its power-type growth during the middle stages with the exponents depending on time, and the saturation (currently) due to the protective measures. The two-phase solution we propose for the total number of detected cases of Covid-19 describes the actual curves in many countries almost with the accuracy of physics laws. Bessel functions play the key role in our approach. The differential equations we obtain are of universal type; they can describe general momentum and transient responses in behavioral psychology, invasion ecology, etc. Due to a very small number of parameters, namely, the initial transmission rate and the intensity of the hard and soft measures, we obtain a convincing explanation of the surprising uniformity of the curves of the spread in many different areas. This theory can serve as a tool for forecasting the epidemic spread and evaluating the efficiency of the protective measures, which is very much needed for epidemics. As its practical application, the computer programs aimed at providing projections for late stages of Covid-19 proved to be remarkably stable in many countries, including Western Europe, the USA and some in Asia. We provide a projection for the saturation of the 3rd wave in the USA: the corresponding number of total, detected or not, cases can presumably reach then the herd immunity levels (G-strains). This can be used to analyze the efficiency of the vaccinations.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.20.20235754,2020-11-23,https://medrxiv.org/cgi/content/short/2020.11.20.20235754,High infectiousness immediately before COVID-19 symptom onset highlights the importance of contact tracing,William S Hart; Philip K Maini; Robin N Thompson; Anna Gaulton; Daniel C Posner; Sonja A Swanson; Yuk Lam Ho; Sudha K Iyengar; Nicole M Kosik; Marijana Vujkovic; David R Gagnon; A Patricia Bento; Pedro Beltrao; Inigo Barrio Hernandez; Lars Ronnblom; Niklas Hagberg; Christian Lundtoft; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"University of Oxford; University of Oxford; University of Oxford; European Molecular Biology Laboratory, European Bioinformatics Institute; VA Boston Healthcare System; Erasmus Medical Center; VA Boston Healthcare System; Case Western Reserve University and Louis Stoke Cleveland VAMC; VA Boston Healthcare System; The Corporal Michael J. Crescenz VA Medical Center, the University of Pennsylvania Perelman School of Medicine; Boston University, VA Boston Healthcare System; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; Uppsala University; Uppsala University; Uppsala University; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","Understanding changes in infectiousness during COVID-19 infections is critical to assess the effectiveness of public health measures such as contact tracing. Data from known source-recipient pairs can be used to estimate the average infectiousness profile of infected individuals, and to evaluate the proportion of presymptomatic transmissions. Here, we infer the infectiousness profile of COVID-19 infections using a mechanistic approach, and show that this method provides an improved fit to data from source-recipient pairs compared to previous studies. Our results indicate a higher proportion of presymptomatic transmissions than previously thought, with many transmissions occurring shortly before symptom onset. High infectiousness immediately prior to symptom onset highlights the importance of contact tracing, even if contacts from a short time window before symptom onset alone are traced.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.20.20235242,2020-11-23,https://medrxiv.org/cgi/content/short/2020.11.20.20235242,Outbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus,Mert Aziz Ipekci; Diana Buitrago-Garcia; Kaspar Walter Meili; Fabienne Krauer; Nirmala Prajapati; Shabnam Thapa; Lea Wildisen; Lucia Araujo Chaveron; Lukas Baumann; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, Graduate School of Health Sciences, University of Bern, Bern, Switzerland; Department of Epidemiology and Global Health, Umea University, Umea, Sweden; Centre for Ecological and Evolutionary Synthesis (CEES), University of Oslo, Norway; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Department of Internal Medicine, Kantonsspital Olten, Olten, Switzerland; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","BackgroundOutbreaks of infectious diseases generate outbreaks of scientific evidence. In 2016 epidemics of Zika virus emerged, largely in Latin America and the Caribbean. In 2020, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic of coronavirus disease 2019 (COVID-19). We compared patterns of scientific publications for the two infections over time.

MethodsWe used living systematic review methods to search for and annotate publications according to study design. For Zika virus, a review team performed the tasks for publications in 2016. For SARS-CoV-2, a crowd of 25 volunteer scientists performed the tasks for publications up to May 24, 2020. We used descriptive statistics to categorise and compare study designs over time.

FindingsWe found 2,286 publications about Zika virus in 2016 and 21,990 about SARS-CoV-2 up to 24 May 2020, of which we analysed a random sample of 5294. For both infections, there were more epidemiological than laboratory science studies. Amongst epidemiological studies for both infections, case reports, case series and cross-sectional studies emerged first, cohort and case-control studies were published later. Trials were the last to emerge. Mathematical modelling studies were more common in SARS-CoV-2 research. The number of preprints was much higher for SARS-CoV-2 than for Zika virus.

InterpretationSimilarities in the overall pattern of publications might be generalizable, whereas differences are compatible with differences in the characteristics of a disease. Understanding how evidence accumulates during disease outbreaks helps us understand which types of public health questions we can answer and when.

FundingMJC and HI are funded by the Swiss National Science Foundation (SNF grant number 176233). NL acknowledges funding from the European Unions Horizon 2020 research and innovation programme - project EpiPose (grant agreement number 101003688). DBG is funded by the Swiss government excellence scholarship (2019.0774) and the Swiss School of Public Health Global P3HS.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.19.20229856,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20229856,Typhoon Eye Effect vs. Ripple Effect: The Role of Family Size on the Mental Health under the COVID-19 Pandemic in Pakistan,Tooba Lateef; Jiyao Chen; Muhammad Tahir; Teba Abdul Lateef; Bryan Chen; Jizhen Li; Stephen X. Zhang; Lucia Araujo Chaveron; Lukas Baumann; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"University of Karachi; Oregon State University; Sir Syed University of Engineering and Technology; University of Karachi; Crescent Valley High School; Tsinghua University; University of Adelaide; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Department of Internal Medicine, Kantonsspital Olten, Olten, Switzerland; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","BackgroundThe recent outbreak of COVID-19 impacts the mental health of people worldwide. The mental conditions and the associated predictors of adults in Pakistan, the fifth most populous country in the world, during the COVID-19 remains understudied. We aim to investigate distress, anxiety and overall mental health and their associated predictors among Pakistani adults in this pandemic. We specifically examine the mental health issues based on the distance to the epicenter, a predictor that has revealed opposing evidence in other countries based on the theories of typhoon eye effect and ripple effect. The samples consist of 601 adults who were surveyed online about 2.5 months into the outbreak across Pakistan with varying distance to the epicenter of COVID-19 of Karachi in Pakistan.

ResultsThe results showed that 9.2% and 19.0% of the participants surpassed the cut-off of distress and anxiety disorders, respectively. Overall, the distance to the epicenter positively predicted the mental health of adults in Pakistan, and family size negatively moderated this effect. The distance to the epicenter negatively predicted distress and anxiety disorders for adults in large families, which are quite common in Pakistan.

ConclusionThe evidence of the study interestingly finds the prediction of the mental health of people by their distance to the epicenter depends on the family. The evidence of this study can help to provide the initial indicator for mental health care providers to screen vulnerable groups in Pakistan, a populous country that continues to struggle to cope with the COVID-19 pandemic.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.11.19.20231670,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20231670,Are pregnant women satisfied with perinatal standards of care during COVID-19 pandemic?,Claudia Ravaldi; Laura Mosconi; Giada Crescioli; Valdo Ricca; Alfredo Vannacci; Jizhen Li; Stephen X. Zhang; Lucia Araujo Chaveron; Lukas Baumann; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"PeaRL Perinatal Research Laboratory, University of Florence; CiaoLapo Foundation for Perinatal Health, Prato, Italy; CiaoLapo Foundation for Perinatal Health, Prato, Italy; PeaRL Perinatal Research Laboratory, University of Florence; CiaoLapo Foundation for Perinatal Health, Prato, Italy; Department of Health Sciences, University of Florence, Florence, Italy; PeaRL Perinatal Research Laboratory, University of Florence; CiaoLapo Foundation for Perinatal Health, Prato, Italy; Tsinghua University; University of Adelaide; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Department of Internal Medicine, Kantonsspital Olten, Olten, Switzerland; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","COVID-19 restrictive measures severely impacted maternity services worldwide, but little is known about the differences in womens concerns, perception of the modifications of maternity services and childbirth programs at different times during the pandemic. Here we report data from the first COVID-19 wave in Italy, during the 2020 national lockdown (March-April) and soon after lockdown release (May).

1307 pregnant women answered the survey during national lockdown (phase 1) or after restrictive measures were released (phase 2). Women reported a significantly higher COVID-19 concern during phase 1 than during phase 2 (2.34 SD 0.5 vs 2.12 SD 0.5 on a Likert scale 0-3; p<0.001). Several domains of perinatal care were affected during COVID-19 lockdown: while antenatal visits, the use of technology to keep in touch with healthcare professionals, and closeness of caregivers were generally more appreciated (especially during phase 2), women reported the greatest difficulties in receiving clear information on hospitalization, birth plan and partners presence at birth.

Italian pregnant womens worries about the effects of the pandemic on health and their perception of quality in the organization of maternity services improved during lockdown, but they continued to represent a challenge in May, especially regarding organizational aspects of hospitalization and childbirth.",public and global health,exact,100,100
medRxiv,10.1101/2020.11.20.20235291,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.20.20235291,Isolation thresholds for curbing SARS-CoV-2 resurgence,Laith Yakob; Laura Mosconi; Giada Crescioli; Valdo Ricca; Alfredo Vannacci; Jizhen Li; Stephen X. Zhang; Lucia Araujo Chaveron; Lukas Baumann; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"London School of Hygiene & Tropical Medicine; CiaoLapo Foundation for Perinatal Health, Prato, Italy; PeaRL Perinatal Research Laboratory, University of Florence; CiaoLapo Foundation for Perinatal Health, Prato, Italy; Department of Health Sciences, University of Florence, Florence, Italy; PeaRL Perinatal Research Laboratory, University of Florence; CiaoLapo Foundation for Perinatal Health, Prato, Italy; Tsinghua University; University of Adelaide; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Department of Internal Medicine, Kantonsspital Olten, Olten, Switzerland; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","Self-instigated isolation is heavily relied on to curb SARS-CoV-2 transmission. Accounting for uncertainty in the latent and prepatent periods, as well as the proportion of infections that remain asymptomatic, the limits of this intervention at different phases of infection resurgence are estimated. We show that by October, SARS-CoV-2 transmission rates in England had already begun exceeding levels that could be interrupted using this intervention alone, lending support to the second national lockdown on November 5th.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.19.20234948,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20234948,A simple direct RT-LAMP SARS-CoV-2 saliva diagnostic,Michael J. Flynn; Olga Snitser; Idan Yelin; James Flynn; Samantha Green; Moran Szwarcwort; Roy Kishony; Michael B. Elowitz; Lukas Baumann; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"California Institute of Technology; Israel Institute of Technology; Israel Institute of Technology; Catholic Medical Center; Catholic Medical Center; Rambam Health Care Campus; Israel Institute of Technology; California Institute of Technology; Department of Internal Medicine, Kantonsspital Olten, Olten, Switzerland; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","Widespread, frequent testing is essential for curbing the ongoing COVID-19 pandemic. Because its simplicity makes it ideal for widely distributed, high throughput testing, RT-LAMP provides an attractive alternative to RT-qPCR. However, most RT-LAMP protocols require the purification of RNA, a complex and low-throughput bottleneck that has often been subject to reagent supply shortages. Here, we report an optimized RT-LAMP-based SARS-CoV-2 diagnostic protocol for saliva and swab samples. In the protocol we replace RNA purification with a simple sample preparation step using a widely available chelating agent, as well as optimize key protocol parameters. When tested on clinical swab and saliva samples, this assay achieves a limit of detection of 105 viral genomes per ml, with sensitivity close to 90% and specificity close to 100%, and takes 45 minutes from sample collection to result, making it well suited for a COVID-19 surveillance program.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.18.20232892,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.18.20232892,A follow-up study shows no new infections caused by patients with repeat positive of COVID-19 in Wuhan,Xiaomin Wu; Zengmiao Wang; Zhenyu He; Yapin Li; Yating Wu; Huaiji Wang; Yonghong Liu; Fanghua Hao; Huaiyu Tian; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"Wuhan Center for Disease Control and Prevention, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Wuhan Center for Disease Control and Prevention, Wuhan, China; Central Theater Center for Disease Control and Prevention of PLA, Beijing, China; Wuhan Center for Disease Control and Prevention, Wuhan, China; Wuhan Center for Disease Control and Prevention, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Central China Normal University, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","BackgroundIt has been reported that a few recovered COVID-19 patients could suffer repeat positive, testing positive for the SARS-CoV-2 virus again after they were discharged from hospital. Understanding the epidemiological characteristics of patients with repeat positive is vital in preventing a second wave of COVID-19.

MethodsIn this study, the epidemiological and clinical features for 20,280 COVID-19 patients from multiple centers between 31 December 2019 and 4 August 2020 in Wuhan were collected and followed. In addition, the RT-qPCR testing results for 4,079 individuals who had close contact with the patients suffering repeat positive were also obtained.

Results2,466 (12.16%) of 20,280 patients presented with a repeat positive of SARS-CoV-2 after they were discharged from hospital. 4,079 individuals had close contact with them. The PCR result were negative for the 4,079 individuals.

ConclusionsBy a follow-up study in Wuhan, we show the basic characteristics of patients with repeat positive and no new infections caused by patients with repeat positive of COVID-19.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.19.20233437,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20233437,Viruses such as SARS-CoV-2 can be partially shielded from UV radiation when in particles generated by sneezing or coughing: Numerical simulations,David C Doughty III; Steven C Hill; Daniel W Mackowski; Yapin Li; Yating Wu; Huaiji Wang; Yonghong Liu; Fanghua Hao; Huaiyu Tian; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"US Army DEVCOM Army Research Laboratory; US Army DEVCOM Army Research Laboratory; Auburn University; Central Theater Center for Disease Control and Prevention of PLA, Beijing, China; Wuhan Center for Disease Control and Prevention, Wuhan, China; Wuhan Center for Disease Control and Prevention, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Central China Normal University, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","UV radiation can inactivate viruses such as SARS-CoV-2. However, designing effective UV germicidal irradiation (UVGI) systems can be difficult because the effects of dried respiratory droplets and other fomites on UV light intensities are poorly understood. Numerical modeling of UV intensities inside virus-containing particles on surfaces can increase understanding of these possible reductions in UV intensity. We model UV intensities within spherical approximations of virions randomly positioned within spherical particles. The model virions and dried particles have sizes and optical properties to approximate SARS-CoV-2 and dried particles formed from respiratory droplets, respectively. Wavelengths used are 260 nm (germicidal UVC) and 302 nm (solar UVB). In 5- and 9-m diameter particles on a surface, illuminated by 260-nm UV light from a direction perpendicular to the surface, 10% and 18% (respectively) of simulated virions are exposed to intensities less than 1/100th of intensities in individually exposed virions (i.e., they are partially shielded). Even for 302-nm light, where the absorption is small, 11% of virions in 9-{micro}m particles have exposures 1/100th those of individually exposed virions. Calculated results show that shielding of virions in a particle can be strongly reduced by illuminating a particle either from multiple widely separated incident directions, or by illuminating a particle rotating in air (because of turbulence, Brownian diffusion, etc.) for a time sufficient to rotate through all orientations with respect to the UV illumination. Because highly UV-reflective paints and surfaces can increase the angular ranges of illumination, they appear likely to be useful for reducing shielding of virions.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2020.11.19.20234567,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20234567,Association of HLA class I genotypes with age at death of COVID-19 patients,Maxim Shkurnikov; Stepan Nersisyan; Tatjana Jankevic; Alexei Galatenko; Ivan Gordeev; Valery Vechorko; Alexander Tonevitsky; Fanghua Hao; Huaiyu Tian; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"HSE University; HSE University; Pirogov Russian National Research Medical University; Lomonosov Moscow State University; O.M. Filatov City Clinical Hospital; O.M. Filatov City Clinical Hospital; HSE University; Central China Normal University, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","BackgroundHLA class I molecules play a crucial role in the development of a specific immune response to viral infections by presenting viral peptides to cell surface where they will be further recognized by T cells. In the present manuscript we explored whether HLA class I genotype can be associated with critical course of COVID-19 by searching possible connections between genotypes of deceased patients and their age at death.

Methods and FindingsHLA-A, HLA-B and HLA-C genotypes of n = 111 deceased patients with COVID-19 (Moscow, Russia) and n = 428 volunteers were identified with targeted next-generation sequencing. Deceased patients were splitted into two groups according to age at death: n = 26 adult patients with age at death below 60 completed years (inclusively) and n = 85 elderly patients over 60. With the use of HLA class I genotypes we developed a risk score which is associated with the ability to present SARS-CoV-2 peptides by an individuals HLA class I molecule set. The resulting risk score was significantly higher in the group of deceased adults compared to elderly adults (p = 0.00348, AUC ROC = 0.68). In particular, presence of HLA-A*01:01 allele was associated with high risk, while HLA-A*02:01 and HLA-A*03:01 mainly contributed to the low risk group. The analysis of homozygous patients highlighted the results even stronger: homozygosity by HLA-A*01:01 mainly accompanied early deaths, while only one HLA-A*02:01 homozygote died before 60.

ConclusionsThe obtained results suggest the important role of HLA class I peptide presentation in the development of a specific immune response to COVID-19. While prediction of age at death by HLA class I genotype had a reliable performance, involvement of HLA class II genotype can make it even higher in the future studies.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.11.19.20235036,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20235036,Statistical techniques to estimate the SARS-CoV-2 infection fatality rate,Mikael Mieskolainen; Robert Bainbridge; Oliver Buchmueller; Louis Lyons; Nicholas Wardle; Valery Vechorko; Alexander Tonevitsky; Fanghua Hao; Huaiyu Tian; Sanam Shah; Tessa Whiteley; Gonzalo Solis-Garcia; Foteini Tsotra; Ivan Zhelyazkov; Hira Imeri; Nicola Low; Michel Jacques Counotte; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; O.M. Filatov City Clinical Hospital; HSE University; Central China Normal University, Wuhan, China; State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Ecole des Hautes Etudes en Sante Publique (EHESP), Saint Denis, France; Pediatrics Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","AO_SCPLOWBSTRACTC_SCPLOWThe determination of the infection fatality rate (IFR) for the novel SARS-CoV-2 coronavirus is a key aim for many of the field studies that are currently being undertaken in response to the pandemic. The IFR together with the basic reproduction number R0, are the main epidemic parameters describing severity and transmissibility of the virus, respectively. The IFR can be also used as a basis for estimating and monitoring the number of infected individuals in a population, which may be subsequently used to inform policy decisions relating to public health interventions and lockdown strategies. The interpretation of IFR measurements requires the calculation of confidence intervals. We present a number of statistical methods that are relevant in this context and develop an inverse problem formulation to determine correction factors to mitigate time-dependent effects that can lead to biased IFR estimates. We also review a number of methods to combine IFR estimates from multiple independent studies, provide example calculations throughout this note and conclude with a summary and ""best practice"" recommendations. The developed code is available online.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.19.20234849,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20234849,Community factors and excess mortality in first wave of the COVID-19 pandemic.,Bethan Davies; Brandon L Parkes; James Bennett; Daniela Fecht; Marta Blangiardo; Majid Ezzati; Paul Elliott; Cameron Martino; Rachel Diner; Gibraan Rahman; Daniel McDonald; George Armstrong; Sho Kodera; Sonya Donato; Gertrude Ecklu-Mensah; Neil Gottel; Mariana Salas Garcia; Leslie Chiang; Rodolfo A. Salido; Justin P. Shaffer; MacKenzie Bryant; Karenina Sanders; Greg Humphrey; Gail Ackermann; Niina Haiminen; Kristen L. Beck; Ho-Cheol Kim; Anna Paola Carrieri; Laxmi Parida; Yoshiki Vazquez-Baeza; Francesca J. Torriani; Rob Knight; Jack Gilbert; Daniel Sweeney; Sarah M. Allard; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; IBM; IBM; IBM; IBM; IBM; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","Risk factors for increased risk of death from Coronavirus Disease 19 (COVID-19) have been identified1,2 but less is known on characteristics that make communities resilient or vulnerable to the mortality impacts of the pandemic. We applied a two-stage Bayesian spatial model to quantify inequalities in excess mortality at the community level during the first wave of the pandemic in England. We used geocoded data on all deaths in people aged 40 years and older during March-May 2020 compared with 2015-2019 in 6,791 local communities. Here we show that communities with an increased risk of excess mortality had a high density of care homes, and/or high proportion of residents on income support, living in overcrowded homes and/or high percent of people with a non-White ethnicity (including Black, Asian and other minority ethnic groups). Conversely, after accounting for other community characteristics, we found no association between population density or air pollution and excess mortality. Overall, the social and environmental variables accounted for around 15% of the variation in mortality at community level. Effective and timely public health and healthcare measures that target the communities at greatest risk are urgently needed if England and other industrialised countries are to avoid further widening of inequalities in mortality patterns during the second wave.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.10.20229146,2020-11-13,https://medrxiv.org/cgi/content/short/2020.11.10.20229146,"Awareness, knowledge and trust in the Greek authorities towards COVID-19 pandemic: results from the Epirus Health Study cohort",Afroditi Kanellopoulou; Fotios Koskeridis; Georgios Markozannes; Emmanouil Bouras; Chrysa Soutziou; Konstantinos Chaliasos; Michail T Doumas; Dimitrios E Sigounas; Vasilios T Tzovaras; Agapios Panos; Yiolanda Stergiou; Kassiani Mellou; Dimitrios Papamichail; Eleni Aretouli; Dimitrios Chatzidimitriou; Fani Chatzopoulou; Eleni Bairaktari; Ioanna Tzoulaki; Evangelos Evangelou; Evangelos C Rizos; Evangelia Ntzani; Konstantinos Vakalis; Konstantinos K Tsilidis; Malabika Sarker; Ian Y Goon; Anu Kasturiratne; Jaspal S Kooner; Prasad Katulanda; Sujeet Jha; Ranjit Mohan Anjana; Malay K Mridha; Franco Sassi; John Chambers,"University of Ioannina; University of Ioannina; University of Ioannina; University of Ioannina, Aristotle University of Thessaloniki; Ioannina Medical Care; University of Ioannina; Ioannina Medical Care; Ioannina Medical Care; Ioannina Medical Care; University of Ioannina; University of Ioannina; Hellenic National Public Health Organization; University of West Attica; University of Ioannina, Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; University of Ioannina; University of Ioannina, Imperial College London; University of Ioannina, Imperial College London; University Hospital of Ioannina, European University of Cyprus; University of Ioannina, Brown University; Ioannina Medical Care; University of Ioannina, Imperial College London; BRAC James P Grant School of Public Health, BRAC University; School of Public Health, Imperial College London; University of Kelaniya Faculty of Medicine; NHLI, Imperial College London; Faculty of Medicine, University of Colombo; Max Healthcare; Madras Diabetes Research Foundation, Chennai, India; BRAC James P Grant School of Public Health, BRAC University; Imperial College Business School; Imperial College London","BackgroundTo assess the level of knowledge and trust in the policy decisions taken regarding the coronavirus disease (COVID-19) pandemic among Epirus Health Study (EHS) participants.

MethodsThe EHS is an ongoing and deeply-phenotyped prospective cohort study that has recruited 667 participants in northwest Greece until August 31st, 2020. Level of knowledge on coronavirus (SARS-CoV-2) transmission and COVID-19 severity was labeled as poor, moderate or good. Variables assessing knowledge and beliefs towards the pandemic were summarized overall and by gender, age group (25-39, 40-49, 50-59, [&ge;]60 years) and period of report (before the lifting of lockdown measures in Greece: March 30th to May 3rd, and two post-lockdown time periods: May 4th to June 31st, July 1st to August 31st). An exposure-wide association analysis was conducted to evaluate the associations between 153 explanatory variables and participants knowledge. Correction for multiple comparisons was applied using a false discovery rate (FDR) threshold of 5%.

ResultsA total of 563 participants (49 years mean age; 60% women) had available information on the standard EHS questionnaire, the clinical and biochemical measurements, and the COVID-19-related questionnaire. Percentages of poor, moderate and good knowledge status regarding COVID-19 were 4.5%, 10.0% and 85.6%, respectively. The majority of participants showed absolute or moderate trust in the Greek health authorities for the management of the epidemic (90.1%), as well as in the Greek Government (84.7%) and the official national sources of information (87.4%). Trust in the authorities was weaker in younger participants and those who joined the study after the lifting of lockdown measures (p-value[&le;]0.001). None of the factors examined was associated with participants level of knowledge after correction for multiple testing.

ConclusionsHigh level of knowledge about the COVID-19 pandemic and trust in the Greek authorities was observed, possibly due to the plethora of good quality publicly available information and the timely management of the pandemic at its early stages in Greece. Information campaigns for the COVID-19 pandemic should be encouraged even after the lifting of lockdown measures to increase public awareness.",public and global health,exact,100,100
medRxiv,10.1101/2020.11.11.20223800,2020-11-13,https://medrxiv.org/cgi/content/short/2020.11.11.20223800,The Use of Saliva as a Diagnostic Specimen for SARS CoV-2 Molecular Diagnostic Testing for Pediatric Patients,Meghan Delaney; Bobbe Thomas; Christal J Ralph; Kyah Draper; Mahdi Moshgriz; Joyce Granados; Michael Evangelista; Mark McGuire; Roberta L DeBiasi; Joelle Simpson; Joseph Campos; Kassiani Mellou; Dimitrios Papamichail; Eleni Aretouli; Dimitrios Chatzidimitriou; Fani Chatzopoulou; Eleni Bairaktari; Ioanna Tzoulaki; Evangelos Evangelou; Evangelos C Rizos; Evangelia Ntzani; Konstantinos Vakalis; Konstantinos K Tsilidis; Malabika Sarker; Ian Y Goon; Anu Kasturiratne; Jaspal S Kooner; Prasad Katulanda; Sujeet Jha; Ranjit Mohan Anjana; Malay K Mridha; Franco Sassi; John Chambers,"Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Children's National Hospital; Hellenic National Public Health Organization; University of West Attica; University of Ioannina, Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; University of Ioannina; University of Ioannina, Imperial College London; University of Ioannina, Imperial College London; University Hospital of Ioannina, European University of Cyprus; University of Ioannina, Brown University; Ioannina Medical Care; University of Ioannina, Imperial College London; BRAC James P Grant School of Public Health, BRAC University; School of Public Health, Imperial College London; University of Kelaniya Faculty of Medicine; NHLI, Imperial College London; Faculty of Medicine, University of Colombo; Max Healthcare; Madras Diabetes Research Foundation, Chennai, India; BRAC James P Grant School of Public Health, BRAC University; Imperial College Business School; Imperial College London","BackgroundChildren are an important population to test for COVID-19 infection, particularly because they may shed the virus without displaying symptoms. Testing children for COVID-19 via sensitive molecular methods is important, although collecting nasopharyngeal (NP) specimens can be challenging. A less invasive mode of specimen collection that yields test results comparable to those from NP specimens would be beneficial to simplify sample collection.

MethodsTo demonstrate that saliva is a suitable specimen for collection from children, the clinical usability/acceptability and the analytic performance of saliva were compared to NP specimens suspended in viral transport medium. Four different FDA EUA-approved real-time RT-PCR assays and one EUA approved saliva collection device were investigated.

ResultsThe study population included 526 patients between the ages of 3 and 61 years, 461 (88%) were <18 years, 425 were asymptomatic (81.1%), 92 were symptomatic (17.6%). Saliva mixed with saliva stabilizing buffer was found to yield comparable sensitivity to NP specimens when tested on the AllPlex SARS-CoV-2 molecular test (Seegene Inc). The analytic sensitivity of the AllPlex assay during testing of spiked saliva mixed with SpectrumDNA saliva stabilizer was found to be 250 genomic copies/mL.

ConclusionsOf the four FDA EUA-approved SARS-CoV-2 PCR assays studied, we found the AllPlex assay to be best suited for testing saliva specimens collected from children 5 years of age or older. The sensitivity of viral detection was equivalent to NP specimens when saliva specimens were mixed with the saliva stabilizer.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.06.20227108,2020-11-07,https://medrxiv.org/cgi/content/short/2020.11.06.20227108,Primary school staff reflections on school closures due to COVID-19 and recommendations for the future: a national qualitative survey,Emily Marchant; Charlotte Todd; Michaela James; Tom Crick; Russell Dwyer; Sinead Brophy; Miguel Luna; Nadia Guerrero; Jose Medina; Isabel Sandoval; Edith Solis; Manuel Loayza; Benjamin S Glicksberg; Matthew Levin; David Reich; Dennis Charney; Erwin P Bottinger; Laurie Keefer; Mayte Suarez-Farinas; Girish N Nadkarni; Zahi A Fayad,"Swansea University; Swansea University; Swansea University; Swansea University; St Thomas Community Primary School; Swansea University; 1.	Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades, Ministerio de Salud. Lima-Peru.; 1.	Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades, Ministerio de Salud. Lima-Peru.; 1.	Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades, Ministerio de Salud. Lima-Peru.; Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades, Ministerio de Salud. Lima-Peru.; Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades, Ministerio de Salud. Lima-Peru.; Universidad Ricardo Palma. Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades, Ministerio de Salud. Lima-Peru.; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai","School closures due to the COVID-19 global pandemic are likely to have a range of negative consequences spanning the domains of child development, education and health, in addition to the widening of inequalities and inequities. Research is required to improve understanding of the impact of school closures on the education, health and wellbeing of pupils and school staff, the challenges posed during reopening and importantly to identify how countries can ensure a safe return to education and to inform policy. This qualitative study aimed to reflect on the experience of primary school staff (pupils aged 3-11) in Wales regarding school closures and the initial reopening of schools and to identify recommendations for the future. A total of 208 school staff completed a national online survey through the HAPPEN primary school network, consisting of questions about school closures, the phased reopening of schools and a return to full-time education. Thematic analysis of survey responses identified five recommendations; (i) prioritise the health and wellbeing of pupils and staff. This includes more focus on wellbeing activities and less focus on attainment/assessments and protecting staff breaks to promote workplace wellbeing; (ii) focus on enabling parental engagement and support. Introduce support sessions for parents and include regular check ins during periods of home learning; (iii) improve digital competence amongst pupils, teachers and parents. Ensure the provision of equipment and training in building digital skills. Offer a combination of paper-based and digital home learning activities; (iv) consider opportunities for smaller class sizes and additional staffing. Ensure support is directed to need whilst providing pastoral care; and (v) improve the mechanism of communication between schools and families, and between government and schools. Ensure that schools receive advance notice of local or national changes in guidance.",public and global health,exact,100,100
medRxiv,10.1101/2020.11.03.20220699,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.03.20220699,A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital,Daniel J Cooper; Sara Lear; Laura Watson; Ashley Shaw; Mark Ferris; Rainer Doffinger; Rachel Bousfield; Katherine Sharrocks; Michael Weekes; Ben Warne; Dominic Sparkes; Nick K Jones; Lucy Rivett; Matthew Routledge; Afzal Chaudhry; Katherine Dempsey; Montgomery Matson; Adil Lakha; George Gathercole; Olivia O'Connor; Emily Wilson; Orthi Shahzad; Kieran Toms; Rachel Thompson; Ian Halsall; David Halsall; Sally Houghton; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR Cambridge Clinical Research Facility; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR Cambridge Clinical Research Facility.; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundThe COVID-19 pandemic continues to grow at an unprecedented rate. Healthcare workers (HCWs) are at higher risk of SARS-CoV-2 infection than the general population but risk factors for HCW infection are not well described.

MethodsWe conducted a prospective sero-epidemiological study of HCWs at a UK teaching hospital using a SARS-CoV-2 immunoassay. Risk factors for seropositivity were analysed using multivariate logistic regression.

Findings410/5,698 (7{middle dot}2%) staff tested positive for SARS-CoV-2 antibodies. Seroprevalence was higher in those working in designated COVID-19 areas compared with other areas (9{middle dot}47% versus 6{middle dot}16%) Healthcare assistants (aOR 2{middle dot}06 [95%CI 1{middle dot}14-3{middle dot}71]; p=0{middle dot}016) and domestic and portering staff (aOR 3{middle dot}45 [95% CI 1{middle dot}07-11{middle dot}42]; p=0{middle dot}039) had significantly higher seroprevalence than other staff groups after adjusting for age, sex, ethnicity and COVID-19 working location. Staff working in acute medicine and medical sub-specialities were also at higher risk (aOR 2{middle dot}07 [95% CI 1{middle dot}31-3{middle dot}25]; p<0{middle dot}002). Staff from Black, Asian and minority ethnic (BAME) backgrounds had an aOR of 1{middle dot}65 (95% CI 1{middle dot}32 - 2{middle dot}07; p<0{middle dot}001) compared to white staff; this increased risk was independent of COVID-19 area working. The only symptoms significantly associated with seropositivity in a multivariable model were loss of sense of taste or smell, fever and myalgia; 31% of staff testing positive reported no prior symptoms.

InterpretationRisk of SARS-CoV-2 infection amongst HCWs is heterogeneous and influenced by COVID-19 working location, role, age and ethnicity. Increased risk amongst BAME staff cannot be accounted for solely by occupational factors.

FundingWellcome Trust, Addenbrookes Charitable Trust, National Institute for Health Research, Academy of Medical Sciences, the Health Foundation and the NIHR Cambridge Biomedical Research Centre.

Research in context

Evidence before this studySpecific risk factors for SARS-CoV-2 infection in healthcare workers (HCWs) are not well defined. Additionally, it is not clear how population level risk factors influence occupational risk in defined demographic groups. Only by identifying these factors can we mitigate and reduce the risk of occupational SARS-CoV-2 infection. We performed a review of the evidence for HCW-specific risk factors for SARS-CoV-2 infection. We searched PubMed with the terms ""SARS-CoV-2"" OR ""COVID-19"" AND ""Healthcare worker"" OR ""Healthcare Personnel"" AND ""Risk factor"" to identify any studies published in any language between December 2019 and September 2020. The search identified 266 studies and included a meta-analysis and two observational studies assessing HCW cohort seroprevalence data. Seroprevalence and risk factors for HCW infections varied between studies, with contradictory findings. In the two serological studies, one identified a significant increased risk of seroprevalence in those working with COVID-19 patients (Eyre et al 2020), as well as associations with job role and department. The other study (Dimcheff et al 2020) found no significant association between seropositivity and any identified demographic or occupational factor. A meta-analysis of HCW (Gomez-Ochoa et al 2020) assessed >230,000 participants as a pooled analysis, including diagnoses by both RT-PCR and seropositivity for SARS-CoV-2 antibodies and found great heterogeneity in study design and reported contradictory findings. Of note, they report a seropositivity rate of 7% across all studies reporting SARS-CoV-2 antibodies in HCWs. Nurses were the most frequently affected healthcare personnel and staff working in non-emergency inpatient settings were the most frequently affected group. Our search found no prospective studies systematically evaluating HCW specific risk factors based entirely on seroprevalence data.

Added value of this studyOur prospective cohort study of almost 6,000 HCWs at a large UK teaching hospital strengthens previous findings from UK-based cohorts in identifying an increased risk of SARS-CoV-2 exposure amongst HCWs. Specifically, factors associated with SARS-CoV-2 exposure include caring for confirmed COVID-19 cases and identifying as being within specific ethnic groups (BAME staff). We further delineated the risk amongst BAME staff and demonstrate that occupational factors alone do not account for all of the increased risk amongst this group. We demonstrate for the first time that healthcare assistants represent a key at-risk occupational group, and challenge previous findings of significantly higher risk amongst nursing staff. Seroprevalence in staff not working in areas with confirmed COVID-19 patients was only marginally higher than that of the general population within the same geographical region. This observation could suggest the increased risk amongst HCWs arises through occupational exposure to confirmed cases and could account for the overall higher seroprevalence in HCWs, rather than purely the presence of staff in healthcare facilities. Over 30% of seropositive staff had not reported symptoms consistent with COVID-19, and in those who did report symptoms, differentiating COVID-19 from other causes based on symptom data alone was unreliable.

Implications of all the available evidenceInternational efforts to reduce the risk of SARS-CoV-2 infection amongst HCWs need to be prioritised. The risk of SARS-CoV-2 infection amongst HCWs is heterogenous but also follows demonstrable patterns. Potential mechanisms to reduce the risk for staff working in areas with confirmed COVID-19 patients include improved training in hand hygiene and personal protective equipment (PPE), better access to high quality PPE, and frequent asymptomatic testing. Wider asymptomatic testing in healthcare facilities has the potential to reduce spread of SARS-CoV-2 within hospitals, thereby reducing patient and staff risk and limiting spread between hospitals and into the wider community. The increased risk of COVID-19 amongst BAME staff cannot be explained by purely occupational factors; however, the increased risk amongst minority ethnic groups identified here was stark and necessitates further evaluation.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.03.20224972,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.03.20224972,A Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive Droplet Digital PCR,Fang Wang; Umar Pervaiz; Hongwei Tian; Mariam Omar Ahmed Omar Al Gahdary; Mahasin Abdallah Mohammed Hamid; Degui Wang; Rachel Bousfield; Katherine Sharrocks; Michael Weekes; Ben Warne; Dominic Sparkes; Nick K Jones; Lucy Rivett; Matthew Routledge; Afzal Chaudhry; Katherine Dempsey; Montgomery Matson; Adil Lakha; George Gathercole; Olivia O'Connor; Emily Wilson; Orthi Shahzad; Kieran Toms; Rachel Thompson; Ian Halsall; David Halsall; Sally Houghton; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Center of Medical experiment,School of Basic Medicine,Lanzhou University; School of Basic Medicine, Lanzhou University; Department of General Surgery, Gansu Provincial People's Hospital; School of Basic Medicine, Lanzhou University; School of Basic Medicine, Lanzhou University; School of Basic Medicine, Lanzhou University; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR Cambridge Clinical Research Facility.; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundThe current increase in the spread of (SARS-CoV-2) critically needs a multitarget diagnostic assays to promote analytical sensitivity to facilitate the public health actions.

ObjectiveThe aim of this study was to develop a new primer-probe set targeting N gene of SARS-CoV-2 to improve the sensitivity for detection of COVID-19(Corona Virus Disease 2019)in multiplex rRT-PCR (Reversetranscript Realtime PCR) and ddPCR (Droplet Digital PCR).

ResultsWe designed primers/probes set N(LZU3) targeting the N gene of 2019-nCov and proved its sensitivity in both rRT-PCR and ddPCR. When the quantity of template was 105 copies/reaction, the mean Ct value of N(LZU3) was 32.563, the detection rate was 91.7%. If the quantity of template was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, and the detection rate was 83.3%, which were similar with that of N(CDC) and N(USA). The calculated lower limit of detection (LOD) of the new primer-probe set N(LZU3) used in rRT-PCR was 118 copies/reaction. We also did one-step ddPCR for detection the same serial dilution of RNA template. It shows good linearity for primer/probe sets N(LZU3). The calculated lower limit of detection (LOD) of N(LZU3) was 22.4 copies/reaction, which was 1.12 copies/ul.

ConclusionThe novel primer-probe set(LZU3) targeting N gene of SARS-CoV-2 could be both used in rRT-PCR and ddPCR with better sensitivity, furthermore, ddPCR method had higer sensitivity than rRT-PCR, hence it could significantly improve SARS-CoV-2 detection efficiency in low virus load and asymptomatic infection.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.02.20224816,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224816,Profiling SARS-CoV-2 mutation fingerprints that range from the viral pangenome to individual infection quasispecies,Billy T Lau; Dmitri Pavlichin; Anna C Hooker; Alison F Almeda; GiWon Shin; Jiamin Chen; Malaya K Sahoo; ChunHong Huang; Benjamin A Pinsky; HoJoon Lee; Hanlee Ji; Nick K Jones; Lucy Rivett; Matthew Routledge; Afzal Chaudhry; Katherine Dempsey; Montgomery Matson; Adil Lakha; George Gathercole; Olivia O'Connor; Emily Wilson; Orthi Shahzad; Kieran Toms; Rachel Thompson; Ian Halsall; David Halsall; Sally Houghton; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, United States; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, United States; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, United States; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR Cambridge Clinical Research Facility.; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundThe genome of SARS-CoV-2 is susceptible to mutations during viral replication due to the errors generated by RNA-dependent RNA polymerases. These mutations enable the SARS-CoV-2 to evolve into new strains. Viral quasispecies emerge from de novo mutations that occur in individual patients. In combination, these sets of viral mutations provide distinct genetic fingerprints that reveal the patterns of transmission and have utility in contract tracing.

MethodsLeveraging thousands of sequenced SARS-CoV-2 genomes, we performed a viral pangenome analysis to identify conserved genomic sequences. We used a rapid and highly efficient computational approach that relies on k-mers, short tracts of sequence, instead of conventional sequence alignment. Using this method, we annotated viral mutation signatures that were associated with specific strains. Based on these highly conserved viral sequences, we developed a rapid and highly scalable targeted sequencing assay to identify mutations, detect quasispecies and identify mutation signatures from patients. These results were compared to the pangenome genetic fingerprints.

ResultsWe built a k-mer index for thousands of SARS-CoV-2 genomes and identified conserved genomics regions and landscape of mutations across thousands of virus genomes. We delineated mutation profiles spanning common genetic fingerprints (the combination of mutations in a viral assembly) and rare ones that occur in only small fraction of patients. We developed a targeted sequencing assay by selecting primers from the conserved viral genome regions to flank frequent mutations. Using a cohort of SARS-CoV-2 clinical samples, we identified genetic fingerprints consisting of strain-specific mutations seen across populations and de novo quasispecies mutations localized to individual infections. We compared the mutation profiles of viral samples undergoing analysis with the features of the pangenome.

ConclusionsWe conducted an analysis for viral mutation profiles that provide the basis of genetic fingerprints. Our study linked pangenome analysis with targeted deep sequenced SARS-CoV-2 clinical samples. We identified quasispecies mutations occurring within individual patients, mutations demarcating dominant species and the prevalence of mutation signatures, of which a significant number were relatively unique. Analysis of these genetic fingerprints may provide a way of conducting molecular contact tracing.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.02.20224824,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224824,"The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers",Sheila F Lumley; Jia Wei; Nicole Stoesser; Philippa Matthews; Alison Howarth; Stephanie Hatch; Brian Marsden; Stuart Cox; Tim James; Liam Peck; Thomas Ritter; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundSARS-CoV-2 IgG antibody measurements can be used to estimate the proportion of a population exposed or infected and may be informative about the risk of future infection. Previous estimates of the duration of antibody responses vary.

MethodsWe present 6 months of data from a longitudinal seroprevalence study of 3217 UK healthcare workers (HCWs). Serial measurements of IgG antibodies to SARS-CoV-2 nucleocapsid were obtained. Bayesian mixed linear models were used to investigate antibody waning and associations with age, gender, ethnicity, previous symptoms and PCR results.

ResultsIn this cohort of working age HCWs, antibody levels rose to a peak at 24 (95% credibility interval, CrI 19-31) days post-first positive PCR test, before beginning to fall. Considering 452 IgG seropositive HCWs over a median of 121 days (maximum 171 days) from their maximum positive IgG titre, the mean estimated antibody half-life was 85 (95%CrI, 81-90) days. The estimated mean time to loss of a positive antibody result was 137 (95%CrI 127-148) days. We observed variation between individuals; higher maximum observed IgG titres were associated with longer estimated antibody half-lives. Increasing age, Asian ethnicity and prior self-reported symptoms were independently associated with higher maximum antibody levels, and increasing age and a positive PCR test undertaken for symptoms with longer antibody half-lives.

ConclusionIgG antibody levels to SARS-CoV-2 nucleocapsid wane within months, and faster in younger adults and those without symptoms. Ongoing longitudinal studies are required to track the long-term duration of antibody levels and their association with immunity to SARS-CoV-2 reinfection.

SummarySerially measured SARS-CoV-2 anti-nucleocapsid IgG titres from 452 seropositive healthcare workers demonstrate levels fall by half in 85 days. From a peak result, detectable antibodies last a mean 137 days. Levels fall faster in younger adults and following asymptomatic infection.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.11.02.20224774,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224774,Sharing ventilators in the Covid-19 pandemics. A bench study,Claude Guerin; Martin Cour; Neven Stevic; Florian Degivry; Erwan L'Her; Bruno Louis; Laurent Argaud; Stuart Cox; Tim James; Liam Peck; Thomas Ritter; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Hospices civils de Lyon; Hospices civils de Lyon; Hospices civils de Lyon; Hospices Civils de Lyon; CHU DE BREST; Institut Mondor de Recherches Biomedicales; Hospices civils de Lyon; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","COVID-19 pandemics sets the healthcare system to a shortage of ventilators. We aimed at assessing tidal volume (VT) delivery and air recirculation during expiration when one ventilator is divided into 2 patients. The study was performed in a research laboratory in a medical ICU of a University hospital. An ICU-dedicated (V500) and a lower-level ventilator (Elisee 350) were attached to two test-lungs (QuickLung) through a dedicated flow-splitter. A 50 mL/cmH2O Compliance (C) and 5 cmH2O/L/s Resistance (R) were set in both A and B lungs (step1), C50R20 in A / C20R20 in B (step 2), C20R20 in A / C10R20 in B (step 3), and C50R20 in A / C20R5 in B (step 4). Each ventilator was set in volume and pressure control mode to deliver 0.8L VT. We assessed VT from a pneumotachograph placed immediately before each lung, rebreathed volume, and expiratory resistance (circuit and valve). Values are median (1st-3rd quartiles) and compared between ventilators by non-parametric tests. Between Elisee 350 and V500 in volume control VT in A/B patients were 0.381/0.387 vs. 0.412/0.433L in step 1, 0.501/0.270 vs. 0.492/0.370L in step 2, 0.509/0.237 vs. 0.496/0.332L in step 3, and 0.496/0.281 vs. 0.480/0.329L in step 4. In pressure control the corresponding values were 0.373/0.336 vs. 0.430/0.414L, 0.416/0.185/0.322/0.234L, 0.193/0.108 vs. 0.176/0.092L and 0.422/0.201 vs. 0.481/0.329L, respectively (P<0.001 between ventilators at each step for each volume). Rebreathed air volume ranged between 0.7 to 37.8 ml and negatively correlated with expiratory resistance in steps 2 and 3. The lower-level ventilator performed closely to the ICU-dedicated ventilator. Due to dependence of VT to C pressure control should be used to maintain adequate VT at least in one patient when C and/or R changes abruptly and monitoring of VT should be done carefully. Increasing expiratory resistance should reduce rebreathed volume.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.11.02.20224642,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224642,Vascular Thrombosis in COVID-19: A Potential Association with Antiphospholipid Antibodies. A Rapid Systematic Review,Aneesh S Kallapur; Eric Y Yen; Ram Raj Singh; Florian Degivry; Erwan L'Her; Bruno Louis; Laurent Argaud; Stuart Cox; Tim James; Liam Peck; Thomas Ritter; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"University of California, Los Angeles; University of California, Los Angeles; UCLA; Hospices Civils de Lyon; CHU DE BREST; Institut Mondor de Recherches Biomedicales; Hospices civils de Lyon; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundVascular thrombosis is common in patients with coronavirus disease 2019 (COVID-19). Etiologies underlying this complication are unclear.

PurposeTo determine the prevalence of antiphospholipid (aPL), including lupus anticoagulant, anti-cardiolipin and anti-{beta}2-glycoprotein-1 antibodies, and its possible association with thrombotic manifestations of COVID-19.

Data SourcesWe searched MEDLINE indexed journals on September 24, 2020 using the tool LitCovid and the pre-print server medRxIV.

Study SelectionOriginal investigations (cross-sectional studies, cohort studies, case series, and research letters) on COVID-19 and thrombosis were included.

Data ExtractionData were independently extracted, and compiled into spreadsheets based on the PRISMA principles.

Data SynthesisHospitalized patients with COVID-19 showed a higher prevalence of lupus anticoagulant compared to non-COVID-19 patients. Temporally, lupus anticoagulant was generally positive early in the course of illness, whereas anti-cardiolipin and anti-{beta}2-glycoprotein-1 antibodies appeared to emerge later in the disease. Some patients who were aPL-negative at an early time-point after disease onset became aPL-positive at a later time-point. Lupus anticoagulant was independently associated with thrombosis in 60 COVID-19 patients in New York had who had 32 thrombotic events (8 arterial and 24 venous). In 88 patients in Wuhan, who had more than 20 each of arterial and venous thrombotic events, medium/high positivity for multiple aPL was significantly associated with arterial thrombosis. However, the association of aPL with thrombosis was not evident in reports that had an overall lower number of or predominantly venous thrombotic events. Analysis of pooled patients revealed that aPL were significantly more frequent in COVID-19 patients with stroke than stroke patients in the general population. Furthermore, injection of IgG aPL fractions from COVID-19 patients into mice accelerated venous thrombosis.

LimitationLimited data and paucity of prospective studies.

ConclusionThe aPL are prevalent in patients with COVID-19 and their presence is associated with thrombosis. Importantly, these antibodies may be a key mechanism of thrombosis in COVID-19. Follow-up studies are required to understand the relationship between aPL and the spectrum of vascular thrombosis during and after infection with SARS-CoV-2.

Primary Funding SourceNone.",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.11.02.20224709,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224709,"Gender-affirming care, mental health, and economic stability in the time of COVID-19: a global cross-sectional study of transgender and non-binary people",Brooke Jarrett; Sarah M Peitzmeier; Arjee Restar; Tyler Adamson; Sean Howell; Stefan Baral; S. Wilson Beckham; Stuart Cox; Tim James; Liam Peck; Thomas Ritter; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Johns Hopkins Bloomberg School of Public Health; University of Michigan School of Nursing; JohnsHopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Hornet; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundTransgender and non-binary people are disproportionately burdened by barriers to quality healthcare, mental health challenges, and economic hardship. This study examined the impact of the novel coronavirus disease (COVID-19) pandemic and subsequent control measures on gender-affirming care, mental health, and economic stability among transgender and non-binary people globally.

MethodsWe collected global cross-sectional data from 964 transgender and non-binary adult users of the Hornet and Her apps from April to August 2020 to characterize changes in gender-affirming care, mental health, and economic stability as a result of the COVID-19 pandemic. We conducted Poisson regression models to assess if access to gender-affirming care and ability to live according to ones gender were related to depressive symptoms, anxiety, and changes in suicidal ideation.

ResultsIndividuals resided in 76 countries, including Turkey (27.4%,n=264/964) and Thailand (20.6%,n=205). A majority were non-binary (66.8%,n=644) or transfeminine (29.4%,n=283). Due to the COVID-19 pandemic, 55.0% (n=320/582) reported reduced access to gender- affirming resources, and 38.0% (n=327/860) reported reduced time lived according to their gender. About half screened positive for depression (50.4%,442/877) and anxiety (45.8%,n=392/856). One in six (17.0%,n=112/659) expected losses of health insurance, and 77.0% (n=724/940) expected income reductions. The prevalence of depressive symptoms, anxiety, and increased suicidal ideation were 1.63 (95% CI: 1.36-1.97), 1.61 (95% CI: 1.31-1.97), and 1.74 (95% CI: 1.07-2.82) times higher for individuals whose access to gender- affirming resources was reduced versus not.

DiscussionThe COVID-19 pandemic has reduced access to gender-affirming resources and the ability of transgender and non-binary people to live according to their gender worldwide. These reductions may drive the increased depressive symptoms, anxiety, and suicidal ideation reported in this sample. To improve transgender and non-binary health globally, increased access to gender-affirming resources should be achieved through policies (e.g., digital prescriptions), flexible interventions (e.g., telehealth), and support for existing transgender health initiatives.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.03.20225268,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.03.20225268,"Test-adjusted results of mortality for Covid-19 in Germany, USA, UK",Juergen Mimkes; Rainer Janssen; Arjee Restar; Tyler Adamson; Sean Howell; Stefan Baral; S. Wilson Beckham; Stuart Cox; Tim James; Liam Peck; Thomas Ritter; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Paderborn University; Engineering Office, Paderborn; JohnsHopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Hornet; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","In a disease, where all infected persons show symptoms, it is reasonable to calculate mortality by case to fatality rate CFR. Deaths follow infections by a certain time lag. However, in the Covid-19 pandemic many infectious patients show no or hardly any symptoms. The reported infections and deaths do not run parallel, but diverge with the volume of tests.

Our investigations for Germany, USA and UK indicate that deaths do not follow the number of infections, but the positive rate of tests, multiplied by a constant factor F and shifted by about two weeks. These test adjusted results of mortality allow for the estimation of the number of deaths of Covid-19 about two weeks ahead, even in a sharply rising state of the pandemic. This gives medical authorities two weeks of time to plan for resources.",epidemiology,exact,100,100
medRxiv,10.1101/2020.11.02.20224667,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224667,The impact of lockdown during the COVID-19 pandemic on mental and social health of children and adolescents,Michiel A.J. Luijten; Maud M. van Muilekom; Lorynn Teela; Hedy A. van Oers; Caroline B. Terwee; Josjan Zijlmans; Leonie Klaufus; Arne Popma; Kim J. Oostrom; Tinca J.C. Polderman; Lotte Haverman; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Public Health Service Amsterdam; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","ImportanceIt is unknown how a lockdown during the COVID-19 pandemic impacts childrens and adolescents mental and social health.

ObjectiveTo compare mental and social health of children and adolescents during the COVID-19 lockdown versus before, identify associated factors, describe the change in atmosphere at home and qualitatively assess the impact of COVID-19 regulations on daily life.

DesignCross-sectional study comparing two Dutch representative samples of children and adolescents (8-18 years); before COVID-19 (Dec2017-July2018) and during the COVID-19 lockdown (April/May 2020).

SettingPopulation-based

ParticipantsChildren and adolescents aged 8-18 years (M=13.4, 47.4% male), representative of the Dutch population on key demographics.

Exposure(s)COVID-19 pandemic lockdown

Main Outcome(s) and Measure(s)Patient-Reported Outcomes Measurement Information System (PROMIS(R)) domains: Global Health, Peer Relationships, Anxiety, Depressive Symptoms, Anger and Sleep-Related Impairment. Single item on atmosphere at home and open question regarding the impact of the regulations on the child/adolescents daily life

ResultsChildren and adolescents reported significantly worse PROMIS T-scores on all domains (absolute mean difference range, 2.1-7.1; absolute 95% CI range, 1.3-7.9) during the COVID-19 lockdown as compared to before COVID-19. More children reported severe Anxiety (during 16.7% vs. before 8.6%; relative risk 1.95; 95% CI 1.55-2.46) and Sleep-Related Impairment (during 11.5% vs. before 6.1%; relative risk 1.89; 95% CI 1.29-2.78). Fewer children reported poor Global Health (during 1.7 vs. before 4.6%; relative risk 0.36; 95% CI 0.20-0.65). More mental and social health complaints during the COVID-19 lockdown were found in children and adolescents growing up in a single-parent family, having [&ge;]three children in the family, a negative change in work situation of parents due to COVID-19 regulations, and having a relative/friend infected with COVID-19. A small effect was found on atmosphere at home during the lockdown compared to before (mean difference, -3.1; 95% CI, -4.1 --2.1). A large majority (>90%) reported a negative impact of the COVID-19 regulations on their daily life.

Conclusions and RelevanceThis study showed that governmental regulations regarding lockdown pose a serious mental and social health threat on children and adolescents that should be brought to the forefront of political decision making and mental health care policy, intervention and prevention.

Key pointsO_ST_ABSQuestionC_ST_ABSWhat is the impact of lockdown during the COVID-19 pandemic on mental and social health in children and adolescents compared to before COVID-19?

FindingsThis population-based study shows that during the COVID-19 lockdown children and adolescents report lower mental and social health, especially on anxiety and depressive symptoms.

MeaningIn proposing new COVID regulations (e.g., closing schools) governments should be mindful of the negative impact of a lockdown on mental and social health of children and adolescents.",pediatrics,exact,100,100
medRxiv,10.1101/2020.11.02.20221622,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20221622,Reproducibility and sensitivity of 36 methods to quantify the SARS-CoV-2 genetic signal in raw wastewater: findings from an interlaboratory methods evaluation in the U.S.,Brian M Pecson; Emily Darby; Charles N Haas; Yamrot Amha; Mitchel Bartolo; Richard Danielson; Yeggie Dearborn; George Di Giovanni; Christobel Ferguson; Stephanie Fevig; Erica Gaddis; Don Gray; George Lukasik; Bonnie Mull; Liana Olivas; Adam Olivieri; Yan Qu; - SARS-CoV-2 Interlaboratory Consortium; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Este Trk; Ian G. Goodfellow; Stephen Baker,"Trussell Technologies Inc.; Trussell Technologies Inc.; Drexel University; Trussell Technologies Inc.; Trussell Technologies Inc.; Cel Analytical Inc.; Cel Analytical Inc.; Metropolitan Water District of Southern California; The Water Research Foundation; The Water Research Foundation; Utah Department of Environmental Quality; East Bay Municipal Utilities District; BCS Laboratories Inc.; BCS Laboratories Inc.; Trussell Technologies Inc.; EOA Inc.; Trussell Technologies Inc.; ; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","1In response to COVID-19, the international water community rapidly developed methods to quantify the SARS-CoV-2 genetic signal in untreated wastewater. Wastewater surveillance using such methods has the potential to complement clinical testing in assessing community health. This interlaboratory assessment evaluated the reproducibility and sensitivity of 36 standard operating procedures (SOPs), divided into eight method groups based on sample concentration approach and whether solids were removed. Two raw wastewater samples were collected in August 2020, amended with a matrix spike (betacoronavirus OC43), and distributed to 32 laboratories across the U.S. Replicate samples analyzed in accordance with the projects quality assurance plan showed high reproducibility across the 36 SOPs: 80% of the recovery-corrected results fell within a band of +/- 1.15-log10 genome copies/L with higher reproducibility observed within a single SOP (standard deviation of 0.13-log10). The inclusion of a solids removal step and the selection of a concentration method did not show a clear, systematic impact on the recovery-corrected results. Other methodological variations (e.g., pasteurization, primer set selection, and use of RT-qPCR or RT-dPCR platforms) generally resulted in small differences compared to other sources of variability. These findings suggest that a variety of methods are capable of producing reproducible results, though the same SOP or laboratory should be selected to track SARS-CoV-2 trends at a given facility. The methods showed a 7-log10 range of recovery efficiency and limit of detection highlighting the importance of recovery correction and the need to consider method sensitivity when selecting methods for wastewater surveillance.",public and global health,exact,100,100
medRxiv,10.1101/2020.10.29.20222414,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.29.20222414,How well does societal mobility restriction help control the COVID-19 pandemic? Evidence from real-time evaluation,Juhwan Oh; Hwa-Young Lee; Khuong Quynh Long; Jeffery F Marcuns; Chris Bullen; Osvaldo Enrique Artaza Barrios; Seung-sik Hwang; Young Sahng Suh; Judith McCool; S. Patrick Kaucher; Chang-Chung Chan; Soonman Kwon; Naoki Kondo; Hoang Van Minh; J. Robin Moon; Mikael Rostila; Ole F. Norheim; Myoungsoon You; Mellissa Withers; Mu Li; Eun-Jeung Lee; Caroline Benski; Soo Kyung Park; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"1. Harvard University T.H.Chan School of Public Health 2. Seoul National University College of Medicine; 1. Harvard University T H Chan School of Public Health  2. Institute of Convergence Science, Convergence Science Academy, Yonsei University,; Hanoi University of Public Health; Boston University School of Medicine; The University of Auckland School of Population Health; The University of the Americas; Seoul National University Graduate School of Public Health; Harvard University T.H.Chan School of Public Health; The University of Auckland School of Population Health; Mailman School of Public Health, Columbia University; National Taiwan University College of Public Health; Seoul National University Graduate School of Public Health; Kyoto University School of Public Health; Hanoi University of Public Health; City University of New York Graduate School of Public Health & Health Policy; Stockholm University; 1.University of Bergen 2. Harvard University T.H.Chan School of Public Health; Seoul National University Graduate School of Public Health; University of Southern California; The University of Sydney; Berlin Free University; University Hospital of Geneva; National Health Insurance Research Institute; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","ObjectivesTo determine the impact of restrictions on mobility on reducing transmission of COVID-19.

DesignDaily incidence rates lagged by 14 days were regressed on mobility changes using LOESS regression and logit regression between the day of the 100th case in each country to August 31, 2020.

Setting34 OECD countries plus Singapore and Taiwan.

ParticipantsGoogle mobility data were obtained from people who turned on mobile device-based global positioning system (GPS) and agreed to share their anonymized position information with Google.

InterventionsWe examined the association of COVID-19 incidence rates with mobility changes, defined as changes in categories of domestic location, against a pre-pandemic baseline, using country-specific daily incidence data on newly confirmed COVID-19 cases and mobility data.

ResultsIn two thirds of examined countries, reductions of up to 40% in commuting mobility (to workplaces, transit stations, retailers, and recreation) were associated with decreased COVID-19 incidence, more so early in the pandemic. However, these decreases plateaued as mobility remained low or decreased further. We found smaller or negligible associations between mobility restriction and incidence rates in the late phase in most countries.

ConclusionMild to moderate degrees of mobility restriction in most countries were associated with reduced incidence rates of COVID-19 that appear to attenuate over time, while some countries exhibited no effect of such restrictions. More detailed research is needed to precisely understand the benefits and limitations of mobility restrictions as part of the public health response to the COVID-19 pandemic.

WHAT IS ALREADY KNOWN ON THIS TOPICSince SARS-CoV-2 became a pandemic, restrictions on mobility such as limitations on travel and closure of offices, restaurants, and shops have been imposed in an unprecedented way in both scale and scope to prevent the spread of COVID-19 in the absence of effective treatment options or a vaccine. Although mobility restriction has also brought about tremendous costs such as negative economic growth and other collateral impacts on health such as increased morbidity and mortality from lack of access to other essential health services, little evidence exists on the effectiveness of mobility restriction for the prevention of disease transmission. A search of PUBMED and Google Scholar for publications on this topic through Sep 20, 2020 revealed that most of the evidence on the effectiveness of physical distancing comes from mathematical modeling studies using a variety of assumptions. One study investigated only the combined effect of several interventions, including physical distancing, among SARS-CoV-2 infected patients.

WHAT THIS STUDY ADDSThis is the first study to investigate the association between change in mobility and incidence of COVID-19 globally using real-time measures of mobility at the population level. For this, we used Google Global Mobility data and the daily incidence of COVID-19 for 36 countries from the day of 100th case detection through August 31, 2020. Our findings from LOESS regression show that in two-thirds of countries, reductions of up to 40% in commuting mobility were associated with decreased COVID-19 incidence, more so early in the pandemic. This decrease, however, plateaued as mobility decreased further. We found that associations between mobility restriction and incidence became smaller or negligible in the late phase of the pandemic in most countries. The reduced incidence rate of COVID-19 cases with a mild to moderate degree of mobility restriction in most countries suggests some value to limited mobility restriction in early phases of epidemic mitigation. The lack of impact in some others, however, suggests further research is needed to confirm these findings and determine the distinguishing factors for when mobility restrictions are helpful in decreasing viral transmission. Governments should carefully consider the level and period of mobility restriction necessary to achieve the desired benefits and minimize harm.",health policy,exact,100,100
medRxiv,10.1101/2020.10.30.20222984,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20222984,"Modeling COVID-19 Transmissions and Evaluation of Large Scale Social Restriction in Jakarta, Indonesia",Agus Hasan; Yuki Nasution; Hadi Susanto; Endah Putri; Venansius Tjahjono; Dilla Puspita; Kamal Sukandar; Nuning Nuraini; Widyastuti Widyastuti; S. Patrick Kaucher; Chang-Chung Chan; Soonman Kwon; Naoki Kondo; Hoang Van Minh; J. Robin Moon; Mikael Rostila; Ole F. Norheim; Myoungsoon You; Mellissa Withers; Mu Li; Eun-Jeung Lee; Caroline Benski; Soo Kyung Park; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"University of Southern Denmark; Universitas Mulawarman; Khalifa University; Institut Teknologi Sepuluh November; Institut Teknologi Sepuluh Nopember; Institut Teknologi Bandung; Institut Teknologi Bandung; Institut Teknologi Bandung; Dinas Kesehatan Jakarta; Mailman School of Public Health, Columbia University; National Taiwan University College of Public Health; Seoul National University Graduate School of Public Health; Kyoto University School of Public Health; Hanoi University of Public Health; City University of New York Graduate School of Public Health & Health Policy; Stockholm University; 1.University of Bergen 2. Harvard University T.H.Chan School of Public Health; Seoul National University Graduate School of Public Health; University of Southern California; The University of Sydney; Berlin Free University; University Hospital of Geneva; National Health Insurance Research Institute; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","This paper presents mathematical modeling and quantitative evaluation of Large Scale Social Restriction (LSSR) in Jakarta between 10 April and 4 June 2020. The special capital region of Jakarta is the only province among 34 provinces in Indonesia with an average Testing Positivity Rate (TPR) below 5% recommended by the World Health Organization (WHO). The transmission model is based on a discrete-time compartmental epidemiological model incorporating suspected cases. The quantitative evaluation is measured based on the estimation of the time-varying effective reproduction number ([R]t). Our results show the LSSR has been successfully suppressed the spread of COVID-19 in Jakarta, which was indicated by [R]t < 1. However, once the LSSR was relaxed, the effective reproduction number increased significantly. The model is further used for short-term forecasting to mitigate the course of the pandemic.",health policy,exact,100,100
medRxiv,10.1101/2020.10.30.20215301,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20215301,"Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study",Robert Flisiak; Dorota Zarebska-Michaluk; Aleksandra Berkan-Kawinska; Magdalena Tudrujek-Zdunek; Magdalena Rogalska; Anna Piekarska; Dorota Kozielewicz; Krzysztof Klos; Marta Rorat; Beata Bolewska; Anna Szymanek-Pasternak; Wlodzimierz Mazur; Beata Lorenc; Regina Podlasin; Katarzyna Sikorska; Barbara Oczko-Grzesik; Cezary Iwaszkiewicz; Bartosz Szetela; Pawel Pabjan; Malgorzata Pawlowska; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Poland; Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw, Poland; Department of Forensic Medicine, Wroclaw Medical University, Wroclaw, Poland & First Infectious Diseases Ward, Gromkowski Regional Specialist Hospital in Wrocla; Department of Infectious Diseases, University of Medical Sciences, Poznan, Poland; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Clinical Department of Infectious Diseases in Chorzow, Medical University of Silesia, Katowice, Poland; Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdansk, Gdansk, Poland; Hospital of Infectious Diseases in Warsaw, Warsaw, Poland; Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Gdansk Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznan, Poland; Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wroclaw, Poland; Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","BackgroundRemdesivir (RDV) is the only antiviral drug registered currently for treatment of COVID-19 after a few clinical trials with controversial results. The purpose of this study was to evaluate the effectiveness and safety of RDV in patients with COVID-19 in real world settings.

MethodsPatients were selected from 1496 individuals included in the SARSTer national database; 122 of them received therapy with RDV and 211 were treated with lopinavir/ritonavir (LPV/r)-based therapy. The primary end-point of effectiveness was clinical improvement in the ordinal 8-point scale, which was defined as a 2-point decrease from baseline to 7, 14, 21 and 28 days of hospitalization. The secondary end-points of effectiveness included: death rate, rate of no clinical improvement within 28 days of hospitalization in the ordinal scale, rate of the need for constant oxygen therapy, duration of oxygen therapy, rate of the need for mechanical ventilation, total hospitalization time, and rate of positive RT PCR for SARS-CoV-2 after 30 days.

FindingsSignificantly higher rates of clinical improvement, by 15% and 10% respectively, were observed after RDV treatment compared to LPV/r at days 21 and 28. The difference between regimens increased with worsening of oxygen saturation (SpO2) and depending on the baseline score from the ordinal scale. Statistically significant differences supporting RDV were also noted regarding the rate of no clinical improvement within 28 days of hospitalization and hospitalization duration in patients with baseline SpO2 [&le;]90%. In the logistic regression model only the administration of remdesivir was independently associated with at least a 2-point improvement in the ordinal scale between baseline and day 21.

InterpretationIn conclusion, data collected in this retrospective, observational, real world study supported use of remdesivir for treatment of SARS-CoV-2 infection particularly in patients with oxygen saturation [&le;]95%.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20222604,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20222604,Growth of respiratory droplets in cold and humid air,Chong Shen Ng; Kai Leong Chong; Rui Yang; Mogeng Li; Roberto Verzicco; Detlef Lohse; Dorota Kozielewicz; Krzysztof Klos; Marta Rorat; Beata Bolewska; Anna Szymanek-Pasternak; Wlodzimierz Mazur; Beata Lorenc; Regina Podlasin; Katarzyna Sikorska; Barbara Oczko-Grzesik; Cezary Iwaszkiewicz; Bartosz Szetela; Pawel Pabjan; Malgorzata Pawlowska; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"University of Twente; University of Twente; University of Twente; University of Twente; University of Rome 'Tor Vergata'; University of Twente; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw, Poland; Department of Forensic Medicine, Wroclaw Medical University, Wroclaw, Poland & First Infectious Diseases Ward, Gromkowski Regional Specialist Hospital in Wrocla; Department of Infectious Diseases, University of Medical Sciences, Poznan, Poland; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Clinical Department of Infectious Diseases in Chorzow, Medical University of Silesia, Katowice, Poland; Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdansk, Gdansk, Poland; Hospital of Infectious Diseases in Warsaw, Warsaw, Poland; Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Gdansk Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznan, Poland; Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wroclaw, Poland; Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","The ambient conditions surrounding liquid droplets determine their growth or shrinkage. However, the precise fate of a liquid droplet expelled from a respiratory puff as dictated by its surroundings and the puff itself has not yet been fully quantified. From the view of airborne disease transmission, such as SARS-CoV-2, knowledge of such dependencies are critical. Here we employ direct numerical simulations (DNS) of a turbulent respiratory vapour puff and account for the mass and temperature exchange with respiratory droplets and aerosols. In particular, we investigate how droplets respond to different ambient temperatures and relative humidity (RH) by tracking their Lagrangian statistics. We reveal and quantify that in cold and humid environments, as there the respiratory puff is supersaturated, expelled droplets can first experience significant growth, and only later followed by shrinkage, in contrast to the monotonic shrinkage of droplets as expected from the classical view by William F. Wells (1934). Indeed, cold and humid environments diminish the ability of air to hold water vapour, thus causing the respiratory vapour puff to super-saturate. Consequently, the super-saturated vapour field drives the growth of droplets that are caught and transported within the humid puff. To analytically predict the likelihood for droplet growth, we propose a model for the axial RH based on the assumption of a quasi-stationary jet. Our model correctly predicts super-saturated RH conditions and is in good quantitative agreement with our DNS. Our results culminate in a temperature-RH map that can be employed as an indicator for droplet growth or shrinkage.

Significance StatementInfluence of environmental conditions on airborne diseases transmission is an important issue, especially during the pandemic of COVID-19. Human-to-human transmission is mediated by the transport of virus-laden respiratory droplets. Here we investigate the problem from a fluid mechanics perspective by conducting numerical simulations to quantify the fate of respiratory droplets in a warm humid coughing puff under different ambient conditions. We reveal a non-intuitive regime with considerable growth of respiratory droplets, dominated by a super-saturated vapour field, preferentially occurring in cold and humid environments. We further propose a theoretical model that accurately predicts the condition for droplet growth. Our work should inform socializing policies and ventilation strategies for controlling indoor ambient conditions to mitigate dispersion of droplets from asymptomatic individuals.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20222877,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20222877,Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system,Julia M Baker; Kristin N Nelson; Elizabeth Overton; Benjamin A Lopman; Timothy L Lash; Mark Photakis; Jesse T Jacob; John Roback; Scott K Fridkin; James P Steinberg; Anna Szymanek-Pasternak; Wlodzimierz Mazur; Beata Lorenc; Regina Podlasin; Katarzyna Sikorska; Barbara Oczko-Grzesik; Cezary Iwaszkiewicz; Bartosz Szetela; Pawel Pabjan; Malgorzata Pawlowska; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Rollins School of Public Health, Emory University; Rollins School of Public Health, Emory University; Emory Healthcare; Rollins School of Public Health, Emory University; Rollins School of Public Health, Emory University; Emory Healthcare; Emory University School of Medicine, Emory University; Emory University School of Medicine, Emory University; Emory University School of Medicine, Emory University; Emory University School of Medicine, Emory University; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Clinical Department of Infectious Diseases in Chorzow, Medical University of Silesia, Katowice, Poland; Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdansk, Gdansk, Poland; Hospital of Infectious Diseases in Warsaw, Warsaw, Poland; Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Gdansk Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznan, Poland; Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wroclaw, Poland; Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","BackgroundQuantifying occupational risk factors for SARS-CoV-2 infection among healthcare workers can inform efforts to improve healthcare worker and patient safety and reduce transmission. This study aimed to quantify demographic, occupational, and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large metropolitan healthcare system.

MethodsWe analyzed data from a cross-sectional survey conducted from April through June of 2020 linking risk factors for occupational and community exposure to COVID-19 with SARS-CoV-2 seropositivity. A multivariable logistic regression model was fit to quantify risk factors for infection. Participants were employees and medical staff members who elected to participate in SARS-CoV-2 serology testing offered to all healthcare workers as part of a quality initiative, and who completed a survey on exposure to COVID-19 and use of personal protective equipment. Exposures of interest included known demographic risk factors for COVID-19, residential zip code incidence of COVID-19, occupational exposure to PCR test-positive healthcare workers or patients, and use of personal protective equipment. The primary outcome of interest was SARS-CoV-2 seropositivity.

ResultsSARS-CoV-2 seropositivity was estimated to be 5.7% (95% CI: 5.2%-6.1%) among 10,275 healthcare workers. Community contact with a person known or suspected to have COVID-19 (aOR=1.9, 95% CI:1.4-2.5) and zip code level COVID-19 incidence (aOR: 1.4, 95% CI: 1.0-2.0) increased the odds of infection. Black individuals were at high risk (aOR=2.0, 95% CI:1.6-2.4). Overall, occupational risk factors accounted for 27% (95% CI: 25%-30%) of the risk among healthcare workers and included contact with a PCR test-positive healthcare worker (aOR=1.2, 95% CI:1.0-1.6).

ConclusionsCommunity risk factors, including contact with a COVID-19 positive individual and residential COVID-19 incidence, are more strongly associated with SARS-CoV-2 seropositivity among healthcare workers than exposure in the workplace.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20223099,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223099,"Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells",Catherine Riou; Georgia Schafer; Elsa Du Bruyn; Rene Goliath; Cari Stek; Huihui Mou; Deli Hung; Katalin Andrea Wilkinson; Robert John Wilkinson; James P Steinberg; Anna Szymanek-Pasternak; Wlodzimierz Mazur; Beata Lorenc; Regina Podlasin; Katarzyna Sikorska; Barbara Oczko-Grzesik; Cezary Iwaszkiewicz; Bartosz Szetela; Pawel Pabjan; Malgorzata Pawlowska; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; The Scripps Research Institute; The Scripps Research Institute; The Francis Crick Institute; Imperial College London; Emory University School of Medicine, Emory University; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Clinical Department of Infectious Diseases in Chorzow, Medical University of Silesia, Katowice, Poland; Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdansk, Gdansk, Poland; Hospital of Infectious Diseases in Warsaw, Warsaw, Poland; Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Gdansk Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznan, Poland; Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wroclaw, Poland; Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Rapid tests to evaluate SARS-CoV-2-specific T cell responses are urgently needed to decipher protective immunity and aid monitoring vaccine-induced immunity. Using a rapid whole blood assay requiring minimal amount of blood, we measured qualitatively and quantitatively SARS-CoV-2-specific CD4 T cell responses in 31 healthcare workers, using flow cytometry. 100% of COVID-19 convalescent participants displayed a detectable SARS-CoV-2-specific CD4 T cell response. SARS-CoV-2-responding cells were also detected in 40.9% of participants with no COVID-19-associated symptoms or who tested PCR negative. Phenotypic assessment indicated that, in COVID-19 convalescent participants, SARS-CoV-2 CD4 responses displayed an early differentiated memory phenotype with limited capacity to produce IFN{gamma}. Conversely, in participants with no reported symptoms, SARS-CoV-2 CD4 responses were enriched in late differentiated cells, co-expressing IFN{gamma} and TNF and also Granzyme B. This proof of concept study presents a scalable alternative to PBMC-based assays to enumerate and phenotype SARS-CoV-2-responding T cells, thus representing a practical tool to monitor adaptive immunity in vaccine trials.

SummaryIn this proof of concept study, we show that SARS-CoV-2 T cell responses are easily detectable using a rapid whole blood assay requiring minimal blood volume. Such assay could represent a suitable tool to monitor adaptive immunity in vaccine trials.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20223149,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223149,Availability of personal protective equipment and satisfaction of healthcare professionals during COVID-19 pandemic in Ethiopia,Wakgari Deressa; Alemayehu Worku; Workeabeba Abebe; Muluken Gizaw; Wondwossen Amogne; Huihui Mou; Deli Hung; Katalin Andrea Wilkinson; Robert John Wilkinson; James P Steinberg; Anna Szymanek-Pasternak; Wlodzimierz Mazur; Beata Lorenc; Regina Podlasin; Katarzyna Sikorska; Barbara Oczko-Grzesik; Cezary Iwaszkiewicz; Bartosz Szetela; Pawel Pabjan; Malgorzata Pawlowska; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"School of Public Health, College of Health Sciences, Addis Ababa University; School of Public Health, College of Health Sciences, Addis Ababa University; School of Medicine, College of Health Sciences, Addis Ababa University; School of Public Health, College of Health Sciences, Addis Ababa University; School of Medicine, College of Health Sciences, Addis Ababa University; The Scripps Research Institute; The Scripps Research Institute; The Francis Crick Institute; Imperial College London; Emory University School of Medicine, Emory University; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Clinical Department of Infectious Diseases in Chorzow, Medical University of Silesia, Katowice, Poland; Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdansk, Gdansk, Poland; Hospital of Infectious Diseases in Warsaw, Warsaw, Poland; Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Gdansk Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznan, Poland; Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wroclaw, Poland; Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Healthcare professionals (HCPs) are at the frontline in the fight against COVID-19 and are at an increased risk of becoming infected with coronavirus. Risk of infection can be minimized by use of proper personal protective equipment (PPE). This study assessed the availability of PPE and satisfaction of HCPs in six public hospitals in Addis Ababa, Ethiopia. A cross-sectional study was conducted from 9th to 26th June 2020. The study hospitals included: Tikur Anbessa Specialized Hospital, Zewditu Memorial Hospital, Ghandi Memorial Hospital, Menelik II Hospital, Yekatit 12 Hospital Medical College and St. Paul Hospital Millennium Medical College. Data were collected using a self-administered questionnaire. Descriptive statistics were used to describe the data and Chi-square test was used to assess the association between the groups. Bivariate and multivariable logistic regression models were used to assess factors associated with the satisfaction level of healthcare workers with regard to the availability and use of proper PPE during the current COVID-19 pandemic. A total of 1,134 (92.3%) valid questionnaires from a possible 1,228 were included in the analysis. The mean ({+/-}SD) age of the participants was 30.26{+/-}6.43 year and 52.6% were females. Nurses constituted about 40% of the overall sample, followed by physicians (22.2%), interns (10.8%), midwives (10.3%) and others (16.7%). An overall shortage of PPE was reported in all study hospitals. The majority (77%) of the healthcare professionals reported that their hospital did not have adequate PPE. A critical shortage of N95 respirator was particularly reported, the self-reported availability of N95 increased from 13% to 24% before and during COVID-19, respectively. The self-reported use of N95 increased from 9% to 21% before and during COVID-19, respectively. Almost 72% of the respondents were dissatisfied with the availability of PPE in their hospital. The independent predictors of the respondents satisfaction level about PPE were male gender (adjusted OR=1.39, 95% CI:1.05-1.85), healthcare workers who reported that PPE was adequately available in the hospital (adjusted OR=7.53, 95% CI:5.08-11.16), and preparedness to provide care to COVID-19 cases (adjusted OR=1.65, 95% CI:1.22-2.12). A critical shortage of appropriate PPE both before and during COVID-19 was identified. The high level of dissatisfaction with the availability of PPE might potentially lead to a lower level of preparedness and readiness to fight against COVID-19. Therefore, urgent efforts are needed to adequately supply the healthcare facilities with appropriate PPE to alleviate the challenges.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20223081,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223081,"Transmission routes of SARS-CoV-2 among healthcare workers of a French university hospital in Paris, France: a case-control study",Adrien CONTEJEAN; Jeremie LEPORRIER; Etienne CANOUI; Jacques FOURGEAUD; Alice-Andree MARIAGGI; Fanny ALBY-LAURENT; Emmanuel LAFONT; Lauren BEAUDEAU; Claire ROUZAUD; Fabienne LECIEUX; Agnes GREFFET; Anne-Sophie L'HONNEUR; Jean-Marc TRELUYER; Fanny LANTERNIER; Anne CASETTA; Pierre FRANGE; Marianne LERUEZ-VILLE; Flore ROZENBERG; Olivier LORTHOLARY; Solen KERNEIS; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Equipe Mobile d'Infectiologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe Mobile d'Infectiologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Laboratoire de virologie, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris, France; Departement de virologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe Mobile d'Infectiologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Service de sante au travail, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de sante au travail, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris, France; Departement de virologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Universite de Paris, Faculte de Medecine, F-75006 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe operationnelle d'hygiene hospitaliere, AP-HP, Hopital Cochin, F-75014 Paris, France; Laboratoire de microbiologie clinique, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris,; Laboratoire de virologie, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris, France; Departement de virologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe Mobile d'Infectiologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","In this case-control study on 564 healthcare workers of a university hospital in Paris (France), contacts without protection with COVID-19 patients or with colleagues were associated with infection with SARS-CoV-2, while working in a COVID-dedicated unit, using public transportation and having children kept in childcare facilities were not.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20223180,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223180,Risk perceptions and preventive practices of COVID-19 among healthcare professionals in public hospitals in Ethiopia,Wakgari Deressa; Alemayehu Worku; Workeabeba Abebe; Muluken Gizaw; Wondwossen Amogne; Fanny ALBY-LAURENT; Emmanuel LAFONT; Lauren BEAUDEAU; Claire ROUZAUD; Fabienne LECIEUX; Agnes GREFFET; Anne-Sophie L'HONNEUR; Jean-Marc TRELUYER; Fanny LANTERNIER; Anne CASETTA; Pierre FRANGE; Marianne LERUEZ-VILLE; Flore ROZENBERG; Olivier LORTHOLARY; Solen KERNEIS; Krzysztof Tomasiewicz; Joanna Polanska; Jerzy Jaroszewicz; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"School of Public Health, College of Health Sciences, Addis Ababa University; School of Public Health, College of Health Sciences, Addis Ababa University; Scool of Medicine, College of Health Sciences, Addis Ababa University; School of Public Health, College of Health Sciences, Addis Ababa University; School of Medicine, College of Health Sciences, Addis Ababa University; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe Mobile d'Infectiologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Service de sante au travail, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de sante au travail, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris, France; Departement de virologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Universite de Paris, Faculte de Medecine, F-75006 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe operationnelle d'hygiene hospitaliere, AP-HP, Hopital Cochin, F-75014 Paris, France; Laboratoire de microbiologie clinique, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris,; Laboratoire de virologie, AP-HP, Hopital Necker-Enfants malades, F-75015 Paris, France; Departement de virologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hopital Necker-Enfants malades, F-75015 Paris, France; Equipe Mobile d'Infectiologie, AP-HP, Hopital Cochin, F-75014 Paris, France; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland; Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Healthcare professionals are at higher risk of contracting the novel coronavirus due to their work exposure in the healthcare settings. Practicing appropriate preventive measures to control COVID-19 infection is one of the most important interventions that healthcare workers are expected to use. The aim of this study was to assess the level of risk perception and practices of preventive measures of COVID-19 among health workers in Addis Ababa, Ethiopia. A hospital-based cross-sectional study was conducted from 9th to 26th June 2020 among healthcare professionals working at six public hospitals in Addis Ababa. Data were collected using a self-administered structured questionnaire. Frequency, percentage, and mean were used to summarize the data. A binary logistic regression analyses were performed to identify factors associated with risk perception about COVID-19. A total of 1,134 participants were surveyed. Wearing facemask (93%), hand washing for at least 20 seconds (93%), covering mouth and nose while coughing or sneezing (91%), and avoiding touching eyes, nose, and mouth (91%) were the commonly self-reported preventive practices. About 88% perceived that they were worried about the risk of becoming infected with coronavirus, and majority (91%) worried about the risk of infection to their family. The mean score of overall fear and worry of COVID-19 was 2.37 on a scale of 1 to 3. Respondents who ever provided clinical care to COVID-19 patients were more likely to report fear and worry (adjusted OR=1.34, 95% CI:1.02-1.91), however those who ever participated in Ebola or SARS outbreaks were less likely to report fear and worry due to COVID-19 crisis (adjusted OR=0.66, 95% CI:0.48-0.90). This study has revealed widespread practices of preventive measures and the highest perceived risk of COVID-19 among healthcare workers. Therefore, an effective risk communication intervention should be implemented to ensure the maintenance of appropriate practices during the current COVID-19 pandemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.29.20221036,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.29.20221036,Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States,Bingyi Yang; Angkana T. Huang; Bernardo Garcia-Carreras; William E. Hart; Andrea Staid; Matt Hitchings; Elizabeth C. Lee; Chanelle J. Howe; Kyra H. Grantz; Amy Wesolowski; Joseph Chadi Lemaitre; Susan M Rattigan; Carlos Moreno; Brooke A. Borgert; Celeste L. Dale; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,University of Florida; University of Florida; University of Florida; Sandia National Laboratories; Sandia National Laboratories; University of Florida; Johns Hopkins Bloomberg School of Public Health; Brown University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; EPFL; University of Florida; University of Florida; University of Florida; University of Florida; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine,"Non-pharmaceutical interventions (NPIs) remain the only widely available tool for controlling the ongoing SARS-CoV-2 pandemic. We estimated weekly values of the effective basic reproductive number (Reff) using a mechanistic metapopulation model and associated these with county-level characteristics and NPIs in the United States (US). Interventions that included school and leisure activities closure and nursing home visiting bans were all associated with an Reff below 1 when combined with either stay at home orders (median Reff 0.97, 95% confidence interval (CI) 0.58-1.39)* or face masks (median Reff 0.97, 95% CI 0.58-1.39)*. While direct causal effects of interventions remain unclear, our results suggest that relaxation of some NPIs will need to be counterbalanced by continuation and/or implementation of others.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.30.20222893,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20222893,Estimating the potential impact of COVID-19-related disruptions on HIV incidence and mortality among men who have sex with men in the United States: a modelling study,Kate M Mitchell; Dobromir Dimitrov; Romain Silhol; Lily Geidelberg; Mia Moore; Albert Liu; Chris Beyrer; Kenneth H Mayer; Stefan Baral; Marie-Claude Boily; Joseph Chadi Lemaitre; Susan M Rattigan; Carlos Moreno; Brooke A. Borgert; Celeste L. Dale; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Imperial College London; Fred Hutchinson Cancer Research Center; Imperial College London; Imperial College London; Fred Hutchinson Cancer Research Center; University of California San Francisco, San Francisco Department of Public Health; Johns Hopkins Bloomberg School of Public Health; The Fenway Institute, Harvard Medical School; Johns Hopkins School of Public Health; Imperial College London; EPFL; University of Florida; University of Florida; University of Florida; University of Florida; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","BackgroundDuring the COVID-19 pandemic, gay and other men who have sex with men (MSM) in the United States (US) report similar or fewer sexual partners and reduced HIV testing and care access. Pre-exposure prophylaxis (PrEP) use has declined. We estimated the potential impact of COVID-19 on HIV incidence and mortality among US MSM.

MethodsWe used a calibrated HIV transmission model for MSM in Baltimore, Maryland, and available data on COVID-19-related disruptions to predict impacts of data-driven reductions in sexual partners(0%,25%,50%), condom use(5%), HIV testing(20%), viral suppression(10%), PrEP initiations(72%), PrEP use(9%) and ART initiations(50%), exploring different disruption durations and magnitudes. We estimated the median (95% credible interval) change in cumulative new HIV infections and deaths among MSM over one and five years, compared with a scenario without COVID-19-related disruptions.

FindingsA six-month 25% reduction in sexual partners among Baltimore MSM, without HIV service changes, could reduce new HIV infections by 12{middle dot}2%(11{middle dot}7,12{middle dot}8%) and 3{middle dot}0%(2{middle dot}6,3{middle dot}4%) over one and five years, respectively. In the absence of changes in sexual behaviour, the six-month data-driven disruptions to condom use, testing, viral suppression, PrEP initiations, PrEP use and ART initiations combined were predicted to increase new HIV infections by 10{middle dot}5%(5{middle dot}8,16{middle dot}5%) over one year, and by 3{middle dot}5%(2{middle dot}1,5{middle dot}4%) over five years. A 25% reduction in partnerships offsets the negative impact of these combined service disruptions on new HIV infections (overall reduction 3{middle dot}9%(-1{middle dot}0,7{middle dot}4%), 0{middle dot}0%(-1{middle dot}4,0{middle dot}9%) over one, five years, respectively), but not on HIV deaths (corresponding increases 11{middle dot}0%(6{middle dot}2,17{middle dot}7%), 2{middle dot}6%(1{middle dot}5,4{middle dot}3%)). The predicted impacts of reductions in partnerships or viral suppression doubled if they lasted 12 months or if disruptions were twice as large.

InterpretationMaintaining access to ART and adherence support is of the utmost importance to minimise excess HIV-related mortality due to COVID-19 restrictions in the US, even if accompanied by reductions in sexual partnerships.

FundingNIH

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThe COVID-19 pandemic and responses to it have disrupted HIV prevention and treatment services and led to changes in sexual risk behaviour in the United States, but the overall potential impact on HIV transmission and HIV-related mortality is not known. We searched PubMed for articles documenting COVID-related disruptions to HIV prevention and treatment and changes in sexual risk behaviour in the United States, published between 1st January and 7th October 2020, with no language restrictions, using the terms COVID* AND (HIV OR AIDS) AND (""United States"" OR US). We identified three cross-sectional surveys assessing changes in sexual risk behaviour among men who have sex with men (MSM) in the United States, one finding a reduction, one a slight increase, and one no change in partner numbers during COVID-19 restrictions. Two of these studies also found reductions in reported HIV testing, HIV care and/or access to pre-exposure prophylaxis (PrEP) among MSM due to COVID-19. A separate study from a San Francisco clinic found declines in viral suppression among its clients during lockdown. We searched PubMed for articles estimating the impact of COVID-related disruptions on HIV transmission and mortality published between 1st January 2020 and 12th October 2020, with no language restrictions, using the following terms: COVID* AND model* AND (HIV OR AIDS). We identified two published studies which had used mathematical modelling to estimate the impact of hypothetical COVID-19-related disruptions to HIV programmes on HIV-related deaths and/or new HIV infections in Africa, another published study using modelling to estimate the impact of COVID-19-related disruptions and linked HIV and SARS-CoV-2 testing on new HIV infections in six cities in the United States, and a pre-print reporting modelling of the impact of COVID-19-related disruptions on HIV incidence among men who have sex with men in Atlanta, United States. None of these studies were informed by data on the size of these disruptions. The two African studies and the Atlanta study assessed the impact of disruptions to different healthcare disruptions separately, and all found that the greatest negative impacts on new HIV infections and/or deaths would arise from interruptions to antiretroviral therapy. They all found smaller effects on HIV-related mortality and/or incidence from other healthcare disruptions, including HIV testing, PrEP use and condom supplies. The United States study assessing the impact of linked HIV and SARS-CoV-2 testing estimated that this could substantially reduce HIV incidence.

Added value of this studyWe used mathematical modelling to derive estimates of the potential impact of the COVID-19 pandemic and associated restrictions on HIV incidence and mortality among MSM in the United States, directly informed by data from the United States on disruptions to HIV testing, antiretroviral therapy and pre-exposure prophylaxis services and reported changes in sexual risk behaviour during the COVID-19 pandemic. We also assessed the impact of an HIV testing campaign during COVID-19 lockdown.

Implications of all the available evidenceIn the United States, maintaining access to antiretroviral therapy and adherence support for both existing and new users will be crucial to minimize excess HIV-related deaths arising from the COVID-19 pandemic among men who have sex with men. While reductions in sexual risk behaviour may offset increases in new HIV infections arising from disruptions to HIV prevention and treatment services, this will not offset the additional HIV-related deaths which are also predicted to occur. There are mixed findings on the impact of an HIV testing campaign among US MSM during COVID-19 lockdown. Together, these studies highlight the importance of maintaining effective HIV treatment provision during the COVID-19 pandemic.",hiv aids,exact,100,100
medRxiv,10.1101/2020.10.30.20223057,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223057,Rapid classification and prediction of COVID-19 severity by MALDI-TOF mass spectrometry analysis of serum peptidome,Rosa M Gomila; Gabriel Martorell; Pablot A Fraile-Ribot; Antonio Domenech-Sanchez; Antonio Oliver; Mercedes Garcia-Gasalla; Sebastian Alberti; Kenneth H Mayer; Stefan Baral; Marie-Claude Boily; Joseph Chadi Lemaitre; Susan M Rattigan; Carlos Moreno; Brooke A. Borgert; Celeste L. Dale; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Universidad de las Islas Baleares; Universidad de las Islas Baleares; Hospital Universitario Son Espases; Universidad de las Islas Baleares; Hospital Universitario Son Espases; Hospital Universitario Son Espases; Universidad de las Islas Baleares; The Fenway Institute, Harvard Medical School; Johns Hopkins School of Public Health; Imperial College London; EPFL; University of Florida; University of Florida; University of Florida; University of Florida; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Classification and early detection of severe COVID-19 patients is urgently required to establish an effective treatment. Here, we tested the utility of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to classify and predict the severity of COVID-19 in a clinical setting. We used this technology to analyse the mass spectra profiles of the sera from 80 COVID-19 patients, clinically classified as mild (33), severe (26) and critical (21), and 20 healthy controls. We found a clear variability of the serum peptidome profile depending on COVID-19 severity. Seventy-eight peaks were significantly different and 12 at least four fold more intense in the set of critical patients than in the mild ones. Analysis of the resulting matrix of peak intensities by machine learning approaches classified severe (severe and critical) and non-severe (mild) patients with a 90% of accuracy. Furthermore, machine learning predicted correctly the favourable outcome of the severe patients in 85% of the cases and the unfavourable in 38% of the cases. Finally, liquid chromatography mass spectrometry analysis of sera identified five proteins that were significantly upregulated in the critical patients. They included serum amyloid proteins A1 and A2, which probably yielded the most intense peaks with m/z 11,530 and 11,686 detected by MALDI-TOF MS.

In summary, we demonstrated the potential of the MALDI-TOF MS as a bench to bedside technology to aid clinicians in their decisions to classify COVID-19 patients and predict their evolution.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.29.20222661,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.29.20222661,Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study,Priyamadhaba Behera; Binod Kumar Patro; Arvind Kumar Singh; Pradnya Dilip Chandanshive; Ravikumar S R; Somen Kumar Pradhan; Siva Santosh Kumar Pentapati; Gitanjali Batmanabane; Biswa Mohan Padhy; Shakti Bal; Sudipta Ranjan Singh; Rashmi Ranjan Mohanty; Carlos Moreno; Brooke A. Borgert; Celeste L. Dale; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar; Director, All India Institute of Medical Sciences, Bhubaneswar; Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar; Department of  Pulmonary Medicine and Critical Care, All India Institute of Medical Sciences, Bhubaneswar; Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Bhubaneswar; Department of General Medicine, All India Institute of Medical Sciences, Bhubaneswar; University of Florida; University of Florida; University of Florida; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","BackgroundIvermectin is one among several potential drugs explored for its therapeutic and preventive role in COVID-19 infection. The study was aimed to explore the association between ivermectin prophylaxis and development of COVID-19 infection among healthcare workers.

MethodsA hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for COVID-19 infection.

ResultsIvermectin prophylaxis was taken by 77 controls and 38 cases. Two-dose ivermectin prophylaxis (0.27, 95% CI, 0.15-0.51) was associated with 73% reduction of COVID-19 infection among healthcare workers for the following one month, those who were involved in physical activity (3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract COVID-19 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with COVID-19 infection.

ConclusionTwo-dose ivermectin prophylaxis at a dose of 300 g/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month. Further research is required before its large scale use.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20215335,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20215335,Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model,Prashant Dogra; Javier Ruiz-Ramirez; Kavya Sinha; Joseph D. Butner; Maria J. Pelaez; Manmeet Rawat; Venkata K. Yellepeddi; Renata Pasqualini; Wadih Arap; H. Dirk Sostman; Vittorio Cristini; Zhihui Wang; Carlos Moreno; Brooke A. Borgert; Celeste L. Dale; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,Houston Methodist Research Institute; Houston Methodist Research Institute; Houston Methodist Hospital; Houston Methodist Research Institute; Houston Methodist Research Institute; University of New Mexico School of Medicine; University of Utah; Rutgers New Jersey Medical School; Rutgers New Jersey Medical School; Houston Methodist Academic Institute; Houston Methodist Research Institute; Houston Methodist Research Institute; University of Florida; University of Florida; University of Florida; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pathogen of immense public health concern. Efforts to control the disease have only proven mildly successful, and the disease will likely continue to cause excessive fatalities until effective preventative measures (such as a vaccine) are developed. To develop disease management strategies, a better understanding of SARS-CoV-2 pathogenesis and population susceptibility to infection are needed. To this end, physiologically-relevant mathematical modeling can provide a robust in silico tool to understand COVID-19 pathophysiology and the in vivo dynamics of SARS-CoV-2. Guided by ACE2-tropism (ACE2 receptor dependency for infection) of the virus, and by incorporating cellular-scale viral dynamics and innate and adaptive immune responses, we have developed a multiscale mechanistic model for simulating the time-dependent evolution of viral load distribution in susceptible organs of the body (respiratory tract, gut, liver, spleen, heart, kidneys, and brain). Following calibration with in vivo and clinical data, we used the model to simulate viral load progression in a virtual patient with varying degrees of compromised immune status. Further, we conducted global sensitivity analysis of model parameters and ranked them for their significance in governing clearance of viral load to understand the effects of physiological factors and underlying conditions on viral load dynamics. Antiviral drug therapy, interferon therapy, and their combination was simulated to study the effects on viral load kinetics of SARS-CoV-2. The model revealed the dominant role of innate immunity (specifically interferons and resident macrophages) in controlling viral load, and the impotance of timing when initiating therapy following infection.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC=""FIGDIR/small/20215335v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (43K):
org.highwire.dtl.DTLVardef@54d70eorg.highwire.dtl.DTLVardef@1f2f0ecorg.highwire.dtl.DTLVardef@a71f28org.highwire.dtl.DTLVardef@1eeaeb8_HPS_FORMAT_FIGEXP  M_FIG C_FIG",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20223123,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223123,High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 round 6 interim report,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","BackgroundREACT-1 measures prevalence of SARS-CoV-2 infection in representative samples of the population in England using PCR testing from self-administered nose and throat swabs. Here we report interim results for round 6 of observations for swabs collected from the 16th to 25th October 2020 inclusive.

MethodsREACT-1 round 6 aims to collect data and swab results from 160,000 people aged 5 and above. Here we report results from the first 86,000 individuals. We estimate prevalence of PCR-confirmed SARS-CoV-2 infection, reproduction numbers (R) and temporal trends using exponential growth or decay models. Prevalence estimates are presented both unweighted and weighted to be representative of the population of England, accounting for response rate, region, deprivation and ethnicity. We compare these interim results with data from round 5, based on swabs collected from 18th September to 5th October 2020 inclusive.

ResultsOverall prevalence of infection in the community in England was 1.28% or 128 people per 10,000, up from 60 per 10,000 in the previous round. Infections were doubling every 9.0 (6.1, 18) days with a national reproduction number (R) estimated at 1.56 (1.27, 1.88) compared to 1.16 (1.05, 1.27) in the previous round. Prevalence of infection was highest in Yorkshire and The Humber at 2.72% (2.12%, 3.50%), up from 0.84% (0.60%, 1.17%), and the North West at 2.27% (1.90%, 2.72%), up from 1.21% (1.01%, 1.46%), and lowest in South East at 0.55% (0.45%, 0.68%), up from 0.29% (0.23%, 0.37%). Clustering of cases was more prevalent in Lancashire, Manchester, Liverpool and West Yorkshire, West Midlands and East Midlands. Interim estimates of R were above 2 in the South East, East of England, London and South West, but with wide confidence intervals. Nationally, prevalence increased across all age groups with the greatest increase in those aged 55-64 at 1.20% (0.99%, 1.46%), up 3-fold from 0.37% (0.30%, 0.46%). In those aged over 65, prevalence was 0.81% (0.58%, 0.96%) up 2-fold from 0.35% (0.28%, 0.43%). Prevalence remained highest in 18 to 24-year olds at 2.25% (1.47%, 3.42%).

ConclusionThe co-occurrence of high prevalence and rapid growth means that the second wave of the epidemic in England has now reached a critical stage. Whether via regional or national measures, it is now time-critical to control the virus and turn R below one if further hospital admissions and deaths from COVID-19 are to be avoided.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.30.20223305,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223305,A New Approach to the Dynamic Modeling of an Infectious Disease,B Shayak; Mohit Manoj Sharma; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,Cornell University; Weill Cornell Medicine; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine,"In this work we propose a delay differential equation as a lumped parameter or compartmental infectious disease model featuring high descriptive and predictive capability, extremely high adaptability and low computational requirement. Whereas the model has been developed in the context of COVID-19, it is general enough to be applicable mutatis mutandis to other diseases as well. Our fundamental modeling philosophy consists of a decoupling of public health intervention effects, immune response effects and intrinsic infection properties into separate terms. All parameters in the model are directly related to the disease and its management; we can measure or calculate their values a priori basis our knowledge of the phenomena involved, instead of having to extrapolate them from solution curves. Our model can accurately predict the effects of applying or withdrawing interventions, individually or in combination, and can quickly accommodate any newly released information regarding, for example, the infection properties and the immune response to an emerging infectious disease. After demonstrating that the baseline model can successfully explain the COVID-19 case trajectories observed all over the world, we systematically show how the model can be expanded to account for heterogeneous transmissibility, detailed contact tracing drives, mass testing endeavours and immune responses featuring different combinations of limited-time sterilizing immunity, severity-reducing immunity and antibody dependent enhancement.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.30.20223156,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223156,"COVID-19 Pandemic Among Immigrant Latinx Farmworker and Non-farmworker Families: A Rural-Urban Comparison of Economic, Educational, Healthcare, and Immigration Concerns",Sara A. Quandt; Natalie J. LaMonto; Dana C. Mora; Jennifer W. Talton; Paul J. Laurienti; Thomas A. Arcury; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Nicole E. Quigley; Andrew Cummings; Alize McLorg; Kaelene LoMonaco; Sarah Schlossberg; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,Wake Forest School of Medicine; Lawrence University; Wake Forest School of Medicine; Wake Forest School of Medicine; Wake Forest School of Medicine; Wake Forest School of Medicine; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; University of Florida; Syracuse University; Syracuse University; University of Florida; Tulane University; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine,"COVID-19 has highlighted social and health injustices in the US. Structural inequalities have increased the likelihood of immigrants contracting COVID-19, by being essential workers and through poverty that forces this population to continue working. Rural and urban immigrant families may face different concerns. Using a telephone survey in May 2020 of 105 Latinx families in an existing study, quantitative and qualitative data were gathered on work and household economics, childcare and education, healthcare, and community climate. Analyses show that, although rural and urban groups experienced substantial economic effects, impacts were more acute for urban families. Rural workers reported fewer workplace protective measures for COVID-19. For both groups, fear and worry, particularly about finances and children, dominated reports of their situations with numerous reports of experiencing stress and anxiety. The experience of the pandemic is interpreted as an example of contextual vulnerability of a population already experiencing structural violence through social injustice.",infectious diseases,exact,100,100
bioRxiv,10.1101/2020.11.02.364729,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.02.364729,Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants,Chao Hu; Meiying Shen; XiaoJian Han; Qian Chen; Luo Li; Siyin Chen; Jing Zhang; Fengxia Gao; Wang Wang; Yingming Wang; Tingting Li; Shenglong Li; Jingjing Huang; Jianwei Wang; Ju Zhu; Dan Chen; Qingchen Wu; Kun Tao; Da Pang; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Nangang District, Harbin, 150081, China; Chongqing Medical University; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; 4Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing, 400016, China 5; 4Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing, 400016, China 5; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Nangang District, Harbin, 150081, China; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Despite the growing knowledge of T cell responses and their epitopes in COVID-19 patients, there is a lack of detailed characterizations for T cell-antigen interactions and T cell functions. Using a peptide library predicted with HLA class I-restriction, specific CD8+ T cell responses were identified in over 75% of COVID-19 convalescent patients. Among the 15 SARS-CoV-2 epitopes identified from the S and N proteins, N361-369 (KTFPPTEPK) was the most dominant epitope. Importantly, we discovered 2 N361-369-specific T cell receptors (TCRs) with high functional avidity, and they exhibited complementary cross-reactivity to reported N361-369 mutant variants. In dendritic cells (DCs) and the lung organoid model, we found that the N361-369 epitope could be processed and endogenously presented to elicit the activation and cytotoxicity of CD8+ T cells ex vivo. Our study evidenced potential mechanisms of cellular immunity to SARS-CoV-2, illuminating natural ways of viral clearance with high relevancy in the vaccine development.",immunology,exact,100,100
bioRxiv,10.1101/2020.11.03.366138,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.03.366138,Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate,Yin-Feng Kang; Cong Sun; Zhen Zhuang; Run-Yu Yuan; Qing-Bing Zheng; Ping-Ping Zhou; Jiang-Ping Li; Xin-Chun Chen; Xiao Zhang; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Guangdong Provincial Center for Disease Control and Prevention; Xiamen University; Guangdong Provincial Center for Disease Control and Prevention; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","The ongoing of coronavirus disease 2019 (COVID-19) pandemic caused by novel SARS-CoV-2 coronavirus, resulting in economic losses and seriously threating the human health in worldwide, highlighting the urgent need of a stabilized, easily produced and effective preventive vaccine. The SARS-COV-2 spike protein receptor binding region (RBD) plays an important role in the process of viral binding receptor angiotensin-converting enzyme 2 (ACE2) and membrane fusion, making it an ideal target for vaccine development. In this study, we designed three different RBD-conjugated nanoparticles vaccine candidates, RBD-Ferritin (24-mer), RBD-mi3 (60-mer) and RBD-I53-50 (120-mer), with the application of covalent bond linking by SpyTag-SpyCatcher system. It was demonstrated that the neutralizing capability of sera from mice immunized with three RBD-conjugated nanoparticles adjuvanted with AddaVax or Sigma Systerm Adjuvant (SAS) after each immunization was ~8-to 120-fold greater than monomeric RBD group in SARS-CoV-2 pseudovirus and authentic virus neutralization assay. Most importantly, sera from RBD-conjugated NPs groups more efficiently blocked the binding of RBD to ACE2 or neutralizing antibody in vitro, a further proof of promising immunization effect. Besides, high physical stability and flexibility in assembly consolidated the benefit for rapid scale-up production of vaccine. These results supported that our designed SARS-CoV-2 RBD-conjugated nanoparticle was competitive vaccine candidate and the carrier nanoparticles could be adopted as universal platform for future vaccine development.",microbiology,exact,100,100
bioRxiv,10.1101/2020.11.03.366757,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.03.366757,Structure of nonstructural protein 1 from SARS-CoV-2.,Lauren K. Clark; Todd J. Green; Chad M. Petit; Run-Yu Yuan; Qing-Bing Zheng; Ping-Ping Zhou; Jiang-Ping Li; Xin-Chun Chen; Xiao Zhang; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; Guangdong Provincial Center for Disease Control and Prevention; Xiamen University; Guangdong Provincial Center for Disease Control and Prevention; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","The periodic emergence of novel coronaviruses (CoVs) represents an ongoing public health concern with significant health and financial burden worldwide. The most recent occurrence originated in the city of Wuhan, China where a novel coronavirus (SARS-CoV-2) emerged causing severe respiratory illness and pneumonia. The continual emergence of novel coronaviruses underscores the importance of developing effective vaccines as well as novel therapeutic options that target either viral functions or host factors recruited to support coronavirus replication. The CoV nonstructural protein 1 (nsp1) has been shown to promote cellular mRNA degradation, block host cell translation, and inhibit the innate immune response to virus infection. Interestingly, deletion of the nsp1-coding region in infectious clones prevented the virus from productively infecting cultured cells. Because of nsp1s importance in the CoV lifecycle, it has been highlighted as a viable target for both antiviral therapy and vaccine development. However, the fundamental molecular and structural mechanisms that underlie nsp1 function remain poorly understood, despite its critical role in the viral lifecycle. Here we report the high-resolution crystal structure of the amino, globular portion of SARS-CoV-2 nsp1 (residues 10 - 127) at 1.77[A] resolution. A comparison of our structure with the SARS-CoV-1 nsp1 structure reveals how mutations alter the conformation of flexible loops, inducing the formation of novel secondary structural elements and new surface features. Paired with the recently published structure of the carboxyl end of nsp1 (residues 148 - 180), our results provide the groundwork for future studies focusing on SARS-CoV-2 nsp1 structure and function during the viral lifecycle.

IMPORTANCEThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent for the COVID-19 pandemic. One protein known to play a critical role in the coronavirus lifecycle is nonstructural protein1 (nsp1). As such, it has been highlighted in numerous studies as a target for both the development of antivirals and for the design of live-attenuated vaccines. Here we report the high-resolution crystal structure of nsp1 derived from SARS-CoV-2 at 1.77[A] resolution. This structure will facilitate future studies focusing on understanding the relationship between structure and function for nsp1. In turn, understanding these structure-function relationships will allow nsp1 to be fully exploited as a target for both antiviral development and vaccine design.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.30.360545,2020-11-03,https://biorxiv.org/cgi/content/short/2020.10.30.360545,Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus in vitro,Bruno Frank; Carina Conzelmann; Tatjana Weil; Ruediger Gross; Peggy Jungke; Maren Eggers; Janis A Mueller; Jan Muench; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"CogniVerde GmbH; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; Technische Universitaet Dresden; Labor Prof. Dr. G. Enders MVZ GbR; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Many plant juices, extracts and teas have been shown to possess antiviral activity. We here analyzed the virucidal activity of black chokeberry (Aronia melanocarpa), pomegranate (Punica granatum), and elderberry (Sambucus nigra) juice, as well as green tea (Camellia sinensis) against different respiratory viruses. We found that all tested plant derived products effectively inactivated influenza virus, whereas only chokeberry juice diminished SARS-CoV-2 and vaccinia virus infectivity. None of the products inactivated non-enveloped human adenovirus type 5. Thus, black chokeberry juice exerts virucidal activity against different enveloped viral pathogens under in vitro conditions. Whether application of virucidal juices or green tea as oral rinses may lower viral loads in the oral cavity in vivo remains to be evaluated.",microbiology,exact,100,100
bioRxiv,10.1101/2020.11.02.363598,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.02.363598,Potential Opportunity Of Antisense Therapy Of COVID-19 on an in vitro model,Anton Nikolaevich Goryachev; Sergey Artemovich Kalantarov; Anna Gennadievna Severova; Anna Sergeevna Goryacheva; Peggy Jungke; Maren Eggers; Janis A Mueller; Jan Muench; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"City Clinical Hospital of Pyatigorsk; City Clinical Hospital of Pyatigorsk; Medical Center Profmed; Medical Center Profmed; Technische Universitaet Dresden; Labor Prof. Dr. G. Enders MVZ GbR; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Data on potential effectiveness and prospects of treatment of new coronavirus infection of COVID-19 caused by virus SARS-CoV-2 with the help of antisense oligonucleotides acting against RNA of virus on an in vitro model are given. The ability of antisense oligonucleotides to suppress viral replication in diseases caused by coronaviruses using the example of SARS and MERS is shown. The identity of the initial regulatory section of RNA of various coronaviruses was found within 50 - 100 nucleotides from the 5-end, which allows using antisense suppression of this RNA fragment. A new RNA fragment of the virus present in all samples of coronovirus SARS-CoV-2 has been identified, the suppression of which with the help of an antisense oligonucleotide can be effective in the treatment of COVID-19. The study of the synthesized antisense oligonucleotide 5 - AGCCGAGTGACAGCC ACACAG, complementary to the selected virus RNA sequence, was carried out. The low toxicity of the preparations of this group in the cell culture study and the ability to reduce viral load at high doses according to real time-PCR data are shown. The cytopathogenic dose exceeds 2 mg / ml. At a dosage of 1 mg / ml, viral replication is reduced by 5-13 times. Conclusions are made about the prospects of this direction and the feasibility of using the inhalation way of drug administration into the body.",molecular biology,exact,100,100
bioRxiv,10.1101/2020.11.02.365551,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.02.365551,"COVID-19 risk haplogroups differ between populations, deviate from Neanderthal haplotypes and compromise risk assessment in non-Europeans",Inken Wohlers; Vernica Calonga-Sols; Jan-Niklas Jobst; Hauke Busch; Peggy Jungke; Maren Eggers; Janis A Mueller; Jan Muench; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"University of Lbeck; University of Lbeck; University of Lbeck; University of Lbeck; Technische Universitaet Dresden; Labor Prof. Dr. G. Enders MVZ GbR; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Recent genome wide association studies (GWAS) have identified genetic risk factors for developing severe COVID-19 symptoms. The first published study reported a 1bp insertion rs11385942 on chromosome 3 (1) and subsequent studies single nucleotide variants (SNVs) such as rs35044562, rs67959919 (2) and rs13078854 (3), all highly correlated with each other. Zeberg and Paabo (4) subsequently traced them back to Neanderthal origin. They found that a 49.4 kb genomic region including the risk allele of rs35044562 is inherited from Neanderthals of Vindija in Croatia. Here we add a differently focused evaluation of this major genetic risk factor to these recent analyses. We show that (i) COVID-19-related genetic factors of three previously assessed Neanderthals deviate from those of modern humans and that (ii) they differ among world-wide human populations, which compromises risk prediction in non-Europeans. Currently, caution is thus advised in the genetic risk assessment of non-Europeans during this world-wide COVID-19 pandemic.",genetics,exact,100,100
medRxiv,10.1101/2020.10.27.20219717,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.27.20219717,COVID-19 Mortality Following Mass Gatherings,Oren Miron; Kun-Hsing Yu; Rachel Wilf-Miron; Nadav Davidovitch; Peggy Jungke; Maren Eggers; Janis A Mueller; Jan Muench; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Ben Gurion University; Harvard Medical School; Tel Aviv University; Ben Gurion University; Technische Universitaet Dresden; Labor Prof. Dr. G. Enders MVZ GbR; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","We examined Coronavirus Disease-2019 (COVID-19) mortality following 5 mass gatherings at outdoor rallies in the United States, during August 2020. We found that COVID-19 mortality started increasing 19-24 days after the mass gathering. In a 50-mile radius there was a 2.1-fold increase in COVID-19 mortality, and in a 51-100 miles radius there was a 1.4-fold increase. Our results suggest that precautions should be taken in mass gatherings and in at least a 50-mile radius, in order to limit COVID-19 mortality.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.27.20220707,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.27.20220707,Association of Mass Gatherings and COVID-19 Hospitalization,Oren Miron; Kun-Hsing Yu; Rachel Wilf-Miron; Nadav Davidovitch; Peggy Jungke; Maren Eggers; Janis A Mueller; Jan Muench; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"Ben Gurion University; Harvard Medical School; Tel Aviv University; Ben Gurion University; Technische Universitaet Dresden; Labor Prof. Dr. G. Enders MVZ GbR; Institute of Molecular Virology, Ulm University Medical Center; Institute of Molecular Virology, Ulm University Medical Center; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","We examined COVID-19 hospitalizations following mass gatherings in Wisconsin and Minnesota, United States (September 17-18, 2020). We found that the hospitalization rate increased 15-fold in the Minnesota gathering county, and 12.7-fold in the Wisconsin gathering county. On the state level, it increased 2-fold in Minnesota, and 2.3-fold in Wisconsin, while not increasing significantly in states without gatherings. Our findings suggest that mass gatherings are followed by increased COVID-19 hospitalizations, and that precautions should be taken.",public and global health,exact,100,100
bioRxiv,10.1101/2020.11.03.366609,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.03.366609,Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design,Dnes Berta; Sam Alexander Martino; Andrei Pisliakov; Nadia Elghobashi-Meinhardt; Geoffrey Wells; Sarah A Harris; Elisa Frezza; Edina Rosta; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"University College London; University College London; University of Dundee; Technische Universitt Berlin; University College London; University of Leeds; Universit de Paris; University College London; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Having claimed over 1 million lives worldwide to date, the ongoing COVID-19 pandemic has created one of the biggest challenges to develop an effective drug to treat infected patients. Among all the proteins expressed by the virus, RNA helicase is a fundamental protein for viral replication, and it is highly conserved among the coronaviridae family. To date, there is no high-resolution structure of helicase bound with ATP and RNA. We present here structural insights and molecular dynamics (MD) simulation results of the SARS-CoV-2 RNA helicase both in its apo form and in complex with its natural substrates. Our structural information of the catalytically competent helicase complex provides valuable insights for the mechanism and function of this enzyme at the atomic level, a key to develop specific inhibitors for this potential COVID-19 drug target.",biochemistry,exact,100,100
bioRxiv,10.1101/2020.11.02.365049,2020-11-03,https://biorxiv.org/cgi/content/short/2020.11.02.365049,Computational prediction of SARS-CoV-2 encoded miRNAs and their putative host targets,Sonia Verma; Abhisek Dwivedy; Neeraj Kumar; Bichitra Kumar Biswal; Geoffrey Wells; Sarah A Harris; Elisa Frezza; Edina Rosta; Uwe Kessler; Xiao-Hui Yu; Xiang-Wei Kong; Qian-Ying Zhu; Miao Xu; Nan-Shan Zhong; Yi-Xin Zeng; Guo-Kai Feng; Chang-Wen Ke; Jin-Cun Zhao; Mu-Sheng Zeng; Aishun Jin; Drew W. Barron-Kraus; Harrison C. Shrock; - UFCOVID Interventions Team; Justin Lessler; Carl D. Laird; Derek A.T. Cummings; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"All India Institute of Medical Sciences; National Institute of Immunology; All India Institute of Medical Sciences; National Institute of Immunology; University College London; University of Leeds; Universit de Paris; University College London; CogniVerde GmbH; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center, Sun Yat-sen University; Sun Yat-sen University Cancer Center; Guangdong Provincial Center for Disease Control and Prevention; the First Affiliated Hospital of Guangzhou Medical University; Sun Yat-sen University Cancer Center; 1Department of Immunology, College of Basic Medicine, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China 2Chongqing Key ; University of Florida; University of Florida; ; Johns Hopkins Bloomberg School of Public Health; Sandia National Laboratories; University of Florida; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","Over the past two decades, there has been a continued research on the role of small non-coding RNAs including microRNAs (miRNAs) in various diseases. Studies have shown that viruses modulate the host cellular machinery and hijack its metabolic and immune signalling pathways by miRNA mediated gene silencing. Given the immensity of coronavirus disease 19 (COVID-19) pandemic and the strong association of viral encoded miRNAs with their pathogenesis, it is important to study Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) miRNAs. To address this unexplored area, we identified 8 putative novel miRNAs from SARS-CoV-2 genome and explored their possible human gene targets. A significant proportion of these targets populated key immune and metabolic pathways such as MAPK signalling pathway, maturity-onset diabetes, Insulin signalling pathway, endocytosis, RNA transport, TGF-{beta} signalling pathway, to name a few. The data from this work is backed up by recently reported high-throughput transcriptomics datasets obtains from SARS-CoV-2 infected samples. Analysis of these datasets reveal that a significant proportion of the target human genes were down-regulated upon SARS-CoV-2 infection. The current study brings to light probable host metabolic and immune pathways susceptible to viral miRNA mediated silencing in a SARS-CoV-2 infection, and discusses its effects on the host pathophysiology.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.11.01.20222315,2020-11-02,https://medrxiv.org/cgi/content/short/2020.11.01.20222315,Association between living with children and outcomes from COVID-19: an OpenSAFELY cohort study of 12 million adults in England,Harriet Forbes; Caroline E Morton; Seb Bacon; Helen I McDonald; Caroline Minassian; Jeremy Brown; Christopher T. Rentsch; Rohini T. Mathur; Anna Schultze; Nicholas J DeVito; Brian MacKenna; William J Hulme; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Medicine and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","BackgroundClose contact with children may provide cross-reactive immunity to SARs-CoV-2 due to more frequent prior coryzal infections from seasonal coronaviruses. Alternatively, close contact with children may increase risk of SARs-CoV-2 infection. We investigated whether risk of infection with SARs-CoV-2 and severe outcomes differed between adults living with and without children.

MethodsWorking on behalf of NHS England, we conducted a population-based cohort study using primary care data and pseudonymously-linked hospital and intensive care admissions, and death records, from patients registered in general practices representing 40% of England. Using multivariable Cox regression, we calculated fully-adjusted hazard ratios (HR) of outcomes from 1st February-3rd August 2020 comparing adults living with and without children in the household.

FindingsAmong 9,157,814 adults [&le;]65 years, living with children 0-11 years was not associated with increased risks of recorded SARS-CoV-2 infection, COVID-19 related hospital or ICU admission but was associated with reduced risk of COVID-19 death (HR 0.75, 95%CI 0.62-0.92). Living with children aged 12-18 years was associated with a small increased risk of recorded SARS-CoV-2 infection (HR 1.08, 95%CI 1.03-1.13), but not associated with other COVID-19 outcomes. Living with children of any age was also associated with lower risk of dying from non-COVID-19 causes. Among 2,567,671 adults >65 years there was no association between living with children and outcomes related to SARS-CoV-2. We observed no consistent changes in risk following school closure.

InterpretationFor adults living with children there is no evidence of an increased risk of severe COVID-19 outcomes. These findings have implications for determining the benefit-harm balance of children attending school in the COVID-19 pandemic.

FundingThis work was supported by the Medical Research Council MR/V015737/1.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched MEDLINE on 19th October 2020 for population-based epidemiological studies comparing the risk of SARS-CoV-2 infection and COVID-19 disease in people living with and without children. We searched for articles published in 2020, with abstracts available, and terms ""(children or parents or dependants) AND (COVID or SARS-CoV-2 or coronavirus) AND (rate or hazard or odds or risk), in the title, abstract or keywords. 244 papers were identified for screening but none were relevant. One additional study in preprint was identified on medRxiv and found a reduced risk of hospitalisation for COVID-19 and a positive SARS-CoV-2 infection among adult healthcare workers living with children.

Added value of this studyThis is the first population-based study to investigate whether the risk of recorded SARS-CoV-2 infection and severe outcomes from COVID-19 differ between adults living in households with and without school-aged children during the UK pandemic. Our findings show that for adults living with children there is no evidence of an increased risk of severe COVID-19 outcomes although there may be a slightly increased risk of recorded SARS-CoV-2 infection for working-age adults living with children aged 12 to 18 years. Working-age adults living with children 0 to 11 years have a lower risk of death from COVID-19 compared to adults living without children, with the effect size being comparable to their lower risk of death from any cause. We observed no consistent changes in risk of recorded SARS-CoV-2 infection and severe outcomes from COVID-19 comparing periods before and after school closure.

Implications of all the available evidenceOur results demonstrate no evidence of serious harms from COVID-19 to adults in close contact with children, compared to those living in households without children. This has implications for determining the benefit-harm balance of children attending school in the COVID-19 pandemic.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.11.01.362319,2020-11-02,https://biorxiv.org/cgi/content/short/2020.11.01.362319,Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection,Jianmin Zuo; Alex Dowell; Hayden Pearce; Kriti Verma; Heather Long; Jusnara Begum; Felicity Aiano; Zahin Amin-Chowdhury; Bassam Hallis; Lorrain Stapley; Ray Borrow; Ezra Linley; Shazaad Ahmad; Ben Parker; Alex Horsley; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunoassay Lab, National Infection Service, Porton Down SP4 0JG; Immunoassay Lab, National Infection Service, Porton Down SP4 0JG; Sero-epidemiology Unit, PHE,  Manchester Royal Infirmary, Manchester, M13 9WL; Sero-epidemiology Unit, PHE,  Manchester Royal Infirmary, Manchester, M13 9WL; Manchester University NHS Foundation Trust; NIHR Manchester Clinical Research Facility, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL; University of Manchester and NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester M23 9LT; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","The immune response to SARS-CoV-2 is critical in both controlling primary infection and preventing re-infection. However, there is concern that immune responses following natural infection may not be sustained and that this may predispose to recurrent infection. We analysed the magnitude and phenotype of the SARS-CoV-2 cellular immune response in 100 donors at six months following primary infection and related this to the profile of antibody level against spike, nucleoprotein and RBD over the previous six months. T-cell immune responses to SARS-CoV-2 were present by ELISPOT and/or ICS analysis in all donors and are characterised by predominant CD4+ T cell responses with strong IL-2 cytokine expression. Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a  setpoint for cellular immunity that lasts for at least 6 months. The T-cell responses to both spike and nucleoprotein/membrane proteins were strongly correlated with the peak antibody level against each protein. The rate of decline in antibody level varied between individuals and higher levels of nucleoprotein-specific T cells were associated with preservation of NP-specific antibody level although no such correlation was observed in relation to spike-specific responses. In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection.",immunology,exact,100,100
bioRxiv,10.1101/2020.11.02.363242,2020-11-02,https://biorxiv.org/cgi/content/short/2020.11.02.363242,Ivermectin reduces coronavirus infection in vivo: a mouse experimental model,Ana Paula Arevalo; Romina Pagotto; Jorge Porfido; Hellen Daghero; Mercedes Segovia; Kanji Yamasaki; Belen Varela; Marcelo Hill; Jose Manuel Verdes; Maite Duhalde Vega; Mariela Bollati-Fogolin; Martina Crispo; Shazaad Ahmad; Ben Parker; Alex Horsley; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Transgenic and Experimental Animal Unit, Institut Pasteur de Montevideo; Cell Biology Unit, Institut Pasteur de Montevideo; Transgenic and Experimental Animal Unit, Institut Pasteur de Montevideo; Cell Biology Unit, Institut Pasteur de Montevideo; Laboratory of Immunoregulation and Inflammation, Institut Pasteur de Montevideo; Pathobiology Department, Faculty of Veterinary; Pathobiology Department, Faculty of Veterinary; Laboratory of Immunoregulation and Inflammation, Institut Pasteur de Montevideo; Pathobiology Department, Faculty of Veterinary; Institute of Biological Chemistry and Chemical Physics (UBA-CONICET). School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Laboratory of ; Cell Biology Unit, Institut Pasteur de Montevideo; Transgenic and Experimental Animal Unit, Institut Pasteur de Montevideo; Manchester University NHS Foundation Trust; NIHR Manchester Clinical Research Facility, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL; University of Manchester and NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester M23 9LT; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","SARS-CoV2 is a single strand RNA virus member of the type 2 coronavirus family, responsible for causing COVID-19 disease in humans. The objective of this study was to test the ivermectin drug in a murine model of coronavirus infection using a type 2 family RNA coronavirus similar to SARS-CoV2, the mouse hepatitis virus (MHV). BALB/cJ female mice were infected with 6,000 PFU of MHV-A59 (Group Infected; n=20) and immediately treated with one single dose of 500 g/kg of ivermectin (Group Infected + IVM; n=20), or were not infected and treated with PBS (Control group; n=16). Five days after infection/treatment, mice were euthanized to obtain different tissues to check general health status and infection levels. Overall results demonstrated that viral infection induces the typical MHV disease in infected animals, with livers showing severe hepatocellular necrosis surrounded by a severe lymphoplasmacytic inflammatory infiltration associated with a high hepatic viral load (52,158 AU), while ivermectin administration showed a better health status with lower viral load (23,192 AU; p<0.05) and few livers with histopathological damage (p<0.05), not showing statistical differences with control mice (P=NS). Furthermore, serum transaminase levels (aspartate aminotransferase and alanine aminotransferase) were significantly lower in treated mice compared to infected animals. In conclusion, ivermectin seems to be effective to diminish MHV viral load and disease in mice, being a useful model for further understanding new therapies against coronavirus diseases.",pathology,exact,100,100
bioRxiv,10.1101/2020.11.02.364661,2020-11-02,https://biorxiv.org/cgi/content/short/2020.11.02.364661,Liquid chalk is an antiseptic against SARS-CoV-2 and influenza A respiratory viruses,Julie  L. McAuley; Joshua  M. Deerain; William Hammersla; Turgut  E. Aktepe; Damian  J.F. Purcell; Jason Mackenzie; Belen Varela; Marcelo Hill; Jose Manuel Verdes; Maite Duhalde Vega; Mariela Bollati-Fogolin; Martina Crispo; Shazaad Ahmad; Ben Parker; Alex Horsley; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"University of Melbourne; University of Melbourne; Urban Climb; University of Melbourne; University of Melbourne; University of Melbourne; Pathobiology Department, Faculty of Veterinary; Laboratory of Immunoregulation and Inflammation, Institut Pasteur de Montevideo; Pathobiology Department, Faculty of Veterinary; Institute of Biological Chemistry and Chemical Physics (UBA-CONICET). School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Laboratory of ; Cell Biology Unit, Institut Pasteur de Montevideo; Transgenic and Experimental Animal Unit, Institut Pasteur de Montevideo; Manchester University NHS Foundation Trust; NIHR Manchester Clinical Research Facility, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL; University of Manchester and NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester M23 9LT; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","The COVID-19 pandemic has impacted and enforced significant restrictions within our societies, including the attendance of the public and professional athletes in gyms. Liquid chalk is a commonly used accessories in gyms and is comprised of magnesium carbonate and alcohol that quickly evaporates on the hands to leave a layer of dry chalk. We investigated whether liquid chalk is an antiseptic against highly pathogenic human viruses including, SARS-CoV-2, influenza virus and noroviruses. Chalk was applied before or after virus inoculum and recovery of infectious virus was determined to mimic the use in the gym. We observed that addition of chalk before or after virus contact lead to a significant reduction on recovery of infectious SARS-CoV-2 and influenza but had little impact on norovirus. These observations suggest that the use and application of liquid chalk can be an effective and suitable antiseptic for major sporting events, such as the Olympic Games.",microbiology,exact,100,100
medRxiv,10.1101/2020.10.27.20220897,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.27.20220897,The effect of eviction moratoriums on the transmission of SARS-CoV-2,Anjalika Nande; Justin Sheen; Emma L Walters; Brennan Klein; Matteo Chinazzi; Andrei Gheorghe; Ben Adlam; Julianna Shinnick; Maria Florencia Tejeda; Samuel V Scarpino; Alessandro Vespignani; Andrew J Greenlee; Daniel Schneider; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Program for Evolutionary Dynamics, Harvard University, Cambridge, MA, 02138; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104; Department of Urban and Regional Planning, University of Illinois at Urbana-Champaign, Champaign, IL 61820; Northeastern University Network Science Institute; Northeastern University Network Science Institute; Program for Evolutionary Dynamics, Harvard University, Cambridge, MA, 02138; Program for Evolutionary Dynamics, Harvard University, Cambridge, MA, 02138; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104; Northeastern University Network Science Institute; Northeastern University Network Science Institute; Department of Urban and Regional Planning, University of Illinois at Urbana-Champaign, Champaign, IL 61820; Department of Urban and Regional Planning, University of Illinois at Urbana-Champaign, Champaign, IL 61820; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","Massive unemployment during the COVID-19 pandemic could result in an eviction crisis in US cities. Here we model the effect of evictions on SARS-CoV-2 epidemics, simulating viral transmission within and among households in a theoretical metropolitan area. We recreate a range of urban epidemic trajectories and project the course of the epidemic under two counterfactual scenarios, one in which a strict moratorium on evictions is in place and enforced, and another in which evictions are allowed to resume at baseline or increased rates. We find, across scenarios, that evictions lead to significant increases in infections. Applying our model to Philadelphia using locally-specific parameters shows that the increase is especially profound in models that consider realistically heterogenous cities in which both evictions and contacts occur more frequently in poorer neighborhoods. Our results provide a basis to assess municipal eviction moratoria and show that policies to stem evictions are a warranted and important component of COVID-19 control.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.27.20221028,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.27.20221028,Remote fingerstick blood collection for SARS-CoV-2 antibody testing,Wilfredo F Garcia-Beltran; Tyler E. Miller; Grace Kirkpatrick; Andrea Nixon; Michael G. Astudillo; Diane Yang; Lisa M. Mahanta; Mandakolathur Murali; Anand Dighe; Jochen Lennerz; Julia Thierauf; Vivek Naranbhai; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Mass General Brigham Biobank; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","The rapid worldwide spread of SARS-CoV-2 infection has propelled the accelerated development of serological tests that can detect anti-SARS-CoV-2 antibodies. These have been used for studying the prevalence and spread of infection in different populations, helping establish a recent diagnosis of COVID-19, and will likely be used to confirm humoral immunity after infection or vaccination. However, nearly all lab-based high-throughput SARS-CoV-2 serological assays require a serum sample from venous blood draw, limiting their applications and scalability. Here, we present a method that enables large scale SARS-CoV-2 serological studies by combining self or office collection of fingerprick blood with a volumetric absorptive microsampling device (Mitra, Neoteryx, LLC) with a high-throughput electrochemiluminescence-based SARS-CoV-2 total antibody assay (Roche Elecsys, Roche Diagnostics, Inc.) that is EUA approved for use on serum samples and widely used by clinical laboratories around the world. We found that the Roche Elecsys assay has a high dynamic range that allows for accurate detection of SARS-CoV-2 antibodies in serum samples diluted 1:20 as well as contrived dried blood extracts. Extracts of dried blood from Mitra devices acquired in a community seroprevalence study showed near identical sensitivity and specificity in detection of SARS-CoV-2 antibodies as compared to neat sera using predefined thresholds for each specimen type. Overall, this study affirms the use of Mitra dried blood collection device with the Roche Elecsys SARS-CoV-2 total antibody assay for remote or at-home testing as well as large-scale community seroprevalence studies.",pathology,exact,100,100
medRxiv,10.1101/2020.10.28.20221226,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.28.20221226,The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease. A report from Central and Eastern Europe,Justyna Dominika Kowalska; Kerstin Kase; Anna Vassilenko; Arjan Harxhi; Botond Lakatos; Gordana Dragovic Lukic; Antonija Verhaz; Nina Yancheva; Florentina Dumitrescu; David Jilich; Ladislav Machala; Raimonda Matulionyte; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Medical University of Warsaw; West Tallinn Central Hospital, Estonia; Belarusian State Medical University, Minsk, Belarus; University Hospital Center of Tirana, Infectious Disease Service, Albania; National Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, National Center of HIV, Hungary; Department of pharmacology, clinical pharmacology and toxicology, School of Medicine, University of Belgrade, Serbia; Clinic for Infectious Diseases, University Clinical Centre of the Republic of Srpska, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina; Department for; Department for AIDS. Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Bulgaria; Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital; Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital; Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital; Department of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania.; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","BackgroundThere is currently no evidence suggesting that COVID-19 takes a different course in HIV-positive patients on antiretroviral treatment compared to the general population. However, little is known about the relation between specific HIV-related factors and the severity of the COVID-19 disease.

MethodsWe performed a retrospective analysis of cases collected through an on-line survey distributed by the Euroguidelines in Central and Eastern Europe Network Group. In statistical analyses characteristics of HIV-positive patients asymptomatic/moderate and moderate/severe course were compared.

ResultsIn total 34 HIV-positive patients diagnosed with COVID-19 were reported by 12 countries (Estonia, Czech Republic, Lithuania, Albania, Belarus, Romania, Serbia, Bosnia and Herzegovina, Poland, Russia, Hungary, Bulgaria). Asymptomatic courses of COVID-19 were reported in four (12%) cases, 11 (32%) patients presented with mild disease not requiring hospitalization, moderate disease with respiratory and/or systemic symptoms was observed in 14 (41%) cases, and severe disease with respiratory failure was found in five (15%) patients. The only HIV-related characteristics differentiating a moderate/severe course of the disease from asymptomatic/mild disease course was the use of or PI or NNRTI as part of the cART regimen (40.0% vs. 5.3%, p=0.0129 for PI and 31.6 % vs. 0.0%, p= 0.0239 for NNRTI).

ConclusionsIn our analyses HIV viral suppression and immunological status were not playing a role in the course of COVID-19 disease. On the contrary the cART regimen could contribute to severity of SARS-CoV-2 infection. Large and prospective studies are necessary to further investigate this relations.",hiv aids,exact,100,100
medRxiv,10.1101/2020.10.28.20221119,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.28.20221119,Features of creatine-kinase in COVID-19 patients within various specific periods: A cohort study,Shanshan Wan; Gaojing Qu; Hui Yu; Haoming Zhu; Guoxin Huang; Lei Chen; Meiling Zhang; Jiangtao Liu; Bin Pei; David Jilich; Ladislav Machala; Raimonda Matulionyte; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Postgraduate Training Basement of Jinzhou Medical University, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital; Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital; Department of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania.; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","BackgroundCoronavirus disease 2019 (COVID-19) has been declared as a threat to the global. Due to the lack of efficient treatments, indicators were urgently needed during the evolvement of disease to analyze the illness and prognosis, and prevent the aggravation of COVID-19.

MethodsPatients general information, clinical type, all CK values and outcome were collected. CK value of all cases during disease course started from different initial time were analyzed.

ResultsAll cases underwent 504 tests of CK since symptom onset and the median value was 51.7 (35.0-91.5) U/L. The first median value on the day 8 from exposure onset was 78.1 (69.1-85.8) U/L then showed an upward trend from the day 8 to the day 12 (reaching a peak of 279.3 U/L), finally showed a fluctuation decline after the day 12. The CK median value in critical cases reached the peak (625.5 U/L) on the transforming date, and then decreased rapidly to the normal range. Before death, the CK median value in dead cases firstly increased until the day -14 with a peak as 470.0 U/L, then decreased with fluctuation until day -2, and finally increased again on the day 0.

ConclusionsCK reached its peak on the day when it became critical type, dynamic detection of CK can guide clinical judgment of prognosis. The increase of CK is a high risk factor of death. Severe cell damage 2 weeks before death might determines the outcome of the disease even if CK drops to the normal range afterward.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.27.20219196,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.27.20219196,Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test,Qing Sun; Jonathan Li; Hui Ren; Larry Pastor; Yulia Loginova; Roberta Madej; Kristopher Taylor; Joseph K Wong; Zhao Zhang; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Diacarta Inc; Diacarta Inc; Diacarta Inc; Diacarta Inc; Diacarta Inc; Diacarta Inc; University of California and VA Healthcare System; UC San Francisco; Diacarta Inc; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","BackgroundSensitive and high throughput molecular detection assays are essential during the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vast majority of the SARS-CoV-2 molecular assays use nasopharyngeal swab (NPS) or oropharyngeal swab (OPS) specimens collected from suspected individuals. However, using NPS or OPS as specimens has apparent drawbacks, e.g. the collection procedures for NPS or OPS specimens can be uncomfortable to some people and may cause sneezing and coughing which in turn generate droplets and/or aerosol particles that are of risk to healthcare workers, requiring heavy use of personal protective equipment. There have been recent studies indicating that self-collected saliva specimens can be used for molecular detection of SARS-CoV-2 and provides more comfort and ease of use for the patient. Here we report the performance of QuantiVirus SARS-CoV-2 multiplex test using saliva as the testing specimens with or without pooling.

MethodsDevelopment and validation studies were conducted following FDA-EUA and molecular assay validation guidelines. Using SeraCare Accuplex SARS-CoV-2 reference panel, the limit of detection (LOD) and clinical evaluation studies were performed with the QuantiVirus SARS-CoV-2 multiplex test. For clinical evaluation, 85 known positive and 90 known negative clinical NPS samples were tested. Additionally, twenty paired NPS and saliva samples collected from recovering COVID-19 patients were tested and the results were further compared to that of the Abbott m2000 SARS-CoV-2 PCR assay. Results of community collected 389 saliva samples for COVID-19 screening by QuantiVirus SARS-CoV-2 multiplex test were also obtained and analyzed. Moreover, saliva pooling with 6 and 12 samples together were also evaluated.

ResultsThe LOD for the QuantiVirus SARS-CoV-2 multiplex test was confirmed to be 100-200 copies/mL. The clinical evaluation using contrived saliva samples indicated that the positive percentage agreement (PPA) of the QuantiVirus SARS-CoV-2 multiplex test is 100% at 1xLOD, 1.5xLOD and 2.5xLOD. No cross-reactivity was observed for the QuantiVirus SARS-CoV-2 multiplex test with common respiratory pathogens. Testing of clinical samples showed a positive percentage agreement (PPA) of 100% (95% CI: 94.6% to 100%) and a negative percentage agreement (NPA) of 98.9% (95% CI: 93.1% to 99.9%). QuantiVirus SARS CoV-2 multiplex test had 80% concordance rate and no significant difference (p=0.13) in paired saliva and NPS specimens by Wilcoxon matched pairs signed rank test. Positive test rate was 1.79% for 389 saliva specimens collected from the communities for COVID-19 screening. Preliminary data showed that saliva sample pooling up to 6 samples for SARS-CoV-2 detection is feasible (sensitivity 94.8% and specificity 100%).

ConclusionThe studies demonstrated that the QuantiVirus SARS-CoV-2 multiplex test has a LOD of 200 copies/mL in contrived saliva samples. The clinical performance of saliva-based testing is comparable to that of NPS-based testing. Pooling of saliva specimens for SARS-CoV-2 detection is feasible. Saliva based and high-throughput QuantiVirusSARS-CoV-2 multiplex test offers a highly desirable test during the ongoing COVID-19 pandemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20219667,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.28.20219667,Performance evaluation of the Simtomax CoronaCheck rapid diagnostic test,Percevent Jeremy Ducrest; Antoine Freymond; Jean-Manuel Segura; Larry Pastor; Yulia Loginova; Roberta Madej; Kristopher Taylor; Joseph K Wong; Zhao Zhang; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"GaDia SA; Institute of Life Technologies - School of Engineering; HES-SO // University of Applied Sciences Western Switzerland; Sion; Switzerland; Institute of Life Technologies - School of Engineering; HES-SO // University of Applied Sciences Western Switzerland; Sion; Switzerland; Diacarta Inc; Diacarta Inc; Diacarta Inc; University of California and VA Healthcare System; UC San Francisco; Diacarta Inc; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","The aim of this study was to evaluate the diagnostic performance of Simtomax(R) CoronaCheck, a serology rapid diagnostic test (RDT) for the detection of IgG and IgM against SARS-CoV-2. 48 plasma samples positive for SARS-CoV-2 based on RT-PCR and 98 negative control samples were studied. Diagnostic performance of the IgG/IgM RDT was assessed against RT-PCR and the electro-chemiluminescence immunoassay (ECLIA) Elecsys(R) Anti-SARS-CoV-2 total Ig. Overall, the RDT sensitivity was 92% (95% confidence interval [95%CI]: 79-97), specificity 97% (95% CI: 91-99%), PPV 94% (95% CI: 81-98) and the NPV 96% (95% CI: 89-99). When considering only samples collected [&ge;] 15 days post-symptoms (DPS), the sensitivity increased to 98% (95%CI: 86-100) and the specificity was 97% (95% CI: 91-99%). Two samples with 180 DPS were still positive for IgG. Globally, this IgG/IgM RDT displayed a high diagnostic accuracy for SARS-CoV-2 IgG/IgM detection in plasma samples in high COVID-19 prevalence settings. It could be effectively used, in absence of facilities for routine diagnostic serology, for samples with a DPS between 15 and 180 days.

Highlights- The rapid diagnostic test Simtomax CoronaCheck displays a high sensitivity of 98% and a high specificity of 97% for SARS-CoV-2 IgG/IgM detection in plasma samples after 15 days post-symptoms.
- The rapid diagnostic test Simtomax CoronaCheck can detect SARS-CoV-2 antibodies in plasma up to 180 days after symptom onset.
- The rapid diagnostic test Simtomax CoronaCheck could be effectively used as an alternative to serological analysis using laboratory facilities.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.27.20220905,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.27.20220905,Longitudinal monitoring of SARS-CoV-2 RNA on high-touch surfaces in a community setting,Abigail P. Harvey; Erica R. Fuhrmeister; Molly Cantrell; Ana K. Pitol; Jenna M. Swarthout; Julie E. Powers; Maya L. Nadimpalli; Timothy R. Julian; Amy J. Pickering; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Tufts University; Tufts University; Tufts University; Imperial College London; Tufts University; Tufts University; Tufts University; Eawag; University of California, Berkeley; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","Environmental surveillance of surface contamination is an unexplored tool for understanding transmission of SARS-CoV-2 in community settings. We conducted longitudinal swab sampling of high-touch non-porous surfaces in a Massachusetts town during a COVID-19 outbreak from April to June 2020. Twenty-nine of 348 (8.3 %) surface samples were positive for SARS-CoV-2, including crosswalk buttons, trash can handles, and door handles of essential business entrances (grocery store, liquor store, bank, and gas station). The estimated risk of infection from touching a contaminated surface was low (less than 5 in 10,000), suggesting fomites play a minimal role in SARS-CoV-2 community transmission. The weekly percentage of positive samples (out of n=33 unique surfaces per week) best predicted variation in city-level COVID-19 cases using a 7-day lead time. Environmental surveillance of SARS-CoV-2 RNA on high-touch surfaces could be a useful tool to provide early warning of COVID-19 case trends.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20221127,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.28.20221127,"Features of -Hydroxybutyrate Dehydrogenase during various specific periods in COVID-19 patients within Xiangyang, China: a cohort study",Haoming Zhu; Gaojing Qu; Hui Yu; Guoxin Huang; Lei Chen; Meiling Zhang; Shanshan Wan; Bin Pei; Amy J. Pickering; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Postgraduate Training Basement of Jinzhou Medical University, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; Center of Evidence-Based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China; University of California, Berkeley; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","BackgroundCoronavirus disease-2019 (COVID-19) has spread all over the world and brought extremely huge losses. There is no study to systematically analyse the features of hydroxybutyrate dehydrogenase (-HBDH) in COVID-19 patients during the periods before and after illness progression, before death and course from exposure onset.

MethodsWe collected all included patients general information, clinical type, -HBDH value and outcome, and analyzed -HBDH values within different initial time and different periods.

ResultsIn the first 30 days after symptom onset, the -HBDH median value was 156.33 U/L. The first test of -HBDH since exposure onset appeared on the 8th day, it increased from the 8th day to 18th day and decreased after the 18th day. -HBDH median value showed a slight change until it started to increase 1 day before transforming to severe type, while it continued to increase during 4 days before and after transforming to critical type. The -HBDH median value ranged from 191.11 U/L to 455.11U/L before death.

Conclusions-HBDH value increases in some COVID-19 patients, obviously in severe type, critical type and death patients, and mainly in 18 days after exposure onset and 10 days after symptom onset. -HBDH increases 1 day before transforming to severe type, continues to increase in critical type and death patients, increases rapidly 5 days before death. The increase of -HBDH suggests that COVID-19 patients have tissues and organs damage, mainly in heart. In brief, -HBDH is an important indicator to judge the severity and prognosis of COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20221093,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.28.20221093,"Features of creatine-kinase in COVID-19 patients with different ages, clinical types and outcomes: A cohort study",Shanshan Wan; Gaojing Qu; Hui Yu; Haoming Zhu; Guoxin Huang; Lei Chen; Meiling Zhang; Jiangtao Liu; Bin Pei; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Postgraduate Training Basement of Jinzhou Medical University, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","ObjectivesTo study the features of creatine-kinase (CK) in COVID-19 patients with different ages, clinical types and outcomes and quantify the relationship between CK value and clinical type.

MethodsAll laboratory confirmed COVID-19 patients hospitalized in Xiangyang No.1 Peoples Hospital were included. Patients general information, clinical type, all CK values and outcome were collected.

ResultsThe peak median value of CK in cases aged [&ge;] 71 years old (appeared at T2) was higher than that in cases aged [&le;] 70 years old. There was statistical difference between the two groups (P=0.001). Similarly, the peak in critical cases (appeared at T2) was higher than moderate and severe types, and significant difference were existed among moderate, severe, and critical types (P=0.000). Moreover, the peak value in death group (appeared at T2) was higher than those in survival group. Significant difference was also found between them (P=0.000). According to the optimal scale regression model, the CK value (P=0.000) and age (P=0.000) were associated with the clinical type.

ConclusionsDifference of the CK in different ages, clinical types, and outcomes were significant. The results of the optimal scale regression model are helpful to judge the clinical type of COVID-19 patients.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20221069,2020-11-01,https://medrxiv.org/cgi/content/short/2020.10.28.20221069,Psychological and social impact of COVID-19 in Pakistan: Need for Gender Responsive Policies,Dr. Fauziah Rabbani; Dr. Hyder Ali Khan; Dr. Suneel Piryani; Areeba Raza Khan; Dr. Fahad Abid; Lei Chen; Meiling Zhang; Jiangtao Liu; Bin Pei; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Aga Khan University; Aga Khan University; Aga Khan University; Aga Khan University; Specialist Early Intervention in Psychosis Pakistan; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","BACKGROUNDCOVID-19 has rapidly crossed borders, infecting people throughout the world. Women may be especially vulnerable to depression and anxiety due to the pandemic,

AIMSThis study attempted to assess how gender impacts risk perceptions, anxiety levels behavioral responses to the COVID 19 pandemic in Pakistan in order to recommend gender responsive health policies

METHODSA cross-sectional online survey was conducted. Participants were asked to complete a sociodemographic data form, the Hospital Anxiety and Depression Scale (HADS), and questions on their risk perceptions, preventive behavior and information exposure. Regression analysis was used to assess effects of factors such as age, gender and household income on anxiety levels.

RESULTSOf the 1390 respondents, 478 were women, and 913 were men. Women considered their chances of survival to be relatively lower than men (59 % women vs 73% men). They were also more anxious (62% women vs 50% men), and more likely to adopt precautionary behavior, such as avoiding going to the hospital (78% women vs. 71% men), not going to work (72% women and 57% men), and using disinfectants (93% women and 86% men). Men were more likely to trust friends, family and social media as reliable sources of COVID-19 information, while women were more likely to trust doctors.

CONCLUSIONWomen experience a disproportion burden of the psychological and social impact of the pandemic compared to men. Involving doctors in healthcare communication targeting women, might prove effective. Social media and radio programs may be effective in disseminating information related to COVID among men.",public and global health,exact,100,100
bioRxiv,10.1101/2020.10.31.363473,2020-11-01,https://biorxiv.org/cgi/content/short/2020.10.31.363473,"TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney",Bruce R. Stevens; Dr. Hyder Ali Khan; Dr. Suneel Piryani; Areeba Raza Khan; Dr. Fahad Abid; Lei Chen; Meiling Zhang; Jiangtao Liu; Bin Pei; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"University of Florida College of Medicine; Aga Khan University; Aga Khan University; Aga Khan University; Specialist Early Intervention in Psychosis Pakistan; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","COVID-19 outcomes reflect organ-specific interplay of SARS-CoV-2 and its receptor, ACE2, with TMPRSS2 and ADAM17. Confirmed active tropism of SARS-CoV-2 in epithelial cells of intestine and kidney proximal tubule, and in aging cardiomyocytes, capriciously manifests extra-pulmonary organ-related clinical symptoms in about half of COVID-19 patients, occurring by poorly understood mechanisms. We approached this knowledge gap by recognizing a clue that these three particular cell types share a common denominator kindred of uniquely expressing the SLC6A19 neutral amino acid transporter B0AT1 protein (alternatively called NBB, B, B0) serving glutamine and tryptophan uptake. B0AT1 is a cellular trafficking chaperone partner of ACE2, shown by cryo-EM to form a thermodynamically-favored stabilized 2ACE2:2B0AT1 dimer-of-heterodimers. The gut is the bodys site of greatest magnitude expression depot of both ACE2 and B0AT1. This starkly contrasts with pulmonary pneumocyte expression of monomeric ACE2 with conspicuously undetectable B0AT1. We hypothesized that B0AT1 steers the organ-related interplay amongst ACE2, TMPRSS2, ADAM17, and SARS-CoV-2 RBD. The present study employed molecular docking modeling that indicated active site catalytic pocket residues of TMPRSS2 and ADAM17 each formed bonds [&le;] 2 A with monomer ACE2 specific residues within a span R652-D713 involved in cleaving sACE2 soluble ectodomain release. These bonds are consistent with competitive binding interactions of experimental anti-SARS-CoV-2 drug small molecules including Camostat and Nafamostat. Without B0AT1, ACE2 residues K657 and N699 dominated docking bonding with TMPRSS2 or ADAM17 active sites, with ACE2 R710 and R709 contributing electrostatic attractions, but notably ACE2 S708 never closer than 16-44 A. However, in the dimer-of-heterodimers arrangement all ACE2 neck region residues were limited to TMPRSS2 or ADAM17 approaches 35 A, with the interference directly attributed to the presence of a neighboring B0AT1 subunit complexed to the partnering ACE2 subunit of 2ACE2:2B0AT1; ADAM17 failed to dock by bumping its active site pocket oriented dysfunctionally outwardly facing 1800 away. Results were the same whether the dimer-of-heterodimers was in either the ""closed"" or ""open"" conformation, or whether or not SARS-CoV-2 RBD was complexed to ACE2. The results implicate B0AT1-and in particular the 2ACE2:2B0AT1 complex-as a maJor player in the landscape of COVID-19 pathophysiology engaging TMPRSS2 and ADAM17, consistent with experimental evidence in the literature and in clinical reports. These findings provide a gateway to understanding the roles of B0AT1 relating to COVID-19 manifestations putatively assigned to intestinal and renal epithelial cells and cardiomyocytes, with underpinnings useful for considerations in public hygiene policy and drug development.",biochemistry,exact,100,100
bioRxiv,10.1101/2020.10.30.363002,2020-11-01,https://biorxiv.org/cgi/content/short/2020.10.30.363002,"An insight into SARS-CoV-2 Membrane protein interaction with Spike, Envelope, and Nucleocapsid proteins",Amit Kumar; Prateek Kumar; Neha Garg; Rajanish Giri; Dr. Fahad Abid; Lei Chen; Meiling Zhang; Jiangtao Liu; Bin Pei; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"Indian Institute of Technology Mandi; Indian Institute of Technology Mandi; Banaras Hindu University, Varanasi, Uttar Pradesh; Indian Institute of Technology Mandi; Specialist Early Intervention in Psychosis Pakistan; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","Intraviral protein-protein interactions are crucial for replication, pathogenicity, and viral assembly. Among these, virus assembly is a critical step as it regulates the arrangements of viral structural proteins and helps in the encapsulation of genomic material. SARS-CoV-2 structural proteins play an essential role in the self-rearrangement, RNA encapsulation, and mature virus particle formation. In SARS-CoV, the membrane protein interacts with the envelope and spike protein in Endoplasmic Reticulum Golgi Intermediate Complex (ERGIC) to form an assembly in the lipid bilayer, followed by membrane-ribonucleoprotein (nucleocapsid) interaction. In this study, using protein-protein docking, we tried to understand the interaction of membrane proteins interaction with envelope, spike and nucleocapsid proteins. Further, simulation studies performed up to 100ns agreed that protein complexes M-E, M-S, and M-N were stable. Moreover, the calculated free binding energy and dissociation constant values support the protein complex formation. The interaction identified in the study will be of great importance, as it provides valuable insight into the protein complex, which could be the potential drug targets for future studies.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.10.31.363309,2020-11-01,https://biorxiv.org/cgi/content/short/2020.10.31.363309,Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 Main Protease complexes reveal the role of lateral pocket in enhancing the ligand affinity,Ying Li Weng; Shiv Rakesh Naik; Nadia Dingelstad; Subha Kalyaanamoorthy; Aravindhan Ganesan; Lei Chen; Meiling Zhang; Jiangtao Liu; Bin Pei; Aiguo Zhang; Chuanyi M Lu; Michael Y. Sha; A. John Iafrate; Michael Z. Levy; Alison L Hill; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss; Peter Inglesby; Henry Drysdale; Angel Wong; Jonathan Cockburn; Robert Mcmanus; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Stephen JW Evans; Krishnan Bhaskaran; Rosalind M Eggo; Ben Goldacre; Laurie Tomlinson,"University of Waterloo; University of Waterloo; University of Waterloo; University of Waterloo; University of Waterloo; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Center of Evidence-based Medicine, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China; Diacarta Inc; University of California and VA Healthcare System; Diacarta Inc; Massachusetts General Hospital, Department of Pathology; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","The 2019 novel coronavirus pandemic caused by SARS-CoV-2 remains a serious health threat to humans and a number of countries are already in the middle of the second wave of infection. There is an urgent need to develop therapeutics against this deadly virus. Recent scientific evidences have suggested that the main protease (Mpro) enzyme in SARS-CoV-2 can be an ideal drug target due to its crucial role in the viral replication and transcription processes. Therefore, there are ongoing research efforts to identify drug candidates against SARS-CoV-2 Mpro that resulted in hundreds of X-ray crystal structures of ligand bound Mpro complexes in the protein data bank (PDB) that describe structural details of different chemotypes of fragments binding within different sites in Mpro. In this work, we perform rigorous molecular dynamics (MD) simulation of 62 reversible ligand-Mpro complexes in the PDB to gain mechanistic insights about their interactions at atomic level. Using a total of ~2.25 s long MD trajectories, we identified and characterized different pockets and their conformational dynamics in the apo Mpro structure. Later, using the published PDB structures, we analyzed the dynamic interactions and binding affinity of small ligands within those pockets. Our results identified the key residues that stabilize the ligands in the catalytic sites and other pockets in Mpro. Our analyses unraveled the role of a lateral pocket in the catalytic site in Mpro that is critical for enhancing the ligand binding to the enzyme. We also highlighted the important contribution from HIS163 in this lateral pocket towards ligand binding and affinity against Mpro through computational mutation analyses. Further, we revealed the effects of explicit water molecules and Mpro dimerization in the ligand association with the target. Thus, comprehensive molecular level insights gained from this work can be useful to identify or design potent small molecule inhibitors against SARS-CoV-2 Mpro.",biophysics,exact,100,100
medRxiv,10.1101/2020.10.29.20222174,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.29.20222174,COVID-19 collateral: Indirect acute effects of the pandemic on physical and mental health in the UK,Kathryn E Mansfield; Rohini Mathur; John Tazare; Alasdair D Henderson; Amy Mulick; Helena Carreira; Anthony A Matthews; Patrick Bidulka; Alicia Gayle; Harriet Forbes; Sarah Cook; Angel Wong; Helen Strongman; Kevin Wing; Charlotte Warren-Gash; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; Karolinska Institutet; London School of Hygiene and Tropical Medicine; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","BackgroundConcerns have been raised that the response to the UK COVID-19 pandemic may have worsened physical and mental health, and reduced use of health services. However, the scale of the problem is unquantified, impeding development of effective mitigations. We asked what has happened to general practice contacts for acute physical and mental health outcomes during the pandemic?

MethodsUsing electronic health records from the Clinical Research Practice Datalink (CPRD) Aurum (2017-2020), we calculated weekly primary care contacts for selected acute physical and mental health conditions (including: anxiety, depression, acute alcohol-related events, asthma and chronic obstructive pulmonary disease [COPD] exacerbations, cardiovascular and diabetic emergencies). We used interrupted time series (ITS) analysis to formally quantify changes in conditions after the introduction of population-wide restrictions ( lockdown) compared to the period prior to their introduction in March 2020.

FindingsThe overall population included 9,863,903 individuals on 1st January 2017. Primary care contacts for all conditions dropped dramatically after introduction of population-wide restrictions. By July 2020, except for unstable angina and acute alcohol-related events, contacts for all conditions had not recovered to pre-lockdown levels. The largest reductions were for contacts for: diabetic emergencies (OR: 0.35, 95% CI: 0.25-0.50), depression (OR: 0.53, 95% CI: 0.52-0.53), and self-harm (OR: 0.56, 95% CI: 0.54-0.58).

InterpretationThere were substantial reductions in primary care contacts for acute physical and mental conditions with restrictions, with limited recovery by July 2020. It is likely that much of the deficit in care represents unmet need, with implications for subsequent morbidity and premature mortality. The conditions we studied are sufficiently severe that any unmet need will have substantial ramifications for the people experiencing the conditions and healthcare provision. Maintaining access must be a key priority in future public health planning (including further restrictions).

FundingWellcome Trust Senior Fellowship (SML), Health Data Research UK.

RESULTS IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSA small study in 47 GP practices in a largely deprived, urban area of the UK (Salford) reported that primary care consultations for four broad diagnostic groups (circulatory disease, common mental health problems, type 2 diabetes mellitus and malignant cancer) declined by 16-50% between March and May 2020, compared to what was expected based on data from January 2010 to March 2020. We searched Medline for other relevant evidence of the indirect effect of the COVID-19 pandemic on physical and mental health from inception to September 25th 2020, for articles published in English, with titles including the search terms (""covid*"" or ""coronavirus"" or ""sars-cov-2""), and title or abstracts including the search terms (""indirect impact"" or ""missed diagnos*"" or ""missing diagnos*"" or ""delayed diagnos*"" or ((""present*"" or ""consult*"" or ""engag*"" or ""access*"") AND (""reduction"" or ""decrease"" or ""decline"")). We found no further studies investigating the change in primary care contacts for specific physical- and mental-health conditions indirectly resulting from the COVID-19 pandemic or its control measures. There has been a reduction in hospital admissions and presentations to accident and emergency departments in the UK, particularly for myocardial infarctions and cerebrovascular accidents. However, there is no published evidence specifically investigating the changes in primary care contacts for severe acute physical and mental health conditions.

Added value of this studyTo our knowledge this is the first study to explore changes in healthcare contacts for acute physical and mental health conditions in a large population representative of the UK. We used electronic primary care health records of nearly 10 million individuals across the UK to investigate the indirect impact of COVID-19 on primary care contacts for mental health, acute alcohol-related events, asthma/chronic obstructive pulmonary disease (COPD) exacerbations, and cardiovascular and diabetic emergencies up to July 2020. For all conditions studied, we found primary care contacts dropped dramatically following the introduction of population-wide restriction measures in March 2020. By July 2020, with the exception of unstable angina and acute alcohol-related events, primary care contacts for all conditions studied had not recovered to pre-lockdown levels. In the general population, estimates of the absolute reduction in the number of primary care contacts up to July 2020, compared to what we would expect from previous years varied from fewer than 10 contacts per million for some cardiovascular outcomes, to 12,800 per million for depression and 6,600 for anxiety. In people with COPD, we estimated there were 43,900 per million fewer contacts for COPD exacerbations up to July 2020 than what we would expect from previous years.

Implicatins of all the available evidenceWhile our results may represent some genuine reduction in disease frequency (e.g. the restriction measures may have improved diabetic glycaemic control due to more regular daily routines at home), it is more likely the reduced primary care conatcts we saw represent a substantial burden of unmet need (particularly for mental health conditions) that may be reflected in subsequent increased mortality and morbidity. Health service providers should take steps to prepare for increased demand in the coming months and years due to the short and longterm ramifications of reduced access to care for severe acute physical and mental health conditions. Maintaining access to primary care is key to future public health planning in relation to the pandemic.",primary care research,exact,100,100
medRxiv,10.1101/2020.10.28.20220996,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.28.20220996,Durable SARS-CoV-2 B cell immunity after mild or severe disease,Clinton O. Ogega; Nicole E. Skinner; Paul W Blair; Han-Sol Park; Kirsten Littlefield; Abhinaya Ganesan; Pranay Ladiwala; Annukka AR Antar; Stuart C. Ray; Michael J. Betenbaugh; Andrew Pekosz; Sabra Klein; Yukari C Manabe; Andrea L. Cox; Justin R. Bailey; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University; The Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health,; The Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from COVID-19. However, memory B cells (MBC) could provide durable humoral immunity even if serum neutralizing antibody titers decline. We performed multi-dimensional flow cytometric analysis of S protein receptor binding domain (S-RBD)-specific MBC in cohorts of ambulatory COVID-19 patients with mild disease, and hospitalized patients with moderate to severe disease, at a median of 54 (39-104) days after onset of symptoms. We detected S-RBD-specific class-switched MBC in 13 out of 14 participants, including 4 of the 5 participants with lowest plasma levels of anti-S-RBD IgG and neutralizing antibodies. Resting MBC (rMBC) made up the largest proportion of S-RBD-specific class-switched MBC in both cohorts. FCRL5, a marker of functional memory when expressed on rMBC, was dramatically upregulated on S-RBD-specific rMBC. These data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched MBC that phenotypically resemble germinal center-derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell-mediated immunity against SARS-CoV-2 after recovery from mild or severe COVID-19 disease.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=125 SRC=""FIGDIR/small/20220996v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (26K):
org.highwire.dtl.DTLVardef@89a49borg.highwire.dtl.DTLVardef@95cac0org.highwire.dtl.DTLVardef@320bc1org.highwire.dtl.DTLVardef@1a1da2a_HPS_FORMAT_FIGEXP  M_FIG C_FIG",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.29.20222224,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.29.20222224,Projecting the impact of behaviour and isolation interventions and super spreader events from mass gatherings and international travel on Malaysia's COVID-19 epidemic trajectories using an augmented SEIR model,Aidonna Jan Ayub; Gregory Wai Son Ho; Khayriyyah Mohd Hanafiah; Han-Sol Park; Kirsten Littlefield; Abhinaya Ganesan; Pranay Ladiwala; Annukka AR Antar; Stuart C. Ray; Michael J. Betenbaugh; Andrew Pekosz; Sabra Klein; Yukari C Manabe; Andrea L. Cox; Justin R. Bailey; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"Khazanah Research Institute; Khazanah Research Institute; Universiti Sains Malaysia; The Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health,; The Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","BackgroundVarious levels of lockdown implemented to contain the rapid spread of COVID-19 are not long-term solutions due to socioeconomic implications.

MethodsTo inform safe reopening, we used an augmented SEIR model to project the impact of 1) interventions and potential new epidemic trajectories arising from super spreader (SS) events and/or international travel and 2) re-introducing strong behavioural interventions on resurgence trajectories.

ResultsOur model suggests that 50% behaviour intervention effectiveness (BIE) (from enforced social distancing during lockdown, early in the epidemic), along with 50% isolation intervention effectiveness (IIE) (from increased testing and isolating infected individuals) was achieved during lockdown, which curbed COVID-19 transmission in Malaysia. Post-lockdown, BIE plays a minimal role if IIE reaches or exceeds 46.9% when other variables are held constant. At IIE of 30% and BIE of 21.3%, SS events of 5,000 active cases risks COVID-19 resurgence, with 4-year projected 12.9mn cumulative cases and 1.1mn deaths. Earlier action to increase BIE to 50% on day 98 compared to day 111, prevented an additional 21,401 recovered cases and 257 deaths.

ConclusionUntil a safe and effective vaccine is widely available, the risk of COVID-19 resurgence from large SS events warrants caution in decisions to allow for mass gatherings and regular international travel.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20221655,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.28.20221655,"Pre-existing conditions are associated with long-COVID patients hospitalization, despite confirmed clearance of SARS-CoV-2 virus",Colin Pawlowski; AJ Venkatakrishnan; Eshwan Ramudu; Christian Kirkup; Arjun Puranik; Nikhil Kayal; Gabriela Berner; Akash Anand; Rakesh Barve; John C O'Horo; Andrew D Badley; Venky Soundararajan; Yukari C Manabe; Andrea L. Cox; Justin R. Bailey; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"nference; nference; nference; nference; nference; nference; nference; nference Labs; nference Labs; Mayo Clinic; Mayo Clinic; nference; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","The current diagnostic gold-standard for SARS-CoV-2 clearance from infected patients is two consecutive negative PCR test results. However, there are anecdotal reports of hospitalization from protracted COVID complications despite such confirmed viral clearance, presenting a clinical conundrum. We conducted a retrospective analysis of 266 COVID patients to compare those that were admitted/re-admitted post-viral clearance (hospitalized post-clearance cohort, n=93) with those that were hospitalized pre-clearance but were not re-admitted post-viral clearance (non-hospitalized post-clearance cohort, n=173). In order to differentiate these two cohorts, we used neural network models for the augmented curation of comorbidities and complications with positive sentiment in the EHR physician notes. In the year preceding COVID onset, acute kidney injury (n=15 (16.1%), p-value: 0.03), anemia (n=20 (21.5%), p-value: 0.02), and cardiac arrhythmia (n=21 (22.6%), p-value: 0.05) were significantly enriched in the physician notes of the hospitalized post-clearance cohort. This study highlights that these specific pre-existing conditions are associated with amplified hospitalization risk in COVID patients, despite their successful SARS-CoV-2 viral clearance. Our finding that pre-COVID anemia amplifies risk of post-COVID hospitalization is particularly concerning given the high prevalence and endemic nature of anemia in many low- and middle-income countries (per the World Bank definition; e.g. India, Brazil), which are unfortunately also seeing high rates of SARS-CoV-2 infection and COVID-induced mortality. This study motivates follow-up prospective research into the specific risk factors we have identified that appear to predispose some patients towards the after effects of COVID-19.

Article summary - Strengths and limitations of this studyO_LIThis is the first study at a major healthcare center analyzing risk factors for post-viral clearance hospitalization of COVID-19 patients.
C_LIO_LIThis analysis uses augmented curation methods to identify complications and comorbidities from the physician notes, rather than relying upon ICD codes.
C_LIO_LIThe statistical analysis identifies specific comorbidities in the year preceding PCR diagnosis of SARS-CoV-2 which are associated with increased rates of post-viral clearance hospitalization.
C_LIO_LIThe dataset used for this study is limited to a single healthcare system, so the underlying clinical characteristics of the study population are biased to reflect the clinical characteristics of individuals that receive medical treatment in certain regions of the United States (Arizona, Florida, Minnesota).
C_LIO_LIIn this study, we use the first of two consecutive negative PCR tests to estimate the viral clearance date for each patient, however the true viral clearance date for each patient is unknown.
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20221234,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.28.20221234,Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use,Mingwang Shen; Jian Zu; Christopher K. Fairley; Jose A. Pagan; Li An; Zhanwei Du; Yuming Guo; Libin Rong; Yanni Xiao; Guihua Zhuang; Yan Li; Lei Zhang; Yukari C Manabe; Andrea L. Cox; Justin R. Bailey; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"Xi'an Jiaotong University; Xi'an Jiaotong University; Monash University; New York University; San Diego State University; The University of Texas at Austin; Monash University; University of Florida; Xi'an Jiaotong University; Xi'an Jiaotong University; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","BackgroundMultiple candidates of COVID-19 vaccines have entered Phase III clinical trials in the United States (US). There is growing optimism that social distancing restrictions and face mask requirements could be eased with widespread vaccine adoption soon.

MethodsWe developed a dynamic compartmental model of COVID-19 transmission for the four most severely affected states (New York, Texas, Florida, and California). We evaluated the vaccine effectiveness and coverage required to suppress the COVID-19 epidemic in scenarios when social contact was to return to pre-pandemic levels and face mask use was reduced. Daily and cumulative COVID-19 infection and death cases were obtained from the Johns Hopkins University Coronavirus resource center and used for model calibration.

ResultsWithout a vaccine, the spread of COVID-19 could be suppressed in these states by maintaining strict social distancing measures and face mask use levels. But relaxing social distancing restrictions to the pre-pandemic level without changing the current face mask use would lead to a new COVID-19 outbreak, resulting in 0.8-4 million infections and 15,000-240,000 deaths across these four states over the next 12 months. In this scenario, introducing a vaccine would partially offset this negative impact even if the vaccine effectiveness and coverage are relatively low. However, if face mask use is reduced by 50%, a vaccine that is only 50% effective (weak vaccine) would require coverage of 55-94% to suppress the epidemic in these states. A vaccine that is 80% effective (moderate vaccine) would only require 32-57% coverage to suppress the epidemic. In contrast, if face mask usage stops completely, a weak vaccine would not suppress the epidemic, and further major outbreaks would occur. A moderate vaccine with coverage of 48-78% or a strong vaccine (100% effective) with coverage of 33-58% would be required to suppress the epidemic. Delaying vaccination rollout for 1-2 months would not substantially alter the epidemic trend if the current interventions are maintained.

ConclusionsThe degree to which the US population can relax social distancing restrictions and face mask use will depend greatly on the effectiveness and coverage of a potential COVID-19 vaccine if future epidemics are to be prevented. Only a highly effective vaccine will enable the US population to return to life as it was before the pandemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.27.20220970,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.27.20220970,"A Machine Learning Study of 534,023 Medicare Beneficiaries with COVID-19: Implications for Personalized Risk Prediction",Chen Dun; Christi Walsh; Sunjae Bae; Amesh Adalja; Eric Toner; Timothy A Lash; Farah Hashim; Joseph Paturzo; Dorry L Segev; Martin A Makary; Yan Li; Lei Zhang; Yukari C Manabe; Andrea L. Cox; Justin R. Bailey; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University Center for Health Security; Johns Hopkins University Center for Health Security; West Health Institute; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","BackgroundGlobal demand for a COVID-19 vaccine will exceed the initial limited supply. Identifying individuals at highest risk of COVID-19 death may help allocation prioritization efforts. Personalized risk prediction that uses a broad range of comorbidities requires a cohort size larger than that reported in prior studies.

MethodsMedicare claims data was used to identify patients age 65 years or older with diagnosis of COVID-19 between April 1, 2020 and August 31, 2020. Demographic characteristics, chronic medical conditions, and other patient risk factors that existed before the advent of COVID-19 were identified. A random forest model was used to empirically explore factors associated with COVID-19 death. The independent impact of factors identified were quantified using multivariate logistic regression with random effects.

ResultsWe identified 534,023 COVID-19 patients of whom 38,066 had an inpatient death. Demographic characteristics associated with COVID-19 death included advanced age (85 years or older: aOR: 2.07; 95% CI, 1.99-2.16), male sex (aOR, 1.88; 95% CI, 1.82-1.94), and non-white race (Hispanic: aOR, 1.74; 95% CI, 1.66-1.83). Leading comorbidities associated with COVID-19 mortality included sickle cell disease (aOR, 1.73; 95% CI, 1.21-2.47), chronic kidney disease (aOR, 1.32; 95% CI, 1.29-1.36), leukemias and lymphomas (aOR, 1.22; 95% CI, 1.14-1.30), heart failure (aOR, 1.19; 95% CI, 1.16-1.22), and diabetes (aOR, 1.18; 95% CI, 1.15-1.22).

ConclusionsWe created a personalized risk prediction calculator to identify candidates for early vaccine and therapeutics allocation (www.predictcovidrisk.com). These findings may be used to protect those at greatest risk of death from COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.28.20221333,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.28.20221333,Clinical Suspicion of COVID-19 in Nursing Home residents: symptoms and mortality risk factors,Jeanine J.S. Rutten; Anouk M. van Loon; Janine van Kooten; Laura W. van Buul; Karlijn J. Joling; Martin Smalbrugge; Cees M.P.M. Hertogh; Joseph Paturzo; Dorry L Segev; Martin A Makary; Yan Li; Lei Zhang; Yukari C Manabe; Andrea L. Cox; Justin R. Bailey; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sinad Langan; Maria R. Copabianchi; Suresh Jain; J.B. Gupta; Gaya K. Amarasinghe; Michael S. Diamond; James Rini; Sachdev Sidhu,"Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam University Medical Center; Amsterdam UMC; Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam University Medical Center; Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam University Medical Center; Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam University Medical Center; Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam University Medical Center; Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam University Medical Center; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; National Institute for Infectious Diseases ""L. Spallanzani"" IRCCS; Virna Therapeutics; Virna Therapeutics; Washington University School of Medicine; Washington University School of Medicine; University of Toronto; University of Toronto","ObjectivesTo describe symptomatology, mortality and risk factors for mortality in a large group of Dutch nursing home (NH) residents with clinically-suspected COVID-19 who were tested with a Reverse Transcription Polymerase Chain Reaction (RT-PCR) test.

DesignProspective cohort study.

Setting and participantsResidents of Dutch NHs with clinically-suspected COVID-19 and who received RT-PCR test.

MethodsWe collected data of NH residents with clinically-suspected COVID-19, via electronic health records between March 18th and May 13th, 2020. Registration was performed on diagnostic status (confirmed (COVID-19+)/ruled out (COVID-19-)) and symptomatology (typical and atypical symptoms). Information on mortality and risk factors for mortality were extracted from usual care data.

ResultsIn our sample of residents with clinically-suspected COVID-19 (N=4007), COVID-19 was confirmed in 1538 residents (38%). Although, symptomatology overlapped between residents with COVID-19+ and COVID-19-, those with COVID-19+ were three times more likely to die within 30 days (hazard ratio (HR), 3{middle dot}1; 95% CI, 2{middle dot}7 to 3{middle dot}6). Within this group, mortality was higher for men than for women (HR, 1{middle dot}8; 95%, 1{middle dot}5-2{middle dot}2) and we observed a higher mortality for residents with dementia, reduced kidney function, and Parkinsons Disease, even when corrected for age, gender, and comorbidities.

Conclusions and implicationsAbout 40% of the residents with clinically-suspected COVID-19 actually had COVID-19, based on the RT-PCR test. Despite an overlap in symptomatology, mortality rate was three times higher for residents with COVID-19+. This emphasizes the importance of using low-threshold testing in NH residents which is an essential prerequisite to using limited personal protective equipment and isolation measures efficiently.",infectious diseases,exact,100,100
bioRxiv,10.1101/2020.10.29.339317,2020-10-30,https://biorxiv.org/cgi/content/short/2020.10.29.339317,"COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning",- The COVID Moonshot Consortium; Hagit Achdout; Anthony Aimon; Elad Bar-David; Haim Barr; Amir Ben-Shmuel; James Bennett; Melissa L Bobby; Juliane Brun; Sarma BVNBS; Mark Calmiano; Anna Carbery; Emma Cattermole; John D. Chodera; Austin Clyde; Joseph E. Coffland; Galit Cohen; Jason Cole; Alessandro Contini; Lisa Cox; Milan Cvitkovic; Alex Dias; Alice Douangamath; Shirly Duberstein; Tim Dudgeon; Louise Dunnett; Peter K. Eastman; Noam Erez; Michael Fairhead; Daren Fearon; Oleg Fedorov; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"; Israel Institute for Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; Israel Institute for Biological Research; The Weizmann Institute of Science; Israel Institute for Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center;Weil Cornell Medical College; University of Oxford; Sai Life Sciences; UCB; University of Oxford;Diamond Light Source; University of Oxford; Memorial Sloan Kettering Cancer Center; Argonne National Laboratory; Couldron Development; The Weizmann Institute of Science; Cambridge Crystallographic Data Centre; University of Milan; Life Compass Consulting Ltd; PostEra Inc.; Diamond Light Source Ltd; Research Complex at Harwell; Diamond Light Source Ltd; Research Complex at Harwell; The Weizmann Institute of Science; Informatics Matters; Diamond Light Source Ltd; Research Complex at Harwell; Department of Bioengineering until Sept. 1, then Department of Chemistry; Israel Institute for Biological Research; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; University of Oxford; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","Herein we provide a living summary of the data generated during the COVID Moonshot project focused on the development of SARS-CoV-2 main protease (Mpro) inhibitors. Our approach uniquely combines crowdsourced medicinal chemistry insights with high throughput crystallography, exascale computational chemistry infrastructure for simulations, and machine learning in triaging designs and predicting synthetic routes. This manuscript describes our methodologies leading to both covalent and non-covalent inhibitors displaying protease IC50 values under 150 nM and viral inhibition under 5 uM in multiple different viral replication assays. Furthermore, we provide over 200 crystal structures of fragment-like and lead-like molecules in complex with the main protease. Over 1000 synthesized and ordered compounds are also reported with the corresponding activity in Mpro enzymatic assays using two different experimental setups. The data referenced in this document will be continually updated to reflect the current experimental progress of the COVID Moonshot project, and serves as a citable reference for ensuing publications. All of the generated data is open to other researchers who may find it of use.",biochemistry,exact,100,100
bioRxiv,10.1101/2020.10.29.361287,2020-10-30,https://biorxiv.org/cgi/content/short/2020.10.29.361287,A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies,Xun Chen; Matteo Gentili; Nir Hacohen; Aviv Regev; Haim Barr; Amir Ben-Shmuel; James Bennett; Melissa L Bobby; Juliane Brun; Sarma BVNBS; Mark Calmiano; Anna Carbery; Emma Cattermole; John D. Chodera; Austin Clyde; Joseph E. Coffland; Galit Cohen; Jason Cole; Alessandro Contini; Lisa Cox; Milan Cvitkovic; Alex Dias; Alice Douangamath; Shirly Duberstein; Tim Dudgeon; Louise Dunnett; Peter K. Eastman; Noam Erez; Michael Fairhead; Daren Fearon; Oleg Fedorov; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Broad Institute of MIT and Harvard; Broad Institute of MIT and Harvard; Broad Institute of MIT and Harvard; MIT and Broad Inst. of MIT &  Harvard; The Weizmann Institute of Science; Israel Institute for Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center;Weil Cornell Medical College; University of Oxford; Sai Life Sciences; UCB; University of Oxford;Diamond Light Source; University of Oxford; Memorial Sloan Kettering Cancer Center; Argonne National Laboratory; Couldron Development; The Weizmann Institute of Science; Cambridge Crystallographic Data Centre; University of Milan; Life Compass Consulting Ltd; PostEra Inc.; Diamond Light Source Ltd; Research Complex at Harwell; Diamond Light Source Ltd; Research Complex at Harwell; The Weizmann Institute of Science; Informatics Matters; Diamond Light Source Ltd; Research Complex at Harwell; Department of Bioengineering until Sept. 1, then Department of Chemistry; Israel Institute for Biological Research; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; University of Oxford; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","Antibody engineering technologies face increasing demands for speed, reliability and scale. We developed CeVICA, a cell-free antibody engineering platform that integrates a novel generation method and design for camelid heavy-chain antibody VHH domain-based synthetic libraries, optimized in vitro selection based on ribosome display and a computational pipeline for binder prediction based on CDR-directed clustering. We applied CeVICA to engineer antibodies against the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike proteins and identified >800 predicted binder families. Among 14 experimentally-tested binders, 6 showed inhibition of pseudotyped virus infection. Antibody affinity maturation further increased binding affinity and potency of inhibition. Additionally, the unique capability of CeVICA for efficient and comprehensive binder prediction allowed retrospective validation of the fitness of our synthetic VHH library design and revealed direction for future refinement. CeVICA offers an integrated solution to rapid generation of divergent synthetic antibodies with tunable affinities in vitro and may serve as the basis for automated and highly parallel antibody generation.",bioengineering,exact,100,100
bioRxiv,10.1101/2020.10.30.360115,2020-10-30,https://biorxiv.org/cgi/content/short/2020.10.30.360115,PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2,Saumyabrata Mazumder; Ruchir Rastogi; Avinash Undale; Kajal Arora; Nupur Mehrotra Arora; Biswa Pratim Das Purkayastha; Dilip Kumar; Abyson Joseph; Bhupesh Mali; Vidya Bhushan Arya; Sriganesh Kalyanaraman; Abhishek Mukherjee; Aditi Gupta; Swaroop Potdar; Sourav Singha Roy; Deepak Parashar; Jeny Paliwal; Sudhir Kumar Singh; Aelia Naqvi; Apoorva Srivastava; Manglesh Kumar Singh; Devanand Kumar; Sarthi Bansal; Satabdi Rautray; Indrajeet Singh; Pankaj Fengade; Bivekanand Kumar; Manish Saini; Kshipra Jain; Reeshu Gupta; Prabuddha K Kundu; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the worlds first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-{gamma} levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)-biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans.",immunology,exact,100,100
bioRxiv,10.1101/2020.10.30.352914,2020-10-30,https://biorxiv.org/cgi/content/short/2020.10.30.352914,Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses,Kathryn Kistler; Trevor Bedford; Avinash Undale; Kajal Arora; Nupur Mehrotra Arora; Biswa Pratim Das Purkayastha; Dilip Kumar; Abyson Joseph; Bhupesh Mali; Vidya Bhushan Arya; Sriganesh Kalyanaraman; Abhishek Mukherjee; Aditi Gupta; Swaroop Potdar; Sourav Singha Roy; Deepak Parashar; Jeny Paliwal; Sudhir Kumar Singh; Aelia Naqvi; Apoorva Srivastava; Manglesh Kumar Singh; Devanand Kumar; Sarthi Bansal; Satabdi Rautray; Indrajeet Singh; Pankaj Fengade; Bivekanand Kumar; Manish Saini; Kshipra Jain; Reeshu Gupta; Prabuddha K Kundu; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","Seasonal coronaviruses (OC43, 229E, NL63 and HKU1) are endemic to the human population, regularly infecting and reinfecting humans while typically causing asymptomatic to mild respiratory infections. It is not known to what extent reinfection by these viruses is due to waning immune memory or antigenic drift of the viruses. Here, we address the influence of antigenic drift on immune evasion of seasonal coronaviruses. We provide evidence that at least two of these viruses, OC43 and 229E, are undergoing adaptive evolution in regions of the viral spike protein that are exposed to human humoral immunity. This suggests that reinfection may be due, in part, to positively-selected genetic changes in these viruses that enable them to escape recognition by the immune system. It is possible that, as with seasonal influenza, these adaptive changes in antigenic regions of the virus would necessitate continual reformulation of a vaccine made against them.",evolutionary biology,exact,100,100
medRxiv,10.1101/2020.10.27.20221085,2020-10-29,https://medrxiv.org/cgi/content/short/2020.10.27.20221085,"How Emergency Care Congestion Increases Covid-19 Mortality: Evidence from Lombardy, Italy",Gabriele Ciminelli; Silvia Garcia-Mandico; Avinash Undale; Kajal Arora; Nupur Mehrotra Arora; Biswa Pratim Das Purkayastha; Dilip Kumar; Abyson Joseph; Bhupesh Mali; Vidya Bhushan Arya; Sriganesh Kalyanaraman; Abhishek Mukherjee; Aditi Gupta; Swaroop Potdar; Sourav Singha Roy; Deepak Parashar; Jeny Paliwal; Sudhir Kumar Singh; Aelia Naqvi; Apoorva Srivastava; Manglesh Kumar Singh; Devanand Kumar; Sarthi Bansal; Satabdi Rautray; Indrajeet Singh; Pankaj Fengade; Bivekanand Kumar; Manish Saini; Kshipra Jain; Reeshu Gupta; Prabuddha K Kundu; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Asia School of Business in collaboration with MIT Sloan Management; Organisation for Economic Co-operation and Development; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","BackgroundThe Covid-19 pandemic has caused generous and well-developed healthcare systems to collapse. This paper quantifies how much system congestion may have increased mortality rates, using distance to the ICU as a proxy for access to emergency care.

MethodsWe match daily death registry data for almost 1,500 municipalities in Lombardy, Italy, to data on geographical location of all ICU beds in the region. We then analyze how system congestion increases mortality in municipalities that are far from the ICU through a differences-in-differences regression model.

FindingsWe find that Covid-19 mortality is up to 60% higher in the average municipality - which is 15 minutes driving away from the closest ICU - than in a municipality with an ICU in town. This difference is larger in areas and in days characterized by an abnormal number of calls to the emergency line.

InterpretationWe interpret these results as suggesting that a sudden surge of critical patients may have congested the healthcare system, forcing emergency medical services to prioritize patients in the most proximate communities in order to maximize the number of lives saved. Through some back-of-the-envelope calculations, we estimate that Lombardys death toll from the first Covid-19 outbreak could have been 25% lower had all municipalities had ready access to the ICU. Drawing a lesson from Lombardys tale, governments should strengthen the emergency care response and palliate geographical inequalities to ensure that everyone in need can receive critical care on time during new outbreaks.

FundingNo funding.",health policy,exact,100,100
medRxiv,10.1101/2020.10.28.20221176,2020-10-29,https://medrxiv.org/cgi/content/short/2020.10.28.20221176,"The unexpected spectacular 2020 October COVID-19 boost in European countries correlated with the latitude, but not with the temperature.",Stephan Walrand; Silvia Garcia-Mandico; Avinash Undale; Kajal Arora; Nupur Mehrotra Arora; Biswa Pratim Das Purkayastha; Dilip Kumar; Abyson Joseph; Bhupesh Mali; Vidya Bhushan Arya; Sriganesh Kalyanaraman; Abhishek Mukherjee; Aditi Gupta; Swaroop Potdar; Sourav Singha Roy; Deepak Parashar; Jeny Paliwal; Sudhir Kumar Singh; Aelia Naqvi; Apoorva Srivastava; Manglesh Kumar Singh; Devanand Kumar; Sarthi Bansal; Satabdi Rautray; Indrajeet Singh; Pankaj Fengade; Bivekanand Kumar; Manish Saini; Kshipra Jain; Reeshu Gupta; Prabuddha K Kundu; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Cliniques universitaires Saint-Luc; Organisation for Economic Co-operation and Development; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","PurposeDetermining the triggering factor of the sudden surge of the daily new COVID-19 cases arising in most European countries during 2020 Autumn.

MethodsThe dates of the surge were determined using a fitting of the two last months reported daily new cases in 18 European countries of latitude ranging from 39{degrees} to 62{degrees}.

ResultsThe study proves no correlation between the country surge date and its 2 weeks preceding temperature or humidity, but shows an impressive linear correlation with its latitude. The country surge date corresponds to the time when its sun UV daily dose drops below {approx} 34% of that of 0{degrees} latitude. Introducing reported seasonal blood 25-hydroxyvitamin D (25(OH)D) concentration variation into reported link between acute respiratory track infection risk with 25(OH)D concentration quantitatively explains the surge dynamics.

ConclusionsSeveral studies already substantiated a 25(OH)D concentration impact on COVID-19 severity. However by comparing different patients populations, discriminate whether low 25(OH)D concentration is a real factor of covid-19 severity or only a marker of another weakness being the primary severity factor can be challenging. The date of the surge is an intrapopulation observation and has the benefit to be only triggered by a parameter globally affecting the population, i.e. the sun UV daily dose decreases. The results support that low 25(OH)D concentration is thus well a contributing factor of COVID-19 severity, which joined with the previous studies makes a convincing bundle of evidence",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.29.20218750,2020-10-29,https://medrxiv.org/cgi/content/short/2020.10.29.20218750,Rapid Support for older adults during the initial stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry helpline,Anna-Sophia Wahl; Gloria S. Benson; Lucrezia Hausner; Sandra Schmitt; Annika Knoll; Adriana Ferretti-Bondy; Dimitri Hefter; Lutz Froelich; Bhupesh Mali; Vidya Bhushan Arya; Sriganesh Kalyanaraman; Abhishek Mukherjee; Aditi Gupta; Swaroop Potdar; Sourav Singha Roy; Deepak Parashar; Jeny Paliwal; Sudhir Kumar Singh; Aelia Naqvi; Apoorva Srivastava; Manglesh Kumar Singh; Devanand Kumar; Sarthi Bansal; Satabdi Rautray; Indrajeet Singh; Pankaj Fengade; Bivekanand Kumar; Manish Saini; Kshipra Jain; Reeshu Gupta; Prabuddha K Kundu; Matteo Ferla; Holly Foster; Richard Foster; Ronen Gabizon; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Central Institute of Mental Health, Mannheim, University of Heidelberg; Central Institute of Mental Health Mannheim, University of Heidelberg; Central Institute of Mental Health, Mannheim, University of Heidelberg; Central Institute of Mental Health, Mannheim, University of Heidelberg; Central Institute of Mental Health, Mannheim, University of Heidelberg; Central Institute of Mental Health, Mannheim, University of Heidelberg; Central Institute of Mental Health, Mannheim, University of Heidelberg; Central Institute of Mental Health, Mannheim, University of Heidelberg; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; Premas Biotech Pvt Ltd; University of Oxford; University of Leeds; University of Leeds; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","BackgroundThe COVID-19 pandemic and governmental lockdown measures disproportionally impacts older adults. This study presents the results from a psychiatric helpline for older adults in Mannheim, Germany, during the lockdown, set up to provide information and psychosocial support measures. We aim to elucidate the needs of older adults, their reported changes and the psychological impact during the initial stages of the health crisis.

Methods55 older adults called the psychiatric helpline between April and June 2020. Information on demographics, previous diagnosis of psychiatric and somatic diseases as well as changes in daily life due to the pandemic was collected anonymously. Current mental health status was assessed using the depression HAMD-7 and the anxiety HAM-A scales.

ResultsMost callers were women, older adults (M = 74.69 years), single and retired. 69% of callers reported new or an increase in psychiatric symptoms, with anxiety and depressive symptoms being the most common ones. Age was significantly negatively correlated to higher levels of anxiety and depression symptoms. Individuals with a previous diagnosis of a psychiatric disease reported significantly higher levels of depressive and anxiety symptoms than those without a diagnosis.

ConclusionIn older adults, the perceived psychological impact of the COVID-19 crisis appears to ameliorate with age. Individuals with a history of psychiatric disease are most vulnerable to negative mental health outcomes. Rapid response in the form of a geriatric helpline are useful initiatives to support the needs and the psychological well-being of older adults during a health crisis.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.10.28.20217455,2020-10-29,https://medrxiv.org/cgi/content/short/2020.10.28.20217455,Anakinra To Prevent Respiratory Failure In COVID-19,Evdoxia Kyriazopoulou; Periklis Panagopoulos; Simeon Metallidis; George Dalekos; Garyfallia Poulakou; Nikolaos Gatselis; Eleni Karakike; Maria Saridaki; Georgia Loli; Aggelos Stefos; Danai Prasianaki; Sarah Georgiadou; Olga Tsachouridou; Vasileios Petrakis; Konstantinos Tsiakos; Maria Kosmidou; Vassiliki Lygoura; Maria Dareioti; Haralampos Milionis; Ilias C Papanikolaou; Karolina Akinosoglou; Dimitra-Melia Myrodia; Areti Gravani; Aliki Stamou; Theologia Gkavogianni; Konstantina Katrini; Theodoros Marantos; Ioannis P Trontzas; Konstantinos Syrigos; Lukas Chatzis; Stamatios Chatzis; Nikolaos Vechlidis; Christina Avgoustou; Stamatios Chalvatzis; Miltiades Kyprianou; Jos WM van der Meer; jesper eugen-olsen; Mihai Netea; Evangelos Giamarellos-Bourboulis; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"National and Kapodistrian University of Athens; Democritus University of Thrace; Aristotle University of Thessaloniki; General University Hospital of Larissa; National and Kapodistrian University of Athens; General University Hospital of Larissa; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; Aristotle University of Thessaloniki; General University Hospital of Larissa; National and Kapodistrian University of Athens; General University Hospital of Larissa; Aristotle University of Thessaloniki; Democritus University of Thrace; National and Kapodistrian University of Athens; University of Ioannina; General University Hospital of Larissa; National and Kapodistrian University of Athens; University of Ioannina; General Hospital of Kerkyra; University of Patras; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; National and Kapodistrian University of Athens; Radboud University Nijmegen; Copenhagen University Hospital Hvidovre; Radboud University Nijmegen; National and Kapodistrian University of Athens; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","IntroductionThe management of pneumonia caused by SARS-CoV-2 should rely on early recognition of the risk for progression to severe respiratory failure (SRF) and its prevention. We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.

MethodsIn this open-label prospective trial, 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels [&ge;]6 g/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome was the incidence of SRF at day 14. Secondary outcomes were 30-day mortality, changes in sequential organ failure assessment (SOFA) score, of cytokine-stimulation pattern and of circulating inflammatory mediators. Equal number of propensity score-matched comparators for comorbidities, severity on admission and standard-of care (SOC) were studied.

ResultsThe incidence of SRF was 22.3% (95% CI, 16.0-30.2%) among anakinra-treated patients and 59.2% (95% CI, 50.6-67.3%; P: 4.6 x 10-8) among SOC comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46). 30-day mortality was 11.5% (95% CI, 7.1-18.2%) and 22.3% (95% CI, 16.0-30.2%) respectively (hazard ratio 0.49; 95% CI 0.25-0.97%; P: 0.041). Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score. Duration of stay at the intensive care unit and at hospital was shortened compared to the SOC group; the cost of hospitalization was decreased.

ConclusionsEarly suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.

Trial RegistrationClinicalTrials.gov, NCT04357366",infectious diseases,exact,100,100
bioRxiv,10.1101/2020.10.28.359935,2020-10-29,https://biorxiv.org/cgi/content/short/2020.10.28.359935,Global Absence and Targeting of Protective Immune States in Severe COVID-19.,Alexis J Combes; Tristan Courau; Nicholas F Kuhn; Kenneth H Hu; Arja Ray; William S Chen; Simon J Clearly; Nayvin W Chew; Divyashree Kushnoor; Gabriella C Reeder; Alan Shen; Jessica Tsui; Kamir J Hiam-Galvez; Priscila Munoz-Sandoval; Wandi S Zhu; David S Lee; Yang Sun; Ran You; Melia Magnen; Lauren Rodriguez; Aleksandra Leligdowicz; Colin R Zamecnik; Rita P Loudermilk; Michael R Wilson; Chun J Ye; Gabriela K Fragiadakis; Mark R Looney; Vincent Chan; Alyssa Ward; Sidney Carrillo; Michael Matthay; David J Erle; Prescott G Woodruff; Charles Langelier; Kristen Kangelaris; Carolyn M Hendrickson; Carolyn Calfee; Arjun Arkal Rao; Matthew F Krummel; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","While SARS-CoV-2 infection has pleiotropic and systemic effects in some patients, many others experience milder symptoms. We sought a holistic understanding of the severe/mild distinction in COVID-19 pathology, and its origins. We performed a whole-blood preserving single-cell analysis protocol to integrate contributions from all major cell types including neutrophils, monocytes, platelets, lymphocytes and the contents of serum. Patients with mild COVID-19 disease display a coordinated pattern of interferon-stimulated gene (ISG) expression across every cell population and these cells are systemically absent in patients with severe disease. Severe COVID-19 patients also paradoxically produce very high anti-SARS-CoV-2 antibody titers and have lower viral load as compared to mild disease. Examination of the serum from severe patients demonstrates that they uniquely produce antibodies with multiple patterns of specificity against interferon-stimulated cells and that those antibodies functionally block the production of the mild disease-associated ISG-expressing cells. Overzealous and auto-directed antibody responses pit the immune system against itself in many COVID-19 patients and this defines targets for immunotherapies to allow immune systems to provide viral defense.

One Sentence SummaryIn severe COVID-19 patients, the immune system fails to generate cells that define mild disease; antibodies in their serum actively prevents the successful production of those cells.",immunology,exact,100,100
bioRxiv,10.1101/2020.10.28.359836,2020-10-29,https://biorxiv.org/cgi/content/short/2020.10.28.359836,Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model,Yanwen Fu; Junki Maruyama; Alok Singh; Reyna Lim; Arthur Ledesma; Daniel Lee; Laura Rivero-Nava; Jamie Ko; Ianne Rivera; Rachel A. Sattler; John T. Manning; Lisa Kerwin; Heyue Zhou; Mark Brunswick; Damien Bresson; Henry Ji; Slobodan Paessler; Robert D Allen; Melia Magnen; Lauren Rodriguez; Aleksandra Leligdowicz; Colin R Zamecnik; Rita P Loudermilk; Michael R Wilson; Chun J Ye; Gabriela K Fragiadakis; Mark R Looney; Vincent Chan; Alyssa Ward; Sidney Carrillo; Michael Matthay; David J Erle; Prescott G Woodruff; Charles Langelier; Kristen Kangelaris; Carolyn M Hendrickson; Carolyn Calfee; Arjun Arkal Rao; Matthew F Krummel; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Sorrento Therapeutics, Inc., San Diego, CA 92121; University of Texas Medical Branch, Department of Pathology, Galveston National Laboratory, Galveston, TX 77555; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; University of Texas Medical Branch, Department of Pathology, Galveston National Laboratory, Galveston, TX 77555; University of Texas Medical Branch, Department of Pathology, Galveston National Laboratory, Galveston, TX 77555; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; University of Texas Medical Branch, Department of Pathology, Galveston National Laboratory, Galveston, TX 77555; Sorrento Therapeutics, Inc., San Diego, CA 92121; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","We have previously reported that the SARS-CoV-2 neutralizing antibody, STI-2020, potently inhibits cytopathic effects of infection by genetically diverse clinical SARS-CoV-2 pandemic isolates in vitro, and has demonstrated efficacy in a hamster model of COVID-19 when administered by the intravenous route immediately following infection. We now have extended our in vivo studies of STI-2020 to include disease treatment efficacy, profiling of biodistribution of STI-2020 in mice when antibody is delivered intranasally (IN) or intravenously (IV), as well as pharmacokinetics in mice following IN antibody administration. Importantly, SARS-CoV-2-infected hamsters were treated with STI-2020 using these routes, and treatment effects on severity and duration of COVID-19-like disease in this model were evaluated. In SARS-CoV-2 infected hamsters, treatment with STI-2020 12 hours post-infection using the IN route led to a decrease in severity of clinical disease signs and a more robust recovery during 9 days of infection as compared to animals treated with an isotype control antibody. Treatment via the IV route using the same dose and timing regimen resulted in a decrease in the average number of consecutive days that infected animals experienced weight loss, shortening the duration of disease and allowing recovery to begin more rapidly in STI-2020 treated animals. Following IN administration in mice, STI-2020 was detected within 10 minutes in both lung tissue and lung lavage. The half-life of STI-2020 in lung tissue is approximately 25 hours. We are currently investigating the minimum effective dose of IN-delivered STI-2020 in the hamster model as well as establishing the relative benefit of delivering neutralizing antibodies by both IV and IN routes.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.29.360578,2020-10-29,https://biorxiv.org/cgi/content/short/2020.10.29.360578,Novel SARS-CoV-2 Whole-genome sequencing technique using Reverse Complement PCR enables fast and accurate outbreak analysis,Femke Wolters; Jordy P.M. Coolen; Alma Tostmann; Lenneke F.J. van Groningen; Chantal P. Bleeker-Rovers; Edward C.T.H. Tan; Nannet van der Geest-Blankert; Jeannine L.A. Hautvast; Joost Hopman; Heiman F.L. Wertheim; Janette C. Rahamat-Langendoen; Marko Storch; Willem J.G. Melchers; Mark Brunswick; Damien Bresson; Henry Ji; Slobodan Paessler; Robert D Allen; Melia Magnen; Lauren Rodriguez; Aleksandra Leligdowicz; Colin R Zamecnik; Rita P Loudermilk; Michael R Wilson; Chun J Ye; Gabriela K Fragiadakis; Mark R Looney; Vincent Chan; Alyssa Ward; Sidney Carrillo; Michael Matthay; David J Erle; Prescott G Woodruff; Charles Langelier; Kristen Kangelaris; Carolyn M Hendrickson; Carolyn Calfee; Arjun Arkal Rao; Matthew F Krummel; Robert Glen; Itai Glinert; Marian Gorichko; Tyler Gorrie-Stone; Edward J Griffen; Jag Heer; Michelle Hill; Sam Horrell; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Eric Jnoff; Tobias John; Anastassia L. Kantsadi; Peter W. Kenny; John L. Kiappes; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Alpha Albert Lee; Bruce A. Lefker; Haim Levy; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Beth MacLean; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Sharon Melamed; Oleg Michurin; Halina Mikolajek; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Jose Brandao Neto; Vladas Oleinikovas; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; St Patrick Reid; Efrat Resnick; Matthew C. Robinson; Ralph P. Robinson; Dominic Rufa; Christopher Schofield; Aarif Shaikh; Jiye Shi; Khriesto Shurrush; Assa Sittner; Rachael Skyner; Adam Smalley; Mihaela D. Smilova; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Rachael Tennant; Andrew Thompson; Warren Thompson; Susana Tomasio; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Annette von Delft; Frank von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Conor Francis Wild; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Daniel Zaidmann; Hadeer Zidane; Nicole Zitzmann,"Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Regional Public Health Service, Nijmegen, the Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen, The Netherlands; Imperial College London; Radboud university medical center, Nijmegen, The Netherlands; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; Sorrento Therapeutics, Inc., San Diego, CA 92121; University of Texas Medical Branch, Department of Pathology, Galveston National Laboratory, Galveston, TX 77555; Sorrento Therapeutics, Inc., San Diego, CA 92121; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; University of Cambridge; Israel Institute for Biological Research; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; UCB; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Temple University; Israel Institute for Biological Research; PostEra Inc.; UCB; University of Oxford; University of Oxford; Universidade de Sao Paulo; University of Oxford; University of Oxford; M2M solutions, s.r.o; University of Oxford; University of Cambridge; Thames Pharma Partners LLC; Israel Institute for Biological Research; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Israel Institute for Biological Research; Enamine Ltd; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc; University of Oxford; University of Nebraska at Kearney; Relay Therapeutics; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institute for Biological Research; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Israel Institute of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; University of Nebraska; The Weizmann Institute of Science; PostEra Inc.; Thames Pharma Partners LLC; Memorial Sloan Kettering Cancer Center; University of Oxford; Sai Life Sciences; UCB; The Weizmann Institute of Science; Israel Institute of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; UCB; University of Oxford; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institute of Biological Research; Lhasa Ltd. UK; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Collaborative Drug Discovery; University of Oxford; University of Oxford; Radboud University Medical Center; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institute of Biological Research; Temple University; University of Oxford; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institute of Biological Research; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institute of Biological Research; The Weizmann Institute of Science; The Weizmann Institute of Science; University of Oxford","BackgroundCurrent transmission rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still increasing and many countries are facing second waves of infections. Rapid SARS-CoV-2 whole-genome sequencing (WGS) is often unavailable but could support public health organizations and hospitals in monitoring and determining transmission links. Here we report the use of reverse complement polymerase chain reaction (RC-PCR), a novel technology for WGS of SARS-CoV-2 enabling library preparation in a single PCR saving time, resources and enables high throughput screening. Additionally, we show SARS-CoV-2 diversity and possible transmission within the Radboud university medical center (Radboudumc) during September 2020 using RC-PCR WGS.

MethodsA total of 173 samples tested positive for SARS-CoV-2 between March and September 2020 were selected for whole-genome sequencing. Ct values of the samples ranged from 16 to 42. They were collected from 83 healthcare workers and three patients at the Radboudumc, in addition to 64 people living in the area around the hospital and tested by the local health services. For validation purposes, nineteen of the included samples were previously sequenced using Oxford Nanopore Technologies and compared to RC-PCR WGS results. The applicability of RC-PCR WGS in outbreak analysis for public health service and hospitals was tested on six suspected clusters containing samples of healthcare workers and patients with an epidemiological link.

FindingsRC-PCR resulted in sequencing data for 146 samples. It showed a genome coverage of up to 98,2% for samples with a maximum Ct value of 32. Comparison to Oxford Nanopore technologies gives a near-perfect agreement on 95% of the samples (18 out of 19). Three out of six clusters with a suspected epidemiological link were fully confirmed, in the others, four healthcare workers were not associated. In the public health service samples, a previously unknown chain of transmission was confirmed.

Significance statementSAR-CoV-2 whole-genome sequencing using RC-PCR is a reliable technique and applicable for use in outbreak analysis and surveillance. Its ease of use, high-trough screening capacity and wide applicability makes it a valuable addition or replacement during this ongoing SARS-CoV-2 pandemic.

FundingNone

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSAt present whole genome sequencing techniques for SARS-CoV-2 have a large turnover time and are not widely available. Only a few laboratories are currently able to perform large scale SARS-CoV-2 sequencing. This restricts the use of sequencing to aid hospital and community infection prevention.

Added value of this studyHere we present clinical and technical data on a novel Whole Genome Sequencing technology, implementing reverse-complement PCR. It is able to obtain high genome coverage of SARS-CoV-2 and confirm and exclude epidemiological links in 173 healthcare workers and patients. The RC-PCR technology simplifies the workflow thereby reducing hands on time. It combines targeted PCR and sequence library construction in a single PCR, which normally takes several steps. Additionally, this technology can be used in concordance with the widely available range of Illumina sequencers.

Implications of all the available evidenceRC-PCR whole genome sequencing technology enables rapid and targeted surveillance and response to an ongoing outbreak that has great impact on public health and society. Increased use of sequencing technologies in local laboratories can help prevent increase of SARS-CoV-2 spreading by better understanding modes of transmission.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.26.356014,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.26.356014,"COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms",Marek Ostaszewski; Anna Niarakis; Alexander Mazein; Inna Kuperstein; Robert Phair; Aurelio Orta-Resendiz; Vidisha Singh; Sara Sadat Aghamiri; Marcio Luis Acencio; Enrico Glaab; Andreas Ruepp; Gisela Fobo; Corinna Montrone; Barbara Brauner; Goar Frishman; Julia Somers; Matti Hoch; Shailendra Kumar Gupta; Julia Scheel; Hanna Borlinghaus; Tobias Czauderna; Falk Schreiber; Arnau Montagud; Miguel Ponce de Leon; Akira Funahashi; Yusuke Hiki; Noriko Hiroi; Takahiro G Yamada; Andreas Drager; Alina Renz; Muhammad Naveez; Zsolt Bocskei; Daniela Bornigen; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Biology, Univ. Evry, University of Paris-Saclay, GenHotel, Genopole, 91025, Evry, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Institut Curie, PSL Research University, Paris, France.; Integrative Bioinformatics, Inc., 346 Paul Ave, Mountain View, CA, USA; Institut Pasteur, HIV, Inflammation and Persistence Unit, Paris, France; Laboratoire Europeen de Recherche pour la Polyarthrite Rhumatoide - Genhotel, Univ Evry, Universite Paris-Saclay, 2, rue Gaston Cremieux, 91057 EVRY-GENOPOLE ce; Inserm- Institut national de la sante et de la recherche medicale. Saint-Louis Hospital 1 avenue Claude Vellefaux Pavillon Bazin 75475 Paris; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Oregong Health & Sciences Univerity; Department of Molecular and Medical Genetics; 3222 SW Research Drive, Portland, Oregon, U.S.A 97239; Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany; Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany; Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany; Department of Computer and Information Science, University of Konstanz, Konstanz, Germany; Monash University, Faculty of Information Technology, Department of Human-Centred Computing, Wellington Rd, Clayton VIC 3800, Australia; Department of Computer and Information Science, University of Konstanz, Konstanz, Germany; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522; Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522; Sanyo-Onoda City University, Faculty of Pharmaceutical Sciences, University St.1-1-1, Yamaguchi, Japan 756-0884; Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Riga Technical University, Institute of Applied Computer Systems,1 Kalku Street, LV-1658 Riga, Latvia; Sanofi R&D Translational Sciences; Bioinformatics Core Facility, Universitaetsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","We hereby describe a large-scale community effort to build an open-access, interoperable, and computable repository of COVID-19 molecular mechanisms - the COVID-19 Disease Map. We discuss the tools, platforms, and guidelines necessary for the distributed development of its contents by a multi-faceted community of biocurators, domain experts, bioinformaticians, and computational biologists. We highlight the role of relevant databases and text mining approaches in enrichment and validation of the curated mechanisms. We describe the contents of the map and their relevance to the molecular pathophysiology of COVID-19 and the analytical and computational modelling approaches that can be applied to the contents of the COVID-19 Disease Map for mechanistic data interpretation and predictions. We conclude by demonstrating concrete applications of our work through several use cases.",systems biology,exact,100,100
bioRxiv,10.1101/2020.10.28.358614,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.358614,Induced pulmonary comorbidities render CD-1 mice sensitive to SARS-CoV-2,Reut Falach; Liat Bar-On; Shlomi Lazar; Tamar Kadar; Ohad Mazor; Moshe Aftalion; David Gur; Ohad Shifman; Ofir Israeli; Inbar Cohen-Gihon; Galia Zaide; Hila Gutman; Yentl Evgy; Yaron Vagima; Efi Makdasi; Dana Stein; Ronit Rosenfeld; Ron Alcalay; Eran Zahavy; Haim Levy; Itai Glinert; Amir Ben-Shmuel; Tomer Israely; Sharon Melamed; Boaz Politi; Hagit Achdout; Shmuel Yitzhaky; Chanoch Kronman; Tamar Sabo; Alina Renz; Muhammad Naveez; Zsolt Bocskei; Daniela Bornigen; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Riga Technical University, Institute of Applied Computer Systems,1 Kalku Street, LV-1658 Riga, Latvia; Sanofi R&D Translational Sciences; Bioinformatics Core Facility, Universitaetsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Severe manifestations of COVID-19 are mostly restricted to people with comorbidities. Here we report that induced mild pulmonary morbidities render SARS-CoV-2-refractive CD-1 mice to be susceptible to this virus. Specifically, SARS-CoV-2 infection after application of low-doses of the acute-lung-injury stimulants bleomycin or ricin caused a severe disease in CD-1 mice, manifested by sustained body weight loss and mortality rates of >50%. Further studies revealed markedly higher levels of viral RNA in the lungs, heart and serum of low-dose-ricin pretreated, as compared to non-pretreated mice. Notably, the deleterious effects of SARS-CoV-2 infection were effectively alleviated by passive transfer of polyclonal or monoclonal antibodies generated against SARS-CoV-2 RBD. Thus, viral cell entry in the sensitized mice seems to involve viral RBD binding, albeit by a mechanism other than the canonical ACE2-mediated uptake route. In summary, we present a novel mice-based animal model for the study of comorbidity-dependent severe COVID-19.",pathology,exact,100,100
bioRxiv,10.1101/2020.10.28.359356,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.359356,A genome-wide CRISPR/Cas9 knock-out screen identifies the DEAD box RNA helicase DDX42 as a broad antiviral inhibitor,Boris Bonaventure; Antoine Rebendenne; Francisco Garcia de Gracia; Marine Tauziet; Joe McKellar; Ana Luiza Chaves Valado; Valrie Courgnaud; Eric Bernard; Laurence Briant; Nathalie Gros; Wassila Djilli; Mary Arnaud-Arnould; Hugues Parrinello; Stphanie Rialle; Olivier Moncorg; Caroline Goujon; Ronit Rosenfeld; Ron Alcalay; Eran Zahavy; Haim Levy; Itai Glinert; Amir Ben-Shmuel; Tomer Israely; Sharon Melamed; Boaz Politi; Hagit Achdout; Shmuel Yitzhaky; Chanoch Kronman; Tamar Sabo; Alina Renz; Muhammad Naveez; Zsolt Bocskei; Daniela Bornigen; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IGMM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; CEMIPAI, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; Montpellier GenomiX; Montpellier GenomiX; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Riga Technical University, Institute of Applied Computer Systems,1 Kalku Street, LV-1658 Riga, Latvia; Sanofi R&D Translational Sciences; Bioinformatics Core Facility, Universitaetsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Genome-wide CRISPR/Cas9 knock-out genetic screens are powerful approaches to unravel new regulators of viral infections. Here, we took advantage of the ability of interferon (IFN) to restrict HIV-1 infection, in order to create an environment hostile to replication and reveal new inhibitors through a CRISPR screen. This approach led to the identification of the RNA helicase DDX42 as an intrinsic inhibitor of HIV-1. Depletion of endogenous DDX42 increased HIV-1 DNA accumulation and infection in cell lines and primary cells, irrespectively of IFN treatment. DDX42 overexpression inhibited HIV-1, whereas a dominant-negative mutant of DDX42 increased infection. Importantly, DDX42 impacted retrotransposition of long interspersed elements-1 (LINE-1), infection with other retroviruses and positive-strand RNA viruses, including Chikungunya virus (CHIKV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, DDX42 did not inhibit infection with negative-strand RNA viruses such as influenza A virus (IAV), arguing against a general, unspecific effect on target cells. Proximity ligation assays showed DDX42 in the vicinity of viral elements during infection, and RNA immunoprecipitation confirmed DDX42 interaction with LINE-1 RNAs. This strongly suggested a direct mode of action of DDX42 on viral ribonucleoprotein complexes. Taken together, our results identify DDX42 as a new, broadly active intrinsic antiviral inhibitor.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.27.354563,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.27.354563,Aglycone polyether ionophores as broad-spectrum agents inhibit multiple enveloped viruses including SARS-CoV-2 in vitro and successfully cure JEV infected mice,Tiangang Liu; Jia-Qi Li; Minjian Huang; Ya-Nan Zhang; Ran Liu; Zhe-Rui Zhang; Qiu-Yan Zhang; Yong Wang; Jing Liu; Zixin Deng; Bo Zhang; Han-Qing Ye; Hugues Parrinello; Stphanie Rialle; Olivier Moncorg; Caroline Goujon; Ronit Rosenfeld; Ron Alcalay; Eran Zahavy; Haim Levy; Itai Glinert; Amir Ben-Shmuel; Tomer Israely; Sharon Melamed; Boaz Politi; Hagit Achdout; Shmuel Yitzhaky; Chanoch Kronman; Tamar Sabo; Alina Renz; Muhammad Naveez; Zsolt Bocskei; Daniela Bornigen; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Wuhan University; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Wuhan university), Ministry of Education, Wuhan University School of Pharmaceutical Sciences; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of ; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Wuhan university), Ministry of Education, Wuhan University School of Pharmaceutical Sciences; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Wuhan University School of Pharmaceutical Sciences; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Montpellier GenomiX; Montpellier GenomiX; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Riga Technical University, Institute of Applied Computer Systems,1 Kalku Street, LV-1658 Riga, Latvia; Sanofi R&D Translational Sciences; Bioinformatics Core Facility, Universitaetsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Infections with zoonotic viruses, such as flaviviruses, influenza virus, and the SARS-CoV-2 pandemic coronavirus constitute an increasing global risk. Hence, an urgent need exists for the development of broad-spectrum antivirals to prevent such outbreaks. Here, we show that the maduramycin and CP-80,219 aglycone polyether ionophores exhibit effective broad-spectrum antiviral activity, against various viruses, including Japanese encephalitis virus (JEV), Dengue virus (DENV), Zika virus (ZIKV), and Chikungunya virus (CHIKV), while also exhibiting promising activity against PR8 influenza virus and SARS-CoV-2. Moreover, liposome-encapsulated maduramycin and CP-80,219 provide full protection for mice from infection with JEV in vivo. Mechanistic studies suggest that aglycone polyether ionophores primarily inhibit the viral replication step without blocking endosome acidification to promote the fusion between viral and cellular membranes. The successful application of liposomes containing aglycone polyether ionophores in JEV-infected mice offers hope to the development of broad-spectrum antiviral drugs like penicillin back to 1940s.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.28.358481,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.358481,Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir,Goran Kokic; Hauke Sven Hillen; Dimitry Tegunov; Christian Dienemann; Florian Seitz; Jana Schmitzova; Lucas Farnung; Aaron Siewert; Claudia Hoebartner; Patrick Cramer; Bo Zhang; Han-Qing Ye; Hugues Parrinello; Stphanie Rialle; Olivier Moncorg; Caroline Goujon; Ronit Rosenfeld; Ron Alcalay; Eran Zahavy; Haim Levy; Itai Glinert; Amir Ben-Shmuel; Tomer Israely; Sharon Melamed; Boaz Politi; Hagit Achdout; Shmuel Yitzhaky; Chanoch Kronman; Tamar Sabo; Alina Renz; Muhammad Naveez; Zsolt Bocskei; Daniela Bornigen; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Max Planck Institute for Biophysical Chemistry; Max Planck Institute for Biophysical Chemistry; Institute for Cellular Biochemistry, University Medical Center, Georg-August-Universitaet Goettingen; Max Planck Institute for Biophysical Chemistry; Max Planck Institute for Biophysical Chemistry; Universitaet Wuerzburg, Lehrstuhl fuer Organische Chemie I; Max Planck Institute for Biophysical Chemistry; Max Planck Institute for Biophysical Chemistry; Universitaet Wuerzburg, Lehrstuhl fuer Organische Chemie I; Universitaet Wuerzburg, Lehrstuhl fuer Organische Chemie I; Max Planck Institute for Biophysical Chemistry; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences; Montpellier GenomiX; Montpellier GenomiX; IRIM, CNRS, Montpellier University; IRIM, CNRS, Montpellier University; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Israel Institute for Biological Research; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Riga Technical University, Institute of Applied Computer Systems,1 Kalku Street, LV-1658 Riga, Latvia; Sanofi R&D Translational Sciences; Bioinformatics Core Facility, Universitaetsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients1-4. The active form of remdesivir acts as a nucleoside analogue and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-25-7. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls6,8. Here we use synthetic RNA chemistry, biochemistry and cryo-electron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3-nucleotide of the RNA product is matched with the template base, and this may prevent proofreading by the viral 3-exonuclease that recognizes mismatches9,10. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication.",biochemistry,exact,100,100
bioRxiv,10.1101/2020.10.28.356667,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.356667,"Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice",Raife Dilek Turan; Cihan Tastan; Derya Dilek Kancagi; Bulut Yurtsever; Gozde Sir Karakus; Samed Ozer; Selen Abanuz; Didem Cakirsoy; Gamze Tumentemur; Sevda Demir; Utku Seyis; Recai Kuzay; Muhammer Elek; Miyase Ezgi Kocaoglu; Gurcan Ertop; Serap Arbak; Merve Acikel Elmas; Cansu Hemsinlioglu; Ozden Hatirnaz Ng; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Animal Application and Research Center, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Histology and Embryology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Histology and Embryology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A, oral polio vaccine, and smallpox proved to be reliable approaches for immunization for prolonged periods. During the pandemic, we produced an inactivated SARS-CoV-2 vaccine candidate, having the advantages of being manufactured rapidly and tested easily in comparison with recombinant vaccines. In this study, an inactivated virus vaccine that includes a gamma irradiation process for the inactivation as an alternative to classical chemical inactivation methods so that there is no extra purification required has been optimized. The vaccine candidate (OZG-38.61.3) was then applied in mice by employing the intradermal route, which decreased the requirement of a higher concentration of inactivated virus for proper immunization, unlike most of the classical inactivated vaccine treatments. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 1013 or 1014 viral copy per dose) of OZG-38.61.3 was initially determined in Balb/c mice. This was followed by testing the immunogenicity and protective efficacy of OZG-38.61.3. Human ACE2-encoding transgenic mice were immunized and then infected with a dose of infective SARS-CoV-2 virus for the challenge test. Findings of this study show that vaccinated mice have lower SARS-CoV-2 viral copy number in oropharyngeal specimens along with humoral and cellular immune responses against the SARS-CoV-2, including the neutralizing antibodies similar to those shown in Balb/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.",immunology,exact,100,100
bioRxiv,10.1101/2020.10.28.357137,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.357137,Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice.,Katarzyna Polak; Nomie Greze; Malle Lachat; Delphine Merle; Steve Chiumento; Christelle Bertrand-Gaday; Bernadette Trentin; Robert Z. Mamoun; Gamze Tumentemur; Sevda Demir; Utku Seyis; Recai Kuzay; Muhammer Elek; Miyase Ezgi Kocaoglu; Gurcan Ertop; Serap Arbak; Merve Acikel Elmas; Cansu Hemsinlioglu; Ozden Hatirnaz Ng; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Ciloa SAS, Montpellier, France; Ciloa SAS, Montpellier, France; Ciloa SAS, Montpellier, France; Ciloa SAS, Montpellier, France; Ciloa SAS, Montpellier, France; DMEM, Univ Montpellier, INRAE, Montpellier, France; Ciloa SAS, Montpellier, France; Ciloa SAS, Montpellier, France; Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Histology and Embryology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Histology and Embryology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Extracellular vesicles (EVs) emerge as essential mediators of intercellular communication. DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice. Thus, EVs may serve as vaccine platforms against emerging diseases, going beyond traditional strategies, with the antigen displayed identically to the original protein embedded in the viral membrane and presented as such to the immune system. Compared to their viral and pseudotyped counterparts, EV-based vaccines overcome many safety issues including pre-existing immunity against these vectors. Here, we applied our technology in natural EVs engineering, to express the S proteins of SARS-CoV-2 embedded in the EVs, which mimic the virus with its fully native spikes. Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants. CoVEVax would be the prototype of vaccines, where the sole exchange of the envelope proteins on EVs leads to the generation of new vaccine candidates against emerging viruses.",immunology,exact,100,100
bioRxiv,10.1101/2020.10.27.358259,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.27.358259,SARS-CoV-2 desensitizes host cells to interferon through inhibition of the JAK-STAT pathway,Da-Yuan Chen; Nazimuddin Khan; Brianna J. Close; Raghuveera K. Goel; Benjamin Blum; Alexander H. Tavares; Devin Kenney; Hasahn L. Conway; Jourdan K. Ewoldt; Sebastian Kapell; Vipul C. Chitalia; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Loyola University; Boston University; Boston University; Boston University; Boston University School of Medicine; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","SARS-CoV-2 can infect multiple organs, including lung, intestine, kidney, heart, liver, and brain. The molecular details of how the virus navigates through diverse cellular environments and establishes replication are poorly defined. Here, we performed global proteomic analysis of the virus-host interface in a newly established panel of phenotypically diverse, SARS-CoV-2-infectable human cell lines representing different body organs. This revealed universal inhibition of interferon signaling across cell types following SARS-CoV-2 infection. We performed systematic analyses of the JAK-STAT pathway in a broad range of cellular systems, including immortalized cell lines and primary-like cardiomyocytes, and found that several pathway components were targeted by SARS-CoV-2 leading to cellular desensitization to interferon. These findings indicate that the suppression of interferon signaling is a mechanism widely used by SARS-CoV-2 in diverse tissues to evade antiviral innate immunity, and that targeting the viral mediators of immune evasion may help block virus replication in patients with COVID-19.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.28.355305,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.355305,5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro,Yasuteru Sakurai; Mya Myat Ngwe Tun; Yohei Kurosaki; Takaya Sakura; Daniel Ken Inaoka; Kiyotaka Fujine; Kiyoshi Kita; Kouichi Morita; Jiro Yasuda; Sebastian Kapell; Vipul C. Chitalia; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; neopharma Japan Co., Ltd.; Nagasaki University; Nagasaki University; Nagasaki University; Boston University; Boston University; Boston University; Boston University; Boston University; Loyola University; Boston University; Boston University; Boston University; Boston University School of Medicine; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is a candidate as an oral antiviral drug for COVID-19.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.28.359257,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.359257,"In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzyme and proteins against a human coronavirus",Alison Green; Glyn Roberts; Timothy Tobery; Carol Vincent; Matteo Barili; Carolyn Jones; Kiyoshi Kita; Kouichi Morita; Jiro Yasuda; Sebastian Kapell; Vipul C. Chitalia; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Unilever Research and Development Port Sunlight, Quarry Road East, Bebington, Wirral, UK, CH63 3JW; Unilever Research and Development Port Sunlight, Quarry Road East, Bebington, Wirral, UK, CH63 3JW; Unilever Research and Development Trumbull, 40 Merritt Boulevard, Trumbull, CT 06611, USA; Unilever Research and Development Trumbull, 40 Merritt Boulevard, Trumbull, CT 06611, USA; Unilever Oral Care, Via Lever Gibbs, 3, Casalpusterlengo, 26841, LO, Italy; Unilever Oral Care, Via Lever Gibbs, 3, Casalpusterlengo, 26841, LO, Italy; Nagasaki University; Nagasaki University; Nagasaki University; Boston University; Boston University; Boston University; Boston University; Boston University; Loyola University; Boston University; Boston University; Boston University; Boston University School of Medicine; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Backgroundsaliva is established to contain high counts SARS-CoV-2 virus and contact with saliva droplets, contaminated surfaces or airborne particles are sources of viral transmission. The generation of infective aerosols during clinical procedures is of particular concern. Therefore, a fuller understanding of the potential of mouthwash to reduce viral counts and modulate the risk of transmission in medical professional and public context is an important research topic.

Methodwe determined the virucidal activity of four anti-bacterial mouthwashes against a surrogate for SARS-CoV-2, Human CoV-SARS 229E, using a standard ASTM suspension test, with dilution and contact times applicable to recommended mouthwash use.

Resultsthe mouthwash formulated with 0.07% Cetylpyridinium Chloride exhibited virucidal effects providing a [&ge;]3.0 log reduction HCoV-229E viral count. Mouthwashes containing 15.7% ethanol, 0.2% zinc sulphate heptahydrate and a mix of enzymes and proteins did not demonstrate substantive virucidal activity in this test.

Conclusionmouthwash containing 0.07% Cetylpyridinium Chloride warrants further laboratory and clinical assessment to determine their potential benefit in reducing the risk of SARS-CoV-2.

HighlightsSARS-CoV-2 can be transmitted through contact with infective saliva.

Studies are needed to understand if mouthwash can lower SARS-CoV-2 transmission risk.

0.07% Cetylpyridinium Chloride (CPC) mouthwash exhibited virucidal effects against HCoV-SARS 229E.

Further studies on potential of 0.07% CPC mouthwash against SARS-CoV-2 are warranted.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.28.358945,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.358945,SARS-CoV-2 replication triggers an MDA-5-dependent interferon production which is unable to efficiently control replication,Antoine Rebendenne; Ana Luiza Chaves Valado; Marine Tauziet; Ghizlane Maarifi; Boris Bonaventure; Rmi Plans; Joe McKellar; Sbastien Nisole; Mary Arnaud-Arnould; Olivier Moncorg; Caroline Goujon; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; CNRS, Montpellier University; Boston University; Boston University; Boston University; Loyola University; Boston University; Boston University; Boston University; Boston University School of Medicine; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic coronavirus to spill over to humans in less than 20 years, after SARS-CoV-1 in 2002-2003 and Middle East respiratory syndrome (MERS)-CoV in 2012. SARS-CoV-2 is the etiologic agent of coronavirus disease 19 (COVID-19), which ranges from mild respiratory symptoms to severe lung injury and death in the most severe cases. The COVID-19 pandemic is currently a major health issue worldwide. Immune dysregulation characterized by altered innate cytokine responses is thought to contribute to the pathology of COVID-19 patients, which is a testimony of the fundamental role of the innate immune response against SARS-CoV-2. Here, we further characterized the host cell antiviral response against SARS-CoV-2 by using primary human airway epithelia and immortalized model cell lines. We mainly focused on the type I and III interferon (IFN) responses, which lead to the establishment of an antiviral state through the expression of IFN-stimulated genes (ISGs). Our results demonstrate that both primary airway epithelial cells and model cell lines elicit a robust immune response characterized by a strong induction of type I and III IFN through the detection of viral pathogen molecular patterns (PAMPs) by melanoma differentiation associated gene (MDA)-5. However, despite the high levels of type I and III IFNs produced in response to SARS-CoV-2 infection, the IFN response was unable to control viral replication, whereas IFN pre-treatment strongly inhibited viral replication and de novo production of infectious virions. Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses.",microbiology,exact,100,100
bioRxiv,10.1101/2020.10.28.359042,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.28.359042,Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models,Xiaoquan Li; Petr Lidsky; Yinghong Xiao; Chien-Ting Wu; Miguel Garcia-Knight; Junjiao Yang; Tsuguhisa Nakayama; Jayakar V. Nayak; Peter K. Jackson; Raul Andino; Xiaokun Shu; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"UCSF; UCSF; UCSF; Stanford; UCSF; UCSF; Stanford; Stanford; Stanford; UCSF; UCSF; Boston University; Boston University; Boston University; Loyola University; Boston University; Boston University; Boston University; Boston University School of Medicine; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","SARS-CoV-2 is the coronavirus that causes the respiratory disease COVID-19, which is now the third-leading cause of death in the United States. The FDA has recently approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though recent data from the WHO shows little to no benefit with use of this anti-viral agent. Here we report the discovery of ethacridine, a safe antiseptic use in humans, as a potent drug for use against SARS-CoV-2 (EC50 ~ 0.08 M). Ethacridine was identified via high-throughput screening of an FDA-approved drug library in living cells using a fluorescent assay. Interestingly, the main mode of action of ethacridine is through inactivation of viral particles, preventing their binding to the host cells. Indeed, ethacridine is effective in various cell types, including primary human nasal epithelial cells. Taken together, these data identify a promising, potent, and new use of the old drug possessing a distinct mode of action for inhibiting SARS-CoV-2.",microbiology,exact,100,100
medRxiv,10.1101/2020.10.27.20220665,2020-10-28,https://medrxiv.org/cgi/content/short/2020.10.27.20220665,ACE2 Netlas: In-silico functional characterization and drug-gene interactions of ACE2 gene network to understand its potential involvement in COVID-19 susceptibility,Gita A Pathak; Frank Wendt; Aranyak Goswami; Flavio De Angelis; - COVID-19 Host Genetics Initiative; Renato Polimanti; Tsuguhisa Nakayama; Jayakar V. Nayak; Peter K. Jackson; Raul Andino; Xiaokun Shu; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Sezer Akyoney; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community; Nicole Zitzmann,"Yale University; Yale School of Medicine; Yale University; Yale Univeristy; ; Yale University; Stanford; Stanford; Stanford; UCSF; UCSF; Boston University; Boston University; Boston University; Loyola University; Boston University; Boston University; Boston University; Boston University School of Medicine; Medical Biology Department, Acibadem Mehmet Ali Aydinlar University Istanbul, Turkey; Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Maslak Hospital, Pathology Laboratory, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Department of Medical Biology, Medical School of Kocaeli University, Kocaeli, Turkey; Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey; Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -; University of Oxford","Angiotensin-converting enzyme-2 (ACE2) receptor has been identified as the key adhesion molecule for the transmission of the SARS-CoV-2. However, there is no evidence that human genetic variation in ACE2 is singularly responsible for COVID-19 susceptibility. Therefore, we performed a multi-level characterization of genes that interact with ACE2 (ACE2-gene network) for their over-represented biological properties in the context of COVID-19.

The phenome-wide association of 51 genes including ACE2 with 4,756 traits categorized into 26 phenotype categories, showed enrichment of immunological, respiratory, environmental, skeletal, dermatological, and metabolic domains (p<4e-4). Transcriptomic regulation of ACE2-gene network was enriched for tissue-specificity in kidney, small intestine, and colon (p<4.7e-4). Leveraging the drug-gene interaction database we identified 47 drugs, including dexamethasone and spironolactone, among others.

Considering genetic variants within {+/-} 10 kb of ACE2-network genes we characterized functional consequences (among others) using miRNA binding-site targets. MiRNAs affected by ACE2-network variants revealed statistical over-representation of inflammation, aging, diabetes, and heart conditions. With respect to variants mapped to the ACE2-network, we observed COVID-19 related associations in RORA, SLC12A6 and SLC6A19 genes.

Overall, functional characterization of ACE2-gene network highlights several potential mechanisms in COVID-19 susceptibility. The data can also be accessed at https://gpwhiz.github.io/ACE2Netlas/",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.10.26.20219352,2020-10-28,https://medrxiv.org/cgi/content/short/2020.10.26.20219352,Pandemic impacts on healthcare utilisation: a systematic review,Ray Moynihan; Sharon Sanders; Zoe A Michaleff; Anna Scott; Justin Clark; Emma J To; Mark Jones; Eliza Kitchener; Melissa Fox; Minna Johansson; Eddy Lang; Anne Duggan; Ian Scott; Loai Albarqouni; Rasha El-Owaidy; Wojciech Feleszko; Vincenzo Fierro; Alessandro Fiocchi; Luis Garcia-Marcos; Anne Goh; Elham M. Hossny; Yunuen R. Huerta Villalobos; Tuomas Jartti; Pascal Le Roux; Julia Levina; Aida Ines Lopez Garcia; Angel Mazon Ramos; Mario Morais Almeida; Clare Murray; Karthik Nagaraju; Major K. Nagaraju; Elsy Maureen Navarrete Rodriguez; Leyla Namazova-Baranova; Antonio Nieto Garcia; Cesar Fireth Pozo Beltran; Thanaporn Ratchataswan; Daniela Rivero Yeverino; Erendira Rodriguez Zagal; Cyril E Schweitzer; Marleena Tulkki; Katarzyna Wasilczuk; Dan XU; - PeARL Collaborators; - PeARL Think Tank,"Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; University of Calgary, 2500 University Drive, Calgary, Alberta, T2N1N4, Canada; Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; Griffith University, Brisbane, Queensland, Australia; Health Consumers Queensland, Level 3, 340 Adelaide St., Brisbane, Queensland, 4000, Australia; Cochrane Sustainable Healthcare Field, Sweden; University of Calgary, 2500 University Drive, Calgary, Alberta, T2N1N4, Canada; Australian Commission on Safety and Quality in Healthcare, Sydney, Australia; Princess Alexander Hospital, 199 Ipswich Rd, Brisbane, Queensland, Australia; Institute for Evidence-Based Healthcare; Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.; Department of Pediatric Pneumonology and Allergy, The Medical University of Warsaw, Warsaw, Poland.; Allergy Department, Bambino Gesu Children  Hospital IRCCS, Roma, Italy.; Allergy Department, Bambino Gesu Children Hospital IRCCS, Roma, Italy.; Pediatric Respiratory and Allergy Units, Virgen de la Arrixaca Children University Clinical Hospital, University of Murcia, Murcia, Spain.  Institute for Biomed; Department of Internal Medicine, Rush Medical College, Chicago.; Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt; Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico.; Department of Pediatrics and Adolescent Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland.; Department of pediatrics, Groupe hospitalier Le Havre, France.; Pediatric and Child Health Research Institute of the Central Clinical Hospital of the Russian Academy of Sciences, Russia.; Allergy and Clinical Immunology Service of the University Hospital of Puebla, Mexico.; Pediatric Pulmonology & Allergy Unit Children Hospital la Fe, Valencia, Spain.; Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.; VN Allergy & Asthma Research Centre, Chennai, Tamilnadu, India.; Professor & Head, Department of Allergy & Clinical Immunology, Saveetha Medical College, Chennai, India.; Pediatric Allergy and Clinical Immunology Service, Hospital Infantil, til de Mexico Federico Gomez, Mexico.; Pediatric and Child Health Research Institute of the Central Clinical Hospital of the Russian Academy of Sciences, Russia. Pirogov Russian National Research Med; Pediatric Pulmonology & Allergy Unit Children Hospital la Fe, Valencia, Spain.; Teaching and Research Department and Paediatric Allergy department, Hospital with Specialties Juan Maria de Salvatierra, La Paz, Baja California Sur Mexico.  Al; Department of Allergy and Immunology, Boston Children Hospital, Boston, Massachusetts, USA.; Allergy and Clinical Immunology Department, Hospital Universitario de Puebla, Puebla, Mexico.; Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico.; CHRU de Nancy, Hopital d Enfants, Rue du Morvan, 54511 Vandoeuvre, France.; Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.; Department of Pediatric Pneumonology and Allergy, The Medical University of Warsaw, Warsaw, Poland; Department of pulmonology, the children hospital, Zhejiang University school of medicine, national clinical research center for child health, Hangzhou, Zhejiang; ; ","ObjectivesTo determine the extent and nature of changes in utilisation of healthcare services during COVID-19 pandemic.

DesignSystematic review

EligibilityEligible studies compared utilisation of services during COVID-19 pandemic to at least one comparable period in prior years. Services included visits, admissions, diagnostics, and therapeutics. Studies were excluded if from single-centres or studied only COVID-19 patients.

Data sourcesPubMed, Embase, Cochrane COVID-19 Study Register, and pre-prints were searched, without language restrictions, until August 10, using detailed searches with key concepts including COVID-19, health services and impact.

Data analysisRisk of bias was assessed by adapting ROBINS-I and Cochrane Effective Practice and Organization of Care tool. Results were analysed using descriptive statistics, graphical figures, and narrative synthesis.

Outcome measuresPrimary outcome was change in service utilisation between pre-pandemic and pandemic periods. Secondary outcome was the change in proportions of users of healthcare services with milder or more severe illness (e.g. triage scores).

Results3097 unique references were identified, and 81 studies across 20 countries included, reporting on >11 million services pre-pandemic and 6.9 million during pandemic. For the primary outcome, there were 143 estimates of changes, with a median 37% reduction in services overall (interquartile range -51% to -20%), comprising median reductions for visits of 42%(-53% to -32%), admissions, 28%(-40% to -17%), diagnostics, 31%(-53% to -24%), and for therapeutics, 30%(-57% to -19%). Among 35 studies reporting secondary outcomes, there were 60 estimates, with 27(45%) reporting larger reductions in utilisation among people with a milder spectrum of illness, and 33 (55%) reporting no change.

ConclusionsHealthcare utilisation decreased by about a third during the pandemic, with considerable variation, and with greater reductions among people with less severe illness. While addressing unmet need remains a priority, studies of health impacts of reductions may help health-systems prioritise higher-value care in the post-pandemic recovery.

Funding, Study registrationNo funding was required. PROSPERO: CRD42020203729

Strengths and limitations of this study- The review is the first broad synthesis of global studies of pandemic related changes in utilisation across all categories of healthcare services.
- The review provides novel findings informing design of future studies of pandemic-related changes in utilisation and its impacts.
- Limitations include the possibility of publication bias and the potential of our eligibility criteria to exclude important data sources such as studies in single-centres and unpublished datasets from health systems.
- Heterogenous designs and settings precluding meta-analysis.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.10.27.20220566,2020-10-28,https://medrxiv.org/cgi/content/short/2020.10.27.20220566,Prevalence and outcomes of co-infection and super-infection with SARS-CoV-2 and other pathogens: A Systematic Review and Meta-analysis,Jackson Ssentalo Musuuza; Lauren Watson; Vishala Parmasad; Nathan Putman-Buehler; Leslie Christensen; Nasia Safdar; Mark Jones; Eliza Kitchener; Melissa Fox; Minna Johansson; Eddy Lang; Anne Duggan; Ian Scott; Loai Albarqouni; Rasha El-Owaidy; Wojciech Feleszko; Vincenzo Fierro; Alessandro Fiocchi; Luis Garcia-Marcos; Anne Goh; Elham M. Hossny; Yunuen R. Huerta Villalobos; Tuomas Jartti; Pascal Le Roux; Julia Levina; Aida Ines Lopez Garcia; Angel Mazon Ramos; Mario Morais Almeida; Clare Murray; Karthik Nagaraju; Major K. Nagaraju; Elsy Maureen Navarrete Rodriguez; Leyla Namazova-Baranova; Antonio Nieto Garcia; Cesar Fireth Pozo Beltran; Thanaporn Ratchataswan; Daniela Rivero Yeverino; Erendira Rodriguez Zagal; Cyril E Schweitzer; Marleena Tulkki; Katarzyna Wasilczuk; Dan XU; - PeARL Collaborators; - PeARL Think Tank,"William S. Middleton Memorial Veterans Hospital; Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Ebling Library for the Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD, 4229, Australia; Griffith University, Brisbane, Queensland, Australia; Health Consumers Queensland, Level 3, 340 Adelaide St., Brisbane, Queensland, 4000, Australia; Cochrane Sustainable Healthcare Field, Sweden; University of Calgary, 2500 University Drive, Calgary, Alberta, T2N1N4, Canada; Australian Commission on Safety and Quality in Healthcare, Sydney, Australia; Princess Alexander Hospital, 199 Ipswich Rd, Brisbane, Queensland, Australia; Institute for Evidence-Based Healthcare; Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.; Department of Pediatric Pneumonology and Allergy, The Medical University of Warsaw, Warsaw, Poland.; Allergy Department, Bambino Gesu Children  Hospital IRCCS, Roma, Italy.; Allergy Department, Bambino Gesu Children Hospital IRCCS, Roma, Italy.; Pediatric Respiratory and Allergy Units, Virgen de la Arrixaca Children University Clinical Hospital, University of Murcia, Murcia, Spain.  Institute for Biomed; Department of Internal Medicine, Rush Medical College, Chicago.; Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt; Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico.; Department of Pediatrics and Adolescent Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland.; Department of pediatrics, Groupe hospitalier Le Havre, France.; Pediatric and Child Health Research Institute of the Central Clinical Hospital of the Russian Academy of Sciences, Russia.; Allergy and Clinical Immunology Service of the University Hospital of Puebla, Mexico.; Pediatric Pulmonology & Allergy Unit Children Hospital la Fe, Valencia, Spain.; Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.; VN Allergy & Asthma Research Centre, Chennai, Tamilnadu, India.; Professor & Head, Department of Allergy & Clinical Immunology, Saveetha Medical College, Chennai, India.; Pediatric Allergy and Clinical Immunology Service, Hospital Infantil, til de Mexico Federico Gomez, Mexico.; Pediatric and Child Health Research Institute of the Central Clinical Hospital of the Russian Academy of Sciences, Russia. Pirogov Russian National Research Med; Pediatric Pulmonology & Allergy Unit Children Hospital la Fe, Valencia, Spain.; Teaching and Research Department and Paediatric Allergy department, Hospital with Specialties Juan Maria de Salvatierra, La Paz, Baja California Sur Mexico.  Al; Department of Allergy and Immunology, Boston Children Hospital, Boston, Massachusetts, USA.; Allergy and Clinical Immunology Department, Hospital Universitario de Puebla, Puebla, Mexico.; Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico.; CHRU de Nancy, Hopital d Enfants, Rue du Morvan, 54511 Vandoeuvre, France.; Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.; Department of Pediatric Pneumonology and Allergy, The Medical University of Warsaw, Warsaw, Poland; Department of pulmonology, the children hospital, Zhejiang University school of medicine, national clinical research center for child health, Hangzhou, Zhejiang; ; ","IntroductionThe recovery of other respiratory viruses in patients with SARS-CoV-2 infection has been reported, either at the time of a SARS-CoV-2 infection diagnosis (co-infection) or subsequently (superinfection). However, data on the prevalence, microbiology and outcomes of co-infection and super infection are limited. The purpose of this study was to examine occurrence of respiratory co-infections and superinfections and their outcomes among patients with SARS-CoV-2 infection.

Patients and MethodsWe searched literature databases for studies published from October 1, 2019, through June 11, 2020. We included studies that reported clinical features and outcomes of co-infection or super-infection of SARS-CoV-2 and other pathogens in hospitalized and non-hospitalized patients. We followed PRISMA guidelines and we registered the protocol with PROSPERO as: CRD42020189763.

ResultsOf 1310 articles screened, 48 were included in the random effects meta-analysis. The pooled prevalence of co-infection was 12% (95% confidence interval (CI): 6%-18%, n=29, I2=98%) and that of super-infection was 14% (95% CI: 9%-21%, n=18, I2=97%). Pooled prevalence of pathogen type stratified by co- or super-infection: viral co-infections, 4% (95% CI: 2%-7%); viral super-infections, 2% (95% CI: 0%-7%); bacterial co-infections, 4% (95% CI: 1%-8%); bacterial super-infections, 6% (95% CI: 2%-11%); fungal co-infections, 4% (95% CI: 1%-8%); and fungal super-infections, 4% (95% CI: 0%-11%). Compared to those with co-infections, patients with super-infections had a higher prevalence of mechanical ventilation [21% (95% CI: 13%-31%) vs. 7% (95% CI: 2%-15%)] and greater average length of hospital stay [mean=12.5 days, standard deviation (SD) =5.3 vs. mean=10.2 days, SD= 6.7].

ConclusionsOur study showed that as many as 14% of patients with COVID-19 have super-infections and 12% have co-infections. Poor outcomes were associated with super-infections. Our findings have implications for diagnostic testing and therapeutics, particularly in the upcoming respiratory virus season in the Northern Hemisphere.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.25.20219048,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.25.20219048,Viral load in community SARS-CoV-2 cases varies widely and temporally,Ann Sarah Walker; Emma Pritchard; Thomas House; Julie V Robotham; Paul J Birrell; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Jodie Hay; Karina-Doris Vihta; Timothy EA Peto; Nicole Stoesser; Philippa C Matthews; David W Eyre; Koen Pouwels; - the COVID-19 Infection Survey team; Alexander Watts; Isaac I. Bogoch; Kamran Khan; - COG-UK consortium; David Aanensen; Moritz U.G. Kraemer; Andrew Rambaut; Oliver Pybus,"University of Oxford; University of Oxford; University of Manchester; Public Health England; Public Health England; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Glasgow; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto; University of Toronto; University of Toronto; ; University of Oxford; University of Oxford; University of Edinburgh; University of Oxford","BackgroundInformation on COVID-19 in representative community surveillance is limited, particularly regarding cycle threshold (Ct) values (a proxy for SARS-CoV-2 viral load) and symptoms.

MethodsWe included all positive nose and throat swabs between 26 April-11 October 2020 from the UKs national COVID-19 Infection Survey, tested by RT-PCR for the N, S and ORF1ab genes. We investigated predictors of median Ct value using quantile regression.

Results1892(0.22%) of 843,851 results were positive, 1362(72%), 185(10%) and 345(18%) for 3, 2 or 1 genes respectively. Ct for different genes were strongly correlated (rho=0.99) with overall median Ct 26.2 (IQR 19.7-31.1; range 10.3-37.6), corresponding to [~]2,500 dC/ml (IQR 80-240,000). Ct values were independently lower in those reporting symptoms, with more genes detected, and in first (vs. subsequent) positives per-participant, with no evidence of independent effects of sex, ethnicity, age, deprivation or other test characteristics (p>0.20). Whilst single-gene positives without reported symptoms almost invariably had Ct>30, triple-gene positives without reported symptoms had widely varying Ct. Incorporating pre-test probability and Ct values, 1547(82%) and 112(6%) positives had ""higher"" or ""lower"" supporting evidence for genuine infection. Ct values, symptomatic percentages and supporting evidence changed over time. With lower positivity in the summer, there were proportionally more ""lower"" evidence positives, and ""higher"" evidence positives had higher Ct values (p<0.0001), suggesting lower viral burden. Declines in mean/median Ct values were apparent throughout August and preceded increases in positivity rates.

ConclusionsCommunity SARS-CoV-2 infections show marked variation in viral load. Ct values could be a useful epidemiological early-warning indicator.

SUMMARYCycle threshold (Ct) values in community SARS-CoV-2 infections from national surveillance vary markedly, including over time and by symptoms (1892 (0.22%) positive nose and throat swabs, 843,851 tested). Ct values could be a useful epidemiological early warning indicator.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.25.20219147,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.25.20219147,Fluctuating High Throughput Serological Assay Results in Recurrent Convalescent Plasma Donors,Larry L Luchsinger; Shiraz Rehmani; Andrew Opalka; Donna Strauss; Christopher D Hillyer; Patricia Shi; Bruce S Sachais; John N Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Jodie Hay; Karina-Doris Vihta; Timothy EA Peto; Nicole Stoesser; Philippa C Matthews; David W Eyre; Koen Pouwels; - the COVID-19 Infection Survey team; Alexander Watts; Isaac I. Bogoch; Kamran Khan; - COG-UK consortium; David Aanensen; Moritz U.G. Kraemer; Andrew Rambaut; Oliver Pybus,"New York Blood Center; New York Blood Center; New York Blood Center; New York Blood Center; New York Blood Center; New York Blood Center; New York Blood Center; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Glasgow; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto; University of Toronto; University of Toronto; ; University of Oxford; University of Oxford; University of Edinburgh; University of Oxford","The clinical and scientific communities rely on serology testing to analyze the degree of antibody-mediated immunity afforded to recovered patients from SARS-CoV-2 infection. Neutralizing antibodies present in COVID-19 convalescent plasma (CCP) remains a practical therapy to treat COVID-19 patients requiring hospitalization. However, it remains unclear how long antibody levels persist in CCP donors after recovery. An accurate estimation of antibody kinetics in CCP donors provide an important observation to further define the extent of long-term immunity in recovered patient and simultaneously inform CCP collection processes in efforts to improve CCP dosing and therapeutic outcome. In this study, we analyzed 63 donors and measured antibody levels using two high throughput screening assays (HTSA) designed to detect antibodies targeting the spike protein (S1) and nucleocapsid protein (NP) of SARS-CoV-2 and monitored antibody levels between 2-8 consecutive donations. We show that anti-S1 antibody levels, as measured using the Ortho Total Ig HTSA, increased over time in repeat CCP donors while anti-NP antibody levels, as measured using the Abbott IgG HTSA, were unchanged or decreased over time. When we normalized these data, we found that both the absolute levels of anti-S1 antibodies and the ratio between S1 and NP antibodies tends to increase over time. These data have important implications for the convalescent donation process, patient protection from future infection and characterization of the SARS-CoV-2 immune response.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.26.20219428,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219428,Community prevalence of SARS-CoV-2 in England during April to September 2020: Results from the ONS Coronavirus Infection Survey,Koen B Pouwels; Thomas House; Emma Pritchard; Julie V Robotham; Paul Birrell; Andrew Gelman; Karina-Doris Vihta; Nikola Bowers; Ian Boreham; Heledd Thomas; James Lewis; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Ann Sarah Walker; RAKHI MAIWALL; Shiv K Sarin,University of Oxford; University of Manchester; University of Oxford; Public Health England; Public Health England; Columbia University; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; INSTITUTE OF LIVER AND BILIARY SCIENCES; Institute of Liver and Biliary Sciences (ILBS),"BackgroundDecisions regarding the continued need for control measures to contain the spread of SARS-CoV-2 rely on accurate and up-to-date information about the number of people and risk factors for testing positive. Existing surveillance systems are not based on population samples and are generally not longitudinal in design.

MethodsFrom 26 April to 19 September2020, 514,794 samples from 123,497 individuals were collected from individuals aged 2 years and over from a representative sample of private households from England. Participants completed a questionnaire and nose and throat swab were taken. The percentage of individuals testing positive for SARS-CoV-2 RNA was estimated over time using dynamic multilevel regression and post-stratification, to account for potential residual non-representativeness. Potential changes in risk factors for testing positive over time were also evaluated using multilevel regression models.

FindingsBetween 26 April and 19 September 2020, in total, results were available from 514,794 samples from 123,497 individuals, of which 489 were positive overall from 398 individuals. The percentage of people testing positive for SARS-CoV-2 changed substantially over time, with an initial decrease between end of April and June, followed by low levels during the summer, before marked increases end of August and September 2020. Having a patient-facing role and working outside your home were important risk factors for testing positive in the first period but not (yet) in the second period of increased positivity rates, and age (young adults) being an important driver of the second period of increased positivity rates. A substantial proportion of infections were in individuals not reporting symptoms (53%-70%, dependent on calendar time).

InterpretationImportant risk factors for testing positive varied substantially between the initial and second periods of higher positivity rates, and a substantial proportion of infections were in individuals not reporting symptoms, indicating that continued monitoring for SARS-CoV-2 in the community will be important for managing the epidemic moving forwards.

FundingThis study is funded by the Department of Health and Social Care. KBP, ASW, EP and JVR are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). AG is supported by U.S. National Institute of Health and Office of Naval Research. ASW is also supported by the NIHR Oxford Biomedical Research Centre and by core support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_12023/22] and is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health, or PHE.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSUnprecedented control measures, such as national lockdowns, have been widely implemented to contain the spread of SARS-CoV-2. Decisions regarding the continued need for social distancing measures in the overall population, specific subgroups and geographic areas heavily rely on accurate and up-to-date information about the number of people and risk factors for testing positive. We searched PubMed and medRxiv and bioRxiv preprint servers up to 6 June 2020 for epidemiological studies using the terms ""SARS-CoV-2"" and ""prevalence"" or ""incidence"" without data or language restrictions. Most studies were small or had only information about current presence of the virus for a small subset of patients, or used data not representative of the community, such as hospital admissions, deaths or self-reported symptoms. Large population-based studies, such as the current study, are required to understand risk factors and the dynamics of the epidemic.

Added value of this studyThis is the first longitudinal community survey of SARS-CoV-2 infection at national and regional levels in the UK. With more than 500,000 swabs from more than 120,000 individuals this study provides robust evidence that the percentage of individuals from the general community in England testing positive for SARS-CoV-2 clearly declined between end of April and June 2020,, followed by consistently low levels during the summer, before marked increases end of August and September 2020. Risk factors for testing positive varied substantially between the initial and second periods of higher positivity rates, with having a patient-facing role and working outside your home being important risk factors in the first period but not (yet) in the second period, and age (young adults) being an important driver of the second period of increased positivity rates. Positive tests commonly occurred without symptoms being reported.

Implications of all the available evidenceThe observed decline in the percentage of individuals testing positive adds to the increasing body of empirical evidence and theoretical models that suggest that the lockdown imposed on 23 March 2020 in England was associated, at least temporarily, with a decrease in infections. Important risk factors for testing positive varied substantially between the initial and second periods of higher positivity rates, and a substantial proportion of infections were in individuals not reporting symptoms, indicating that continued monitoring for SARS-CoV-2 in the community will be important for managing the epidemic moving forwards.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.26.20219576,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219576,Impact of the COVID-19 pandemic on remote mental healthcare and prescribing in psychiatry,Rashmi Patel; Jessica Irving; Aimee Brinn; Matthew Broadbent; Hitesh Shetty; Megan Pritchard; Johnny Downs; Robert Stewart; Robert Harland; Philip McGuire; David A Drew; Long H Nguyen; Tove Fall; Maria F Gomez; Paul W Franks; Andrew T Chan; Richard Davies; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; Massachusetts General Hospital; Massachusetts General Hospital; Uppsala University; Lund University; Lund University; Massachusetts General Hospital; Zoe Global Limited; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","ObjectivesThe recent COVID-19 pandemic has disrupted mental healthcare delivery, with many services shifting from in- person to remote patient contact. We investigated the impact of the pandemic on the use of remote consultation and on the prescribing of psychiatric medications.

Design and settingThe Clinical Record Interactive Search tool (CRIS) was used to examine de-identified electronic health records (EHRs) of people receiving mental healthcare from the South London and Maudsley (SLaM) NHS Foundation Trust. Data from the period before and after the onset of the pandemic were analysed using linear regression, and visualised using locally estimated scatterplot smoothing (LOESS).

ParticipantsAll patients receiving care from SLaM between 7th January 2019 and 20th September 2020 (around 37,500 patients per week).

Outcome measuresO_LIThe number of clinical contacts (in-person, remote or non-attended) with mental healthcare professionals per week
C_LIO_LIPrescribing of antipsychotic and mood stabiliser medications per week
C_LI

ResultsFollowing the onset of the pandemic, the frequency of in-person contacts was significantly reduced compared to that in the previous year ({beta} coefficient: -5829.6 contacts, 95% CI -6919.5 to -4739.6, p<0.001), while the frequency of remote contacts significantly increased ({beta} coefficient: 3338.5 contacts, 95% CI 3074.4 to 3602.7, p<0.001). Rates of remote consultation were lower in older adults than in working age adults, children and adolescents. Despite this change in the type of patient contact, antipsychotic and mood stabiliser prescribing remained at similar levels.

ConclusionsThe COVID-19 pandemic has been associated with a marked increase in remote consultation, particularly among younger patients. However, there was no evidence that this has led to changes in psychiatric prescribing. Nevertheless, further work is needed to ensure that older patients are able to access mental healthcare remotely.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.10.26.20219634,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219634,Who is (Not) Complying with the Social Distancing Directive and Why? Testing a General Framework of Compliance with Multiple Measures of Social Distancing,Russell H. Fazio; Benjamin C. Ruisch; Courtney A. Moore; Javier A. Granados Samayoa; Shelby T. Boggs; Jesse T. Ladanyi; Johnny Downs; Robert Stewart; Robert Harland; Philip McGuire; David A Drew; Long H Nguyen; Tove Fall; Maria F Gomez; Paul W Franks; Andrew T Chan; Richard Davies; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"The Ohio State University; The Ohio State University; The Ohio State University; The Ohio State University; The Ohio State University; The Ohio State University; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; Massachusetts General Hospital; Massachusetts General Hospital; Uppsala University; Lund University; Lund University; Massachusetts General Hospital; Zoe Global Limited; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","A study involving over 2000 online participants tested a general framework regarding compliance with a directive in the context of the COVID-19 pandemic. The study featured not only a self-report measure of social distancing but also behavioral measures -- simulations that presented participants with graphical depictions mirroring multiple real-world scenarios and asked them to position themselves in relation to others in the scene. The conceptual framework highlights three essential components of a directive: (1) the source, some entity is advocating for a behavioral change; (2) the surrounding context, the directive is in response to some challenge; and (3) the target, the persons to whom the directive is addressed. Belief systems relevant to each of these three components are predicted, and were found, to relate to compliance with the social distancing directive. The implications of the findings for public service campaigns encouraging people to engage in social distancing are discussed.",public and global health,exact,100,100
medRxiv,10.1101/2020.10.25.20219279,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.25.20219279,Inconsistent with the intent of public health strategies on incidence and fatality in states with extra mandatory stay-at-home and face masks orders during COVID-19 pandemic in the US,Samuel Xi Wu; Xin Wu; Courtney A. Moore; Javier A. Granados Samayoa; Shelby T. Boggs; Jesse T. Ladanyi; Johnny Downs; Robert Stewart; Robert Harland; Philip McGuire; David A Drew; Long H Nguyen; Tove Fall; Maria F Gomez; Paul W Franks; Andrew T Chan; Richard Davies; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"Department of Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX 77807; Texas A&M Health Science Center College of Medicine; The Ohio State University; The Ohio State University; The Ohio State University; The Ohio State University; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; Massachusetts General Hospital; Massachusetts General Hospital; Uppsala University; Lund University; Lund University; Massachusetts General Hospital; Zoe Global Limited; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","In addition to the United States CDC recommendations, many states imposed stay-at-home (SAH) and mandatory face mask (MFM) orders during COVID-19 pandemic. The purpose of this study was to characterize the relationship between SAH and MFM approaches with the incidence and fatality during the pandemic period until the 2020-08-23 (about 171 days). States with SAH orders showed potential decreases of infection and fatality during SAH period (about 45 days). However, many results in this study were inconsistent with the intent of public health strategies of SAH and MFM. There were similar incidence rates among SAH + MFM, SAH + no-MFM and no-SAH + no-MFM states. After normalized to population density, there were no significant differences in total positive cases, average daily new cases and average daily fatality among the 3 groups during the pandemic period. This study suggested that SAH and MFM orders in the general public alone, probably have limited effects in lowering transmission and fatality. From the policy-making level, if we cannot strictly isolate contagious patients with effective contact tracing, we presume that following the CDC recommendations could be appropriate in helping mitigate the COVID-19 disaster and limiting collateral social-economic damage with close monitoring of healthcare capacity.",public and global health,exact,100,100
medRxiv,10.1101/2020.10.26.20219550,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219550,Human movement can inform the spatial scale of interventions against COVID-19 transmission,Hamish Gibbs; Emily Nightingale; Yang Liu; James Cheshire; Leon Danon; Liam Smeeth; Carl AB Pearson; Chris Grundy; - LSHTM CMMID COVID-19 Working Group; Adam J Kucharski; Rosalind M Eggo; Yanni Xiao; Guihua Zhuang; Alexis Zebrowski; Brendan G. Carr; Yan Li; Lei Zhang; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; University of Exeter; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Xi'an Jiaotong University; Xi'an Jiaotong University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","The UK enacted an intensive, nationwide lockdown on March 23 2020 to mitigate transmission of COVID-19. As restrictions began to ease, resurgence in transmission has been targeted by geographically-limited interventions of various stringencies. Determining the optimal spatial scale for local interventions is critical to ensure interventions reach the most at risk areas without unnecessarily restricting areas at low risk of resurgence. Here we use detailed human mobility data from Facebook to determine the spatially-explicit network community structure of the UK before and during the lockdown period, and how that has changed in response to the easing of restrictions and to locally-targeted interventions. We found that the mobility network became more sparse and the number of mobility communities decreased under the national lockdown. During this period, there was no evidence of re-routing in the network. Communities in which locally-targeted interventions have happened following resurgence did not show reorganization but did show small decreases in measurable mobility effects in the Facebook dataset. We propose that geographic communities detected in Facebook or other mobility data be part of decision making for determining the spatial extent or boundaries of interventions in the UK. These data are available in near real-time, and allow quantification of changes in the distribution of the population across the UK, as well as peoples travel patterns to give data-driven metrics for geographically-targeted interventions.

Significance StatementLarge-scale intensive interventions in response to the COVID-19 pandemic have affected human movement patterns. Mobility data show spatially-explicit network structure, but it is not clear if that structure changed in response to national or locally-targeted interventions. We used daily Facebook for Good mobility data to quantify changes in the travel network in the UK during the national lockdown, and in response to local interventions. The network community structure inherent in these networks can help quantify which areas are at risk of resurgence, or the extent of locally-targeted interventions aiming to suppress transmission. We showed that spatial mobility data available in real-time can give information on connectivity that can be used to optimise the scale of geographically-targeted interventions.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.26.20219683,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219683,PREVALENCE OF MOLECULAR AND SEROLOGICAL TESTS OF THE NEW CORONAVIRUS (SARS-CoV-2) IN CARLOS CHAGAS-SABIN LABORATORIES IN CUIABA,Cristiane Coimbra de Paula; Joao Pedro Castoldo Passos; Walkiria Shimoya Bittencour IV; Caroline Aquino Vieira de Lamare II; Ruberlei Godinho de Oliveira Sr.; Liam Smeeth; Carl AB Pearson; Chris Grundy; - LSHTM CMMID COVID-19 Working Group; Adam J Kucharski; Rosalind M Eggo; Yanni Xiao; Guihua Zhuang; Alexis Zebrowski; Brendan G. Carr; Yan Li; Lei Zhang; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"Centro Universitario de Varzea Grande (Univag) e Universidade Federal de Mato Grosso (UFMT)-Cuiaba-MT-Brasil; Centro Universitario de Varzea Grande (Univag)-MT-Brasil; Universidade de Cuiaba (UNIC), Cuiaba, Mato Grosso, Brasil.; a P Graduate program in Sciences Applied to Hospital Care, Hospital Universitario Julio Muller (HUJM), Cuiaba, MT, Brazil.; a P Graduate program in Sciences Applied to Hospital Care, Hospital Universitario Julio Muller (HUJM); London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Xi'an Jiaotong University; Xi'an Jiaotong University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","BACKGROUNDCOVID-19, the disease caused by the new coronavirus (SARS-CoV-2), became a pandemic in 2020 with mortality rate of 2% and high transmissibility, which makes studies with an epidemiological profile essential.

OBJECTIVESTo characterize the population that performed the SARS-CoV-2 molecular and serological tests in Carlos Chagas-Sabin laboratories in Cuiaba.

METHODSA retrospective cross-sectional study was carried out with all the samples collected from nasal swab tested by RT-PCR and serological for SARM-CoV-2 IgM / IgG from the population served between April and July 2020.

FINDINGSIn the analyzed period, 11,113 PCR-Covid-19 exams were registered. Of this total of cases, 3,912 (35.20%) tested positive, while 6,889 (61.90%) did not detect viral RNA and 312 (2.80%) of the visits resulted as undetermined. The peak of positive RT-PCR performed in July (n = 5878), with 35.65% (n = 2096). A total of 6,392 tests performed on SOROVID-19, with a peak of 1161 (18.16%) of the positive tests for SARS-CoV-2 in July.

MAIN CONCLUSIONSMolecular positivity and serological tests, both peaked in July 2020, were mostly present in women aged 20-39, characterizing Cuiaba as the epicenter of the Midwest region in this period due to the high rate of transmissibility of SARS-CoV-2.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.26.20219626,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219626,Hyper-Exponential Growth of COVID-19 during Resurgence of the Disease in Russia,Hemanta Kumar Baruah; Joao Pedro Castoldo Passos; Walkiria Shimoya Bittencour IV; Caroline Aquino Vieira de Lamare II; Ruberlei Godinho de Oliveira Sr.; Liam Smeeth; Carl AB Pearson; Chris Grundy; - LSHTM CMMID COVID-19 Working Group; Adam J Kucharski; Rosalind M Eggo; Yanni Xiao; Guihua Zhuang; Alexis Zebrowski; Brendan G. Carr; Yan Li; Lei Zhang; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"The Assam Royal Global University; Centro Universitario de Varzea Grande (Univag)-MT-Brasil; Universidade de Cuiaba (UNIC), Cuiaba, Mato Grosso, Brasil.; a P Graduate program in Sciences Applied to Hospital Care, Hospital Universitario Julio Muller (HUJM), Cuiaba, MT, Brazil.; a P Graduate program in Sciences Applied to Hospital Care, Hospital Universitario Julio Muller (HUJM); London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Xi'an Jiaotong University; Xi'an Jiaotong University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","In Russia, COVID-19 has currently been growing hyper-exponentially. This type of a spread pattern was not seen during the first wave of the pandemic the world over. Indeed when the disease had first appeared, in the accelerating stage the spread pattern was observed to have followed a highly nonlinear pattern that could be said to be approximately exponential or sub-exponential. As to why in the resurgence the growth has become hyper-exponential is another matter. But this has been happening in Europe and how long this would continue cannot be predicted. It may so happen that in the countries in which retardation has already been taking place, there may be resurgence of the disease. It was observed that in the World as a whole, retardation was on the threshold during the second half of September. But if the resurgence happens to follow the hyper-exponential growth pattern in different countries, there may be resurgence in the World as a whole.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.22.20184630,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.22.20184630,COVID-19 infections following outdoor mass gatherings in low incidence areas: retrospective cohort study,Oren Miron; Kun-Hsing Yu; Rachel Wilf-Miron; Nadav Davidovich; Ruberlei Godinho de Oliveira Sr.; Liam Smeeth; Carl AB Pearson; Chris Grundy; - LSHTM CMMID COVID-19 Working Group; Adam J Kucharski; Rosalind M Eggo; Yanni Xiao; Guihua Zhuang; Alexis Zebrowski; Brendan G. Carr; Yan Li; Lei Zhang; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"Ben Gurion University; Harvard Medical School; Tel Aviv University; Ben Gurion University; a P Graduate program in Sciences Applied to Hospital Care, Hospital Universitario Julio Muller (HUJM); London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Xi'an Jiaotong University; Xi'an Jiaotong University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","ObjectiveIndoor mass gatherings in counties with high COVID-19 incidence have been linked to infections. We examined if outdoor mass gatherings in counties with low COVID-19 incidence are also followed by infections.

MethodsWe retrospectively examined COVID-19 incidence in 20 counties that held mass gathering rallies (19 outdoor and 1 indoor) in the United States in August-September 2020. They were compared to the rest of the United States counties. We utilized a 7-day moving average and compared the change on the gathering date and 15 days later, based on the 95% confidence interval. For control counties we used the median of the gathering dates.

SettingThe United States

Population8.4 million in the counties holding mass gatherings, and 324 Million in the rest of the counties in the United States.

Main Outcome MeasureChange in COVID-19 incidence rate per 100,000 capita during the two weeks following mass gatherings.

ResultsIn the two weeks following the gatherings, the COVID-19 incidence increased significantly in 14 of 20 counties. The county with the highest incidence increase (3.8-fold) had the 2nd lowest incidence before the gathering. The county with the highest decrease (0.4-fold) had the 3rd highest incidence before the gathering. At the gathering date, the average incidence of counties with gatherings was lower than the rest of the United States, and after the gathering, it increased 1.5-fold, while the rest of the United States increased 1.02-fold.

ConclusionThese results suggest that even outdoor gatherings in areas with low COVID-19 incidence are followed by increased infections, and that further precautions should be taken at such gatherings.

What is already known on the topicMass gatherings have been linked to COVID-19 infections, but it is less clear how much it happens outdoors, and in areas with low incidence.

What this study addsCOVID-19 infections increased significantly in 14 of 20 counties that held mass gathering rallies in the United States, 19 of which were outdoors. The county with the highest incidence increase (3.8-fold) was outdoors and had a low incidence before the gathering. The average incidence of all 20 counties with gatherings was lower at the gathering day compared with the rest of the United State, and it increased 1.5-fold following the gatherings. Our findings suggest a need for precautions in mass gatherings, even when outdoors and in areas with a low incidence of COVID-19.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.26.20219972,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219972,Development of Multiplexed RT-LAMP for Detection of SARS-CoV-2 and Influenza Viral RNA,Yinhua Zhang; Nathan A Tanner; Rachel Wilf-Miron; Nadav Davidovich; Ruberlei Godinho de Oliveira Sr.; Liam Smeeth; Carl AB Pearson; Chris Grundy; - LSHTM CMMID COVID-19 Working Group; Adam J Kucharski; Rosalind M Eggo; Yanni Xiao; Guihua Zhuang; Alexis Zebrowski; Brendan G. Carr; Yan Li; Lei Zhang; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz,"New England Biolabs; New England Biolabs; Tel Aviv University; Ben Gurion University; a P Graduate program in Sciences Applied to Hospital Care, Hospital Universitario Julio Muller (HUJM); London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Xi'an Jiaotong University; Xi'an Jiaotong University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Xi'an Jiaotong University; Zoe Global Limited; King's College London; King's College London; King's College London; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France; Unit of Cell Biology and Cancer, Institut Curie; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.","The ongoing COVID-19 pandemic has demonstrated the utility of widespread molecular testing for surveillance and diagnostic detection of SARS-CoV-2. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) has enabled testing outside of the standard clinical laboratory PCR infrastructure, with simple and rapid tests supplementing the existing, standard methods. However, current LAMP tests have detected single targets and required separate reactions for controls or multiple targets. As flu season arrives in the Northern Hemisphere the ability to screen for multiple viral targets will be increasingly important, and the ability to include internal control assays in the RT-LAMP test allows for decreased resource use and increased throughput. Here we describe a multiplexing approach to RT-LAMP with four targets (SARS-CoV-2, Influenza A, Influenza B, and internal control human RNA) in a single reaction using real-time and endpoint fluorescence detection. This increase to the functionality of RT-LAMP will, we hope, enable even broader adoption of this power molecular testing approach to aid in the global fight against this continuing public health threat.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.26.20219725,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219725,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",Helen Ward; Graham Cooke; Christina J Atchison; Matthew Whitaker; Joshua Elliott; Maya Moshe; Jonathan C Brown; Barney Flower; Anna Daunt; Kylie E. C. Ainslie; Deborah Ashby; Christl A. Donnelly; Steven Riley; Ara Darzi; Wendy Barclay; Paul Elliott; Robert Maile; Will Lovell; Shannon Wallet; Natalie M Bowman; Suzanne L Meinig; Matthew C Wolfgang; Saibyasachi N. Choudhury; Mark Novotny; Brian D Aevermann; Richard Scheuermann; Gabrielle Cannon; Carlton Anderson; Julie Marchesan; Mandy Bush; Marcelo Freire; Adam Kimple; Daniel L Herr; Joseph Rabin; Alison Grazioli; Benjamin N. French; Thomas JF Pranzatelli; John A. Chiorini; David E. Kleiner; Stefania Pittaluga; Stephen Hewitt; Peter D. Burbelo; Daniel Chertow; - NIH COVID-19 Autopsy Consortium; - HCA Oral and Craniofacial Biological Network; Karen M Frank; Janice Lee; Richard C. Boucher C. Boucher; Sarah A. Teichmann; Blake M Warner,"Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; University of North Carolina at Chapel Hill; University of North Carolina Adams School of Dentistry; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina Adams School of Dentistry; University of North Carolina Adams School of Dentistry; J. Craig Venter Institute; University of North Carolina at Chapel Hill; University of Maryland School of Medicine; University of Maryland School of Medicine; National Institutes of Health; National Institute of Health; National Institutes of Health; National Institutes of Health; National Institutes of Health; National Institutes of Health; National Institutes of Health; National Institutes of Health; National Institutes of Health; ; ; National Institutes of Health; National Institutes of Health; University of North Carolina at Chapel Hill; Wellcome Sanger Institute; National Institutes of Health","BackgroundThe prevalence and persistence of antibodies following a peak SARS-CoV-2 infection provides insights into its spread in the community, the likelihood of reinfection and potential for some level of population immunity.

MethodsPrevalence of antibody positivity in England, UK (REACT2) with three cross-sectional surveys between late June and September 2020. 365104 adults used a self-administered lateral flow immunoassay (LFIA) test for IgG. A laboratory comparison of LFIA results to neutralization activity in panel of sera was performed.

ResultsThere were 17,576 positive tests over the three rounds. Antibody prevalence, adjusted for test characteristics and weighted to the adult population of England, declined from 6.0% [5.8, 6.1], to 4.8% [4.7, 5.0] and 4.4% [4.3, 4.5], a fall of 26.5% [-29.0, -23.8] over the three months of the study. There was a decline between rounds 1 and 3 in all age groups, with the highest prevalence of a positive result and smallest overall decline in positivity in the youngest age group (18-24 years: -14.9% [-21.6, -8.1]), and lowest prevalence and largest decline in the oldest group (75+ years: -39.0% [-50.8, -27.2]); there was no change in antibody positivity between rounds 1 and 3 in healthcare workers (+3.45% [-5.7, +12.7]).

The decline from rounds 1 to 3 was largest in those who did not report a history of COVID-19, (-64.0% [-75.6, -52.3]), compared to -22.3% ([-27.0, -17.7]) in those with SARS-CoV-2 infection confirmed on PCR.

DiscussionThese findings provide evidence of variable waning in antibody positivity over time such that, at the start of the second wave of infection in England, only 4.4% of adults had detectable IgG antibodies using an LFIA. Antibody positivity was greater in those who reported a positive PCR and lower in older people and those with asymptomatic infection. These data suggest the possibility of decreasing population immunity and increasing risk of reinfection as detectable antibodies decline in the population.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.14.20212555,2020-10-16,https://medrxiv.org/cgi/content/short/2020.10.14.20212555,Multi-organ impairment in low-risk individuals with long COVID,Andrea Dennis; Malgorzata Wamil; Sandeep Kapur; Johann Alberts; Andrew Badley; Gustav Anton Decker; Stacey A Rizza; Rajarshi Banerjee; Amitava Banerjee; Mauro Giudici; Giovanni Naldi; Sabrina Gaito; Silvana Castaldi; Elia Biganzoli,"Perspectum; Great Western Hospitals NHS Foundation Trust; Mayo Clinic Healthcare; Alliance Medical; Mayo Clinic; Mayo Clinic International; Mayo Clinic; Perspectum; University College London; Department of Earth Sciences, University of Milan, Milan, Italy; Department of Environmental Science and Policy, University of Milan, Milan, Italy; Department of Computer Science, University of Milan, Milan, Italy; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; Fondazione IRCCS Ca Granda Ospedale Maggiore, Milan, Italy; Department of Clinical Sciences and Community Health & Data Science Research Center, University of Milan, Milan, Italy","BackgroundSevere acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection has disproportionately affected older individuals and those with underlying medical conditions. Research has focused on short-term outcomes in hospital, and single organ involvement. Consequently, impact of long COVID (persistent symptoms three months post-infection) across multiple organs in low-risk individuals is yet to be assessed.

MethodsAn ongoing prospective, longitudinal, two-centre, observational study was performed in individuals symptomatic after recovery from acute SARS-CoV-2 infection. Symptoms and organ function (heart, lungs, kidneys, liver, pancreas, spleen) were assessed by standardised questionnaires (EQ-5D-5L, Dyspnoea-12), blood investigations and quantitative magnetic resonance imaging, defining single and multi-organ impairment by consensus definitions.

FindingsBetween April and September 2020, 201 individuals (mean age 44 (SD 11.0) years, 70% female, 87% white, 31% healthcare workers) completed assessments following SARS-CoV-2 infection (median 140, IQR 105-160 days after initial symptoms). The prevalence of pre-existing conditions (obesity: 20%, hypertension: 6%; diabetes: 2%; heart disease: 4%) was low, and only 18% of individuals had been hospitalised with COVID-19. Fatigue (98%), muscle aches (88%), breathlessness (87%), and headaches (83%) were the most frequently reported symptoms. Ongoing cardiorespiratory (92%) and gastrointestinal (73%) symptoms were common, and 42% of individuals had ten or more symptoms.

There was evidence of mild organ impairment in heart (32%), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%). Single (66%) and multi-organ (25%) impairment was observed, and was significantly associated with risk of prior COVID-19 hospitalisation (p<0.05).

InterpretationIn a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in one or more organs four months after initial symptoms of SARS-CoV-2 infection. There are implications not only for burden of long COVID but also public health approaches which have assumed low risk in young people with no comorbidities.

FundingThis work was supported by the UKs National Consortium of Intelligent Medical Imaging through the Industry Strategy Challenge Fund, Innovate UK Grant 104688, and also through the European Unions Horizon 2020 research and innovation programme under grant agreement No 719445.",health policy,exact,100,100
medRxiv,10.1101/2020.10.12.20211227,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.12.20211227,High and increasing prevalence of SARS-CoV-2 swab positivity in England during end September beginning October 2020: REACT-1 round 5 updated report,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Steffen Stenger; Karl-Klaus Conzelmann; Jan Muench; Daniel Sauter; Florian Ingo Schmidt; Axel Imhof; Frank Kirchhoff; Konstantin Maria Johannes Sparrer,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Institute for Medical Microbiology and Hygiene, Ulm University Medical Center, 89081 Ulm, Germany; Gene Center and Max von Pettenkofer-Institute of Virology, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany; Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany; Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany; Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany; Biomedical Center, Protein Analysis Unit, Department of Molecular Biology, Ludwig-Maximilians- University of Munich, 82152 Planegg-Martinsried, Germany; Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany; Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany","BackgroundREACT-1 is quantifying prevalence of SARS-CoV-2 infection among random samples of the population in England based on PCR testing of self-administered nose and throat swabs. Here we report results from the fifth round of observations for swabs collected from the 18th September to 5th October 2020. This report updates and should be read alongside our round 5 interim report.

MethodsRepresentative samples of the population aged 5 years and over in England with sample size ranging from 120,000 to 175,000 people at each round. Prevalence of PCR-confirmed SARS-CoV-2 infection, estimation of reproduction number (R) and time trends between and within rounds using exponential growth or decay models.

Results175,000 volunteers tested across England between 18th September and 5th October. Findings show a national prevalence of 0.60% (95% confidence interval 0.55%, 0.71%) and doubling of the virus every 29 (17, 84) days in England corresponding to an estimated national R of 1.16 (1.05, 1.27). These results correspond to 1 in 170 people currently swab-positive for the virus and approximately 45,000 new infections each day. At regional level, the highest prevalence is in the North West, Yorkshire and The Humber and the North East with strongest regional growth in North West, Yorkshire and The Humber and West Midlands.

ConclusionRapid growth has led to high prevalence of SARS-CoV-2 virus in England, with highest rates in the North of England. Prevalence has increased in all age groups, including those at highest risk. Improved compliance with existing policy and, as necessary, additional interventions are required to control the spread of SARS-CoV-2 in the community and limit the numbers of hospital admissions and deaths from COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.11.20210658,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.11.20210658,What is the evidence for transmission of COVID-19 by children in schools? A living systematic review,Wei Xu; Xue Li; Marshall Dozier; Yazhou He; Amir Kirolos; Zhongyu Lang; Catherine Mathews; Nandi Siegfried; Evropi Theodoratou; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA; Shawn N Murphy,"University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; South African Medical Research Council; South African Medical Research Council; University of Edinburgh; Department of Infectious Disease, Imperial College London, London, UK; National Infection Service, Public Health England, UK; National Infection Service, Public Health England, UK; Blizard Institute & Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Division of Infection and Immunity, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK 8Department of Infection, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK; Department of Infection, Barts Health NHS Trust, London, UK; Department of Virology, Barts Health NHS Trust, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; National Infection Service, Public Health England, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & William Harvey Research Institute, Barts and the London School of Medicine a; Division of Infection and Immunity, University College London, London, UK; National Infection Service, Public Health England, Porton Down, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; -; Department of Infectious Disease, Imperial College London, London, UK; -; Department of Immunology and Inflammation, Imperial College London, London, UK; Department of Infectious Disease, Imperial College London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Department of Infectious Disease, Imperial College London, London, UK & Lung Division, Royal Brompton & Harefiled NHS Foundation Trust, London, UK; University of Oxford; Massachusetts General Hospital and Mass General Brigham","BackgroundIt is of paramount importance to understand the transmission of SARS-CoV-2 in schools, which could support the decision-making about educational facilities closure or re-opening with effective prevention and control measures in place.

MethodsWe conducted a systematic review and meta-analysis to investigate the extent of SARS-CoV-2 transmission in schools. We performed risk of bias evaluation of all included studies using the Newcastle-Ottawa Scale (NOS).

Results2,178 articles were retrieved and 11 studies were included. Five cohort studies reported a combined 22 student and 21 staff index cases that exposed 3,345 contacts with 18 transmissions [overall infection attack rate (IAR): 0.08% (95% CI: 0.00%-0.86%)]. IARs for students and school staff were 0.15% (95% CI: 0.00%-0.93%) and 0.70% (95% CI: 0.00%-3.56%) respectively. Six cross-sectional studies reported 639 SARS-CoV-2 positive cases in 6,682 study participants tested [overall SARS-CoV-2 positivity rate: 8.00% (95% CI: 2.17%-16.95%)]. SARS-CoV-2 positivity rate was estimated to be 8.74% (95% CI: 2.34%-18.53%) among students, compared to 13.68% (95% CI: 1.68%-33.89%) among school staff. Gender differences were not found for secondary infection (OR: 1.44, 95% CI: 0.50-4.14, P= 0.49) and SARS-CoV-2 positivity (OR: 0.90, 95% CI: 0.72-1.13, P= 0.36) in schools. Fever, cough, dyspnea, ageusia, anosmia, rhinitis, sore throat, headache, myalgia, asthenia, and diarrhoea were all associated with the detection of SARS-CoV-2 antibodies (based on two studies). Overall, study quality was judged to be poor with risk of performance and attrition bias, limiting the confidence in the results.

ConclusionsThere is limited high-quality evidence available to quantify the extent of SARS-CoV-2 transmission in schools or to compare it to community transmission. Emerging evidence suggests lower IAR and SARS-CoV-2 positivity rate in students compared to school staff. Future prospective and adequately controlled cohort studies are necessary to confirm this finding.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.11.20211037,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.11.20211037,Symptom-based testing in a compartmental model of COVID-19,Ferenc A. Bartha; Jnos Karsai; Tams Tekeli; Gergely Rst; Amir Kirolos; Zhongyu Lang; Catherine Mathews; Nandi Siegfried; Evropi Theodoratou; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA; Shawn N Murphy,"Bolyai Institute, University of Szeged; Bolyai Institute, University of Szeged; Bolyai Institute, University of Szeged; Bolyai Institute, University of Szeged; University of Edinburgh; University of Edinburgh; South African Medical Research Council; South African Medical Research Council; University of Edinburgh; Department of Infectious Disease, Imperial College London, London, UK; National Infection Service, Public Health England, UK; National Infection Service, Public Health England, UK; Blizard Institute & Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Division of Infection and Immunity, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK 8Department of Infection, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK; Department of Infection, Barts Health NHS Trust, London, UK; Department of Virology, Barts Health NHS Trust, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; National Infection Service, Public Health England, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & William Harvey Research Institute, Barts and the London School of Medicine a; Division of Infection and Immunity, University College London, London, UK; National Infection Service, Public Health England, Porton Down, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; -; Department of Infectious Disease, Imperial College London, London, UK; -; Department of Immunology and Inflammation, Imperial College London, London, UK; Department of Infectious Disease, Imperial College London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Department of Infectious Disease, Imperial College London, London, UK & Lung Division, Royal Brompton & Harefiled NHS Foundation Trust, London, UK; University of Oxford; Massachusetts General Hospital and Mass General Brigham","Testing and isolation of cases is an important component of our strategies to fight SARS-CoV-2. In this work, we consider a compartmental model for COVID-19 including a nonlinear term representing symptom-based testing. We analyze how the considered clinical spectrum of symptoms and the testing rate affect the outcome and the severity of the outbreak.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.13.20211813,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.13.20211813,"Precautionary breaks: planned, limited duration circuit breaks to control the prevalence of COVID-19",Matt J Keeling; Glen Guyver-Fletcher; Alexander Holmes; Louise J Dyson; Michael Tildesley; Edward M Hill; Graham F Medley; Nandi Siegfried; Evropi Theodoratou; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA; Shawn N Murphy,"University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; London School of Hygiene and Tropical Medicine; South African Medical Research Council; University of Edinburgh; Department of Infectious Disease, Imperial College London, London, UK; National Infection Service, Public Health England, UK; National Infection Service, Public Health England, UK; Blizard Institute & Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Division of Infection and Immunity, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK 8Department of Infection, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK; Department of Infection, Barts Health NHS Trust, London, UK; Department of Virology, Barts Health NHS Trust, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; National Infection Service, Public Health England, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & William Harvey Research Institute, Barts and the London School of Medicine a; Division of Infection and Immunity, University College London, London, UK; National Infection Service, Public Health England, Porton Down, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; -; Department of Infectious Disease, Imperial College London, London, UK; -; Department of Immunology and Inflammation, Imperial College London, London, UK; Department of Infectious Disease, Imperial College London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Department of Infectious Disease, Imperial College London, London, UK & Lung Division, Royal Brompton & Harefiled NHS Foundation Trust, London, UK; University of Oxford; Massachusetts General Hospital and Mass General Brigham","The COVID-19 pandemic in the UK has been characterised by periods of exponential growth and decline, as different non-pharmaceutical interventions (NPIs) are brought into play. During the early uncontrolled phase of the outbreak (early March 2020) there was a period of prolonged exponential growth with epidemiological observations such as hospitalisation doubling every 3-4 days (growth rate r {approx} 0.2). The enforcement of strict lockdown measures led to a noticeable decline in all epidemic quantities (r {approx} -0.06) that slowed during the summer as control measures were relaxed (r {approx} -0.02). Since August, infections, hospitalisations and deaths have been rising (precise estimation of the current growth rate is difficult due to extreme regional heterogeneity and temporal lags between the different epidemiological observations) and various NPIs have been applied locally throughout the UK in response.

Controlling any rise in infection is a compromise between public health and societal costs, with more stringent NPIs reducing cases but damaging the economy and restricting freedoms. Currently, NPI imposition is made in response to the epidemiological state, are of indefinite length and are often imposed at short notice, greatly increasing the negative impact. An alternative approach is to consider planned, limited duration periods of strict NPIs aiming to purposefully reduce prevalence before such emergency NPIs are required. These ""precautionary breaks"" may offer a means of keeping control of the epidemic, while their fixed duration and the forewarning may limit their society impact. Here, using simple analysis and age-structured models matched to the unfolding UK epidemic, we investigate the action of precautionary breaks. In particular we consider their impact on the prevalence of infection, as well as the total number of predicted hospitalisations and deaths. We find that precautionary breaks provide the biggest gains when the growth rate is low, but offer a much needed brake on increasing infection when the growth rate is higher, potentially allowing other measures (such as contact tracing) to regain control.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.12.20211557,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.12.20211557,Nonspecific blood tests as proxies for COVID-19 hospitalization: are there plausible associations after excluding noisy predictors?,Gerson Ishikawa; Graziela Argenti; Cristina Berger Fadel; Louise J Dyson; Michael Tildesley; Edward M Hill; Graham F Medley; Nandi Siegfried; Evropi Theodoratou; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA; Shawn N Murphy,"Universidade Tecnologica Federal do Parana; Universidade Estadual de Ponta Grossa; Universidade Estadual de Ponta Grossa; University of Warwick; University of Warwick; University of Warwick; London School of Hygiene and Tropical Medicine; South African Medical Research Council; University of Edinburgh; Department of Infectious Disease, Imperial College London, London, UK; National Infection Service, Public Health England, UK; National Infection Service, Public Health England, UK; Blizard Institute & Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Division of Infection and Immunity, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK 8Department of Infection, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK; Department of Infection, Barts Health NHS Trust, London, UK; Department of Virology, Barts Health NHS Trust, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; National Infection Service, Public Health England, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & William Harvey Research Institute, Barts and the London School of Medicine a; Division of Infection and Immunity, University College London, London, UK; National Infection Service, Public Health England, Porton Down, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; -; Department of Infectious Disease, Imperial College London, London, UK; -; Department of Immunology and Inflammation, Imperial College London, London, UK; Department of Infectious Disease, Imperial College London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Department of Infectious Disease, Imperial College London, London, UK & Lung Division, Royal Brompton & Harefiled NHS Foundation Trust, London, UK; University of Oxford; Massachusetts General Hospital and Mass General Brigham","This study applied causal criteria in directed acyclic graphs for handling covariates in associations for prognosis of severe COVID-19 (Corona virus disease 19) cases. To identify nonspecific blood tests and risk factors as predictors of hospitalization due to COVID-19, one has to exclude noisy predictors by comparing the concordance statistics (AUC) for positive and negative cases of SARS-CoV-2 (acute respiratory syndrome coronavirus 2). Predictors with significant AUC at negative stratum should be either controlled for their confounders or eliminated (when confounders are unavailable). Models were classified according to the difference of AUC between strata. The framework was applied to an open database with 5644 patients from Hospital Israelita Albert Einstein in Brazil with SARS-CoV-2 RT-PCR (Reverse Transcription - Polymerase Chain Reaction) exam. C-reactive Protein (CRP) was a noisy predictor: hospitalization could have happen due to causes other than COVID-19 even when SARS-CoV-2 RT-PCR is positive and CRP is reactive, as most cases are asymptomatic to mild. Candidates of characteristic response from moderate to severe inflammation of COVID-19 were: combinations of eosinophils, monocytes and neutrophils, with age as risk factor; and creatinine, as risk factor, sharpens the odds ratio of the model with monocytes, neutrophils, and age.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.13.20212118,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.13.20212118,Does autism protect against COVID quarantine effects?,Marco Guidotti; Adrien Gateau; Joelle Malvy; Frederique Bonnet-Brilhault; Michael Tildesley; Edward M Hill; Graham F Medley; Nandi Siegfried; Evropi Theodoratou; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA; Shawn N Murphy,"EXcellence Center in Autism and neurodevelopmental disorders - Tours; EXcellence Center in Autism and neurodevelopmental disorders - Tours; EXcellence Center in Autism and neurodevelopmental disorders - Tours; EXcellence Center in Autism and neurodevelopmental disorders - Tours; University of Warwick; University of Warwick; London School of Hygiene and Tropical Medicine; South African Medical Research Council; University of Edinburgh; Department of Infectious Disease, Imperial College London, London, UK; National Infection Service, Public Health England, UK; National Infection Service, Public Health England, UK; Blizard Institute & Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Division of Infection and Immunity, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK 8Department of Infection, Barts Health NHS Trust, London, UK; Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK; Department of Infection, Barts Health NHS Trust, London, UK; Department of Virology, Barts Health NHS Trust, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; National Infection Service, Public Health England, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & William Harvey Research Institute, Barts and the London School of Medicine a; Division of Infection and Immunity, University College London, London, UK; National Infection Service, Public Health England, Porton Down, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK & Institute of Cardiovascular Science, University College London, UK; -; Department of Infectious Disease, Imperial College London, London, UK; -; Department of Immunology and Inflammation, Imperial College London, London, UK; Department of Infectious Disease, Imperial College London, London, UK; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Department of Infectious Disease, Imperial College London, London, UK & Lung Division, Royal Brompton & Harefiled NHS Foundation Trust, London, UK; University of Oxford; Massachusetts General Hospital and Mass General Brigham","IntroductionCOVID-19 outbreak has imposed an eight-week confinement in France. During this period, children and their families were exposed to a full-time home life. The aim of this study was to assess the emotional experience and tolerance of children with autism spectrum disorder (ASD) in this particular context.

MethodA clinical survey was proposed to parents and rated by professionals once a week during the quarantine period in France. 95 autistic children followed by the child and adolescent psychiatry department of Tours university hospital were assessed from the 18th of March to the 8th of May. The following clinical points were investigated: child anxiety, family anxiety, behavior problems, impact on sleep, impact on appetite, impact on school work, family tension, confinement intolerance, difficulties to follow a schedule, isolation behavior.

ResultsDespite minor changes in family anxiety and school work, no difference was highlighted between clinical scores collected at the beginning and at the end of this period. ASD children with or without intellectual disability had non-significant clinical changes during quarantine. This evolution was also independent of the accommodation type (house or apartment) and the parental status (relationship, separated or isolated).

ConclusionThe sameness dimension in autism and parents adaptation may be involved in this clinical stability during COVID confinement. Moreover, specialized tools and support provided by professionals could have participated to these outcomes and must be regularly promoted in order to help families in this still difficult period.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.10.11.20210625,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.11.20210625,Mental health service activity during COVID-19 lockdown among individuals with learning disabilities: South London and Maudsley data on services and mortality from January to July 2020,Evangelia Martin; Eleanor Nuzum; Matthew Broadbent; Robert Stewart; Daniela Obando; Enio Garcia; Jyotirmayee Turuk; Asit Mansingh; Hariram Choudhury; Girish Chandra Dash; Niranjan Mishra; Durga Madhab Satapathy; Sanjaya Kumar Sahoo; Sanghamitra Pati; - RMRC Odisha Serosurvey team; Hardip Gopani; Anusha Dias; Khang Tran; Minnie Zacharia; Xiaobo Gu; Lianne Boeglin; Sudha Chivukula; Ron Swearingen; Victoria Landolfi; Tong-Ming Fu; Frank DeRosa; Danilo Casimiro; Ke Xu,"King's College London; King's College London; South London and Maudsley NHS Foundation Trust; King's College London; Health Ministry of Buenos Aires Province, Argentina; Health Ministry of Buenos Aires Province, Argentina; RMRC Bhubaneswar; RMRC Bhubaneswar; RMRC Bhubaneswar; RMRC Bhubaneswar; Government of Odisha; MKCG Medical College; MKCG Medical College; Regional Medical Research Centre; ; Translate Bio; Translate Bio; Translate Bio; Translate Bio; Translate Bio; Translate Bio; Sanofi Pasteur; Translate Bio; Sanofi Pasteur; Sanofi Pasteur; Translate Bio; Sanofi Pasteur; Wuhan University","The lockdown and social distancing policy imposed due to the COVID-19 pandemic is likely to have had a widespread impact on mental healthcare service provision and use. Previous reports from the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for 1.2m residents in South London) highlighted a shift to virtual contacts among those accessing community mental health and home treatment teams and an increase in deaths over the pandemics first wave. However, there is a need to quantify this for individuals with particular vulnerabilities, including those with learning disabilities and other neurodevelopmental disorders. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource with 24-hourly updates of electronic mental health records data, this paper describes daily caseloads and contact numbers (face-to-face and virtual) for individuals with potential neurodevelopmental disorders across community, specialist, crisis and inpatient services. The report focussed on the period 1st January to 31st July 2020. We also report on daily accepted and discharged trust referrals, total trust caseloads and daily inpatient admissions and discharges for individuals with potential neurodevelopmental disorders. In addition, daily deaths are described for all current and previous SLaM service users with potential neurodevelopmental disorders over this period. In summary, comparing periods before and after 16th March 2020 there was a shift from face-to-face contacts to virtual contacts across all teams. The largest declines in caseloads and total contacts were seen in Home Treatment Team, Liaison/A&E and Older Adult teams. Reduced accepted referrals and inpatient admissions were observed and there was an 103% increase in average daily deaths in the period after 16th March, compared to the period 1st January to 15th March (or a 282% increase if the 2-month period from 16th March to 15th May was considered alone).",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.10.09.20209957,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.09.20209957,Development and validation of the 4C Deterioration model for adults hospitalised with COVID-19,Rishi K Gupta; Ewen M Harrison; Antonia Ho; Annemarie B Docherty; Stephen R Knight; Maarten van Smeden; Ibrahim Abubakar; Marc Lipman; Matteo Quartagno; Riinu B Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University College London; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Medical Research Council University of Glasgow Centre for Virus Research, Glasgow, UK; University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Institute for Global Health, University College London, Gower Street, London, WC1E 6BT; UCL Respiratory, Division of Medicine, University College London, London, UK; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK; University of Edinburgh; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Prognostic models to predict the risk of clinical deterioration in acute COVID-19 are required to inform clinical management decisions. Among 75,016 consecutive adults across England, Scotland and Wales prospectively recruited to the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) study, we developed and validated a multivariable logistic regression model for in-hospital clinical deterioration (defined as any requirement of ventilatory support or critical care, or death) using 11 routinely measured variables. We used internal-external cross-validation to show consistent measures of discrimination, calibration and clinical utility across eight geographical regions. We further validated the final model in held-out data from 8,252 individuals in London, with similarly consistent performance (C-statistic 0.77 (95% CI 0.75 to 0.78); calibration-in-the-large 0.01 (-0.04 to 0.06); calibration slope 0.96 (0.90 to 1.02)). Importantly, this model demonstrated higher net benefit than using other candidate scores to inform decision-making. Our 4C Deterioration model thus demonstrates unprecedented clinical utility and generalisability to predict clinical deterioration among adults hospitalised with COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.08.20208785,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.08.20208785,Rapid and Low-cost Sampling for Detection of Airborne SARS-CoV-2 in Dehumidifier Condensate,Parikshit Moitra; Maha Alafeef; Ketan Dighe; Priyanka Ray; James Chang; Sai Sathish Ramamurthy; Xudong Ge; Dipanjan Pan; Govind Rao; Riinu B Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University of Maryland School of Medicine; University ofMaryland School of Medicine and University of Illinois at Urbana-Champaign; University ofMaryland Baltimore County and University of Maryland School of Medicine; University of Maryland Baltimore County and University of Maryland School of Medicine; University of maryland Medical Center; University of Maryland Baltimore County and Sri Sathya Sai Insistute of Higher Learning; University of Maryland Baltimore County; University of Maryland baltimore County and University of Maryland School of Medicine; UMBC; University of Edinburgh; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Airborne spread of COVID-19 by infectious aerosol is all but certain. However, easily implemented approaches to assess the actual environmental threat are currently unavailable. We present a simple approach with the potential to rapidly provide information about the prevalence of SARS-CoV-2 in the atmosphere at any location. We used a portable dehumidifier as a readily available and affordable tool to collect airborne virus in the condensate. The dehumidifiers were deployed in selected locations of a hospital ward with patients reporting flu like symptoms which could possibly be due to COVID-19 over three separate periods of one week. Samples were analyzed frequently for both virus envelope protein and SARS-CoV-2 RNA. In several samples across separate deployments, condensate from dehumidifiers tested positive for the presence of SARS-CoV-2 antigens and confirmed using two independent assays. RNA was detected, but not attributable to SARS-CoV-2. Our results point to a facile pool testing method to sample air in any location in the world and assess the presence and concentration of the infectious agent in order to obtain quantitative risk assessment of exposure, designate zones as  hot spots and minimize the need for individual testing which may often be time consuming, expensive and laborious.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.08.20208991,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.08.20208991,Covid Pandemic Analysis using Regression,Raji P; Deeba Lakshmi G R; Ketan Dighe; Priyanka Ray; James Chang; Sai Sathish Ramamurthy; Xudong Ge; Dipanjan Pan; Govind Rao; Riinu B Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"NMIT; NMIT; University ofMaryland Baltimore County and University of Maryland School of Medicine; University of Maryland Baltimore County and University of Maryland School of Medicine; University of maryland Medical Center; University of Maryland Baltimore County and Sri Sathya Sai Insistute of Higher Learning; University of Maryland Baltimore County; University of Maryland baltimore County and University of Maryland School of Medicine; UMBC; University of Edinburgh; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Covid-19 is a pandemic which has affected all parts of the world. Covid-19 is a pandemic which can be controlled only by maintaining social distancing, proper hygiene, wearing mask, hand sanitation and to a extend by wearing face shield. Even though each state has followed their own ways of controlling the infection, awareness among citizens and behaving as responsible citizens is very important in controlling this disease. Contact tracing plays an important role in controlling this pandemic. This paper deals with the effect of Covid-19 in various states of India and also forecasts its effect using machine learning techniques. Regression analysis like Linear and polynomial have been used for analysis of Covid-19, where Kaggle dataset has been used. This helps in understanding the much-affected states in India and helps to understand the infrastructure requirements to handle this pandemic efficiently.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.09.20209981,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.09.20209981,"The risk for a new COVID-19 wave -- and how it depends on $R_0$, the current immunity level and current restrictions",Tom Britton; Pieter Trapman; Frank G Ball; Priyanka Ray; James Chang; Sai Sathish Ramamurthy; Xudong Ge; Dipanjan Pan; Govind Rao; Riinu B Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Stockholm University; Stockholm University; University of Nottingham; University of Maryland Baltimore County and University of Maryland School of Medicine; University of maryland Medical Center; University of Maryland Baltimore County and Sri Sathya Sai Insistute of Higher Learning; University of Maryland Baltimore County; University of Maryland baltimore County and University of Maryland School of Medicine; UMBC; University of Edinburgh; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","The COVID-19 pandemic has hit different parts of the world differently: some regions are still in the rise of the first wave, other regions are now facing a decline after a first wave, and yet other regions have started to see a second wave. The current immunity level i in a region is closely related to the cumulative fraction infected, which primarily depends on two factors: a) the initial potential for COVID-19 in the region (often quantified by the basic reproduction number R0), and b) the timing, amount and effectiveness of preventive measures put in place. By means of a mathematical model including heterogeneities owing to age, social activity and susceptibility, and allowing for time-varying preventive measures, the risk for a new epidemic wave and its doubling time, and how they depend on R0, i and the overall effect of the current preventive measures, are investigated. Focus lies on quantifying the minimal overall effect of preventive measures pMin needed to prevent a future outbreak. The first result shows that the current immunity level i plays a more influential roll than when immunity is obtained from vaccination. Secondly, by comparing regions with different R0 and i it is shown that regions with lower R0 and low i may now need higher preventive measures (pMin) compared with other regions having higher R0 but also higher i, even when such immunity levels are far from herd immunity.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.09.20209734,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.09.20209734,Determinants of Developing Symptomatic Disease in Ethiopian COVID-19 Patients,Tigist W Leulseged; Degu G Alemahu; Ishmael S Hassen; Endalkachew H Maru; Wuletaw C Zewde; Nigat W Chamesew; Kalkidan T Yegile; Daniel S Abebe; Firaol M Abdi; Etsegenet Y Menyelshewa; Tegenu G Gerbi; Helen T Hagos; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","BackgroundStudies show that having some symptoms seems to be associated with more severe disease and poor prognosis. Therefore, knowing who is more susceptible to symptomatic COVID-19 disease is important to provide targeted preventive and management practice. The aim of the study was to assess the determinants of having symptomatic disease among COVID-19 patients admitted to Millennium COVID-19 Care Center in Ethiopia.

MethodsA case-control study was conducted from August to September 2020 among a randomly selected 765 COVID-19 patients (372 Asymptomatic and 393 Symptomatic patients). Chi-square test and independent t-test were used to detect the presence of a statistically significant difference in the characteristics of the cases (symptomatic) and controls (asymptomatic), where p-value of <0.05 considered as having a statistically significant difference. Multivariable binary logistic regression was used to assess a statistically significant association between the independent variables and developing symptomatic COVID-19 where Adjusted Odds ratio (AOR), 95% CIs for AOR, and P-values were used for testing significance and interpretation of results.

ResultsThe result of the multivariable binary logistic regression shows that age group (AOR= 1.818, 95% CI= 1.210, 2.731, p-value=0.004 for 30-39 years; AOR= 1.611, 95% CI= 1.016, 2.554, p-value=0.043 for 40-49 years and AOR= 4.076, 95% CI= 2.582, 6.435, p-value=0.0001 for years and above), sex (AOR= 1.672, 95% CI= 1.216, 2.299, p-value=0.002) and history of diabetes mellitus (AOR= 2.406, 95% CI= 1.384, 4.181, p-value=0.002) were found to be significant factors that determine the development of symptomatic disease in COVID-19 patients.

ConclusionsDeveloping a symptomatic COVID-19 disease was found to be determined by exposures of old age, male sex, and being diabetic. Therefore, patients with the above factors should be given enough attention in the prevention and management process, including inpatient management, to pick symptoms earlier and to manage accordingly so that these patients can have a favorable treatment outcome.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.08.20209643,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.08.20209643,Explaining the Effective Reproduction Number of COVID-19 through Mobility and Enterprise Statistics: Evidence from the First Wave in Japan,Yoshio Kajitani; Michinori Hatayama; Ishmael S Hassen; Endalkachew H Maru; Wuletaw C Zewde; Nigat W Chamesew; Kalkidan T Yegile; Daniel S Abebe; Firaol M Abdi; Etsegenet Y Menyelshewa; Tegenu G Gerbi; Helen T Hagos; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Kagawa Univeristy; Kyoto University; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","This study uses mobility statistics combined with business census data for the eight Japanese prefectures with the highest COVID-19 infection rates to study the effect of mobility reductions on the effective reproduction number (i.e., the average number of secondary cases caused by one infected person). Mobility statistics are a relatively new data source created by compiling smartphone location data. Based on data for the first wave of infections in Japan, we found that reductions targeting the hospitality industry were more effective than restrictions on general business activities. Specifically, we found that to hold back the pandemic (that is, to reduce the effective reproduction number to one or less for all days), a 20-35% reduction in weekly mobility is required, depending on the region. A lesser goal, 80% of days with one or less observed transmission, can be achieved with a 6-30% reduction in weekly mobility. These are the results if other potential causes of spread are ignored; more careful observations and expanded data sets are needed.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.09.20209999,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.09.20209999,COVID-19 Disease Severity and Determinants among Ethiopian Patients: A study of the Millennium COVID-19 Care Center,Tigist W. Leulseged; Kindalem G. Abebe; Ishmael S. Hassen; Endalkachew H. Maru; Wuletaw C Zewde; Nigat W Chamesew; Kalkidan T. Yegile; Abdi B. Bayisa; Dagne F. Siyoum; Mesay G. Edo; Edmealem G. Mesfin; Meskerem N. Derejie; Hilina K. Shiferaw; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","BackgroundUnderstanding determinants of developing severe COVID-19 disease is important as studies show that severe disease is associated with worse outcomes.

ObjectiveThe study aimed to assess the determinants of COVID-19 disease severity among COVID-19 patients admitted to Millennium COVID-19 Care Center in Ethiopia.

MethodsA cross-sectional study was conducted from June to August 2020 among randomly selected 686 patients. Chi-square test was used to detect the presence of a statistically significant difference in the characteristics of the patients based on disease severity (Mild Vs Moderate Vs Severe), where p-value of <0.05 was considered as having a statistically significant difference. A Multivariable multinomial logistic regression model was used to assess the presence of a significant association between the independent variables and COVID-19 disease severity where Adjusted Odds ratio (AOR), 95% CIs for AOR and P-values were used for testing significance and interpretation of results.

ResultsHaving moderate as compared with mild disease was significantly associated with having hypertension (AOR= 2.302, 95% CI= 1.266, 4.184, p-value=0.006), diabetes mellitus (AOR=2.607, 95% CI= 1.307, 5.198, p-value=0.007 for diabetes mellitus), fever (AOR= 6.115, 95% CI= 2.941, 12.716, p-value=0.0001) and headache (AOR= 2.695, 95% CI= 1.392, 5.215, p-value=0.003). Similarly, having severe disease as compared with mild disease was associated with age group (AOR= 4.428, 95% CI= 2.497, 7.853, p-value=0.0001 for 40-59 years and AOR=18.070, 95% CI=9.292, 35.140, p-value=0.0001 for [&ge;] 60 years), sex (AOR=1.842, 95% CI=1.121, 3.027, p-value=0.016), hypertension (AOR= 1.966, 95% CI= 1.076, 3.593, p-value=0.028), diabetes mellitus (AOR= 3.926, 95% CI= 1.964, 7.847, p-value=0.0001), fever (AOR= 13.218, 95% CI= 6.109, 28.601, p-value=0.0001) and headache (AOR= 4.816, 95% CI= 2.324, 9.979, p-value=0.0001). In addition, determinants of severe disease as compared with moderate disease were found to be age group (AOR= 4.871, 95% CI= 2.854, 8.315, p-value=0.0001 for 40-59 years and AOR= 18.906, 95% CI= 9.838, 36.334, p-value=0.0001 for [&ge;] 60 years), fever (AOR= 2.161, 95% CI= 1.286, 3.634, p-value=0.004) and headache (AOR= 1.787, 95% CI= 1.028, 3.107, p-value=0.039).

ConclusionsBeing old, male sex, hypertension, diabetes mellitus, and having symptoms of fever and headache were found to be determinants of developing a more severe COVID-19 disease category. We recommend a better preventive practice to be set in place so that these groups of patients can be protected from acquiring the disease. And for those who are already infected, a more careful follow-up and management should be given so that complication and death can be prevented. Furthermore, considering the above non respiratory symptoms as disease severity indicator could be important.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.09.20209601,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.09.20209601,Cleaning and Re-Use of cobas(R) 6800/8800 Processing Plates for the SARS-CoV-2 Assay,R Matthew Sperling; Ryan F Relich; Bryan H Schmitt; Drew Bell; Lauren A Cooper; Nigat W Chamesew; Kalkidan T. Yegile; Abdi B. Bayisa; Dagne F. Siyoum; Mesay G. Edo; Edmealem G. Mesfin; Meskerem N. Derejie; Hilina K. Shiferaw; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Indiana University Health; Indiana University School of Medicine; Indiana University School of Medicine; Indiana University School of Medicine; Indiana University School of Medicine; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Real-time reverse transcription polymerase chain reaction (rRT-PCR) is the primary method used for the detection and diagnosis of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since SARS-CoV-2s entrance into the United States, numerous clinical laboratories and in vitro diagnostic companies have developed rRT-PCR assays, some requiring specialized materials and reagents. One such assay includes the cobas(R) SARS-CoV-2 Qualitative Assay for use on the cobas(R) 6800/8800 (Roche Molecular Systems, Inc.). Since initiation of this assay at our facility, our ability to run testing at full capacity has been limited due to restricted supply of the omni cobas(R) Processing Plate (Product Number 05534917001), a 96 deep well plate used for all sample processing and total nucleic acid extraction via MagNA Pure magnetic beads. To work around this limiting factor, we have successfully designed and tested a cleaning protocol utilizing the widely available laboratory resources of bleach, ethyl-alcohol and autoclaving, for omni cobas(R) Processing Plate re-use.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.10.11.20210831,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.11.20210831,The SIR model estimates incorrectly the basic reproduction number for the covid-19 epidemic,Hyun Mo Yang; Luis Pedro Lombardi Junior; Ariana Campos Yang; Drew Bell; Lauren A Cooper; Nigat W Chamesew; Kalkidan T. Yegile; Abdi B. Bayisa; Dagne F. Siyoum; Mesay G. Edo; Edmealem G. Mesfin; Meskerem N. Derejie; Hilina K. Shiferaw; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Unicamp; State University of Campinas; Division of Allergy and Immunology, General Hospital of the Medicine School of University of So Paulo; Indiana University School of Medicine; Indiana University School of Medicine; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","The transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes pandemic but presents different incidences in the world. Mathematical models were formulated to describe the coronavirus disease 2019 (CoViD-19) epidemic in each country or region. At the beginning of the pandemic, many authors used the SIR (susceptible, infectious, and recovered compartments) and SEIR (including exposed compartment) models to estimate the basic reproduction number R0 for the CoViD-19 epidemic. These simple deterministic models assumed that the only available collection of the severe CoViD-19 cases transmitted the SARS-CoV-2 and estimated lower values for R0, ranging from 1.5 to 3.0. However, the major flaw in the estimation of R0 provided by the SIR and SEIR models was that the severe CoViD-19 patients were hospitalized, and, consequently, not transmitting. Hence, we proposed a more elaborate model considering the natural history of CoViD-19: the inclusion of asymptomatic, pre-symptomatic, mild and severe CoViD-19 compartments. The model also encompassed the fatality rate depending on age. This SEAPMDR model estimated R0 using the severe CoViD-19 data from Sao Paulo State (Brazil) and Spain, yielding higher values for R0, that is, 6.54 and 5.88, respectively. It is worth stressing that this model assumed that severe CoViD-19 cases were not participating in the SARS-CoV-2 transmission chain. Therefore, the SIR and SEIR models are not suitable to estimate R0 at the beginning of the epidemic by considering the isolated severe CoViD-19 data as transmitters.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.08.20204222,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.08.20204222,Estimating epidemiologic dynamics from single cross-sectional viral load distributions,James A Hay; Lee Kennedy-Shaffer; Sanjat Kanjilal; Marc Lipsitch; Michael J Mina; Nigat W Chamesew; Kalkidan T. Yegile; Abdi B. Bayisa; Dagne F. Siyoum; Mesay G. Edo; Edmealem G. Mesfin; Meskerem N. Derejie; Hilina K. Shiferaw; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Harvard T H Chan School of Public Health; Vassar College; Harvard Pilgrim Health Care Institute; Harvard T H Chan School of Public Health; Harvard T H Chan School of Public Health; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Virologic testing for SARS-CoV-2 has been central to the COVID-19 pandemic response, but interpreting changes in incidence and fraction of positive tests towards understanding the epidemic trajectory is confounded by changes in testing practices. Here, we show that the distribution of viral loads, in the form of Cycle thresholds (Ct), from positive surveillance samples at a single point in time can provide accurate estimation of an epidemics trajectory, subverting the need for repeated case count measurements which are frequently obscured by changes in testing capacity. We identify a relationship between the population-level cross-sectional distribution of Ct values and the growth rate of the epidemic, demonstrating how the skewness and median of detectable Ct values change purely as a mathematical epidemiologic rule without any change in individual level viral load kinetics or testing. Although at the individual level measurement variation can complicate interpretation of Ct values for clinical use, we show that population-level properties reflect underlying epidemic dynamics. In support of these theoretical findings, we observe a strong relationship between the time-varying effective reproductive number, R(t), and the distribution of Cts among positive surveillance specimens, including median and skewness, measured in Massachusetts over time. We use the observed relationships to derive a novel method that allows accurate inference of epidemic growth rate using the distribution of Ct values observed at a single cross-section in time, which, unlike estimates based on case counts, is less susceptible to biases from delays in test results and from changing testing practices. Our findings suggest that instead of discarding individual Ct values from positive specimens, incorporation of viral loads into public health data streams offers a new approach for real-time resource allocation and assessment of outbreak mitigation strategies, even where repeat incidence data is not available. Ct values or similar viral load data should be regularly reported to public health officials by testing centers and incorporated into monitoring programs.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.10.12.335919,2020-10-12,https://biorxiv.org/cgi/content/short/2020.10.12.335919,Within-patient genetic diversity of SARS-CoV-2,Jack Kuipers; Aashil  A Batavia; Kim Philipp Jablonski; Fritz Bayer; Nico Borgsmller; Arthur Dondi; Monica-Andreea Drgan; Pedro Ferreira; Katharina Jahn; Lisa Lamberti; Martin Pirkl; Susana Posada-Cspedes; Ivan Topolsky; Ina Nissen; Natascha Santacroce; Elodie Burcklen; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"ETH Zurich; ETH Zrich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","SARS-CoV-2, the virus responsible for the current COVID-19 pandemic, is evolving into different genetic variants by accumulating mutations as it spreads globally. In addition to this diversity of consensus genomes across patients, RNA viruses can also display genetic diversity within individual hosts, and co-existing viral variants may affect disease progression and the success of medical interventions. To systematically examine the intra-patient genetic diversity of SARS-CoV-2, we processed a large cohort of 3939 publicly-available deeply sequenced genomes with specialised bioinformatics software, along with 749 recently sequenced samples from Switzerland. We found that the distribution of diversity across patients and across genomic loci is very unbalanced with a minority of hosts and positions accounting for much of the diversity. For example, the D614G variant in the Spike gene, which is present in the consensus sequences of 67.4% of patients, is also highly diverse within hosts, with 29.7% of the public cohort being affected by this coexistence and exhibiting different variants. We also investigated the impact of several technical and epidemiological parameters on genetic heterogeneity and found that age, which is known to be correlated with poor disease outcomes, is a significant predictor of viral genetic diversity.

Author SummarySince it arose in late 2019, the new coronavirus (SARS-CoV-2) behind the COVID-19 pandemic has mutated and evolved during its global spread. Individual patients may host different versions, or variants, of the virus, hallmarked by different mutations. We examine the diversity of genetic variants coexisting within patients across a cohort of 3939 publicly accessible samples and 749 recently sequenced samples from Switzerland. We find that a small number of patients carry most of the diversity, and that patients with more diversity tend to be older. We also find that most of the diversity is concentrated in certain regions and positions of the virus genome. In particular, we find that a variant reported to increase infectivity is among the most diverse positions. Our study provides a large-scale survey of within-patient diversity of the SARS-CoV-2 genome.",genomics,exact,100,100
medRxiv,10.1101/2020.10.07.20208413,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208413,Determinants of Time to Convalescence among COVID-19 Patients at Millennium COVID-19 Care Center in Ethiopia: A prospective cohort study,Tigist Workneh Leulseged; Ishmael Shemsedin Hassen; Endalkachew Hailu Maru; Wuletaw Chane Zewde; Nigat W/Hawaryat Chamesew; Kalkidan Tilahun Yegile; Abdi Bekele Bayisa; Tariku Bahiru Jagema; Teketel Tilahun Admasu; Mesay Gemechu Edo; Eyosias Kebede Gurara; Meseret Damte Hassen; Etsegenet Yeshitla Menyelshewa; Firaol Mame Abdi; Mahlet Birhanu Tefera; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","AimTo estimate time to recovery/convalescence and identify determinants among COVID-19 infected patients admitted to Millennium COVID-19 Care Center in Addis Ababa, Ethiopia.

MethodsA prospective cohort study was conducted among a randomly selected sample of 360 COVID-19 patients who were on follow up from 2nd June to 5th July 2020. Kaplan Meier plots, median survival times, and Log-rank test were used to describe the data and compare survival distribution between groups. Association between time to recovery/ convalescence and determinants was assessed using the Cox proportional hazard survival model, where hazard ratio, P-value, and 95% CI for hazard ratio were used for testing significance.

ResultsThe mean age of the participants was 32.4 years ({+/-} 12.5 years). On admission, 86.9 % had mild COVID-19, 78.6% were asymptomatic and 11.4% of the patients had a history of pre-existing co-morbid illness. The Median time to recovery/ convalescence among the study population was 16 days. The log-rank test shows that having non-mild (moderate and severe) disease, having one or more symptoms at presentation, and presenting with respiratory and constitutional symptoms seems to extend the time needed to achieve recovery. The Final Cox regression result shows that the presence of symptom at presentation was found to be a significant factor that affects time to recovery/ convalescence, the rate of achieving recovery/ convalescence among symptomatic patients was 44% lower than patients who were asymptomatic at presentation (HR= 0.560, 95% CI= 0.322-0.975, p-value=0.040).

ConclusionsPresence of symptom was found to be associated with delayed viral clearance. This implies symptomatic patients are more likely to be infectious because of the prolonged viral shedding in addition to the presence of a more concentrated virus in the upper respiratory tract that enhances the transmission. Therefore, attention should be given in the isolation and treatment practice of COVID-19 patients with regard to presence of symptom.

Key MessagesO_LIThe study assessed the time to RT-PCR proven recovery (two consecutive negative viral shedding) and identified determinants that affected the time.
C_LIO_LISymptomatic infection is associated with delayed viral clearance.
C_LIO_LIThe finding of the study could be used to guide the isolation and treatment practice.
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.07.20208520,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208520,Variability of Salivary and Nasal Specimens for SARS-CoV-2 Detection,Yukari C Manabe; Carolyn Reuland; Tong Yu; Razvan Azamfirei; Taylor Church; Diane M Brown; Thelio T Sewell; Justin P Hardick; Paul W Blair; Christopher D Heaney; Andrew Pekosz; David L Thomas; Etsegenet Yeshitla Menyelshewa; Firaol Mame Abdi; Mahlet Birhanu Tefera; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University School of Medicine; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","In a large cohort of ambulatory confirmed COVID-19 patients with multiple self-collected sample time points, we compared 202 matched nasal-oropharyngeal swabs and oral salivary fluid sample pairs by RT-PCR. Nasal-oropharyngeal swabs were more sensitive than this salivary sample type (oral crevicular fluid) suggesting that not all saliva sample types have equivalent sensitivity. However, all samples that were Vero E6-TMPRSS2 cell culture positive (e.g., infectious virus) were also oral fluid RT-PCR positive suggesting that oral fluid may find the patients most likely to transmit disease to others.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.07.20207647,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20207647,Rapid detection of SARS-CoV2 by Ambient Mass Spectrometry Techniques,Lauren Louise Ford; Daniel Simon; Julia Balog; Natasha Jiwa; James Higginson; Emrys Jones; Eftychios Manoli; Sam Mason; Vincen Wu; Stefania Stavrakaki; James McKenzie; Daniel McGill; Hanifa Koguna; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Imperial College London; Imperial College London; Waters Research Centre; Imperial College London; Imperial College London; Waters Corporation; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Rosalind Franklin Institute; Imperial College London; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Ambient Ionisation Mass Spectrometry techniques: Desorption Electrospray Ionisation (DESI) and Laser Desorption - Rapid Evaporative Ionisation Mass Spectrometry (LD-REIMS) were used to detect the SARS-CoV-2 in dry nasal swabs. 45 patients were studied from samples collected between April - June 2020 in a clinical feasibility study. Diagnostic accuracy was calculated as 86.7% and 84% for DESI and LD-REIMS respectively. Results can be acquired in seconds providing robust and quick analysis of COVID-19 status which could be carried out without the need for a centralised laboratory. This technology has the potential to provide an alternative to population testing and enable the track and trace objectives set by governments and curtail the effects of a second surge in COVID-19 positive cases. In contrast to current PCR testing, using this technique there is no requirement of specific reagents which can cause devastating delays upon breakdowns of supply chains, thus providing a promising alternative testing method.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.07.20208710,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208710,Safely Reopening K-12 Schools During the COVID-19 Pandemic,Courtney D Shelley; Philippa S Chadwick; Carrie Manore; Sara Y Del Valle; James Higginson; Emrys Jones; Eftychios Manoli; Sam Mason; Vincen Wu; Stefania Stavrakaki; James McKenzie; Daniel McGill; Hanifa Koguna; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Los Alamos National Laboratory; Los Alamos National Laboratory; Los Alamos National Laboratory; Los Alamos National Laboratory; Imperial College London; Waters Corporation; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Rosalind Franklin Institute; Imperial College London; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Early school closures were a consistent, nationwide response to the COVID-19 pandemic in mid-March due to the role that children play in spreading influenza. This left us with limited understanding of COVID-19 transmission in children until several states reopened schools for the 2020-2021 school year. While early school closures were likely beneficial in protecting children in the initial stages of the pandemic in the U.S., long-term closures pose significant cumulative effects in children who rely on schools for instruction and additional social services, and for parents who need to balance work and childcare obligations. Reopening schools safely is a high priority for many interested stakeholders.

Proposed in-person school reopening plans include traditional, 100% school capacity, five days per week instruction, hybrid scenarios with reduced in-person instruction and virtual learning, and various reduced school capacity schedules with non-pharmaceutical interventions in place. To assess the potential impacts of different reopening plans, we created a modified SIR-type transmission model that captures multiple known pathways of COVID-19 transmission in a 100,000-person community.

Our results show that plans that utilize consecutive days in school and divide students into separated smaller cohorts who attend school together, as well as plans that emphasize distance learning, are better able to suppress disease spread and reduce risk from an introduced infective into the community. Plans with more consecutive school days are protective for both the schoolchildren and surrounding community by acting to separate the larger intermixing population into smaller intermixing subpopulations. The ""Five-Day Switch"" plan, which separates students into two cohorts, each of whom attend in-person learning for five consecutive days followed by five days of distance learning, best captures these protective attributes. All modeled plans assumed initially disease-free communities and that childrens interactions with the community are greatly reduced during instructional days, both for in-person and distance learning.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.10.07.20208686,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208686,An Innovative Non-Pharmaceutical Intervention to Mitigate SARS-CoV02 Spread: Probability Sampling to Identify and Isolate Asymptomatic Cases,Nathalie E Williams; Xiaozheng Yao; Ankita Pall; Xiaolu Qian; Mansi Rathod; Chang Xu; Adrian Dobra; Sam Mason; Vincen Wu; Stefania Stavrakaki; James McKenzie; Daniel McGill; Hanifa Koguna; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University of Washington; Virginia Tech; University of Washington; University of Washington; University of Washington; University of Washington; University of Washington; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Rosalind Franklin Institute; Imperial College London; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Studies estimate that a substantial proportion of SARS-CoV-2 transmission occurs through individuals who do not exhibit symptoms. Mitigation strategies test only those who are moderately to severely symptomatic, excluding the substantial portion of cases that are asymptomatic yet still infectious and likely responsible for a large proportion of the virus spread (1-8). While isolating asymptomatic cases will be necessary to effectively control viral spread, these cases are functionally invisible and there is no current method to identify them for isolation. To address this major omission in COVID-19 control, we develop a strategy, Sampling-Testing-Quarantine (STQ), for identifying and isolating individuals with asymptomatic SARS-CoV-2 in order to mitigate the epidemic. STQ uses probability sampling in the general population, regardless of symptoms, then isolates the individuals who test positive along with their household members who are high probability for asymptomatic infections. To test the potential efficacy of STQ, we use an agent-based model, designed to computationally simulate the epidemic in the Seattle with infection parameters, like R0 and asymptomatic fraction, derived from population data. Our results suggest that STQ can substantially slow and decrease the spread of COVID-19, even in the absence of school and work shutdowns. Results also recommend which sampling techniques, frequency of implementation, and population subject to isolation are most efficient in reducing spread with limited numbers of tests.

Significance StatementA substantial portion of SARS-CoV-2 infections are spread through asymptomatic carriers. Until a vaccine is developed, research indicates an urgent need to identify these asymptomatic infections to control COVID-19, but there is currently no effective strategy to do so. In this study, we develop such a strategy, a procedure called Sampling-Testing-Quarantine (STQ), that combines techniques from survey methods for sampling from the general population and testing and isolation techniques from epidemiology. With computational simulations, we demonstrate that STQ procedures can dramatically decrease and slow COVID-19 spread, even in the absence of widespread work, school, and community lockdowns. We also find particular implementation strategies (including sampling techniques, frequencies of implementation, and people who are subject to isolation) are most efficient in mitigating spread.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.07.20208421,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208421,Forecasting COVID-19 cases in the Philippines using various mathematical models,Monica C Torres; Christian Alvin H Buhat; Ben Paul C Dela Cruz; Edd Francis O. Felix; Eleanor B Gemida; Jonathan B. Mamplata; Adrian Dobra; Sam Mason; Vincen Wu; Stefania Stavrakaki; James McKenzie; Daniel McGill; Hanifa Koguna; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University of the Philippines Los Banos; University of the Philippines Los Banos; University of the Philippines Los Banos; University of the Philippines Los Banos; University of the Philippines Los Banos; University of the Philippines Los Banos; University of Washington; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Rosalind Franklin Institute; Imperial College London; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Due to the rapid increase of COVID-19 infection cases in many countries such as the Philippines, many efforts in forecasting the daily infections have been made in order to better manage the pandemic, and respond effectively. In this study, we consider the cumulative COVID-19 infection cases in the Philippines from March 6 to July 31,2020 and forecast the cases from August 1 - 15, 2020 using various mathematical models --weighted moving average, exponential smoothing, Susceptible-Exposed-Infected-Recovered (SEIR) model, Ornstein-Uhlenbeck process, Autoregressive Integrated Moving Average (ARIMA) model, and random forest. We then compare the results to the actual data using traditional error metrics. Our results show that the ARIMA(1,2,1) model has the closest forecast values to the actual data. Policymakers can use our result in determining which forecast method to use for their community in order to have a data-based information for the preparation of their personnel and facilities.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.07.20208504,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208504,Using test positivity and reported case rates to estimate state-level COVID-19 prevalence in the United States,Weihsueh chiu; Martial L Ndeffo-Mbah; Ben Paul C Dela Cruz; Edd Francis O. Felix; Eleanor B Gemida; Jonathan B. Mamplata; Adrian Dobra; Sam Mason; Vincen Wu; Stefania Stavrakaki; James McKenzie; Daniel McGill; Hanifa Koguna; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Texas A&M University; Texas A&M University; University of the Philippines Los Banos; University of the Philippines Los Banos; University of the Philippines Los Banos; University of the Philippines Los Banos; University of Washington; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Rosalind Franklin Institute; Imperial College London; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Accurate estimates of infection prevalence and seroprevalence are essential for evaluating and informing public health responses needed to address the ongoing spread of COVID-19 in the United States. A data-driven Bayesian single parameter semi-empirical model was developed and used to evaluate state-level prevalence and seroprevalence of COVID-19 using daily reported cases and test positivity ratios. COVID-19 prevalence is well-approximated by the geometric mean of the positivity rate and the reported case rate. As of December 8, 2020, we estimate nation-wide a prevalence of 1.4% [Credible Interval (CrI): 0.8%-1.9%] and a seroprevalence of 11.1% [CrI: 10.1%-12.2%], with state-level prevalence ranging from 0.3% [CrI: 0.2%-0.4%] in Maine to 3.0% [CrI: 1.1%-5.7%] in Pennsylvania, and seroprevalence from 1.4% [CrI: 1.0%-2.0%] in Maine to 22% [CrI: 18%-27%] in New York. The use of this simple and easy-to-communicate model will improve the ability to make public health decisions that effectively respond to the ongoing pandemic.

Biographical Sketch of AuthorsDr. Weihsueh A. Chiu, is a professor of environmental health sciences at Texas A&M University. He is an expert in data-driven Bayesian modeling of public health related dynamical systems. Dr. Martial L. Ndeffo-Mbah, is an Assistant Professor of Epidemiology at Texas A&M University. He is an expert in mathematical and computational modeling of infectious diseases.

Summary LineRelying on reported cases and test positivity rates individually can result in incorrect inferences as to the spread of COVID-19, and public health decision-making can be improved by instead using their geometric mean as a measure of COVID-19 prevalence and transmission.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.07.20208314,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208314,Evaluating the impact of curfews and other measures on SARS-CoV-2 transmission in French Guiana,Alessio Andronico; Cecile Tran Kiem; Juliette Paireau; Tiphanie Succo; Paolo Bosetti; Noemie Lefrancq; Mathieu Nacher; Felix Djossou; Alice Sanna; Claude Flamand; Henrik Salje; Cyril Rousseau; Simon Cauchemez; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Institut Pasteur; Institut Pasteur; Institut Pasteur; Sante Publique France Guyane; Institut Pasteur; Institut Pasteur; Centre d'Investigation Clinique Antilles Guyane, CIC INSERM 1424, Centre Hospitalier Andree Rosemon; Service des Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne; Agence Regionale de Sante de Guyane; Institut Pasteur Guyane; University of Cambridge; Sante Publique France Guyane; Institut Pasteur; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","While general lockdowns have proven effective to control SARS-CoV-2 epidemics, they come with enormous costs for society. It is therefore essential to identify control strategies with lower social and economic impact. Here, we report and evaluate the control strategy implemented during a large SARS-CoV-2 epidemic in June-July 2020 in French Guiana that relied on curfews, targeted lockdowns and other measures. We find that the combination of these interventions reduced the basic reproduction number of SARS-CoV-2 from 1.7 to 1.1, which was sufficient to avoid saturation of hospitals. We estimate that thanks to the young demographics across the territory, the risk of hospitalisation following infection was 0.3 times that of metropolitan France and that about 20% of the population was infected by July. Our model projections are consistent with a recent seroprevalence study. The study showcases how mathematical modeling can be used to support healthcare planning and decision making in a context of high uncertainty.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.07.20208488,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208488,SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing antibodies and increase during convalescence.,Sushma Boppana; Kai Qin; Jacob K Files; Ronnie M. Russell; Regina Stoltz; Frederic Bibollet-Ruche; Anju Bansal; Nathan Erdmann; Beatrice H. Hahn; Paul A. Goepfert; Henrik Salje; Cyril Rousseau; Simon Cauchemez; James Kinross; Zoltan Takats; Siham Seid Ali; Tobias Schr; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Univ of Alabama at Birmingham; University of Alabama at Birmingham; University of Pennsylvania; University of Alabama at Birmingham; University of Cambridge; Sante Publique France Guyane; Institut Pasteur; Imperial College London; Imperial College London; Millennium COVID-19 Care Center, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia; ETH Zurich; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","T-cell immunity is likely to play a role in protection against SARS-CoV-2 by helping generate neutralizing antibodies. We longitudinally studied CD4 T-cell responses to the M, N, and S structural proteins of SARS-CoV-2 in 21 convalescent individuals. Within the first two months following symptom onset, a majority of individuals (81%) mount at least one CD4 T-cell response, and 48% of individuals mount detectable SARS-CoV-2-specific peripheral T follicular helper cells (pTfh, defined as CXCR5+PD1+ CD4 T cells). SARS-CoV-2-specific pTfh responses across all three protein specificities correlate with antibody neutralization with the strongest correlation observed for S protein-specific responses. When examined over time, pTfh responses increase in frequency and magnitude in convalescence, and robust responses with magnitudes greater than 5% were detected only at the second convalescent visit, an average of 38 days post-symptom onset. These data deepen our understanding of antigen-specific pTfh responses in SARS-CoV-2 infection, suggesting that M and N protein-specific pTfh may also assist in the development of neutralizing antibodies and that pTfh response formation may be delayed in SARS-CoV-2 infection.

Author SummarySince December 2019, the Coronavirus Disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Most currently licensed vaccines are understood to protect against infection by inducing neutralizing antibodies. As such, ongoing COVID-19 vaccine trials have focused on antibody neutralization as a primary immunologic endpoint. It is well established that T follicular helper cells are essential to the development of neutralizing antibodies and that a subset of these cells, peripheral T follicular helper cells (pTfh), can be studied in the blood. However, little is known about Tfh responses mounted in SARS-CoV-2 infection. Here, we studied pTfh to three major structural proteins in individuals recovered from COVID-19. We find that SARS-CoV-2-specific pTfh frequencies correlate with neutralizing antibody responses, especially those directed against the spike protein. We also find that pTfh responses to SARS-CoV-2 increase over time. Our findings suggest that pTfh responses against proteins other than the spike protein may contribute to the development of neutralizing antibodies and suggests that formation of pTfh responses in SARS-CoV-2 infection may be delayed.",infectious diseases,exact,100,100
bioRxiv,10.1101/2020.10.09.332734,2020-10-12,https://biorxiv.org/cgi/content/short/2020.10.09.332734,Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2,Dan Zhao; Weifan Xu; Xiaofan Zhang; Xiaoting Wang; Enming Yuan; Yuanpeng Xiong; Shenyang Wu; Shuya Li; Nian Wu; Tingzhong Tian; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Tsinghua University; Silexon AI Technology Co., Ltd., Nanjing, Jiangsu Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Bioinformatics Division, BNRIST/Department of Computer Science and Technology, Tsinghua University, Beijing, China; Protein Preparation and Identification Facility, Technology Center for Protein Science, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","The ongoing coronavirus disease 2019 (COVID-19) pandemic has raised an urgent need to develop effective therapeutics against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a potential antiviral drug target, the nucleocapsid (N) protein of SARS-CoV-2 functions as a viral RNA chaperone and plays vital and multifunctional roles during the life cycle of coronavirus1-3. In this study, we discovered that the N protein of SARS-CoV-2 undergoes liquid-liquid phase separation (LLPS) both in vitro and in vivo, which is further modulated by viral RNA. In addition, we found that, the core component of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, nsp12, preferentially partitions into the N protein condensates. Moreover, we revealed that, two small molecules, i.e., CVL218 and PJ34, can be used to intervene the N protein driven phase separation and loosen the compact structures of the condensates of the N-RNA-nsp12 complex of SARS-CoV-2. The discovery of the LLPS-mediated interplay between N protein and nsp12 and the corresponding modulating compounds illuminates a feasible way to improve the accessibility of antiviral drugs (e.g., remdesivir) to their targets (e.g., nsp12/RdRp), and thus may provide useful hints for further development of effective therapeutic strategies against SARS-CoV-2.",biophysics,exact,100,100
bioRxiv,10.1101/2020.10.09.333948,2020-10-12,https://biorxiv.org/cgi/content/short/2020.10.09.333948,The effect of salt on the dynamics of CoV-2 RBD at ACE2,Emanuel Peter; Alexander Schug; Xiaofan Zhang; Xiaoting Wang; Enming Yuan; Yuanpeng Xiong; Shenyang Wu; Shuya Li; Nian Wu; Tingzhong Tian; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Forschungszentrum Jlich; Forschungszentrum Jlich; Tsinghua University; Silexon AI Technology Co., Ltd., Nanjing, Jiangsu Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Bioinformatics Division, BNRIST/Department of Computer Science and Technology, Tsinghua University, Beijing, China; Protein Preparation and Identification Facility, Technology Center for Protein Science, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","In this article, we investigate the effect of electrolytes on the stability of the complex between the coronavirus type 2 spike protein receptor domain (CoV-2 RBD) and ACE2, which plays an important role in the activation cascade at the viral entry of CoV-2 into human cells. At the cellular surface, electrolytes play an important role, especially in the interaction of proteins near the membrane surface. Additionally, the binding interface of the CoV-2 RBD - ACE2 complex is highly hydrophilic. We simulated the CoV-2 RBD - ACE2 complex at varying salt concentrations over the concentration range from 0.03 M to 0.3 M of calcium and sodium chloride over an individual simulation length of 750 ns in 9 independent simulations (6.75 {micro}s total). We observe that the CoV-2 RBD - ACE2 complex is stabilized independent of the salt concentration. We identify a strong negative electrostatic potential at the N-terminal part of CoV-2 RBD and we find that CoV-2 RBD binds even stronger at higher salt concentrations. We observe that the dynamics of the N-terminal part of CoV-2 RBD stabilize the protein complex leading to strong collective motions and a stable interface between CoV-2 RBD and ACE2. We state that the sequence of CoV-2 RBD might be optimized for a strong binding to ACE2 at varying salt concentrations at the cellular surface, which acts as a key component in the activation of CoV-2 for its viral entry.

SIGNIFICANCEA novel coronavirus, coronavirus type 2 (CoV-2), was identified as primary cause for a worldwide pandemic of the severe acute respiratory syndrome (SARS CoV-2). The CoV-2 spike protein is a major target for the development of a vaccine and potential strategies to inhibit the viral entry into human cells. At the cellular surface, CoV-2 activation involves the direct interaction between ACE2 and CoV-2 RBD. At the cellular surface, electrolytes play an important role, especially in the interaction of proteins near the membrane surface. We thus investigate the effect of ion conditions on the interaction of the CoV-2 RBD - ACE2 complex and find stabilizing effects. We speculate that CoV-2 RBD is optimized for strong binding to ACE2 at varying salt concentrations.",biophysics,exact,100,100
medRxiv,10.1101/2020.10.07.20208660,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208660,"Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California",Tim-Allen Bruckner; Daniel M. Parker; Scott Bartell; Veronica Vieira; Saahir Khan; Andrew Noymer; Emily Drum; Bruce Albala; Matthew Zahn; Bernadette Boden-Albala; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Public Health, University of California, Irvine; Public Health, University of California, Irvine; Department of Statistics, University of California, Irvine; Public Health, University of California, Irvine; School of Medicine, University of California, Irvine; Public Health, University of California, Irvine; Public Health, University of California, Irvine; Center for Clinical Research, School of Medicine, University of California, Irvine; Orange County Health Care Agency; Public Health, University of California, Irvine; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","BackgroundClinic-based estimates of SARS-CoV-2 may considerably underestimate the total number of infections. Access to testing in the US has been heterogeneous and symptoms vary widely in infected persons. Public health surveillance efforts and metrics are therefore hampered by underreporting. We set out to provide a minimally biased estimate of SARS-CoV-2 seroprevalence among adults for a large and diverse county (Orange County, CA, population 3.2 million).

MethodsWe implemented a surveillance study that minimizes response bias by recruiting adults to answer a survey without knowledge of later being offered a SARS-CoV-2 test. Several methodologies were used to retrieve a population-representative sample. Participants (n=2,979) visited one of 11 drive-thru test sites from July 10th to August 16th, 2020 (or received an in-home visit) to provide a finger pin-prick sample. We applied a robust SARS-CoV-2 Antigen Microarray technology, which has superior measurement validity relative to FDA-approved tests.

FindingsParticipants include a broad age, gender, racial/ethnic, and income representation. Adjusted seroprevalence of SARS-CoV-2 infection was 11.5% (95% CI: 10.5% to 12.4%). Formal bias analyses produced similar results. Prevalence was elevated among Hispanics (vs. other non-Hispanic: prevalence ratio [PR]= 1.47, 95% CI: 1.22 to 1.78) and household income <$50,000 (vs. >$100,000: PR= 1.42, 95% CI: 1.14 to 1.79).

InterpretationResults from a diverse population using a highly specific and sensitive microarray indicate a SARS-CoV-2 seroprevalence of [~]12 percent. This population-based seroprevalence is seven-fold greater than that using official County statistics. In this region, SARS-CoV-2 also disproportionately affects Hispanic and low-income adults.

FundingOrange County Healthcare Agency",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.10.20203034,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.10.20203034,Clarifying predictions for COVID-19 from testing data: the example of New-York State,Pierre Griette; Pierre Magal; Scott Bartell; Veronica Vieira; Saahir Khan; Andrew Noymer; Emily Drum; Bruce Albala; Matthew Zahn; Bernadette Boden-Albala; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University of Bordeaux; University of Bordeaux; Department of Statistics, University of California, Irvine; Public Health, University of California, Irvine; School of Medicine, University of California, Irvine; Public Health, University of California, Irvine; Public Health, University of California, Irvine; Center for Clinical Research, School of Medicine, University of California, Irvine; Orange County Health Care Agency; Public Health, University of California, Irvine; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","In this article, we use testing data as an input of a new epidemic model. We get nice a concordance between the best fit the model to the reported cases data for New-York state. We also get a good concordance of the testing dynamic and the epidemics dynamic in the cumulative cases. Finally, we can investigate the effect of multiplying the number of tests by 2, 5, 10, and 100 to investigate the consequences on the reduction of the number of reported cases.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.07.20208744,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208744,One size fits all?: Modeling face-mask fit on population-based faces,Tomas Solano; Rajat Mittal; Kourosh Shoele; Veronica Vieira; Saahir Khan; Andrew Noymer; Emily Drum; Bruce Albala; Matthew Zahn; Bernadette Boden-Albala; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"Florida State University; Johns Hopkins University; Florida State University; Public Health, University of California, Irvine; School of Medicine, University of California, Irvine; Public Health, University of California, Irvine; Public Health, University of California, Irvine; Center for Clinical Research, School of Medicine, University of California, Irvine; Orange County Health Care Agency; Public Health, University of California, Irvine; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","The use of face masks by the general population during viral outbreaks such as the COVID-19 pandemic, although at times controversial, has been effective in slowing down the spread of the virus. The fit of simple cloth masks on the face as well as the resulting perimeter leakage and face mask efficacy are expected to be highly dependent on the type of mask and facial topology. However, this effect has to date, not been examined and quantified. Here, we study the leakage of a rectangular cloth mask on a large virtual population of subjects with diverse facial features, using computational mechanics modeling. The effect of weight, age, gender, and height on the leakage is studied. The Centers for Disease Control and Prevention (CDC) recommended mask size was used as a basis for comparison and was found not to be the most effective design for all subjects. Thin, feminine, and young faces benefit from mask sizes smaller than that recommended by the CDC. The results show that side-edge tuck-in of the masks could lead to a larger localized gap opening in many face categories, and is therefore not recommended for all. The perimeter leakage from the face mask worn by thin/feminine faces is mostly from the leakage area along the bottom edge of the mask and therefore, a tuck-in of the bottom edge of the mask or a mask smaller than the CDC recommended mask size are proposed as a more effective design. The leakage from the top edge of the mask is determined to be largely unaffected by mask size and tuck-in ratio, meaning that other mechanical alterations such as a nose wire strip are necessary to reduce the leakage at this site.",public and global health,exact,100,100
medRxiv,10.1101/2020.10.07.20208801,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.07.20208801,Level of Knowledge in the COVID-19 Pandemic: A Cross-Sectional Survey of Canadian Medical Students,Kacper Niburski; Rachel Vaughan; Elitsa Papazova; Keith Todd; Saahir Khan; Andrew Noymer; Emily Drum; Bruce Albala; Matthew Zahn; Bernadette Boden-Albala; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"McGill University, Montreal, Quebec, Canada; McGill University, Montreal, Quebec, Canada; University of Montreal, Montreal, Quebec, Canada; Department of Family Medicine, McGill University and Attending Physician Herzl Family Practice Centre and Jewish General Hospital, Montreal, Quebec; School of Medicine, University of California, Irvine; Public Health, University of California, Irvine; Public Health, University of California, Irvine; Center for Clinical Research, School of Medicine, University of California, Irvine; Orange County Health Care Agency; Public Health, University of California, Irvine; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","BackgroundDuring health crises medical education is often derailed as was the case during the current COVID-19 pandemic. Medical trainees face the daunting task of having to gather, filter and synthesize new information about the evolving situation often without the standardized resources they are used to.

MethodsWe surveyed Canadian medical students, in the hardest hit province of Quebec, on how they were acquiring knowledge as well as what they knew of the pandemic. Google Forms was used, with the survey being distributed to each medical school in Quebec (McGill, ULaval, Udem) both through email and through social media pages for each class year. Two analyses, Mann-Whitney and ANOVA tests, were performed for year of study and degree obtained.

ResultsWe received responses from 111 medical students from three universities, which represents 5% of the students invited to complete the survey. Students reported using mass media most frequently (83%) and also had a high rate of use of social media (to gather information about the pandemic. They rated these resources low in terms of their trustworthiness despite the high rates of use (average 2.91 and 2.03 of 5 respectively). Medical students also endorsed using more formal resources like public health information, scientific journals and faculty-provided information that they trusted more, however, they accessed these resources at lower rates. Of note, medical students had correct answered 60% of COVID-19 prevention strategies, 73% clinical correct answers, 90% epidemiological correct answers. Additionally, students who were training in the larger city of Montreal, where the worst of the outbreak was focused, tended to significantly perform better (p<0.0001) than their colleagues who were not located there.

ConclusionThese finding indicate a wide use of information resources intended for public consumption rather than more rigorous and trustworthy sources. Furthermore, there seems to be a knowledge gap amongst medical students responding to this survey that suggests an opportunity to improve the delivery of educational content during this rapidly evolving pandemic.",medical education,exact,100,100
medRxiv,10.1101/2020.10.08.20209304,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.08.20209304,Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: a matched cohort study using linked English electronic health records data,Helena Carreira; Helen Strongman; Maria Peppa; Helen I McDonald; Isabel dos-Santos-Silva; Susannah Stanway; Liam Smeeth; Krishnan Bhaskaran; Matthew Zahn; Bernadette Boden-Albala; Xiaolong Feng; Hantao Shu; Peng Lang; Xiaokun Shen; Haitao Li; Pilong Li; Jianyang Zeng; Vincenzo Capece; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; NIHR Health Protection Research Unit in Immunisation; London School of Medicine and Tropical Medicine, NIHR Health Protection Research Unit in Immunisation; London School of Hygiene and Tropical Medicine; The Royal Marsden NHS Foundation Trust; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Orange County Health Care Agency; Public Health, University of California, Irvine; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; Convalife (Shanghai) Co., Ltd., Shanghai, China.; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medic; Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Join; Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.; ETH Zurich; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","BackgroundPeople with active cancer are recognised as at risk of COVID-19 complications, but it is unclear whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by comparing cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epidemic respiratory viruses.

MethodsWe included survivors ([&ge;]1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from UK primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities.

Findings108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had more asthma, other respiratory, cardiac, diabetes, neurological, renal, and liver disease, and less obesity, compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR 2.22, 1.31-3.74).

InterpretationRisks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when available, COVID-19, should be encouraged in cancer survivors.

FundingWellcome Trust, Royal Society, NIHR.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSFew data are available to date on how COVID-19 affects cancer survivors. We searched PubMed with the keywords ""influenza cancer survivors"" to identify studies that compared severe influenza outcomes in cancer survivors and in a control group. No study was identified.

Added value of this studyIn this matched cohort study of routinely collected electronic health records, we demonstrated raised risks of influenza hospitalisation or mortality in survivors from haematological malignancies for >10 years after diagnosis, and in survivors from solid cancers up to 5 years after diagnosis.

Implications of all the available evidenceCancer survivorship appears to be an important risk factor for severe influenza outcomes, suggesting that cancer survivors may also be at raised risk of poor COVID-19 outcomes. This should be taken into account in public health policies targeted at protecting clinical risk groups. Influenza vaccination should be encouraged in this group, and may need to be extended to a wider population of medium- to long-term cancer survivors than currently recommended.",oncology,exact,100,100
medRxiv,10.1101/2020.10.08.20209593,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.08.20209593,"COVID-19 Susceptibility and Severity Risks in a Survey of Over 500,000 People",Spencer C Knight; Shannon R McCurdy; Brooke Rhead; Marie V Coignet; Danny S Park; Genevieve H L Roberts; Nathan D Berkowitz; Miao Zhang; David Turissini; Karen Delgado; Milos Pavlovic; AncestryDNA Science Team; Asher K Haug Baltzell; Harendra Guturu; Kristin A Rand; Ahna R Girshick; Eurie L Hong; Catherine A Ball; Christiane Beckmann; Olivier Kobel; Christoph Noppen; Maurice Redondo; Sarah Nadeau; Sophie Seidel; Noemi Santamaria de Souza; Christian Beisel; Tanja Stadler; Niko Beerenwinkel; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043; AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043; AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043; AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107; Viollier AG; Viollier AG; Viollier AG; Viollier AG; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; ETH Zurich; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","The growing toll of the COVID-19 pandemic has heightened the urgency of identifying individuals most at risk of infection and severe outcomes, underscoring the need to assess susceptibility and severity patterns in large datasets.1 The AncestryDNA COVID-19 Study collected self-reported survey data on symptoms, outcomes, risk factors, and exposures for over 563,000 adult individuals in the U.S., including over 4,700 COVID-19 cases as measured by a self-reported positive nasal swab test. We observed significant associations between several risk factors and COVID-19 susceptibility and severity outcomes. Many of the susceptibility associations were accounted for by differences in known exposures; a notable exception was elevated susceptibility odds for males after adjusting for known exposures and age. We also leveraged the dataset to build risk models to robustly predict individualized COVID-19 susceptibility (area under the curve [AUC]=0.84) and severity outcomes including hospitalization and life-threatening critical illness amongst COVID-19 cases (AUC=0.87 and 0.90, respectively). The results highlight the value of self-reported epidemiological data at scale to provide public health insights into the evolving COVID-19 pandemic.",health informatics,exact,100,100
medRxiv,10.1101/2020.10.03.20206375,2020-10-06,https://medrxiv.org/cgi/content/short/2020.10.03.20206375,"Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients",Yi Zhang; Shikai Yu; Yawei Xu; Bryan Williams; Gabriel Pizarro; Jos Manuel Munita; Rafael Araos; Thomas Weitzel; David Nickle; Ke Hao; Don D Sin,"Shanghai Tenth Peoples Hospital; Shanghai Tenth People's Hospital, Tongji University School of Medicine; Shanghai Tenth People Hospital; University College London; Clnica Alemana, Universidad del Desarrollo; Clnica Alemana, Universidad del Desarrollo; Clnica Alemana, Universidad del Desarrollo; Clnica Alemana, Universidad del Desarrollo; Merck Research Laboratories, Genetics and Pharmacogenomics, Boston, Massachusetts; Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New ; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada","BackgroundEarly observational studies suggested that the use of the renin angiotensin system (RAS) inhibitors, specifically angiotensin converting enzyme inhibitors or angiotensin receptor blockers, may increase the risk of infection with SARS-CoV-2 and adversely affect the prognosis or survival of infected patients. To explore the impact of RAS inhibitor use on the risk of SARS-CoV-2 infection and the prognosis of SARS-CoV-2 infected patients, from all published studies.

Methods and FindingsA systematic review and meta-analysis of the use of RAS inhibitors in relation to infection with SARS-CoV-2 and/or the severity and mortality associated with COVID-19 was conducted. English language bibliographic databases PubMed, Web of Science, OVID Embase, Scopus, MedRxiv, BioRxiv, searched from Jan 1st, 2020 to July 20th, 2020. 58 observational studies (69,200 COVID-19 patients and 3,103,335 controls) were included. There was no difference in the susceptibility to SARS-CoV-2 infection between RAS inhibitor users and non-users (unadjusted OR 1.05, 95% CI 0.90 to 1.21), (adjusted OR 0.93, 95% CI 0.85 to 1.02), (adjusted HR 1.07, 95% CI 0.87 to 1.31). There was no significant difference in the severe Covid-19 case rate between RAS inhibitor users and non-users (unadjusted OR 1.05, 95% CI 0.81 to 1.36), (adjusted OR 0.76, 95% CI 0.52 to 1.12), or in mortality due to COVID-19 between RAS inhibitor users and non-users (unadjusted OR 1.12, 95% CI 0.88 to 1.44), (adjusted OR 0.97, 95% CI 0.77 to 1.23), (adjusted HR 0.62, 95% CI 0.34 to 1.14).

ConclusionsIn the most comprehensive analysis of all available data to date, treatment with RAS inhibitors was not associated with increased risk of infection, severity of disease, or mortality due to COVID-19. The best available evidence suggests that these treatments should not be discontinued on the basis of concern about risk associated with COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.30.20204727,2020-10-02,https://medrxiv.org/cgi/content/short/2020.09.30.20204727,High prevalence of SARS-CoV-2 swab positivity in England during September 2020: interim report of round 5 of REACT-1 study,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E. Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","BackgroundREACT-1 is a community survey of PCR confirmed swab-positivity for SARS-CoV-2 among random samples of the population in England. This interim report includes data from the fifth round of data collection currently underway for swabs sampled from the 18th to 26th September 2020.

MethodsRepeated cross-sectional surveys of random samples of the population aged 5 years and over in England with sample size ranging from 120,000 to 160,000 people in each round of data collection. Collection of self-administered nose and throat swab for PCR and questionnaire data. Prevalence of swab-positivity by round and by demographic variables including age, sex, region, ethnicity. Estimation of reproduction number (R) between and within rounds, and time trends using exponential growth or decay model. Assessment of geographical clustering based on boundary-free spatial model.

ResultsOver the 9 days for which data are available, we find 363 positives from 84,610 samples giving a weighted prevalence to date of 0.55% (0.47%, 0.64%) in round 5. This implies that 411,000 (351,000, 478,000) people in England are virus-positive under the assumption that the swab assay is 75% sensitive. Using data from the most recent two rounds, we estimate a doubling time of 10.6 (9.4, 12.0) days covering the period 20th August to 26th September, corresponding to a reproduction number R of 1.47 (1.40, 1.53). Using data only from round 5 we estimate a reproduction number of 1.06 (0.74, 1.46) with probability of 63% that R is greater than 1. Between rounds 4 and 5 there was a marked increase in unweighted prevalence at all ages. In the most recent data, prevalence was highest in the 18 to 24 yrs age group at 0.96% (0.68%, 1.36%). At 65+ yrs prevalence increased [~]7-fold between rounds 4 and 5 from 0.04% (0.03%, 0.07%) to 0.29% (0.23%, 0.37%). Prevalence increased in all regions between rounds 4 and 5, giving the highest unweighted prevalence in round 5 in the North West at 0.86% (0.69%, 1.06%). In London, prevalence increased [~]5-fold from 0.10% (0.06%, 0.17%) to 0.49% (0.36%, 0.68%). Regional R values ranged from 1.32 (1.16,1.50) in Yorkshire and the Humber to 1.63 (1.42, 1.88) in the East Midlands over the same period. In the most recent data, there was extensive clustering in the North West, Midlands and in and around London with pockets of clustering in other regions including the South West, North East and East of England. Odds of swab-positivity were [~]2-fold higher in people of Asian and Black ethnicity compared with white participants.

ConclusionRapid growth has led to high prevalence of SARS-CoV-2 virus in England among all regions and age groups, including those age groups at highest risk. Although there is evidence of a recent deceleration in the epidemic, current levels of prevalence will inevitably result in additional hospitalisations and mortality in coming weeks. A re-doubling of public health efforts is needed to return to a declining phase of the epidemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.27.20202739,2020-10-02,https://medrxiv.org/cgi/content/short/2020.09.27.20202739,"COVID-19 era, Preventive effect of no going out against co-infection of the seasonal influenza virus and SARS-CoV-2",Takuma Hayashi; Nobuo Yaegashi; Ikuo Konishi; Caroline E. Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"National Hospital Organization Kyoto Medical Center; Tohoku University Graduate School of Medicine; National Hospital Organization Kyoto Medical Center/Kyoto University School of Medicine; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","In the situation where expansion of coronavirus infectious disease-2019 (COVID-19) does not stop, there is concern about co-infection of people with the seasonal influenza infections from late autumn to winter 2020. Therefore, the importance of supplying vaccines against the seasonal influenza has been pointed out all over the world. As an example in Japan, the number of people infected with the seasonal influenza, hand-foot-and-mouth disease (HFMD), epidemic keratoconjunctivitis, and pharyngoconjunctival fever (PCF), which are the seasonal infectious diseases in the 2020 season, has decreased remarkably compared to the number of people infected each year. It is believed that the significant reduction in the number of people infected with these seasonal infectious diseases is a result of the pervasive hand washing, wearing masks and maintaining social distance in COVID-19 rea. To examine the correlation between the three factors of the number of people with each seasonal infectious disease, the mask wearing rate, and the outing rate, we created a three-dimensional scatter plot based on these three factors using principal component analysis. Our research findings demonstrated preventive effect of no going out against co-infection with the seasonal influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.30.20204917,2020-10-02,https://medrxiv.org/cgi/content/short/2020.09.30.20204917,Epidemiological and clinical characteristics of COVID-19 in Brazil using digital technology,Faissal Nemer Hajar; Miguel Morita Fernandes-Silva; Gustavo S. Pereira da Cunha; Geny Herrera; Ali Hamud; Valderilio F Azevedo; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"Federal University of Parana; Federal University of Parana; Federal University of Parana; TOTVS labs; B.Braun Group; Universidade Federal do Parana; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","BackgroundBrazil has the third-highest number of Coronavirus disease 2019 (COVID-19) cases worldwide. Understanding the epidemiology of COVID-19 from reported cases is challenging due to heterogeneous testing rates. We estimated the number of COVID-19 cases in Brazil on a national and regional level using digital technology.

MethodsWe used a web-based application to perform a population-based survey from March 21st to August 29th, 2020 in Brazil. We obtained responses from 243 461 individuals across all federative units, who answered questions on COVID-19-related symptoms, chronic diseases and address of residence. COVID-19 was defined as at least one of the following: fever, cough, dyspnea and nasal flaring, associated with a history of close contact with a suspect or confirmed COVID-19 case in the previous 14 days. A stratified two-stage weighted survey analysis was performed to estimate the population level prevalence of COVID-19 cases.

ResultsAfter calibration weighing, we estimated that 10 339 461 cases of COVID-19 occurred, yielding a 2.75 estimated infection per officially reported case. Estimated/reported ratios varied across Brazilian states and were higher in states with lower human development indexes. Areas with lower income levels displayed higher rates of COVID-19 cases (66 vs 38 cases/1000 people in the lowest and highest income strata respectively, p<0.001), but presented lower rates of COVID-19 testing.

ConclusionIn this population-based survey using digital technology in Brazil, we estimated that the COVID-19 case rates were 2.75 times higher than officially reported. The estimated per reported case ratios were higher in areas with worse socioeconomic status.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.30.20204842,2020-10-02,https://medrxiv.org/cgi/content/short/2020.09.30.20204842,Oil Immersed Lossless Total Analysis System (OIL-TAS): Integrated RNA Extraction and Detection for SARS-CoV-2 Testing,Duane S Juang; Terry D Juang; Dawn M Dudley; Christina M Newman; Thomas C Friedrich; David H O'Connor; David J Beebe; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","The coronavirus disease 2019 (COVID-19) pandemic exposed difficulties in scaling current quantitative PCR (qPCR)-based diagnostic methodologies for large-scale infectious disease testing. Bottlenecks include the lengthy multi-step process of nucleic acid extraction followed by qPCR readouts, which require costly instrumentation and infrastructure, as well as reagent and plastic consumable shortages stemming from supply chain constraints. Here we report a novel Oil Immersed Lossless Total Analysis System (OIL-TAS), which integrates RNA extraction and detection onto a single device that is simple, rapid, cost effective, uses minimal supplies and requires reduced infrastructure to perform. We validated the performance of OIL-TAS using contrived samples containing inactivated SARS-CoV-2 viral particles, which show that the assay can reliably detect an input concentration of 10 copies/L and sporadically detect down to 1 copy/L. The OIL-TAS method can serve as a faster, cheaper, and easier-to-deploy alternative to current qPCR-based methods for infectious disease testing.",public and global health,exact,100,100
medRxiv,10.1101/2020.10.01.20205187,2020-10-02,https://medrxiv.org/cgi/content/short/2020.10.01.20205187,Vulnerability to rumors during the COVID-19 pandemic:Results of a national survey,Victoria Jane En Long; Wei Shien Koh; Young Ern Saw; Jean CJ Liu; Thomas C Friedrich; David H O'Connor; David J Beebe; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"Duke-NUS Medical School; Duke-NUS Medical School; Yale-NUS College; Yale-NUS College; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","Amidst the COVID-19 pandemic, many rumors have emerged. Given prior research linking rumor exposure to mental well-being, we conducted a nation-wide survey to document the base rate of rumor exposure and factors associated with rumor vulnerability. Between March to July 2020, 1237 participants were surveyed on 5 widely-disseminated COVID-19 rumors (that drinking water frequently could be preventive, that eating garlic could be preventive, that the outbreak arose because of bat soup consumption, that the virus was created in an American lab, and that the virus was created in a Chinese lab). For each rumor, participants reported whether they had heard, shared or believed each rumor. Although most participants had been exposed to COVID-19 rumors, few shared or believed these. Sharing behaviors sometimes occurred in the absence of belief; however, education emerged as a protective factor for both sharing and belief. Together, our results suggest that campaigns targeting skills associated with higher education (e.g. epistemology) may prove more effective than counter-rumor messages.

HighlightsO_LIPrior studies linked exposure to COVID-19 rumors with poor mental health.
C_LIO_LIIn a community sample, most participants reported having heard rumors.
C_LIO_LIFew participants shared or believed rumors.
C_LIO_LISharing sometimes occurred in the absence of belief.
C_LIO_LIMore educated individuals believed and shared fewer rumors.
C_LI",public and global health,exact,100,100
medRxiv,10.1101/2020.10.01.20205021,2020-10-02,https://medrxiv.org/cgi/content/short/2020.10.01.20205021,Theta autoregressive neural network model for COVID-19 outbreak predictions,TANUJIT CHAKRABORTY; Arinjita Bhattacharyya; Monalisha Pattnaik; Jean CJ Liu; Thomas C Friedrich; David H O'Connor; David J Beebe; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"Indian Statistical Institute; University of Louisville, Kentucky; Sambalpur University, India; Yale-NUS College; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Wisconsin-Madison; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","An unprecedented outbreak of the novel coronavirus (COVID-19) in the form of peculiar pneumonia has spread globally since its first case at Wuhan, China, in December 2019, increasing infected cases and mortality at a pandemic speed. Thus, forecasting the COVID-19 pandemic became a key research interest for both the epidemiologists and statisticians. These future predictions are useful for the effective allocation of health care resources, stockpiling, and help in strategic planning for clinicians, government authorities, and public-health policymakers after understanding the extent of the effect. The main objective of this paper is to develop the most suitable forecasting model that can generate real-time short-term (ten days) and long-term (fifty days) out-of-sample forecasts of COVID-19 outbreaks for eight profoundly affected countries, namely the United States of America, Brazil, India, Russia, South Africa, Mexico, Spain, and Iran. A novel hybrid approach based on the Theta model and Autoregressive neural network (ARNN) model, named Theta-ARNN (TARNN) model, is proposed. The proposed method outperforms previously available single and hybrid forecasting models for COVID-19 predictions in most data sets. In addition, the ergodicity and asymptotic stationarity of the proposed TARNN model are established which is of particular interest in nonlinear time series literature. An R-Shiny application is created for implementation of TARNN model and is publicly available1.",epidemiology,exact,100,100
medRxiv,10.1101/2020.10.02.20188136,2020-10-02,https://medrxiv.org/cgi/content/short/2020.10.02.20188136,The SARS-CoV-2 effective reproduction rate has a high correlation with a contact index derived from large-scale individual location data using GPS-enabled mobile phones in Germany,Sten Ruediger; Stefan Konigorski; Jonathan Edelman; Detlef Zernick; Alexander Henry Thieme; Christoph Lippert; David J Beebe; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson,"NET CHECK GmbH; Hasso-Plattner Institut; Hasso-Plattner Institut; NET CHECK GmbH; Charite; Hasso-Plattner Institut; University of Wisconsin-Madison; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Medicine Service, VA Ann Arb; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Physiologic Imaging, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Genetic Medicine, We; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, AZ, USA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; ; ; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; New York Genome Center, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA","Over the last months, cases of SARS-CoV-2 surged repeatedly in many countries and could often be controlled with non-pharmaceutical interventions such as social distancing. We analyzed de-identified GPS tracking data from 1.15 to 1.4 million cell phones in Germany per day between March-November 2020 to identify encounters between individuals and statistically evaluate large-scale contact behavior. Using graph sampling theory we estimated the contact index (CI), a metric for number and heterogeneity of contacts and found that the contact index, and not the total number of contacts, is an accurate predsictor for the effective reproduction number R. A high correlation between CI and R occurring more than two weeks later allows timely assessment of the social behavior well before the infections become detectable. The CI quantifies the role of superspreading and allows assigning risks to specific contact behavior. We provide a critical CI-value beyond which R is expected to rise above 1 and propose to use it to leverage the social distancing interventions for the coming months.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.28.20202929,2020-09-29,https://medrxiv.org/cgi/content/short/2020.09.28.20202929,T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses,Ane Ogbe; Barbara Kronsteiner; Donal T Skelly; Matthew Pace; Anthony Brown; Emily Adland; Kareena Adair; Hossain Delowar Akhter; Mohammad Ali; Serat-E Ali; Adrienn Angyal; M. Azim Ansari; Carolina V Arancibia-Carcamo; Helen Brown; Senthil Chinnakannan; Christopher P Conlon; Catherine de Lara; Thushan de Silva; Christina Dold; Tao Dong Dong; Timothy Donnison; David W Eyre; Amy Flaxman; Helen A Fletcher; Joshua Gardner; James T Grist; Carl-Philipp Hackstein; Kanoot Jaruthamsophon; Katie Jeffrey; Teresa Lambe; Lian Lee; Wenqin Li; Nicholas Lim; Philippa C Matthews; Alexander J Mentzer; Shona C Moore; Dean J Naisbitt; Monday Ogese; Graham Ogg; Peter Openshaw; Munir Pirmohamed; Andrew J Pollard; Narayan Ramamurthy; Patpong Rongkard; Sarah Rowland-Jones; Oliver L Sampson; Gavin Screaton; Alessandro Sette; Lizzie Stafford; Craig Thompson; Paul J Thomson; Ryan Thwaites; Vinicius Vieira; Daniela Weiskopf; Panagiota Zacharopoulou; - Oxford Immunology Network Covid-19 Response T cell Consortium; - Oxford Protective T cell Immunology for COVID-19 (OPTIC) Clinical team; Lance Turtle; Paul Klenerman; Philip Goulder; John Frater; Eleanor Barnes; Susanna Dunachie,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Liverpool; University of Oxford; University of Oxford; University of Liverpool; University of Sheffield; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Sheffield; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Liverpool; University of Oxford; University of Oxford; University of Liverpool; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Liverpool; University of Liverpool; University of Liverpool; University of Oxford; Imperial College; University of Liverpool; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; La Jolla Institute for Immunology; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Liverpool; Imperial College; University of Oxford; La Jolla Institute for Immunology; University of Oxford; ; ; University of Liverpool; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"A major issue in identification of protective T cell responses against SARS-CoV-2 lies in distinguishing people infected with SARS-CoV-2 from those with cross-reactive immunity generated by exposure to other coronaviruses. We characterised SARS-CoV-2 T cell immune responses in 168 PCR-confirmed SARS-CoV-2 infected subjects and 118 seronegative subjects without known SARS-CoV-2 exposure using a range of T cell assays that differentially capture immune cell function. Strong ex vivo ELISpot and proliferation responses to multiple antigens (including M, NP and ORF3) were found in those who had been infected by SARS-CoV-2 but were rare in pre-pandemic and unexposed seronegative subjects. However, seronegative doctors with high occupational exposure and recent COVID-19 compatible illness showed patterns of T cell responses characteristic of infection, indicating that these readouts are highly sensitive. By contrast, over 90% of convalescent or unexposed people showed proliferation and cellular lactate responses to spike subunits S1/S2, indicating pre-existing cross-reactive T cell populations. The detection of T cell responses to SARS-CoV-2 is therefore critically dependent on the choice of assay and antigen. Memory responses to specific non-spike proteins provides a method to distinguish recent infection from pre-existing immunity in exposed populations.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.26.20202150,2020-09-28,https://medrxiv.org/cgi/content/short/2020.09.26.20202150,Comparison of mental health service activity before and shortly after UK social distancing responses to the COVID-19 pandemic: February-March 2020,Robert Stewart; Evangelia Martin; Ioannis Bakolis; Matthew Broadbent; Nicola Byrne; Sabine Landau; Dorit Oriya Shorka; Yuval Cohen; Tzahi Bar; Rafi Yechieli; Michal Tepperberg Oikawa; Dana Venkert; Michal Linial; Esther Oiknine-Djian; Michal Mandelboim; Zvi Livneh; Gilat Shenhav-Saltzman; Ella Mendelson; Dana Wolf; Moran Szwarcwort-Cohen; Orna Mor; Yair Lewis; Danny Zeevi,"King's College London; South London and Maudsley NHS Foundation Trust; King's College London; King's College London; South London and Maudsley NHS Foundation Trust; King's College London; Hadassah Medical Center, Jerusalem, Israel; Directorate of Defense Research & Development, Israeli Ministry of Defense, Israel; Independent Researcher, Israel; Independent Researcher, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; Department of Neurobiology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel; Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel; Hadassah Medical Center, Jerusalem, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; School of Public Health, Sackler; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Internal Medicine, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; School of Public Health, Sackler; Hadassah Medical Center, Jerusalem, Israel; Virology Laboratory, Rambam Health Care Campus, Haifa, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; School of Public Health, Sackler; Navina AI Medical Technologies, Tel Aviv, Israel; Department of Biotechnology, Hadassah Academic College, Jerusalem, Israel","This study sought to provide an early description of mental health service activity before and after national implementation of social distancing for COVID-19. A time series analysis was carried out of daily service-level activity on data from a large mental healthcare provider in southeast London, from 01.02.2020 to 31.03.2020, comparing activity before and after 16.03.2020: i) inpatient admissions, discharges and numbers, ii) contact numbers and daily caseloads (Liaison, Home Treatment Teams, Community Mental Health Teams); iii) numbers of deaths for past and present patients. Daily face-to-face contact numbers fell for liaison, home treatment and community services with incomplete compensatory rises in non-face-to-face contacts. Daily caseloads fell for all services, apart from working age and child/adolescent community teams. Inpatient numbers fell 13.6% after 16th March, and daily numbers of deaths increased by 61.8%.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.09.26.20202382,2020-09-28,https://medrxiv.org/cgi/content/short/2020.09.26.20202382,Estimation of the fraction of COVID-19 infected people in U.S. states and countries worldwide,Jungsik Noh; Gaudenz Danuser; Ioannis Bakolis; Matthew Broadbent; Nicola Byrne; Sabine Landau; Dorit Oriya Shorka; Yuval Cohen; Tzahi Bar; Rafi Yechieli; Michal Tepperberg Oikawa; Dana Venkert; Michal Linial; Esther Oiknine-Djian; Michal Mandelboim; Zvi Livneh; Gilat Shenhav-Saltzman; Ella Mendelson; Dana Wolf; Moran Szwarcwort-Cohen; Orna Mor; Yair Lewis; Danny Zeevi,"UT Southwestern Medical Center; UT Southwestern Medical Center; King's College London; King's College London; South London and Maudsley NHS Foundation Trust; King's College London; Hadassah Medical Center, Jerusalem, Israel; Directorate of Defense Research & Development, Israeli Ministry of Defense, Israel; Independent Researcher, Israel; Independent Researcher, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; Department of Neurobiology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel; Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel; Hadassah Medical Center, Jerusalem, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; School of Public Health, Sackler; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Internal Medicine, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; School of Public Health, Sackler; Hadassah Medical Center, Jerusalem, Israel; Virology Laboratory, Rambam Health Care Campus, Haifa, Israel; Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, P.O. Box 5265601, Ramat-Gan, Israel; School of Public Health, Sackler; Navina AI Medical Technologies, Tel Aviv, Israel; Department of Biotechnology, Hadassah Academic College, Jerusalem, Israel","Since the beginning of the COVID-19 pandemic, daily counts of confirmed cases and deaths have been publicly reported in real-time to control the virus spread. However, substantial undocumented infections have obscured the true prevalence of the virus. A machine learning framework was developed to estimate time courses of actual new COVID-19 cases and current infections in 50 countries and 50 U.S. states from reported test results and deaths, as well as published epidemiological parameters. Severe under-reporting of cases was found to be universal. Our framework projects for countries like Belgium, Brazil, and the U.S. ~10% of the population has been once infected. In the U.S. states like Louisiana, Georgia, and Florida, more than 4% of the population is estimated to be currently infected, as of September 3, 2020, while in New York the fraction is 0.12%. The estimation of the actual fraction of currently infected people is crucial for any definition of public health policies, which up to this point may have been misguided by the reliance on confirmed cases.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.24.20200048,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200048,Genetic mechanisms of critical illness in Covid-19,Erola Pairo-Castineira; Sara Clohisey; Lucija Klaric; Andrew Bretherick; Konrad Rawlik; Nicholas Parkinson; Dorota Pasko; Susan Walker; Anne Richmond; Max Head Fourman; Andy Law; James Furniss; Elvina Gountouna; Nicola Wrobel; Clark D Russell; Loukas Moutsianas; Bo Wang; Alison Meynert; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Fiona Griffith; Wilna Oosthuyzen; Barbara Shih; Sen Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; The Roslin Institute; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; Genomics England; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK; Genomics England; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs[PMID: 32526193] and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but may harm some non-critical cases.[PMID: 32678530] Since susceptibility to life-threatening infections and immune-mediated diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic targets for therapeutic development in Covid-19.[PMID: 24855243] GenOMICC (Genetics Of Mortality In Critical Care, <a href=""https://genomicc.org"">genomicc.org</a>) is a global collaborative study to understand the genetic basis of critical illness. Here we report the results of a genome-wide association study (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95% of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project and Generation Scotland. We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p = 3.98 x 10-12), within the gene encoding dipeptidyl peptidase 9 (DPP9), at chr12q24.13 (rs10735079, p = 1.65 x 10-8) in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), and at chr21q22.1 (rs2236757, p = 4.99 x 10-8) in the interferon receptor gene IFNAR2. Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 3p21.31 locus than previous studies (rs73064425, p = 4.77 x 10-30).",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.09.24.20200576,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200576,Implications of Monsoon Season & UVB Radiation for COVID-19 in India,Rahul Kalippurayil Moozhipurath; Lennart Kraft; Lucija Klaric; Andrew Bretherick; Konrad Rawlik; Nicholas Parkinson; Dorota Pasko; Susan Walker; Anne Richmond; Max Head Fourman; Andy Law; James Furniss; Elvina Gountouna; Nicola Wrobel; Clark D Russell; Loukas Moutsianas; Bo Wang; Alison Meynert; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Fiona Griffith; Wilna Oosthuyzen; Barbara Shih; Sen Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Goethe University Frankfurt am Main; Goethe University Frankfurt am Main; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; Genomics England; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK; Genomics England; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Background: India has recorded 66,333 deaths over 36 administrative regions placing India third in the world after the US and Brazil for COVID-19 deaths as of 2 September 2020. Studies indicate that south-west monsoon season plays a role in the dynamics of contagious diseases, which tend to peak post-monsoon season. Recent studies show that vitamin D and its primary source Ultraviolet-B radiation (UVB) may play a protective role in mitigating COVID-19 deaths. However, the combined roles of the monsoon season and UVB in COVID-19 in India are still unclear. In this observational study, we empirically study the respective roles of monsoon season and UVB, whilst further exploring, whether monsoon season negatively impacts the protective role of UVB in COVID-19 deaths in India. Methods: We use a log-linear Mundlak model to a panel dataset of 36 administrative regions in India from 14 March 2020 - 8 August 2020 (n=4005). We use the cumulative COVID-19 deaths as the dependent variable. We isolate the association of monsoon season and UVB as measured by Ultraviolet Index (UVI) from other confounding time-constant and time-varying region-specific factors. Findings: After controlling for various confounding factors, we observe that the monsoon season and a unit increase in UVI are separately associated with 12.8 percentage points and 2.0 percentage points decline in growth rates of COVID-19 deaths in the long run. These associations translate into substantial relative changes. For example, the current monsoon season, that has been going on for two weeks, is associated with a reduction in growth rates of COVID-19 deaths of 59%, whereas a permanent unit increase of UVI is associated with a reduction in growth rates of COVID-19 deaths of 37%. However, the current monsoon season, also reduces the protective role of UVI by 16.3% [0.33 percentage points], plausibly due to lower UVB exposure. Interpretation: We find independent protective roles of both the monsoon season and UVI in mitigating COVID-19 deaths. Furthermore, we find evidence that monsoon season is associated with a significant reduction in the protective role of UVI. The protective role of monsoon season is plausibly due to limited outdoor activities of people. Our study outlines the role of the monsoon season and UVB in COVID-19 in India and supports health-related policy decision making in India.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.24.20200790,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200790,Clinical manifestations along with biochemical and psychological outcomes of COVID-19 cases in diabetic individuals in Bangladesh,Farhana Akter; Adnan Mannan; H. M. Hamidullah Mehedi; Abdur Rob; Shakeel Ahmed; Asma Salauddin; Md. Shakhawat Hossain; Md Mahbub Hasan; Anne Richmond; Max Head Fourman; Andy Law; James Furniss; Elvina Gountouna; Nicola Wrobel; Clark D Russell; Loukas Moutsianas; Bo Wang; Alison Meynert; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Fiona Griffith; Wilna Oosthuyzen; Barbara Shih; Sen Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Chittagong Medical College; Department of Genetic Engineering & Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chattogram-4331, Bangladesh.; 250 beded General Hospital Chittagong, Chattogram, Bangladesh.; 250 beded General Hospital Chittagong, Chattogram, Bangladesh.; Department of Microbiology, Bangladesh Institute of Tropical & Infectious Diseases, Chattogram 4217, Bangladesh; Department of Genetic Engineering & Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chattogram-4331, Bangladesh.; Department of Genetic Engineering & Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chattogram-4331, Bangladesh; Department of Genetic Engineering & Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chattogram-4331, Bangladesh; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK; Genomics England; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Background and aims: This study investigated the clinical manifestations, outcomes and long-term complications of COVID-19 inpatients in Bangladesh while emphasizing on individuals having diabetes. Methods: A cross-sectional study was conducted for a sample of COVID-19 inpatients across four different hospitals of Bangladesh between April 1st and June 30, 2020. Variation in clinical characteristics, contact history, comorbidities, treatment pattern, and long-term complications were investigated. Results: There were 734 COVID-19 presentations in this study of which 19.8% of patients had diabetes. 76% were male and 85% of the patients had been administered with all vaccine doses during childhood. The most frequently occurring blood groups among patients with diabetes were B (+) ve (35%) and O (+) ve (31%). Among biochemical parameters, glucose, D-dimer, C- reactive protein (CRP) and Troponin levels were significantly elevated amidst the cohort with diabetes. The frequency of insulin dependent individuals increased three-fold during COVID-19. A number of COVID-19 patients with diabetes have been suffering from long term complications post recovery including pain, discomfort, memory loss and sleep disturbance. Conclusion: Individuals with diabetes have experienced severe manifestation of COVID-19 and post disease complications. Further in-depth studies focused on larger sample sizes are entailed to assess the relationships elaborately.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.23.20165639,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.23.20165639,First phylogenetic analysis of Malian SARS-CoV-2 sequences provide molecular insights into the genomic diversity of the Sahel region,Bourema Kouriba; Angela Duerr; Alexandra Rehn; Abdoul Karim Sangare; Brehima Youssouf Traoure; Malena S Bestehorn-Willmann; Judicael LJ Ouedraogo; Asli Heitzer; Elisabeth Sogodogo; Abderrhamane Maiga; Mathias C Walter; Fee Zimmermann; Roman Woelfel; Markus H Antwerpen; Clark D Russell; Loukas Moutsianas; Bo Wang; Alison Meynert; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Fiona Griffith; Wilna Oosthuyzen; Barbara Shih; Sen Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Centre d'Infectiologie Charles Merieux du Mali, Bamako, Mali; Bundeswehr Institute of Microbiology, Munich, Germany; Bundeswehr Institute of Microbiology, Munich, Germany; Centre d'Infectiologie Charles Merieux du Mali, Bamako, Mali; Centre d'Infectiologie Charles Merieux du Mali, Bamako, Mali; Bundeswehr Institute of Microbiology, Munich, Germany; Centre d'Infectiologie Charles Merieux du Mali, Bamako, Mali; Bundeswehr Institute of Microbiology, Munich, Germany; Centre d'Infectiologie Charles Merieux du Mali, Bamako, Mali; Centre d'Infectiologie Charles Merieux du Mali, Bamako, Mali; Bundeswehr Institute of Microbiology, Munich, Germany; Bundeswehr Institute of Microbiology, Munich, Germany; Bundeswehr Institute of Microbiology, Munich, Germany; Bundeswehr Institute of Microbiology, Munich, Germany; University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK; Genomics England; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","We are currently facing a pandemic of COVID-19, caused by a spillover from an animal-originating coronavirus to humans occuring in the Wuhan region, China, in December 2019. From China the virus has spread to 188 countries and regions worldwide, reaching the Sahel region on the 2nd of March 2020. Since whole genome sequencing (WGS) data is very crucial to understand the spreading dynamics of the ongoing pandemic, but only limited sequence data is available from the Sahel region to date, we have focused our efforts on generating the first Malian sequencing data available. Screening of 217 Malian patient samples for the presence of SARS-CoV-2 resulted in 38 positive isolates from which 21 whole genome sequences were generated. Our analysis shows that both, the early A (19B) and the fast evolving B (20A/C) clade, are present in Mali indicating multiple and independent introductions of the SARS-CoV-2 to the Sahel region.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.24.20200543,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200543,Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study,Andrew Jeremijenko; Hiam Chemaitelly; Houssein H. Ayoub; Moza Abdellatif Hassan Abdulla; Abdul Badi Abou-Samra; Jameela Ali A.A. Al Ajmi; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Hamad Medical Corporation; Weill Cornell Medicine-Qatar; Qatar University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Background: Qatar experienced a large severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual workers (CMWs) who constitute 60% of the population. This study aimed to investigate level of immunity in communities within this population as well as infection exposure required to achieve herd immunity. Methods: Anti-SARS-CoV-2 seropositivity was assessed in ten CMW communities between June 21 and September 9, 2020. PCR positivity, infection positivity (antibody and/or PCR positive), and infection severity rate were also estimated. Associations with anti-SARS-CoV-2 positivity were investigated using regression analyses. Results: Study included 4,970 CMWs who were mostly men (95.0%) and <40 years of age (71.5%). Seropositivity ranged from 54.9% (95% CI: 50.2-59.4%) to 83.8% (95% CI: 79.1-87.7%) in the different CMW communities. Pooled mean seropositivity across all communities was 66.1% (95% CI: 61.5-70.6%). PCR positivity ranged from 0.0% to 10.5% (95% CI: 7.4-14.8%) in the different CMW communities. Pooled mean PCR positivity was 3.9% (95% CI: 1.6-6.9%). Median cycle threshold (Ct) value was 34.0 (range: 15.8-37.4). The majority (79.5%) of PCR-positive individuals had Ct value >30 indicative of earlier rather than recent infection. Infection positivity (antibody and/or PCR positive) ranged from 62.5% (95% CI: 58.3-66.7%) to 83.8% (95% CI: 79.1-87.7%) in the different CMW communities. Pooled mean infection positivity was 69.5% (95% CI: 62.8-75.9%). Only five infections were ever severe and one was ever critical, an infection severity rate of 0.2% (95% CI: 0.1-0.4%). Conclusions: Based on an extended range of epidemiological measures, active infection is rare in these communities with limited if any sustainable infection transmission for clusters to occur. At least some CMW communities in Qatar have reached or nearly reached herd immunity for SARS-CoV-2 infection at a proportion of ever infection of 65-70%.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.24.20201061,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20201061,Quantifying the impact of quarantine duration on COVID-19 transmission,Peter Ashcroft; Sonja Lehtinen; Daniel C Angst; Nicola Low; Sebastian Bonhoeffer; Jameela Ali A.A. Al Ajmi; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Institute of Integrative Biology, ETH Zurich, Switzerland; Institute of Integrative Biology, ETH Zurich, Switzerland; Institute of Integrative Biology, ETH Zurich, Switzerland; University of Bern; Institute of Integrative Biology, ETH Zurich, Switzerland; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","The numbers of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are increasing in many places. Consequently, the number of individuals placed into quarantine is increasing too. The large number of individuals in quarantine has high societal and economical costs. There is ongoing debate about the duration of quarantine, particularly since the fraction of individuals in quarantine who eventually test positive is perceived as being low. We present a mathematical model that uses empirically determined distributions of incubation period, infectivity, and generation time to quantify how the duration of quarantine affects transmission. We use this model to examine two quarantine scenarios: traced contacts of confirmed SARS-CoV-2 cases and returning travellers. We quantify the impact of shortening the quarantine duration in terms of prevented transmission and the ratio of prevented transmission to days spent in quarantine. We also consider the impact of i) test-and-release strategies; ii) reinforced hygiene measures upon release after a negative test; iii) the development of symptoms during quarantine; iv) the relationship between quarantine duration and adherence; and v) the fraction of individuals in quarantine that are infected. When considering the ratio of prevented transmission to days spent in quarantine, we find that the diminishing impact of longer quarantine on transmission prevention may support a quarantine duration below 10 days. This ratio can be increased by implementing a test-and-release strategy, and this can be even further strengthened by reinforced hygiene measures post-release. We also find that unless a test-and-release strategy is considered, the fraction of individuals in quarantine that are infected does not affect the optimal duration of quarantine under our utility metric. Ultimately, we show that there are quarantine strategies based on a test-and-release protocol that, from an epidemiological viewpoint, perform almost as well as the standard 10 day quarantine, but with a lower cost in terms of person days spent in quarantine. This applies to both travellers and contacts, but the specifics depend on the context.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.24.20200667,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200667,Impact of COVID-19 on the mortality rates for the resident population of the Umbria region in Italy,Carla Bietta; Mattia Morini; Asiya Kamber Zaidi; Francesco Cozzolino; Puya Dehgani-Mobaraki; Jameela Ali A.A. Al Ajmi; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Epidemiology Department of Prevention, Azienda USL Umbria 1, Perugia, Italy.; Voluntary collaboration  with UOSD Epidemiology Department of Prevention, Azienda USL Umbria 1, Perugia, Italy.; Association Naso Sano , Umbria Regional Registry of volunteer activities, Corciano, Italy; Hygiene and Public Health Service Department of Prevention, Azienda USL Umbria 1, Perugia, Italy.; Founder and President, Association Naso Sano, Umbria Regional Registry of volunteer activities, Corciano, Italy; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","The mortality figures related to the coronavirus pandemic has been the topic of debate lately. Several hypothesis are made regarding the expected number of deaths in a region but there are various factors governing the same. In this paper, we have discussed the mortality figures in the Umbria region after analyzing the data from the national Health registry between December 2019 to April 2020; the period of infection and its comparison with the data from previous five years. The factors governing these figures were studied including temperature, standard mortality rates, territorial distribution, death due to all cases as well as the non-COVID deaths. A sharp increase in mortality figures was observed for the month of march and low temperature also had a role to play. However the difference when compared to previous 5 years was not significant as was expected at the start of the study. A single factor cannot be responsible for the total mortality figures in a region as is frequently predicted.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.23.20200147,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.23.20200147,Identifying gaps in COVID-19 health equity data reporting in Canada using a scorecard approach,Alexandra Blair; Kahiye Warsame; Harsh Naik; Walter Byrne; Abtin Parnia; Arjumand Siddiqi; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"University of Toronto Dalla Lana School of Public Health; University of Toronto Dalla Lana School of Public Health; University of Toronto Dalla Lana School of Public Health; University of Toronto Dalla Lana School of Public Health; University of Toronto Dalla Lana School of Public Health; University of Toronto Dalla Lana School of Public Health; Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, USA; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Objective: To assess health equity-oriented COVID-19 data reporting across Canadian provinces and territories, using a scorecard approach. Method: A scan was performed of provincial and territorial reporting of five data elements (cumulative totals of tests, cases, hospitalizations, deaths and population size) across three units of aggregation (province or territory-level, health regions, and local areas) (15 ""overall"" indicators), and for two vulnerable settings (long term care and detention facilities) and six social markers (age, sex, immigration status, race/ethnicity, essential worker status, and income) (120 ""equity-related"" indicators). Per indicator, one point was awarded if case-delimited data were released, 0.7 points if only summary statistics were reported, and 0 if neither was provided. Results were presented using a scorecard approach. Results: Overall, information on cases and deaths was more complete than for tests, hospitalizations and population size denominators needed for rate estimation. Information provided on jurisdictions and their regions, overall, tended to be more available (average score of 53%, ""B"") than for equity-related indicators (average score of 21%, ""D""). Only British Columbia and Alberta provided case-delimited data, and only Alberta provided information for local areas. No jurisdiction reported on outcomes according to patients' individual-level immigration status, race, or income. Only Ontario and Quebec provided detailed information for long-term care settings and detention facilities. Conclusion: Socially stratified reporting for COVID-19 outcomes is sparse in Canada. However, several best practices in health equity-oriented reporting were observed and set a relevant precedent for all jurisdictions to follow for this pandemic and future ones.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.24.20200766,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200766,On the Analysis of Mortality Risk Factors for Hospitalized COVID-19 Patients: a Data-driven Study Using the Major Brazilian Database,Fernanda Sumika Hojo Souza; Natlia Satchiko Hojo-Souza; Ben Divide de Oliveira Batista; Cristiano Maciel da Silva; Daniel Ludovico Guidoni; Arjumand Siddiqi; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Federal University of So Joo del-Rei; Fundao Oswaldo Cruz; Federal University of So Joo del-Rei; Federal University of So Joo del-Rei; Federal University of So Joo del-Rei; University of Toronto Dalla Lana School of Public Health; Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, USA; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Background: Brazil became the epicenter of the COVID-19 epidemic in a brief period of a few months after the first officially registered case. The knowledge of the epidemiological/clinical profile and the risk factors of Brazilian COVID-19 patients can assist in the decision making of physicians in the implementation of early and most appropriate measures for poor prognosis patients. However, these reports are missing. Here we present a comprehensive study that addresses this demand. Methods: This data-driven study was based on the Brazilian Ministry of Health Database (SIVEP-Gripe, 2020) regarding notified cases of hospitalized COVID-19 patients during the period from February 26 to August 10, 2020. Demographic data, clinical symptoms, comorbidities and other additional information of patients were analyzed. Results: The hospitalization rate was higher for male gender (56.56%) and for older age patients of both sexes. Overall, the mortality rate was quite high (41.28%) among hospitalized patients, especially those over 60 years of age. Most prevalent symptoms were cough, dyspnoea, fever, low oxygen saturation and respiratory distress. Heart disease, diabetes, obesity, kidney disease, neurological disease, and pneumopathy were the most prevalent comorbidities. A high prevalence of hospitalized COVID-19 patients with heart disease (65.7%) and diabetes (53.55%) and with a high mortality rate of around 50% was observed. The ICU admission rate was 39.37% and of these 62.4% died. 24.4% of patients required invasive mechanical ventilation (IMV), with high mortality among them (82.98%). The main mortality risk predictors were older age and IMV requirement. In addition, socioeconomic conditions have been shown to significantly influence the disease outcome, regardless of age and comorbidities. Conclusion: Our study provides a comprehensive overview of the hospitalized Brazilian COVID-19 patients profile and the mortality risk factors. The analysis also evidenced that the disease outcome is influenced by multiple factors, as unequally affects different segments of population.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.23.20200006,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.23.20200006,FeverIQ - A Privacy-Preserving COVID-19 SymptomTracker with 3.6 Million Reports,Ankit Ranjan; Serena Li; Boyuan Chen; Alan Chiu; Karthik Jagadeesh; Jan Liphardt; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Nuffield Department of Surgical Sciences, University of Oxford; Henry M. Gunn High School; Enya Inc.; Enya Inc.; Broad Institute of MIT and Harvard; Department of Bioengineering, Stanford University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Population-scale COVID-19 management benefits from timely and honest information from billions of people. Here, we provide a first report on the FeverIQ symptom tracker, a global effort to collect symptom and test data which has received more than 3.6 million submissions. Unlike other trackers, FeverIQ uses secure multiparty computation (SMC) to cryptographically guarantee user privacy while providing insights to scientists and public health efforts. We performed basic integrity checks of the FeverIQ dataset, such as by comparing it to other publicly released data. We then trained a linear classifier on diagnosis scores which were computed securely, without unprotected symptom data ever leaving a user's phone or computer. FeverIQ is currently the world's largest application of SMC in a health context, demonstrating the practicality of privacy-preserving analytics for population-scale digital health interventions.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.24.20200782,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200782,Risk assessment of COVID-19 airborne infection during hybrid learning,Luis Alfredo Anchordoqui; Eugene M. Chudnovsky; Thomas C Paul; Alan Chiu; Karthik Jagadeesh; Jan Liphardt; Nasser Ali Asad Al-Ansari; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"City University of New York; City University of New York; City University of New York; Enya Inc.; Broad Institute of MIT and Harvard; Department of Bioengineering, Stanford University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Converging lines of evidence seem to indicate that SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic, can be transmitted from person-to-person via aerosols that waft through the air and accumulate over time. The airborne nature of the virus could be a threat in indoor spaces in general and in particular for in-class education. We provide an assessment of the risk of SARS-CoV-2 infection during a 7-hour school day in elementary schools. We show that existing data are insufficient to establish a low (below 1\%) probability of infection with high accuracy. The use of facemasks and social distancing could significantly decrease this risk.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.24.20200865,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200865,What have we learned about positive changes experienced during COVID-19 lockdown? Evidence of the social patterning of change,Lynn Williams; Lesley Rollins; David Young; Leanne Fleming; Madeleine Grealy; Xanne Janssen; Alison Kirk; Bradley MacDonald; Paul Flowers; Einas Al Kuwari; Ahmed Al-Mohammed; Naema Hassan Abdulla Al Molawi; Huda Mohamad Al Naomi; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"University of Strathclyde; University of Strathclyde; University of Strathclyde; University of Strathclyde; University of Strathclyde; University of Strathclyde; University of Strathclyde; University of Strathclyde; University of Strathclyde; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","BackgroundMultiple studies have highlighted the negative impact of COVID-19 and its particular effects on vulnerable sub-populations. Complementing this work, here, we report on the social patterning of self-reported positive changes experienced during COVID-19 national lockdown in Scotland.

MethodsThe CATALYST study collected data from 3342 adults in Scotland during weeks 9-12 of a national lockdown. Using a cross-sectional design, participants completed an online questionnaire providing data on key sociodemographic and health variables, and completed a measure of positive change. The positive change measure spanned diverse domains (e.g., more quality time with family, developing new hobbies, more physical activity, and better quality of sleep). We used univariate analysis and stepwise regression to examine the contribution of a range of sociodemographic factors (e.g., age, gender, ethnicity, educational attainment, and employment status) in explaining positive change.

ResultsThere were clear sociodemographic differences across positive change scores. Those reporting higher levels of positive change were female, from younger age groups, married or living with their partner, employed, and in better health.

ConclusionOverall our results highlight the social patterning of positive changes during lockdown in Scotland. These findings begin to illuminate the complexity of the unanticipated effects of national lockdown and will be used to support future intervention development work sharing lessons learned from lockdown to increase positive health change amongst those who may benefit.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.24.20200873,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200873,"Anti-SARS-CoV-2 IgM and IgG antibodies in health workers in Sergipe, Brazil",MONICA SANTOS DE MELO Sr.; LYSANDRO PINTO BORGES Sr.; DANIELA RAGUER VALADAO SOUZA Sr.; ALINE FAGUNDES MARTINS Sr.; JOSE MELQUIADES DE REZENDE NETO Sr.; ANDERSON ALVES RIBEIRO Sr.; ARYANNE SANTOS Jr.; GRAZIELLY BISPO DA INVENCAO Jr.; IGOR LEONARDO SANTOS MATOS Jr.; KEZIA ALVES DO SANTOS Jr.; NICOLAS ALESSANDRO ALVES SOUZA Jr.; PAMELA CHAVES BORGES Jr.; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"UNIVERSIDADE FEDERAL DE SERGIPE; UNIVERSIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; Federal University of the Southern Border; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVESIDADE FEDERAL DE SERGIPE; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Background: The exponential growth of COVID-19 cases in Brazil is overloading health systems with overcrowding of hospitals and overflowing intensive care units. Increasing infection rates in health professionals can lead to the collapse of the health system and further worsen the pandemic. The aim of this study was to evaluate the seroprevalence of IgM and IgG for SARS-CoV-2 in health workers in Sergipe, Brazil. Methods: The targeted tests involved health professionals working on the front line to combat COVID-19. The samples were collected in the month of June, in six hospital units in the state of Sergipe. Results: 471 health professionals were tested. Of these, 28 workers (5.95%) tested positive for IgM and 64 (13.59%) tested positive for IgG. 9 workers (1.91%) tested positive for IgM and were also positive for IgG. Discussion: Health workers must be monitored constantly, because if they are infected, they can spread the virus to colleagues, hospitalized patients and even family members. Conclusion: Knowing the prevalence of antibodies to the virus in health workers is an important measure of viral spread control. Keywords: SARS-CoV-2, COVID-19, Health workers, Immunofluorescence assays.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.23.20199877,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.23.20199877,"A low-cost, rapidly scalable, emergency use ventilator for the COVID-19 crisis",Samuel J Raymond; Trevor Wesolowski; Sam Baker; Yuzhe Liu; Jordan L Edmunds; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Stanford University; 219 Design LLC; Stanford University; Stanford University; University of California, Berkeley; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","For the past 50 years, positive pressure ventilation has been a cornerstone of treatment for respiratory failure. Consensus surrounding the epidemiology of respiratory failure has permitted a relatively good fit between the supply of ventilators and the demand. However, the current COVID-19 pandemic has increased demand for mechanical ventilators well beyond supply. Respiratory failure complicates most critically ill patients with COVID-19 and is characterized by highly heterogeneous pulmonary parenchymal involvement, profound hypoxemia and pulmonary vascular injury. The profound increase in the incidence of respiratory failure has exposed critical shortages in the supply of mechanical ventilators, and those with the necessary skills to treat. While most traditional ventilators rely on an internal compressor and mixer to moderate and control the gas mixture delivered to a patient, the current emergency climate has catalyzed alternative designs that might enable greater flexibility in terms of supply chain, manufacturing, storage and maintenance. Design considerations of these 'emergency response' ventilators have generally fallen into two categories: those that rely on mechanical compression of a known volume of gas and those powered by an internal compressor to deliver time cycled pressure- or volume-limited gas to the patient. The present work introduces a low-cost, ventilator designed and built in accordance with the Emergence Use guidance provided by the US Food and Drug Administration (FDA) wherein an external gas supply feeds into the ventilator and time limited flow interruption guarantees tidal volume. The goal of this device is to allow a patient to be treated by a single ventilator platform, capable of supporting the various treatment paradigms during a potential COVID-19 related hospitalization. This is a unique aspect of this design as it attempts to become a one-device-one-visit solution to the problem. The device is designed as a single use ventilator that is sufficiently robust to treat a patient being mechanically ventilated. The overall design philosophy and its applicability in this new crisis-laden world view is first described, followed by both bench top and animal testing results used to confirm the precision, capability, safety and reliability of this low cost and novel approach to mechanical ventilation during the COVID-19 pandemic. The ventilator is shown to perform in a range of critical requirements listed in the FDA emergency regulations and can safely and effectively ventilate a porcine subject. As of August 2020, only 13 emergency ventilators have been authorized by the FDA, and this work represents the first to publish animal data using the ventilator. This proof-of-concept provides support for this cost-effective, readily mass-produced ventilator that can be used to support patients when the demand for ventilators outstrips supply in hospital settings worldwide. More details for this project can be found at https://ventilator.stanford.edu/",emergency medicine,exact,100,100
medRxiv,10.1101/2020.09.24.20200436,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200436,"When it is available, will we take it? Public perception of hypothetical COVID-19 vaccine in Nigeria",Yusuff Adebayo Adebisi; Aishat Jumoke Alaran; Obasanjo Afolabi Bolarinwa; Wuraola Akande-Sholabi; Don Eliseo Lucero-Prisno III; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"University of Ibadan, Ibadan, Nigeria; Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria; University of Kwazulu-Natal, Durban; University of Ibadan, Ibadan, Nigeria; London School of Hygiene and Tropical Medicine, London, United Kingdom; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","IntroductionCOVID-19 pandemic is a global public health threat facing mankind. There is no specific antiviral treatment for COVID-19, and no vaccine is currently available. This study aimed to understand the perception of the public towards a hypothetical COVID-19 vaccine in Nigeria.

MethodWe conducted a cross-sectional survey in August 2020 across the 36 states of Nigeria using an online questionnaire. The questionnaire includes sections on the demographic characteristics of the respondents and their perception regarding a hypothetical COVID-19 vaccine. A total of 517 respondents completed and returned the informed consent along with the questionnaire electronically. Data were coded and abstracted into the Microsoft Excel spreadsheet and loaded into the STATA 14 software for final analysis.

ResultsThe results showed that more than half of the respondents were male 294 (56.9%). Most of the respondents (385, 74.5%) intend to take the COVID-19 vaccine when it becomes available. Among the 132 respondents that would not take the COVID-19 vaccine, the major reason for non-acceptance was unreliability of the clinical trials 49 (37.1%), followed by the belief that their immune system was sufficient to combat the virus 36 (27.3%). There were significant association between the age of the respondents and the COVID-19 vaccine acceptance (P-value=0.00) as well as geographical location and COVID-19 vaccine acceptance (P-value=0.02).

ConclusionIt was observed that most of the respondents were willing to take the COVID-19 vaccine. Our findings reiterate the need to reassure the public that any vaccine that becomes available will be safe and effective. In addition, there is a need for the national health authorities to ensure the public trust is earned and all communities, including the marginalized populations, are engaged properly to ensure an optimal COVID-19 vaccine acceptance.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.24.20201178,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20201178,"Face Masks, Public Policies and Slowing the Spread of COVID-19: Evidence from Canada",Alexander Karaivanov; Shih En Lu; Hitoshi Shigeoka; Cong Chen; Stephanie Pamplona; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Simon Fraser University; Simon Fraser University; Simon Fraser University; Simon Fraser University; Simon Fraser University; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","We estimate the impact of mask mandates and other non-pharmaceutical interventions (NPI) on COVID-19 case growth in Canada, including regulations on businesses and gatherings, school closures, travel and self-isolation, and long-term care homes. We partially account for behavioural responses using Google mobility data. Our identification strategy exploits variation in the timing of indoor face mask mandates staggered over two months in the 34 public health districts in Ontario, Canadas most populous province. We find that mask mandates are associated with a 25 percent or larger weekly reduction in new COVID-19 cases in July and August, relative to the trend in absence of mask mandate. Additional analysis with province-level data provides corroborating evidence. Counterfactual policy simulations suggest that mandating indoor masks nationwide in early July could have reduced the number of new cases in Canada by 25 to 40 percent in mid-August, which corresponds to 700 to 1,100 fewer cases per week.

JEL codesI18, I12, C23",health economics,exact,100,100
medRxiv,10.1101/2020.09.24.20201293,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20201293,Personal protective equipment for reducing the risk of COVID-19 infection among healthcare workers involved in emergency trauma surgery during the pandemic: an umbrella review,Dylan Paul Griswold; Andres Gempeler; Angelos Kolias; Peter Hutchinson; Andres Rubiano; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Cambridge University; Fundacion Valle del Lili, Cali, Colombia; University of Cambridge; University of Cambridge; Universidad El Bosque; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Objective: The objective of this review was to summarise the effects of different personal protective equipment (PPE) for reducing the risk of COVID-19 infection in health personnel caring for patients undergoing trauma surgery. The purpose of the review was to inform recommendations for rational use of PPE for emergency surgery staff, particularly in low resources environments where PPE shortages and high costs are expected to hamper the safety of healthcare workers (HCWs) and affect the care of trauma patients. Introduction: Many healthcare facilities in low-and middle-income countries are inadequately resourced. COVID-19 has the potential to decimate these already strained surgical healthcare services unless health systems take stringent measures to protect healthcare workers from viral exposure. Inclusion criteria: This review included systematic reviews, experimental and observational studies evaluating the effect of different PPE on the risk of COVID-19 infection in HCWs involved in emergency trauma surgery. Indirect evidence from other healthcare settings was considered, as well as evidence from other viral outbreaks summarised and discussed for the COVID-19 pandemic. Methods: We conducted searches in the LOVE (Living OVerview of Evidence) platform for COVID-19, a system that performs automated regular searches in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and over thirty other sources. The risk of bias assessment of the included studies was planned with the AMSTAR II tool for systematic reviews, the RoBII tool for randomised controlled trials, and the ROBINS-I tool for non-randomised studies. Data were extracted using a standardised data extraction tool and summarised narratively. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach for grading the certainty of the evidence was followed. Results: We identified 17 systematic reviews that fulfilled our selection criteria and were included for synthesis. We did not identify randomised controlled trials during COVID-19 or studies additional to those included in the reviews that discussed other similar viral respiratory illnesses. Conclusions: The use of PPE drastically reduces the risk of COVID-19 compared with no mask use in HCWs in the hospital setting. N95 and N95 equivalent respirators provided more protection and were found to halve the risk of COVID-19 contagion in HCWs from moderate and high-risk environments. Eye protection also offers additional security and is associated with reduced incidence of contagion. These effects apply to emergency trauma care. Decontamination and reuse appear as feasible, cost-effective measures that would likely help overcome PPE shortages and enhance the allocation of limited resources. SUMMARY OF FINDINGS There is high certainty that the use of N95 respirators and surgical masks are associated with a reduced risk of coronaviruses respiratory illness when compared with no mask use. In moderate to high-risk environments, especially in aerosol-generating procedures, N95 respirators are associated with a more significant reduction in risk of COVID-19 infection compared with surgical masks. Eye protection also reduces the risk of contagion. Decontamination of masks and respirators with ultraviolet germicidal irradiation, vaporous hydrogen peroxide, or dry heat is effective and does not affect PPE performance or fit.",health policy,exact,100,100
medRxiv,10.1101/2020.09.24.20201319,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20201319,"Reproductive Maternal and Newborn Health providers assessment of facility preparedness and its Determinants during the COVID-19 pandemic in Lagos, Nigeria",Charles A Ameh; Aduragbemi A Banke-Thomas; Mobolanle Balogun; Christian Chigozie Makwe; Bosede Afolabi; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Liverpool School of Tropical Medicine; London School of Economics and Political Science; College of Medicine, University of Lagos; College of Medicine, University of Lagos; College of Medicine, University of Lagos; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","The global COVID-19 pandemic is predicted to compromise the achievement of global reproductive, maternal and newborn health (RMNH) targets. The objective of this study was to determine the health facility (HF) preparedness for RMNH service delivery during the outbreak from the perspective of RMNH providers and to determine what factors significantly predict this. An anonymous cross-sectional online survey of RMNH providers was conducted from 1st to 21st July 2020 in Lagos state Nigeria. We conducted a descriptive and ordinal regression analysis, with RMNH worker perception of HF preparedness for RMNH service delivery during the outbreak as the dependent variable. Two hundred and fifty-six RMNH workers participated, 35.2% reported that RMNH services were unavailable at some time since March 2020, 39% felt moderate or extreme work-related burnout, 84% were moderately or extremely concerned about the availability of PPE and related guidelines, and only 11.7% were extremely satisfied with the preparedness of their HFs. Our final model was a statistically significant predictor of RMNH worker perception of HF preparedness explaining 54.7% of the variation in the outcome variable. A one-unit increase in the level of satisfaction with the communication from HF management and level of concern about the availability of PPE and COVID-19 guidelines would increase the odds of observing a higher category of satisfaction with HF COVID-19 preparedness (OR 0.79-2.92, p<0.001 and 0.02-0.15 p<0.001 respectively). Adequate support of RMNH providers particularly provision of PPE and guidelines, appropriate communications about COVID-19 should be prioritised as part of health system preparedness.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.09.25.20201376,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.25.20201376,COVID-19 mortality rate in Russia: forecasts and reality evaluation,Marina Lifshits; Natalia Neklyudova; Mobolanle Balogun; Christian Chigozie Makwe; Bosede Afolabi; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Institute of Economics of the Ural Branch of the Russian Academy of Sciences; Institute of Economics, Ural Branch of the Russian Academy of Sciences, Yekaterinburg, Russia; College of Medicine, University of Lagos; College of Medicine, University of Lagos; College of Medicine, University of Lagos; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","COVID-19 is an extremely dangerous disease that not only spreads quickly, but is also characterized by a high mortality rate. Therefore, predicting the number of deaths from the new coronavirus is an urgent task. The aim of the study is to analyze the factors affecting COVID-19 mortality rate in various countries, to predict direct and indirect victims of the pandemic in the Russian Federation, and to estimate additional mortality during the pandemic based on the demographic data. The main research method is econometric modeling. Comparison of various data was also applied. The authors' calculations were based on data from the RSSS, the World Bank, as well as specialized sites with coronavirus statistics in Russia and in the world. A predictive estimation of the deceased number of people due to the pandemic in Russia was made. It is confirmed that the deaths proportion of the completed cases of the disease depends on the level of testing. It is shown that the revealed mortality of the disease depends on the proportion of completed cases, on the population age structure, and on how early the pandemic entered the country compared to the other countries. It is determined that the number of additional deaths due to the coronavirus is approximately 31 thousand people. The analysis revealed that the relatively low proportion of COVID in Russia is the result of a special approach to the cause of death determination. The mortality rate in Russia in April 2020 was about 3% higher than in April 2019. The share of the deceased health workers in the total coronavirus mortality in the Russian Federation is higher than in the developed countries, which indicates an underestimation of the data on COVID- 19 deaths in the Russian Federation, and the unsatisfactory quality of the Russian healthcare system. The number of direct and indirect victims of the pandemic in the Russian Federation at the end of July was approximately 43 thousand people.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.24.20200303,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200303,Serum SARS-CoV-2 nucleocapsid antigen detection is essential for primary diagnostics of SARS-CoV-2-associated pneumonia,Yuri S. Lebedin; Olga V. Lyang; Anaida G. Galstyan; Vsevolod V. Belousov; Denis V. Rebrikov; Mauricio J Bustamante; Brett Ley; Dwayne Free; Michel Maharbiz; Ryan Van Wert; David N Cornfield; David B Camarillo; MAKSON GLEYDSON BRITO DE OLIVEIRA Sr.; Adeel A Butt; Peter Coyle; Reham Awni El Kahlout; Imtiaz Gillani; Anvar Hassan Kaleeckal; Naseer Ahmad Masoodi; Anil George Thomas; Hanaa Nafady-Hego; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Nourah B M Younes; Hanan F. Abdul Rahim; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Xema-Medica Co. Ltd; Pirogov Russian National Research Medical University; Federal Center of Brain Research and Neurotechnologies; Federal Center of Brain Research and Neurotechnologies; Pirogov Russian National Research Medical University; University of California, Berkeley; Kaiser Pulmonology and Critical Care; Stanford University; University of California, Berkeley; Stanford University; Stanford University; Stanford University; UNIVERSIDADE FEDERAL DE SERGIPE; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation and Microbiology and Immunology Department, Faculty of Medicine, Assiut University; Hamad Medical Corporation; Hamad Medical Corporation; Hamad Medical Corporation; Qatar University; Qatar University; Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","The article highlights the diagnostic value of SARS-CoV-2 seroconversion in patients with pneumonia based on the results of a retrospective study conducted at the height of the COVID-19 pandemic in Moscow, Russia",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.25.20201459,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.25.20201459,Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama,Alcibiades Villarreal; Giselle Rangel; Xu Zhang; Digna Wong; Carolina De La Guardia; Gabrielle Britton; Patricia L. Fernandez; Carlos M Restrepo; Ambar Perez; Diana Oviedo; Maria B Carreira; Gilberto A. Eskildsen; Dilcia Sambrano; Yamitzel Zaldivar; Danilo Franco; Sandra Lopez Verges; Dexi Zhang; Fangjing Fan; Baojun Wang; Xavier Saez-Llorens; Rodrigo DeAntonio; Ivonne Torres-Atencio; Fernando Diaz Subia; Eduardo Ortega-Barria; Rao Kosagisharaf; Ricardo Lleonart; Chong Li; Amador Goodridge; - COVID-19 SEROLOGY COLLABORATOR GROUP; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"INDICASAT-AIP; INDICASAT-AIP; CAS; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; GORGAS; GORGAS; GORGAS; CAS; CAS; KEWEI; CEVAXIN; CEVAXIN; UP; Pacifica Salud; GSK; INDICASAT-AIP; INDICASAT-AIP; CAS; INDICASAT-AIP; ; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, which has reached 28 million cases worldwide in eight months. The serological detection of antibodies against the virus will play a pivotal role in complementing molecular tests to improve diagnostic accuracy, contact tracing, vaccine efficacy testing and seroprevalence surveillance. Here, we aimed first to evaluate a lateral flow assays ability to identify specific IgM and IgG antibodies against SARS-CoV-2 and second, to report the seroprevalence of these antibodies among health care workers and healthy volunteer blood donors in Panama. We recruited study participants between April 30th and July 7th, 2020. For the test validation and performance evaluation, we analyzed serum samples from participants with clinical symptoms and confirmed positive RT-PCR for SARS-CoV-2, and a set of pre-pandemic serum samples. We used two by two table analysis to determine the test sensitivity and specificity as well as the kappa agreement value with a 95% confidence interval. Then, we used the lateral flow assay to determine seroprevalence among serum samples from COVID-19 patients, potentially exposed health care workers, and healthy volunteer donors. Our results show this assay reached a positive percent agreement of 97.2% (95% CI 84.2-100.0%) for detecting both IgM and IgG. The assay showed a kappa of 0.898 (95%CI 0.811-0.985) and 0.918 (95% CI 0.839-0.997) for IgM and IgG, respectively. The evaluation of serum samples from hospitalized COVID-19 patients indicates a correlation between test sensitivity and the number of days since symptom onset; the highest positive percent agreement (87% (95% CI 67.0-96.3%)) was observed at [&ge;]15 days post-symptom onset. We found an overall antibody seroprevalence of 11.6% (95% CI 8.5-15.8%) among both health care workers and healthy blood donors. Our findings suggest this lateral flow assay could contribute significantly to implementing seroprevalence testing in locations with active community transmission of SARS-CoV-2.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.24.20200394,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200394,Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer,Naveen K Singh; Partha Ray; Aaron F Carlin; Celestine Magallanes; Sydney Morgan; Louise C Laurent; Eliah Aronoff-Spencer; Drew A. Hall; Ambar Perez; Diana Oviedo; Maria B Carreira; Gilberto A. Eskildsen; Dilcia Sambrano; Yamitzel Zaldivar; Danilo Franco; Sandra Lopez Verges; Dexi Zhang; Fangjing Fan; Baojun Wang; Xavier Saez-Llorens; Rodrigo DeAntonio; Ivonne Torres-Atencio; Fernando Diaz Subia; Eduardo Ortega-Barria; Rao Kosagisharaf; Ricardo Lleonart; Chong Li; Amador Goodridge; - COVID-19 SEROLOGY COLLABORATOR GROUP; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"University of California, San Diego; University of California, San Diego; University of California, San Diego; University of California, San Diego; University of California, San Diego; University of California, San Diego; UC San Diego; University of California, San Diego; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; GORGAS; GORGAS; GORGAS; CAS; CAS; KEWEI; CEVAXIN; CEVAXIN; UP; Pacifica Salud; GSK; INDICASAT-AIP; INDICASAT-AIP; CAS; INDICASAT-AIP; ; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of effective antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf glucometer. The test was engineered around a glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally making the test highly scalable with an infrastructure that is already in place. Furthermore, many glucometers connect to smartphones providing an opportunity to integrate with contract tracing apps, medical providers, and electronic medical records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within one hour, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach can provide an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.25.20200956,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.25.20200956,"An easy, reliable and rapid SARS-CoV2 RT-LAMP based test for Point-of-Care and diagnostic lab",Meriadeg AR GOUILH; Renaud CASSIER; Elodie MAILLE; Cecile Schanen; Louis-Marie ROCQUE; Astrid VABRET; Eliah Aronoff-Spencer; Drew A. Hall; Ambar Perez; Diana Oviedo; Maria B Carreira; Gilberto A. Eskildsen; Dilcia Sambrano; Yamitzel Zaldivar; Danilo Franco; Sandra Lopez Verges; Dexi Zhang; Fangjing Fan; Baojun Wang; Xavier Saez-Llorens; Rodrigo DeAntonio; Ivonne Torres-Atencio; Fernando Diaz Subia; Eduardo Ortega-Barria; Rao Kosagisharaf; Ricardo Lleonart; Chong Li; Amador Goodridge; - COVID-19 SEROLOGY COLLABORATOR GROUP; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Normandie Univ, UNICAEN, UNIROUEN, EA2656, Caen F-14033, France & Laboratoire de Virologie, Centre ; Loop Dee Science, Caen F-14000, France.; Loop Dee Science, Caen F-14000, France.; Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Normandie Univ, UNICAEN, UNIROUEN, EA2656, Caen F-14033, France & Laboratoire de Virologie, Centre ; Loop Dee Science, Caen F-14000, France.; Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Normandie Univ, UNICAEN, UNIROUEN, EA2656, Caen F-14033, France & Laboratoire de Virologie, Centre ; UC San Diego; University of California, San Diego; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; INDICASAT-AIP; GORGAS; GORGAS; GORGAS; CAS; CAS; KEWEI; CEVAXIN; CEVAXIN; UP; Pacifica Salud; GSK; INDICASAT-AIP; INDICASAT-AIP; CAS; INDICASAT-AIP; ; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","This study presents and evaluates a rapid and all-in-one SARS-CoV-2 RT-LAMP based molecular detection system, including RNA extraction or not, for point-of-care or massive testing of naso-pharyngeal swabs. The point-of-care format uses LoopX(C), a small portative device ensuring optimal LAMP reaction and automated reading with 95.2% and 95.5% sensitivity and specificity respectively. This system might also be useful for testing other sample types such as saliva.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.24.20201285,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20201285,"CHARACTERISTICS, MANAGEMENT AND OUTCOMES OF CRITICALLY ILL COVID-19 PATIENTS ADMITTED TO ICU IN HOSPITALS IN BANGLADESH: A RETROSPECTIVE STUDY",Ayan Saha; Mohammad Moinul Ahsan; Tarek-Ul Quader; Mohammad Umer Sharif Shohan; Sabekun Naher; Preya Dutta; Al-Shahriar Akash; H M Hamidullah Mehedi; A S M Arman Ullah Chowdhury; Hasanul Karim; Tazrina Rahman; Ayesha Parvin; Dilcia Sambrano; Yamitzel Zaldivar; Danilo Franco; Sandra Lopez Verges; Dexi Zhang; Fangjing Fan; Baojun Wang; Xavier Saez-Llorens; Rodrigo DeAntonio; Ivonne Torres-Atencio; Fernando Diaz Subia; Eduardo Ortega-Barria; Rao Kosagisharaf; Ricardo Lleonart; Chong Li; Amador Goodridge; - COVID-19 SEROLOGY COLLABORATOR GROUP; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Disease Biology and Molecular Epidemiology Research Group, Chattogram, Bangladesh; Intensive Care Unit, 250 Beded General Hospital Chittagong, Chattogram, Bangladesh; Intensive Care Unit, Chittagong Medical College, Chattogram, Bangladesh; Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh; Department of Microbiology, University of Chittagong, Chattogram, Bangladesh; Department of Pharmacy, BGC Trust University, Chattogram, Bangladesh; Department of Genetic Engineering and Biotechnology, University of Chittagong, Chattogram, Bangladesh; Department of Medicine, 250 Beded General Hospital Chittagong, Bangladesh; Intensive Care Unit, 250 Beded General Hospital Chittagong, Chattogram, Bangladesh; Intensive Care Unit, 250 Beded General Hospital Chittagong, Chattogram, Bangladesh; Department of Microbiology, Chittagong Medical College, Chattogram, Bangladesh; Department of Biochemistry, Chittagong Medical College, Chattogram, Bangladesh; INDICASAT-AIP; GORGAS; GORGAS; GORGAS; CAS; CAS; KEWEI; CEVAXIN; CEVAXIN; UP; Pacifica Salud; GSK; INDICASAT-AIP; INDICASAT-AIP; CAS; INDICASAT-AIP; ; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","Objectives: This study aimed to analyse the epidemiological and clinical characteristics of critical COVID-19 cases and investigate risk factors including comorbidities and age in relation with the clinical aftermath of COVID-19 in critical cases in Bangladesh. Methods: In this retrospective study, epidemiological and clinical characteristics, complications, laboratory results, and clinical management of the patients were studied from data obtained from 168 individuals diagnosed with an advanced prognosis of COVID-19 admitted in two hospitals in Bangladesh. Results: Individuals in the study sample contracted COVID-19 through community transmission. 56.5% (n = 95) cases died in intensive care units (ICU) during the study period. The median age was 56 years and 79.2% (n=134) were male. Typical clinical manifestation included Acute respiratory distress syndrome (ARDS) related complications (79.2%), fever (54.2%) and cough (25.6%) while diabetes mellitus (52.4%), hypertension (41.1%) and heart diseases (16.7%) were the conventional comorbidities. Clinical outcomes were detrimental due to comorbidities rather than age and comorbid individuals over 50 were at more risk. In the sample, oxygen saturation was low (< 95% SpO2) in 135 patients (80.4%) and 158 (93.4%) patients received supplemental oxygen. Identical biochemical parameters were found in both deceased and surviving cases. Administration of antiviral drug Remdesivir and the glucocorticoid, Dexamethasone increased the proportion of surviving patients slightly. Conclusions: Susceptibility to developing critical illness due to COVID-19 was found more in comorbid males. These atypical patients require more clinical attention from the prospect of controlling mortality rate in Bangladesh.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.09.24.20197293,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20197293,Poor inhibitory control and stress as risk-factors for alcohol (mis)use during the COVID-19 pandemic in the UK: a national cross-sectional study across four generations,James M Clay; Lorenzo D Stafford; Matthew O Parker; Mohammad Umer Sharif Shohan; Sabekun Naher; Preya Dutta; Al-Shahriar Akash; H M Hamidullah Mehedi; A S M Arman Ullah Chowdhury; Hasanul Karim; Tazrina Rahman; Ayesha Parvin; Dilcia Sambrano; Yamitzel Zaldivar; Danilo Franco; Sandra Lopez Verges; Dexi Zhang; Fangjing Fan; Baojun Wang; Xavier Saez-Llorens; Rodrigo DeAntonio; Ivonne Torres-Atencio; Fernando Diaz Subia; Eduardo Ortega-Barria; Rao Kosagisharaf; Ricardo Lleonart; Chong Li; Amador Goodridge; - COVID-19 SEROLOGY COLLABORATOR GROUP; Roberto Bertollini; Laith J Abu-Raddad; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"University of Portsmouth; University of Portsmouth; University of Portsmouth; Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh; Department of Microbiology, University of Chittagong, Chattogram, Bangladesh; Department of Pharmacy, BGC Trust University, Chattogram, Bangladesh; Department of Genetic Engineering and Biotechnology, University of Chittagong, Chattogram, Bangladesh; Department of Medicine, 250 Beded General Hospital Chittagong, Bangladesh; Intensive Care Unit, 250 Beded General Hospital Chittagong, Chattogram, Bangladesh; Intensive Care Unit, 250 Beded General Hospital Chittagong, Chattogram, Bangladesh; Department of Microbiology, Chittagong Medical College, Chattogram, Bangladesh; Department of Biochemistry, Chittagong Medical College, Chattogram, Bangladesh; INDICASAT-AIP; GORGAS; GORGAS; GORGAS; CAS; CAS; KEWEI; CEVAXIN; CEVAXIN; UP; Pacifica Salud; GSK; INDICASAT-AIP; INDICASAT-AIP; CAS; INDICASAT-AIP; ; Ministry of Public Health, Doha, Qatar; Weill Cornell Medicine-Qatar; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","AimsThis study had two primary aims: (1) to assess change in alcohol use and hazardous drinking since the start of the COVID-19 pandemic in the UK; (2) to investigate the extent to which poor inhibitory control and stress were associated with a change in alcohol use and hazardous drinking since the pandemic began.

MethodsWe interrogated cross-sectional data from the first sweep of the COVID-19 survey, comprising four birth cohorts (13, 453 respondents, aged 19-62 years). Alcohol use, stress, and inhibitory control were self-reported. Change in drinking and hazardous alcohol use were regressed on stress and inhibitory control, adjusting for sex, ethnicity and socioeconomic status.

ResultsBetween fourteen to thirty percent of individuals reported an increase in alcohol use since the start of the pandemic, depending on age and sex. Of these, a substantial proportion (approximately four to ten percent) reported drinking hazardously, thus were at high risk of alcohol-related harm. The effects of stress and inhibitory control were age dependent. In thirty-year-olds, those reporting feeling stressed since the start of the pandemic were around four times more likely to engage in hazardous drinking (OR = 3.92, 95% CI = 1.17-13.15). Among nineteen-year-olds, a one unit increase in impatience was associated with a fourteen percent (ORadjusted = 1.14, 95% CI = 1.05-1.23) increase in the likelihood of drinking more during the lockdown, and a twenty-one percent (ORadjusted= 1.21, 95% CI = 1.05-1.41) increase in the likelihood of drinking hazardously. For those aged thirty or fifty, a one-unit increase in risk-taking was associated with an eighteen (ORadjusted = 1.18, 95% CI = 1.05-1.33) or six percent (ORadjusted = 1.06, 95% CI = 1.01, 1.12) increase in the likelihood of drinking hazardously, respectively. The findings related to the interaction between stress and inhibitory control were relatively complex. For example, thirty-year-olds that rated themselves as impatient and reported less stress tended to drink more (ORadjusted = 1.22, 95% CI = 1.00-1.48).

ConclusionsData from four nationally representative birth cohorts suggests that alcohol use during the pandemic increased in up to thirty percent of individuals. Hazardous drinking was observed in up to ten percent of respondents. Stress and inhibitory control were related to this but effects were age dependent. Governments should carefully consider the impact of personality and stress that may affect alcohol consumption in at-risk individuals.",addiction medicine,exact,100,100
medRxiv,10.1101/2020.09.22.20198754,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.22.20198754,"Ethnic differences in COVID-19 infection, hospitalisation, and mortality: an OpenSAFELY analysis of 17 million adults in England",Rohini Mathur; Christopher T. Rentsch; Caroline Morton; William J Hulme; Anna Schultze; Brian MacKenna; Rosalind M Eggo; Krishnan Bhaskaran; Angel YS Wong; Elizabeth J Williamson; Harriet Forbes; Kevin Wing; Helen I McDonald; Chris Bates; Seb Bacon; Alex J Walker; David Evans; Peter Inglesby; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Background: COVID-19 has had a disproportionate impact on ethnic minority populations, both in the UK and internationally. To date, much of the evidence has been derived from studies within single healthcare settings, mainly those hospitalised with COVID-19. Working on behalf of NHS England, the aim of this study was to identify ethnic differences in the risk of COVID-19 infection, hospitalisation and mortality using a large general population cohort in England. Methods: We conducted an observational cohort study using linked primary care records of 17.5 million adults between 1 February 2020 and 3 August 2020. Exposure was self-reported ethnicity collapsed into the 5 and 16 ethnicity categories of the English Census. Multivariable Cox proportional hazards regression was used to identify ethnic differences in the risk of being tested and testing positive for SARS-CoV-2 infection, COVID-19 related intensive care unit (ICU) admission, and COVID-19 mortality, adjusted for socio-demographic factors, clinical co-morbidities, geographic region, care home residency, and household size. Results: A total of 17,510,002 adults were included in the study; 63% white (n=11,030,673), 6% south Asian (n=1,034,337), 2% black (n=344,889), 2% other (n=324,730), 1% mixed (n=172,551), and 26% unknown (n=4,602,822). After adjusting for measured explanatory factors, south Asian, black, and mixed groups were marginally more likely to be tested (south Asian HR 1.08, 95%CI 1.07-1.09; black HR 1.08; 95%CI 1.06-1.09, mixed HR 1.03, 95%CI 1.01-1.05), and substantially more likely to test positive for SARS-CoV-2 compared with white adults (south Asian HR 2.02. 95% CI 1.97-2.07; black HR 1.68, 95%CI 1.61-1.76; mixed HR 1.46, 95%CI 1.36-1.56). The risk of being admitted to ICU for COVID-19 was substantially increased in all ethnic minority groups compared with white adults (south Asian HR 2.22, 95%CI 1.96-2.52; black HR 3.07, 95%CI 2.61-3.61; mixed HR 2.86, 95%CI 2.19-3.75, other HR 2.86, 95%CI 2.31-3.63). Risk of COVID-19 mortality was increased by 25-56% in ethnic minority groups compared with white adults (south Asian HR 1.27, 95%CI 1.17-1.38; black HR 1.55, 95%CI 1.38-1.75; mixed HR 1.40, 95%CI 1.12-1.76; other HR 1.25, 95%CI 1.05-1.49). We observed heterogeneity of associations after disaggregation into detailed ethnic groupings; Indian and African groups were at higher risk of all outcomes; Pakistani, Bangladeshi and Caribbean groups were less or equally likely to be tested for SARS-CoV-2, but at higher risk of all other outcomes, Chinese groups were less likely to be tested for and test positive for SARS-CoV-2, more likely to be admitted to ICU, and equally likely to die from COVID-19. Conclusions: We found evidence of substantial ethnic inequalities in the risk of testing positive for SARS-CoV-2, ICU admission, and mortality, which persisted after accounting for explanatory factors, including household size. It is likely that some of this excess risk is related to factors not captured in clinical records such as occupation, experiences of structural discrimination, or inequitable access to health and social services. Prioritizing linkage between health, social care, and employment data and engaging with ethnic minority communities to better understand their lived experiences is essential for generating evidence to prevent further widening of inequalities in a timely and actionable manner.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.20.20197368,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.20.20197368,Modelling the risk of SARS-CoV-2 infection through PPE doffing in a hospital environment,Marco-Felipe King; Amanda Marie Wilson; Mark H Weir; Martin Lopez-Garcia; Jessica Proctor; Waseem Hiwar; Amirul Khan; Louise A Fletcher; P Andrew Sleigh; Ian Clifton; Stephanie Jane Dancer; Mark H. Wilcox; Kelly A. Reynolds; Catherine J Noakes; Seb Bacon; Alex J Walker; David Evans; Peter Inglesby; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of Leeds; University of Arizona; The Ohio State University; University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Leeds; Leeds Cystic Fibrosis Trust Strategic Research Centre; Hairmyres Hospital; eLeeds Teaching Hospital & University of Leeds; University of Arizona; University of Leeds; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Self-contamination during doffing of personal protective equipment (PPE) is a concern for healthcare workers (HCW) following SARS-CoV-2 positive patient care. Staff may subconsciously become contaminated through improper glove removal, so quantifying this risk is critical for safe working procedures. HCW surface contact sequences on a respiratory ward were modelled using a discrete-time Markov chin for: IV-drip care, blood pressure monitoring and doctors' rounds. Accretion of viral RNA on gloves during care was modelled using a stochastic recurrence relation. The HCW then doffed PPE and contaminated themselves in a fraction of cases based on increasing case load. The risk of infection from this exposure was quantified using a dose-response methodology. A parametric study was conducted to analyse the effect of: 1a) increasing patient numbers on the ward, 1b) the proportion of COVID-19 cases, 2) the length of a shift and 3) the probability of touching contaminated PPE. The driving factors for infection risk were surface contamination and number of surface contacts. HCWs on a 100% COVID-19 ward were less than 2-fold more at risk than on a 50% COVID ward (1.6% vs 1%), whilst on a 5% COVID-19 ward, the risk dropped to 0.1% per shift (sd=0.6%). IV-drip care resulted in higher risk than blood pressure monitoring (1.1% vs 1% p<0.0001), whilst doctors' rounds produced a 0.6% risk (sd=0.8%). Recommendations include supervised PPE doffing procedures such as the ""doffing buddy"" scheme, maximising hand hygiene compliance post-doffing and targeted surface cleaning for surfaces away from the patient vicinity.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.11.20193029,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.11.20193029,Covid-19 Cases in India: A Visual Exploratory Data Analysis Model,Jayesh S Jr.; Shilpa Sreedharan Jr.; Mark H Weir; Martin Lopez-Garcia; Jessica Proctor; Waseem Hiwar; Amirul Khan; Louise A Fletcher; P Andrew Sleigh; Ian Clifton; Stephanie Jane Dancer; Mark H. Wilcox; Kelly A. Reynolds; Catherine J Noakes; Seb Bacon; Alex J Walker; David Evans; Peter Inglesby; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"School of Engineering,Cochin University of Science and Technology; Wellness Solutions; The Ohio State University; University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Leeds; Leeds Cystic Fibrosis Trust Strategic Research Centre; Hairmyres Hospital; eLeeds Teaching Hospital & University of Leeds; University of Arizona; University of Leeds; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Covid-19 outbreak was first reported in Wuhan, China. The deadly virus spread not just the disease, but fear around the globe. On January 2020, WHO declared COVID-19 as a Public Health Emergency of International Concern (PHEIC). First case of Covid-19 in India was reported on January 30, 2020. By the time, India was prepared in fighting against the virus. India has taken various measures to tackle the situation. In this paper, an exploratory data analysis of Covid-19 cases in India is carried out. Data namely number of cases, testing done, Case Fatality ratio, Number of deaths, change in visits stringency index and measures taken by the government is used for modelling and visual exploratory data analysis.",health informatics,exact,100,100
medRxiv,10.1101/2020.09.21.20196220,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20196220,"Privacy-Protecting, Reliable Response Data Discovery Using COVID-19 Patient Observations",Jihoon Kim; Larissa Neumann; Paulina Paul; Michael Aratow; Douglas S Bell; Jason N Doctor; Ludwig C Hinske; Xiaoqian Jiang; Katherine K Kim; Michael E Matheny; Daniella Meeker; Mark J Pletcher; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of California San Diego; Ludwig Maximilian University of Munich; University of California San Diego; San Mateo Medical Center; University of California Los Angeles; University of Southern California; Ludwig Maximilian University; University of Texas Health Science Center at Houston; University of California Davis; Vanderbilt University; University of Southern California; University of California San Francisco; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","There is an urgent need to answer questions related to COVID-19's clinical course and associations with underlying conditions and health outcomes. Multi-center data are necessary to generate reliable answers, but centralizing data in a single repository is not always possible. Using a privacy-protecting strategy, we launched a public Questions & Answers web portal (https://covid19questions.org) with analyses of comorbidities, medications and laboratory tests using data from 202 hospitals (59,074 COVID-19 patients) in the USA and Germany. We find, for example, that 8.6% of hospitalizations in which the patient was not admitted to the ICU resulted in the patient returning to the hospital within seven days from discharge and that, when adjusted for age, mortality for hospitalized patients was not significantly different by gender or ethnicity.",health informatics,exact,100,100
medRxiv,10.1101/2020.09.21.20195537,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20195537,Downregulation of Defensin genes in SARS-CoV-2 infection,Mohammed M Idris; Sarena Banu; Archana B Siva; Ramakrishnan Nagaraj; Douglas S Bell; Jason N Doctor; Ludwig C Hinske; Xiaoqian Jiang; Katherine K Kim; Michael E Matheny; Daniella Meeker; Mark J Pletcher; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"CSIR - Centre for Cellular and Molecular Biology; CSIR - Centre for Cellular and Molecular Biology; CSIR - Centre for Cellular and Molecular Biology; CSIR-Centre for Cellular and Molecular Biology; University of California Los Angeles; University of Southern California; Ludwig Maximilian University; University of Texas Health Science Center at Houston; University of California Davis; Vanderbilt University; University of Southern California; University of California San Francisco; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Defensins, crucial components of the innate immune system, play a vital role against infection as part of frontline immunity. Association of SARS-CoV-2 infection with defensins has not been investigated till date. In this study, we have investigated the expression of defensin genes in the buccal cavity during COVID-19 infection. Nasopharyngeal/Oropharyngeal swab samples collected for screening SARS-CoV-2 infection were analyzed for the expression of major defensin genes by the quantitative real-time reverse transcription polymerase chain reaction, qRT-PCR. 40 SARS-CoV-2 infected positive and 40 negative swab samples were selected for the study. Based on the RT-PCR analysis involving gene specific primer for defensin genes, 10 defensin genes were found to be expressed in the Nasopharyngeal/Oropharyngeal cavity. Six defensin genes were further found to be significantly downregulated in SARS-CoV-2 infected patients as against the control, negative samples based on differential expression analysis. The genes significantly downregulated were defensin beta 4A, 4B, 106B, 107B, 103A and defensin alpha 1B. Downregulation of several defensin genes suggests that innate immunity provided by defensins is or may be compromised in SARS-CoV-2 infection resulting in progression of the disease caused by the virus. Upregulation of defensin gene expression and use of defensin peptides could be attractive therapeutic interventions.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.21.20194019,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20194019,Putting (Big) Data in Action: Saving Lives with Countrywide Population Movement Monitoring Using Mobile Devices during the COVID-19 Crisis,Miklos Karoly Szocska; Peter Pollner; Istvan Schiszler; Tamas Joo; Tamas Palicz; Martin McKee; - Magyar Telekom Nyrt.; - Telenor Magyarorszag Zrt.; Adam Sohonyai; Jozsef Szoke; Adam Toth; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of London,  London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy; ; ; Vodafone Hungary; Vodafone Hungary; Vodafone Hungary; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Many countries have implemented strict social distancing measures in the hope of reducing transmission of SARS-CoV-2 but the effectiveness of these measures is determined by the willingness of populations to comply with restrictions. Consequently, a system of monitoring population movement using existing data sources can inform those making decisions about policy responses to the COVID-19 pandemic. We describe a collaboration with all 3 major domestic telecommunication companies in Hungary to use aggregated anonymous mobile phone usage data to calculate two indices for assessing the effect of movement restrictions: a ""mobility-index"" and a ""stay-at-home (or resting) index"". The strengths and weaknesses of this approach are compared with the smartphone-based, COVID-19 Community Mobility Reports from Google. Data generated by mobile phones have long been identified as a potential means to analyse mass population movement, but its operationalisation raises several technical questions, such as making sense of Call Detail Records, collation of data from different mobile network providers, and personal data protection concerns. The method described here addresses these issues and offers an effective and inexpensive tool to monitor the impact of social distancing measures, achieving high levels of accuracy and resolution. Especially in populations where uptake of smartphones is modest, this method has certain advantages over app-based solutions, with greater population coverage, but it is not an alternative to smartphone-based solutions used for contact tracing and quarantine monitoring. We believe that this method can easily be adapted by other countries.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.21.20196725,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20196725,An expert judgment model to predict early stages of the COVID-19 outbreak in the United States,Thomas Charles McAndrew; Nicholas G Reich; Istvan Schiszler; Tamas Joo; Tamas Palicz; Martin McKee; - Magyar Telekom Nyrt.; - Telenor Magyarorszag Zrt.; Adam Sohonyai; Jozsef Szoke; Adam Toth; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of Massachusetts at Amherst; University of Massachusetts at Amherst; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of London,  London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy; ; ; Vodafone Hungary; Vodafone Hungary; Vodafone Hungary; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","During early stages of the COVID-19 pandemic, forecasts provided actionable information about disease transmission to public health decision-makers. Between February and May 2020, experts in infectious disease modeling made weekly predictions about the impact of the pandemic in the U.S. We aggregated these predictions into consensus predictions. In March and April 2020, experts predicted that the number of COVID-19 related deaths in the U.S. by the end of 2020 would be in the range of 150,000 to 250,000, with scenarios of near 1m deaths considered plausible. The wide range of possible future outcomes underscored the uncertainty surrounding the outbreak's trajectory. Experts' predictions of measurable short-term outcomes had varying levels of accuracy over the surveys but showed appropriate levels of uncertainty when aggregated. An expert consensus model can provide important insight early on in an emerging global catastrophe.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.22.20128140,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.22.20128140,Subclinical ocular inflammation in persons recovered from ambulatory COVID-19,Mathieu F Bakhoum; Michele Ritter; Anupam Garg; Alison X Chan; Christine Y Bakhoum; Davey Smith; - Magyar Telekom Nyrt.; - Telenor Magyarorszag Zrt.; Adam Sohonyai; Jozsef Szoke; Adam Toth; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; ; ; Vodafone Hungary; Vodafone Hungary; Vodafone Hungary; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Coronavirus disease 2019 (COVID-19) is characterized by striking variability in clinical severity, and a hyperinflammatory response in the lung is associated with high mortality. Little is known about the extent and duration of inflammation in persons recovering from COVID-19. Here, we used spectral domain optical coherence tomography (SD-OCT) to detect the presence of inflammatory cells in the vitreous cavity, an immune-privileged microenvironment, in persons recovered from COVID- 19. Our results provide quasi-histologic evidence that neuroinflammation is present in persons who recovered from COVID-19, only one of whom required hospitalization. Our results also suggest that persons who feel that their recovery is incomplete have evidence of subclinical eye inflammation, which may be a marker of residual inflammation elsewhere as well.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.21.20191288,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20191288,Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT),Benjamin Meyer; Johan Reimerink; Giulia Torriani; Fion Brouwer; Gert-Jan Godeke; Sabine Yerly; Marieke Hoogerwerf; Nicolas Vuilleumier; Laurent Kaiser; Isabella Eckerle; Chantal Reusken; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of Geneva; RIVM; University of Geneva; RIVM; RIVM; University hospitals of Geneva; RIVM; University hospitals of Geneva; University of Geneva Hospitals; University hospitals of Geneva; RIVM; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","To understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays such as virus neutralizing assays are needed. So far, assays to determine SARS-CoV-2 neutralizing antibodies rely on cell-culture based infection assays either using wild type SARS-CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety facilities and are difficult to standardize. Recently, a new surrogate virus neutralisation assay (sVNT) was described that uses the principle of an ELISA to measure the neutralization capacity of anti-SARS-CoV-2 antibodies directed against the receptor binding domain. Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples collected before 2020 and compared it to cell-based neutralization assays. We found a high specificity of 99.2 (95%CI: 96.9-99.9) and overall sensitivity of 80.3 (95%CI: 74.9-84.8) for the sVNT. Clinical sensitivity increased between early (<14 days post symptom onset or post diagnosis, dpos/dpd) and late sera (>14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1 (76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3 (56.4-86.9) and 98.2 (89.4-99.9) for titres [&ge;]10 to <40 and [&ge;]40 to <160, respectively. Only samples with a titre [&ge;]160 were always positive in the sVNT. In conclusion, the sVNT can be used as an additional assay to determine the immune status of COVID-19 infected of vaccinated individuals but its value needs to be assessed for the specific context of use.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.18.20185744,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.18.20185744,Analysis of external quality assessment samples revealed crucial performance differences between commercial RT-PCR assays for SARS-CoV-2 detection when taking extraction methods and real-time-PCR instruments into account,Monika Malecki; Jessica Luesebrink; Andreas Wendel; Frauke Mattner; Gert-Jan Godeke; Sabine Yerly; Marieke Hoogerwerf; Nicolas Vuilleumier; Laurent Kaiser; Isabella Eckerle; Chantal Reusken; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"Kliniken der Stadt Koeln gGmbH; Kliniken der Stadt Koeln gGmbH; Kliniken der Stadt Koeln gGmbH; Kliniken der Stadt Koeln gGmbH; RIVM; University hospitals of Geneva; RIVM; University hospitals of Geneva; University of Geneva Hospitals; University hospitals of Geneva; RIVM; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","In limelight of the ongoing pandemic SARS-CoV-2 testing is critical for the diagnosis of infected patients, contact-tracing and mitigating the transmission. Diagnostic laboratories are expected to provide appropriate testing with maximum accuracy. Real-time reverse transcriptase PCR (RT-PCR) is the diagnostic standard yet many commercial diagnostic kits have become available. However, only a handful of studies have reviewed their performance in clinical settings. The aim of this study was to compare the performance of the overall analytical matrix including the extraction kit (BD MAX, Promega, Qiagen), the PCR instrument (Agilent Mx3005P, BD MAX, Qiagen Rotor-Gene, Roche Cobas z 480) and the RT-PCR assay (Altona Diagnostics, CerTest Biotec, R-Biopharm AG) using predefined samples from proficiency testing organizers. The greatest difference of the Ct values between the matrices was 9 cycles. One borderline sample could not be detected by 3 out of 12 analytical matrices and yielded a false negative result. We therefore conclude that diagnostic laboratories should take the complete analytical matrix in addition to the performance values published by the manufacturer for a respective RT-PCR kit into account. With limited resources laboratories have to validate a wide range of kits to determine appropriate analytical matrices for detecting SARS-CoV-2 reliably. The interpretation of clinical results has to be adapted accordingly.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.17.20192872,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.17.20192872,Cold plasma for SARS-CoV-2 Inactivation,Zhitong Chen; Gustavo Garcia Jr.; Vaithilingaraja Arumugaswami; Richard E. Wirz; Gert-Jan Godeke; Sabine Yerly; Marieke Hoogerwerf; Nicolas Vuilleumier; Laurent Kaiser; Isabella Eckerle; Chantal Reusken; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; RIVM; University hospitals of Geneva; RIVM; University hospitals of Geneva; University of Geneva Hospitals; University hospitals of Geneva; RIVM; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","SARS-CoV-2 infectious virions are viable on various surfaces (e.g., plastic, metals, cardboard) for several hours. This presents a transmission cycle for the human infection that can be broken by developing new inactivation approaches. We employed an efficient cold atmospheric plasma (CAP) with argon feed gas to inactivate SARS-CoV-2 on various surfaces including plastic, metal, cardboard, basketball composite leather, football leather, and baseball leather. These results demonstrate the great potential of CAP as a safe and effective means to prevent virus transmission and infections.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.17.20195867,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.17.20195867,DOSING OF THROMBOPROPHYLAXIS AND MORTALITY IN CRITICALLY ILL COVID-19 PATIENTS,Sandra Jonmarker; Jacob Hollenberg; Martin Dahlberg; Otto Stackelberg; Jacob Litorell; sa Everhov; Hans Jrnbert-Pettersson; Mrten Sderberg; Jonathan Grip; Anna Schandl; Mattias Gnther; Maria Cronhjort; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sdersjukhuset; Karolinska Institutet; Karolinska Institutet; Sdersjukhuset; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Background: A substantial proportion of critically ill COVID-19 patients develop thromboembolic complications, but it is unclear whether higher doses of thromboprophylaxis are associated with lower mortality rates. The purpose of the study was to evaluate the association of initial dosing strategy of thromboprophylaxis in critically ill COVID-19 patients and the risk of death, thromboembolism, and bleeding. Method: All critically ill COVID-19 patients admitted to two intensive care units in March and April 2020 were eligible. Patients were categorized into three groups according to initial daily dose of thromboprophylaxis: low (2500-4500 IU tinzaparin or 2500-5000 IU dalteparin), medium (>4500 IU but <175 IU/kilogram, kg, of body weight tinzaparin or >5000 IU but <200 IU/kg of body weight dalteparin), and high dose ([&ge;] 175 IU/kg of body weight tinzaparin or [&ge;]200 IU/kg of body weight dalteparin). Thromboprophylaxis dosage was based on local standardized recommendations, not on degree of critical illness or risk of thrombosis. Cox proportional hazards regression was used to estimate hazard ratios with corresponding 95% confidence intervals of death within 28 days from ICU admission. Multivariable models were adjusted for sex, age, body-mass index, Simplified Acute Physiology Score III, invasive respiratory support, and initial dosing strategy of thromboprophylaxis. Results: A total of 152 patients were included; 67 received low, 48 medium, and 37 high dose thromboprophylaxis. Baseline characteristics did not differ between groups. Mortality was lower in high (13.5%) vs medium (25.0%) and low dose thromboprophylaxis (38.8%) groups, p{equiv}0.02. The hazard ratio of death was 0.33 (95% confidence intervals 0.13 - 0.87) among those who received high dose, respectively 0.88 (95% confidence intervals 0.43 - 1.83) among those who received medium dose, as compared with those who received low dose thromboprophylaxis. There were fewer thromboembolic events in the high (2.7%) vs medium (18.8%) and low dose thromboprophylaxis (17.9%) groups, p{equiv}0.04, but no difference in the proportion of bleeding events, p{equiv}0.16. Conclusions: Among critically ill COVID-19 patients with respiratory failure, high dose thromboprophylaxis was associated with a lower risk of death and a lower cumulative incidence of thromboembolic events compared with lower doses.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.09.20.20197608,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.20.20197608,At home and online during the early months of the COVID-19 pandemic and the relationship to alcohol consumption in a national sample of U.S. adults,Karen G Chartier; Jeanine P.D. Guidry; Catherine A. Lee; Otto Stackelberg; Jacob Litorell; sa Everhov; Hans Jrnbert-Pettersson; Mrten Sderberg; Jonathan Grip; Anna Schandl; Mattias Gnther; Maria Cronhjort; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"Virginia Commonwealth University; Virginia Commonwealth University; George Mason University; Karolinska Institutet; Sdersjukhuset; Karolinska Institutet; Karolinska Institutet; Sdersjukhuset; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; University of Texas Health Science Center at Houston; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","Objective: The current study seeks to understand the links between social media use and alcohol consumption during the early months of the COVID-19 pandemic. Method: Data were from the national Understanding American Study, a probability-based Internet panel weighted to represent the U.S. population. Subjects (N=5874; 51% female) were adults, 18 years and older, who completed a March survey (wave 1) and a follow-up survey one month later (wave 3). Analyses assessed the relationship of social media use at wave 1 with wave 3 alcohol use, accounting for wave 1 alcohol use and the socio-demographic characteristics of the sample. We examined the effect of working or studying from home as a moderator. Results: Twitter and Instagram users, but not Facebook users, drank more frequently at wave 3 than non-users. For Instagram users, more frequent alcohol use at wave 3 was at least partially attributed to the frequency of drinking at wave 1. The interaction between Twitter use and working or studying from home was statistically significant. The combination of being on Twitter and working or studying from home was associated with drinking more days a week. Conclusions: Exposure to content about COVID-19 and increased alcohol consumption during the pandemic may contribute to more frequent alcohol use for some social media users, especially those sheltering at home. The study of public health messaging via social media to change alcohol use behaviors during traumatic events is warranted.",addiction medicine,exact,100,100
medRxiv,10.1101/2020.09.20.20196907,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.20.20196907,Microfluidic Affinity Profiling reveals a Broad Range of Target Affinities for Anti-SARS-CoV-2 Antibodies in Plasma of Covid Survivors,Matthias M. Schneider; Marc Emmenegger; Catherine K. Xu; Itzel Condado Morales; Priscilla Turelli; Manuela R. Zimmermann; Beat M. Frey; Sebastian Fiedler; Viola Denninger; Georg Meisl; Vasilis Kosmoliaptsis; Heike Fiegler; Didier Trono; Tuomas P. J. Knowles; Adriano AA Aguzzi; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"University of Cambridge; Institute of Neuropathology; University of Cambridge; Insitute of Neuropathology, University Hospital Zurich; Ecole Polytechnique Federale de Lausanne; University of Cambridge; University of Cambridge; Fluidic Analytics; Fluidic Analytics; University of Cambridge; University of Cambridge; Fluidic Analytics; Ecole Polytechnique Federale de Lausanne; University of Cambridge; University of Zurich; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","The clinical outcome of SARS-CoV-2 infections can range from asymptomatic to lethal, and is thought to be crucially shaped by the quality of the immune response which includes antibody titres and affinity for their targets. Using Microfluidic Antibody Affinity Profiling (MAAP), we determined the aggregate affinities and concentrations of anti-SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 23 of whom were confirmed to be SARS-CoV-2-positive by PCR testing. We found that dissociation constants (Kd) of anti-RBD antibodies spanned more than two orders of magnitude from 80 pM to 25 nM, despite having similar antibody concentrations. Individual patients showed progressively higher antibody concentrations but constant Kd values, suggesting that affinities did not mature over time. 33 sera showed affinities higher than that of the CoV2 spike for its ACE2 receptor. Accordingly, addition of seropositive plasma to pre-formed spike-ACE2 receptor complexes led to their dissociation. Finally, we observed that the RBD of HKU1, OC43, and SARS-CoV coronaviruses, but not unrelated control proteins, were able to compete substantially with the RBD of SARS-CoV-2 in solution. Therefore, the affinity of total plasma immunoglobulins to SARS-CoV-2 is an indicator of the quality of the immune response to SARS-CoV-2, and may help select the most efficacious samples for therapeutic plasmapheresis.",allergy and immunology,exact,100,100
medRxiv,10.1101/2020.09.23.20197756,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.23.20197756,"A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China",Xiaoli Wang; Wenjing Gao; Shujuan Cui; Yi Zhang; Ke Zheng; Ji Ke; Jun Lv; Canqing Yu; Dianjianyi Sun; Quanyi Wang; Liming Li; Heike Fiegler; Didier Trono; Tuomas P. J. Knowles; Adriano AA Aguzzi; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"Beijing Center for Disease Control and Prevention, Beijing Research Center for Preventive Medicine; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Beijing Center for Disease Control and Prevention, Beijing Research Center for Preventive Medicine; Beijing Center for Disease Control and Prevention, Beijing Research Center for Preventive Medicine; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Beijing Center for Disease Control and Prevention, Beijing Research Center for Preventive Medicine; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Fluidic Analytics; Ecole Polytechnique Federale de Lausanne; University of Cambridge; University of Zurich; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","BACKGOUND The spread of Coronavirus Disease 2019 (COVID-19) had been controlled in China. The seroprevalence of COVID-19 in Beijing has not been evaluated. METHODS In April, residents in Beijing were randomly enrolled. Blood samples were collected and antibodies to SARS-CoV-2 were tested by two colloidal gold kits. All colloidal gold positive serums were then tested by Micro-neutralization assay. RESULTS None of 2,184 residents participated was tested positive by micro-neutralization assay. The seroprevalence of COVID-19 in Beijing was estimated < 0.17%. CONCLUSIONS The seroprevalence of COVID-19 was low in April suggesting that community-wide spread was prevented in Beijing.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.21.20166934,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20166934,Potentials of constrained sliding mode control as an intervention guide to manage COVID19 spread,Sebastian Nuez; Fernando A. Inthamoussou; Fernando Valenciaga; Hernan De Battista; Fabricio Garelli; Ji Ke; Jun Lv; Canqing Yu; Dianjianyi Sun; Quanyi Wang; Liming Li; Heike Fiegler; Didier Trono; Tuomas P. J. Knowles; Adriano AA Aguzzi; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi,"Universidad Nacional de La Plata - CONICET; Universidad Nacional de La Plata - CONICET; Universidad Nacional de La Plata - CONICET; Universidad Nacional de La Plata - CONICET; Universidad Nacional de La Plata - CONICET; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Beijing Center for Disease Control and Prevention, Beijing Research Center for Preventive Medicine; Department of Epidemiology and Biostatistics, School of Public Health, Peking University; Fluidic Analytics; Ecole Polytechnique Federale de Lausanne; University of Cambridge; University of Zurich; University of California Irvine; University of California San Diego; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Intensive Care National Audit and Research Centre; Intensive Care National Audit and Research Centre; University of Leicester; University College London; London School of Hygiene and Tropical Medicine; University of Oxford; Escola de Enfermagem de Ribeirao Preto EERP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Bioquimica e Imunologia. Faculdade de Medicina de Ribeirao Preto  FMRP. Universidade de Sao Paulo USP, Ribeirao Preto, SP, Brazil.; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Programa de Pos Graduacao em Imunologia Basica e Aplicada  PPGIBA. Instituto de Ciencias Biologicas, Universidade Federal do Amazonas  UFAM, Manaus, AM, Brazil.; Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Analises Clinicas, Toxicologicas e Bromatologicas. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto FCFRP. Universidade de Sao Paulo  USP, ; Departamento de Quimica. Faculdade de Filosofia, Ciencias e Letras de Ribeirao Preto  FFCLRP. Universidade de Sao Paulo  USP, Ribeirao Preto, SP, Brazil","This work evaluates the potential of using sliding mode reference conditioning (SMRC) techniques as a guide for non-pharmaceutical interventions and population confinement to control the COVID-19 pandemic. SMRC technique allows robustly delimiting a given variable in dynamical systems. In particular, for the epidemiological problem addressed here, it can be used to compute day by day the contact rate reduction requirement in order to limit the intense care units occupancy to a given threshold. What is more, it could impose a given approaching rate to the health care system limits. Simulations are performed using the well-known SEIR model fitted to the Argentinian case to demonstrate what this control strategy suggests, while the effect of realistic period transitions between different confinement levels are also considered.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.21.20196428,2020-09-22,https://medrxiv.org/cgi/content/short/2020.09.21.20196428,"Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland",Rachael Wood; Emma C Thomson; Robert Galbraith; Ciara Gribben; David Caldwell; Jennifer Bishop; Martin Reid; Anoop Shah; Kate Templeton; David Goldberg; Chris Robertson; Sharon Hutchinson; Helen M Colhoun; Paul M McKeigue; David McAllister,"University of Edinburgh, Public Heath Scotland; University of Glasgow; Retired; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; London School of Hygiene and Tropical Medicine; University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Edinburgh; University of Edinburgh; University of Glasgow","Background Children are relatively protected from novel coronavirus infection (COVID-19). The reasons for this protection are not well understood but differences in the immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) have been implicated. If such differences are due to differential exposure to non-SARS-CoV-2 infectious agents, adults who are close contacts of children may partly share in this protection. Such a protective effect would have important implications for the lives of children, not least in terms of schooling. Methods Using a Scotland-wide record-linkage based occupational cohort comprising healthcare workers and members of their households, we examined whether sharing a household with young children (aged 0 to 11) attenuated the risk of hospitalisation with COVID-19, and/or testing positive for COVID-19 infection of any severity (any case of Covid-19). All healthcare workers directly employed by the National health Service (NHS) in Scotland, or contracted to provide general practice services, were included. Outcome and covariate data were obtained via linkage to Scotland-wide microbiology, drug prescribing, hospitalisation and death data. Results 241,266 adults did not share a household with young children; 41,198, 23,783 and 3,850 shared a household with 1, 2 and 3 or more young children respectively. The risk of hospitalisation with COVID-19 was lower in those with one child and lower still in those with two or more children, adjusting for age the hazard ratio (HR) was 0.83 per child (95% CI 0.70-0.99). On additionally adjusting for sex, socioeconomic deprivation, occupation, professional role, staff/non-staff status, the number of adults and adolescents in each household, and comorbidity, the HR was 0.89 per child (95% CI 0.74-1.06). An association of the same magnitude, but more precisely estimated, was obtained for any case of COVID-19 (fully adjusted model, HR per child 0.89; 95% CI 0.84-0.95). Conclusion Increased household exposure to young children was associated with an attenuated risk of testing positive for SARS-CoV-2 and appeared to also be associated with an attenuated risk of COVID-19 disease severe enough to require hospitalisation.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.15.20194795,2020-09-18,https://medrxiv.org/cgi/content/short/2020.09.15.20194795,"Acute, non-COVID related medical admissions during the first wave of COVID-19: A retrospective comparison of changing patterns of disease",Bridget Riley; Mary Packer; Suzy Gallier; Elizabeth Sapey; Catherine Atkin; Dorothy Ng Hui Lin; Indumathi Venkatachalam; Jay Lim Kheng Sit; Ling Moi Lin; Lynette Oon; Bee Tin Goh; Jean Sim Xiang Ying; Michael Sonntagbauer; Maria JGT Vehreschild; Claudio Conrad; Florian Tran; Philip Rosenstiel; Robert Markewitz; Klaus-Peter Wandinger; Jan Rybniker; Matthias Kochanek; Frank Leypoldt; Oliver A Cornely; Philipp Koehler; Andre Franke; Alexander Scheffold,"University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; PIONEER Hub, University Hospitals Birmingham NHS Foundation Trust; PIONEER Hub, University of Birmingham; PIONEER Hub, University of Birmingham; Department of Infectious Diseases, Singapore General Hospital, Singapore; Department of Infectious Diseases, Singapore General Hospital, Singapore; Department of Urology, Singapore General Hospital, Singapore; Department of Infection Prevention and Epidemiology, Singapore General Hospital, Singapore; Department of Microbiology, Singapore General Hospital, Singapore; Singapore Oral Microbiomics Initiative, National Dental Research Institute Singapore (NDRIS), National Dental Centre Singapore, Oral Health ACP, Duke NUS Medica; Department of Infectious Disease, Singapore General Hospital, Singapore; Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt am Main, Germany.; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt & Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Internal Medicine, Hospital of Preetz, Preetz, Germany; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.; University of Cologne, Medical Faculty and University Hospital Cologne, Department I of Internal Medicine, 50937 Cologne, Germany; University of Cologne, Medical Faculty and University Hospital Cologne, Department I of Internal Medicine, 50937 Cologne, Germany; Neuroimmunology, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Germany; University of Cologne, Medical Faculty and University Hospital Cologne, Department I of Internal Medicine, 50937 Cologne, Germany; University of Cologne, Medical Faculty and University Hospital Cologne, Department I of Internal Medicine, 50937 Cologne, Germany; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany; Institute of Immunology, Christian Albrechts University of Kiel, Kiel, Germany","Background: The COVID 19 pandemic was associated with social restrictions in the UK from 16th March 2020. It was unclear if the lockdown period was associated with differences in the case-mix of non-COVID acute medical admissions compared with the previous year. Methods: Retrospective data were collected for 1st to 30th April 2019 and 1st to 30th April 2020 from University Hospitals Birmingham NHS Foundation Trust, one of the largest hospitals in the UK with over 2 million patient contacts per year. The latter time period was chosen to coincide with the peak of COVID-19 cases in the West Midlands. All patients admitted under acute medicine during these time periods were included. COVID-19 was confirmed by SARS-Cov-2 swab or a probable case of COVID-19 based on World Health Organization diagnostic parameters. Non-COVID patients were those with a negative SARS-Cov-2 swab and no suspicion of COVID-19. Data was sourced from the UHB in-house electronic health system (EHS). Results: The total number of acute medical admissions fell comparing April 2019 (n=2409) to April 2020 (n=1682). As a proportion of total admissions, those aged under 45 years decreased, while those aged 46 and over did not change. The number of admissions due to psychiatric conditions and overdoses was higher in April 2020 (p < 0.001). When viewed as a proportion of admissions, alcohol-related admissions (p = 0.004), psychiatric conditions and overdoses (p<0.001) increased in April 2020 than in April 2019. The proportion of patients who were in hospital due to falls also increased in April 2020 (p<0.001). In the same period, the absolute number and the proportion of admissions that were due to non-specific chest pain, to musculoskeletal complaints and patients who self-discharged prior to assessment decreased (p=0.02, p=0.01 and p = 0.002 respectively). There were no significant differences in non-COVID-related intensive care admissions or mortality between the same months in the two years. Conclusion: In this large, single-centre study, there was a change in hospitalised case-mix when comparing April 2019 with April 2020: an increase in conditions which potentially reflect social isolation (falls, drug and alcohol misuse and psychiatric illness) and a decrease in conditions which rarely require in-patient hospital treatment (musculoskeletal pain and non-cardiac chest pain) especially among younger adults. These results highlight two areas for further research; the impact of social isolation on health and whether younger adults could be offered alternative health services to avoid potentially unnecessary hospital assessment.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.09.12.20191973,2020-09-14,https://medrxiv.org/cgi/content/short/2020.09.12.20191973,Inequality in access to health and care services during lockdown - Findings from the COVID-19 survey in five UK national longitudinal studies,Constantin-Cristian Topriceanu; Andrew Wong; James C Moon; Alun Hughes; David Bann; Nishi Chaturvedi; Praveetha Patalay; Gabriella Conti; Gabriella Captur; Ilaria Dorigatti; Michael Tristem; William D Pearse; Volkan Atalay; Makoto Miyara; Guy Gorochov; Amelie Guihot; Christophe Combadiere; Duraipandian Thavaselvam; Devendra Kumar Dubey; Paul Lin; Hila Shaim; Sean G Yates; David Marin; Indreshpal Kaur; Sheetal Rao; Duncan Mak; Angelique Lin; Qi Miao; Jinzhuang Dou; Ken Chen; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani,"University College London; UCL; UCL; UCL; University College London; UCL; University College London; UCL; University College London; Imperial College London; Imperial College London; Imperial College London; METU; AP-HP; AP-HP/Sorbonne-universite; AP-HP; INSERM; COVID-19 Diagnosis Task Force Virology Division Defence Research Development Establishment Jhansi Road Gwalior 474002 India; COVID-19 Diagnosis Task Force Virology Division Defence Research Development Establishment Jhansi Road Gwalior 474002 India; The University of Texas, MD Anderson Cancer Center; The University of Texas Medical Branch; The University of Texas Medical Branch; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center","Background: Access to health services and adequate care is influenced by sex, ethnicity, socio-economic position (SEP) and burden of co-morbidities. However, it is unknown whether the COVID-19 pandemic further deepened these already existing health inequalities. Methods: Participants were from five longitudinal age-homogenous British cohorts (born in 2001, 1990, 1970, 1958 and 1946). A web and telephone-based survey provided data on cancelled surgical or medical appointments, and the number of care hours received during the UK COVID-19 national lockdown. Using binary or ordered logistic regression, we evaluated whether these outcomes differed by sex, ethnicity, SEP and having a chronic illness. Adjustment was made for study-design, non-response weights, psychological distress, presence of children or adolescents in the household, keyworker status, and whether participants had received a shielding letter. Meta-analyses were performed across the cohorts and meta-regression evaluated the effect of age as a moderator. Findings: 14891 participants were included. Females (OR 1.40, 95% confidence interval [1.27,1.55]) and those with a chronic illness (OR 1.84 [1.65-2.05]) experienced significantly more cancellations during lockdown (all p<0.0001). Ethnic minorities and those with a chronic illness required a higher number of care hours during the lockdown (both OR approx. 2.00, all p<0.002). Age was not independently associated with either outcome in meta-regression. SEP was not associated with cancellation or care hours. Interpretation: The UK government's lockdown approach during the COVID-19 pandemic appears to have deepened existing health inequalities, impacting predominantly females, ethnic-minorities and those with chronic illnesses. Public health authorities need to implement urgent policies to ensure equitable access to health and care for all in preparation for a second wave.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.13.20193680,2020-09-14,https://medrxiv.org/cgi/content/short/2020.09.13.20193680,Lack of consideration of sex and gender in clinical trials for COVID-19,Emer Brady; Mathias Wullum Nielsen; Jens Peter Andersen; Sabine Oertelt-Prigione; David Bann; Nishi Chaturvedi; Praveetha Patalay; Gabriella Conti; Gabriella Captur; Ilaria Dorigatti; Michael Tristem; William D Pearse; Volkan Atalay; Makoto Miyara; Guy Gorochov; Amelie Guihot; Christophe Combadiere; Duraipandian Thavaselvam; Devendra Kumar Dubey; Paul Lin; Hila Shaim; Sean G Yates; David Marin; Indreshpal Kaur; Sheetal Rao; Duncan Mak; Angelique Lin; Qi Miao; Jinzhuang Dou; Ken Chen; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani,"Aarhus University; Copenhagen University; Aarhus University; Radboud University Medical Center; University College London; UCL; University College London; UCL; University College London; Imperial College London; Imperial College London; Imperial College London; METU; AP-HP; AP-HP/Sorbonne-universite; AP-HP; INSERM; COVID-19 Diagnosis Task Force Virology Division Defence Research Development Establishment Jhansi Road Gwalior 474002 India; COVID-19 Diagnosis Task Force Virology Division Defence Research Development Establishment Jhansi Road Gwalior 474002 India; The University of Texas, MD Anderson Cancer Center; The University of Texas Medical Branch; The University of Texas Medical Branch; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center","Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences characterize the frequency and severity of pharmacological side effects. A large number of clinical trials are ongoing to develop new therapeutic approaches and vaccines for COVID-19. We investigated the inclusion of sex and/or gender in currently registered studies on ClinicalTrials.gov. Only 416 (16.7%) of the 2,484 registered SARS-CoV-2/COVID-19 trials mention sex/gender as recruitment criterion and only 103 (4.1%) allude to sex/gender in the description of the analysis phase. None of the 11 clinical trials published in scientific journals on June 2020 reported sex-disaggregated results. Hence, lack of consideration upon registration does not seem to be corrected during trial execution and reporting. Given the biological relevance and the potential risks of unwanted side effects, we urge researchers to focus on sex-disaggregated analyses already at the planning stage of COVID-19 trials.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.13.20193524,2020-09-14,https://medrxiv.org/cgi/content/short/2020.09.13.20193524,Differences in innate Intracellular viral suppression competencies may explain variations in morbidity and mortality from SARS-CoV-2 infection.,Shaibu Oricha Bello; Ehimario Igumbor; Yusuf Yahaya Deeni; Chinwe Lucia Ochu; Mustapha Ayodele Popoola; Nishi Chaturvedi; Praveetha Patalay; Gabriella Conti; Gabriella Captur; Ilaria Dorigatti; Michael Tristem; William D Pearse; Volkan Atalay; Makoto Miyara; Guy Gorochov; Amelie Guihot; Christophe Combadiere; Duraipandian Thavaselvam; Devendra Kumar Dubey; Paul Lin; Hila Shaim; Sean G Yates; David Marin; Indreshpal Kaur; Sheetal Rao; Duncan Mak; Angelique Lin; Qi Miao; Jinzhuang Dou; Ken Chen; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani,"College Of Health Sciences, Usmanu Danfodiyo University; School of Public Health, University of the Western Cape, Cape Town, South Africa; Department of Microbiology & Biotechnology, Federal University Dutse, PMB 7156, Jigawa State, Nigeria.; Nigeria Center for Disease Control, Abuja, Nigeria; .  Research & Development Matters, Tertiary Education Trust Fund, Abuja; UCL; University College London; UCL; University College London; Imperial College London; Imperial College London; Imperial College London; METU; AP-HP; AP-HP/Sorbonne-universite; AP-HP; INSERM; COVID-19 Diagnosis Task Force Virology Division Defence Research Development Establishment Jhansi Road Gwalior 474002 India; COVID-19 Diagnosis Task Force Virology Division Defence Research Development Establishment Jhansi Road Gwalior 474002 India; The University of Texas, MD Anderson Cancer Center; The University of Texas Medical Branch; The University of Texas Medical Branch; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center; The University of Texas, MD Anderson Cancer Center","SARS-CoV-2 infection and COVID-19 ravage the world with wide variations in morbidity and mortality that have remained largely unexplained, even by mutations in protein coding regions. In this study, we analyzed available complete SARS-CoV-2 sequences using the CpG index as a signature of Zinc finger antiviral protein (ZAP) activity to examine population variations in innate intracellular antiviral competencies. The result suggests that differential ZAP activity may be a major determinant of the outcome of SARS-CoV-2 infection. SARS-CoV-2 sequences from Africa, Asia, and pools of asymptomatic patients had I_CpG signature evidence of high ZAP activity, while SARS-CoV-2 sequences from North America and Intensive Care Unit or Deceased patients had I_CpG signature of low ZAP activity. ZAP activity is linked to the interferon system. Low ZAP activity may be part of the explanation for the increased morbidity of SARS-CoV-2 in the elderly and with comorbidities like diabetes, obesity, and hypertension. It may also provide some insight into the discrepancies between invitro anti-SARS-CoV-2 activities of candidate therapies and performance in clinical trials. Furthermore, our results suggest that asymptomatic patients may paradoxically shed a more dangerous virus.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.10.20191841,2020-09-11,https://medrxiv.org/cgi/content/short/2020.09.10.20191841,The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in an occupational sample,Daniel Leightley; Valentina Vitiello; Gabriella Bergin-Cartwright; Alice Wickersham; Katrina A S Davis; Sharon Stevelink; Matthew Hotopf; Reza Razavi; - On behalf of the KCL CHECK research team; Bui Duc Thang; Nguyen Thi Hoai Thu; Le Thi Kim Chi; Nguyen Thi Hanh; Nguyen Huy Hoang; Chau Nguyen; Guy Thwaites; Do Thai Hung; Le Van Tan; Ngo Thi Kim Yen,"Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and   Medicine, King's College London, London, UK.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London; ; Da Nang CDC, Vietnam; Da Nang CDC, Vietnam; Da Nang CDC, Vietnam; Da Nang University of Medical Technology and Pharmacy, Da Nang city, Vietnam; Da Nang University of Medical Technology and Pharmacy, Da Nang city, Vietnam; Hospital for Tropical Diseases; OUCRU, Vietnam; IP, Nha Trang, Vietnam; OUCRU-VN; DoH, Da Nang, Vietnam","We report test results for SARS-CoV-2 antibodies in an occupational group of postgraduate research students and current members of staff at Kings College London. Between June and July 2020, antibody testing kits were sent to n=2296 participants; n=2004 (86.3%) responded, of whom n=1882 (93.9%) returned valid test results. Of those that returned valid results, n=124 (6.6%) tested positive for SARS-CoV-2 antibodies, with initial comparisons showing variation by age group and clinical exposure.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.09.20191643,2020-09-11,https://medrxiv.org/cgi/content/short/2020.09.09.20191643,Spatial and temporal trends in social vulnerability and COVID-19 incidence and death rates in the United States,Brian Neelon; Fedelis Mutiso; Noel T Mueller; John L Pearce; Sara E Benjamin-Neelon; Sharon Stevelink; Matthew Hotopf; Reza Razavi; - On behalf of the KCL CHECK research team; Bui Duc Thang; Nguyen Thi Hoai Thu; Le Thi Kim Chi; Nguyen Thi Hanh; Nguyen Huy Hoang; Chau Nguyen; Guy Thwaites; Do Thai Hung; Le Van Tan; Ngo Thi Kim Yen,"Medical University of South Carolina; Medical University of South Carolina; Johns Hopkins Bloomberg School of Public Health; Medical University of South Carolina; Johns Hopkins Bloomberg School of Public Health; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London; ; Da Nang CDC, Vietnam; Da Nang CDC, Vietnam; Da Nang CDC, Vietnam; Da Nang University of Medical Technology and Pharmacy, Da Nang city, Vietnam; Da Nang University of Medical Technology and Pharmacy, Da Nang city, Vietnam; Hospital for Tropical Diseases; OUCRU, Vietnam; IP, Nha Trang, Vietnam; OUCRU-VN; DoH, Da Nang, Vietnam","Background: Emerging evidence suggests that socially vulnerable communities are at higher risk for coronavirus disease 2019 (COVID-19) outbreaks in the United States. However, no prior studies have examined temporal trends and differential effects of social vulnerability on COVID-19 incidence and death rates. The purpose of this study was to examine temporal trends among counties with high and low social vulnerability and to quantify disparities in these trends over time. We hypothesized that highly vulnerable counties would have higher incidence and death rates compared to less vulnerable counties and that this disparity would widen as the pandemic progressed. Methods: We conducted a retrospective longitudinal analysis examining COVID-19 incidence and death rates from March 1 to August 31, 2020 for each county in the US. We obtained daily COVID-19 incident case and death data from USAFacts and the Johns Hopkins Center for Systems Science and Engineering. We classified counties using the Social Vulnerability Index (SVI), a percentile-based measure from the Centers for Disease Control and Prevention in which higher scores represent more vulnerability. Using a Bayesian hierarchical negative binomial model, we estimated daily risk ratios (RRs) comparing counties in the first (lower) and fourth (upper) SVI quartiles. We adjusted for percentage of the county designated as rural, percentage in poor or fair health, percentage of adult smokers, county average daily fine particulate matter (PM2.5), percentage of primary care physicians per 100,000 residents, and the proportion tested for COVID-19 in the state. Results: In unadjusted analyses, we found that for most of March 2020, counties in the upper SVI quartile had significantly fewer cases per 100,000 than lower SVI quartile counties. However, on March 30, we observed a crossover effect in which the RR became significantly greater than 1.00 (RR = 1.10, 95% PI: 1.03, 1.18), indicating that the most vulnerable counties had, on average, higher COVID-19 incidence rates compared to least vulnerable counties. Upper SVI quartile counties had higher death rates on average starting on March 30 (RR = 1.17, 95% PI: 1.01,1.36). The death rate RR achieved a maximum value on July 29 (RR = 3.22, 95% PI: 2.91, 3.58), indicating that most vulnerable counties had, on average, 3.22 times more deaths per million than the least vulnerable counties. However, by late August, the lower quartile started to catch up to the upper quartile. In adjusted models, the RRs were attenuated for both incidence cases and deaths, indicating that the adjustment variables partially explained the associations. We also found positive associations between COVID-19 cases and deaths and percentage of the county designated as rural, percentage of resident in fair or poor health, and average daily PM2.5. Conclusions: Results indicate that the impact of COVID-19 is not static but can migrate from less vulnerable counties to more vulnerable counties over time. This highlights the importance of protecting vulnerable populations as the pandemic unfolds.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.08.20190769,2020-09-11,https://medrxiv.org/cgi/content/short/2020.09.08.20190769,Estimating the Risk of Outbreaks of COVID-19 Associated with Shore Leave by Merchant Ship Crews: Simulation Studies for a Case Country,Nick Wilson; Tony Blakely; Michael Baker; Martin Eichner; Sara E Benjamin-Neelon; Sharon Stevelink; Matthew Hotopf; Reza Razavi; - On behalf of the KCL CHECK research team; Bui Duc Thang; Nguyen Thi Hoai Thu; Le Thi Kim Chi; Nguyen Thi Hanh; Nguyen Huy Hoang; Chau Nguyen; Guy Thwaites; Do Thai Hung; Le Van Tan; Ngo Thi Kim Yen,"University of Otago, Wellington; University of Melbourne; University of Otago, Wellington; Epimos; Johns Hopkins Bloomberg School of Public Health; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London; ; Da Nang CDC, Vietnam; Da Nang CDC, Vietnam; Da Nang CDC, Vietnam; Da Nang University of Medical Technology and Pharmacy, Da Nang city, Vietnam; Da Nang University of Medical Technology and Pharmacy, Da Nang city, Vietnam; Hospital for Tropical Diseases; OUCRU, Vietnam; IP, Nha Trang, Vietnam; OUCRU-VN; DoH, Da Nang, Vietnam","Aim: We aimed to estimate the risk of COVID-19 outbreaks in a case study COVID-free destination country, associated with shore leave for merchant ship crews. Methods: A stochastic version of the SEIR model CovidSIM v1.1, designed specifically for COVID-19 was utilised. It was populated with parameters for SARS-CoV-2 transmission, shipping characteristics, and plausible control measures. Results: When no control interventions were in place, an outbreak of COVID-19 in our case study destination country (New Zealand; NZ) was estimated to occur after a median time of 23 days (assuming a global average for source country incidence of 2.66 new infections per 1000 population per week, a crew of 20, a voyage length of 10 days, 1 day of shore leave both in NZ and abroad, and 108 port visits by international merchant ships per week). For this example the uncertainty around when outbreaks occur is wide (an outbreak occurs with 95% probability between 1 and 124 days). The combined use of a PCR test on arrival, self-reporting of symptoms with contact tracing, and mask use during shore leave, increased this median time to 1.0 year (14 days to 5.4 years). Scenario analyses found that onboard infection chains could persist for well over 4 weeks even with crews of only 5 members. Conclusion: Introduction of SARS-CoV-2 through shore leave from international shipping crews is likely, even after long voyages. The risk can be substantially mitigated by control measures such as PCR testing and mask use.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.11.20192492,2020-09-11,https://medrxiv.org/cgi/content/short/2020.09.11.20192492,Resurgence of SARS-CoV-2 in England: detection by community antigen surveillance,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Carlos E. Milla; Angela J. Rogers; Paul L. Bollyky; Marcus VG Lacerda; Pedro M Moraes-Vieira; Helder I Nakaya,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Stanford University; Stanford University; Stanford University; Fundacao de Medicina Tropical Dr Heitor Vieira Dourado; University of Campinas; University of Sao Paulo","Background Based on cases and deaths, transmission of SARS-CoV-2 in England peaked in late March and early April 2020 and then declined until the end of June. Since the start of July, cases have increased, while deaths have continued to decrease. Methods We report results from 594,000 swabs tested for SARS-CoV-2 virus obtained from a representative sample of people in England over four rounds collected regardless of symptoms, starting in May 2020 and finishing at the beginning of September 2020. Swabs for the most recent two rounds were taken between 24th July and 11th August and for round 4 between 22nd August and 7th September. We estimate weighted overall prevalence, doubling times between and within rounds and associated reproduction numbers. We obtained unweighted prevalence estimates by sub-groups: age, sex, region, ethnicity, key worker status, household size, for which we also estimated odds of infection. We identified clusters of swab-positive participants who were closer, on average, to other swab-positive participants than would be expected. Findings Over all four rounds of the study, we found that 72% (67%, 76%) of swab-positive individuals were asymptomatic at the time of swab and in the week prior. The epidemic declined between rounds 1 and 2, and rounds 2 and 3. However, the epidemic was increasing between rounds 3 and 4, with a doubling time of 17 (13, 23) days corresponding to an R value of 1.3 (1.2, 1.4). When analysing round 3 alone, we found that the epidemic had started to grow again with 93% probability. Using only the most recent round 4 data, we estimated a doubling time of 7.7 (5.5, 12.7) days, corresponding to an R value of 1.7 (1.4, 2.0). Cycle threshold values were lower (viral loads were higher) for rounds 1 and 4 than they were for rounds 2 and 3. In round 4, we observed the highest prevalence in participants aged 18 to 24 years at 0.25% (0.16%, 0.41%), increasing from 0.08% (0.04%, 0.18%) in round 3. We observed the lowest prevalence in those aged 65 and older at 0.04% (0.02%, 0.06%) which was stable compared with round 3. Participants of Asian ethnicity had elevated odds of infection. We identified clusters in and around London, transient clusters in the Midlands, and an expanding area of clustering in the North West and more recently in Yorkshire and the Humber. Interpretation Although low levels of transmission persisted in England through to mid-summer 2020, the prevalence of SARS-CoV-2 is now increasing. We found evidence of accelerating transmission at the end of August and beginning of September. Representative community antigen sampling can increase situational awareness and help improve public health decision making even at low prevalence.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.04.20187781,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.04.20187781,Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study,Christopher T Rentsch; Nicholas J DeVito; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Anna Schultze; William J Hulme; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background. Hydroxychloroquine has been shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, but early clinical studies found no benefit treating patients with coronavirus disease 2019 (COVID-19). We set out to evaluate the effectiveness of hydroxychloroquine for prevention, as opposed to treatment, of COVID-19 mortality. Methods. We pre-specified and conducted an observational, population-based cohort study using national primary care data and linked death registrations in the OpenSAFELY platform, representing 40% of the general population in England. We used Cox regression to estimate the association between ongoing routine hydroxychloroquine use prior to the COVID-19 outbreak in England and risk of COVID-19 mortality among people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). Model adjustment was informed by a directed acyclic graph. Findings. Of 194,637 patients with RA or SLE, 30,569 (15.7%) received [&ge;]2 prescriptions of hydroxychloroquine in the six months prior to 1 March 2020. Between 1 March 2020 and 13 July 2020, there were 547 COVID-19 deaths, 70 among hydroxychloroquine users. Estimated standardised cumulative COVID-19 mortality was 0.23% (95% CI 0.18-0.29) among users and 0.22% (95% CI 0.20-0.25) among non-users; an absolute difference of 0.008% (95% CI -0.051-0.066). After accounting for age, sex, ethnicity, use of other immunuosuppressives, and geographic region, no association with COVID-19 mortality was observed (HR 1.03, 95% CI 0.80-1.33). We found no evidence of interactions with age or other immunosuppressives. Quantitative bias analyses indicated observed associations were robust to missing information regarding additional biologic treatments for rheumatological disease. We observed similar associations with the negative control outcome of non-COVID-19 mortality. Interpretation. We found no evidence of a difference in COVID-19 mortality among patients who received hydroxychloroquine for treatment of rheumatological disease prior to the COVID-19 outbreak in England.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.07.20189860,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189860,Ongoing natural selection drives the evolution of SARS-CoV-2 genomes,Qi Liu; Shilei Zhao; Yali Hou; Wenmin Zhao; Yimin Bao; Yongbiao Xue; Hua Chen; William J Hulme; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Beijing Institute of Genomics, CAS; Beijing Institute of Genomics, CAS; Beijing Institute of Genomics, CAS; Beijing Institute of Genomics, CAS; Beijing Institute of Genomics, CAS; Beijing Institute of Genomics, CAS; Beijing Institute of Genomics; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","SARS-CoV-2 is a new RNA virus affecting humans and spreads extensively through world populations since its first outbreak in late December, 2019. Whether the transmissibility and pathogenicity of SARS-CoV-2 is actively evolving, and driven by adaptation to the new host and environments is still unknown. Understanding the evolutionary mechanism underlying epidemiological and pathological characteristics of COVID-19 is essential for predicting the epidemic trend, and providing guidance for disease control and treatments. Interrogating 22,078 SARS-CoV-2 genome sequences of 84 countries, we demonstrate with convincing evidence that (i) SARS-CoV-2 genomes are overall conserved under purifying selection. (ii) Ongoing positive selection is actively driving the evolution of specific genes. Notably, genes related to coronavirus infection and host immune system defense are under adaptive evolution while genes related to viral RNA replication, transcription and translation are under purifying selection. A spatial and temporal landscape of 54 critical mutants is constructed based on their divergence among viral haplotype clusters, of which multiple mutants potentially conferring viral transmissibility, infectivity and virulence of SARS-CoV-2 are highlighted.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20189597,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189597,COVID-19 control across urban-rural gradients,Konstans Wells; Miguel Lurgi; Brendan Collins; Biagio Lucini; Rowland Raymond Kao; Alun L. Lloyd; Simon D.W. Frost; Mike B. Gravenor; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Swansea University; Swansea University; Department of Public Health and Policy, University of Liverpool, Liverpool L69 3GB, UK; Department of Mathematics, Swansea University, Swansea SA2 8PP, Wales, UK; University of Edinburgh; Biomathematics Graduate Program and Department of Mathematics, North Carolina State University, Raleigh, NC 27695, USA; Microsoft Research Lab, Redmond, Washington, WA 98052, USA and London School of Hygiene and Tropical Medicine, London, WC1E 7HT; Swansea University Medical School, Swansea University, Swansea SA2 8PP, Wales, UK; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Controlling the regional re-emergence of SARS-CoV-2 after its initial spread in ever-changing personal contact networks and disease landscapes is a challenging task. In a landscape context, contact opportunities within and between populations are changing rapidly as lockdown measures are relaxed and a number of social activities re-activated. Using an individual-based metapopulation model, we explored the efficacy of different control strategies across an urban-rural gradient in Wales, UK. Our model shows that isolation of symptomatic cases, or regional lockdowns in response to local outbreaks, have limited efficacy unless the overall transmission rate is kept persistently low. Additional isolation of non-symptomatic infected individuals, who may be detected by effective test and trace strategies, is pivotal to reduce the overall epidemic size over a wider range of transmission scenarios. We define an urban-rural gradient in epidemic size as a correlation between regional epidemic size and connectivity within the region, with more highly connected urban populations experiencing relatively larger outbreaks. For interventions focused on regional lockdowns, the strength of such gradients in epidemic size increased with higher travel frequencies, indicating a reduced efficacy of the control measure in the urban regions under these conditions. When both non-symptomatic and symptomatic individuals are isolated or regional lockdown strategies are enforced, we further found the strongest urban-rural epidemic gradients at high transmission rates. This effect was reversed for strategies targeted at symptomatics only. Our results emphasise the importance of test-and-tracing strategies and maintaining low transmission rates for efficiently controlling COVID19 spread, both at landscape scale and in urban areas.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20184887,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20184887,Age-structured SIR model and resource growth dynamics: A preliminary COVID-19 study,S. G. Babajanyan; Kang Hao Cheong; Brendan Collins; Biagio Lucini; Rowland Raymond Kao; Alun L. Lloyd; Simon D.W. Frost; Mike B. Gravenor; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Singapore University of Technology and Design; Singapore University of Technology and Design; Department of Public Health and Policy, University of Liverpool, Liverpool L69 3GB, UK; Department of Mathematics, Swansea University, Swansea SA2 8PP, Wales, UK; University of Edinburgh; Biomathematics Graduate Program and Department of Mathematics, North Carolina State University, Raleigh, NC 27695, USA; Microsoft Research Lab, Redmond, Washington, WA 98052, USA and London School of Hygiene and Tropical Medicine, London, WC1E 7HT; Swansea University Medical School, Swansea University, Swansea SA2 8PP, Wales, UK; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","In this paper, we discuss three different response strategies to a disease outbreak and their economic implications in an age-structured population. We have utilized the classical age structured SIR-model, thus assuming that recovered people will not be infected again. Available resource dynamics is governed by the well-known logistic growth model, in which the reproduction coefficient depends on the disease outbreak spreading dynamics. We further investigate the feedback interaction of the disease spread dynamics and resource growth dynamics with the premise that the quality of treatment depends on the current economic situation. The very inclusion of mortality rates and economic considerations in the same model may be incongruous under certain positions, but in this model, we take a 'realpolitik' approach by exploring all of these factors together as it is done in reality.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20189977,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189977,Performance and Robustness of Machine Learning-based Radiomic COVID-19 Severity Prediction,Stephen S.F. Yip; Zan Klanecek; Shotaro Naganawa; John Kim; Andrej Studen; Luciano Rivetti; Robert Jeraj; Mike B. Gravenor; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"University of Wisconsin at Madison; University of Ljubljana, Ljubljana, Slovenia; University of Michigan, Ann Arbor; University of Michigan, Ann Arbor; University of Ljubljana, Ljubljana, Slovenia; FUESMEN-FADESA, Mendoza, Argentina; University of Wisconsin, Madison; Swansea University Medical School, Swansea University, Swansea SA2 8PP, Wales, UK; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Objectives: This study investigated the performance and robustness of radiomics in predicting COVID-19 severity in a large public cohort. Methods: A public dataset of 1110 COVID-19 patients (1 CT/patient) was used. Using CTs and clinical data, each patient was classified into mild, moderate, and severe by two observers: (1) dataset provider and (2) a board-certified radiologist. For each CT, 107 radiomic features were extracted. The dataset was randomly divided into a training (60%) and holdout validation (40%) set. During training, features were selected and combined into a logistic regression model for predicting severe cases from mild and moderate cases. The models were trained and validated on the classifications by both observers. AUC quantified the predictive power of models. To determine model robustness, the trained models was cross-validated on the inter-observer classifications. Results: A single feature alone was sufficient to predict mild from severe COVID-19 with AUC_valid^provider=0.85 and AUC_valid^radiologist=0.74 (p<<0.01). The most predictive features were the distribution of small size-zones (GLSZM-SmallAreaEmphasis) for provider classification and linear dependency of neighboring voxels (GLCM-Correlation) for radiologist classification. Cross-validation showed that both AUC_valid^ {approx}0.80 (p<<0.01). In predicting moderate from severe COVID-19, first-order-Median alone had sufficient predictive power of AUC_valid^provider=0.65 (p=0.01). For radiologist classification, the predictive power of the model increased to AUC_valid^radiologist=0.66 (p<<0.01) as the number of features grew from 1 to 5. Cross-validation yielded AUC_valid^radiologist=0.63 (p=0.002) and AUC_valid^provider=0.60 (p=0.09). Conclusions: Radiomics significantly predicted different levels of COVID-19 severity. The prediction was moderately sensitive to inter-observer classifications, and thus need to be used with caution.",radiology and imaging,exact,100,100
medRxiv,10.1101/2020.09.07.20189936,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189936,Self-learning on COVID-19 among medical students and their preparedness to participate in government's COVID-19 response in Bhutan: a cross-sectional study,Thinley Dorji; Saran Tenzin Tamang; TVSVGK Tilak; John Kim; Andrej Studen; Luciano Rivetti; Robert Jeraj; Mike B. Gravenor; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Jigme Dorji Wangchuck National Referral Hospital; Faculty of Postgraduate Medicine, Khesar Gyalpo University of Medical Sciences of Bhutan, Thimphu; Armed Forces Medical College, Maharashtra University of Health Sciences, India; University of Michigan, Ann Arbor; University of Ljubljana, Ljubljana, Slovenia; FUESMEN-FADESA, Mendoza, Argentina; University of Wisconsin, Madison; Swansea University Medical School, Swansea University, Swansea SA2 8PP, Wales, UK; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background: Bhutan lacks a medical school and all their medical students are trained outside in Sri Lanka, Bangladesh and India. When the COVID-19 pandemic let to closure of medical schools in these countries, the Bhutanese medical students were repatriated in March-April 2020. Upon return, they were kept in government-sponsored facility quarantine for 21 days. This study assessed their knowledge on COVID-19 as a part of self-learning and attitude as part of preparedness towards participation in government's health response to COVID-19. Method: This was a cross-sectional study among medical students who had returned to the country. This survey was conducted through an online questionnaire while the students were in 21-day facility quarantine. The sample size calculated was 129 and a convenient sampling was used. Knowledge was assessed using 20 questions, each scored 1/20. Cumulative score of score of >=80% was categorized as ""good knowledge"", score of >=60-79% was considered ""satisfactory knowledge"", and score <60% was considered ""poor knowledge."" Correlation between knowledge score and duration of clinical clerkship was tested using Pearson's correlation coefficient. Attitude of students towards their willingness to participate in the national COVID-19 response were tested using rating scales. Data were analysed using Stata 13.1. Results: 120 medical students responded to this survey (response rate = 93%). Eighty-eight (74%) had good knowledge, 28 (23%) had satisfactory knowledge and only four (3%) had poor knowledge on COVID-19. The students scored high on the symptomatology, mode of transmission, prevention and treatment options and on local epidemiology; and scored low on the forms of mechanical ventilations and on the home-management of non-critical cases. The knowledge score correlated with duration of clinical clerkship (r = 0.326, p = 0.001). The primary source of information were social media sites (102, 85%), television (94, 78%) and newspapers (76, 63%). The majority (78, 65%) were willing to participate in the government's COVID-19 response but could not identify what roles they could play. The fear of contracting COVID-19 was reported in only in 8.7%. Conclusions: The medical students had good knowledge on COVID-19 and were self-learned through social media, television and newspapers. The students held positive attitude towards participation in the government's COVID-19 response.",medical education,exact,100,100
medRxiv,10.1101/2020.09.08.20187559,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20187559,The role of NIH funding in vaccine readiness; foundational research and NIH funding underlying candidate SARS-CoV-2 vaccines,Anthony E Kiszewski; Ekaterina I Galkina Cleary; Matthew J Jackson; Fred D Ledley; Andrej Studen; Luciano Rivetti; Robert Jeraj; Mike B. Gravenor; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Bentley University; Bentley University; Bentley University; Bentley University; University of Ljubljana, Ljubljana, Slovenia; FUESMEN-FADESA, Mendoza, Argentina; University of Wisconsin, Madison; Swansea University Medical School, Swansea University, Swansea SA2 8PP, Wales, UK; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","This work characterizes the NIH contribution to vaccine technologies being employed in ""warp speed"" development of vaccines for COVID-19, as well as the lack of sustained NIH funding for published research against recognized epidemic threats. Using quantitative methods, we examined the advance of published research on ten of the vaccine technologies incorporated in the 165 candidate vaccines entering development through July 2020 as well as the NIH funding that supported this research. Live, attenuated virus, inactivated virus, and adjuvant technologies have been used in successful products since the 1950s and continue to exhibit steady advance. Synthetic (recombinant) vaccines, viral vectors, DNA, and TLR9 agonists as adjuvants emerged since the 1980s, and exhibit a logistic, ""S-curve"" pattern of growth characteristic of emerging technologies that have passed an analytically-defined established point. In contrast, mRNA, virus-like particle, and nanoparticle technologies show exponential growth characteristic of technologies short of their established points. The body of research and NIH funding for established and emerging vaccine technologies exhibited sustained growth through the late 2010s, supported by >16,000 thousand project years of NIH funding totaling over $17.2 billion (2000-2019), the majority through cooperative agreements and intramural programs. NIH funding for published research on vaccines for recognized zoonotic threats including coronavirus, Zika, Ebola, and dengue, however, has been inconsistent and reactive to disease outbreaks. These data are considered in the context of the high failure rate for candidate vaccines and evidence that technological maturity is a significant factor in the efficiency of product development. Sustained funding for both enabling technologies and vaccine development is essential to ensure a rapid response to COVID and future pandemic threats.",health policy,exact,100,100
medRxiv,10.1101/2020.09.08.20190488,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190488,Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2,Felipe Perez-Garcia; Ramon Perez-Tanoira; Maria Esther Iglesias; Juan Romanyk; Teresa Arroyo; Pena Gomez-Herruz; Rosa Gonzalez; Juan Cuadros-Gonzalez; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Objectives: Serologic techniques can serve as a complement to diagnose SARS-CoV-2 infection. The objective of our study was to compare the diagnostic performance of six immunoassays to detect antibodies against SARS-CoV-2: three lateral flow immunoassays (LFAs), one ELISA and two chemiluminescence assays (CLIAs). Methods: We evaluated three LFAs (Alltest, One Step and SeroFlash), one ELISA (Dia.Pro) and two CLIAs (Elecsys and COV2T). To assess the specificity, 60 pre-pandemic sera were used. To evaluate the sensitivity, we used 80 serum samples from patients with positive PCR for SARS-CoV-2. Agreement between techniques was evaluated using the kappa score (k). Results: All immunoassays showed a specificity of 100% except for SeroFlash (96.7%). Overall sensitivity was 61.3%, 73.8%, 67.5%, 85.9%, 88.0% and 92.0% for Alltest, One Step, SeroFlash, Dia.Pro, Elecsys and COV2T, respectively. Sensitivity increased throughout the first two weeks from the onset of symptoms, reaching sensitivities over 85% from 14 days for all LFAs, being One Step the most sensitive (97.6%), followed by SeroFlash (95.1%). Dia.Pro, Elecsys and COV2T showed sensitivities over 97% from 14 days, being 100% for COV2T. One Step showed the best agreement results among LFAs, showing excellent agreement with Dia.Pro (agreement=94.2%, k=0.884), COV2T (99.1%, k=0.981) and Elecsys (97.3%, k=0.943). Dia.Pro, COV2T and Elecsys also showed excellent agreement between them. Conclusions: One Step, Dia.Pro, Elecsys and COV2T obtained the best diagnostic performance results. All these techniques showed a specificity of 100% and sensitivities over 97% from 14 days after the onset of symptoms, as well as excellent levels of agreement.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.09.20191213,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.09.20191213,Airborne contamination of COVID-19 in hospitals: a scoping review of the current evidence.,GABRIEL BIRGAND; Nathan PEIFFER-SMADJA; Sandra Fournier; Solen Kerneis; Francois Xavier Lescure; Jean-Christophe Lucet; Rosa Gonzalez; Juan Cuadros-Gonzalez; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,Imperial College London; APHP; APHP; APHP; APHP; APHP; Hospital Universitario Principe de Asturias; Hospital Universitario Principe de Asturias; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Introduction A controversy remains worldwide regarding the transmission routes of SARS-CoV-2 in hospital settings. We reviewed the current evidence on the air contamination with SARS-CoV-2 in hospital settings, and the factors associated to the contamination including the viral load and the particles size. Methods The MEDLINE, Embase, Web of Science databases were systematically interrogated for original English-language articles detailing COVID-19 air contamination in hospital settings between 1 December 2019 and 21 July 2020. This study was conducted in accordance with the PRISMA-ScR guidelines. The positivity rate of SARS-CoV-2 viral RNA and culture were described and compared according to the setting, clinical context, air ventilation system, and distance from patient. The SARS-CoV-2 RNA concentrations in copies per m3 of air were pooled and their distribution were described by hospital areas. Particle sizes and SARS-CoV-2 RNA concentrations in copies or TCID50 per m3 were analysed after categorization of sizes in <1 micrometers, 1-4 micrometers, and >4 micrometers. Results Among 2,034 records identified, 17 articles were included in the review. Overall, 27.5% (68/247) of air sampled from close patients environment were positive for SARS-CoV-2 RNA, without difference according to the setting (ICU: 27/97, 27.8%; non-ICU: 41/150, 27.3%; p=0.93), the distance from patients (<1 meter: 1/64, 1.5%; 1-5 meters: 4/67, 6%; p=0.4). In other areas, the positivity rate was 23.8% (5/21) in toilets, 9.5% (20/221) in clinical areas, 12.4% (15/121) in staff areas, and 34.1% (14/41) in public areas. A total of 78 viral cultures were performed in three studies, and 3 (4%) were positive, all from close patients environment. The median SARS-CoV-2 RNA concentrations varied from 1.103 copies per m3 (IQR: 0.4.103-9.103) in clinical areas to 9.7.103 (5.1.103-14.3.103) in the air of toilets or bathrooms. The protective equipment removal and patients rooms had high concentrations/titre of SARS-CoV-2 with aerosol size distributions that showed peaks in the <1 micrometers region, and staff offices in the >4 micrometers region. Conclusion In hospital, the air near and away from COVID-19 patients is frequently contaminated with SARS-CoV-2 RNA, with however, rare proofs of their viability. High viral loads found in toilet/bathrooms, staff and public hallways suggests to carefully consider these areas.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.07.20180448,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20180448,EARLY VIRAL CLEARANCE AMONG COVID-19 PATIENTS WHEN GARGLING WITH POVIDONE-IODINE AND ESSENTIAL OILS: A PILOT CLINICAL TRIAL,NURUL AZMAWATI MOHAMED; NIZAM BAHAROM; WAN SHAHIDA WAN SULAIMAN; ZETTI ZAINOL RASHID; KON KEN WONG; UMI KALSOM ALI; SITI NORLIA OTHMAN; MUTTAQILLAH NAJIHAN ABD SAMAD; NAJMA KORI; PETRICK PERIYASAMY; NOR AZIZAN ZAKARIA; AGNI NHIRMAL KUMAR SUGUMAR; NUR EZZATY MOHAMMAD KAZMIN; XIONG KHEE CHEONG; SITI MARIYAM SANIMAN; ILINA ISAHAK; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,Universiti Sains Islam Malaysia; UNIVERSITI SAINS ISLAM MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background: Gargling had been reported to have significant roles in the prevention and treatment of respiratory tract infections. The purpose of this study was to assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx. Methodology: This pilot, open labeled, randomized, parallel study compared the effect of 30 seconds, 3 times/day gargling using 1% povidone-iodine (PVP-I), essential oils and tap water on SARS-CoV-2 viral clearance among COVID-19 patients in a tertiary hospital in Kuala Lumpur. Progress was monitored by day 4,6 and 12 PCR (Ct value), gargling and symptoms diary as well as clinical observations. Results: Five confirmed Stage 1 COVID-19 patients were recruited for each arm. The age range was from 22 to 56 years old. The majority were males. Two respondents had co-morbidities, which were asthma and obesity. Viral clearance was achieved at day 6 in 100%, 80%, 20% and 0% for 1% PVP-I, essential oils, tap water and control group respectively. Analysis of 1% PVP-I group versus control group showed significant p-value for comparison of PCR results on Day 4, Day 6 and Day 12. Conclusions: This preliminary study showed that gargling with 1% PVP-I and essential oils show great potential to be part of the treatment and management of Stage 1 COVID-19. Larger studies are required to ascertain the benefit of gargling for different stages of COVID-19 patients. This study was registered in clinicaltrial.gov (NCT04410159).",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.07.20190165,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20190165,Insufficient hyperfibrinolysis in COVID-19: a systematic review of thrombolysis based on meta-analysis and meta-regression,Hong-Long J Ji; Zhenlei Su; Runzhen Zhao; Andrey A Komissarov; Guohua Yi; Shan-Lu Liu; Steven Idell; Michael A Matthay; NAJMA KORI; PETRICK PERIYASAMY; NOR AZIZAN ZAKARIA; AGNI NHIRMAL KUMAR SUGUMAR; NUR EZZATY MOHAMMAD KAZMIN; XIONG KHEE CHEONG; SITI MARIYAM SANIMAN; ILINA ISAHAK; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"University of Texas Health Science Center at Tyler; Department of Respiratory and Critical Care Medicine, Xinxiang Central Hospital; University of Texas Health Science Center at Tyler; University of Texas Health Science Center at Tyler; University of Texas Health Science Center at Tyler; The Ohio State University; University of Texas Health Science Center at Tyler; University of California San Francisco; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background How aberrant fibrinolysis influences the clinical progression of COVID-19 presents a clinicopathological dilemma challenging intensivists. To investigate whether abnormal fibrinolysis is a culprit or protector or both, we associated elevated plasma D-dimer with clinical variables to identify a panoramic view of the derangements of fibrinolysis that contribute to the pathogenesis of COVID-19 based on studies available in the literature. Methods We performed this systematic review based on both meta-analysis and meta-regression to compute the correlation of D-dimer at admission with clinical features of COVID-19 patients in retrospective studies or case series. We searched the databases until Aug 18, 2020, with no limitations by language. The first hits were screened, data extracted, and analyzed in duplicate. We did the random-effects meta-analyses and meta-regressions (both univariate and multivariate). D-dimer associated clinical variables and potential mechanisms were schematically reasoned and graphed. Findings Our search identified 42 observational, or retrospective, or case series from six countries (n=14,862 patients) with all races and ages from 1 to 98-year-old. The weighted mean difference of D-dimer was 0.97 g/mL (95% CI 0.65, 1.29) between relatively mild (or healthy control) and severely affected groups with significant publication bias. Univariate meta-regression identified 58 of 106 clinical variables were associated with plasma D-dimer levels, including 3 demographics, 5 comorbidies, 22 laboratory tests, 18 organ injury biomarkers, 8 severe complications, and 2 outcomes (discharge and death). Of these, 11 readouts were negatively associated with the level of plasma D-dimer. Further, age and gender were confounding factors for the identified D-dimer associated variables. There were 22 variables independently correlated with the D-dimer level, including respiratory rate, dyspnea plasma K+, glucose, SpO2, BUN, bilirubin, ALT, AST, systolic blood pressure, and CK. We thus propose that ""insufficient hyperfibrinolysis (fibrinolysis is accelerated but unable to prevent adverse clinical impact for clinical deterioration COVID-19)"" as a peculiar mechanism. Interpretation The findings of this meta-analysis- and meta-regression-based systematic review supports elevated D-dimer as an independent predictor for mortality and severe complications. D-dimer-associated clinical variables draw a landscape integrating the aggregate effects of systemically suppressive and locally (i.e., in the lung) hyperactive derangements of fibrinolysis. D-dimer and associated clinical biomarkers and conceptually parameters could be combined for risk stratification, potentially for tracking thrombolytic therapy or alternative interventions.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.07.20190066,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20190066,"Understanding SARSCOV-2 propagation, impacting factors to derive possible scenarios and simulations",Lewis E. Mehl-Madrona; Francois Bricaire; Adrian Cuyugan; Jovan Barac; Asadullah Parvaiz; Ali Bin Jamil; Sajid Iqbal; Meryem Koliali; Ryan Vally; Mohamed Karim Sellier; NOR AZIZAN ZAKARIA; AGNI NHIRMAL KUMAR SUGUMAR; NUR EZZATY MOHAMMAD KAZMIN; XIONG KHEE CHEONG; SITI MARIYAM SANIMAN; ILINA ISAHAK; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"University of Maine; Sorbonne University, Paris, France; Aspire Technologies, Paris, France; Aspire Technologies, Paris, France; Aspire Technologies, Paris, France; Aspire Technologies, Paris, France; Aspire Technologies, Paris, France; BCB, Paris, France; BCB, Paris, France; Aspire Technologies, Paris, France; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI KEBANGSAAN MALAYSIA; UNIVERSITI SAINS ISLAM MALAYSIA; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","We aimed to analyze factors impacting the Covid-19 epidemic on a macro level, comparing multiple countries across the world and verifying the occurrence at a micro level through cluster analysis. The severity of the epidemic was most strongly related to exposure to ultraviolet light and extrapolated levels of vitamin D and to the health of the population, especially with regards to obesity. We found no county with an obesity level < 8% with a severe epidemic. We also found that countries where the population benefited from sun exposure or vitamin D supplementation and spent time outside fared well. Factors related to increased propagation of the virus included the use of heating ventilation and air conditioning (HVAC), population density, poorly aerated gatherings, relative humidity, timely policies of closing clustering places until aeration was improved, and daily amount of ridership on public transportation, especially subways. Population lockdowns, masks, and blood type did not provide much explanatory power. Contact tracing was not analyzed as very few countries applied it for long enough. The excess mortality observed is within the ranges of severe past influenza epidemics of 2016/2017 or 1999/2000 and lower than older severe influenza epidemics of the 1940s or 1970s. We estimated that COVID mortality death counts in European countries is over estimated when taking into account excess mortality further confirming the important role of comorbidities independently of lockdown policy. A few countries observed an under-mortality despite of some deaths counts attributed to COVID-19. Treatments or vaccines should protect the fraction of the population that is not suffering from severe comorbidities. Our study suggested that prevention measures should be directed to improving aeration systems, enhancing diets and exercise, and ensuring adequate levels of vitamin D. Prevention measures and attention should be paid to anxiety resulting from this episode which may be associated with increases in obesity, addictions, vitamin D deficiency, depression, suicide, and hunger ultimately weakening population resiliency.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.07.20188813,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20188813,Tracking Smell Loss to Identify Healthcare Workers with SARS-CoV-2 Infection,Julian J Weiss; Tuki N Attuquayefio; Elizabeth B White; Fangyong Li; Rachel S Herz; Theresa L White; Melissa Campbell; Bertie Geng; Rupak Datta; Anne L Wyllie; Nathan D Grubaugh; Arnau Casanovas-Massana; M Catherine Muenker; Ryan Handoko; Akiko Iwasaki; - The Yale IMPACT Research Team; Richard A Martinello; Albert I Ko; Dana M Small; Shelli F Farhadian; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Yale School of Medicine; Yale School of Medicine; Yale School of Public Health; Yale School of Public Health; Alpert Medical School of Brown University; Le Moyne College, SUNY Upstate Medical University; Yale School of Medicine; Yale School of Medicine; Yale School of Medicine; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Medicine; Yale School of Medicine; ; Yale School of Medicine; Yale School of Public Health; Yale University; Yale School of Medicine; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background: Healthcare workers (HCW) treating COVID-19 patients are at high risk for infection and may also spread infection through their contact with vulnerable patients. Smell loss has been associated with SARS-CoV-2 infection, but it is unknown whether monitoring for smell loss can be used to identify asymptomatic infection among high risk individuals, like HCW. Methods: We performed a prospective cohort study, tracking 473 HCW across three months to determine if smell loss could predict SARS-CoV-2 infection in this high-risk group. HCW subjects completed a longitudinal, novel behavioral at-home assessment of smell function with household items, as well as detailed symptom surveys that included a parosmia screening questionnaire, and RT-qPCR testing to identify SARS-CoV-2 infection. Results: SARS-CoV-2 was identified in 17 (3.6%) of 473 HCW. Among the 17 infected HCW, 53% reported smell loss, and were more likely to report smell loss than COVID-negative HCW on both the at-home assessment and the screening questionnaire (P < .01). 67% reported smell loss prior to having a positive SARS-CoV-2 test, and smell loss was reported a median of two days before testing positive. Neurological symptoms were reported more frequently among COVID-positive HCW who reported smell loss (P < .01). Conclusions: In this prospective study of HCW, self-reported changes in smell using two different measures were predictive of COVID-19 infection. Smell loss frequently preceded a positive test and was associated with neurological symptoms.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.09.20190389,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.09.20190389,"Passive, open access data measures movement and predicts COVID-19 cases",Christina L. Faust; Brian Lambert; Cale Kochenour; Anthony C. Robinson; Nita Bharti; Theresa L White; Melissa Campbell; Bertie Geng; Rupak Datta; Anne L Wyllie; Nathan D Grubaugh; Arnau Casanovas-Massana; M Catherine Muenker; Ryan Handoko; Akiko Iwasaki; - The Yale IMPACT Research Team; Richard A Martinello; Albert I Ko; Dana M Small; Shelli F Farhadian; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Penn State University; Penn State University; Penn State University; Penn State University; Penn State University; Le Moyne College, SUNY Upstate Medical University; Yale School of Medicine; Yale School of Medicine; Yale School of Medicine; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Medicine; Yale School of Medicine; ; Yale School of Medicine; Yale School of Public Health; Yale University; Yale School of Medicine; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background. In the months following the global spread of SARS-CoV-2, the lack of effective pharmaceutical interventions led to widespread implementation of behavioral interventions aimed at reducing contacts and transmission. In the US, state and local governments introduced and enforced the bulk of interventions, including university closures. As universities closed, student departures decreased the total population size of college towns while state-level interventions decreased contacts among remaining residents. Though the pandemic continues without pharmaceutical interventions, businesses have begun to reopen, and many universities have resumed operations. These actions have increased contacts and population sizes in college towns. Monitoring movement to implement adaptive policies will be critical for outbreak management. Methods. We use publicly available remotely-sensed nighttime lights and traffic cameras to measure the impact of restriction policies on movement and activities in the university town of State College, and the surrounding areas of Centre County, Pennsylvania, USA. Results. At the county level, nighttime radiance did not differ significantly across restriction phases and largely reflected seasonal fluctuations seen in previous years. Throughout the county, traffic volumes were lowest during the most severe period of restrictions ('Red phase' in Pennsylvania). As restrictions eased, traffic volumes grew, indicating increased movement within and between population centers. We show that real-time, publicly available traffic data captured behavioral responses and compliance to different restrictions phases. We also demonstrate that these increases in activity levels precede increases in reported COVID-19 cases. Conclusion. Passively collected data can measure population-level movement in response to restrictions and changes in these measured movements are reflected in observed SARS-CoV-2 transmission. Measuring these changes in movements and contacts in near real time can inform local adaptive interventions to curtail outbreaks.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20190108,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20190108,Covid-19 Belgium: Extended SEIR-QD model with nursery homes and long-term scenarios-based forecasts from school opening,Nicolas Franco; Brian Lambert; Cale Kochenour; Anthony C. Robinson; Nita Bharti; Theresa L White; Melissa Campbell; Bertie Geng; Rupak Datta; Anne L Wyllie; Nathan D Grubaugh; Arnau Casanovas-Massana; M Catherine Muenker; Ryan Handoko; Akiko Iwasaki; - The Yale IMPACT Research Team; Richard A Martinello; Albert I Ko; Dana M Small; Shelli F Farhadian; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"University of Namur; Penn State University; Penn State University; Penn State University; Penn State University; Le Moyne College, SUNY Upstate Medical University; Yale School of Medicine; Yale School of Medicine; Yale School of Medicine; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Medicine; Yale School of Medicine; ; Yale School of Medicine; Yale School of Public Health; Yale University; Yale School of Medicine; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","We model the evolution of the covid-19 epidemic in Belgium with an age-structured extended SEIR-QD epidemic model with separated consideration for nursing homes. All parameters of the model are estimated using a MCMC method, except integrated data on social contacts. The model is calibrated on hospitals data, number of deaths, nursing homes tests and serological tests. We present the current situation in November 2020 as well as long-term scenarios-based forecasts concerning the second wave and subsequent lifting of measures.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20189779,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189779,Influenza may facilitate the spread of SARS-CoV-2,Matthieu Domenech de Celles; Jean-Sebastien Casalegno; Bruno Lina; Lulla Opatowski; Nita Bharti; Theresa L White; Melissa Campbell; Bertie Geng; Rupak Datta; Anne L Wyllie; Nathan D Grubaugh; Arnau Casanovas-Massana; M Catherine Muenker; Ryan Handoko; Akiko Iwasaki; - The Yale IMPACT Research Team; Richard A Martinello; Albert I Ko; Dana M Small; Shelli F Farhadian; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Max Planck Institute for Infection Biology; Virpath, Centre International de Recherche en Infectiologie (CIRI); Virpath, Centre International de Recherche en Infectiologie (CIRI); Institut Pasteur; Penn State University; Le Moyne College, SUNY Upstate Medical University; Yale School of Medicine; Yale School of Medicine; Yale School of Medicine; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Public Health; Yale School of Medicine; Yale School of Medicine; ; Yale School of Medicine; Yale School of Public Health; Yale University; Yale School of Medicine; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","As in past pandemics, co-circulating pathogens may play a role in the epidemiology of coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe. We developed a population-based model of SARS-CoV-2 transmission, combined with mortality incidence data in four European countries, to test a range of assumptions about the impact of influenza. We found consistent evidence for a 2-2.5-fold population-level increase in SARS-CoV-2 transmission associated with influenza during the period of co-circulation. These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.08.20190504,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190504,First report on the Latvian SARS-CoV-2 isolate genetic diversity,Nikita Zrelovs; Monta Ustinova; Ivars Silamikelis; Liga Birzniece; Kaspars Megnis; Vita Rovite; Lauma Freimane; Laila Silamikele; Laura Ansone; Janis Pjalkovskis; Davids Fridmanis; Baiba Vilne; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; Riga Stradins University, Dzirciema 16, Riga, LV-1007; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Remaining a major healthcare concern with nearly 27 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus - 2 (SARS-CoV-2) has caused more than 880 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, nine days prior to the pandemic declaration by WHO. Since then, more than 230 000 tests were carried out confirming a total of 1330 cases of COVID-19 in the country as of 20th of August 2020. Rapidly reacting to the spread of the infection, an ongoing sequencing campaign was started mid-March in collaboration with the local testing laboratories, with an ultimate goal in sequencing as much local viral isolates as possible, resulting in first full-length SARS-CoV-2 isolate genome sequences from the Baltics region being made publicly available in early April. With 109 viral isolates representing ~8.2% of the total COVID-19 cases in the country being completely sequenced as of today, here we provide a first report on the genetic diversity of Latvian SARS-CoV-2 isolates.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20189050,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189050,"Seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires",Andrea Silva; Maria Fernanda Aguirre; Christian Ballejo; Maria Jimena Marro; ANDREA GAMARNIK; Gaston Vargas; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; FUNDACION INSTITUTO LELOIR; Sanitary Region VIII, Mar del Plata, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Introduction: The aim of this study was to estimate the seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires during June 2020. Methods: a cross-sectional design was used. A probabilistic sampling by two-stage conglomerates was carried out. Data were collected from a self-administered questionnaire and a blood sample for antibody identification. The COVIDAR IgG and IgM test were used. RESULTS: 738 health workers were included; the overall response rate was 73.80%. 71.83% of that were women; age showed a normal distribution. Nurses and doctors accounted for more than half of the staff. 75.86% of people claimed to always use Personal Protective Equipment. 5.61% of people had close contact with a confirmed case of COVID-19. 4.60% of people had previously had a nasopharyngeal swab with a negative result. Five workers had positive IgG for SARS-CoV-2 (four women and one man) with negative IgM. The mean age of the cases was 35 years old; two of them were asymptomatic; neither of them had a swab sample taken. The overall seroprevalence was 0.75%, with no significant differences between strata. Discussion: the seroprevalence found was low; indicating a large proportion of workers was susceptible to infection. We stress the need to complement passive epidemiological surveillance strategies with serological monitoring in health workers.",epidemiology,exact,100,100
medRxiv,10.1101/2020.09.07.20189621,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20189621,COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: A single-centre cohort study,Abu Z M Dayem Ullah; Lavanya Sivapalan; Claude Chelala; Hemant M Kocher; ANDREA GAMARNIK; Gaston Vargas; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Barts Cancer Institute; Barts Cancer Institute; Barts Cancer Institute; Barts Cancer Institute; FUNDACION INSTITUTO LELOIR; Sanitary Region VIII, Mar del Plata, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Objective The impact of COVID-19 in patients with pre-existing hepato-pancreato-biliary (HPB) conditions is not clearly understood. To explore risk factors associated with COVID-19 susceptibility and survival in this patient group, we conducted a single-centre retrospective cohort study. Design We interrogated linked electronic health records for patients diagnosed with HPB diseases in East London since 2008 (n=15 586), and identified 212 confirmed COVID-19 cases between February 12 and June 12, 2020. We conducted risk analyses to identify the effect of demographics, comorbidities and associated medication use, and lifestyle factors and with appropriate adjustment for gender, ethnicity, age group and HPB diagnoses on COVID-19 incidence and mortality. Results We observed an increased risk of COVID-19 for men (Relative Risk, RR=1.59; 95% CI 1.21 to 2.09) and Black ethnicity (RR=2.2; 95% CI 1.5 to 3.18). Substance mis-users were at more risk of infection, so were patients on Vitamin D treatment. The higher risks associated with South Asian ethnicity, patients with pre-existing non-malignant pancreatic or liver conditions, age>70, and past smokers were due to co-existing comorbidities; surprisingly current smokers were associated with a lower risk. Increased mortality risk was observed for Black ethnicity (RR=2.4; 95% CI 1.35 to 3.48), and patients with a pre-existing kidney condition (RR=2.13; 95% CI 1.16 to 3.55) - particularly when accompanied with an acute episode of renal complications (RR=2.74; 95% CI 1.32 to 5.13). Conclusions This large multi-ethnic population-based study of HPB patients shows a higher risk of acquiring COVID-19 for male gender, Black ethnicity, medical co-morbidities, and substance mis-users. Particular attention should be paid to patients with a pre-existing kidney disease for further renal insult to prevent fatality.",gastroenterology,exact,100,100
medRxiv,10.1101/2020.09.07.20190124,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20190124,The impact of COVID-19 on the lives and mental health of Australian adolescents,Sophie Li; Joanne Beames; Jill Newby; Kate Maston; Helen Christensen; Aliza Werner-Seidler; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Black Dog Institute & School of Psychology, UNSW Sydney; Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Objective: There has been significant disruption to the lives and mental health of adolescents during the COVID-19 pandemic, but the exact nature of the effects is not known. The purpose of this study was to assess the psychological and lifestyle impact of the pandemic on Australian adolescents, using an online survey, administered during and after the peak of the outbreak (June-July 2020). Method: Self-report surveys were administered online to a sample of 760 Australian adolescents aged 12-18 years old. Surveys assessed worry about contracting COVID-19, behavioral change in response to the pandemic, impact on education, peer and family relationships, lifestyle factors including exercise, technology use and sleep, as well as mental health outcomes including psychological distress, loneliness, health anxiety and wellbeing. Results: Overall, young people expressed significant concern and worry about contracting the virus, and most (>85%) engaged in behaviors to reduce the risk of transmission. Three quarters of the sample reported a worsening of their mental health since the pandemic began, with negative impacts reported by most respondents on learning, friendships and family relationships. More than 40% of young people reported a decrease in exercise and 70% reported an increase in technology use since the outbreak. There were high levels of uncertainty about the future reported by respondents, and their scores on validated measures indicated higher levels of sleep disturbance, psychological distress and health anxiety, and lower levels of wellbeing, relative to normative samples. Reponses on the Kessler Psychological Distress Scale indicated that 48.3% of the sample were experiencing distress consistent with a probable mental illness, which is much higher than pre-pandemic prevalence rates. Effects on mental health were worse among those who reported a previous diagnosis of depression and/or anxiety relative to those without a history of depression and/or anxiety. Conclusion: These results indicate high levels of disruption and psychological distress experienced by adolescents during the current COVID-19 pandemic. Adolescents are already vulnerable to the onset of mental illness at this developmental stage, and the current research underscores the need to find rapid and accessible ways to support adolescent mental health during times of crisis. There is a need for longitudinal research to evaluate the enduring effects of the pandemic on adolescents.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.09.07.20190058,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.07.20190058,Demographic Differences in US Adult Intentions to Receive a Potential Coronavirus Vaccine and Implications for Ongoing Study,Richard M. Carpiano; Joanne Beames; Jill Newby; Kate Maston; Helen Christensen; Aliza Werner-Seidler; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"University of California, Riverside; Black Dog Institute, UNSW Sydney; Black Dog Institute & School of Psychology, UNSW Sydney; Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Abstract Background: The coronavirus pandemic's public health and economic impacts have led to much hope in the US regarding the prospect of a safe, effective vaccine to either prevent infection or minimize symptoms and reduce mortality risk. However, recent US polls indicate a concerning level of hesitancy that will likely lead to suboptimal uptake if such a vaccine becomes available. This study investigated demographic differences regarding US adults' intent, uncertainty, and refusal to receive a potential coronavirus vaccine and specific reasons for intention to receive it. Methods and findings: Multivariable analysis of Associated Press (AP)-NORC Center for Public Affairs Research cross-sectional survey data collected in May 2020 from a US nationally representative panel of adults (n=1000). Respondents were asked if they would receive a coronavirus vaccine (yes, unsure, no). Among those answering yes, the specific reasons were: to protect self, family, and community; chronic health condition; and having a doctor who recommends vaccines. Multinomial logistic regression models indicated numerous subgroup differences between participants who indicating (1) uncertainty versus refusal, (2) intent versus refusal, and (3) intent versus uncertainty, with the highest number of significant differences observed in the third comparison. Overall, higher likelihood of intention to receive the vaccine versus uncertainty and refusal were mostly observed among respondents with a college education or greater, White, non-Hispanic racial-ethnic identity, ages 60 or older, and more liberal (versus conservative) ideology. Despite variation in endorsement across the five reasons for wanting to receive the vaccine, subgroup differences were fairly consistent across these specific reasons when comparing respondents endorsing such intentions versus, respectively, refusal and uncertainty in separate analyses. Conclusions: These findings suggest that the approval of a vaccine will potentially face problems with overall uptake due to uncertainty or refusal and contribute to creating significant demographic disparities in COVID-19 morbidity and mortality risk. Ongoing assessment of such attitudes are needed as Phase III trials proceed, but the findings highlight need for measuring uncertainty and its underlying reasons, as well as multiple types of education and outreach efforts for those who are uncertain as well as avoidant.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.08.20190710,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190710,COVID-19 Transmission Dynamics and Effectiveness of Public Health Interventions in New York City during the 2020 Spring Pandemic Wave,Wan Yang; Jaimie Shaff; Jeffrey Shaman; Kate Maston; Helen Christensen; Aliza Werner-Seidler; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Columbia University; New York City Department of Health and Mental Hygiene; Columbia University; Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Black Dog Institute, UNSW Sydney; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","As COVID-19 continues to pose significant public health threats, quantifying the effectiveness of different public health interventions is crucial to inform intervention strategies. Using detailed epidemiological and mobility data available for New York City and comprehensive modeling accounting for under-detection, we reconstruct the COVID-19 transmission dynamics therein during the 2020 spring pandemic wave and estimate the effectiveness of two major non-pharmaceutical interventions--lockdown-like measures that reducing contact rates and universal masking. Lockdown-like measures were associated with >50% transmission reduction for all age groups. Universal masking was associated with a [~]7% transmission reduction overall and up to 20% reduction for 65+ year-olds during the first month of implementation. This result suggests that face covering can substantially reduce transmission when lockdown-like measures are lifted but by itself may be insufficient to control SARS-CoV-2 transmission. Overall, findings support the need to implement multiple interventions simultaneously to effectively mitigate COVID-19 spread before the majority of population can be protected through mass-vaccination.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.09.20190454,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.09.20190454,The risk of introducing SARS-CoV-2 to the UK via international travel in August 2020,Rachel Taylor; Catherine A McCarthy; Virag Patel; Ruth Moir; Louise Kelly; Emma Snary; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Epidemiology and Risk Policy Advice, Animal and Plant Health Agency (APHA), UK; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK; Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","International travel poses substantial risks for continued introduction of SARS-CoV-2. As of the 17th August 2020, travellers from 12 of the top 25 countries flying into the UK are required to self-isolate for 14 days. We estimate that 895 (CI: 834-958) infectious travellers arrive in a single week, of which 87% (779, CI: 722-837) originate from countries on the UK quarantine list. We compare alternative measures to the 14 day self-isolation (78.0% effective CI: 74.4-81.6) which could be more feasible long-term. A single RT-PCR taken upon arrival at the airport is 39.6% (CI: 35.2-43.7) effective, or equivalently, it would only detect 2 in 5 infectious passengers. Alternatively, testing four days after arrival is 64.3% (CI: 60.0-68.3) effective whereas a test at the airport plus additional test four days later is 68.9% (CI: 64.9-73.0) effective. Rapidly implementing control measures for travellers from risky countries is vital to protect public health; this methodology can be quickly updated to assess the impact of any further changes to international travel policy or disease occurrence.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.08.20190397,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190397,The impact of COVID-19 restriction measures on loneliness among older adults in Austria,Erwin Stolz; Hannes Mayerl; Wolfgang Freidl; Ruth Moir; Louise Kelly; Emma Snary; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Medical University of Graz; Medical University of Graz; Medical University of Graz; Epidemiology and Risk Policy Advice, Animal and Plant Health Agency (APHA), UK; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK; Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background: To halt the spread of COVID-19, Austria implemented a 7-week shut-down of public life in March/April 2020 which was followed by a gradual withdrawal of these restriction measures in May/June 2020. We expect that the ensuing reduction in social contacts led to increased loneliness among older adults (60+). Methods: We conducted three analyses to assess the association between COVID-19 public health restriction measures and loneliness: (1) A comparison between pre-pandemic (SHARE: 2013-2017) and pandemic (May 2020) levels of loneliness (UCLA-3 scale), (2) an analysis of the correlation between being affected by COVID-19 restriction measures and loneliness based on cross-sectional survey data from early May 2020, and (3) a longitudinal analysis of weekly changes in loneliness (Corona panel data) from late March to early June 2020. Results: We found (1) loneliness levels to have increased in 2020 in comparison with previous years, (2) an association between the number of restriction measures older adults reported to be affected from and loneliness, and (3) that loneliness was higher during shut-down compared to the subsequent re-opening phase, particularly among those who live alone. Discussion: Our results provide evidence that COVID-19 restriction measures in Austria have indeed resulted in increased levels of loneliness among older adults. However, these effects seem to be short-lived, and thus we do not expect strong negative consequences for older adults mental health downstream. Nonetheless, effects of longer and/or repeated future restriction measures aiming at social distancing should be closely monitored.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.08.20190470,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190470,Modelling the epidemic growth of preprints on COVID-19 and SARS-CoV-2,Giovani L. Vasconcelos; Luan P. Cordeiro; Gerson C. Duarte-Filho; Arthur A. Brum; Louise Kelly; Emma Snary; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Universidade Federal do Parana; Universidade Federal do Parana; Universidade Federal de Sergipe; Universidade Federal de Pernambuco; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK; Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","The response of the scientific community to the global health emergency caused by the COVID-19 pandemic has produced an unprecedented number of manuscripts in a short period of time, the vast majority of which has been shared in the form of preprints posted before peer review on preprint repositories. This surge in preprint publications has in itself attracted considerable attention, although mostly in the bibliometric literature. In the present study we apply a mathematical growth model, known as the generalized Richards model, to describe the time evolution of the cumulative number of COVID-19 related preprints. This mathematical approach allows us to infer several important aspects concerning the underlying growth dynamics, such as its current stage and its possible evolution in the near future. We also analyze the rank-frequency distribution of preprints servers, ordered by the number of COVID-19 preprints they host, and find that it follows a power-law decay. This Zipf-like law indicates the presence of a cumulative advantage effect, whereby servers that already have more preprints receive more submissions.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.08.20190785,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190785,Analysis of internet trends related to medications for COVID-19in ten countries with the highest number of cases,Josimar E. Chire Saire; Roselyn Lemus-Martin; Gerson C. Duarte-Filho; Arthur A. Brum; Louise Kelly; Emma Snary; Marina Pifano; Teresa Varela; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"University of Sao Paulo; Genomics Medicine Institute; Universidade Federal de Sergipe; Universidade Federal de Pernambuco; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK; Department of Epidemiological Sciences, Animal and Plant Health Agency (APHA), UK; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","During the last months, the pandemic generated by coro- navirus SARS-CoV-2 moved governments, research groups and health organizations to plan, test and execute health policies. At the beginning, the treatment was not clear but in the next months, research groups have conducted studies to recommend or ban some medicines. At the same time, countries with most cases were changing from Asia, Europe to America. Different treatments and medications have been tested and recommended in many countries, such as Hydroxycloroquine ,Ivermectin, Azithromycin, Dexametha- sone, Prednisone, Remdesivir . This paper is a preliminary study about which medications people are searching on the Internet, considering ten countries with most cases in the world such as Chile, Spain, United Kingdom, Brazil, United States, India, Russia, South Africa, Peru and Mexico.",public and global health,exact,100,100
medRxiv,10.1101/2020.09.09.20191247,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.09.20191247,"Early indirect impact of COVID-19 pandemic on utilization and outcomes of reproductive, maternal, newborn, child and adolescent health services in Kenya",DUNCAN N SHIKUKU; Irene Nyaoke; Sylvia Gichuru; Onesmus Maina; Martin Eyinda; Pamela Godia; Lucy Nyaga; Charles Ameh; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Marta Priedite; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"LIVERPOOL SCHOOL OF TROPICAL MEDICINE; Liverpool School of Tropical Medicine (Kenya); Liverpool School of Tropical Medicine (Kenya); Liverpool School of Tropical Medicine (Kenya); Liverpool School of Tropical Medicine (Kenya); Liverpool School of Tropical Medicine (Kenya) and University of Nairobi (School of Public Health); Liverpool School of Tropical Medicine (Kenya); Liverpool School of Tropical Medicine (UK) and University of Nairobi (Department of Obstetrics and Gynaecology); Ministry of Health of Buenos Aires, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Instituto Nacional de Epidemiologia ""Dr. Juan H Jara"" (Administracion Nacional de Laboratorios e Institutos de Salud -ANLIS-), Mar del Plata, Argentina; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; Centrala Laboratorija, Ltd, Sarlotes 1B, Riga, Latvia, LV-1001; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; E. Gulbja Laboratorija, Ltd, Brivibas gatve 366, Riga, Latvia, LV-1006; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; Riga East University hospital, Laboratory Service, Latvian Centre of Infectious Diseases laboratory, National Microbiology Reference Laboratory, Molecular biolo; The Centre for Disease Prevention and Control (CDPC) of Latvia, Infectious Diseases Risk Analysis and Prevention Department, Infectious Diseases Surveillance an; University of Latvia, Faculty of Medicine, Jelgavas 3, Riga, Latvia, LV-1004; Pauls Stradins Clinical University Hospital, Pilsonu 13, Riga, Latvia, LV-1002; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background: The COVID-19 global pandemic is expected to result in 8.3-38.6% additional maternal deaths in many low-income countries. The objective of this paper was to determine the initial impact of COVID-19 pandemic on reproductive, maternal, newborn, child and adolescent health (RMNCAH) services in Kenya. Methods: Data for the first four months (March-June) of the pandemic and the equivalent period in 2019 were extracted from Kenya Health Information System. Two-sample test of proportions for hospital attendance for select RMNCAH services between the two periods were computed. Results: There were no differences in monthly mean ({+/-}SD) attendance between March-June 2019 vs 2020 for antenatal care (400,191.2{+/-}12,700.0 vs 384,697.3{+/-}20,838.6), hospital births (98,713.0{+/-}4,117.0 vs 99,634.5{+/-}3,215.5), family planning attendance (431,930.5{+/-}19,059.9 vs 448,168.3{+/-}31,559.8), post-abortion care (3,206.5{+/-}111.7 vs 448,168.3{+/-}31,559.8) and pentavalent 1 immunisation (114,701.0{+/-}3,701.1 vs 110,915.8{+/-}7,209.4), p>0.05. However, there were increasing trends for adolescent pregnancy rate, significant increases in FP utilization among young people (25.7% to 27.0%), injectable (short-term) FP method uptake (58.2% to 62.3%), caesarean section rate (14.6% to 15.8%), adolescent maternal deaths (6.2% to 10.9%) and fresh stillbirths (0.9% to 1.0%) with a reduction in implants (long-term) uptake (16.5% to 13.0%) (p<0.05). No significant change in maternal mortality ratio between the two periods (96.6 vs 105.8/100,000 live births, p=0.1023) although the trend was increasing. Conclusion: COVID-19 may have contributed to increased adolescent pregnancy, adolescent maternal death and stillbirth rates in Kenya. If this trend persists, recent gains achieved in maternal and perinatal health in Kenya will be lost. With uncertainty around the duration of the pandemic, strategies to mitigate against catastrophic indirect maternal health outcomes are urgently needed. Key words: COVID-19, maternal, reproductive, stillbirths, family planning, adolescent, mortality, Kenya.",sexual and reproductive health,exact,100,100
medRxiv,10.1101/2020.09.08.20190272,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.08.20190272,Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity,Sara Falck-Jones; Sindhu Vangeti; Meng Yu; Ryan Falck-Jones; Alberto Cagigi; Isabella Badolati; Bjorn Osterberg; Maximilian Julius Lautenbach; Eric Ahlberg; Ang Lin; Inga Szurgot; Klara Lenart; Fredrika Hellgren; Jorgen Salde; Jan Albert; Niclas Johansson; Max Bell; Karin Lore; Anna Farnert; Anna Smed-Sorensen; Janis Klovins; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,"Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Health Care Services Stockholm County (SLSO); Karolinska Institute; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, Latvia, LV-1067; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","The immunopathology of COVID-19 remains enigmatic, exhibiting immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor cells (M-MDSC) are T cell suppressors that expand in inflammatory conditions, but their role in acute respiratory infections remains unclear. We studied blood and airways of COVID-19 patients across disease severity at multiple timepoints. M-MDSC frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of COVID-19 patients compared to controls. M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFN{gamma} production partly via an arginase-1 (Arg-1) dependent mechanism. Furthermore, patients showed increased Arg-1 and IL-6 plasma levels. COVID-19 patients had fewer T cells, and displayed downregulated expression of the CD3{zeta} chain. Ordinal regression showed that early M-MDSC frequency predicted subsequent disease severity. In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.09.02.20185892,2020-09-07,https://medrxiv.org/cgi/content/short/2020.09.02.20185892,Prognostic accuracy of emergency department triage tools for adults with suspected COVID-19: The PRIEST observational cohort study,Ben Thomas; Steve Goodacre; Ellen Lee; Laura Sutton; Amanda Loban; Simon Waterhouse; Richard Simmonds; Katie Biggs; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter; Diana Schneider; Bernadette Jesionek; Bianca Saenger; Ann-Kathrin Wallisch; Yvonne Feuchter; Hanna Junginger; Stefanie Krumm; Andre Heinen; Petra Adams-Quack; Julia Schlereth; Christoph Kroener; Shannan Hall-Ursone; Kathleen Brasky; Matthew C Griffor; Seungil Han; Joshua Lees; Ellene Mashalidis; Parag Sahasrabudhe; Charles Tan; Danka Pavliakova; Guy Singh; Camila Fontes-Garfias; Michael Pride; Ingrid Scully; tara Ciolino; Jennifer Obregon; Michal Gazi; Ricardo Carrion; Kendra Alfson; Warren Kalina; Deepak Kaushal; Pei-Yong Shi; Thorsten Klamp; Corinna Rosenbaum; Andreas Kuhn; Oezlem Tuereci; Philip Dormitzer; Kathrin Jansen; Ugur Sahin; Akhilesh Kumar Maurya; K Hemanth; K Nagamani; K Sudha; T Ravi Chandra; K Tushara Rao; J Vyshnavi; Rashmi Upadhyay; Shalini Bahadur; Rambha Pathak; Shikha Seth; Rakesh Gupta; Rita Saxena; Preksha Dwivedi; Reeni Malik; Deepti Chourasia; Jaya Lalwani; UM Sharma; JL Marko; Amit Suri; Vijay Kumar; Rajnish Kaushik; Parul Kodan; Bhabani Prasad Acharya; Kuldeep Kumar Gaur; Anubhav Gupta; Prerna Sachdeva; Shruti Dogra; Aikaj Jindal; M Joseph John; Avtar Singh Dhanju; Ranjana Khetrepal; Neeraj Sharma; Neetu Kukar; Divya Kavita; Rajesh Kumar; Rajesh Mahajan; Gurpreet Singh; Jaspreet Kaur; Raminder Pal Singh; Rajni Bassi; Swapneil Parikh; Om Shrivastav; Jayanthi Shastri; Maherra Desai; Shreevatsa Udupa; Varun A Bafna; Vijay Barge; Rajendra Madane; Sheetal Yadav; Sanjeev Mishra; Archana Bajpayee; M K Garg; G K Bohra; Vijaylakshmi Nag; Puneeth Babu Anne; Mohd Nadeem; Pallavi Singh; Ram Niwas; Niranjan Shiwaji Khaire; Rattiram Sharma; Mini p Singh; Naresh Sachdeva; Suchet Sachdev; Rekha Hans; Vikas Suri; L N Yaddanapudi; PVM Lakshmi; Neha Singh; Divendu Bhushan; Neeraj Kumar; Muralidhar Tambe; Sonali Salvi; Nalini Kadgi; Shashikala Sangle; Leena Nakate; Samir Joshi; Rajesh Karyakarte; Suraj Goyanka; Nimisha Sharma; Nikhil Verma; Asim Das; Monika Bahl; Nitya Wadhwa; Shreepad Bhat; Shweta Deshmukh; Vrushali Wagh; Atul Kulkarni; Tanvi Yardi; Ram S Kalgud; Purushottam Reddy; Kavitha Yevoor; Prashanth Gajula; Vivek Maleyur; Medini S; Mohith HN; Anil Gurtoo; Ritika Sud; Sangeeta Pahuja; Anupam Prakash; Parijat Gogoi; Shailja Shukla; D Himanshu Reddy; Tulika Chandra; Saurabh Pandey; Pradeep Maurya; Ali Wahid; Vivek Kumar; Kamlesh Upadhyay; Nidhi Bhatnagar; Nilima Shah; Mamta Shah; Tarak Patel; Ram Mohan Jaiswal; Ashish Jain; Shweta Sharma; Puneet Rijhwani; Naveen Gupta; Tinkal C Patel; Mahesh G Solu; Jitendra Patel; Yash R Shah; Mayur Jarag; Varsha Godbole; Meenakshi Shah; Rikin Raj; Irfan Nagori; Pramod R Jha; Arti D Shah; Gowtham Yeeli; Archit Jain; Rooppreet Kaur Gill; KV Sreedhar Babu; B Suresh Babu; Alladi Mohan; B Vengamma; K Chandra Sekhar; Srinivasulu Damam; K Narsimhulu; C Aparna; G Baleswari; Ravindranath Reddy K; P Chandrasekhar; Sunil Jodharam Panjwani; Pankaj J Akholkar; Kairavi Parthesh Joshi; Pragnesh H Shah; Manish Barvaliya; Milind Baldi; Ashok Yadav; Manoj Gupta; Nitin Rawat; Dilip Chawda; M Natarajan; M Sintha; David Pradeep Kumar; Fathhur Rabbani; Vrushali Khirid Khadke; Dattatray Patki; Sonali Marathe; Clyde D Souza; Vipul Tadha; Satyam Arora; Devendra Kumar Gupta; Seema Dua; Nitu Chauhan; Ajeet Singh Chahar; Joy John Mammen; Snehil Kumar; Dolly Daniel; Ravindraa Singh; Venkatesh Dhat; Yogesh Agarwal; Sohini Arora; Ashish Pathak; Manju Purohit; Ashish Sharma; Jayashree Sharma; Manisha Madkaikar; Kavita Joshi; Reetika Malik Yadav; Swarupa Bhagwat; Niteen D Karnik; Yojana A Gokhale; Leena Naik; Sangita Margam; Santasabuj Das; Alka Turuk; V Saravana Kumar; K Kanagasabai; R Sabarinathan; Gururaj Deshpande; Sharda Sharma; Rashmi Gunjikar; Anita Shete; Darpan Phagiwala; Chetan Patil; Snehal Shingade; Kajal Jarande; Himanshu Kaushal; Pragya Yadav; Gajanan Sapkal; Priya Abraham,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; BioNTech  RNA Pharmaceuticals GmbH; University of Texas Medical Branch; University of Texas Medical Branch; Pfizer Inc.; Pfizer Inc; Pfizer Inc.; Pfizer Inc.; Pfizer Inc.; Pfizer Inc.; Pfizer Inc.; Pfizer Inc.; University of Texas Medical Branch; Pfizer Inc.; Pfizer Inc.; Pfizer Inc.; Pfizer Inc.; Texas Biomedical Research Institute; University of Texas Medical Branch; Texas Biomedical Research Institute; Pfizer Inc.; Texas Biomedical Research Institute; University of Texas Medical Branch; BioNTech SE; BioNTech SE; BioNTech  RNA Pharmaceuticals GmbH; BioNTech SE; Pfizer Inc.; Pfizer Inc.; BioNTech SE; Department of Internal Medicine,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Internal Medicine,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Microbiology,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Blood Bank,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Internal Medicine,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Internal Medicine,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Internal Medicine,  Gandhi Medical College, Secunderabad, Telangana, India; Department of Pulmonary Medicine,  Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India; Department of Pathalogy,  Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India; Department of Community Medicine,  Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India; Department of Obstetrics and Gynecology,  Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India; Department of Pediatrics,  Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India; Department of Internal Medicine,   Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Internal Medicine,  Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Pathology Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Pathology, Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Pharmacology, Gandhi Medical College, Bhopal, Madhya Pradesh, India; Department of Pulmonary Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Pathology,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Pulmonary Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Internal Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Community Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Internal Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Transfusion Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Transfusion Medicine,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Pathology,  Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India; Department of Transfusion Medicine,  Satguru Partap Singh Hospitals, Ludhiana, Punjab, India; Department of Clinical Hematology, Christian Medical College, Ludhiana, Punjab, India; Department of Internal Medicine, Government Medical College, Amritsar, Punjab, India; Department of Anesthesia,  Government Medical College, Amritsar, Punjab, India; Department of Transfusion,  Government Medical College, Amritsar, Punjab, India; Department of Immunohematology and Blood Transfusion,  Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India; Department of Anaesthesia,  Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India; Department of Immunohematology and Blood Transfusion,  Dayanand Medical College and Hospital, Ludhiana, Punjab, India; Department of Internal Medicine,  Dayanand Medical College and Hospital, Ludhiana, Punjab, India; Department of Respiratory Medicine, Satguru Partap Singh Hospitals, Ludhiana, Punjab, India; Department of Microbiology, Satguru Partap Singh Hospitals, Ludhiana, Punjab, India; Department of Internal Medicine,  Government Medical College, Patiala, Punjab, India; Department of Transfusion Medicine,  Government Medical College, Patiala, Punjab, India; Department of Infectious Diseases,  Kasturba Hospital, Mumbai, Maharashtra, India; Department of Infectious Diseases,  Kasturba Hospital, Mumbai, Maharashtra, India; Department of Microbiology,  Kasturba Hospital, Mumbai, Maharashtra, India; Clinical Research Department,  Kasturba Hospital, Mumbai, Maharashtra, India; Clinical Research Department,  Kasturba Hospital, Mumbai, Maharashtra, India; Department of Medicine,  RCSM Government Medical College, Kolhapur, Maharashtra, India; Department of Medicine,  RCSM Government Medical College, Kolhapur, Maharashtra, India; Department of Blood Bank,  RCSM Government Medical College, Kolhapur, Maharashtra, India; Department of Medicine,  RCSM Government Medical College, Kolhapur, Maharashtra, India; All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Pulmonary Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; Department of Internal Medicine,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Transfusion Medicine,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Virology,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Endocrinology,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Transfusion Medicine,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Transfusion Medicine,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Internal Medicine,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Anesthesiology and Intensive Care,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; School of Public Health,  Post Graduate Institute of Medical Education and Research, Chandigarh, India; Department of Transfusion Medicine,  All India Institute of Medical Sciences, Patna, Bihar, India; Department of Internal Medicine,  All India Institute of Medical Sciences, Patna, Bihar, India; Department of Trauma and Emergency Medicine,  All India Institute of Medical Sciences, Patna, Bihar, India; Department of Community Medicine Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Internal Medicine, Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Pathology, Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Internal Medicine, Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Pathology, Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of E.N.T., Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Microbiology, Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Internal Medicine, Byramjee Jeejeebhoy Medical College, Pune, Maharashtra, India; Department of Immunohematology and blood transfusion,  ESIC Medical College and Hospital, Faridabad, Haryana, India; Department of Internal Medicine,  ESIC Medical College and Hospital, Faridabad, Haryana, India; ESIC Medical College and Hospital, Faridabad, Haryana, India; Clinical Development Services Agency, Translational Health Sciences and Technology Institute, Faridabad, Haryana, India; Clinical Development Services Agency, Translational Health Sciences and Technology Institute, Faridabad, Haryana, India; Department of Internal Medicine,  Smt. Kashi Bai Navale Medical College, Pune, Maharashtra, India; Department of Internal Medicine,  Smt. Kashi Bai Navale Medical College, Pune, Maharashtra, India; Department of Internal Medicine,  Smt. Kashi Bai Navale Medical College, Pune, Maharashtra, India; Department of Blood Bank,  Jankalyan Blood bank, Pune, Maharashtra, India; Department of Blood Bank,  Jankalyan Blood bank, Pune, Maharashtra, India; Department of Internal Medicine, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Pathology, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Pathology, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Internal Medicine, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Internal Medicine, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Internal Medicine, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Internal Medicine, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India; Department of Internal Medicine, Lady Hardinge Medical College, New Delhi, India; Department of Internal Medicine, Lady Hardinge Medical College, New Delhi, India; Department of Transfusion Medicine, Lady Hardinge Medical College, New Delhi, India; Department of Internal Medicine, Lady Hardinge Medical College, New Delhi, India; Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India; Department of Pathology, Lady Hardinge Medical College, New Delhi, India; Department of Internal Medicine,  King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Transfusion Medicine,  King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Internal Medicine,  King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Internal Medicine,  King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Pathology and Biochemistry,  King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Internal Medicine,  King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Internal Medicine,  Byramjee Jeejeebhoy Medical College, Ahmedabad, Gujarat, India; Department of Transfusion Medicine,  Byramjee Jeejeebhoy Medical College, Ahmedabad, Gujarat, India; Department of Internal Medicine,  Byramjee Jeejeebhoy Medical College, Ahmedabad, Gujarat, India; Department of Transfusion Medicine,  Byramjee Jeejeebhoy Medical College, Ahmedabad, Gujarat, India; Department of Transfusion Medicine,  Byramjee Jeejeebhoy Medical College, Ahmedabad, Gujarat, India; Blood Center & Transplant Immunology Lab,  Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India; Department of Respiratory Medicine,  Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India; Department of Pathology,  Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India; Department of Internal Medicine,  Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India; Department of Clinical Hematology,  Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India; Department of Internal Medicine, Government Medical College, Surat, Gujarat, India; Department of Internal Medicine, Government Medical College, Surat, Gujarat, India; Department of Immunology & Blood Transfusion, Government Medical College, Surat, Gujarat, India; Department of Internal Medicine, Government Medical College, Surat, Gujarat, India; Department of Immunology and Blood Transfusion,  Government Medical College, Surat, Gujarat, India; Department of Internal Medicine,  GMERS Medical College and Hospital, Gotri, Vadodara, Gujarat, India; Department of Internal Medicine,  GMERS Medical College and Hospital, Gotri, Vadodara, Gujarat, India; Department of Internal Medicine,  GMERS Medical College and Hospital, Gotri, Vadodara, Gujarat, India; Department of Internal Medicine,  GMERS Medical College and Hospital, Gotri, Vadodara, Gujarat, India; Department of Internal Medicine, Sumandeep Vidyapeeth and Dhiraj Hospital, Vadodara, Gujarat, India; Department of Respiratory Medicine, Sumandeep Vidyapeeth and Dhiraj Hospital, Vadodara, Gujarat, India; Department of Internal Medicine, Sumandeep Vidyapeeth and Dhiraj Hospital, Vadodara, Gujarat, India; Department of Internal Medicine, Sumandeep Vidyapeeth and Dhiraj Hospital, Vadodara, Gujarat, India; Department of Internal Medicine, Sumandeep Vidyapeeth and Dhiraj Hospital, Vadodara, Gujarat, India; Department of Transfusion Medicine,  Sri Venkateswra Institute of Medical Sciences, Tirupati, Andhra Pradesh, India; Department of Transfusion Medicine,  Sri Venkateswra Institute of Medical Sciences, Tirupati, Andhra Pradesh, India; Department of Internal Medicine,  Sri Venkateswra Institute of Medical Sciences, Tirupati, Andhra Pradesh, India; Department of Neurology,  Sri Venkateswra Institute of Medical Sciences,Tirupati, Andhra Pradesh, India; Department of Internal Medicine,  Sri Venkateswra Institute of Medical Sciences,Tirupati, Andhra Pradesh, India; Department of Internal Medicine,  Kurnool Medical College, Kurnool, Andhra Pradesh, India; Department of Internal Medicine,  Kurnool Medical College, Kurnool, Andhra Pradesh, India; Department of Pathology,  Kurnool Medical College, Kurnool, Andhra Pradesh, India; Professor,  Department of Pathology,  Kurnool Medical College, Kurnool, Andhra Pradesh, India; Professor,  Department of Internal Medicine,  Kurnool Medical College, Kurnool, Andhra Pradesh, India; Department of Cardiology,  Kurnool Medical College, Kurnool, Andhra Pradesh, India; Department of Internal Medicine, Government Medical College, Bhavnagar, Gujarat, India; Department of Internal Medicine, Government Medical College, Bhavnagar, Gujarat, India; Department of Microbiology, Government Medical College, Bhavnagar, Gujarat, India; Department of Microbiology, Government Medical College, Bhavnagar, Gujarat, India; Department of Internal Medicine, Government Medical College, Bhavnagar, Gujarat, India; Department of Respiratory Medicine, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India; Department of Transfusion Medicine, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India; Department of Internal Medicine, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India; Department of Internal Medicine, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India; Department of Respiratory Medicine, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India; Department of Internal Medicine,  Madurai Medical College, Madurai, Tamil Nadu, India; Department of Immunohematology and Blood Transfusion,  Madurai Medical College, Madurai, Tamil Nadu, India; Department of Internal Medicine,  Madurai Medical College, Madurai, Tamil Nadu, India; Department of Internal Medicine,  Madurai Medical College, Madurai, Tamil Nadu, India; Department of Interventional Pulmonology, Poona Hospital and Research Center, Pune, Maharashtra, India; Department of Internal Medicine, Poona Hospital and Research Center, Pune, Maharashtra, India; Department of Pathology & Transfusion Medicine, Poona Hospital and Research Center, Pune, Maharashtra, India; Department of Internal Medicine, Poona Hospital and Research Center, Pune, Maharashtra, India; Department of General Medicine, Poona Hospital and Research Center, Pune, Maharashtra, India; Department of Transfusion Medicine, Super Specialty Paediatric Hospital and Post Graduate Teaching Institute, Noida, Uttar Pradesh, India; Department of Paediatric Surgery, Super Specialty Paediatric Hospital and Post Graduate Teaching Institute, Noida, Uttar Pradesh, India; Department of Transfusion Medicine, Super Specialty Paediatric Hospital and Post Graduate Teaching Institute, Noida, Uttar Pradesh, India; Department of Transfusion Medicine, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India; Department of Internal Medicine, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India; Department of Transfusion Medicine, Christian Medical College, Vellore, Tamil Nadu, India; Department of Transfusion Medicine, Christian Medical College, Vellore, Tamil Nadu, India; Department of Transfusion Medicine, Christian Medical College, Vellore, Tamil Nadu, India; Department of Transfusion Medicine, Aditya Birla Memorial Hospital, Pune, Maharashtra, India; Department of Critical Care Medicine, Aditya Birla Memorial Hospital, Pune, Maharashtra, India; Department of Pulmonary Medicine, Aditya Birla Memorial Hospital, Pune, Maharashtra, India; Department of Laboratory Medicine, Aditya Birla Memorial Hospital, Pune, Maharashtra, India; Department of Paediatrics,  RD Gardi Medical College, Ujjain, Madhya Pradesh, India; Department of Pathology,  RD Gardi Medical College, Ujjain, Madhya Pradesh, India; Department of Medicine,  RD Gardi Medical College, Ujjain, Madhya Pradesh, India; Department Transfusion Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India; Indian Council of Medical Research - National Institute of Immunohaematology, Mumbai, Maharashtra, India; Department Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India; Indian Council of Medical Research - National Institute of Immunohaematology, Mumbai, Maharashtra, India; Department of Transfusion Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India; Department of Internal Medicine,  Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai, Maharashtra, India; Department of Internal Medicine,  Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai, Maharashtra, India; Department of Pathology,  Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai, Maharashtra, India; Department of Pathology,  Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai, Maharashtra, India; Division of Clinical Medicine, National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, West Bengal, India; Division of Epidemiology and Communicable Division, Indian Council of Medical Research, New Delhi, India; Epidemiology and Biostatistics Division,  Indian Council of Medical Research - National Institute of Epidemiology, Chennai, Tamil, India; Computing and Informatics Science Division,  Indian Council of Medical Research - National Institute of Epidemiology, Chennai, Tamil, India; Project Division,  Indian Council of Medical Research, National Institute of Epidemiology, Chennai, Tamil, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Senior Technical Officer, Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Maximum Containment Laboratory, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Human Influenza Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Maximum Containment Laboratory,  Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Diagnostic Virology Group, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India; Director, Indian Council of Medical Research, National Institute Virology, Pune, Maharashtra, India","Objectives: The World Health Organisation (WHO) and National Institute for Health and Care Excellence (NICE) recommend various triage tools to assist decision-making for patients with suspected COVID-19. We aimed to estimate the accuracy of triage tools for predicting severe illness in adults presenting to the emergency department (ED) with suspected COVID-19 infection. Methods: We undertook a mixed prospective and retrospective observational cohort study in 70 EDs across the United Kingdom (UK). We collected data from people attending with suspected COVID-19 between 26 March 2020 and 28 May 2020, and used presenting data to determine the results of assessment with the following triage tools: the WHO algorithm, NEWS2, CURB-65, CRB-65, PMEWS and the swine flu adult hospital pathway (SFAHP). We used 30-day outcome data (death or receipt of respiratory, cardiovascular or renal support) to determine prognostic accuracy for adverse outcome. Results: We analysed data from 20892 adults, of whom 4672 (22.4%) died or received organ support (primary outcome), with 2058 (9.9%) receiving organ support and 2614 (12.5%) dying without organ support (secondary outcomes). C-statistics for the primary outcome were: CURB-65 0.75; CRB-65 0.70; PMEWS 0.77; NEWS2 (score) 0.77; NEWS2 (rule) 0.69; SFAHP (6-point) 0.70; SFAHP (7-point) 0.68; WHO algorithm 0.61. All triage tools showed worse prediction for receipt of organ support and better prediction for death without organ support. At the recommended threshold, PMEWS and the WHO criteria showed good sensitivity (0.96 and 0.95 respectively), at the expense of specificity (0.31 and 0.27 respectively). NEWS2 showed similar sensitivity (0.96) and specificity (0.28) when a lower threshold than recommended was used. Conclusion: CURB-65, PMEWS and NEWS2 provide good but not excellent prediction for adverse outcome in suspected COVID-19, and predicted death without organ support better than receipt of organ support. PMEWS, the WHO criteria and NEWS2 (using a lower threshold than usually recommended) provide good sensitivity at the expense of specificity.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.09.01.20185793,2020-09-03,https://medrxiv.org/cgi/content/short/2020.09.01.20185793,Prognostic accuracy of emergency department triage tools for children with suspected COVID-19: The PRIEST observational cohort study,Katie Biggs; Ben Thomas; Steve Goodacre; Ellen Lee; Laura Sutton; Matthew Bursnall; Amanda Loban; Simon Waterhouse; Richard Simmonds; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter; Fikrettin Sahin; Koray Yalcin; Ercument Ovali; Jeremiah J Faith,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust; Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey; Icahn School of Medicine at Mount Sinai (co-senior author)","Objectives: Emergency department clinicians can use triage tools to predict adverse outcome and support management decisions for children presenting with suspected COVID-19. We aimed to estimate the accuracy of triage tools for predicting severe illness in children presenting to the emergency department (ED) with suspected COVID-19 infection. Methods: We undertook a mixed prospective and retrospective observational cohort study in 44 EDs across the United Kingdom (UK). We collected data from children attending with suspected COVID-19 between 26 March 2020 and 28 May 2020, and used presenting data to determine the results of assessment using the WHO algorithm, swine flu hospital pathway for children (SFHPC), Paediatric Observation Priority Score (POPS) and Childrens Observation and Severity Tool (COAST). We recorded 30-day outcome data (death or receipt of respiratory, cardiovascular or renal support) to determine prognostic accuracy for adverse outcome. Results: We collected data from 1530 children, including 26 (1.7%) with an adverse outcome. C-statistics were 0.80 (95% confidence interval 0.73-0.87) for the WHO algorithm, 0.80 (0.71-0.90) for POPS, 0.76 (0.67-0.85) for COAST, and 0.71 (0.59-0.82) for SFHPC. Using pre-specified thresholds, the WHO algorithm had the highest sensitivity (0.85) and lowest specificity (0.75), but POPS and COAST could optimise sensitivity (0.96 and 0.92 respectively) at the expense of specificity (0.25 and 0.38 respectively) by using a threshold of any score above zero instead of the pre-specified threshold. Conclusion: Existing triage tools have good but not excellent prediction for adverse outcome in children with suspected COVID-19. POPS and COAST could achieve an appropriate balance of sensitivity and specificity for supporting decisions to discharge home by considering any score above zero to be positive.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.08.26.20182279,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20182279,COVID-19 infection dynamics in care homes in the East of England: a retrospective genomic epidemiology study,William L Hamilton; Gerry Tonkin-Hill; Emily Smith; Dinesh Aggarwal; Charlotte Houldcroft; Ben Warne; Colin Brown; Luke Meredith; Myra Hosmillo; Aminu Jahun; Martin Curran; Surendra Parmar; Laura Caller; Sarah Caddy; Fahad Khokhar; Anna Yakovleva; Grant Hall; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Nicholas Brown; Sonia Goncalves; Roberto Amato; Ewan Harrison; Mathew Beale; Michael Spencer Chapman; David Jackson; Ian Johnston; Alex Alderton; John Sillitoe; Cordelia Langford; Gordon Dougan; Sharon Peacock; Dominic Kwiatowski; Ian Goodfellow; M. Estee Torok; - COVID-19 Genomics Consortium UK,"University of Cambridge; Wellcome Sanger Institute; Cambridgeshire County Council, UK; Public Health England; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; ","COVID-19 poses a major challenge to care homes, as SARS-CoV-2 is readily transmitted and causes disproportionately severe disease in older people. Here, we report on 6,600 COVID-19 cases from the East of England, 1,167 of which were identified as residents from 337 care homes. Older age and being a care home resident were associated with increased mortality. SARS-CoV-2 genomes were available for 700 residents from 292 care homes. By integrating genomic and temporal data we defined 409 viral clusters within the 292 homes, indicating two different patterns - outbreaks among care home residents and independent introductions with limited onward transmission. Approximately 70% of residents in the genomic analysis were admitted to hospital during the study period, providing extensive opportunities for transmission between care homes and hospitals. Limiting viral transmission between care home residents should be a key target for infection control to reduce COVID-19 mortality in this population.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.26.20182378,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20182378,Predictors of healthcare worker burnout during the COVID-19 pandemic,Amy V Ferry; Ryan Wereski; Fiona E Strachan; Nicholas L Mills; Charlotte Houldcroft; Ben Warne; Colin Brown; Luke Meredith; Myra Hosmillo; Aminu Jahun; Martin Curran; Surendra Parmar; Laura Caller; Sarah Caddy; Fahad Khokhar; Anna Yakovleva; Grant Hall; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Nicholas Brown; Sonia Goncalves; Roberto Amato; Ewan Harrison; Mathew Beale; Michael Spencer Chapman; David Jackson; Ian Johnston; Alex Alderton; John Sillitoe; Cordelia Langford; Gordon Dougan; Sharon Peacock; Dominic Kwiatowski; Ian Goodfellow; M. Estee Torok; - COVID-19 Genomics Consortium UK,University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; ,"Objective We aim to provide a snapshot of the levels of burnout, anxiety, depression and distress among healthcare workers during the COVID-19 pandemic. Design, setting, participants We distributed an online survey via social media in June 2020 that was open to any healthcare worker. The primary outcome measure was symptoms of burnout as measured using the Copenhagen Burnout Inventory (CBI). Secondary outcomes of depression, anxiety and distress as measured using the Patient Health Questionnaire-9, General Anxiety Scale-7, and Impact of Events Scale-Revised were recorded along with subjective measures of stress. Multivariate logistic regression analysis was performed to identify factors associated with burnout, depression, anxiety and distress. Results Of 539 persons responding to the survey, 90% were female, and 26% were aged 41-50 years, 53% were nurses. Participants with moderate-to-severe burnout were younger (49% [206/424] versus 33% [38/115] under 40 years, P=0.004), and more likely to have pre-existing comorbidities (21% versus 12%, P=0.031). They were twice as likely to have been redeployed from their usual role (22% versus 11%; adjusted odds ratio [OR] 2.2, 95% confidence interval [CI] 1.5-3.3, P=0.042), or to work in an area dedicated to COVID-19 patients (50% versus 32%, adjusted OR 1.6, 95% CI 1.4-1.8, P<0.001), and were almost 4-times more likely to have previous depression (24% versus 7%; adjusted OR 3.6, 95% CI 2.2-5.9, P=0.012). A supportive workplace team and male sex protected against burnout reducing the odds by 40% (adjusted OR 0.6, 95% CI 0.5-0.7, P<0.001) and 70% (adjusted OR 0.3, 95% CI 0.2-0.5, P=0.003), respectively. Conclusion Independent predictors of burnout were younger staff, redeployment to a new working area, working with patients with confirmed COVID-19 infection, and being female or having a previous history of depression. Evaluation of existing psychological support interventions is required with targeted approaches to ensure support is available to those most at risk.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2020.08.26.20182352,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20182352,Willingness to pay tuition and risk-taking proclivities among students: A fundamental conundrum for universities,Zafar Zafari; Lee Goldman; Katia Korvizhkin; Peter Muennig; Charlotte Houldcroft; Ben Warne; Colin Brown; Luke Meredith; Myra Hosmillo; Aminu Jahun; Martin Curran; Surendra Parmar; Laura Caller; Sarah Caddy; Fahad Khokhar; Anna Yakovleva; Grant Hall; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Nicholas Brown; Sonia Goncalves; Roberto Amato; Ewan Harrison; Mathew Beale; Michael Spencer Chapman; David Jackson; Ian Johnston; Alex Alderton; John Sillitoe; Cordelia Langford; Gordon Dougan; Sharon Peacock; Dominic Kwiatowski; Ian Goodfellow; M. Estee Torok; - COVID-19 Genomics Consortium UK,University of Maryland; Columbia University; Johns Hopkins University; Columbia University; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; ,"Importance. As universities around the world decide whether to remain open or to close their campuses because of the COVID-19 pandemic, they often are doing so without objective information on the preferences and risk tolerance of their students. Objectives. To quantify: 1) risk tolerance for in-person instruction; 2) willingness to pay for in-person instruction versus online-only instruction; and 3) risk-tolerance for social activities held off campus among knowledgable students. Design, Setting, and Participants. We developed an automated survey tool that administered a standard gamble exercise grounded in game theory to 46 Columbia University public health graduate students who were knowledgeable about COVID-19 and who had experience with both online and offline coursework. Students were asked to trade between the risk of becoming infected with COVID-19 and: 1) attending classes in-person versus online and 2) attending parties in the greater New York City area. We also assessed their willingness to pay for online only tuition, and plans to travel off campus. Main Outcome Measures. The decision point in iterative trade-offs between risk of infection with COVID-19 and a desired goal (taking classes in-person or attending social events). Results. On average, students were willing to accept a 23% (standard error [SE]: 4%) risk of infection on campus over the semester in exchange for the opportunity to attend classes in-person. Students were willing-to-pay only 48% (SE: 3%) of typical in-person tuition were courses held exclusively online, and no students were willing to pay full price for online-only instruction. Students planned to leave campus an average of 3.6 times per week (SE: 0.54), and 15% of the students would be willing to attend a party in the community surrounding the university even if the prevalence of circulating COVID-19 were high. Conclusions and Relevance. Students with a strong knowledge of COVID-19 transmission and risks are an enigma: they are willing to pay only around 50% for online classes but likely to engage in activities that present significant barriers to holding in-person classes. This enigma underscores the conundrum facing universities.",health policy,exact,100,100
medRxiv,10.1101/2020.08.27.20182923,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.27.20182923,Evaluation of production lots of a rapid point-of-care lateral flow serological test intended for identification of IgM and IgG against the N-terminal part of the spike protein (S1) of SARS-CoV-2,Tove Hoffman; Linda Kolstad; Bengt Ronnberg; Ake Lundkvist; Charlotte Houldcroft; Ben Warne; Colin Brown; Luke Meredith; Myra Hosmillo; Aminu Jahun; Martin Curran; Surendra Parmar; Laura Caller; Sarah Caddy; Fahad Khokhar; Anna Yakovleva; Grant Hall; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Nicholas Brown; Sonia Goncalves; Roberto Amato; Ewan Harrison; Mathew Beale; Michael Spencer Chapman; David Jackson; Ian Johnston; Alex Alderton; John Sillitoe; Cordelia Langford; Gordon Dougan; Sharon Peacock; Dominic Kwiatowski; Ian Goodfellow; M. Estee Torok; - COVID-19 Genomics Consortium UK,Uppsala University; Uppsala University; Uppsala University Hospital; Uppsala University; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; ,"Background and objectives: Several antibody tests are available to detect SARS-CoV-2 specific antibodies, many of which address different antigens. Rapid point-of-care (POC) tests have been doubted due to an eventual risk of production errors, although it is unstudied whether such error would affect test sensitivity and/or specificity. We aimed to evaluate two separate production lots of a commercially available test intended for rapid detection of IgM and IgG against the N-terminal part of the SARS-CoV-2 spike protein (S1). Materials and methods: Serum samples from individuals with confirmed SARS-CoV-2 infection, by RT-PCR and/or serology, and pre-COVID-19 negative control sera gathered from a biobank during 2018 were collected. The presence of anti-S1 IgM/IgG was verified by an in-house Luminex-based serological assay, serving as reference method. The index test was a commercially available rapid POC-test (the COVID-19 IgG/IgM Rapid Test Cassette [Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China/Healgen Scientific, LLC, U.S.A.]). Results: One hundred samples were verified positive for anti-S1 IgG (median fluorescence intensity (MFI) greater than or equal to 900) and 74 for anti-S1 IgM (MFI greater than or equal to 700), confirmed by RT-PCR (n=90) and/or serology (n=89). None of the negative controls (n=200; MFI <300) had SARS-CoV-2 anti-S1 IgM, while one tested positive for SARS-CoV-2 anti-S1 IgG. For the two lots, the sensitivities of the rapid test were 93.2% (69/74; 95% CI: 85.1% - 97.1%) and 87.8% (65/74; 95% CI: 78.5% - 93.5%) for IgM, respectively 93.0% (93/100; 95% CI: 86.3% - 96.6%) and 100.0% for IgG (100/100; 95% CI: 96.3% - 100.0%). The specificity for both lots was 100% for IgM (200/200; 95% CI: 98.1% - 100%) and 99.5% for IgG (199/200; 95% CI: 97.2% - 99.9%). The positive predictive value was 100% for IgM and 98.9% and 99.0% for IgG. The negative predictive value was 95.7% and 97.6% for IgM, and 96.6% and 100.0% for IgG. Conclusion: The rapid POC-test used in this study is suitable to assess SARS-CoV-2 anti-S1 specific IgM/IgG, as a measure of previous virus exposure on an individual level. While the specificity was not affected by production lot, external validation of separate lots of rapid POC-tests is encouraged to ensure high sensitivity before market introduction.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.26.20182675,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20182675,"Epidemiological and socio-economic characteristics of the COVID-19 spring outbreak in Quebec, Canada: A population-based study",Rodolphe Jantzen; Nolwenn Noisel; Sophie Camilleri-Broet; Catherine Labbe; Thibault de Malliard; Yves Payette; Philippe Broet; Luke Meredith; Myra Hosmillo; Aminu Jahun; Martin Curran; Surendra Parmar; Laura Caller; Sarah Caddy; Fahad Khokhar; Anna Yakovleva; Grant Hall; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Nicholas Brown; Sonia Goncalves; Roberto Amato; Ewan Harrison; Mathew Beale; Michael Spencer Chapman; David Jackson; Ian Johnston; Alex Alderton; John Sillitoe; Cordelia Langford; Gordon Dougan; Sharon Peacock; Dominic Kwiatowski; Ian Goodfellow; M. Estee Torok; - COVID-19 Genomics Consortium UK,"CARTaGENE, CHU Ste-Justine Research Center, 3175 Chemin de la Cote-Sainte-Catherine, H3T1C5, Montreal, Canada; CARTaGENE, CHU Ste-Justine Research Center, 3175 Chemin de la Cote-Sainte-Catherine, H3T1C5, Montreal, Canada; McGill University; CARTaGENE, CHU Ste-Justine Research Center, 3175 Chemin de la Cote-Sainte-Catherine, H3T1C5, Montreal, Canada; CARTaGENE, CHU Ste-Justine Research Center, 3175 Chemin de la Cote-Sainte-Catherine, H3T1C5, Montreal, Canada; CARTaGENE, CHU Ste-Justine Research Center, 3175 Chemin de la Cote-Sainte-Catherine, H3T1C5, Montreal, Canada; CARTaGENE, CHU Ste-Justine Research Center, 3175 Chemin de la Cote-Sainte-Catherine, H3T1C5, Montreal, Canada; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; ","Background: By mid-July 2020, more than 108,000 COVID-19 cases had been diagnosed in Canada with more than half in the province of Quebec. To be prepared for a potential second wave of COVID-19 in the fall, it seems of utmost importance to analyze the epidemiological and socio-economic characteristics of the spring outbreak in the population. Method: We conducted an online survey of the participants of the CARTaGENE population-based cohort, composed of middle-aged and older adults. We collected information on socio-demographic, lifestyle, health condition, COVID-related symptoms and COVID-19 testing. We studied the association between these factors and two outcomes: the status of having been tested for SARS-CoV-2 and the status of having received a positive test when having been tested. These associations were evaluated with univariate and multivariate analyzes using a hybrid tree-based regression model. Results: Among the 8,129 respondents from the CARTaGENE cohort, 649 were tested for COVID-19 and 41 were positive. Medical workers and individuals having a contact with a COVID-19 patient had the highest probabilities of being tested (32% and 42.4%, respectively) and of being positive (17.2% and 13.0%, respectively) among those tested. 7.6% of the participants declared that they have experienced at least one of the four COVID-related symptoms chosen by the Public Health authorities (fever, cough, dyspnea, anosmia) but were not tested. Results from the tree-based model analyzes adjusted on exposure factors show that the combination of dyspnea, dry cough and fever was highly associated with being tested whereas anosmia, fever, and headache were the most discriminant factors for having a positive test among those tested. During the spring outbreak, more than one third of the participants have experienced a decrease in access to health services. There were sex and age differences in the socio-economic and emotional impacts of the pandemic. Conclusion: We have shown some discrepancies between the symptoms associated with being tested and being positive. In particular, the anosmia is a major discriminant symptom for positivity whereas ear-nose-throat symptoms seem not to be COVID-related. The results also emphasize the need of increasing the accessibility of testing for the general population.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.26.20180950,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20180950,"What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study",Louise Sigfrid; Muge Cevik; Edwin Jesudason; Wei Shen Lim; Jordi Rello; John Humphrey Amuasi; Fernando Bozza; Carlo Palmieri; Daniel Munblit; Jan Cato Holter; Anders Benjamin Kildal; Clark D Russell; Antonia Ho; Lance Turtle; Thomas M Drake; Anna Beltrame; Katrina Hann; Ibrahim Richard Bangura; Rob Fowler; Sulaiman Lakoh; Colin Berry; David J Lowe; Joanne McPeake; Madiha Hashmi; Anne Margarita Dyrhol-Riise; Chloe Donohue; Daniel R Plotkin; Hayley Hardwick; Natalie Elkheir; Nazir Lone; Annemarie B Docherty; Ewen M Harrison; Kenneth J Baille; Gail Carson; Malcolm G Semple; Janet T Scott; M. Estee Torok; - COVID-19 Genomics Consortium UK,"ISARIC Global Support Centre,  University of Oxford; University of St Andrews; NHS Lothian; Nottingham University Hospitals NHS Trust; Vall d Hebron Institute of Research; Kwame Nkrumah University of Science and Technology and Kumasi Center for Collaborative Research in Tropical Medicine; Fundacao Oswaldo Cruz; University of Liverpool; Institute of Childs Health, Sechenov First Moscow State Medical University (Sechenov University); Oslo University Hospital; University Hospital of North Norway; University of Edinburgh; University of Glasgow; University of Liverpool; University of Edinburgh; IRCCS Sacro Cuore Don Calabria Hospital; Sustainable Health Systems; Dorothy Springer Trust; Sunnybrook hospital, University of Toronto; Sustainable Health Systems; University of Glasgow; Queen Elizabeth University Hospital; NHS Greater Glasgow and Clyde, University of Glasgow Institute of Health and Wellbeing; Critical Care Medicine, Ziauddin University, Pakistan Registry of Intensive CarE (PRICE); Oslo University hospital; Liverpool Clinical Trials Centre, University of Liverpool; University of Oxford; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, University of Liverpool; London School of Hygiene and Tropical Medicine; Usher Institute; Usher Institute, University of Edinburgh; Usher Institute,  University of Edinburgh; Roslin Institute, University of Edinburgh; ISARIC, University of Oxford; Health Protection Research Unit In Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; MRC-University of Glasgow Centre for Virus Research; University of Cambridge; ","Introduction Very little is known about possible clinical sequelae that may persist after resolution of the acute Coronavirus Disease 2019 (COVID-19). A recent longitudinal cohort from Italy including 143 patients recovered after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60 day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical ICU patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness. Methods and analysis This is an international open-access prospective, observational multi-site study. It will enrol patients following a diagnosis of COVID-19. Tier 1 is developed for following up patients day 28 post-discharge, additionally at 3 to 6 months intervals. This module can be used to identify sub-sets of patients experiencing specific symptomatology or syndromes for further follow up. A Tier 2 module will be developed for in-clinic, in-depth follow up. The primary aim is to characterise physical consequences in patients post-COVID-19. Secondary aim includes estimating the frequency of and risk factors for post-COVID- 19 medical sequalae, psychosocial consequences and post-COVID-19 mortality. A subset of patients will have sampling to characterize longer term antibody, innate and cell-mediated immune responses to SARS-CoV-2. Ethics and dissemination This collaborative, open-access study aims to characterize the frequency of and risk factors for long-term consequences and characterise the immune response over time in patients following a diagnosis of COVID-19 and facilitate standardized and longitudinal data collection globally. The outcomes of this study will inform strategies to prevent long term consequences; inform clinical management, direct rehabilitation, and inform public health management to reduce overall morbidity and improve outcomes of COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.26.20182709,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20182709,Cardiometabolic Risk Factors for COVID-19 Susceptibility and Severity: A Mendelian Randomization Analysis,Aaron Leong; Joanne Cole; Laura N. Brenner; James B. Meigs; Jose C. Florez; Josep M. Mercader; Fernando Bozza; Carlo Palmieri; Daniel Munblit; Jan Cato Holter; Anders Benjamin Kildal; Clark D Russell; Antonia Ho; Lance Turtle; Thomas M Drake; Anna Beltrame; Katrina Hann; Ibrahim Richard Bangura; Rob Fowler; Sulaiman Lakoh; Colin Berry; David J Lowe; Joanne McPeake; Madiha Hashmi; Anne Margarita Dyrhol-Riise; Chloe Donohue; Daniel R Plotkin; Hayley Hardwick; Natalie Elkheir; Nazir Lone; Annemarie B Docherty; Ewen M Harrison; Kenneth J Baille; Gail Carson; Malcolm G Semple; Janet T Scott; M. Estee Torok; - COVID-19 Genomics Consortium UK,"MASSACHUSETTS GENERAL HOSPITAL; Broad Institute; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Broad Institute; Fundacao Oswaldo Cruz; University of Liverpool; Institute of Childs Health, Sechenov First Moscow State Medical University (Sechenov University); Oslo University Hospital; University Hospital of North Norway; University of Edinburgh; University of Glasgow; University of Liverpool; University of Edinburgh; IRCCS Sacro Cuore Don Calabria Hospital; Sustainable Health Systems; Dorothy Springer Trust; Sunnybrook hospital, University of Toronto; Sustainable Health Systems; University of Glasgow; Queen Elizabeth University Hospital; NHS Greater Glasgow and Clyde, University of Glasgow Institute of Health and Wellbeing; Critical Care Medicine, Ziauddin University, Pakistan Registry of Intensive CarE (PRICE); Oslo University hospital; Liverpool Clinical Trials Centre, University of Liverpool; University of Oxford; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, University of Liverpool; London School of Hygiene and Tropical Medicine; Usher Institute; Usher Institute, University of Edinburgh; Usher Institute,  University of Edinburgh; Roslin Institute, University of Edinburgh; ISARIC, University of Oxford; Health Protection Research Unit In Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; MRC-University of Glasgow Centre for Virus Research; University of Cambridge; ","Importance: Early epidemiological studies report associations of diverse cardiometabolic conditions especially body mass index (BMI), with COVID-19 susceptibility and severity, but causality has not been established. Identifying causal risk factors is critical to inform preventive strategies aimed at modifying disease risk. Objective: We sought to evaluate the causal associations of cardiometabolic conditions with COVID-19 susceptibility and severity. Design: Two-sample Mendelian Randomization (MR) Study. Setting: Population-based cohorts that contributed to the genome-wide association study (GWAS) meta-analysis by the COVID-19 Host Genetics Initiative. Participants: Patients hospitalized with COVID-19 diagnosed by RNA PCR, serologic testing, or clinician diagnosis. Population controls defined as anyone who was not a case in the cohorts. Exposures: Selected genetic variants associated with 17 cardiometabolic diseases, including diabetes, coronary artery disease, stroke, chronic kidney disease, and BMI, at p<5 x 10-8 from published largescale GWAS. Main outcomes: We performed an inverse-variance weighted averages of variant-specific causal estimates for susceptibility, defined as people who tested positive for COVID-19 vs. population controls, and severity, defined as patients hospitalized with COVID-19 vs. population controls, and repeated the analysis for BMI using effect estimates from UKBB. To estimate direct and indirect causal effects of BMI through obesity-related cardiometabolic diseases, we performed pairwise multivariable MR. We used p<0.05/17 exposure/2 outcomes=0.0015 to declare statistical significance. Results: Genetically increased BMI was causally associated with testing positive for COVID-19 [6,696 cases / 1,073,072 controls; p=6.7 x 10-4, odds ratio and 95% confidence interval 1.08 (1.03, 1.13) per kg/m2] and a higher risk of COVID-19 hospitalization [3,199 cases/897,488 controls; p=8.7 x 10-4, 1.12 (1.04, 1.21) per kg/m2]. In the multivariable MR, the direct effect of BMI was abolished upon conditioning on the effect on type 2 diabetes but persisted when conditioning on the effects on coronary artery disease, stroke, chronic kidney disease, and c-reactive protein. No other cardiometabolic exposures tested were associated with a higher risk of poorer COVID-19 outcomes. Conclusions and Relevance: Genetic evidence supports BMI as a causal risk factor for COVID-19 susceptibility and severity. This relationship may be mediated via type 2 diabetes. Obesity may have amplified the disease burden of the COVID-19 pandemic either single-handedly or through its metabolic consequences.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.24.20179192,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20179192,UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records,Jemma L Walker; Daniel J Grint; Helen Strongman; Rosalind M Eggo; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"London School of Hygiene & Tropical Medicine, Public Health England; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","Background This study aimed to describe the population at risk of severe COVID-19 due to underlying health conditions across the United Kingdom in 2019. Methods We used anonymised electronic health records from the Clinical Practice Research Datalink GOLD to describe the point prevalence on 5 March 2019 of the at-risk population following national guidance. Prevalence for any risk condition and for each individual condition is given overall and stratified by age and region. We repeated the analysis on 5 March 2014 for full regional representation and to describe prevalence of underlying health conditions in pregnancy. We additionally described the population of cancer survivors, and assessed the value of linked secondary care records for ascertaining COVID-19 at-risk status. Findings On 5 March 2019, 24.4% of the UK population were at risk due to a record of at least one underlying health condition, including 8.3% of school-aged children, 19.6% of working-aged adults, and 66.2% of individuals aged 70 years or more. 7.1% of the population had multimorbidity. The size of the at-risk population was stable over time comparing 2014 to 2019, despite increases in chronic liver disease and diabetes and decreases in chronic kidney disease and current asthma. Separately, 1.6% of the population had a new diagnosis of cancer in the past five years. Interpretation The population at risk of severe COVID-19 (aged [&ge;]70 years, or with an underlying health condition) comprises 18.5 million individuals in the UK, including a considerable proportion of school-aged and working-aged individuals.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.24.20179226,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20179226,Ethnic differences in SERPINA1 allele frequencies may partially explain national differences in COVID-19 fatality rates,Guy Shapira; Noam Shomron; David Gurwitz; Rosalind M Eggo; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","COVID-19 infection and fatality rates vary considerably between countries. We present preliminary evidence that these variations may in part reflect ethnic differences in the frequencies of polymorphic alleles of SERPINA1, coding for alpha-1 antitrypsin, the major blood serine protease inhibitor.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.24.20179762,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20179762,Stress symptoms and reactions to COVID-19: A multinational survey from six Asian regions,Ricci P.H. Yue; Edmund W. Cheng; Nick H.K. Or; Samson W.H. Yuen; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"Department of Public Policy, City University of Hong Kong; Department of Public Policy, City University of Hong Kong; Department of Public Policy, City University of Hong Kong; Department of Government and International Studies, Hong Kong Baptist University; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","People may experience a heightened level of stress reactions during a pandemic event and in an isolated social environment. A multi-national survey about such mental health information about COVID-19 was conducted in May 2020 across six Asian regions: Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand. Data were collected from a population representative sample of 11,895 adults on their stress symptoms and reactions to COVID-19 and the related public health measures. 59.1% of the respondents showed at least one substantial stress symptom. The situation was particularly worrying in South Korea, where 75% of the respondents reported substantial stress symptoms. Respondents who were young, educated, lived in an urban area, had a high socio-economic status, had a history of chronic illness or mental illness, or who lived with a pregnant woman, elderly or children were most vulnerable to stress during the pandemic. Stress reactions showed a positive relationship with the amount of time spent following news about the COVID-19 outbreak. Asian adults coped with their stress by preparing safety equipment and extra daily commodities (62.4%) and by following government-issued public health measures (60.1%). Most Asian (71%) also frequently checked on the safety of family members and friends to keep each other safe. The COVID-19 pandemic and the associated stringent public health measures have largely increased the prevalence of substantial stress symptoms across multiple Asian regions. Governments should prepare this mental health pandemic and the associated social repercussions.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.24.20180943,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20180943,Monitoring COVID-19 related public Interest and population Health Literacy in South Asia: An Internet Search-Interest Based Model,Hasan Symum; Kh Mohammed Ali; Nick H.K. Or; Samson W.H. Yuen; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"University of South Florida; Dhaka Medical College Hospital,  Dhaka,  Bangladesh; Department of Public Policy, City University of Hong Kong; Department of Government and International Studies, Hong Kong Baptist University; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","BackgroundInformation epidemiology based on internet search data can be used to model COVID-19 pandemic progressions and monitor population health literacy. However, the applicability of internet searches to monitor COVID-19 infections and public health awareness in South Asian countries are unclear.

ObjectivesTo assess the association of public interest and health literacy in COVID-19 with the number of infected cases South Asian countries.

Material and MethodsGoogle Trends data from January to March 2020 were used to correlate public interest and literacy with official data on COVID-19 cases using the relative search volume (RSV) index. Public interest in COVID-19 was retrieved with the search topic ""Coronavirus (Virus)"". Similarly, search terms ""hand wash"", ""face mask"", ""hand sanitizer"", ""face shield"" and ""gloves"" were used to retrieve RSV indices as a surrogate of health literacy. Country-level correlation analyses were performed for a time lag between 30 and +30 days.

ResultsThere were significant positive correlations between COVID-19 related public interest and daily confirmed cases in countries expect Nepal, Bhutan, and Sri Lanka. The highest public interest in South Asian Countries was on average 12 days before the local maximum of new confirmed cases. Similarly, web searches related to personal hygiene and preventive measures in south Asia correlated to the number of confirmed cases as well as national restriction measures.

ConclusionPublic interest indicated by RSV indices can help to monitor the progression of an outbreak such as the current COVID-19 pandemic particularly in countries with a lack of diagnostic and surveillance capacity.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.24.20155713,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20155713,In-house assembled protective devices in laboratory safety against SARS-nCoV-2 in clinical biochemistry laboratory of a COVID dedicated hospital,Abhishek Dubey; Aastha Bansal; Subash Chandra Sonkar; Binita Goswami; Naina Makwane; Vikas Manchanda; Bidhan Chandra Koner; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Multidisciplinary Research Unit, Maulana Azad Medical College and Associated Hospital, New Delhi, India-110002; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Microbiology, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","Background: Health Care Workers (HCWs) of diagnostic laboratory handling COVID positive samples are at risk and need to take protective measures. Many protective materials were not available when the pandemic reached India forcing laboratory managers to take innovative measures to protect the laboratory staffs. Methods: We made face shields from OHP sheets and substitute of biosafety cabinets from cardboard boxes fitted with hypochlorite spraying devices. Here we present if these two in-house developed safety devices when incorporated in standard operating procedure (SOP) of laboratory safety were effective in clinical biochemistry laboratory of dedicated COVID hospitals. Results: We assessed contamination of laboratory surfaces (n=6) and rate of SARS-nCov-2 positivity from their nasal and throat swab by RT-PCR among laboratory personnel (n=18) after 14 days of their use along with other routine safety devices like use of gloves, surgical masks, OT gowns etc. These HCWs were checked regularly for signs and symptoms of COVID-19 and none had any signs and symptoms during these 14days. The SARS-nCov-2 test report was negative for the staff members and no surface contamination was detected. We conclude that innovative and cost effective protective devices can be built in-house with locally available resources and are effective in preventing the spread of COVID 19 among the staff working in clinical biochemistry laboratories. Conclusions: Laboratory managers in resource scarce areas need to be innovative to face such sudden safety challenges like COVID-19 pandemic.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.24.20180695,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20180695,Parameter Estimation of COVID-19 Pandemic Model with Self Protection Behavior Changes,Kassahun Getnet Mekonen; Tatek Getachew Habtemicheal; Shiferaw Feyissa Balcha; Binita Goswami; Naina Makwane; Vikas Manchanda; Bidhan Chandra Koner; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"Adama Science and Technology University; Adama Science and Technology University; Adama Science and Technology University; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Microbiology, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","A mathematical model for the transmission dynamics of Coronavirus diseases (COVID-19) is proposed by incorporating self-protection behavior changes in the population. The disease-free equilibrium point is computed and its stability analysis is studied. The basic reproduction number(R 0 ) of the model is computed and the disease-free equilibrium point is locally and globally stable for R 0<1 and unstable for R 0 >1. Based on the available data the unknown model parameters are estimated using a combination of least square and Bayesian estimation methods for different countries. Using forward sensitivity index the model parameters are carried out to determine and identify the key factors for the spread of disease dynamics. From country to country the sensitive parameters for the spread of the virus varies. It is found out that the reproduction number depends mostly on the infection rates, the threshold value of the force of infection for a population, the recovery rates, and the virus decay rate in the environment. It is also demonstrated that control of the effective transmission rate (recommended human behavioral change towards self-protective measures) is essential to stop the spreading of the virus. Numerical simulations also show that the virus transmission dynamics depend mostly on those sensitive parameters.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.24.20180802,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20180802,Tracheal aspirate with closed suction device: a modified technique developed during COVID-19 outbreak.,Sofia Schverdfinger; Indalecio Carboni Bisso; Romina Famiglietti; Marcelo Di Grazia; Sabrina Di Stefano; Marcos Las Heras; Bidhan Chandra Koner; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"Intensive Care Unit, Hospital Italiano de Buenos Aires; Intensive Care Unit, Hospital Italiano de Buenos Aires; Rehabilitation and Respiratory Care Division - Physiotherapy Service, Hospital Italiano de Buenos Aires; Rehabilitation and Respiratory Care Division - Physiotherapy Service, Hospital Italiano de Buenos Aires; Intensive Care Unit, Hospital Italiano de Buenos Aires; Intensive Care Unit, Hospital Italiano de Buenos Aires; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","Background: Bacterial superinfection as well as ventilation associated pneumonia (VAP) are both frequent events in critical care. During COVID-19 pandemic, usual diagnostic practices such as bronchoalveolar lavage and tracheal aspirate are limited due to their associated high risk of exposure for the operator. In order to set primary focus on the protection of health care personnel, a modified tracheal aspiration (M-TA) technique is developed and used for acquiring a lower respiratory tract of microbiological samples with a closed suction device. Method: Retrospective observational study to evaluate effectiveness of M-TA is conducted. Results: A total of 33 M-TA samples were analyzed. In 66,6% of the cases, results led to a change in medical decision making. A 100% accuracy was achieved regarding COVID-19 diagnosis and a 56% bacterial growth-rate in cultives where VAP was suspected. No health care personnel have developed symptoms nor tested positive for COVID-19 during or after sample collection. Conclusion: M-TA technique presented could be considered as a safe and effective procedure with low percentage of complications.",intensive care and critical care medicine,exact,100,100
bioRxiv,10.1101/2020.08.25.267625,2020-08-26,https://biorxiv.org/cgi/content/short/2020.08.25.267625,MMGB/SA Consensus Estimate of the Binding Free Energy Between the Novel Coronavirus Spike Protein to the Human ACE2 Receptor,Negin Forouzesh; Alexey V Onufriev; Romina Famiglietti; Marcelo Di Grazia; Sabrina Di Stefano; Marcos Las Heras; Bidhan Chandra Koner; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Sheikh Mohammad Al Thani; Roberto Bertollini,"California State University, Los Angeles; Virginia Tech; Rehabilitation and Respiratory Care Division - Physiotherapy Service, Hospital Italiano de Buenos Aires; Rehabilitation and Respiratory Care Division - Physiotherapy Service, Hospital Italiano de Buenos Aires; Intensive Care Unit, Hospital Italiano de Buenos Aires; Intensive Care Unit, Hospital Italiano de Buenos Aires; Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals New Delhi- 110002; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine; Primary Health Care Corporation; Ministry of Public Health; Ministry of Public Health; Ministry of Public Health","The ability to estimate protein-protein binding free energy in a computationally efficient via a physics-based approach is beneficial to research focused on the mechanism of viruses binding to their target proteins. Implicit solvation methodology may be particularly useful in the early stages of such research, as it can offer valuable insights into the binding process, quickly. Here we evaluate the potential of the related molecular mechanics generalized Born surface area (MMGB/SA) approach to estimate the binding free energy {Delta}Gbind between the SARS-CoV-2 spike receptor-binding domain and the human ACE2 receptor. The calculations are based on a recent flavor of the generalized Born model, GBNSR6. Two estimates of {Delta}Gbind are performed: one based on standard bondi radii, and the other based on a newly developed set of atomic radii (OPT1), optimized specifically for protein-ligand binding. We take the average of the resulting two {Delta}Gbind values as the consensus estimate. For the well-studied Ras-Raf protein-protein complex, which has similar binding free energy to that of the SARS-CoV-2/ACE2 complex, the consensus {Delta}Gbind = -11.8 {+/-} 1 kcal/mol, vs. experimental -9.7 {+/-} 0.2 kcal/mol.

The consensus estimates for the SARS-CoV-2/ACE2 complex is {Delta}Gbind = -9.4 {+/-} 1.5 kcal/mol, which is in near quantitative agreement with experiment (-10.6 kcal/mol). The availability of a conceptually simple MMGB/SA-based protocol for analysis of the SARS-CoV-2 /ACE2 binding may be beneficial in light of the need to move forward fast.",biophysics,exact,100,100
medRxiv,10.1101/2020.08.21.20177246,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20177246,Using symptom-based case predictions to identify host genetic factors that contribute to COVID-19 susceptibility,Irene V van Blokland; Pauline Lanting; Anil PS Ori; Judith M Vonk; Robert CA Warmerdam; Johanna C Herkert; Floranne Boulogne; Annique Claringbould; Esteban A Lopera-Maya; Meike Bartels; Jouke-Jan Hottenga; Andrea Ganna; Juha Karjalainen; - Lifelines COVID-19 cohort study; - The COVID-19 Host Genetics Initiative; Caroline Hayward; Chloe Fawns-Ritchie; Archie Campbell; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and University of Groningen, University Medica; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and University of Groningen, University Medica; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Structural Computational Biology unit, EMB; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard, Cambridge, MA, USA and Analytic and Tra; ; ; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","Epidemiological and genetic studies on COVID-19 are hindered by inconsistent and limited testing policies to confirm SARS-CoV-2 infection. Recently, it was shown that it is possible to predict potential COVID-19 cases using cross-sectional self-reported disease-related symptoms. Using a previously reported COVID-19 prediction model, we show that it is possible to conduct a GWAS on predicted COVID-19 which benefits from a larger sample size in order to gain new insights into the genetic susceptibility of the disease. Furthermore, we find suggestive evidence that genetic variants for other viral infectious diseases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have a different genetic architecture compared to COVID-19 susceptibility. Our findings demonstrate the added value of using self-reported symptom assessments to quickly monitor novel endemic viral outbreaks in a scenario of limited testing. Should there be another outbreak of a novel infectious disease, then we recommend repeatedly collecting data of disease-related symptoms.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.08.21.20166355,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20166355,"Platelet-to-lymphocyte ratio (PLR), a novel biomarker to predict the severity of COVID-19 patients: a systematic review and meta-analysis",Daniel Martin Simadibrata; Bashar Adi Wahyu Pandhita; Muammar Emir Ananta; Tamara Tango; Robert CA Warmerdam; Johanna C Herkert; Floranne Boulogne; Annique Claringbould; Esteban A Lopera-Maya; Meike Bartels; Jouke-Jan Hottenga; Andrea Ganna; Juha Karjalainen; - Lifelines COVID-19 cohort study; - The COVID-19 Host Genetics Initiative; Caroline Hayward; Chloe Fawns-Ritchie; Archie Campbell; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"Faculty of Medicine, Universitas Indonesia; Faculty of Medicine, Universitas Indonesia; Faculty of Medicine, Universitas Indonesia; Faculty of Medicine, Universitas Indonesia; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Structural Computational Biology unit, EMB; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard, Cambridge, MA, USA and Analytic and Tra; ; ; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","Background Platelet-to-lymphocyte ratio (PLR), a novel inflammatory marker, has been suggested to be able to predict the severity of COVID-19 patients. This systematic review aims to evaluate the association between PLR levels on admission and the severity of COVID-19 patients. Methods A systematic literature search was done on 23 July 2020 to identify peer-reviewed studies across four different databases (Ovid MEDLINE, EMBASE, SCOPUS, and the Cochrane Library), preprints from two databases (MedRxiv and SSRN), and grey literature from two databases (WHO COVID-19 Global Research Database and Center for Disease Control and Prevention COVID-19 Research Article). Research articles comparing the PLR value on admission in adult patients with COVID-19 with varying degrees of severity were included in the analysis. The following keywords were used for the search: 'COVID-19', 'PLR', 'severity', and 'mortality'. The inverse variance method was used to calculate the pooled effect standardized mean difference (SMD) along with its 95% confidence interval (CI). Results A total of seven studies were included in the meta-analysis, six of which were conducted in China. From a total of 998 participants included, 316 (31.7%) had severe diseases; and those in the severe group were generally older and had underlying diseases compared to the non-severe group. In comparison to non-severe patients, the meta-analysis showed that severe COVID-19 patients had higher PLR levels on admission (SMD 0.68; 95%CI 0.43-0.93; I2 =58%). Conclusion High PLR levels on admission were associated with severe COVID-19 cases. Therefore, on-admission PLR level is a novel, cost-effective, and readily available biomarker with a promising prognostic role for determining the severity of COVID-19 patients.",hematology,exact,100,100
medRxiv,10.1101/2020.08.21.20177923,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20177923,Prevalence and outcome of Covid-19 infection in cancer patients: a national VA study,Nathanael R Fillmore; Jennifer La; Raphael E Szalat; David P Tuck; Vinh Nguyen; Cenk Yildirim; Nhan V Do; Mary T Brophy; Nikhil C Munshi; Meike Bartels; Jouke-Jan Hottenga; Andrea Ganna; Juha Karjalainen; - Lifelines COVID-19 cohort study; - The COVID-19 Host Genetics Initiative; Caroline Hayward; Chloe Fawns-Ritchie; Archie Campbell; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"VA Boston Healthcare System, Harvard Medical School, Dana-Farber Cancer Institute; VA Boston Healthcare System; VA Boston Healthcare System, Dana-Farber Cancer Institute, Boston University School of Medicine; VA Boston Healthcare System, Boston University School of Medicine; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Boston University School of Medicine; VA Boston Healthcare System, Boston University School of Medicine; VA Boston Healthcare System, Harvard Medical School, Dana-Farber Cancer Institute; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard, Cambridge, MA, USA and Analytic and Tra; ; ; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","Background: Emerging data suggest variability in susceptibility and outcome to Covid-19 infection. Identifying the risk-factors associated with infection and outcomes in cancer patients is necessary to develop healthcare recommendations. Methods: We analyzed electronic health records of the US National Veterans Administration healthcare system and assessed the prevalence of Covid-19 infection in cancer patients. We evaluated the proportion of cancer patients tested for Covid-19 and their confirmed positivity, with clinical characteristics, and outcome, and stratified by demographics, comorbidities, cancer treatment and cancer type. Results: Of 22914 cancer patients tested for Covid-19, 1794 (7.8%) were positive. The prevalence of Covid-19 was similar across all ages. Higher prevalence was observed in African-American (AA) (15%) compared to white (5.5%; P<.001), in Hispanic vs non-Hispanic population and in patients with hematologic malignancy compared to those with solid tumors (10.9% vs 7.7%; P<.001). Conversely, prevalence was lower in current smoker patients, patients with other co-morbidities and having recently received cancer therapy (<6 months). The Covid-19 attributable mortality was 10.9%. Highest mortality rates were observed in older patients, those with renal dysfunction, higher Charlson co-morbidity score and with certain cancer types. Recent (<6 months) or past treatment did not influence mortality. Importantly, AA patients had 3.5-fold higher Covid-19 attributable hospitalization, however had similar mortality rate as white patients. Conclusion: Pre-existence of cancer affects both susceptibility to Covid-19 infection and eventual outcome. The overall Covid-19 attributable mortality in cancer patients is affected by age, co-morbidity and specific cancer types, however, race or recent treatment including immunotherapy does not impact outcome.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.21.20178863,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20178863,Next generation sequencing of SARS-CoV-2 from patient specimens of Nevada reveals occurrence of specific nucleotide variants at high frequency,Paul Hartley; Richard L Tillett; Yanji Xu; David P AuCoin; Joel R Sevinsky; Andrew Gorzalski; Mark C Pandori; Erin Buttery; Holly Hansen; Michael Picker; Cyprian C Rossetto; Subhash C Verma; Juha Karjalainen; - Lifelines COVID-19 cohort study; - The COVID-19 Host Genetics Initiative; Caroline Hayward; Chloe Fawns-Ritchie; Archie Campbell; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"Nevada Genomics Center, University of Nevada, Reno; Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas; Nevada Center for Bioinformatics, University of Nevada, Reno; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine; Theiagen Consulting, LLC; Nevada State Public Health Laboratory, University of Nevada, Reno; Nevada State Public Health Laboratory, Pathology & Lab Medicine, University of Nevada, Reno School of Medicine; Southern Nevada Public Health Laboratory of the Southern Nevada Health District, Las Vegas; Southern Nevada Public Health Laboratory of the Southern Nevada Health District, Las Vegas; Southern Nevada Public Health Laboratory of the Southern Nevada Health District, Las Vegas; Department of Microbiology & Immunology,  University of Nevada, Reno School of Medicine; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard, Cambridge, MA, USA and Analytic and Tra; ; ; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","BackgroundSARS-CoV-2 is the etiological agent of coronavirus disease 2019 (COVID-19), which has a wide range of disease manifestations, including relatively mild respiratory illness to severe disease requiring hospitalization. Patients with signs of COVID-19 (fever, coughing, shortness of breath) were tested for the virus by targeting specific SARSCOV-2 genomic loci via RT-PCR using RNA extracted from nasopharyngeal/nasal swabs specimens. However, this testing does not yield genetic information required for identifying viral evolution or variants. Therefore, we sequenced 200 specimens from positively identified cases in Nevada through our robust protocol for sequencing SARSCoV-2 genomes directly from patients nasopharyngeal/nasal swabs. This protocol enabled identification of specific nucleotide variants including those for D614G and clade defining mutations. Additionally, these sequences were used to determine the enabled identification of specific nucleotide variants phylogenetic relationships of SARS-CoV-2 genomes of public health importance occurring in the state of Nevada.

ResultsOur study reports a novel finding of a variant in the nsp12 (RdRp) protein at residue 323 (314aa of orf1b) to Phenylalanine (F) from Proline (P), present in the original isolate of SARS-CoV-2 (Wuhan-1). This 323F variant is found at a very high frequency in Northern Nevada compared to other geographic areas. Structural modeling of the RdRP interface domain indicates the P323F variant did not significantly change the protein conformation.

ConclusionsOur results highlight the introduction and spread of specific SARS-CoV-2 variants at a very high frequency within a distinct geographic location. This is important for clinical and public health perspectives in understanding the transmission and evolution of SARS-CoV-2 as it circulates in humans.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.21.20167965,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20167965,Implications of the school-household network structure on SARS-CoV-2 transmission under different school reopening strategies in England,James D Munday; Katharine Sherratt; Sophie Meakin; Akira Endo; Carl A. B. Pearson; Joel Hellewell; Sam Abbott; Nikos Bosse; - CMMID COVID-19 Working Group; Katherine Elizabeth Atkins; Jacco Wallinga; W. John Edmunds; Albert Jan van Hoek; Sebastian Funk; Antonia Koutsoukou; Evangelos Andreakos; Xiushan Yin; Vicent Pelechano; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"London School of Hygiene and Tropical Medicine; London school of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School Of Hygiene and Tropical Medicine; London School Of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ; University of Edinburgh; Leiden University; London School of Hygiene and Tropical Medicine; RIVM; London School of Hygiene & Tropical Medicine; ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, Sotiria General Hospital of Chest Diseases, Athens,; Biomedical Research Foundation of the Academy of Athens, Athens, Greece; Applied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China; SciLifeLab, Department of Microbiology, Tumor and Cell Biology. Karolinska Institutet, Solna, Sweden.; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","BackgroundSchool closures are a well-established non-pharmaceutical intervention in the event of infectious disease outbreaks, and have been implemented in many countries across the world, including the UK, to slow down the spread of SARS-CoV-2. As governments begin to relax restrictions on public life there is a need to understand the potential impact that reopening schools may have on transmission.

MethodsWe used data provided by the UK Department for Education to construct a network of English schools, connected through pairs of pupils resident at the same address. We used the network to evaluate the potential for transmission between schools, and for long range propagation across the network, under different reopening scenarios.

ResultsAmongst the options evaluated we found that reopening only Reception, Year 1 and Year 6 (4-6 and 10-11 year olds) resulted in the lowest risk of transmission between schools, with outbreaks within a single school unlikely to result in outbreaks in adjacent schools in the network. The additional reopening of Years 10 and 12 (14-15 and 16-17 year olds) resulted in an increase in the risk of transmission between schools comparable to reopening all primary school years (4-11 year olds). However, the majority of schools presented low risk of initiating widespread transmission through the school system. Reopening all secondary school years (11-18 year olds) resulted in large potential outbreak clusters putting up to 50% of households connected to schools at risk of infection if sustained transmission within schools was possible.

ConclusionsReopening secondary school years is likely to have a greater impact on community transmission than reopening primary schools in England. Keeping transmission within schools limited is essential for reducing the risk of large outbreaks amongst school-aged children and their household members.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.21.20177808,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20177808,Quarantine and testing strategies in contact tracing for SARS-CoV-2,Billy J Quilty; Samuel Clifford; Stefan Flasche; Adam J Kucharski; - CMMID COVID-19 Working Group; W John Edmunds; Robert Preissner; Saskia Preissner; Eugenio Angueira; Bart L Haagmans; Pieter LA Fraaij; Reina S Sikkema; Marion P.G. Koopmans; Sebastian Funk; Antonia Koutsoukou; Evangelos Andreakos; Xiushan Yin; Vicent Pelechano; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene and Tropical Medicine; Institute of Physiology, Charite - Universitatsmedizin Berlin; Department Oral and Maxillofacial Surgery, Charite - Universitatsmedizin Berlin; Larkin Health System, South Miami, Florida, USA.; Viroscience, ErasmusMC; Viroscience, ErasmusMC; Viroscience, ErasmusMC; Viroscience, ErasmusMC; London School of Hygiene & Tropical Medicine; ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, Sotiria General Hospital of Chest Diseases, Athens,; Biomedical Research Foundation of the Academy of Athens, Athens, Greece; Applied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China; SciLifeLab, Department of Microbiology, Tumor and Cell Biology. Karolinska Institutet, Solna, Sweden.; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","BackgroundIn most countries, contacts of confirmed COVID-19 cases are asked to quarantine for 14 days following exposure, to limit asymptomatic onward transmission. We assessed the merit of RT-PCR testing in reducing the length of quarantine, using the UK as a case study.

MethodsWe used an agent-based model to simulate an exposed contacts contact tracing detecting delay, incubation period, probability to become symptomatic, infectivity profile, and time-varying PCR detection probability. Assuming self-isolation on symptom onset, we assess the impact of the current 14 day quarantine strategy for all exposed contacts on their onward transmission potential and compare to alternative quarantine lengths with or without PCR tests during quarantine.

FindingsSelf-isolation on symptoms onset alone can prevent 39% (95% Uncertainty Interval for super spreading events: 34, 45%) of onward transmission from secondary cases. An additional 14 days post-exposure quarantine for all contacts reduces transmission by 70% (95% UI: 39, 90%). A negative PCR test taken upon tracing or 7 days after exposure can reduce transmission by 62% (95% UI: 40, 84%) or 68% (95% UI: 40, 88%) respectively. Halving contact tracing delays of currently 4 days reduces pre-tracing transmission potential from 26% (95% UI: 7, 56%) to 14% (95% UI: 5, 42%).

InterpretationPCR testing may allow for a substantial reduction in quarantine needs or even replacing quarantine requirements with no or a small excess in transmission risk respectively. Reducing contact tracing delays can help prevent a substantial amount of transmission.

FundingNational Institute for Health Research, UK Research and Innovation, Wellcome Trust, and EU Horizon 2020.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSDuring the SARS-CoV-2 pandemic, a standard 14-day quarantine period has been required from the day a contact was exposed to an index case to avert onwards transmission. This approach aims to avoid infected contacts returning to their normal life during their pre-symptomatic period. This strategy presents a crucial part in the global pandemic response to interrupt transmission chains, however it places considerable social and economic pressure on contacts. As case numbers are rapidly rising across Europe an effective, practical and widely accepted strategy to limit secondary transmission is key to the control of SARS-CoV-2. To the best of our knowledge, this is the first analysis of optimal strategies to reduce transmission from contact traced secondary cases.

Added value of this studyWe simulated the ability of different quarantine and testing strategies to reduce the transmission potential of secondary cases. We found that the common post-exposure quarantine period of 14 days is equally effective as PCR testing of contacts after 7 days of quarantine. PCR testing immediately on tracing with no quarantine requirements following a negative test result would avert slightly less transmission potential from secondary cases (62% vs 70%). Delays in identifying contacts and hence delayed quarantine as well as low adherence substantially reduces the ability to reduce secondary transmission.

Implications of all the available evidenceThe ability to test timely and at scale could shorten current delays in contact tracing and thereby reduce the risk for secondary transmission. Similarly, such testing capacity would allow to substantially shorten necessary quarantine periods and dampen the economic and social impact while potentially increasing compliance.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.21.20179218,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20179218,"Comparing the COVID-19 pandemic in space and over time in Europe, using numbers of deaths, crude rates and adjusted mortality trend ratios",Valentina Gallo; Paolo Chiodini; Dario Bruzzese; Elias Kondilis; Daniel Howdon; Jochen Mierau; Raj Bhopal; Saskia Preissner; Eugenio Angueira; Bart L Haagmans; Pieter LA Fraaij; Reina S Sikkema; Marion P.G. Koopmans; Sebastian Funk; Antonia Koutsoukou; Evangelos Andreakos; Xiushan Yin; Vicent Pelechano; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"University of Gronongen; University of Campania Luigi Vanvitelli; University of Naples Federico II; Aristotheles University of Thessaloniki; University of Leeds; University of Groningen; University of Ediburgh; Department Oral and Maxillofacial Surgery, Charite - Universitatsmedizin Berlin; Larkin Health System, South Miami, Florida, USA.; Viroscience, ErasmusMC; Viroscience, ErasmusMC; Viroscience, ErasmusMC; Viroscience, ErasmusMC; London School of Hygiene & Tropical Medicine; ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, Sotiria General Hospital of Chest Diseases, Athens,; Biomedical Research Foundation of the Academy of Athens, Athens, Greece; Applied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China; SciLifeLab, Department of Microbiology, Tumor and Cell Biology. Karolinska Institutet, Solna, Sweden.; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","BackgroundSince COVID-19 was declared a pandemic, attempts have been made to monitor trends over time and to compare countries and regions. Insufficient testing for COVID-19 underestimates the incidence and inflates the case-fatality proportion. Given the age- and sex- distribution of morbidity and mortality from COVID-19, the underlying sex- and age-distribution of a population needs to be accounted for. The aim of this paper is to present a method for monitoring trends of COVID-19 using adjusted mortality trend ratios (AMTR).

MethodsAge- and sex-mortality distribution of a reference population composed of the first 14,086 fatalities which occurred before the end of March and were reported in Europe by some countries were used to calculate age- and sex-specific mortality rates per 1,000,000 population. These were applied to each country population to calculate the expected deaths. Adjusted Mortality Trend Ratios (AMTRs) with 95% confidence intervals (C.I.) were calculated for selected European countries from 17/03/2020 to 22/06/2020 by dividing observed cumulative mortality, by expected mortality times the crude mortality of the reference population. These estimated the sex- and age-adjusted mortality for COVID-19 per million population in each country.

ResultsThe cumulative mortality from COVID-19, the crude mortality rates, and the AMTRs were calculated for each country and compared. United Kingdom, Italy, France and Spain registered the highest mortality in Europe. On 22/06/2020 in Europe the total mortality rate from COVID-19 was 352 per 1,000,000 inhabitants; and it was highest in Belgium (850 per 1,000,000 inhabitants) followed by Spain, UK, Italy, Sweden and France. When accounting for the underlying age and sex structure of each country, Belgium remained the single country experiencing the highest AMTR of 929 per million inhabitants on 22/06/2020; however Ireland - which had a CMR in line with the total European population - emerged as having experienced a much more important impact of COVID-19 mortality with an AMTR of 550/million on 22/06/2020, higher than Sweden and Italy.

ConclusionsIn understanding and managing the pandemic of COVID-19, comparable international data is a priority. Our methods allow a fair comparison of mortality in space and over time. The authors urge the WHO, given the absence of age and sex-specific mortality data for direct standardisation, to adopt this method to estimate the comparative mortality from COVID-19 pandemic worldwide.

Key messageO_LIComparing trends of the COVID-19 pandemic over time and in space is essential to monitor the disease and compare different local policies
C_LIO_LIUsing the concept of indirect standardisation we propose a method to effectively compare age- and sex-adjusted mortality rates trends interpretable as deaths for COVID-19 per million inhabitants
C_LIO_LIApplying this methods, interesting features of the infection in Europe emerged; e.g. by 22/06/2020 Belgium is the most severely affected country with an AMTR of 929 per million inhabitants, followed by the UK; Ireland and Sweden rank fourth and fifth most affected country in Europe
C_LIO_LIThe WHO should consider using this method for monitoring the spread of COVID-19, which only requires recording the total number of death from COVID-19 from each country/region
C_LI",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.22.20179770,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.22.20179770,"The impact of COVID-19 on acute Trauma and Orthopaedic referrals and surgery in the UK: the ""golden peak weeks"" of the first national multi-centre observational study. The COVid-Emergency Related Trauma and orthopaedics (COVERT) Collaborative",Kapil Sugand; - COVERT Collaborative; Brendan Case; Samuel V Scarpino; Antoine Allard; Andrew Berdhal; Easton R White; Laurent Hebert-Dufresne; Eugenio Angueira; Bart L Haagmans; Pieter LA Fraaij; Reina S Sikkema; Marion P.G. Koopmans; Sebastian Funk; Antonia Koutsoukou; Evangelos Andreakos; Xiushan Yin; Vicent Pelechano; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"Imperial College London; ; University of Vermont; Northeastern University; Universite Laval; University of Washington; University of Vermont; University of Vermont; Larkin Health System, South Miami, Florida, USA.; Viroscience, ErasmusMC; Viroscience, ErasmusMC; Viroscience, ErasmusMC; Viroscience, ErasmusMC; London School of Hygiene & Tropical Medicine; ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, Sotiria General Hospital of Chest Diseases, Athens,; Biomedical Research Foundation of the Academy of Athens, Athens, Greece; Applied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China; SciLifeLab, Department of Microbiology, Tumor and Cell Biology. Karolinska Institutet, Solna, Sweden.; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","ObjectivesThis is the first national study observing the impact of the COVID-19 pandemic on orthopaedic trauma with respect to referrals, operative caseload and mortality during the first six weeks (namely the ""golden peak weeks"") following the introduction of the national social distancing and lockdown measures from mid-March 2020.

DesignA longitudinal, national, multi-centre, retrospective, observational, cohort study was conducted for the first six weeks from March 17, 2020 from start of the national social distancing and then lockdown compared to the same period in 2019 as a comparative baseline.

SettingHospitals from seven major urban cities were recruited around the UK, including London, representing a comprehensive national picture of the impact of COVID-19 pandemic and its lockdown at its peak.

ParticipantsA total of 4840 clinical encounters were initially recorded. Exclusion criterion consisted of spinal pathology only. Post-exclusion, 4668 clinical encounters were recorded and analysed within the two timeframes.

Main outcome measuresPrimary outcomes included the number of acute trauma referrals and those undergoing operative intervention, patient demographics, mortality rates, and the proportion of patients contracting COVID-19. Secondary outcomes consisted of the mechanism of injury, type of operative intervention and proportion of aerosolising-generating anaesthesia utilised. Demographics for each patient was recorded along with underlying medical co-morbidities. Sub-group analysis compared mortalities between both cohorts. Statistical analyses included mean ({+/-}SD), risk and odds ratios, as well as Fishers exact test to calculate the statistical significance (p[&le;]0.05).

ResultsDuring the COVID-19 period there was a 34% reduction in acute orthopaedic trauma referrals compared to 2019 (1792 down to 1183 referrals), and 29.5% less surgical interventions (993 down to 700 operations). The mortality rate significantly (both statistically and clinically) more than doubled for both risk and odds ratios during the COVID period in all referrals (1.3% vs 3.8%, p = 0.0005) and in those undergoing operative intervention (2.2% vs 4.9%, p = 0.004). Moreover, mortality due to COVID-related complications (versus non-COVID causes) had greater odds by a factor of at least 20 times. The odds ratios of road traffic accidents, sporting injuries, infection, and lower limb injuries were significantly less (by a third to a half) during the COVID period; albeit, the odds of sustaining neck of femur fractures and having falls < 1.5m increased by more than 50%.

For the operative cohorts, there was a greater odds of aerosolising-generating anaesthesia (including those with superimposed regional blocks) by three-quarters as well as doubling of the odds of a Consultant acting as the primary surgeon. Nevertheless, the odds of open reduction and internal fixation reduced by a quarter whereas removal of metalwork or foreign bodies reduced by three-quarters. Six-week Kaplan-Meier survival probability analysis confirmed those patients with neck of femur fracture and pre-existing cardiovascular and cerebrovascular disease were most at risk of mortality during the COVID-19 era.

ConclusionAlthough there was a reduction of acute trauma referrals and those undergoing operative intervention, the mortality rate still more than doubled in odds during the peak of the pandemic compared to the same time interval one year ago. Elderly patients with neck of femur fractures and existing cardiovascular and cerebrovascular comorbidities were at the highest risk stratification for mortality. This was the first national study to assess impact of COVID-19 pandemic on acute Orthopaedic trauma and it will aid clinicians in counselling trauma patients of the increased risk of mortality during the era of COVID-19 as well as acting as a risk-prediction tool influencing policymaking as the pandemic continues with potential subsequent waves. Further studies after the lifting of the lockdown are also required to observe for return of standard practice.",orthopedics,exact,100,100
medRxiv,10.1101/2020.08.18.20177691,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.18.20177691,"Genetically-predicted vitamin D status, ambient UVB during the pandemic and COVID-19 risk in UK Biobank: Mendelian Randomisation study",Xue Li; Jos van Geffen; Michiel van Weele; Xiangrui Meng; XIAOMENG ZHANG; Yazhou He; Maria Timofeeva; Harry Campbell; Malcolm G Dunlop; Lina Zgaga; Evropi Theodoratou; Yuanjia Wang; Lily Wang; Robert L Walraven; Vishal Tomar; Katherine Sherratt; Daniel Sheldon; Robert C Reiner; B. Aditya Prakash; Dave Osthus; Michael Lingzhi Li; Elizabeth C Lee; Ugur Koyluoglu; Pinar Keskinocak; Youyang Gu; Quanquan Gu; Glover E George; Guido Espaa; Sabrina Corsetti; Jagpreet Chhatwal; Sean Cavany; Hannah Biegel; Michal Ben-Nun; Jo Walker; Rachel Slayton; Velma Lopez; Matthew Biggerstaff; Michael A Johansson; Nicholas G Reich; - COVID-19 Forecast Hub Consortium,"School of Public Health and the Second Affiliated Hospital, Zhejiang University; Royal Netherlands Meteorological Institute (KNMI), De Bilt, the Netherlands; Royal Netherlands Meteorological Institute (KNMI), De Bilt, the Netherlands; Vanke School of public Health,Tsinghua University; Usher Institute; Centre for Global Health, Usher Institute, University of Edinburgh; DIAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark; Centre for Global Health, Usher Institute, University of Edinburgh; Institute of Genetics and Molecular Medicine; Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin; University of Edinburgh; Columbia University; Iowa State University; unaffiliated; Auquan Ltd; London School of Hygiene and Tropical Medicine; University of Massachusetts Amherst; University of Washington; Georgia Institute of Technology; Los Alamos National Laboratory; Massachusetts Institute of Technology; Johns Hopkins Bloomberg School of Public Health; Oliver Wyman; Georgia Institute of Technology; unaffiliated; University of California Los Angeles; US Army Engineer Research and Development Center; University of Notre Dame; University of Michigan; Massachusetts General Hospital; University of Notre Dame; University of Arizona; Predictive Science Inc; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; University of Massachusetts - Amherst; ","A growing body of evidence shows that poor vitamin D status has been associated with an increased susceptibility to viral and bacterial respiratory infections. In this study, we aimed to examine the association between vitamin D and COVID-19 risk and outcomes, and to explore potential causal effects. We used logistic regression to identify associations between different vitamin D variables (25-hydroxyvitamin D concentration (25-OHD), ambient UVB and genetically-predicted 25-OHD concentrations) and COVID-19 (risk of infection, hospitalisation and death) in 495,780 participants from UK Biobank. We subsequently performed a Mendelian Randomisation (MR) study to test if there was any causal effect. In total, 1,746 COVID-19 cases and 399 COVID-19 deaths occurred between March and June 2020. We found significant inverse associations between COVID-19 infection and 25-OHD in univariable models, but these associations were non-significant after adjustment for confounders. Ambient UVB was strongly and inversely associated with hospitalization and death. Although the main MR analysis showed that genetically-predicted vitamin D levels were not causally associated with COVID-19 risk, MR sensitivity analysis using weighted mode method indicated a potential causal effect (OR=0.72, 95% CI:0.53-0.98; P=0.041). In conclusion, our study found suggestive evidence of association between vitamin D and the risk or severity of COVID-19 but further studies are needed.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.18.20174540,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.18.20174540,3D Printed Snorkel Mask Adapter for Failed N95 Fit Tests and PPE Shortages,Shiv Dalla; Rohit Shinde; Jack M Ayres; Stephen Waller; Jay Nachtigal; Yazhou He; Maria Timofeeva; Harry Campbell; Malcolm G Dunlop; Lina Zgaga; Evropi Theodoratou; Yuanjia Wang; Lily Wang; Robert L Walraven; Vishal Tomar; Katherine Sherratt; Daniel Sheldon; Robert C Reiner; B. Aditya Prakash; Dave Osthus; Michael Lingzhi Li; Elizabeth C Lee; Ugur Koyluoglu; Pinar Keskinocak; Youyang Gu; Quanquan Gu; Glover E George; Guido Espaa; Sabrina Corsetti; Jagpreet Chhatwal; Sean Cavany; Hannah Biegel; Michal Ben-Nun; Jo Walker; Rachel Slayton; Velma Lopez; Matthew Biggerstaff; Michael A Johansson; Nicholas G Reich; - COVID-19 Forecast Hub Consortium,"University of Kansas School of Medicine; Unaffiliated; University of Kansas School of Medicine; University of Kansas Medical Center; University of Kansas Medical Center; Centre for Global Health, Usher Institute, University of Edinburgh; DIAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark; Centre for Global Health, Usher Institute, University of Edinburgh; Institute of Genetics and Molecular Medicine; Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin; University of Edinburgh; Columbia University; Iowa State University; unaffiliated; Auquan Ltd; London School of Hygiene and Tropical Medicine; University of Massachusetts Amherst; University of Washington; Georgia Institute of Technology; Los Alamos National Laboratory; Massachusetts Institute of Technology; Johns Hopkins Bloomberg School of Public Health; Oliver Wyman; Georgia Institute of Technology; unaffiliated; University of California Los Angeles; US Army Engineer Research and Development Center; University of Notre Dame; University of Michigan; Massachusetts General Hospital; University of Notre Dame; University of Arizona; Predictive Science Inc; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; University of Massachusetts - Amherst; ","Introduction The shortage of personal protective equipment (PPE) across the country has been widely discussed throughout the COVID-19 pandemic. Unfortunately, recent reports indicate that PPE shortages persist amidst continually increasing caseloads nationwide. Additionally, there have been reports of poor-fitting masks, a problem which is magnified by shortages. The lack of adequate access to conventional N95 masks pushed for some to pursue 3D printing and locally distributing their own manufactured masks as substitutes when PPE, including N95 masks, were not readily available. The design presented, the snorkel mask adapter, is one such design born from the local maker community in partnership with local physicians and hospitals. This article discusses the design, manufacturing, and validation of the snorkel mask adapter and its immediate use in the COVID-19 pandemic as well as future use as stopgap PPE. Methods The design presented is an adapter which can be used with a commercially available snorkel mask in order to serve as a full face respirator in either the case of a PPE shortage or more pertinently for those who are unable to pass fit testing with the available N95 respirators at their respective facilities. Mask components were 3D printed, assembled, and then fit tested by qualitative fit testing (QLFT) at The University of Kansas Health System (TUKHS) in Kansas City, KS as a proof of concept.   Results At TUKHS, the mask was fit tested on 22 individuals who required an N95 mask but were not able to pass qualitative fit testing with the masks available to them at the time. Of the 22 tested, all 22 of them were able to pass QLFT with the snorkel mask, adapter, and viral/bacterial filter combination. Conclusion The results of the fit testing at TUKHS is promising for this N95 alternative. More extensive testing can and should be done, including quantitative fit testing. Persistently increasing caseloads and PPE shortages necessitates an urgent dissemination of these preliminary results. The authors do not advocate for this design as a replacement of traditional N95 masks or other PPE but do endorse this design as a stopgap measure, proven to be effective in situations of dire PPE shortage or for individuals who have failed fit testing with conventional PPE.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.19.20177477,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.19.20177477,Machine learning based clinical decision supportsystem for early COVID-19 mortality prediction,Akshaya Karthikeyan; Akshit Garg; P K Vinod; U. Deva Priyakumar; Jay Nachtigal; Yazhou He; Maria Timofeeva; Harry Campbell; Malcolm G Dunlop; Lina Zgaga; Evropi Theodoratou; Yuanjia Wang; Lily Wang; Robert L Walraven; Vishal Tomar; Katherine Sherratt; Daniel Sheldon; Robert C Reiner; B. Aditya Prakash; Dave Osthus; Michael Lingzhi Li; Elizabeth C Lee; Ugur Koyluoglu; Pinar Keskinocak; Youyang Gu; Quanquan Gu; Glover E George; Guido Espaa; Sabrina Corsetti; Jagpreet Chhatwal; Sean Cavany; Hannah Biegel; Michal Ben-Nun; Jo Walker; Rachel Slayton; Velma Lopez; Matthew Biggerstaff; Michael A Johansson; Nicholas G Reich; - COVID-19 Forecast Hub Consortium,"Center for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad; Center for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad; Center for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad; Center for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad; University of Kansas Medical Center; Centre for Global Health, Usher Institute, University of Edinburgh; DIAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark; Centre for Global Health, Usher Institute, University of Edinburgh; Institute of Genetics and Molecular Medicine; Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin; University of Edinburgh; Columbia University; Iowa State University; unaffiliated; Auquan Ltd; London School of Hygiene and Tropical Medicine; University of Massachusetts Amherst; University of Washington; Georgia Institute of Technology; Los Alamos National Laboratory; Massachusetts Institute of Technology; Johns Hopkins Bloomberg School of Public Health; Oliver Wyman; Georgia Institute of Technology; unaffiliated; University of California Los Angeles; US Army Engineer Research and Development Center; University of Notre Dame; University of Michigan; Massachusetts General Hospital; University of Notre Dame; University of Arizona; Predictive Science Inc; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; U.S. Centers for Disease Control and Prevention; University of Massachusetts - Amherst; ","The coronavirus disease 2019 (COVID-19) is an acute respiratory disease that has been classified as a pandemic by World Health Organization (WHO). The sudden spike in the number of infections and high mortality rates have put immense pressure on the public medical systems. Hence, its crucial to identify the key factors of mortality that yield high accuracy and consistency to optimize patient treatment strategy. This study uses machine learning methods to identify a powerful combination of five features that help predict mortality with 96% accuracy: neutrophils, lymphocytes, lactate dehydrogenase (LDH), high-sensitivity C-reactive protein (hs-CRP) and age. Various machine learning algorithms have been compared to achieve a consistent high accuracy across the days that span the disease. Robust testing with three cases confirm the strong predictive performance of the proposed model. The model predicts with an accuracy of 90% as early as 16 days before the outcome. This study would help accelerate the decision making process in healthcare systems for focused medical treatments early and accurately.",health informatics,exact,100,100
medRxiv,10.1101/2020.08.19.20178137,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.19.20178137,Testing for coronavirus (SARS-CoV-2) infection in populations with low infection prevalence: the largely ignored problem of false positives and the value of repeat testing,Cathie Sudlow; Peter Diggle; Oliver Warlow; David Seymour; Ben Gordon; Rhos Walker; Charles Warlow,"BHF Data Science Centre, Health Data Research UK; Usher Institute, University of Edinburgh; University of Lancaster; Health Data Research UK; Ventient Energy; Health Data Research UK; Health Data Research UK; Health Data Research UK; University of Edinburgh","Background: Calls are increasing for widespread SARS-CoV-2 infection testing of people from populations with a very low prevalence of infection. We quantified the impact of less than perfect diagnostic test accuracy on populations, and on individuals, in low prevalence settings, focusing on false positives and the role of confirmatory testing. Methods: We developed a simple, interactive tool to assess the impact of different combinations of test sensitivity, specificity and infection prevalence in a notional population of 100,000. We derived numbers of true positives, true negatives, false positives and false negatives, positive predictive value (PPV, the percentage of test positives that are true positives) and overall test accuracy for three testing strategies: (1) single test for all; (2) add repeat testing in test positives; (3) add further repeat testing in those with discrepant results. We also assessed the impact on test results for individuals having one, two or three tests under these three strategies. Results: With sensitivity of 80%, infection prevalence of 1 in 2,000, and specificity 99.9% on all tests, PPV in the tested population of 100,000 will be only 29% with one test, increasing to >99.5% (100% when rounded to the nearest %) with repeat testing in strategies 2 or 3. More realistically, if specificity is 95% for the first and 99.9% for subsequent tests, single test PPV will be only 1%, increasing to 86% with repeat testing in strategy 2, or 79% with strategy 3 (albeit with 6 fewer false negatives than strategy 2). In the whole population, or in particular individuals, PPV increases as infection becomes more common in the population but falls to unacceptably low levels with lower test specificity. Conclusion: To avoid multiple unnecessary restrictions on whole populations, and in particular individuals, from widespread population testing for SARS-CoV-2, the crucial roles of extremely high test specificity and of confirmatory testing must be fully appreciated and incorporated into policy decisions.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.19.20178343,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.19.20178343,"The Effects of Coronavirus Victimization Distress and Coronavirus Racial Bias on Mental Health Among Black, Indigenous and Latinx Young Adults in the United States",Celia B. Fisher; Xiangyu Tao; Tiffany Yip; David Seymour; Ben Gordon; Rhos Walker; Charles Warlow,Fordham University; Fordham University; Fordham University; Health Data Research UK; Health Data Research UK; Health Data Research UK; University of Edinburgh,"BackgroundPeople of color in the U.S. have been disproportionately impacted by the COVID-19 pandemic in terms of rates of infection and morbidity. Explanations for these disparities include over-representation as essential workers and long-standing inequities in access to health services. Prior to the pandemic, racial discrimination has been associated with depression and general anxiety. However, the effect of discrimination and racial bias specific to the Coronavirus on mental health has not been examined. The aim of this study was to assess the effects of Coronavirus victimization distress and Coronavirus racial bias beliefs on the mental health of young adult people of color.

MethodAn online survey administered to a national sample of 350 Black, Indigenous and Latinx adults (18 - 25 years) included Coronavirus health risks, prescription and financial security, measure of depression and anxiety and 2 new psychometrically validated measures for Coronavirus related victimization distress and racial bias.

ResultsEmployment, number of Coronavirus health risks, Coronavirus victimization distress and Coronavirus racial bias were positively correlated with each other and with depression and anxiety. By contrast, household income and perceived financial and prescription security were negatively correlated with Coronavirus victimization, Coronavirus racial bias and with the mental health indices. Structural equation modeling controlling for demographic variables indicated perceived Coronavirus racial bias mediated the effect of Coronavirus victimization distress on both mental health measures across all groups.

ConclusionsResults suggest the COVID-19 pandemic has created new pathways to mental health disparities among young adults of color by reversing formerly protective factors such as employment, and by exacerbating structural and societal inequities linked to race. Findings highlight the necessity of creating mental health services tailored to the specific needs of racial/ethnic minorities during the current and future health crises.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.08.17.20175117,2020-08-21,https://medrxiv.org/cgi/content/short/2020.08.17.20175117,Real-time spatial health surveillance: mapping the UK COVID-19 epidemic,Richard Fry; Joe Hollinghurst; Helen R Stagg; Daniel A Thompson; Claudio Fronterre; Chris Orton; Ronan A Lyons; David V Ford; Aziz Sheikh; Peter J Diggle; Konstantinos Ritis; Ilenia Manfra; Simona Iacobelli; Markus Huber-Lang; Bo Nilsson; Despina Yancopoulou; E. Sander Connolly; Cecilia Garlanda; Fabio Ciceri; Antonio M. Risitano; Rodrigo T. Calado; John D. Lambris,"Swansea University; Swansea University; Edinburgh University; Swansea University; Lancaster University; Swansea University; Swansea University; Swansea University; Edinburgh University; Lancaster University; Democritus University of Thrace; AORN San Giuseppe Moscati; University of Rome Tor Vergata; Institute for Clinical and Experimental Trauma-Immunology, University Hospital of Ulm; Uppsala University Hospital; Amyndas Pharmaceuticals; Columbia University; Humanitas university; University Vita Salute San Raffaele; Federico II University of Naples; University of Sao Paulo, Ribeirao Preto School of Medicine; University of Pennsylvania","The COVID-19 pandemic has highlighted the need for robust data linkage systems and methods for identifying outbreaks of disease in near real-time. Using self-reported app data and the Secure Anonymised Information Linkage (SAIL) Databank, we demonstrate the use of sophisticated spatial modelling for near-real-time prediction of COVID-19 prevalence at small-area resolution to inform strategic government policy areas. A pre-requisite to an effective control strategy is that predictions need to be accompanied by estimates of their precision, to guard against over-reaction to potentially spurious features of 'best guess' predictions. In the UK, important emerging risk-factors such as social deprivation or ethnicity vary over small distances, hence risk needs to be modelled at fine spatial resolution to avoid aggregation bias. We demonstrate that existing geospatial statistical methods originally developed for global health applications are well-suited to this task and can be used in an anonymised databank environment, thus preserving the privacy of the individuals who contribute their data.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.16.20169979,2020-08-21,https://medrxiv.org/cgi/content/short/2020.08.16.20169979,"Pediatric surgical services in Bangladesh during the COVID 19 pandemic: How they are affected and how to overcome the backlog, keeping healthcare professionals safe.",Md Jafrul Hannan; Mosammat Kohinoor Parveen; Md Samiul Hasan; Daniel A Thompson; Claudio Fronterre; Chris Orton; Ronan A Lyons; David V Ford; Aziz Sheikh; Peter J Diggle; Konstantinos Ritis; Ilenia Manfra; Simona Iacobelli; Markus Huber-Lang; Bo Nilsson; Despina Yancopoulou; E. Sander Connolly; Cecilia Garlanda; Fabio Ciceri; Antonio M. Risitano; Rodrigo T. Calado; John D. Lambris,"South Point Hospital, Chittagong; Rangamati Medical College, Rangamati, Bangladesh; Dhaka Shishu (Children) Hospital; Swansea University; Lancaster University; Swansea University; Swansea University; Swansea University; Edinburgh University; Lancaster University; Democritus University of Thrace; AORN San Giuseppe Moscati; University of Rome Tor Vergata; Institute for Clinical and Experimental Trauma-Immunology, University Hospital of Ulm; Uppsala University Hospital; Amyndas Pharmaceuticals; Columbia University; Humanitas university; University Vita Salute San Raffaele; Federico II University of Naples; University of Sao Paulo, Ribeirao Preto School of Medicine; University of Pennsylvania","Background: Severe Acute Respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has turned into a pandemic. All countries have implemented multiple strategies to try mitigating the losses caused by this virus. To stop the rapid spread of the disease and in compliance with the World Health Organizations social distancing policy, the government of Bangladesh has implemented a number of strategies, one of which is to limit the spread of the virus in hospitals by postponing elective procedures and providing only emergency services in the hospitals. The objective of this survey was to assess the current status of pediatric surgical procedures in different hospitals in Bangladesh and assess the effects of the current restrictions along with their implications in the long run. Materials and Methods: A survey was performed among doctors from public and private hospitals in Bangladesh to evaluate the status on pediatric surgery. Results: The results clearly revealed the lack of a significant reduction in doctors exposure to SARS-CoV-2 by postponing elective procedures. Conclusion: Keeping in mind the socioeconomic and health care conditions of the country, the author recommend resuming elective surgical procedures. Keywords: COVID 19, Pediatric surgery, Surgery during pandemic, Pediatric surgery in Bangladesh, COVID 19 and pediatric surgery.",surgery,exact,100,100
medRxiv,10.1101/2020.08.17.20176909,2020-08-21,https://medrxiv.org/cgi/content/short/2020.08.17.20176909,On COVID-19-safety ranking of seats in intercontinental commercial aircrafts: A preliminary multiphysics computational perspective,Prathamesh S Desai; Nihar Sawant; Andrew Keene; Daniel A Thompson; Claudio Fronterre; Chris Orton; Ronan A Lyons; David V Ford; Aziz Sheikh; Peter J Diggle; Konstantinos Ritis; Ilenia Manfra; Simona Iacobelli; Markus Huber-Lang; Bo Nilsson; Despina Yancopoulou; E. Sander Connolly; Cecilia Garlanda; Fabio Ciceri; Antonio M. Risitano; Rodrigo T. Calado; John D. Lambris,"W. M. Rice University; Courant Institute of Mathematical Sciences; MPR; Swansea University; Lancaster University; Swansea University; Swansea University; Swansea University; Edinburgh University; Lancaster University; Democritus University of Thrace; AORN San Giuseppe Moscati; University of Rome Tor Vergata; Institute for Clinical and Experimental Trauma-Immunology, University Hospital of Ulm; Uppsala University Hospital; Amyndas Pharmaceuticals; Columbia University; Humanitas university; University Vita Salute San Raffaele; Federico II University of Naples; University of Sao Paulo, Ribeirao Preto School of Medicine; University of Pennsylvania","The evolution of coronavirus disease (COVID-19) into a pandemic has severely hampered the usage of public transit systems. In a post-COVID-19 world, we may see an increased reliance on autonomous cars and personal rapid transit (PRT) systems, with inherent physical distancing, over buses, trains, and aircraft for intracity, intercity, and interstate travel. However, air travel would continue to be the dominant mode of intercontinental transportation for humans. In this study, we perform a comprehensive computational analysis of typical intercontinental aircraft ventilation systems to determine the seat where environmental factors are most conducive to human comfort with regards to air quality, protection from orally or nasally released pollutants such as CO2 and coronavirus, and thermal comfort levels. Air velocity, temperature, and air pollutant concentration emitted from the nose/mouth of fellow travelers are considered for both Boeing and Airbus planes. In each plane, first class, business class, and economy class sections were analyzed. We present conclusions as to which is the optimum seat in each section of each plane and provide the data of the environmental conditions to support our inferences. The findings may be used by the general public to decide which seat to occupy for their next intercontinental flight. Alternatively, the commercial airliners can use such a model to plan the occupancy of the aircraft on long-duration intercontinental flights (viz., Airbus A380 and Boeing B747).",occupational and environmental health,exact,100,100
medRxiv,10.1101/2020.08.12.20173690,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20173690,"Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults",Helen Ward; Christina J Atchison; Matthew Whitaker; Kylie E. C. Ainslie; Joshua Elliott; Lucy C Okell; Rozlyn Redd; Deborah Ashby; Christl A. Donnelly; Wendy Barclay; Ara Darzi; Graham Cooke; Steven Riley; Paul Elliott; Rachel Vreeman; Joseph Masci; Nick A Maskell; Shaney Barratt; Carlos Sanchez-Garibay; Gabriela Hernandez-Molina; Criselda Mendoza-Milla; Andrea Dominguez; Julio Granados; Lula Mena-Hernandez; Luis Angel Perez-Buenfil; Guillermo Dominguez-Cheritt; Carlos Cabello-Gutierrez; Cesar Luna-Rivero; Jorge Salas-Hernandez; Patricio Santilla-Doherty; Justino Regalado; Angelica Hernandez-Martinez; Lorena Orozco; Ethel A. Garcia-Latorre; Carmen M. Hernandez-Cardenas; Shabaana A. Khader; Albert Zlotnik; Joaquin Zuniga,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals/Elmhurst; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK; Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Medicina Genomica, Mexico City, Mexico; Instituto Nacional de Medicina Genomica, Mexico City, Mexico; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States; Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico","BackgroundEngland, UK has experienced a large outbreak of SARS-CoV-2 infection. As in USA and elsewhere, disadvantaged communities have been disproportionately affected.

MethodsNational REal-time Assessment of Community Transmission-2 (REACT-2) seroprevalence study using self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020.

ResultsCompleted questionnaires were available for 109,076 participants, yielding 5,544 IgG positive results and adjusted (for test performance), re-weighted (for sampling) prevalence of 6.0% (95% CI: 5.8, 6.1). Highest prevalence was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged 18-24 years (7.9% [7.3, 8.5]). Care home workers with client-facing roles had adjusted odds ratio of 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody positive individuals reported no symptoms. Among symptomatic cases, the majority (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection fatality ratio of 0.90% (0.86, 0.94).

ConclusionThe pandemic of SARS-CoV-2 infection in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection in these groups may explain, at least in part, their increased risk of hospitalisation and mortality from COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.13.20174060,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.13.20174060,Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments,Thomas Hill; Mark Baker; Lawrence Isherwood; Lennard YW Lee; Joshua Elliott; Lucy C Okell; Rozlyn Redd; Deborah Ashby; Christl A. Donnelly; Wendy Barclay; Ara Darzi; Graham Cooke; Steven Riley; Paul Elliott; Rachel Vreeman; Joseph Masci; Nick A Maskell; Shaney Barratt; Carlos Sanchez-Garibay; Gabriela Hernandez-Molina; Criselda Mendoza-Milla; Andrea Dominguez; Julio Granados; Lula Mena-Hernandez; Luis Angel Perez-Buenfil; Guillermo Dominguez-Cheritt; Carlos Cabello-Gutierrez; Cesar Luna-Rivero; Jorge Salas-Hernandez; Patricio Santilla-Doherty; Justino Regalado; Angelica Hernandez-Martinez; Lorena Orozco; Ethel A. Garcia-Latorre; Carmen M. Hernandez-Cardenas; Shabaana A. Khader; Albert Zlotnik; Joaquin Zuniga,"Department of Oncology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, B152GW; Birmingham Medical School, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT; Birmingham Medical School, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT; Department of Oncology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston B15 2GW, United Kingdom. Institute of Cancer and Genomic Sciences, Univer; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals/Elmhurst; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK; Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Instituto Nacional de Medicina Genomica, Mexico City, Mexico; Instituto Nacional de Medicina Genomica, Mexico City, Mexico; Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico; Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States; Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico","Objectives: To identify putative COVID-19 treatments and identify the roles of immunomodulators and antivirals in disease management. Design: Systematic review. Data sources: PubMed, bioRxiv.org and medRxiv.org were searched for studies suggestive of effective treatments for COVID-19. Additional studies were identified via a snowballing method applied to the references of retrieved papers as well as a subsequent targeted search for drug names. Review methods: Inclusion criteria included any case series or randomised control trials in any language that were published from 18th December 2019 to 18th April 2020 and described COVID-19 treatment. Of an initial 2140 studies identified from the initial search, 29 studies were found to meet the inclusion criteria and included in this comprehensive systematic review. Results: 19 studies of antiviral treatments for COVID-19 have been reported and seven studies for immunomodulatory treatments. Six randomised controlled trials have been published with one positive trial for Hydroxychloroquine. This small study consisted of 31 patients though subsequent studies showed contradictory findings. All the remaining studies were observational studies, retrospective case reviews or non-randomised trials and these results are difficult to interpret due to methodological issues. Conclusions: To date, an impressive number of studies have been performed in a short space of time, indicative of a resilient clinical trials infrastructure. However, there is a lack of high quality evidence to support any novel treatments for COVID-19 to be incorporated into the current standard of care. The majority of the studies of treatments for COVID-19 could only be found in pre-print servers. Future clinical reviews should therefore be Comprehensive Systematic Reviews involving pre-print studies to prevent potential unnecessary replications of clinical studies.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.12.20171405,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20171405,OpenSAFELY: Do adults prescribed Non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?,Angel YS Wong; Brian MacKenna; Caroline Morton; Anna Schultze; Alex J Walker; Krishnan Bhaskaran; Jeremy Brown; Christopher T. Rentsch; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,"London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Importance: There has been speculation that non-steroidal anti-inflammatory drugs (NSAIDs) may negatively affect coronavirus disease 2019 (COVID-19) outcomes, yet clinical evidence is limited. Objective: To assess the association between NSAID use and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. Design: Two cohort studies (1st March-14th June 2020). Setting: Working on behalf of NHS England, we used routine clinical data from >17 million patients in England linked to death data from the Office for National Statistics. Participants: Study 1: General population (people with an NSAID prescription in the last three years). Study 2: people with rheumatoid arthritis/osteoarthritis. Exposures: Current NSAID prescription within the 4 months before 1st March 2020. Main Outcome and Measure: We used Cox regression to estimate hazard ratios (HRs) for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, adjusting for age, sex, comorbidities and other medications. Results: In Study 1, we included 535,519 current NSAID users and 1,924,095 non-users in the general population. The crude HR for current use was 1.25 (95% CI, 1.07-1.46), versus non-use. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR, 0.95, 95% CI, 0.80-1.13) in the fully adjusted model. In Study 2, we included 1,711,052 people with rheumatoid arthritis/osteoarthritis, of whom 175,631 (10%) were current NSAID users. The crude HR for current use was 0.43 (95% CI, 0.36-0.52), versus non-use. In the fully adjusted model, we observed a lower risk of COVID-19 related death (HR, 0.78, 95% CI, 0.65-0.94) associated with current use of NSAID versus non-use. Conclusion and Relevance: We found no evidence of a harmful effect of NSAIDs on COVID-19 related deaths. Risks from COVID-19 do not need to influence decisions about therapeutic use of NSAIDs.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.11.20173211,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.11.20173211,"To what extent physical distancing and other COVID-19 preventive measures being implemented among people in Arba Minch town, Southern Ethiopia: exploring evidence for an urgent call for action?",Mekuria Asnakew Asfaw; Tsegaye Yohannes; Chuchu Churko; Alemayehu Bekele; Teklu Wegayehu; Krishnan Bhaskaran; Jeremy Brown; Christopher T. Rentsch; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,"Arba Minch University; Arba Minch University, Ethiopia; Arba Minch University, Ethiopia; Arba Minch University, Ethiopia; Arba Minch University, Ethiopia; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Background The number of confirmed Coronavirus disease 2019 (COVID-19) cases surge substantially in resource-poor settings within the fragile health system. Since there are no proven vaccine and treatment in place against the disease, controlling strategy mainly rely on preventive measures. However, data on the extent of implementing physical distancing and other preventive measures were under estimated. This study, therefore, investigated these gaps among people in Arba Minch town, southern Ethiopia. Methods We conducted a community based cross-sectional study in Arba Minch town; from 15-30 June 2020. Data were collected using interviewer administered questionnaire and checklist. Then, data were cleaned, coded and entered to EpiData version 4.4.2, and exported to SPSS version 20 for analysis. Results Of the total participants (459), 43.6% achieved above the mean score (6) on preventive measures of COVID-19. Only 29.8% of participants kept the recommended physical distance, and surprisingly, in all public gathering places the distance was not kept totally. In addition, of the total participants, only 37.7% had face-mask use practice; 20.5% had hand sanitizer use practice, and 13.1% were measuring their body temperature every two weeks. Moreover, 42.5% of participants avoided attendance in public gatherings; 44.7% stopped touching their nose, eye and mouth; 55.6% practiced stay-at-home; and 60% had frequent hand washing practice. Majority of participants (66.7%) practiced covering their mouth and nose while coughing or sneezing; 68.2% had treatment seeking behavior if they experience flue like symptoms; 69.1% practiced isolating themselves while having flue like symptoms; and 89.3% avoided hand shaking. Conclusions The findings of this study suggest that physical distancing and other COVID-19 preventive measures were inadequately implemented among people in Arba Minch town. Thus, an urgent call for action is demanding to mitigate the spread of the COVID-19 as early as possible before it brings a devastating impact.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.13.20174011,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.13.20174011,"In the face of the pandemic, are all equal? On the suitability of the Gini index to monitor time and geographic trends in incidence and death during the SARS-CoV-2 pandemic",Kirsi Manz; Ulrich Mansmann; Chuchu Churko; Alemayehu Bekele; Teklu Wegayehu; Krishnan Bhaskaran; Jeremy Brown; Christopher T. Rentsch; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,"Ludwig Maximilians University Munich; Ludwig Maximilians University Munich; Arba Minch University, Ethiopia; Arba Minch University, Ethiopia; Arba Minch University, Ethiopia; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Health inequalities across nations reinforce social and economic differences. The European Commission has outlined its commitment to reducing health inequalities. The SARS-CoV-2 pandemic is a disruptive event with global, national, and local effects on every aspect of a societys life. Therefore, it is of interest to quantify and display health (in)equality induced by COVID-19 over time and on different geographic scales (global, continental, national, regional).

We aimed to perform a study of (in)equality regarding COVID-19 related data on infections and deaths using the Gini index (GI). A specific focus of our analysis is the (in)equality of infection fatality rates. The Gini index was developed to explore inequality in wealth within or between nations. It is a relative measure which quantifies the ratio of the mean absolute difference between non-negative numerical observations and their mean: GI=0 describes a situation where all values are equal, GI=1 corresponds to one single positive observation among all non-negative observations. We use global, nation- and statewide data to evaluate the inequality at different geographical scales. We also reflect on the suitability of the Gini index to monitor equality aspects of the pandemic.

Data from the SARS-CoV-2 pandemic show a considerable amount of inequality in the global distribution of infections and deaths. Only few countries contribute largely to the total infection and death toll. Inequality may result from heterogeneous reporting systems, heterogeneous policy making to fight the pandemic, heterogeneous health systems, and demographic structures. Inequality decreases when going from continental to national or regional levels. Time trends at national level reflect local outbreaks. There is inequality in infection fatality rates, too. Because of equality of income or wealth within a society, low GIs ([&le;] 0.4) are related to positive connotations like fairness and justice. In the epidemiological setting, however, a GI=1 reflects the goal striven for: The epidemic is restricted to one region while the surroundings are not affected - the epidemic has failed to spread.

We used the Gini index to reflect inequality between incidence and death rates of nations or geographic regions. The interpretation of the differences between reported GIs is not straightforward. Furthermore, combined with the information presented by maps, the GI is a useful tool.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.11.20170613,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.11.20170613,Automated molecular testing of saliva for SARS-CoV-2 detection,Nancy Matic; Tanya Lawson; Gordon Ritchie; Aleksandra Stefanovic; Victor Leung; Sylvie Champagne; Marc G. Romney; Christopher F. Lowe; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,Providence Health Care; Providence Health Care; Providence Health Care; Providence Health Care; Providence Health Care; Providence Health Care; Providence Health Care; Providence Health Care; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Introduction: With surging global demand for increased SARS-CoV-2 testing capacity, clinical laboratories seek automated, high-throughput molecular solutions, particularly for specimen types which do not rely upon supply of specialized collection devices or viral transport media (VTM). Saliva was evaluated as a diagnostic specimen for SARS-CoV-2 using the cobas SARS-CoV-2 Test on the cobas 6800 instrument. Methods: Saliva specimens submitted from various patient populations under investigation for COVID-19 from March-July 2020 were processed in the laboratory with sterile phosphate-buffered saline in a 1:2 dilution and vortexed with glass beads. The processed saliva samples were tested using a commercial assay for detection of the SARS-CoV-2 E gene (LightMix) in comparison to the cobas SARS-CoV-2 Test. Results: 22/64 (34.4%) of the saliva samples were positive for SARS-CoV-2. Positive and negative concordance between the LightMix and cobas assays were 100%. There was no cross-contamination of samples observed on the cobas 6800. The overall invalid rate for saliva on the cobas 6800 (1/128, 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/VTM and plasma samples. Conclusions: Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas 6800, with potential to improve turnaround time and enhance testing capacity.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.12.20172726,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20172726,Testing of Healthcare Workers Exposed to COVID19 with Rapid Antigen Detection,Victor Herrera; Vincent Hsu; Ademola Adewale; Timothy Hendrix; Lee Johnson; Jeffrey Kuhlman; Neil Finkler; Christopher F. Lowe; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,Adventhealth; AdventHealth; Adventhealth; AdventHealth; Adventhealth; Adventhealth; Adventhealth; Providence Health Care; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"There is a need to develop safe and cost-effective ways to test healthcare workers for COVID19. Here we describe a rapid antigen testing strategy in a cohort of 497 Healthcare workers exposed to SARS-CoV-2 that can be applied by systems facing a surge of COVID19 cases, increased number of exposures in their workforce and limited RT-PCR availability. Our findings support an expanded use for antigen testing beyond its current indication and highlights the importance of further evaluating this modality for the diagnosis of COVID19 on asymptomatic individuals.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.13.20170068,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.13.20170068,A novel approach for evaluating contact patterns and risk mitigation strategies for COVID-19 in English Primary Schools with application of Structured Expert Judgement,Stephen RJ Sparks; William P Aspinall; Ellen Brooks-Pollock; Leon Danon; Roger Cooke; Jenni Barclay; Jane Scarrow; Christopher F. Lowe; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,University of Bristol; University of Bristol; University of Bristol; University of Exeter; Delft University of Technology; University of East Anglia; University of Grenada; Providence Health Care; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Background Contact patterns are the drivers of close-contacts infections, such as COVID-19. In an effort to control COVID-19 transmission in the UK, schools were closed on 23 March 2020. With social distancing in place, Primary Schools were partially re-opened on 1 June 2020, with plans to fully re-open in September 2020. The impact of social distancing and risk mitigation measures on childrens contact patterns is not known. Methods We conducted a structured expert elicitation of a sample of Primary Headteachers to quantify contact patterns within schools in pre-COVID-19 times and how these patterns were expected to change upon re-opening. Point estimates with uncertainty were determined by a formal performance-based algorithm. Additionally, we surveyed school Headteachers about risk mitigation strategies and their anticipated effectiveness. Results Expert elicitation provides estimates of contact patterns that are consistent with contact surveys. We report mean number of contacts per day for four cohorts within schools along with a range at 90% confidence for the variations of contacts among individuals. Prior to lockdown, we estimate that, mean numbers per day, younger children (Reception and Year 1) made 15 contacts [range 8..35] within school, older children (Year 6) 18 contacts [range 5..55], teaching staff 25 contacts [range 4..55) and non-classroom staff 11 contacts [range 2..27]. Compared to pre-COVID times, after schools re-opened the mean number of contacts were reduced by about 53% for young children, about 62% for older children, about 60% for classroom staff and about 64% for other staff. Contacts between teaching and non-teaching staff reduced by 80%, which is consistent with other independent estimates. The distributions of contacts per person are asymmetric indicating a heavy tail of individuals with high contact numbers. Conclusions We interpret the reduction in childrens contacts as a consequence of efforts to reduce mixing with interventions such as forming groups of children (bubbles) who are organized to learn together to limit contacts. Distributions of contacts for children and adults can be used to inform COVID-19 transmission modelling. Our findings suggest that while official DfE guidelines form the basis for risk mitigation in schools, individual schools have adopted their own bespoke strategies, often going beyond the guidelines.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.12.20173047,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20173047,Examining face-mask usage as an effective strategy to control COVID-19 spread,Adam Catching; Sara Capponi; Ming Te Yeh; Simone Bianco; Raul Andino; Jenni Barclay; Jane Scarrow; Christopher F. Lowe; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,"University of California San Francisco; Industrial and Applied Genomics, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA, 95120; University of California, San Francisco; IBM Almaden Research Center; University of California, San Francisco; University of East Anglia; University of Grenada; Providence Health Care; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","The COVID-19 global crisis is facilitated by high virus transmission rates and high percentages of asymptomatic and presymptomatic infected individuals. Containing the pandemic hinged on combinations of social distancing and face mask use. Here we examine the efficacy of these measures, using an agent-based modeling approach that evaluates face masks and social distancing in realistic confined spaces scenarios. By explicitly considering different fractions of asymptomatic individuals, as well as a realistic hypothesis of face mask protection during inhaling and exhaling, we find that face masks are more effective than social distancing in curbing the infection. Importantly, combining face masks with even moderate social distancing provides optimal protection. The finding that widespread usage of face masks limits COVID-19 outbreaks can inform policies to reopening of social functions.

Author summaryThe COVID-19 outbreak has created an enormous burden on the worldwide population. Among the various ways of preventing the spread of the virus, face masks have been proposed as a main way of reducing transmission. Yet, the interplay between the usage of face mask and other forms of Non-Pharmaceutical Intervention is still not completely clear. In this paper we introduce a stochastic individual-based model which aims at producing realistic scenarios of disease spread when mask wearing with different inward and outward efficacy and social distancing are enforced. The model elucidates the conditions which make the two forms of intervention synergistic in preventing the spread of the disease.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.12.20173328,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20173328,Hospital preparedness in epidemics by using simulation. The case of COVID-19,Daniel Garcia-Vicuna; Laida Esparza; Fermin Mallor; Simone Bianco; Raul Andino; Jenni Barclay; Jane Scarrow; Christopher F. Lowe; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,"Public University of Navarre; Hospital Compound of Navarre; Public University of Navarre; IBM Almaden Research Center; University of California, San Francisco; University of East Anglia; University of Grenada; Providence Health Care; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","This paper presents a discrete event simulation model to support the decision-making concerned with the short-term planning of the necessary hospital resources, especially Intensive Care Unit (ICU) beds, to face outbreaks, as the SARS-CoV-2. Being used as a short-term forecasting tool, the simulation model requires an accurate representation of the current system state and high fidelity in mimicking the system dynamics from that state. The two main components of the simulation model are the stochastic modeling of the admission of new patients and the patient flow through the hospital facilities. For the patient arrival process, we analyze different models based on growth curves of the twenty most affected countries (until June 15) and propose the use of the Gompertz curve. The length of stay is divided into several stages, each one modeled separately. We analyze the starting of the simulation model, which requires different procedures depending on the information available about the patients currently hospitalized. We also report the use of this simulation model during the COVID-19 outbreak in the Autonomous Community of Navarre, in Spain. Every day, the research team informed the regional logistic team in charge of planning the health resources, who programmed the ward and ICU beds based on the resulting predictions.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.13.20174045,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.13.20174045,"COVID-19 vaccination intention in the UK: Results from the COVID-19 Vaccination Acceptability Study (CoVAccS), a nationally representative cross-sectional survey",Susan Mary Sherman; Louise E. Smith; Julius Sim; Richard Amlt; Megan Cutts; Hannah Dasch; G James Rubin; Nick Sevdalis; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,Keele University; King's College London; Keele University; Public Health England; Keele University; Kings College London; Kings College London; Kings College London; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"Aim: To investigate factors associated with intention to be vaccinated against COVID-19. Methods: Online cross-sectional survey of 1,500 UK adults, recruited from an existing online research panel. Data were collected between 14th and 17th July 2020. We used linear regression analyses to investigate associations between intention to be vaccinated for COVID-19 when a vaccine becomes available to you and socio-demographic factors, previous influenza vaccination, general vaccine attitudes and beliefs, attitudes and beliefs about COVID-19, and attitudes and beliefs about a COVID-19 vaccination. Results: 64% of participants reported being likely to be vaccinated against COVID-19; 27% were unsure and 9% reported being unlikely to be vaccinated. Personal and clinical characteristics, previous influenza vaccination, general vaccination beliefs, and beliefs and attitudes about COVID-19 and a COVID-19 vaccination explained 77% of the variance in vaccination intention. Intention to be vaccinated was associated with more positive general COVID-19 vaccination beliefs and attitudes, weaker beliefs that the vaccination would cause side effects or be unsafe, greater perceived information sufficiency to make an informed decision about COVID-19 vaccination, greater perceived risk of COVID-19 to others but not oneself, older age, and having been vaccinated for influenza last winter (2019/20). Conclusions: Despite uncertainty around the details of a COVID-19 vaccination, most participants reported intending to be vaccinated for COVID-19. Actual uptake will likely be lower. Vaccination intention reflects general vaccine beliefs and attitudes. Campaigns and messaging about a COVID-19 vaccination should emphasize the risk of COVID-19 to others and necessity for everyone to be vaccinated.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.10.20171496,2020-08-11,https://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,Steve Goodacre; Ben Thomas; Ellen Lee; Laura Sutton; Amanda Loban; Simon Waterhouse; Richard Simmonds; Katie Biggs; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust, Wythenshawe Hospital; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust","Background Hospital emergency departments play a crucial role in the initial management of suspected COVID-19 infection. We aimed to characterise patients attending emergency departments with suspected COVID-19, including subgroups based on sex, ethnicity and COVID-19 test results. Methods We undertook a mixed prospective and retrospective observational cohort study in 70 emergency departments across the United Kingdom (UK). We collected presenting data from 22446 people attending with suspected COVID-19 between 26 March 2020 and 28 May 2020. Outcomes were admission to hospital, COVID-19 result, organ support (respiratory, cardiovascular or renal), and death, by record review at 30 days. Results Adults were acutely unwell (median NEWS2 score 4) and had high rates of admission (67.1%), COVID-19 positivity (31.2%), organ support (9.8%) and death (15.9%). Children had much lower rates of admission (27.4%), COVID-19 positivity (1.2%), organ support (1.4%) and death (0.3%). Adult men and women presented in similar numbers (10210 versus 10506), but men were more likely to be admitted (72.9% v 61.4%), require organ support (12.2% v 7.7%) and die (18.7% v 13.3%). Black or Asian adults tended to be younger than White adults (median age 54, 50 and 67 years), were less likely to be admitted (60.8%, 57.3%, 69.6%) or die (11.9%, 11.2%, 16.8%), but were more likely to require organ support (15.9%, 14.3%, 8.9%) or have a positive COVID-19 test (40.8%, 42.1%, 30.0%). Adults admitted with confirmed COVID-19 had similar age and comorbidities (except chronic lung disease) to those who did not have COVID-19 confirmed, but were much more likely to need organ support (22.2% v 8.9%) or die (32.7% v 15.9%). Conclusions Important differences exist between patient groups presenting to the emergency department with suspected COVID-19. People with confirmed COVID-19 have a poor prognosis, compared with similar emergency admissions without confirmed COVID-19.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.08.10.20171421,2020-08-11,https://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,Garyfallos Konstantinoudis; Tullia Padellini; James E Bennett; Bethan Davies; Majid Ezzati; Marta Blangiardo; Francisco Azzato; Mauro Basconcel; Marcela Castro; Javier Coyle; Ignacio Davolos; Eduardo Esparza; Ignacio Fernandez Criado; Rosana Gregori; Pedro Mastrodonato; Maria Rubio; Sergio Sarquis; Fernando Wahlmann; Rodolfo Pedro Rothlin; Andrew Lee; Ian Maconochie; Darren Walter,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires; Hospital Espanol de Buenos Aires; Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires; Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires; Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires; Hospital Espanol de Buenos Aires; Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires; Hospital Espanol de Buenos Aires; Hospital Espanol de Buenos Aires.; Hospital Espanol de Buenos Aires; Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires; Hospital Espanol de Buenos Aires; Sociedad Argentina de Farmacologia Clinica, Asociacion Medica Argentina; Asociacion Argentina de Medicamentos, Ciudad de Buenos Aires, Argentina; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust","Background: Recent studies suggested a link between long-term exposure to air-pollution and COVID-19 mortality. However, due to their ecological design, based on large spatial units, they neglect the strong localised air-pollution patterns, and potentially lead to inadequate confounding adjustment. We investigated the effect of long-term exposure to NO2 and PM2.5 on COVID-19 deaths up to June 30, 2020 in England using high geographical resolution. Methods: We included 38 573 COVID-19 deaths up to June 30, 2020 at the Lower Layer Super Output Area level in England (n=32 844 small areas). We retrieved averaged NO2 and PM2.5 concentration during 2014-2018 from the Pollution Climate Mapping. We used Bayesian hierarchical models to quantify the effect of air-pollution while adjusting for a series of confounding and spatial autocorrelation. Findings: We find a 0.5% (95% credible interval: -0.2%-1.2%) and 1.4% (-2.1%-5.1%) increase in COVID-19 mortality rate for every 1g/m3 increase in NO2 and PM2.5 respectively, after adjusting for confounding and spatial autocorrelation. This corresponds to a posterior probability of a positive effect of 0.93 and 0.78 respectively. The spatial relative risk at LSOA level revealed strong patterns, similar for the different pollutants. This potentially captures the spread of the disease during the first wave of the epidemic. Interpretation: Our study provides some evidence of an effect of long-term NO2 exposure on COVID-19 mortality, while the effect of PM2.5 remains more uncertain. Funding: Medical Research Council, Wellcome Trust, Environmental Protection Agency and National Institutes of Health.",public and global health,exact,100,100
medRxiv,10.1101/2020.08.10.20171033,2020-08-11,https://medrxiv.org/cgi/content/short/2020.08.10.20171033,Post-exertion oxygen saturation as a prognostic factor for adverse outcome in patients attending the emergency department with suspected COVID-19: Observational cohort study,Steve Goodacre; Ben Thomas; Ellen Lee; Laura Sutton; Katie Biggs; Carl Marincowitz; Amanda Loban; Simon Waterhouse; Richard Simmonds; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust, Wythenshawe Hospital; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust","Background Measurement of post-exertion oxygen saturation has been proposed to assess illness severity in suspected COVID-19 infection. We aimed to determine the accuracy of post-exertional oxygen saturation for predicting adverse outcome in suspected COVID-19. Methods We undertook an observational cohort study across 70 emergency departments during first wave of the COVID-19 pandemic in the United Kingdom. We collected data prospectively, using a standardised assessment form, and retrospectively, using hospital records, from patients with suspected COVID-19, and reviewed hospital records at 30 days for adverse outcome (death or receiving organ support). Patients with post-exertion oxygen saturation recorded were selected for this analysis. Results We analysed data from 817 patients with post-exertion oxygen saturation recorded after excluding 54 in whom measurement appeared unfeasible. The c-statistic for post-exertion change in oxygen saturation was 0.589 (95% confidence interval 0.465 to 0.713), and the positive and negative likelihood ratios of a 3% or more desaturation were respectively 1.78 (1.25 to 2.53) and 0.67 (0.46 to 0.98). Multivariable analysis showed that post-exertion oxygen saturation was not a significant predictor of adverse outcome when baseline clinical assessment was taken into account (p=0.368). Secondary analysis excluding patients in whom post-exertion measurement appeared inappropriate resulted in a c-statistic of 0.699 (0.581 to 0.817), likelihood ratios of 1.98 (1.26 to 3.10) and 0.61 (0.35 to 1.07), and some evidence of additional prognostic value on multivariable analysis (p=0.019). Conclusions Post-exertion oxygen saturation provides modest prognostic information in the assessment of patients attending the emergency department with suspected COVID-19.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.08.07.20169490,2020-08-07,https://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,Krishnan Bhaskaran; Christopher T Rentsch; Brian MacKenna; Anna Schultz; Amir Mehrkar; Chris Bates; Rosalind M Eggo; Caroline E Morton; Seb Bacon; Peter Inglesby; Ian J Douglas; Alex J Walker; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Harriet J Forbes; Helen J Curtis; William Hulme; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre; Mattew Tenser; Ana Aires; Mercedes De Lera Alfonso; Orkhan Alizada; Elsa Azevedo; Nitin Goyal; Zabihollah Babaeepour; Gelareh Banihashemi; Leo H Bonati; Carlo Cereda; Jason J Chang; Miljenko Crnjakovic; GianMarco De Marchis; Massimo del Sette; Seyed Amir Ebrahimadeh; Mehdi Farhoudi; Ilaria Gandoglia; Bruno Goncalves; Christoph Griessenauer; Mehmet Murat Hanci; Aristeidis H. Katsanos; Christos Krogias; Ronen Leker; Lev Lotman; Jeffrey Mai; Shailesh Male; konark Malhotra; Branko Malojcic; Tresa Mesquita; Asadollah Mirghasemi; Hany Mohamed Aref; Zeinab Mohseni Afshar; Junsun Moon; Mika Niemela; Behnam Rezai Jahromi; Lawrence Nolan; Abhi Pandhi; Jong-Ho Park; Joao Pedro Marto; Francisco Purroy; Sakineh Ranji-Burachaloo; Nuno Reis Carreira; Manuel Requena; Marta Rubiera; Seyed Aidin Sajedi; Joao SargentoFreitas; Vijay Sharma; Thorsten Steiner; Kristi Tempro; Guillaume Turc; Yassaman Ahmadzadeh; Mostafa Almasi-Dooghaee; Farhad Assarzadegan; Arefeh Babazadeh; Humain Baharvahdat; Fabricio Cardoso; Apoorva Dev; Mohammad Ghorbani; Ava Hamidi; Zeynab Sadat Hasheminejad; Sahar Hojjat-Anasri Komachali; Fariborz Khorvash; Firas Kobeissy; Hamidreza Mirkarimi; Elahe Mohammadi-Vosough; Debdipto Misra; Alierza Noorian; Peyman Nowrouzi-Sohrabi; Sepideh Paybast; Leila Poorsaadat; mehrdad Roozbeh; Behnam Sabayan; Saeideh Salehizadeh; Alia Saberi; Mercedeh Sepehrnia; Fahimeh Vahabizad; Thomas Yasuda; Ahmadreza Hojati Marvasti; Mojdeh Ghabaee; Nasrin Rahimian; Mohammad Hosein Harirchian; Afshin Borhani-Haghighi; Rohan Arora; Saeed Ansari; Venkatesh Avula; Jian Li; Vida Abedi; Ramin Zand,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California, California, US; Department of Neurology, Sao Joao Hospital Center, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.; Department of Neurology, University of Valladolid, Valladolid, Spain.; Neurosurgery Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; Department of Neurology, Sao Joao Hospital Center, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.; Neurology Department, University of Tennessee Health Science Center, Tennessee, USA; Neurology ward, Valiasr Hospital, Borujen, Iran; Sina hospital (Neurology departement); Department of Neurology, Arak University of Medical Sciences, Arak,Iran; Stroke Center, Neurocenter of Southern Switzerland, Lugano, Switzerland; Department of Neurology, Marry Washington Healthcare, Fredricksburg, Virginia, USA; Intensive Care Unit, Department of Neurology, Clinical Hospital Dubrava, Zagreb, Croatia; Neurorehabilitation Unit, University Center for Medicine of Aging and Rehabilitation Basel, Felix Platter Hospital, University of Basel, Switzerland.; Neurology Unit, Galliera Hospital, Genova, Italy; Department of Radiology, Yasrebi Hospital, Kashan, Iran; Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences,Tabriz, Iran.; Neurology Unit, Galliera Hospital, Genova, Italy; Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite de Paris, INSERM U1266, Paris, France; Neurology Department, Neuroscience Institute, Geisinger Health System, Pennsylvania, USA; Neurosurgery Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; Second Department of Neurology, Attikon University Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; epartment of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany; Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Neurology, Albany Medical Center, Albany, NY; Department of Neurology, Marry Washington Healthcare, Fredricksburg, Virginia, USA; Neurology Department, Vidant Medical Center; Department of Neurology, Allegheny Health Network (AHN),Pittsburgh, PA, USA; TIA Clinic, Department of Neurology, University Hospital Centre Zagreb, Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia.; Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Anesthesiology, University of Ottawa; Department of neurology, Ain Shams University, Cairo, Egypt; Infection Disease Research Center, Kermanshah University of Medical Sciences; Department of Neurology, National Medical Center, Seoul, South Korea; Department of Neurosurgery, Helsinki University Hospital, Finland; Department of Neurosurgery, Helsinki University Hospital, Finland; Department of Neurology, Albany Medical Center, Albany, NY; Neurology Department, University of Tennessee Health Science Center, Tennessee, USA; Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, South Korea.; Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Neurology, Hospital Arnau de Vilanova, Lleida, Spain; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences; Department of Internal Medicine, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal; Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Departament de Medicina, Universitat Autonoma de Barcelona; Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Departament de Medicina, Universitat Autonoma de Barcelona; Neuroscience Research Center, Golestan University of Medical Sciences, Iran; Department of Neurology, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; Division of Neurology, University Medicine Cluster, National University Health System, Singapore, Singapore; Department of Neurology, Klinikum Frankfurt Hochst, Frankfurt Germany; Department of Neurology, Albany Medical Center, Albany, NY; Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite de Paris, INSERM U1266, Paris, France; Hospital for Special Surgery, New York, USA; Divisions of Vascular and Endovascular Neurosurgery and Neurology, Firoozgar Hospital and Rasoul-Akram hospital, Iran University of Medical Sciences, Tehran, Ir; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran.; Neurosurgical Department, Ghaem Hospital, Mashhad University of Medical Sciences; Neurology Department, Centro Medico de Campinas, Brazil; PES university,Bengalore,India; Division of Vascular and Endovascular Neurosurgery, Firoozgar Hospital, Iran University of Medical Sciences; Neutology ward, Gheshm Hospital, Gheshm, Iran; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Department of Neurology, Pirooz hospital, Gilan University of Medical Sciences, Lahijan,Iran; Professor Of Neurology, Isfahan University Of Neurology, Isfahan, Iran; Program of Neurotrauma, Neuroproteomics and Biomarker Research (NNBR), University of Florida, Florida, USA; Neurology ward, Modarres Hospital, Kashmar, Iran; Neurology ward, Modarres Hospital, Kashmar, Iran; Steele Institute of Health & Innovation, Geisinger Health System, Pennsylvania, USA; UCLA stroke program, US; Student Research Committee, Shiraz University of Medical Sciences; Department of Neurology, Bou Ali hospital, Qazvin University of Medical Sciences, Qazvin,Iran; Department of Neurology, Arak University of Medical Sciences, Arak,Iran; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Salahadin Ayubi Hospital, Parastar street, Baneh, Iran.; Neurology Department, Poursina Hospital, Iran; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Sina Hospital; Neurology Department, Centro Medico de Campinas, Brazil; Neurology Department, Tehran University of medical sciences, Iran; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Yasrebi Hospital, Kashan, Iran; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Northwell, USA; Department of Neurology, University of Tennessee, Tennessee, USA; Neurology Department, Neuroscience Institute, Geisinger Health System, Pennsylvania, USA; Geisinger health system, USA; Department of Molecular and Functional Genonic, Geisinger Health System, Pennsylvania, USA; Neurology Department, Neuroscience Institute, Geisinger Health System","Background: It is unclear whether HIV infection is associated with risk of COVID-19 death. We aimed to investigate this in a large-scale population-based study in England. Methods: Working on behalf of NHS England, we used the OpenSAFELY platform to analyse routinely collected electronic primary care data linked to national death registrations. People with a primary care record for HIV infection were compared to people without HIV. COVID-19 death was defined by ICD-10 codes U07.1 or U07.2 anywhere on the death certificate. Cox regression models were used to estimate the association between HIV infection and COVID-19 death, initially adjusted for age and sex, then adding adjustment for index of multiple deprivation and ethnicity, and finally for a broad range of comorbidities. Interaction terms were added to assess effect modification by age, sex, ethnicity, comorbidities and calendar time. Results: 17.3 million adults were included, of whom 27,480 (0.16%) had HIV recorded. People living with HIV were more likely to be male, of black ethnicity, and from a more deprived geographical area than the general population. There were 14,882 COVID-19 deaths during the study period, with 25 among people with HIV. People living with HIV had nearly three-fold higher risk of COVID-19 death than those without HIV after adjusting for age and sex (HR=2.90, 95% CI 1.96-4.30). The association was attenuated but risk remained substantially raised, after adjustment for deprivation and ethnicity (adjusted HR=2.52, 1.70-3.73) and further adjustment for comorbidities (HR=2.30, 1.55-3.41). There was some evidence that the association was larger among people of black ethnicity (HR = 3.80, 2.15-6.74, compared to 1.64, 0.92-2.90 in non-black individuals, p-interaction=0.045) Interpretation: HIV infection was associated with a markedly raised risk of COVID-19 death in a country with high levels of antiretroviral therapy coverage and viral suppression; the association was larger in people of black ethnicity.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.06.20169599,2020-08-07,https://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",Michelle S Chew; Patrik Blixt; Rasmus Ahman; Lars Engerstrom; Henrik Andersson; Ritva Kiiski Berggren; Anders Tegnell; Sarah McIntyre; Seb Bacon; Peter Inglesby; Ian J Douglas; Alex J Walker; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Harriet J Forbes; Helen J Curtis; William Hulme; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre; Mattew Tenser; Ana Aires; Mercedes De Lera Alfonso; Orkhan Alizada; Elsa Azevedo; Nitin Goyal; Zabihollah Babaeepour; Gelareh Banihashemi; Leo H Bonati; Carlo Cereda; Jason J Chang; Miljenko Crnjakovic; GianMarco De Marchis; Massimo del Sette; Seyed Amir Ebrahimadeh; Mehdi Farhoudi; Ilaria Gandoglia; Bruno Goncalves; Christoph Griessenauer; Mehmet Murat Hanci; Aristeidis H. Katsanos; Christos Krogias; Ronen Leker; Lev Lotman; Jeffrey Mai; Shailesh Male; konark Malhotra; Branko Malojcic; Tresa Mesquita; Asadollah Mirghasemi; Hany Mohamed Aref; Zeinab Mohseni Afshar; Junsun Moon; Mika Niemela; Behnam Rezai Jahromi; Lawrence Nolan; Abhi Pandhi; Jong-Ho Park; Joao Pedro Marto; Francisco Purroy; Sakineh Ranji-Burachaloo; Nuno Reis Carreira; Manuel Requena; Marta Rubiera; Seyed Aidin Sajedi; Joao SargentoFreitas; Vijay Sharma; Thorsten Steiner; Kristi Tempro; Guillaume Turc; Yassaman Ahmadzadeh; Mostafa Almasi-Dooghaee; Farhad Assarzadegan; Arefeh Babazadeh; Humain Baharvahdat; Fabricio Cardoso; Apoorva Dev; Mohammad Ghorbani; Ava Hamidi; Zeynab Sadat Hasheminejad; Sahar Hojjat-Anasri Komachali; Fariborz Khorvash; Firas Kobeissy; Hamidreza Mirkarimi; Elahe Mohammadi-Vosough; Debdipto Misra; Alierza Noorian; Peyman Nowrouzi-Sohrabi; Sepideh Paybast; Leila Poorsaadat; mehrdad Roozbeh; Behnam Sabayan; Saeideh Salehizadeh; Alia Saberi; Mercedeh Sepehrnia; Fahimeh Vahabizad; Thomas Yasuda; Ahmadreza Hojati Marvasti; Mojdeh Ghabaee; Nasrin Rahimian; Mohammad Hosein Harirchian; Afshin Borhani-Haghighi; Rohan Arora; Saeed Ansari; Venkatesh Avula; Jian Li; Vida Abedi; Ramin Zand,"Department of Biomedical and Clinical Sciences, Anaesthesiology and Intensive Care, Linkoping University Hospital; Department of Biomedical and Clinical Sciences, Anaesthesiology and Intensive Care, Linkoping University Hospital; Department of Biomedical and Clinical Sciences, Anaesthesiology and Intensive Care, Linkoping University Hospital; Department of Anaesthesia and Intensive Care, Vrinnevi Hospital, Norrkoping, Department of Thoracic and Vascular Surgery, Medical and Health Sciences, Linkoping; Department of Biomedical and Clinical Sciences, Anaesthesiology and Intensive Care, Linkoping University Hospital; Department of Anaesthesia, Intensive Care and Perioperative Services, Umea University Hospital; Department of Public Health Reporting, Public Health Agency of Sweden; Department of Biomedical and Clinical Sciences, Center for Social and Affective Neuroscience, Linkoping University; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California, California, US; Department of Neurology, Sao Joao Hospital Center, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.; Department of Neurology, University of Valladolid, Valladolid, Spain.; Neurosurgery Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; Department of Neurology, Sao Joao Hospital Center, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.; Neurology Department, University of Tennessee Health Science Center, Tennessee, USA; Neurology ward, Valiasr Hospital, Borujen, Iran; Sina hospital (Neurology departement); Department of Neurology, Arak University of Medical Sciences, Arak,Iran; Stroke Center, Neurocenter of Southern Switzerland, Lugano, Switzerland; Department of Neurology, Marry Washington Healthcare, Fredricksburg, Virginia, USA; Intensive Care Unit, Department of Neurology, Clinical Hospital Dubrava, Zagreb, Croatia; Neurorehabilitation Unit, University Center for Medicine of Aging and Rehabilitation Basel, Felix Platter Hospital, University of Basel, Switzerland.; Neurology Unit, Galliera Hospital, Genova, Italy; Department of Radiology, Yasrebi Hospital, Kashan, Iran; Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences,Tabriz, Iran.; Neurology Unit, Galliera Hospital, Genova, Italy; Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite de Paris, INSERM U1266, Paris, France; Neurology Department, Neuroscience Institute, Geisinger Health System, Pennsylvania, USA; Neurosurgery Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; Second Department of Neurology, Attikon University Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; epartment of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany; Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Neurology, Albany Medical Center, Albany, NY; Department of Neurology, Marry Washington Healthcare, Fredricksburg, Virginia, USA; Neurology Department, Vidant Medical Center; Department of Neurology, Allegheny Health Network (AHN),Pittsburgh, PA, USA; TIA Clinic, Department of Neurology, University Hospital Centre Zagreb, Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia.; Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Anesthesiology, University of Ottawa; Department of neurology, Ain Shams University, Cairo, Egypt; Infection Disease Research Center, Kermanshah University of Medical Sciences; Department of Neurology, National Medical Center, Seoul, South Korea; Department of Neurosurgery, Helsinki University Hospital, Finland; Department of Neurosurgery, Helsinki University Hospital, Finland; Department of Neurology, Albany Medical Center, Albany, NY; Neurology Department, University of Tennessee Health Science Center, Tennessee, USA; Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, South Korea.; Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Neurology, Hospital Arnau de Vilanova, Lleida, Spain; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences; Department of Internal Medicine, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal; Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Departament de Medicina, Universitat Autonoma de Barcelona; Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Departament de Medicina, Universitat Autonoma de Barcelona; Neuroscience Research Center, Golestan University of Medical Sciences, Iran; Department of Neurology, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; Division of Neurology, University Medicine Cluster, National University Health System, Singapore, Singapore; Department of Neurology, Klinikum Frankfurt Hochst, Frankfurt Germany; Department of Neurology, Albany Medical Center, Albany, NY; Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite de Paris, INSERM U1266, Paris, France; Hospital for Special Surgery, New York, USA; Divisions of Vascular and Endovascular Neurosurgery and Neurology, Firoozgar Hospital and Rasoul-Akram hospital, Iran University of Medical Sciences, Tehran, Ir; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran.; Neurosurgical Department, Ghaem Hospital, Mashhad University of Medical Sciences; Neurology Department, Centro Medico de Campinas, Brazil; PES university,Bengalore,India; Division of Vascular and Endovascular Neurosurgery, Firoozgar Hospital, Iran University of Medical Sciences; Neutology ward, Gheshm Hospital, Gheshm, Iran; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Department of Neurology, Pirooz hospital, Gilan University of Medical Sciences, Lahijan,Iran; Professor Of Neurology, Isfahan University Of Neurology, Isfahan, Iran; Program of Neurotrauma, Neuroproteomics and Biomarker Research (NNBR), University of Florida, Florida, USA; Neurology ward, Modarres Hospital, Kashmar, Iran; Neurology ward, Modarres Hospital, Kashmar, Iran; Steele Institute of Health & Innovation, Geisinger Health System, Pennsylvania, USA; UCLA stroke program, US; Student Research Committee, Shiraz University of Medical Sciences; Department of Neurology, Bou Ali hospital, Qazvin University of Medical Sciences, Qazvin,Iran; Department of Neurology, Arak University of Medical Sciences, Arak,Iran; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Salahadin Ayubi Hospital, Parastar street, Baneh, Iran.; Neurology Department, Poursina Hospital, Iran; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Sina Hospital; Neurology Department, Centro Medico de Campinas, Brazil; Neurology Department, Tehran University of medical sciences, Iran; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Yasrebi Hospital, Kashan, Iran; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Northwell, USA; Department of Neurology, University of Tennessee, Tennessee, USA; Neurology Department, Neuroscience Institute, Geisinger Health System, Pennsylvania, USA; Geisinger health system, USA; Department of Molecular and Functional Genonic, Geisinger Health System, Pennsylvania, USA; Neurology Department, Neuroscience Institute, Geisinger Health System","Background The mortality of patients admitted to the intensive care unit (ICU) with COVID-19 is unclear due to variable censoring and substantial proportions of undischarged patients at follow-up. Nationwide data have not been previously reported. We studied the outcomes of Swedish patients at 30 days after ICU admission. Methods We conducted a registry-based cohort study of all adult patients admitted to Swedish ICUs from 6 March-6 May, 2020 with laboratory confirmed COVID-19 disease and complete 30-day follow-up. Data including baseline characteristics, comorbidities, intensive care treatments, organ failures and outcomes were collected. The primary outcome was 30-day all-cause mortality. A multivariable model was used to determine the independent association between potential predictor variables and the primary outcome. Results A total of 1563 patients were identified. Median ICU length of stay was 12 (5-21) days, and fifteen patients remained in ICU at the time of follow-up. Median age was 61 (52-69), median Simplified Acute Physiology Score III (SAPS III) was 53 (46-59), and 66.8% had at least one comorbidity. Median PaO2/FiO2 on admission was 97.5 (75.0-140.6) mmHg, 74.7% suffered from moderate to severe acute respiratory distress syndrome (ARDS). The 30-day all-cause mortality was 26.7%. The majority of deaths occurred during ICU admission. Age, male sex (adjusted odds ratio [aOR] 1.5 [1.1-2.1]), SAPS III score (aOR 1.3 [1.2-1.4]), severe ARDS (aOR 3.1 [2.0-4.8], specific COVID-19 pharmacotherapy (aOR 1.4 [1.0-1.9]), and CRRT (aOR 2.2 [1.6-3.0]), were associated with increased mortality. With the exception of chronic lung disease, the presence of comorbidities was not independently associated with mortality. Conclusions Thirty-day mortality rate in COVID-19 patients admitted to Swedish intensive care units is generally lower than previously reported. Mortality appears to be driven by age, baseline disease severity, the degree of organ failure and ICU treatment, rather than preexisting comorbidities.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.08.06.20169797,2020-08-07,https://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,Jennifer R Head; Kristin Andrejko; Qu Cheng; Philip A Collender; Sophie Phillips; Anna Boser; Alexandra K Heaney; Christopher M Hoover; Sean L Wu; Graham R Northrup; Karen Click; Robert Harrison; Joseph A Lewnard; Justin V Remais; Elizabeth J Williamson; David Evans; Harriet J Forbes; Helen J Curtis; William Hulme; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre; Mattew Tenser; Ana Aires; Mercedes De Lera Alfonso; Orkhan Alizada; Elsa Azevedo; Nitin Goyal; Zabihollah Babaeepour; Gelareh Banihashemi; Leo H Bonati; Carlo Cereda; Jason J Chang; Miljenko Crnjakovic; GianMarco De Marchis; Massimo del Sette; Seyed Amir Ebrahimadeh; Mehdi Farhoudi; Ilaria Gandoglia; Bruno Goncalves; Christoph Griessenauer; Mehmet Murat Hanci; Aristeidis H. Katsanos; Christos Krogias; Ronen Leker; Lev Lotman; Jeffrey Mai; Shailesh Male; konark Malhotra; Branko Malojcic; Tresa Mesquita; Asadollah Mirghasemi; Hany Mohamed Aref; Zeinab Mohseni Afshar; Junsun Moon; Mika Niemela; Behnam Rezai Jahromi; Lawrence Nolan; Abhi Pandhi; Jong-Ho Park; Joao Pedro Marto; Francisco Purroy; Sakineh Ranji-Burachaloo; Nuno Reis Carreira; Manuel Requena; Marta Rubiera; Seyed Aidin Sajedi; Joao SargentoFreitas; Vijay Sharma; Thorsten Steiner; Kristi Tempro; Guillaume Turc; Yassaman Ahmadzadeh; Mostafa Almasi-Dooghaee; Farhad Assarzadegan; Arefeh Babazadeh; Humain Baharvahdat; Fabricio Cardoso; Apoorva Dev; Mohammad Ghorbani; Ava Hamidi; Zeynab Sadat Hasheminejad; Sahar Hojjat-Anasri Komachali; Fariborz Khorvash; Firas Kobeissy; Hamidreza Mirkarimi; Elahe Mohammadi-Vosough; Debdipto Misra; Alierza Noorian; Peyman Nowrouzi-Sohrabi; Sepideh Paybast; Leila Poorsaadat; mehrdad Roozbeh; Behnam Sabayan; Saeideh Salehizadeh; Alia Saberi; Mercedeh Sepehrnia; Fahimeh Vahabizad; Thomas Yasuda; Ahmadreza Hojati Marvasti; Mojdeh Ghabaee; Nasrin Rahimian; Mohammad Hosein Harirchian; Afshin Borhani-Haghighi; Rohan Arora; Saeed Ansari; Venkatesh Avula; Jian Li; Vida Abedi; Ramin Zand,"University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California Berkeley; University of California San Francisco; University of California Berkeley; University of California Berkeley; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California, California, US; Department of Neurology, Sao Joao Hospital Center, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.; Department of Neurology, University of Valladolid, Valladolid, Spain.; Neurosurgery Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; Department of Neurology, Sao Joao Hospital Center, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.; Neurology Department, University of Tennessee Health Science Center, Tennessee, USA; Neurology ward, Valiasr Hospital, Borujen, Iran; Sina hospital (Neurology departement); Department of Neurology, Arak University of Medical Sciences, Arak,Iran; Stroke Center, Neurocenter of Southern Switzerland, Lugano, Switzerland; Department of Neurology, Marry Washington Healthcare, Fredricksburg, Virginia, USA; Intensive Care Unit, Department of Neurology, Clinical Hospital Dubrava, Zagreb, Croatia; Neurorehabilitation Unit, University Center for Medicine of Aging and Rehabilitation Basel, Felix Platter Hospital, University of Basel, Switzerland.; Neurology Unit, Galliera Hospital, Genova, Italy; Department of Radiology, Yasrebi Hospital, Kashan, Iran; Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences,Tabriz, Iran.; Neurology Unit, Galliera Hospital, Genova, Italy; Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite de Paris, INSERM U1266, Paris, France; Neurology Department, Neuroscience Institute, Geisinger Health System, Pennsylvania, USA; Neurosurgery Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; Second Department of Neurology, Attikon University Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; epartment of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany; Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Neurology, Albany Medical Center, Albany, NY; Department of Neurology, Marry Washington Healthcare, Fredricksburg, Virginia, USA; Neurology Department, Vidant Medical Center; Department of Neurology, Allegheny Health Network (AHN),Pittsburgh, PA, USA; TIA Clinic, Department of Neurology, University Hospital Centre Zagreb, Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia.; Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Anesthesiology, University of Ottawa; Department of neurology, Ain Shams University, Cairo, Egypt; Infection Disease Research Center, Kermanshah University of Medical Sciences; Department of Neurology, National Medical Center, Seoul, South Korea; Department of Neurosurgery, Helsinki University Hospital, Finland; Department of Neurosurgery, Helsinki University Hospital, Finland; Department of Neurology, Albany Medical Center, Albany, NY; Neurology Department, University of Tennessee Health Science Center, Tennessee, USA; Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, South Korea.; Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Neurology, Hospital Arnau de Vilanova, Lleida, Spain; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences; Department of Internal Medicine, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal; Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Departament de Medicina, Universitat Autonoma de Barcelona; Stroke Unit, Department of Neurology, Hospital Vall d'Hebron, Departament de Medicina, Universitat Autonoma de Barcelona; Neuroscience Research Center, Golestan University of Medical Sciences, Iran; Department of Neurology, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; Division of Neurology, University Medicine Cluster, National University Health System, Singapore, Singapore; Department of Neurology, Klinikum Frankfurt Hochst, Frankfurt Germany; Department of Neurology, Albany Medical Center, Albany, NY; Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite de Paris, INSERM U1266, Paris, France; Hospital for Special Surgery, New York, USA; Divisions of Vascular and Endovascular Neurosurgery and Neurology, Firoozgar Hospital and Rasoul-Akram hospital, Iran University of Medical Sciences, Tehran, Ir; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran.; Neurosurgical Department, Ghaem Hospital, Mashhad University of Medical Sciences; Neurology Department, Centro Medico de Campinas, Brazil; PES university,Bengalore,India; Division of Vascular and Endovascular Neurosurgery, Firoozgar Hospital, Iran University of Medical Sciences; Neutology ward, Gheshm Hospital, Gheshm, Iran; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Department of Neurology, Pirooz hospital, Gilan University of Medical Sciences, Lahijan,Iran; Professor Of Neurology, Isfahan University Of Neurology, Isfahan, Iran; Program of Neurotrauma, Neuroproteomics and Biomarker Research (NNBR), University of Florida, Florida, USA; Neurology ward, Modarres Hospital, Kashmar, Iran; Neurology ward, Modarres Hospital, Kashmar, Iran; Steele Institute of Health & Innovation, Geisinger Health System, Pennsylvania, USA; UCLA stroke program, US; Student Research Committee, Shiraz University of Medical Sciences; Department of Neurology, Bou Ali hospital, Qazvin University of Medical Sciences, Qazvin,Iran; Department of Neurology, Arak University of Medical Sciences, Arak,Iran; Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Salahadin Ayubi Hospital, Parastar street, Baneh, Iran.; Neurology Department, Poursina Hospital, Iran; Department of Neurology, Imam Hosein Hospital, Shahid Beheshti Medical University, Tehran, Iran; Sina Hospital; Neurology Department, Centro Medico de Campinas, Brazil; Neurology Department, Tehran University of medical sciences, Iran; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Yasrebi Hospital, Kashan, Iran; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Northwell, USA; Department of Neurology, University of Tennessee, Tennessee, USA; Neurology Department, Neuroscience Institute, Geisinger Health System, Pennsylvania, USA; Geisinger health system, USA; Department of Molecular and Functional Genonic, Geisinger Health System, Pennsylvania, USA; Neurology Department, Neuroscience Institute, Geisinger Health System","Background Large-scale school closures have been implemented worldwide to curb the spread of COVID-19. However, the impact of school closures and re-opening on epidemic dynamics remains unclear. Methods We simulated COVID-19 transmission dynamics using an individual-based stochastic model, incorporating social-contact data of school-aged children during shelter-in-place orders derived from Bay Area (California) household surveys. We simulated transmission under observed conditions and counterfactual intervention scenarios between March 17-June 1, and evaluated various fall 2020 K-12 reopening strategies. Findings Between March 17-June 1, assuming children <10 were half as susceptible to infection as older children and adults, we estimated school closures averted a similar number of infections (13,842 cases; 95% CI: 6,290, 23,040) as workplace closures (15,813; 95% CI: 9,963, 22,617) and social distancing measures (7,030; 95% CI: 3,118, 11,676). School closure effects were driven by high school and middle school closures. Under assumptions of moderate community transmission, we estimate that fall 2020 school reopenings will increase symptomatic illness among high school teachers (an additional 40.7% expected to experience symptomatic infection, 95% CI: 1.9, 61.1), middle school teachers (37.2%, 95% CI: 4.6, 58.1), and elementary school teachers (4.1%, 95% CI: -1.7, 12.0). Results are highly dependent on uncertain parameters, notably the relative susceptibility and infectiousness of children, and extent of community transmission amid re-opening. The school-based interventions needed to reduce the risk to fewer than an additional 1% of teachers infected varies by grade level. A hybrid-learning approach with halved class sizes of 10 students may be needed in high schools, while maintaining small cohorts of 20 students may be needed for elementary schools. Interpretation Multiple in-school intervention strategies and community transmission reductions, beyond the extent achieved to date, will be necessary to avoid undue excess risk associated with school reopening. Policymakers must urgently enact policies that curb community transmission and implement within-school control measures to simultaneously address the tandem health crises posed by COVID-19 and adverse child health and development consequences of long-term school closures.",epidemiology,exact,100,100
medRxiv,10.1101/2020.08.05.20169078,2020-08-06,https://medrxiv.org/cgi/content/short/2020.08.05.20169078,Transient dynamics of SARS-CoV-2 as England exited national lockdown,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Peter Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Sara J Jenks; Paul Bieniasz; Bianca Judy Choe; Sukantha Chandrasekaran; Evann E. Hilt; Manish J. Butte; Robert Damoiseaux; Aaron R. Cooper; Yi Yin; Lior Pachter; Omai B. Garner; Jonathan Flint; Eleazar Eskin; Chongyuan Luo; Sriram Kosuri; Leonid Kruglyak; Valerie A. Arboleda,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Imperial College London; Imperial College London; Imperial College Healthcare NHS Trust; Imperial College London; Imperial College London; Imperial College Healthcare NHS Trust; Imperial College London School of Public Health; NHS Lothian; Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; Octant Inc.; University of California, Los Angeles; California Institute of Technology; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; Octant Inc.; University of California, Los Angeles; University of California, Los Angeles","Control of the COVID-19 pandemic requires a detailed understanding of prevalence of SARS-CoV-2 virus in the population. Case-based surveillance is necessarily biased towards symptomatic individuals and sensitive to varying patterns of reporting in space and time. The real-time assessment of community transmission antigen study (REACT-1) is designed to overcome these limitations by obtaining prevalence data based on a nose and throat swab RT-PCR test among a representative community-based sample in England, including asymptomatic individuals. Here, we describe results comparing rounds 1 and 2 carried out during May and mid June / early July 2020 respectively across 315 lower tier local authority areas. In round 1 we found 159 positive samples from 120,620 tested swabs while round 2 there were 123 positive samples from 159,199 tested swabs, indicating a downwards trend in prevalence from 0.13% (95% CI, 0.11%, 0.15%) to 0.077% (0.065%, 0.092%), a halving time of 38 (28, 58) days, and an R of 0.89 (0.86, 0.93). The proportion of swab-positive participants who were asymptomatic at the time of sampling increased from 69% (61%, 76%) in round 1 to 81% (73%, 87%) in round 2. Although health care and care home workers were infected far more frequently than other workers in round 1, the odds were markedly reduced in round 2. Age patterns of infection changed between rounds, with a reduction by a factor of five in prevalence in 18 to 24 year olds. Our data were suggestive of increased risk of infection in Black and Asian (mainly South Asian) ethnicities. Using regional and detailed case location data, we detected increased infection intensity in and near London. Under multiple sensitivity analyses, our results were robust to the possibility of false positives. At the end of the initial lockdown in England, we found continued decline in prevalence and a shift in the pattern of infection by age and occupation. Community-based sampling, including asymptomatic individuals, is necessary to fully understand the nature of ongoing transmission.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.08.03.20164897,2020-08-04,https://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households:a nationwide linkage cohort study,Anoop SV Shah; Rachael Wood; Ciara Gribben; David Caldwell; Jennifer Bishop; Amanda Weir; Sharon Kennedy; Martin Reid; Alison Smith-Palmer; David Goldberg; Jim McMenamin; Colin Fischbacher; Chris Robertson; Sharon Hutchinson; Paul M McKeigue; Helen M Colhoun; David McAllister; - the Yale IMPACT Research team; Charles S Dela Cruz; Shelli F Farhadian; Albert I Ko; Akiko Iwasaki; Nathan D Grubaugh; Craig B Wilen; Anne Louise Wyllie; Trevor-Trung Nguyen; Koen Raedschelders; Mohamad A. Rashid; Celine E. Riera; Richard V. Riggs; Sonia Sharma; Kimia Sobhani; Sarah Sternbach; Nancy Sun; Warren G. Tourtellotte; Jennifer E. Van Eyk; Jonathan G. Braun; Susan Cheng,"London School of Hygiene and Tropical Medicine; Public Health Scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Health protection scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; University of Edinburgh; University of Edinburgh; University of Glasgow; ; Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT, 06510, USA; Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, 06510, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA; Department of Medicine, Section of Infectious Diseases; Department of Immunobiology, Yale School of Medicine, New Haven, CT, 06510, USA; Howard Hughes Medical Institute, New Haven, CT 06510, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, 06510, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; La Jolla Institute for Allergy and Immunology; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Cedars-Sinai Medical Center","ObjectiveMany healthcare staff work in high-risk settings for contracting and transmitting Severe Acute Respiratory Syndrome Coronavirus 2. Their risk of hospitalisation for coronavirus disease 2019 (COVID-19), and that of their households, is poorly understood.

Design and settings and participantsDuring the peak period for COVID-19 infection in Scotland (1st March 2020 to 6th June 2020) we conducted a national record linkage study to compare the risk of COVID-19 hospitalisation among healthcare workers (age: 18-65 years), their households and other members of the general population.

Main outcomeHospitalisation with COVID-19

ResultsThe cohort comprised 158,445 healthcare workers, the majority being patient facing (90,733 / 158,445; 57.3%), and 229,905 household members. Of all COVID-19 hospitalisations in the working age population (18-65-year-old), 17.2% (360 / 2,097) were in healthcare workers or their households. Adjusting for age, sex, ethnicity, socio-economic deprivation and comorbidity, the risk of COVID-19 hospitalisation in non-patient facing healthcare workers and their households was similar to the risk in the general population (hazards ratio [HR] 0.81; 95%CI 0.52-1.26 and 0.86; 95%CI 0.49-1.51 respectively). In models adjusting for the same covariates however, patient facing healthcare workers, compared to non-patient facing healthcare workers, were at higher risk (HR 3.30; 95%CI 2.13-5.13); so too were household members of patient facing healthcare workers (HR 1.79; 95%CI 1.10-2.91). On sub-dividing patient-facing healthcare workers into those who worked in front-door, intensive care and non-intensive care aerosol generating settings and other, those in  front door roles were at higher risk (HR 2.09; 95%CI 1.49-2.94). For most patient facing healthcare workers and their households, the estimated absolute risk of COVID-19 hospitalisation was less than 0.5% but was 1% and above in older men with comorbidity.

ConclusionsHealthcare workers and their households contribute a sixth of hospitalised COVID-19 cases. Whilst the absolute risk of hospitalisation was low overall, patient facing healthcare workers and their households had 3- and 2-fold increased risks of COVID-19 hospitalisation.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.30.20165464,2020-08-02,https://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,Stephen R Knight; Antonia Ho; Riinu Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Rishi K Gupta; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter W Horby; Clare Jackson; Kenneth A McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Mahdad Noursadeghi; Piero L Olliaro; Mark G Pritchard; Clark D Russell; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Annemarie B Docherty; Ewen M Harrison,"Centre for Medical Informatics, The Usher Institute, University of Edinburgh; Medical Research Council University of Glasgow Centre for Virus Research, Glasgow, UK; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; Institute of Microbiology & Infection, University of Birmingham; University College London; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, United Kingdom; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, United Kingdom; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; Health Data Research UK, Gibbs Building, 215 Euston Road, London, NW1 2BE; Department of Child Life and Health, University of Edinburgh, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; National Heart and Lung Institute, Imperial College London, London, UK; Roslin Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK","ObjectivesTo develop and validate a pragmatic risk score to predict mortality for patients admitted to hospital with covid-19.

DesignProspective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited between 21 May and 29 June 2020.

Setting260 hospitals across England, Scotland, and Wales.

ParticipantsAdult patients ([&ge;]18 years) admitted to hospital with covid-19 admitted at least four weeks before final data extraction.

Main outcome measuresIn-hospital mortality.

ResultsThere were 34 692 patients included in the derivation dataset (mortality rate 31.7%) and 22 454 in the validation dataset (mortality 31.5%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C risk stratification score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79; 95% CI 0.78 - 0.79; validation cohort 0.78, 0.77-0.79) with excellent calibration (slope = 1.0). Patients with a score [&ge;]15 (n = 2310, 17.4%) had a 67% mortality (i.e., positive predictive value 67%) compared with 1.0% mortality for those with a score [&le;]3 (n = 918, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC range 0.60-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73).

ConclusionsWe have developed and validated an easy-to-use risk stratification score based on commonly available parameters at hospital presentation. This outperformed existing scores, demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients with covid-19 into different management groups. The 4C Mortality Score may help clinicians identify patients with covid-19 at high risk of dying during current and subsequent waves of the pandemic.

Study registrationISRCTN66726260",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.30.20165134,2020-08-01,https://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",John Dennis; Andrew McGovern; Sebastian Vollmer; Bilal A Mateen,University of Exeter; University of Exeter; University of Warwick; The Alan Turing Institute,"ObjectivesTo determine the trend in mortality risk over time in people with severe COVID-19 requiring critical care (high intensive unit [HDU] or intensive care unit [ICU]) management.

MethodsWe accessed national English data on all adult COVID-19 specific critical care admissions from the COVID-19 Hospitalisation in England Surveillance System (CHESS), up to the 29th June 2020 (n=14,958). The study period was 1st March until 30th May, meaning every patient had 30 days of potential follow-up available. The primary outcome was in-hospital 30-day all-cause mortality. Hazard ratios for mortality were estimated for those admitted each week using a Cox proportional hazards models, adjusting for age (non-linear restricted cubic spline), sex, ethnicity, comorbidities, and geographical region.

Results30-day mortality peaked for people admitted to critical care in early April (peak 29.1% for HDU, 41.5% for ICU). There was subsequently a sustained decrease in mortality risk until the end of the study period. As a linear trend from the first week of April, adjusted mortality risk decreased by 11.2% (adjusted HR 0.89 [95% CI 0.87 - 0.91]) per week in HDU, and 9.0% (adjusted HR 0.91 [95% CI 0.88 - 0.94]) in ICU.

ConclusionsThere has been a substantial mortality improvement in people admitted to critical care with COVID-19 in England, with markedly lower mortality in people admitted in mid-April and May compared to earlier in the pandemic. This trend remains after adjustment for patient demographics and comorbidities suggesting this improvement is not due to changing patient characteristics. Possible causes include the introduction of effective treatments as part of clinical trials and a falling critical care burden.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.07.29.20164269,2020-07-30,https://medrxiv.org/cgi/content/short/2020.07.29.20164269,The potential health and economic impact of dexamethasone treatment for patients with COVID-19,RICARDO AGUAS; Adam Mahdi; RIMA SHRETTA; Peter Horby; Martin Landray; Lisa J White; Sarah A Persaud; Rajat Kapoor; Deirdre Leavy; Katie Ridge; Catherine King; Fionnuala Cox; Kate O'Brien; Joanne Dowds; Jamie Sugrue; David Hopkins; Patricia Byrne; Tara Kingston; Cliona Ni Cheallaigh; Parthiban Nadarajan; Anne Marie McLaughlin; Nollaig M Bourke; Colm Bergin; Cliona O'Farrelly; Ciaran Bannan; Niall Conlon,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Indiana University School of Medicine; Indiana University School of Medicine; St James's Hospital; St James's Hospital; St James's Hospital; St James's Hospital; St James's Hospital; St James's Hospital; Trinity College Dublin; Trinity College Dublin; St James's Hospital; St James's Hospital; St James's Hospital; St James's Hospital; St James's Hospital; Trinity College Dublin; St James's Hospital; Trinity College Dublin; St James's Hospital; St James's Hospital,"Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of implementing this intervention. We estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by January 2021. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-income countries.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.26.20161570,2020-07-28,https://medrxiv.org/cgi/content/short/2020.07.26.20161570,"Magnitude, demographics and dynamics of the impact of the first phase of the Covid-19 pandemic on all-cause mortality in 17 industrialised countries",Vasilis Kontis; James E Bennett; Theo Rashid; Robbie M Parks; Jonathan Pearson-Stuttard; Michel Guillot; Perviz Asaria; Bin Zhou; Marco Battaglini; Gianni Corsetti; Martin McKee; Mariachiara Di Cesare; Colin D Mathers; Majid Ezzati,Imperial College London; Imperial College London; Imperial College London; Columbia University; Imperial College London; University of Pennsylvania; Imperial College London; Imperial College London; Italian National Institute of Statistics; Italian National Institute of Statistics; London School of Hygiene & Tropical Medicine; Middlesex University London; Independent Researcher; Imperial College London,"The Covid-19 pandemic affects mortality directly through infection as well as through changes in the social, environmental and healthcare determinants of health1. The impacts on mortality are likely to vary across countries in magnitude, timing, and age and sex composition. Here, we applied an ensemble of 16 Bayesian probabilistic models to vital statistics data, by age group and sex, to consistently and comparably estimate the impacts of the first phase of the pandemic on all-cause mortality for 17 industrialised countries. The models accounted for factors that affect death rates including seasonality, temperature, and public holidays, as well as for medium-long-term secular trends and the dependency of death rates in each week on those in preceding week(s). From mid-February through the end of May 2020, an estimated 202,900 (95% credible interval 179,400-224,900) more people died in these 17 countries than would have had the pandemic not taken place. Nearly three quarters of these excess deaths occurred in England and Wales, Italy and Spain, where less than half of the total population of these countries live. When all-cause mortality is considered, the total number of deaths, deaths per 100,000 people, and relative increase in deaths were similar between men and women in most countries. Further, in many countries, the balance of excess deaths changed from male-dominated early in the pandemic to being equal or female-dominated later on.

Taken over the entire first phase of the pandemic, there was no detectable rise in all-cause mortality in New Zealand, Bulgaria, Hungary, Norway, Denmark and Finland and for women in Austria and Switzerland (posterior probability of an increase in deaths <90%). Women in Portugal and men in Austria experienced relatively small increases in all-cause mortality, with posterior probabilities of 90-99%. For men in Switzerland and Portugal, and both sexes in the Netherlands, France, Sweden, Belgium, Italy, Scotland, Spain and England and Wales, all-cause mortality increased as a result of the pandemic with a posterior probability >99%. After accounting for population size, England and Wales and Spain experienced the highest death toll, nearly 100 deaths per 100,000 people; they also had the largest relative (percent) increase in deaths (37% (95% credible interval 30-44) in England and Wales; 38% (31-44) in Spain). New Zealand, Bulgaria, Hungary, Norway, Denmark and Finland experienced changes in deaths that ranged from possible slight declines to increases of no more than 5%. The large impact in England and Wales stems partly from having experienced (together with Spain) the highest weekly increases in deaths, more than doubling in some weeks, and having had (together with Sweden) the longest duration when deaths exceeded levels that would be expected in the absence of the pandemic.

The heterogeneous magnitude and character of the excess deaths due to the Covid-19 pandemic reflect differences in how well countries have managed the pandemic (e.g., timing, extent and adherence to lockdowns and other social distancing measures; effectiveness of test, trace and isolate mechanisms), and the resilience and preparedness of the health and social care system (e.g., effective facility and community care pathways; minimising spread of infection within hospitals and care homes, and between them and the community).",public and global health,exact,100,100
medRxiv,10.1101/2020.07.24.20149815,2020-07-26,https://medrxiv.org/cgi/content/short/2020.07.24.20149815,Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study,Rishi K Gupta; Michael Marks; Thomas H. A. Samuels; Akish Luintel; Tommy Rampling; Humayra Chowdhury; Matteo Quartagno; Arjun Nair; Marc Lipman; Ibrahim Abubakar; Maarten van Smeden; Wai Keong Wong; Bryan Williams; Mahdad Noursadeghi; Sean Gaine; Patrick Mallon; Brian McCullagh; Fionnuala N inle; Barry Kevane; Patricia B Maguire; Huan Zhang; Huanying Zheng; Min Wan; Linying Lu; Xiaohu Ren; Yujun Cui; Xuan Zou; Tiejian Feng; Junjie Xia; Ruifu Yang; Yingxia Liu; Shujiang Mei; Baisheng Li; Zhengrong Yang; Qinghua Hu,"Institute for Global Health, University College London, London, UK; London School of Hygiene and Tropical Medicine; University College London Hospitals NHS Trust; University College London Hospitals NHS Trust; University College London Hospitals NHS Trust; University College London Hospitals NHS Trust; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK; University College London Hospitals NHS Trust; UCL Respiratory, Division of Medicine, University College London, London, UK; Institute for Global Health, University College London, London, UK; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; University College London Hospitals NHS Trust; NIHR University College London Hospitals Biomedical Research Centre; Division of Infection & Immunity, University College London, UK; Mater Misericordiae University Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland; Guangdong Provincial Center for Disease Control and Prevention, Guangdong, China; Guangdong Provincial Center for Disease Control and Prevention, Guangdong, China; Shenzhen LongHua District Maternity and Child Healthcare Hospital, Shenzhen, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; State Key Discipline of Infectious Disease, National Clinical Research Center for infectious disease, Shenzhen Third People's Hospital, Second Hospital Affiliat; Shenzhen Center for Disease Control and Prevention; Guangdong Provincial Center for Disease Control and Prevention, Guangdong, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China; Shenzhen Center for Disease Control and Prevention, Shenzhen, China","BackgroundThe number of proposed prognostic models for COVID-19, which aim to predict disease outcomes, is growing rapidly. It is not known whether any are suitable for widespread clinical implementation. We addressed this question by independent and systematic evaluation of their performance among hospitalised COVID-19 cases.

MethodsWe conducted an observational cohort study to assess candidate prognostic models, identified through a living systematic review. We included consecutive adults admitted to a secondary care hospital with PCR-confirmed or clinically diagnosed community-acquired COVID-19 (1st February to 30th April 2020). We reconstructed candidate models as per their original descriptions and evaluated performance for their original intended outcomes (clinical deterioration or mortality) and time horizons. We assessed discrimination using the area under the receiver operating characteristic curve (AUROC), and calibration using calibration plots, slopes and calibration-in-the-large. We calculated net benefit compared to the default strategies of treating all and no patients, and against the most discriminating predictor in univariable analyses, based on a limited subset of a priori candidates.

ResultsWe tested 22 candidate prognostic models among a cohort of 411 participants, of whom 180 (43.8%) and 115 (28.0%) met the endpoints of clinical deterioration and mortality, respectively. The highest AUROCs were achieved by the NEWS2 score for prediction of deterioration over 24 hours (0.78; 95% CI 0.73-0.83), and a novel model for prediction of deterioration <14 days from admission (0.78; 0.74-0.82). Calibration appeared generally poor for models that used probability outcomes. In univariable analyses, admission oxygen saturation on room air was the strongest predictor of in-hospital deterioration (AUROC 0.76; 0.71-0.81), while age was the strongest predictor of in-hospital mortality (AUROC 0.76; 0.71-0.81). No prognostic model demonstrated consistently higher net benefit than using the most discriminating univariable predictors to stratify treatment, across a range of threshold probabilities.

ConclusionsOxygen saturation on room air and patient age are strong predictors of deterioration and mortality among hospitalised adults with COVID-19, respectively. None of the prognostic models evaluated offer incremental value for patient stratification to these univariable predictors.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.22.20159632,2020-07-24,https://medrxiv.org/cgi/content/short/2020.07.22.20159632,Excess mortality during the COVID-19 outbreak in Italy: a two-stage interrupted time series analysis,Matteo Scortichini; Rochelle Schneider dos Santos; Francesca De' Donato; Manuela De Sario; Paola Michelozzi; Marina Davoli; Pierre Masselot; Francesco Sera; Antonio Gasparrini,London School of Hygiene and Tropical Medicine; LSHTM; Lazio Regional Health Service; Lazio Regional Health Service; Lazio Regional Health Service; Lazio Regional Health Service; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundItaly was the first country outside China to experience the impact of the COVID-19 pandemic, which resulted in a significant health burden. This study presents an analysis of the excess mortality across the 107 Italian provinces, stratified by sex, age group, and period of the outbreak.

MethodsThe analysis was performed using a two-stage interrupted time series design using daily mortality data for the period January 2015 - May 2020. In the first stage, we performed province-level quasi-Poisson regression models, with smooth functions to define a baseline risk while accounting for trends and weather conditions and to flexibly estimate the variation in excess risk during the outbreak. Estimates were pooled in the second stage using a mixed-effects multivariate meta-analysis.

ResultsIn the period 15 February - 15 May 2020, we estimated an excess of 47,490 (95% empirical confidence intervals: 43,984 to 50,362) deaths in Italy, corresponding to an increase of 29.5% (95%eCI: 26.8 to 31.9%) from the expected mortality. The analysis indicates a strong geographical pattern, with the majority of excess deaths occurring in northern regions, where few provinces experienced up to 800% increase during the peak in late March. There were differences by sex, age, and area both in the overall impact and in its temporal distribution.

ConclusionsThis study offers a detailed picture of excess mortality during the first months of the COVID-19 pandemic in Italy. The strong geographical and temporal patterns can be related to implementation of lockdown policies and multiple direct and indirect pathways in mortality risk.

Key MessagesO_LIThis study evaluated mortality trends in Italy during the COVID-19 pandemic, reporting an excess of 47,490 (95% empirical confidence intervals: 43,984 to 50,362) deaths in the period 15 February - 15 May 2020, corresponding to an increase of 29.5% (95%eCI: 26.8 to 31.9%) from the expected mortality.
C_LIO_LIThere is a strong geographical pattern, with 71.0% of the estimated excess deaths occurring in just three northern regions (Lombardy, Veneto, and Emilia-Romagna), and few provinces showing increases in mortality up to 800% during the peak of the pandemic.
C_LIO_LIThe impact was slightly higher is men compared to women, with 24,655 and 23,125 excess deaths respectively, and varied by age, with higher mortality in the group 70-79 years old and evidence of a lower but measurable risk even in people less than 60.
C_LIO_LIThe analysis by week suggests differential trends, with more delayed impacts in women and elderly, and the risk limited to the early period in Central and Southern Italy, likely related to the implementation of lockdown policies and contributions from direct and indirect risk pathways.
C_LI",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.15.20152967,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.15.20152967,Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.,Gisli Jenkins; Tom Drake; Annemarie B Docherty; Ewan Harrison; Jennifer Quint; Huzaifa Adamali; Sarah Agnew; Suresh Babu; Christopher Barber; Shaney Barratt; Elisabeth Bendstrup; Stephen Bianchi; Diego Castillo; Nazia Chaudhuri; Felix Chua; Robina Coker; William Chang; Anjali Cranshaw; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"University of Nottingham; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, EH16 4UX; University of Edinburgh; University of Edinburgh; Imperial College London; Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB.; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Queen Alexandra Hospital, Portsmouth, UK.; Northern General Hospital, Sheffield, S5 7AU, UK; Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Southmead Hospital, Bristol, UK, BS10 5NB.; Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99,8200 Aarhus N, Denmar; Northern General Hospital, Sheffield, S5 7AU, UK.; ILD Unit, Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Royal Brompton Hospital; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Nottingham University Hospital; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","RationaleThe impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established.

ObjectivesTo assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched population.

MethodsAn international multicentre audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death.

Measurements and Main ResultsData from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and comorbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC [&ge;]80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 1.98, 1.13-3.46).

ConclusionsPatients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.",respiratory medicine,exact,100,100
medRxiv,10.1101/2020.07.14.20153528,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.14.20153528,Calming the Cytokine Storm - Splenic Ultrasound for Treating Inflammatory Disorders and Potentially COVID-19,Rachel Stegeman Graham; Daniel P Zachs; Victoria Cotero; Catherine DAgostino; Despoina Ntiloudi; Claire RW Kaiser; John Graf; Kirk Wallace; Thomas R Coleman; Jeffrey Ashe; John Pellerito; Kevin J Tracey; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"University of Minnesota; University of Minnesota; General Electric Research; North Shore University Hospital; Feinstein Institutes for Medical Research; University of Minnesota; General Electric Research; General Electric Research; Feinstein Institutes for Medical Research,; General Electric Research; North Shore University Hospital; Feinstein Institutes for Medical Research; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","Hyperinflammation and uncontrolled cytokine release, which can be seen in severe cases of COVID-19, require therapy to reduce the innate immune response without hindering necessary adaptive immune mechanisms. Here, we show results from the first in-human trials using non-invasive ultrasound stimulation of the spleen to reduce cytokine release in the context of both an acute response in healthy subjects and a chronic inflammatory condition in rheumatoid arthritis patients. Splenic ultrasound results in a reduction in TNF serum levels, as well as IL-1{beta} and IL-8 transcript levels in monocytes. There is also a down regulation of pathways involved in TNF and IL-6 production, and IFN{gamma}- and NF{kappa}B-regulated genes. Many of these cytokines or pathways are upregulated in COVID-19 patients. There is also a reduction in chemokine transcript levels and other components of the chemotactic response, suggesting that reduction of cellular migration may contribute to the therapeutic effects of ultrasound. There is no inhibition of the adaptive immune response with ultrasound treatment relating to antibody production. This is consistent with a pre-clinical animal model where enhanced antibody production was achieved with splenic ultrasound. Therefore, this new splenic ultrasound approach has the potential to treat acute and chronic hyper-inflammatory diseases, as it lowers cytokine levels without disrupting the normal adaptive immune response. Portable ultrasound technologies are currently being developed and translated to the clinic to treat various inflammatory disorders, with more recent efforts directed towards combatting the hyperinflammation or  cytokine storm in COVID-19 patients.",rheumatology,exact,100,100
medRxiv,10.1101/2020.07.15.20126730,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.15.20126730,Acute Demyelinating Encephalomyelitis (ADEM) in COVID-19 infection: A Case Series.,Michaela McCuddy; Praful Kelkar; Yu Zhao; David Wicklund; Despoina Ntiloudi; Claire RW Kaiser; John Graf; Kirk Wallace; Thomas R Coleman; Jeffrey Ashe; John Pellerito; Kevin J Tracey; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"Department of Family Medicine, University of Minnesota; Minneapolis Clinic of Neurology; Minneapolis Clinic of Neurology; Minneapolis Radiology; Feinstein Institutes for Medical Research; University of Minnesota; General Electric Research; General Electric Research; Feinstein Institutes for Medical Research,; General Electric Research; North Shore University Hospital; Feinstein Institutes for Medical Research; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","ObjectiveTo report three patients infected with COVID-19 with severe respiratory syndrome requiring intubation, who developed acute demyelinating encephalomyelitis (ADEM).

MethodPatient data were obtained from medical records from the North Memorial Health Hospital, Robbinsdale, MN, USA

ResultsThree patients (two men and one woman, aged 38 - 63) presented with fatigue, cough and fever leading to development of acute respiratory distress syndrome secondary to COVID-19 infection requiring intubation and ventilatory support. Two patients were unresponsive, one with strong eye deviation to the left and the third patient had severe diffuse weakness. MRI in all patients showed findings consistent with ADEM. CSF showed elevated protein in all patients with normal cell count and no evidence of infection, including negative COVID-19 PCR. All three of the patients received Convalescent plasma therapy for COVID-19. All patients were treated with intravenous corticosteroids and improved, although two responded minimally. Two patients treated with IVIG showed no further improvement.

ConclusionNeurological complications from COVID-19 are being rapidly recognized. Our three cases highlight the occurrence of ADEM as a postinfectious/immune mediated complication of COVID-19 infection, which may be responsive to corticosteroid treatment. Early recognition of this complication and treatment is important to avoid long term complications.",neurology,exact,100,100
medRxiv,10.1101/2020.07.14.20153429,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.14.20153429,"COVID-19 Pandemic among Latinx Farmworker and Non-farmworker Families in North Carolina: Knowledge, Risk Perceptions, and Preventive Behaviors",Sara A. Quandt; Natalie J. LaMonto; Dana C. Mora; Jennifer W. Talton; Paul J. Laurienti; Thomas A. Arcury; John Graf; Kirk Wallace; Thomas R Coleman; Jeffrey Ashe; John Pellerito; Kevin J Tracey; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"Wake Forest School of MEdicine; Lawrence University; Wake Forest School of Medicine; Wake Forest School of Medicine; Wake Forest School of Medicine; Wake Forest School of Medicine; General Electric Research; General Electric Research; Feinstein Institutes for Medical Research,; General Electric Research; North Shore University Hospital; Feinstein Institutes for Medical Research; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","(1) BackgroundThe COVID-19 pandemic poses substantial threats to Latinx farmworkers and other immigrants in food production and processing. Classified as essential, such workers cannot shelter at home. Therefore, knowledge and preventive behaviors are important to reduce COVID-19 spread in the community.

(2) MethodsRespondents for 67 families with at least one farmworker (FWF) and 38 comparable families with no farmworkers (non-FWF) in North Carolina completed a telephone survey in May, 2020. The survey queried knowledge of COVID-19, perceptions of its severity, self-efficacy, and preventive behaviors. Detailed data were collected to document household members social interaction and use of face coverings.

(3) ResultsKnowledge of COVID-19 and prevention methods was high in both groups, as was its perceived severity. Non-FWF had higher self-efficacy for preventing infection. Both groups claimed to practice preventive behaviors, though FWF emphasized social avoidance and non-FWF emphasized personal hygiene. Detailed social interactions showed high rates of inter-personal contact at home, at work, and in the community with more mask use in non-FWF than FWF.

(4) ConclusionsDespite high levels of knowledge and perceived severity for COVID-19, these immigrant families were engaged in frequent interpersonal contact that could expose community members and themselves to COVID-19.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2020.07.15.20149559,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.15.20149559,Risk Adjusted Non-Pharmaceutical Interventions for the Management of COVID-19 in South Africa,Finn D Stevenson; Bruce Mellado; Joshua Choma; Benjamin Lieberman; Fbio Corra; Salah-Eddine Dahbi; Kentaro Hayashi; Kgomotso Monnakgotla; Jacques Naude; Xifeng Ruan; Caroline Maslo; Kevin J Tracey; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"University of Witwaterstrand; University of Witwaterstrand; University of Witwaterstrand; University of Witwaterstrand; Rhodes University; University of the Witwatersrand; University of Witwaterstrand; University of Witwaterstrand; University of the Witwatersrand; University of Witwaterstrand; Netcare Hospital Division; Feinstein Institutes for Medical Research; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","A global analysis of the impact of non-pharmaceutical interventions (NPIs) on the dynamics of the spread of the COVID-19 indicates that these can be classified using the stringency index proposed by the Oxford COVID-19 Government Response Tracker (OxCGRT) team. The world average for the coefficient that linearises the level of transmission with respect to the OxCGRT stringency index is s = 0.01{+/-}0.0017 (95% C.I.). The corresponding South African coefficient is s = 0.0078 {+/-} 0.00036 (95% C.I.), compatible with the world average. Here, we implement the stringency index for the recently announced 5-tier regulatory alert system. Predictions are made for the spread of the virus for each alert level. Assuming constant rates of recovery and mortality, it is essential to increase s. For the system to remain sub-critical, the rate with which s increases should outpace that of the decrease of the stringency index. Monitoring of s becomes essential to controlling the post-lockdown phase. Data from the Gauteng province obtained in May 2020 has been used to re-calibrate the model, where s was found increase by 20% with respect to the period before lockdown. Predictions for the province are made in this light.",health policy,exact,100,100
medRxiv,10.1101/2020.07.16.20155143,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.16.20155143,"Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seropraevalence and transmission rates",Jakob Peter Armann; Manja Unrath; Carolin Kirsten; Christian Lueck; Alexander Dalpke; Reinhard Berner; Kentaro Hayashi; Kgomotso Monnakgotla; Jacques Naude; Xifeng Ruan; Caroline Maslo; Kevin J Tracey; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"Department of Paediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universitaet Dresden; Department of Paediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universitaet Dresden; Department of Paediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universitaet Dresden; Institute for Virology, Institute for Medical Microbiology and Hygiene, Medical Faculty Carl Gustav Carus, Technische Universitaet Dresden; Institute for Virology, Institute for Medical Microbiology and Hygiene, Medical Faculty Carl Gustav Carus, Technische Universitaet Dresden; Department of Paediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universitaet Dresden; University of Witwaterstrand; University of Witwaterstrand; University of the Witwatersrand; University of Witwaterstrand; Netcare Hospital Division; Feinstein Institutes for Medical Research; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","BackgroundSchool closures are part of the SARS-CoV-2 pandemic control measures in many countries, based on the assumption that children play a similar role in transmitting SARS-CoV-2 as they do in transmitting influenza. We therefore performed a SARS-CoV-2 seropraevalence-study in students and teachers to assess their role in the SARS-CoV-2 transmission.

MethodsStudents grade 8-11 and their teachers in 13 secondary schools in eastern Saxony, Germany, were invited to participate in the SchoolCoviDD19 study. Blood samples were collected between May 25th and June 30th, 2020. Anti-SARS-CoV-2 IgG were assed using chemiluminescence immunoassay technology and all samples with a positive or equivocal test result were re-tested with two additional serological tests.

Findings1538 students and 507 teachers participated in this study. The seropraevalence for SARS-CoV-2 was 0.6%. Even in schools with reported Covid-19 cases before the Lockdown of March 13th no clusters could be identified. 23/24 participants with a household history of COVID-91 were seronegative. By using a combination of three different immunoassays we could exclude 16 participants with a positive or equivocal results after initial testing.

InterpretationStudents and teachers do not play a crucial role in driving the SARS-CoV-2 pandemic in a low prevalence setting. Transmission in families occurs very infrequently, and the number of unreported cases is low in this age group, making school closures not appear appropriate as a strategy in this low prevalence settings.

FundingThis study was supported by a grant from the state of Saxony",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.15.20149617,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.15.20149617,Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: comparison of nine tests in relation with clinical data,Paul Naaber; Kaidi Hunt; Jaana Pesukova; Liis Haljasmagi; Pauliina Rumm; Part Peterson; Jelena Hololejenko; Irina Eero; Piia Jogi; Karolin Toompere; Epp Sepp; Kevin J Tracey; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"SYNLAB Eesti; SYNLAB Eesti; Kuressaare Hospital; University of Tartu; University of Tartu; University of Tartu; SYNLAB Eesti; SYNLAB Eesti; University of Tartu; University of Tartu; University of Tartu; Feinstein Institutes for Medical Research; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","BackgroundHigh number of SARS-CoV-2 antibody tests are available in different formats, detect different types of antibodies, and use different target proteins. Sensitivity of these tests varies and could be also related to clinical symptoms and testing time.

MethodsSerum samples from 97 COVID-19 patients and 100 controls were tested with 9 antibody tests (SNIBE, Epitope, Euroimmun, Roche, Abbott, DiaSorin, Biosensor, LIPS N, and LIPS S-RBD). The results were analyzed in context of clinical data.

FindingsPositivity rate was of tests was following: N-LIPS test (91.8% cases), Epitope (85.6%), Abbott and in-house LIPS S-RBD (both 84.5%), Roche (83.5%), Euroimmun (82.5%), DiaSorin (81.4%), SNIBE (70.1%), and Biosensor (64.9%). Agreement between tests varied (71-95%). Correlation between patient symptoms score and antibody value was test-dependent: varied from strongest in LIPS N ({rho}=0.41; p<0.001) to nonsignificant (LIPS S-RBD). Testing time from symptoms influenced sensitivity in some tests more than anothers.

InterpretationSensitivity of tests varied highly and combination of different tests may improve it. Relation of results to symptoms and testing time was test-dependent. Thus, some antibody tests seems to be more sensitive to detect antibodies early and in asymptomatic patients than others.

FundingStudy was funded by SYNLAB Estonia and Estonian Research Council grant PRG377.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSHigh variation in COVID-19 antibody tests sensitivity has been described. Relation between antibody response and clinical cause has been found in some studies but not in others. Its known that antibody response is time dependent, however seroconversion medians varied in different studies.

Added value of this studyWe confirmed that SARS-CoV-2 antibody response depends on clinical symptoms and time of testing, but we also found that this relation is dependent on test setup and viral antigens used in the tests. This may explain contradictory results of previous studies.

Implications of all the available evidenceOur study has practical implications showing that not all antibody tests work uniformly well in symptomatic and asymptomatic cases and in different time periods from disease onset. This should be taken into consideration in clinical practice for diagnosing COVID-19 and in epidemiological studies evaluating the seroprevalence especially in asymptomatic population.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.14.20153494,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.14.20153494,Creating a safe workplace by universal testing of SARS-CoV-2 infection in patients and healthcare workers in the electrophysiology unit having no symptoms of COVID-19: a multi-center experience,Sanghamitra Mohanty; Dhanunjaya Lakkireddy; Chintan Trivedi; Bryan MacDonald; Angel Mayedo; Domenico G Della Rocca; Rakesh Gopinathannair; Gerald J Gallinghouse; Luigi Di Biase; Rodney Horton; Robert Canby; Andrea Natale; Bryce Binstadt; Sangeeta S Chavan; Stavros Zanos; Christopher Puleo; Erik Peterson; Hubert H Lim; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"Texas Cardiac Arrhythmia Institute; Kansas City Heart Rhythm Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute; Kansas City Heart Rhythm Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute; Texas Cardiac Arrhythmia Institute, St.; University of Minnesota; North Shore University Hospital; North Shore University Hospital; General Electric Research; University of Minnesota; University of Minnesota; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","BackgroundAs the coronavirus cases continue to surge, the urgent need for universal testing to identify positive cases for effective containment of this highly contagious pandemic has become the center of attention worldwide. However, in spite of extensive discussions, very few places have even attempted to implement it. We evaluated the efficacy of widespread testing in creating a safe workplace in our healthcare community including staff and patients.

Furthermore, we assessed the rate of new infections in patients undergoing electrophysiology (EP) procedure, to see if identification and exclusion of positive cases facilitated establishment of a risk-free operating environment.

MethodsUniversal testing was conducted in subjects with no symptoms of COVID-19 including patients and their caregivers and staff in our electrophysiology units along with the Emergency Medical Service (EMS) staff (n=1670)

ResultsOf 1670, 758 (45.4%) were EP patients, and the remaining 912 were caregivers, EMS staff and hospital staff from EP clinic and lab. Viral-RNA test revealed 64 (3.8%) positives in the population. A significant increase in the rate of positives was observed from April to June, 2020 (p=0.02). Procedures of positive cases (n=31) were postponed until they tested negative at retesting on day 14. Staff testing positive (n=33) were retested before going back to work after 2 weeks. Because of suspected exposure, 67 staff were retested and source was traced. No new infections were reported in patients during the hospital stay or within 2-weeks after the procedure.

ConclusionUniversal testing to identify positive cases was helpful in creating and maintaining a safe working environment without exposing patients and staff to new infections in the EP unit at the hospital.

Trial Registration Numberclinicaltrials.gov: NCT04352764",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.14.20153734,2020-07-16,https://medrxiv.org/cgi/content/short/2020.07.14.20153734,"Place and causes of acute cardiovascular mortality during the COVID19 pandemic: retrospective cohort study of 580,972 deaths in England and Wales, 2014 to 2020",Jianhua Wu; Mamas Mamas; Mohamed Mohamed; Chun Shing Kwok; Chris Roebuck; Ben Humberstone; Tom Denwood; Tom Luescher; Mark De Belder; John Deanfield; Chris Gale; Michelle LL McNab; Martyna Adamowicz; Elias T Friman; Toby Hurd; Edward J Jarman; Frederic Li Mow Chee; Jacqueline K Rainger; Marion Walker; Camilla Drake; Dasa Longman; Christine Mordstein; Sophie J Warlow; Stewart McKay; Louise Slater; Morad Ansari; Ian PM Tomlinson; David Moore; Nadine Wilkinson; Jill Shepherd; Kate Templeton; Ingolfur Johannessen; Christine Tait-Burkard; Jrgen G Haas; Nick Gilbert; Ian R Adams; Andrew P Jackson,"University of Leeds; Keele University; Keele University; Keele University; NHS Digital; ONS; NHS Digital; Imperial College; Barts Health NHS Trust; UCL; University of Leeds; Division of Infection Medicine, Edinburgh Medical School, The University of Edinburgh; Centre for Genomic & Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; Centre for Genomic & Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; NHS Lothian, The South East of Scotland Clinical Genetic Service; NHS Lothian, The South East of Scotland Clinical Genetic Service; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; NHS Lothian, The South East of Scotland Clinical Genetic Service; NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh; NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh; NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh; NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh; The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh; Division of Infection Medicine, Edinburgh Medical School, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh","ImportanceThe COVID-19 pandemic has resulted in a decline in admissions with cardiovascular (CV) emergencies. The fatal consequences of this are unknown.

ObjectivesTo describe the place and causes of acute CV death during the COVID-19 pandemic.

DesignRetrospective nationwide cohort.

SettingEngland and Wales.

ParticipantsAll adult (age [&ge;]18 years) acute CV deaths (n=580,972) between 1st January 2014 and 2nd June 2020.

ExposureThe COVID-19 pandemic (defined as from the onset of the first COVID-19 death in England on 2nd March 2020).

Main outcomesPlace (hospital, care home, home) and acute CV events directly contributing to death as stated on the first part of the Medical Certificate of Cause of Death.

ResultsAfter 2nd March 2020, there were 22,820 acute CV deaths of which 5.7% related to COVID-19, and an excess acute CV mortality of 1752 (+8%) compared with the expected daily deaths in the same period. Deaths in the community accounted for nearly half of all deaths during this period. Care homes had the greatest increase in excess acute CV deaths (1065, +40%), followed by deaths at home (1728, +34%) and in hospital (57, +0%). The most frequent cause of acute CV death during this period was stroke (8,290, 36.3%), followed by acute coronary syndrome (ACS) (5,532, 24.2%), heart failure (5,280, 23.1%), pulmonary embolism (2,067, 9.1%) and cardiac arrest (1,037, 4.5%). Deep vein thrombosis had the greatest increase in cause of excess acute CV death (18, +25%), followed pulmonary embolism (340, +19%) and stroke (782, +10%). The greatest cause of excess CV death in care homes was stroke (700, +48%), compared with cardiac arrest (80, +56%) at home, and pulmonary embolism (126, +14%) and cardiogenic shock (41, +14%) in hospital.

Conclusions and relevanceThe COVID-19 pandemic has resulted in an inflation in acute CV deaths above that expected for the time of year, nearly half of which occurred in the community. The most common cause of acute CV death was stroke followed by acute coronary syndrome and heart failure. This is key information to optimise messaging to the public and enable health resource planning.",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.07.14.20152629,2020-07-15,https://medrxiv.org/cgi/content/short/2020.07.14.20152629,Covid-19 infection and attributable mortality in UK Long Term Care Facilities: Cohort study using active surveillance and electronic records (March-June 2020),Peter F Dutey-Magni; Haydn Williams; Arnoupe Jhass; Greta Rait; Harry Hemingway; Andrew C Hayward; Laura Shallcross; Feng Xie; Xin Sun; Weimin Li; Roberto De Vogli; Richard Wilkinson,"University College London; Four Seasons Healthcare Group; UCL; University College London; University College London; University College London; UCL; Center for Health Economics and Policy Analysis, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada; Chinese Evidence-based Medicine Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China; Department of Social Psychology and Development, University of Padova; Division of Epidemiology and Public Health, University of Nottingham UK","BackgroundRates of Covid-19 infection have declined in many countries, but outbreaks persist in residents of long-term care facilities (LTCFs) who are at high risk of severe outcomes. Epidemiological data from LTCFs are scarce. We used population-level active surveillance to estimate incidence of, and risk factors for Covid-19, and attributable mortality in elderly residents of LTCFs.

MethodsCohort study using individual-level electronic health records from 8,713 residents and daily counts of infection for 9,339 residents and 11,604 staff across 179 UK LTCFs. We modelled risk factors for infection and mortality using Cox proportional hazards and estimated attributable fractions.

Findings2,075/9,339 residents developed Covid-19 symptoms (22{middle dot}2% [95% confidence interval: 21{middle dot}4%; 23{middle dot}1%]), while 951 residents (10{middle dot}2% [9{middle dot}6%; 10{middle dot}8%]) and 585 staff (5{middle dot}0% [4{middle dot}7%; 5{middle dot}5%]) had laboratory confirmed infections. Confirmed infection incidence in residents and staff respectively was 152{middle dot}6 [143{middle dot}1; 162{middle dot}6] and 62{middle dot}3 [57{middle dot}3; 67{middle dot}5] per 100,000 person-days. 121/179 (67{middle dot}6%) LTCFs had at least one Covid-19 infection or death. Lower staffing ratios and higher occupancy rates were independent risk factors for infection.

1,694 all-cause deaths occurred in 8,713 (19{middle dot}4% [18{middle dot}6%; 20{middle dot}3%]) residents. 217 deaths occurred in 607 residents with confirmed infection (case-fatality rate: 35{middle dot}7% [31{middle dot}9%; 39{middle dot}7%]). 567/1694 (33{middle dot}5%) of all-cause deaths were attributable to Covid-19, 28{middle dot}0% of which occurred in residents with laboratory-confirmed infection. The remainder of excess deaths occurred in asymptomatic or symptomatic residents in the context of limited testing for infection, suggesting substantial under-ascertainment.

Interpretation1 in 5 residents had symptoms of infection during the pandemic, but many cases were not tested. Higher occupancy and lower staffing levels increase infection risk. Disease control measures should integrate active surveillance and testing with fundamental changes in staffing and care home occupancy to protect staff and residents from infection.

FundingEconomic and Social Research Council [ES/V003887/1].",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.13.20152710,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.13.20152710,Excess mortality in mental health service users during the COVID-19 pandemic described by ethnic group: South London and Maudsley data,Robert Stewart; Matthew Broadbent; Jayati Das-Munshi; Boerge Schmidt; Andreas Stang,"King's College London; South London and Maudsley NHS Foundation Trust; King's College London; University of Duisburg-Essen, medical faculty; University Hospital of Essen, medical faculty","The COVID-19 pandemic in the UK was accompanied by excess all-cause mortality at a national level, only part of which was accounted for by known infections. Excess mortality has previously been described in people who had received care from the South London and Maudsley NHS Foundation Trust (SLaM), a large mental health service provider for 1.2m residents in south London. SLaMs Clinical Record Interactive Search (CRIS) data resource receives 24-hourly updates from its full electronic health record, including regularly sourced national mortality on all past and present SLaM service users. SLaMs urban catchment has high levels of deprivation and is ethnically diverse, so the objective of the descriptive analyses reported in this manuscript was to compare mortality in SLaM service users from 16th March to 15th May 2020 to that for the same period in 2019 within specific ethnic groups: i) White British, ii) Other White, iii) Black African/Caribbean, iv) South Asian, v) Other, and vi) missing/not stated. For Black African/Caribbean patients (the largest minority ethnic group) this ratio was 3.33, compared to 2.47 for White British patients. Considering premature mortality (restricting to deaths below age 70), these ratios were 2.74 and 1.96 respectively. Ratios were also high for those from Other ethnic groups (2.63 for all mortality, 3.07 for premature mortality).",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.07.12.20151753,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.12.20151753,"COVID-19 incidence and R decreased on the Isle of Wight after the launch of the Test, Trace, Isolate programme",Michelle Kendall; Luke Milsom; Lucie Abeler-Dorner; Chris Wymant; Luca Ferretti; Mark Briers; Chris Holmes; David Bonsall; Johannes Abeler; Christophe Fraser; Kan Li; Patti A Calderone; Eva Noble; Hongjiang Gao; Jeanette Rainey; Amra Uzicanin; Jonathan M. Read; Luke Ollivere; Benjamin Ollivere; Huadong Yan; Ting Cai; Guruprasad Aithal; Claire Steves; Anu Kantele; Mikael Kajova; Olli Vapalahti; Antti Sajantila; Rafal Wojtowicz; Waldemar Wierzba; Zbigniew Krol; Artur Zaczynski; Katarzyna Zycinska; Marek Postula; Ivica Luksic; Rok Civljak; Alemka Markotic; Christian Mahnkopf; Andreas Markl; Johannes Brachmann; Benjamin Murray; Sebastien Ourselin; Julio Pascual; Ana M Valdes; Margarita Posso; Juan Horcajada; Xavier Castells; Massimo Allegri; Dragan Primorac; Timothy Spector; Clara Barrios; Gordan Lauc,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Alan Turing Institute; University of Oxford; Alan Turing Institute; University of Oxford; University of Oxford; University of Oxford; University of Pittsburgh; University of Pittsburgh; Johns Hopkins Bloomberg School of Public Health; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; Lancaster University; Nottingham University Trust; University of Nottingham, School of Medicine; Department of Infectious Diseases, Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital, University of Chi; Hwa Mei Hospital, University of Chinese Academy of Sciences; School of Medicine, University of Nottingham; King's College London; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; University of Helsinki; Department of Forensic Medicine, University of Helsinki, Finland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Clinical Hospital Dubrava, Zagreb; Hospital for Infectious Diseases, Zagreb, Croatia; Hospital for Infectious Diseases; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED Kliniken; School of Biomedical Engineering & Imaging Sciences, King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London; Department of Nephrology, Hospital del Mar, Barcelona, Spain; University of Nottingham, School of Medicine, Nottingham NIHR BRC; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Department of Infectious Diseases, Hospital del Mar. Barcelona, Spain; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Pain Therapy Service Policlinico of Monza Hospital - Monza Italy & Italian Pain Group - Milan - Italy; St. Catherine Hospital; King's College London; Hospital del Mar. Barcelona, Spain; University of Zagreb","In May 2020 the UK introduced a Test, Trace, Isolate programme in response to the COVID-19 pandemic. The programme was first rolled out on the Isle of Wight and included Version 1 of the NHS contact tracing app. We used COVID-19 daily case data to infer incidence of new infections and estimate the reproduction number R for each of 150 Upper Tier Local Authorities in England, and at the National level, before and after the launch of the programme on the Isle of Wight. We used Bayesian and Maximum-Likelihood methods to estimate R, and compared the Isle of Wight to other areas using a synthetic control method. We observed significant decreases in incidence and R on the Isle of Wight immediately after the launch. These results are robust across each of our approaches. Our results show that the sub-epidemic on the Isle of Wight was controlled significantly more effectively than the sub-epidemics of most other Upper Tier Local Authorities, changing from having the third highest reproduction number R (of 150) before the intervention to the tenth lowest afterwards. The data is not yet available to establish a causal link. However, the findings highlight the need for further research to determine the causes of this reduction, as these might translate into local and national non-pharmaceutical intervention strategies in the period before a treatment or vaccination becomes available.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.11.20151597,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.11.20151597,"Effectiveness of COCOA, a COVID-19 contact notification application, in Japan",Junko Kurita; Tamie Sugawara; Yasushi Ohkusa; Chris Wymant; Luca Ferretti; Mark Briers; Chris Holmes; David Bonsall; Johannes Abeler; Christophe Fraser; Kan Li; Patti A Calderone; Eva Noble; Hongjiang Gao; Jeanette Rainey; Amra Uzicanin; Jonathan M. Read; Luke Ollivere; Benjamin Ollivere; Huadong Yan; Ting Cai; Guruprasad Aithal; Claire Steves; Anu Kantele; Mikael Kajova; Olli Vapalahti; Antti Sajantila; Rafal Wojtowicz; Waldemar Wierzba; Zbigniew Krol; Artur Zaczynski; Katarzyna Zycinska; Marek Postula; Ivica Luksic; Rok Civljak; Alemka Markotic; Christian Mahnkopf; Andreas Markl; Johannes Brachmann; Benjamin Murray; Sebastien Ourselin; Julio Pascual; Ana M Valdes; Margarita Posso; Juan Horcajada; Xavier Castells; Massimo Allegri; Dragan Primorac; Timothy Spector; Clara Barrios; Gordan Lauc,"Tokiwa University, Ibaraki, Japan; National Institute of Infectious Diseases, Tokyo, Japan; National Institute of Infectious Diseases, Tokyo, Japan; University of Oxford; University of Oxford; Alan Turing Institute; University of Oxford; Alan Turing Institute; University of Oxford; University of Oxford; University of Oxford; University of Pittsburgh; University of Pittsburgh; Johns Hopkins Bloomberg School of Public Health; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; Lancaster University; Nottingham University Trust; University of Nottingham, School of Medicine; Department of Infectious Diseases, Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital, University of Chi; Hwa Mei Hospital, University of Chinese Academy of Sciences; School of Medicine, University of Nottingham; King's College London; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; University of Helsinki; Department of Forensic Medicine, University of Helsinki, Finland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Clinical Hospital Dubrava, Zagreb; Hospital for Infectious Diseases, Zagreb, Croatia; Hospital for Infectious Diseases; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED Kliniken; School of Biomedical Engineering & Imaging Sciences, King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London; Department of Nephrology, Hospital del Mar, Barcelona, Spain; University of Nottingham, School of Medicine, Nottingham NIHR BRC; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Department of Infectious Diseases, Hospital del Mar. Barcelona, Spain; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Pain Therapy Service Policlinico of Monza Hospital - Monza Italy & Italian Pain Group - Milan - Italy; St. Catherine Hospital; King's College London; Hospital del Mar. Barcelona, Spain; University of Zagreb","BackgroundCOCOA, a contact reporting application in Japan, was launched at the end of June 2020.

ObjectWe assessed effectiveness of COCOA.

MethodAfter developing a simple susceptible-infected-recovery model with COCOA and voluntary restrictions against going out (VRG), we assumed that COCOA can reduce infectiousness by 10-50% points through self-quarantine at home after receiving notification from COCOA.

ResultsCOCOA alone is insufficient to halt an outbreak. Even if the entire population were to use COCOA, the reproduction number would be 1.31. However, if VRG were 15%, about half of the maximum VRG effectiveness under the emergency state declaration, then 10% COCOA use by a population can reduce the reproduction number to less than one.

ConclusionSignificant effects of COCOA for reducing the reproduction number were found. However, without VRG, COCOA alone is insufficient to control an outbreak.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.11.20151563,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.11.20151563,Identification of Vulnerable Populations and Areas at Higher Risk of COVID-19 Related Mortality in the U.S.,Esteban Correa-Agudelo; Tesfaye Mersha; Andres Hernandez; Adam J Branscum; Neil J MacKinnon; Diego F Cuadros; Chris Holmes; David Bonsall; Johannes Abeler; Christophe Fraser; Kan Li; Patti A Calderone; Eva Noble; Hongjiang Gao; Jeanette Rainey; Amra Uzicanin; Jonathan M. Read; Luke Ollivere; Benjamin Ollivere; Huadong Yan; Ting Cai; Guruprasad Aithal; Claire Steves; Anu Kantele; Mikael Kajova; Olli Vapalahti; Antti Sajantila; Rafal Wojtowicz; Waldemar Wierzba; Zbigniew Krol; Artur Zaczynski; Katarzyna Zycinska; Marek Postula; Ivica Luksic; Rok Civljak; Alemka Markotic; Christian Mahnkopf; Andreas Markl; Johannes Brachmann; Benjamin Murray; Sebastien Ourselin; Julio Pascual; Ana M Valdes; Margarita Posso; Juan Horcajada; Xavier Castells; Massimo Allegri; Dragan Primorac; Timothy Spector; Clara Barrios; Gordan Lauc,"University of Cincinnati; University of Cincinnati; University of Cincinnati; Oregon State University; University of Cincinnati; University of Cincinnati; University of Oxford; Alan Turing Institute; University of Oxford; University of Oxford; University of Oxford; University of Pittsburgh; University of Pittsburgh; Johns Hopkins Bloomberg School of Public Health; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; Lancaster University; Nottingham University Trust; University of Nottingham, School of Medicine; Department of Infectious Diseases, Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital, University of Chi; Hwa Mei Hospital, University of Chinese Academy of Sciences; School of Medicine, University of Nottingham; King's College London; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; University of Helsinki; Department of Forensic Medicine, University of Helsinki, Finland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Clinical Hospital Dubrava, Zagreb; Hospital for Infectious Diseases, Zagreb, Croatia; Hospital for Infectious Diseases; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED Kliniken; School of Biomedical Engineering & Imaging Sciences, King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London; Department of Nephrology, Hospital del Mar, Barcelona, Spain; University of Nottingham, School of Medicine, Nottingham NIHR BRC; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Department of Infectious Diseases, Hospital del Mar. Barcelona, Spain; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Pain Therapy Service Policlinico of Monza Hospital - Monza Italy & Italian Pain Group - Milan - Italy; St. Catherine Hospital; King's College London; Hospital del Mar. Barcelona, Spain; University of Zagreb","BackgroundThe role of health-related disparities including sociodemographic, environmental, and critical care capacity in the COVID-19 pandemic are poorly understood. In the present study, we characterized vulnerable populations located in areas at higher risk of COVID-19 related mortality and low critical healthcare capacity in the U.S.

MethodsUsing Bayesian multilevel analysis and small area disease risk mapping, we assessed the spatial variation of COVID-19 related mortality risk for the U.S. in relation with healthcare disparities including race, ethnicity, poverty, air quality, and critical healthcare capacity.

ResultsOverall, highly populated, regional air hub areas, and minorities had an increased risk of COVID-19 related mortality. We found that with an increase of only 1 ug/m3 in long term PM2.5 exposure, the COVID-19 mortality rate increased by 13%. Counties with major air hubs had 18% increase in COVID-19 related death compared to counties with no airport connectivity. Sixty-eight percent of the counties with high COVID-19 related mortality risk were also counties with lower critical care capacity than national average. These counties were primary located at the North- and South-Eastern regions of the country.

ConclusionThe existing disparity in health and environmental risk factors that exacerbate the COVID-19 related mortality, along with the regional healthcare capacity, determine the vulnerability of populations to COVID-19 related mortality. The results from this study can be used to guide the development of strategies for the identification and targeting preventive strategies in vulnerable populations with a higher proportion of minority groups living in areas with poor air quality and low healthcare capacity.

KEY POINTSO_ST_ABSQuestionC_ST_ABSWhat are the sociodemographic and environmental drivers of the heterogeneous distribution of the COVID-19 related mortality in the U.S., and what are the vulnerable areas at higher risk of COVID-19 related mortality and low critical healthcare capacity?

FindingsHigher proportions of African American and Latino populations, as well as high levels of air pollution and airport connectivity were linked to higher risk of COVID-19 related mortality. Over 68% of the counties with high COVID-19 related mortality risk were also counties with lower critical care capacity than national average.

MeaningIn a time-limited response, the identification and targeting prevention efforts should focus in vulnerable populations located in high risk areas in which sociodemographic and environmental factors are exacerbating the burden of COVID-19 related deaths.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.11.20151217,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.11.20151217,Impact of COVID-19 Second Wave on Healthcare Networks in the United States,Emad M. Hassan; Hussam Mahmoud; Andres Hernandez; Adam J Branscum; Neil J MacKinnon; Diego F Cuadros; Chris Holmes; David Bonsall; Johannes Abeler; Christophe Fraser; Kan Li; Patti A Calderone; Eva Noble; Hongjiang Gao; Jeanette Rainey; Amra Uzicanin; Jonathan M. Read; Luke Ollivere; Benjamin Ollivere; Huadong Yan; Ting Cai; Guruprasad Aithal; Claire Steves; Anu Kantele; Mikael Kajova; Olli Vapalahti; Antti Sajantila; Rafal Wojtowicz; Waldemar Wierzba; Zbigniew Krol; Artur Zaczynski; Katarzyna Zycinska; Marek Postula; Ivica Luksic; Rok Civljak; Alemka Markotic; Christian Mahnkopf; Andreas Markl; Johannes Brachmann; Benjamin Murray; Sebastien Ourselin; Julio Pascual; Ana M Valdes; Margarita Posso; Juan Horcajada; Xavier Castells; Massimo Allegri; Dragan Primorac; Timothy Spector; Clara Barrios; Gordan Lauc,"Colorado State University; Colorado State University; University of Cincinnati; Oregon State University; University of Cincinnati; University of Cincinnati; University of Oxford; Alan Turing Institute; University of Oxford; University of Oxford; University of Oxford; University of Pittsburgh; University of Pittsburgh; Johns Hopkins Bloomberg School of Public Health; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; US Centers for Disease Control and Prevention; Lancaster University; Nottingham University Trust; University of Nottingham, School of Medicine; Department of Infectious Diseases, Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital, University of Chi; Hwa Mei Hospital, University of Chinese Academy of Sciences; School of Medicine, University of Nottingham; King's College London; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; University of Helsinki; Department of Forensic Medicine, University of Helsinki, Finland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Clinical Hospital Dubrava, Zagreb; Hospital for Infectious Diseases, Zagreb, Croatia; Hospital for Infectious Diseases; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED Kliniken; School of Biomedical Engineering & Imaging Sciences, King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London; Department of Nephrology, Hospital del Mar, Barcelona, Spain; University of Nottingham, School of Medicine, Nottingham NIHR BRC; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Department of Infectious Diseases, Hospital del Mar. Barcelona, Spain; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Pain Therapy Service Policlinico of Monza Hospital - Monza Italy & Italian Pain Group - Milan - Italy; St. Catherine Hospital; King's College London; Hospital del Mar. Barcelona, Spain; University of Zagreb","The risk of overwhelming healthcare systems from a second wave of COVID-19 is yet to be quantified. Here, we investigate the impact of different reopening scenarios of states around the U.S. on COVID-19 hospitalized cases and the risk of overwhelming the healthcare system while considering resources at the county level. We show that the second wave might involve an unprecedented impact on the healthcare system if an increasing number of the population becomes susceptible and/or if the various protective measures are discontinued. Furthermore, we explore the ability of different mitigation strategies in providing considerable relief to the healthcare system. The results can aid healthcare planners, policymakers, and state officials in making decisions on additional resources required and on when to return to normalcy.

One Sentence SummaryA second wave of COVID-19 will have an unprecedented impact on the healthcare system.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.10.20150524,2020-07-11,https://medrxiv.org/cgi/content/short/2020.07.10.20150524,Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Benjamin Jeffrey; Caroline E. Walters; Christina J Atchison; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Graham Taylor; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health","BackgroundEngland has experienced one of the highest rates of confirmed COVID-19 mortality in the world. SARS-CoV-2 virus has circulated in hospitals, care homes and the community since January 2020. Our current epidemiological knowledge is largely informed by clinical cases with far less understanding of community transmission.

MethodsThe REal-time Assessment of Community Transmission (REACT) study is a nationally representative prevalence survey of SARS-CoV-2 virus swab-positivity in the community in England. We recruited participants regardless of symptom status.

ResultsWe found 159 positives from 120,610 swabs giving an average prevalence of 0.13% (95% CI: 0.11%,0.15%) from 1st May to 1st June 2020. We showed decreasing prevalence with a halving time of 8.6 (6.2, 13.6) days, implying an overall reproduction number R of 0.57 (0.45, 0.72). Adults aged 18 to 24 yrs had the highest swab-positivity rates, while those >64 yrs had the lowest. Of the 126 participants who tested positive with known symptom status in the week prior to their swab, 39 reported symptoms while 87 did not, giving an estimate that 69% (61%,76%) of people were symptom-free for the 7 days prior testing positive in our community sample. Symptoms strongly associated with swab-positivity were: nausea and/or vomiting, diarrhoea, blocked nose, loss of smell, loss of taste, headache, chills and severe fatigue. Recent contact with a known COVID-19 case was associated with odds of 24 (16, 38) for swab-positivity. Compared with non-key workers, odds of swab-positivity were 7.7 (2.4, 25) among care home (long-term care facilities) workers and 5.2 (2.9, 9.3) among health care workers. However, some of the excess risk associated with key worker status was explained by recent contact with COVID-19 cases. We found no strong evidence for geographical variability in positive swab results.

ConclusionOur results provide a reliable baseline against which the impact of subsequent relaxation of lockdown can be assessed to inform future public health efforts to control transmission.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.10.20151118,2020-07-11,https://medrxiv.org/cgi/content/short/2020.07.10.20151118,The 4C Initiative (Clinical Care for Cardiovascular disease in the COVID-19 pandemic): monitoring the indirect impact of the coronavirus pandemic on services for cardiovascular diseases in the UK,- TC CVD-COVID-UK Consortium; Simon Ball; Amitava Banerjee; Colin Berry; Jonathan Boyle; Benjamin Bray; William Bradlow; Afzal Chaudhry; Rikki Crawley; John Danesh; Alastair Denniston; Florian Falter; Jonine Figueroa; Christopher Hall; Harry Hemingway; Emily Jefferson; Tom Johnson; Graham King; Ken Lee; Paul McKean; Suzanne Mason; Nicholas Mills; Ewen Pearson; Munir Pirmohamed; Michael TC Poon; Rouven Priedon; Anoop Shah; Reecha Sofat; Jonathan Sterne; Fiona Strachan; Cathie LM Sudlow; Zsolt Szarka; William Whiteley; Mike Wyatt,"; Health Data Research UK Midlands, University of Birmingham; University College London; Institute of Cardiovascular and Medical Sciences, University of Glasgow; Cambridge University Hospitals NHS Foundation Trust; IQVIA; University Hospitals Birmingham NHS Trust; Health Data Research UK Cambridge; Barnsley Hospital NHS Foundation Trust; Health Data Research UK Cambridge; University Hospitals Birmingham NHS Trust; Royal Papworth Hospital NHS Foundation Trust; University of Edinburgh; Health Informatics Centre, University of Dundee; Health Data Research UK London, Institute of Health Informatics, University College London; Population Health and Genomics, University of Dundee; University Hospitals Bristol and Weston NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Centre for Cardiovascular cience, University of Edinburgh; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Health Data Research UK North; Centre for Cardiovascular Science, University of Edinburgh; Health Data Research UK Scotland; Institute of Systems, Molecular and Integrative Biology and MRC Centre for Drug Safety Science, University of Liverpool; Usher Institute, University of Edinburgh; BHF Data Science Centre, Health Data Research UK; Centre for Cardiovascular Science, University of Edinburgh; Health Data Research UK London, Institute of Health Informatics, University College London; Health Data Research UK South West, Population Health Sciences, University of Bristol; Centre for Cardiovascular Science, University of Edinburgh; BHF Data Science Centre, Health Data Research UK; Health Informatics Centre, University of Dundee; Centre for Clinical Brain Sciences, University of Edinburgh; University Hospitals Bristol and Weston NHS Foundation Trust","BackgroundThe coronavirus (COVID-19) pandemic affects cardiovascular diseases (CVDs) directly through infection and indirectly through health service reorganisation and public health policy. Real-time data are needed to quantify direct and indirect effects. We aimed to monitor hospital activity for presentation, diagnosis and treatment of CVDs during the pandemic to inform on indirect effects.

MethodsWe analysed aggregate data on presentations, diagnoses and treatments or procedures for selected CVDs (acute coronary syndromes, heart failure, stroke and transient ischaemic attack, venous thromboembolism, peripheral arterial disease and aortic aneurysm) in UK hospitals before and during the COVID-19 epidemic. We produced an online visualisation tool to enable near real-time monitoring of trends.

FindingsNine hospitals across England and Scotland contributed hospital activity data from 28 Oct 2019 (pre-COVID-19) to 10 May 2020 (pre-easing of lockdown), and for the same weeks during 2018-2019. Across all hospitals, total admissions and emergency department (ED) attendances decreased after lockdown (23 March 2020) by 57.9% (57.1-58.6%) and 52.9% (52.2-53.5%) respectively compared with the previous year. Activity for cardiac, cerebrovascular and other vascular conditions started to decline 1-2 weeks before lockdown, and fell by 31-88% after lockdown, with the greatest reductions observed for coronary artery bypass grafts, carotid endarterectomy, aortic aneurysm repair and peripheral arterial disease procedures. Compared with before the first UK COVID-19 (31 January 2020), activity declined across diseases and specialties between the first case and lockdown (total ED attendances RR 0.94, 0.93-0.95; total hospital admissions RR 0.96, 0.95-0.97) and after lockdown (attendances RR 0.63, 0.62-0.64; admissions RR 0.59, 0.57-0.60). There was limited recovery towards usual levels of some activities from mid-April 2020.

InterpretationSubstantial reductions in total and cardiovascular activities are likely to contribute to a major burden of indirect effects of the pandemic, suggesting they should be monitored and mitigated urgently.

FundingBritish Heart Foundation, Health Data Research UK",public and global health,exact,100,100
medRxiv,10.1101/2020.07.08.20148965,2020-07-10,https://medrxiv.org/cgi/content/short/2020.07.08.20148965,A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19,Rosita Zakeri; Rebecca Bendayan; Mark Ashworth; Daniel M Bean; Hiten Dodhia; Stevo Durbaba; Kevin O Gallagher; Claire Palmer; Vasa Curcin; Elizabeth Aitken; William Bernal; Richard D Barker; Sam Norton; Martin C Gulliford; James T Teo; James Galloway; Richard J Dobson; Ajay M Shah; Trivikram Dasu; Sanjib Bhattacharyya; Yoshihiro Kawaoka; Katia Koelle; David H O'Connor; Thomas C Friedrich; Jeffrey S. Morris; Daniel J. Rader; Michal A. Elovitz; E. John Wherry; Karen M. Puopolo; Scott E. Hensley,"King's College, London; King's College, London; King's College, London; King's College London; King's College, London; King's College, London; King's College, London; King's College Hospital; King's College, London; Lewisham & Greenwich NHS Trust; King's College Hospital; King's College Hospital; King's College, London; King's College London; Kings College Hospital NHS Foundation Trust; King's College, London; King's College London; King's College London; City of Milwaukee Health Department Laboratory; City of Milwaukee Health Department Laboratory; University of Wisconsin-Madison; Emory University; University of Wisconsin-Madison; University of Wisconsin-Madison; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Children's Hospital of Philadelphia and University of Pennsylvania; University of Pennsylvania","BackgroundPeople of minority ethnic background may be disproportionately affected by severe COVID-19 for reasons that are unclear. We sought to examine the relationship between ethnic background and (1) hospital admission for severe COVID-19; (2) in-hospital mortality.

MethodsWe conducted a case-control study of 872 inner city adult residents admitted to hospital with confirmed COVID-19 (cases) and 3,488 matched controls randomly sampled from a primary healthcare database comprising 344,083 people resident in the same region. To examine in-hospital mortality, we conducted a cohort study of 1827 adults consecutively admitted with COVID-19. Data collected included hospital admission for COVID-19, demographics, comorbidities, in-hospital mortality. The primary exposure variable was self-defined ethnicity.

ResultsThe 872 cases comprised 48.1% Black, 33.7% White, 12.6% Mixed/Other and 5.6% Asian patients. In conditional logistic regression analyses, Black and Mixed/Other ethnicity were associated with higher admission risk than white (OR 3.12 [95% CI 2.63-3.71] and 2.97 [2.30-3.85] respectively). Adjustment for comorbidities and deprivation modestly attenuated the association (OR 2.28 [1.87-2.79] for Black, 2.66 [2.01-3.52] for Mixed/Other). Asian ethnicity was not associated with higher admission risk (OR 1.20 [0.86-1.66]). In the cohort study of 1827 patients, 455 (28.9%) died over a median (IQR) of 8 (4-16) days. Age and male sex, but not Black (adjusted HR 0.84 [0.63-1.11]) or Mixed/Other ethnicity (adjusted HR 0.69 [0.43-1.10]), were associated with in-hospital mortality. Asian ethnicity was associated with higher in-hospital mortality (adjusted HR 1.54 [0.98-2.41]).

ConclusionsBlack and Mixed ethnicity are independently associated with greater admission risk with COVID-19 and may be risk factors for development of severe disease. Comorbidities and socioeconomic factors only partly account for this and additional ethnicity-related factors may play a large role. The impact of COVID-19 may be different in Asians.

Funding sourcesBritish Heart Foundation (CH/1999001/11735 and RE/18/2/34213 to AMS); the National Institute for Health Research Biomedical Research Centre (NIHR BRC) at Guys & St Thomas NHS Foundation Trust and Kings College London (IS-BRC-1215-20006); and the NIHR BRC at South London and Maudsley NHS Foundation Trust and Kings College London (IS-BRC-1215-20018).",public and global health,exact,100,100
medRxiv,10.1101/2020.07.06.20147348,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147348,Community prevalence of SARS-CoV-2 in England: Results from the ONS Coronavirus Infection Survey Pilot,Koen B Pouwels; Thomas House; Julie V Robotham; Paul Birrell; Andrew B Gelman; Nikola Bowers; Ian Boreham; Heledd Thomas; James Lewis; Iain Bell; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"University of Oxford; University of Manchester; Public Health England; Public Health England; Columbia University; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","ObjectiveTo estimate the percentage of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) over time in the community in England and to quantify risk factors.

DesignRepeated cross-sectional surveys of population-representative households with longitudinal follow-up if consent given.

SettingEngland

Participants34,992 Individuals aged 2 years and over from 16,722 private residential households. Data were collected in a pilot phase of the survey between 26 April and 28 June 2020.

Main outcome measuresPercentage of individuals in the community testing positive for SARS-CoV-2 RNA using throat and nose swabs. Individuals were asked about any symptoms and potential risk factors.

ResultsThe percentage of people in private-residential households testing positive for SARS-CoV-2 reduced from 0.32% (95% credible interval (CrI) 0.19% to 0.52%) on 26 April to 0.08% (95% CrI 0.05% to 0.12%) on 28 June, although the prevalence stabilised near the end of the pilot. Factors associated with an increased risk of testing positive included having a job with direct patient contact (relative exposure (RE) 4.06, 95% CrI 2.42 to 6.77)), working outside the home (RE 2.49, 95% CrI 1.39 to 4.45), and having had contact with a hospital (RE 2.20, 95% CrI 1.09 to 4.16 for having been to a hospital individually and RE 1.95, 95% CrI 0.81 to 4.09 for a household member having been to a hospital). In 133 visits where individuals tested positive, 82 (61%, 95% CrI 53% to 69%) reported no symptoms, stably over time.

ConclusionThe percentage of SARS-CoV-2 positive individuals declined between 26 April and 28 June 2020. Positive tests commonly occurred without symptoms being reported. Working outside your home was an important risk factor, indicating that continued monitoring for SARS-CoV-2 in the community will be essential for early detection of increases in infections following return to work and other relaxations of control measures.

What is already known on this topic- Unprecedented control measures, such as national lockdowns, have been widely implemented to contain the spread of SARS-CoV-2.
- Previous mass surveillance has been based on data sources such as hospital admission, deaths or self-reported symptoms that do not measure community prevalence of virus directly.
- Decisions regarding the continued need for social distancing measures in the overall population, specific subgroups and geographic areas heavily rely on accurate and up-to-date information about the number of people and risk factors for testing positive.


What this study adds- The percentage of individuals from the general community in England testing positive for SARS-CoV-2 clearly declined between 26 April and 28 June 2020 from around one in three 300 to around one in a thousand.
- Risk factors for testing positive included having a job with direct patient contact, having had (indirect) contact with a hospital in the past 2 weeks, and working outside your home.
- Positive tests commonly occurred without symptoms being reported and the percentage of individuals with a positive test that reported no symptoms was stable over time.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.06.20147272,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147272,Reopening universities during the COVID-19 pandemic: A testing strategy to minimize active cases and delay outbreaks,Lior Rennert; Corey Andrew Kalbaugh; Lu Shi; Christopher McMahan; Andrew B Gelman; Nikola Bowers; Ian Boreham; Heledd Thomas; James Lewis; Iain Bell; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Clemson University; Clemson University; Clemson University; Clemson University; Columbia University; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","BackgroundUniversity campuses present an ideal environment for viral spread and are therefore at extreme risk of serving as a hotbed for a COVID-19 outbreak. While active surveillance throughout the semester such as widespread testing, contact tracing, and case isolation, may assist in detecting and preventing early outbreaks, these strategies will not be sufficient should a larger outbreak occur. It is therefore necessary to limit the initial number of active cases at the start of the semester. We examine the impact of pre-semester NAT testing on disease spread in a university setting.

MethodsWe implement simple dynamic transmission models of SARS-CoV-2 infection to explore the effects of pre-semester testing strategies on the number of active infections and occupied isolation beds throughout the semester. We assume an infectious period of 3 days and vary R0 to represent the effectiveness of disease mitigation strategies throughout the semester. We assume the prevalence of active cases at the beginning of the semester is 5%. The sensitivity of the NAT test is set at 90%.

ResultsIf no pre-semester screening is mandated, the peak number of active infections occurs in under 10 days and the size of the peak is substantial, ranging from 5,000 active infections when effective mitigation strategies (R0 = 1.25) are implemented to over 15,000 active infections for less effective strategies (R0 = 3). When one NAT test is mandated within one week of campus arrival, effective (R0 = 1.25) and less effective (R0 = 3) mitigation strategies delay the onset of the peak to 40 days and 17 days, respectively, and result in peak size ranging from 1,000 to over 15,000 active infections. When two NAT tests are mandated, effective (R0 = 1.25) and less effective (R0 = 3) mitigation strategies delay the onset of the peak through the end of fall semester and 20 days, respectively, and result in peak size ranging from less than 1,000 to over 15,000 active infections. If maximum occupancy of isolation beds is set to 2% of the student population, then isolation beds would only be available for a range of 1 in 2 confirmed cases (R0 = 1.25) to 1 in 40 confirmed cases (R0 = 3) before maximum occupancy is reached.

ConclusionEven with highly effective mitigation strategies throughout the semester, inadequate pre-semester testing will lead to early and large surges of the disease and result in universities quickly reaching their isolation bed capacity. We therefore recommend NAT testing within one week of campus return. While this strategy is sufficient for delaying the timing of the outbreak, pre-semester testing would need to be implemented in conjunction with effective mitigation strategies to reduce the outbreak size.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.05.20146910,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.05.20146910,"Near Term Predictions of Covid-19 Cases in West Bengal, Maharashtra, Delhi and Tamil Nadu in India Based on Basu Model",Santanu Basu; Corey Andrew Kalbaugh; Lu Shi; Christopher McMahan; Andrew B Gelman; Nikola Bowers; Ian Boreham; Heledd Thomas; James Lewis; Iain Bell; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Sparkle Optics Corporation; Clemson University; Clemson University; Clemson University; Columbia University; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis",Four states in India account for nearly two thirds of the Covid-19 cases and the numbers are growing fast. A mathematical model which has been recently developed and which has been applied to other countries and regions in the world has been used in this paper to anchor the available data to date and to make near term projections. The projections can be compared to actual data to take steps in the near term in controlling the spread of this disease.,infectious diseases,exact,100,100
medRxiv,10.1101/2020.07.06.20147256,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147256,Early Diagnosis and Clinical Significance of Acute Cardiac Injury - Under the Iceberg: A Retrospective Cohort Study of 619 Non-critically Ill Hospitalized COVID-19 Pneumonia Patients,Yang Xie; Sichun Chen; Xueli Wang; Baige Li; Tianlu Zhang; Xingwei He; NingLing Sun; Luyan Wang; Hesong Zeng; Yin Shen; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Medical Research Institute, Wuhan University Renmin Hospital, Wuhan University, Wuhan, China; Institute of Central China Development, Wuhan University; Medical Research Institute, Wuhan University Renmin Hospital, Wuhan University, Wuhan, China; zhangtianlu99@163.com; Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Department of Hypertension at Heart Center, People's Hospital, Peking University; Heart Center, Peking University Peoples Hospital; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Eye Center, Wuhan University Renmin Hospital, Wuhan University; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","RationaleCoronavirus disease 2019 (COVID-19) can cause a viral pneumonia together with other extrapulmonary complications. Acute cardiac related injury (ACRI) is common in hospitalized COVID-19 patients.

ObjectiveTo explain the pathological mechanism of ACRI and improve the treatment strategy by retrospectively observing the factors associated with ACRI and factors affecting the prognosis of ACRI with COVID-19 at an early stage.

Methods619 COVID-19 patients were from Tongji Hospital, Wuhan. Students t test was used for continuous variables while Pearson {chi}2 test for categorical factors. Univariable and multivariable logistic regression models were applied to estimate odds ratio (OR) with 95% confidence interval (CI).

ResultsAmong the 619 OOS Level-I hospitalized COVID-19 patients, 102 (16.5%) were defined as ACRI (stage-1: 59 cases, stage-2: 43 cases). 50% of ACRI patients developed into severe cases and 25 patients died(CFR=24.5%), 42 times that of non-ACRI patients. Elderly (OR=2.83, P<0.001), HTN (OR=2.09, P=0.005), {gamma}-globulin (OR=2.08, P=0.004), TCM (OR=0.55, P=0.017), PLT (OR=2.94, P<0.001) and NLR (OR=2.20, P=0.004) were independently correlated with ACRI. SBP [&gt;=] 140, dyspnea, DM, smoking history were correlated with ACRI-stage2 only. In the prognostic subgroup analysis of ACRI patients, {gamma}-globulin treatment could prolong LOS (29.0 {+/-} 7.2 days Vs 23.5 {+/-} 8.1 days, P=0.004). TCM (OR=0.26, P=0.006), SBP [&gt;=] 160 (OR= 22.70, P=0.005), male (OR=2.66, P=0.044) were associated with severe illness while corticosteroids treatment (OR=3.34, P=0.033) and male (OR=4.303, P=0.008) with death. Surprisingly, we found the mortality of non-elderly patients is higher than elderly (32.4% VS 20.0%, P=0.164), and both IKF and RASI treatment were not correlated with any prognostic indicators including severe, death and LOS.

ConclusionThis study observed that several non-traditional issues were associated with early cardiac injury in COVID-19 while many traditional cardiovascular risk factors were not. Besides elderly and male, hypertension was confirmed to be the most important risk factor.",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.07.06.20147124,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147124,Does sub-Saharan Africa truly defy the forecasts of the COVID-19 pandemic? Response from population data,Fokoua Maxime Christophe Dongmo; Amor Ndjabo Monique; Ankobil Amandus; Kiyung Victor Momah; Metomb Franck Steve; Choukem Simeon Pierre; NingLing Sun; Luyan Wang; Hesong Zeng; Yin Shen; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"University of New York State - University at Albany School of Public Health; School of Health Sciences, Catholic University of Central Africa, Yaounde, Cameroon; University of New York State - University at Albany School of Public Health, Albany, USA; School of Health Sciences, Catholic University of Central Africa, Yaounde, Cameroon; Regional Delegation of Public Health for the Center Region, Ministry of Public Health, Yaounde, Cameroon; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon; Department of Hypertension at Heart Center, People's Hospital, Peking University; Heart Center, Peking University Peoples Hospital; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Eye Center, Wuhan University Renmin Hospital, Wuhan University; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","IntroductionSince its identification, the COVID-19 infection has caused substantial mortality and morbidity worldwide, but sub-Saharan Africa seems to defy the predictions. We aimed to verify this hypothesis using strong statistical methods.

MethodsWe conducted a cross-sectional study comparing the projected and actual numbers as well as population proportions of COVID-19 cases in the 46 sub-Saharan African countries on May 1st, May 29th (4 weeks later) and June 26th (8 weeks later). The source of the projected number of cases was a publication by scientists from the Center for Mathematical Modeling of Infectious Diseases of the London School of Hygiene & Tropical Medicine, whereas the actual number of cases was obtained from the WHO situation reports. We calculated the percentage difference between the projected and actual numbers of cases per country. Further, ""N-1"" chi-square tests with Bonferroni correction were used to compare the projected and actual population proportion of COVID-19 cases, along with the 95% confidence interval of the difference between these population proportions. All statistical tests were 2-sided, with 0.05 used as threshold for statistical significance.

ResultsOn May 1st, May 29th and June 26th, respectively 40 (86.95%), 45 (97.82%) and 41 (89.13%) of the sub-Saharan African countries reported a number of confirmed cases that was lower than the predicted number of 1000 cases for May 1st and 10000 for both May 29th and June 26th. At these dates, the population proportions of confirmed Covid-19 cases were significantly lower (p-value <0.05) than the projected proportions of cases. Across all these dates, South-Africa always exceeded the predicted number and population proportion of COVID-19 infections.

ConclusionSub-Saharan African countries did defy the dire predictions of the COVID-19 burden. Preventive measures should be further enforced to preserve this positive outcome.",epidemiology,exact,100,100
medRxiv,10.1101/2020.07.06.20147264,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147264,Clinical characteristics and epidemiology survey of lung transplantation recipients accepting surgeries during the COVID-19 pandemic:from area near Hubei Province,Lingxiao Qiu; Shanshan Chen; Cong Wang; Caihong Liu; Huaqi Wang; Xiaoguang Zhao; Zeming Fang; Siyuan Chang; Gaofeng Zhao; Guojun Zhang; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; King's College London; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","Lung transplantation recipients (LTx) were susceptible to severe acute respiratory syndrome-corona virus-2 (SARS-Cov-2) and suffered a higher mortality risk than healthy subjects. Here we aim to analyze whether it was appropriate or and valuable to maintain lung transplant programs in medical institutions accepting coronavirus disease 2019 (COVID-19) patients. In this study, the clinical characteristics, laboratory testing and epidemiology survey results of 10 LTx recipients undergoing allograft lung transplantation surgeries in the First Affiliated Hospital of Zhengzhou University during the COVID-19 pandemic were collected. A web-based epidemiology questionnaire was used to collect the information of LTx recipients after discharge. Up to now, none of the LTx recipients or their family members get infected with SARS-CoV-2 during the novel coronavirus pandemic. In conclusion, under the premise of taking appropriate preventive measures during hospitalization and after discharge, the lung transplant program can be maintained in the medical institution that accepts patients with COVID-19.",transplantation,exact,100,100
medRxiv,10.1101/2020.07.06.20147629,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147629,Are men dying more than women by COVID-19?,Thaise Pinto de Melo; Delvan Alves Silva; Alexandre Naime Barbosa; Caihong Liu; Huaqi Wang; Xiaoguang Zhao; Zeming Fang; Siyuan Chang; Gaofeng Zhao; Guojun Zhang; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Sao Paulo State University; Sao Paulo State University; Sao Paulo State University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","We aimed to clarify if the infection and death rate by COVID-19 differ among gender in the top 50 countries with the highest death rates. Also, we investigated if secondary variables such as HDI, number of hospital beds, average age, temperature, percentage of elderly, smoker and obesity are contributing to the variability observed among countries. Meta-analyses and meta-regressions approaches were applied to official public data reported by the Word Health Organization and governments until May, 2020. A random effect model was used for the meta-analysis and heterogeneity was calculated by I2 statistic. There was not significative difference between men and women to be infected by COVID-19 (P = 0.42), though a significative difference was observed for death rate (P < 0.0001). High heterogeneity was observed among countries. For both infection and death rates this variability was mainly explained by the HDI (42.3% and 54.2%), average age (40.9% and 40.3%) and temperature (30.1% and 39.3%). Man are dying more than women around the word by COVID-19. Countries with highest HDI present less difference between sexes. These results reinforce that public politics promoting social isolation, health care and general well-being of the population are key factors in combating COVID-19.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.07.07.191676,2020-07-07,https://biorxiv.org/cgi/content/short/2020.07.07.191676,SARS-CoV-2 Nsp1 binds ribosomal mRNA channel to inhibit translation,Katharina Schubert; Evangelos D. Karousis; Ahmad Jomaa; Alain Scaiola; Blanca Echeverria; Lukas-Adrian Gurzeler; Marc Leibundgut; Volker Thiel; Oliver Muehlemann; Nenad Ban; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland; Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland; Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland; Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland; Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland; Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland; Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland; Institute of Virology and Immunology, Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switze; Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland; Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","The non-structural protein 1 (Nsp1), also referred to as the host shutoff factor, is the first viral protein that is synthesized in SARS-CoV-2 infected human cells to suppress host innate immune functions1,2. By combining cryo-electron microscopy and biochemical experiments, we show that SARS-CoV-2 Nsp1 binds to the human 40S subunit in ribosomal complexes including the 43S pre-initiation complex. The protein inserts its C-terminal domain at the entrance to the mRNA channel where it interferes with mRNA binding. We observe potent translation inhibition in the presence of Nsp1 in lysates from human cells. Based on the high-resolution structure of the 40S-Nsp1 complex, we identify residues of Nsp1 crucial for mediating translation inhibition. We further show that the full-length 5 untranslated region of the genomic viral mRNA stimulates translation in vitro, suggesting that SARS-CoV-2 combines inhibition of translation by Nsp1 with efficient translation of the viral mRNA to achieve expression of viral genes3.Competing Interest StatementThe authors have declared no competing interest.View Full Text",molecular biology,exact,100,100
bioRxiv,10.1101/2020.07.07.190967,2020-07-07,https://biorxiv.org/cgi/content/short/2020.07.07.190967,A Small interfering RNA lead targeting RNA-dependent RNA-polymerase effectively inhibit the SARS-CoV-2 infection in Golden Syrian hamster and Rhesus macaque,Se Hun Gu; Chi Ho Yu; Youngjo Song; Na Young Kim; Euni Sim; Jun Young Choi; Dong Hyun Song; Gyeung Haeng Hur; Young Kee Shin; Seong Tae Jeong; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Agency for Defense Development; Agency for Defense Development; Agency for Defense Development; ABION Inc., R&D Center; ABION Inc., R&D Center; ABION Inc., R&D Center; Agency for Defense Development; Agency for Defense Development; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University; Agency for Defense Development; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","A small interfering RNA (siRNA) inhibitors have demonstrated the novel modality for suppressing infectious diseases. Sixty-one siRNA molecules, predicted by the bioinformatics programs, were screened for the possibility of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an in vitro plaque assay. Among six siRNA leads with the efficacy of reducing plaque number, the siRNA targeting RNA-dependent RNA polymerase (RdRp) showed a reduction in SARS-CoV-2 infection-induced fever and virus titer in the Golden Syrian hamster and rhesus macaque. These results suggest the potential for RdRp targeting siRNA as a new treatment for the coronavirus disease 2019 (COVID-19).Competing Interest StatementThe authors have declared no competing interest.View Full Text",microbiology,exact,100,100
bioRxiv,10.1101/2020.07.06.190660,2020-07-07,https://biorxiv.org/cgi/content/short/2020.07.06.190660,The global and local distribution of RNA structure throughout the SARS-CoV-2 genome,Rafael de Cesaris Araujo Tavares; Gandhar Mahadeshwar; Anna Marie Pyle; Na Young Kim; Euni Sim; Jun Young Choi; Dong Hyun Song; Gyeung Haeng Hur; Young Kee Shin; Seong Tae Jeong; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Yale University, Department of Chemistry; Yale University, Department of Molecular Biophysics and Biochemistry; Yale University, Department of Molecular, Cellular and Developmental Biology & Department of Chemistry, Howard Hughes Medical Institute; ABION Inc., R&D Center; ABION Inc., R&D Center; ABION Inc., R&D Center; Agency for Defense Development; Agency for Defense Development; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University; Agency for Defense Development; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","SARS-CoV-2 is the causative viral agent of COVID-19, the disease at the center of the current global pandemic. While knowledge of highly structured regions is integral for mechanistic insights into the viral infection cycle, very little is known about the location and folding stability of functional elements within the massive, ~30kb SARS-CoV-2 RNA genome. In this study, we analyze the folding stability of this RNA genome relative to the structural landscape of other well-known viral RNAs. We present an in-silico pipeline to locate regions of high base pair content across this long genome and also identify well-defined RNA structures, a method that allows for direct comparisons of RNA structural complexity within the several domains in SARS-CoV-2 genome. We report that the SARS-CoV-2 genomic propensity to stable RNA folding is exceptional among RNA viruses, superseding even that of HCV, one of the most highly structured viral RNAs in nature. Furthermore, our analysis reveals varying levels of RNA structure across genomic functional regions, with accessory and structural ORFs containing the highest structural density in the viral genome. Finally, we take a step further to examine how individual RNA structures formed by these ORFs are affected by the differences in genomic and subgenomic contexts. The conclusions reported in this study provide a foundation for structure-function hypotheses in SARS-CoV-2 biology, and in turn, may guide the 3D structural characterization of potential RNA drug targets for COVID-19 therapeutics.View Full Text",biophysics,exact,100,100
bioRxiv,10.1101/2020.07.07.191775,2020-07-07,https://biorxiv.org/cgi/content/short/2020.07.07.191775,Favipiravir and severe acute respiratory syndrome coronavirus 2 in hamster model,Jean-Slim Driouich; Maxime Cochin; Guillaume Lingas; Grgory Moureau; Franck Touret; Paul-Rmi Petit; Graldine Piorkowski; Karine Barthlmy; Bruno Coutard; Jrmie Guedj; Xavier de Lamballerie; Caroline Solas; Antoine Nougairde; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Universit de Paris, IAME, INSERM, F-75018 Paris, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Universit de Paris, IAME, INSERM, F-75018 Paris, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France ; Laboratoire de Pharmacocintique et Toxicologie, Hpital La Timone; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we used a Syrian hamster model to assess the antiviral efficacy of favipiravir, understand its mechanism of action and determine its pharmacokinetics. When treatment was initiated before or simultaneously to infection, favipiravir had a strong dose effect, leading to dramatic reduction of infectious titers in lungs and clinical alleviation of the disease. Antiviral effect of favipiravir correlated with incorporation of a large number of mutations into viral genomes and decrease of viral infectivity. The antiviral efficacy observed in this study was achieved with plasma drug exposure comparable with those previously found during human clinical trials and was associated with weight losses in animals. Thereby, pharmacokinetic and tolerance studies are required to determine whether similar effects can be safely achieved in humans.",microbiology,exact,100,100
bioRxiv,10.1101/2020.07.06.182972,2020-07-07,https://biorxiv.org/cgi/content/short/2020.07.06.182972,Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies,Ethan S. FitzGerald; Amanda M. Jamieson; Guillaume Lingas; Grgory Moureau; Franck Touret; Paul-Rmi Petit; Graldine Piorkowski; Karine Barthlmy; Bruno Coutard; Jrmie Guedj; Xavier de Lamballerie; Caroline Solas; Antoine Nougairde; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"Brown University; Brown University; Universit de Paris, IAME, INSERM, F-75018 Paris, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Universit de Paris, IAME, INSERM, F-75018 Paris, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France ; Laboratoire de Pharmacocintique et Toxicologie, Hpital La Timone; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic. In addition to the acute pulmonary symptoms of COVID-19 (the disease associated with SARS-CoV-2 infection), pulmonary and distal coagulopathies have caused morbidity and mortality in many patients. Currently, the molecular pathogenesis underlying COVID-19 associated coagulopathies are unknown. While there are many theories for the cause of this pathology, including hyper inflammation and excess tissue damage, the cellular and molecular underpinnings are not yet clear. By analyzing transcriptomic data sets from experimental and clinical research teams, we determined that changes in the gene expression of genes important in the extrinsic coagulation cascade in the lung epithelium may be important triggers for COVID-19 coagulopathy. This regulation of the extrinsic blood coagulation cascade is not seen with influenza A virus (IAV)-infected NHBEs suggesting that the lung epithelial derived coagulopathies are specific to SARS-Cov-2 infection. This study is the first to identify potential lung epithelial cell derived factors contributing to COVID-19 associated coagulopathy.

GRAPHICAL ABSTRACT

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC=""FIGDIR/small/182972v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (42K):
org.highwire.dtl.DTLVardef@93cfb7org.highwire.dtl.DTLVardef@2a23c9org.highwire.dtl.DTLVardef@93623borg.highwire.dtl.DTLVardef@161e25_HPS_FORMAT_FIGEXP  M_FIG C_FIG AUTHOR SUMMARYO_ST_ABSWhy was this study done?C_ST_ABSO_LISevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic.
C_LIO_LIIn addition to the acute pulmonary symptoms of COVID-19 (the disease associated with SARS-CoV-2 infection), pulmonary and distal coagulopathies have caused morbidity and mortality in many patients.
C_LIO_LICurrently, the molecular pathogenesis underlying COVID-19 associated coagulopathies are unknown. Understanding the molecular basis of dysregulated blood coagulation during SARS-CoV-2 infection may help promote new therapeutic strategies to mitigate these complications in COVID-19 patients.
C_LI

What did the researchers do and find?O_LIWe analyzed three publicly available RNA sequencing datasets to identify possible molecular etiologies of COVID-19 associated coagulopathies. These data sets include sequencing libraries from clinically isolated samples of bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMCs) from SARS-CoV-2 positive patients and healthy controls. We also analyzed a publicly available RNA sequencing dataset derived from in vitro SARS-CoV-2 infected primary normal human bronchial epithelial (NHBE) cells and mock infected samples.
C_LIO_LIPathway analysis of both NHBE and BALF differential gene expression gene sets. We found that SARS-CoV-2 infection induces the activation of the extrinsic blood coagulation cascade and suppression of the plasminogen activation system in both NHBEs and cells isolated from the BALF. PBMCs did not differentially express genes regulating blood coagulation.
C_LIO_LIComparison with influenza A virus (IAV)-infected NHBEs revealed that the regulation of the extrinsic blood coagulation cascade is unique to SARS-CoV-2, and not seen with IAV infection.
C_LI

What do these findings mean?O_LIThe hyper-activation of the extrinsic blood coagulation cascade and the suppression of the plasminogen activation system in SARS-CoV-2 infected epithelial cells may drive diverse coagulopathies in the lung and distal organ systems.
C_LIO_LIThe gene transcription pattern in SARS-CoV-2 infected epithelial cells is distinct from IAV infected epithelial cells with regards to the regulation of blood coagulation.
C_LI",pathology,exact,100,100
bioRxiv,10.1101/2020.07.07.192005,2020-07-07,https://biorxiv.org/cgi/content/short/2020.07.07.192005,A Fluorescence-based High Throughput-Screening assay for the SARS-CoV RNA synthesis complex,Cecilia Eydoux; Veronique Fattorini; Ashleigh Shannon; Thi-Tuyet-Nhung Le; Bruno Didier; Bruno Canard; Jean-Claude Guillemot; Karine Barthlmy; Bruno Coutard; Jrmie Guedj; Xavier de Lamballerie; Caroline Solas; Antoine Nougairde; Ian Diamond; Pete Benton; Sarah Walker; Emanuela Vaccher; Massimo Clementi; Massimo Galli; Gianguglielmo Zehender; Alessandro Sette; Dennis Hartigan-OConnor; Stephen J. McSorley; John H. Morrison; Nam K. Tran; Graham Simmons; Michael P Busch; Pamela A. Kozlowski; Koen K.A. Van Rompay; Christopher J. Miller; Smita S Iyer,"AMU; CNRS-AMU; CNRS-AMU; CNRS-AMU; Univ. Strasbourg; CNRS; AMU; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Universit de Paris, IAME, INSERM, F-75018 Paris, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France ; Laboratoire de Pharmacocintique et Toxicologie, Hpital La Timone; Unit des Virus mergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France; Office for National Statistics; Office for National Statistics; University of Oxford; Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy.; Microbiology and Virology Unit, ""Vita-Salute"" San Raffaele University, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.; La Jolla Institute for Immunology; UC Davis; UC Davis; UC Davis; UC Davis; University of California, San Francisco; La Jolla Institute for Immunology; Louisiana State University; UC Davis; UC Davis; UC Davis","The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) emergence in 2003 introduced the first serious human coronavirus pathogen to an unprepared world. To control emerging viruses, existing successful anti(retro)viral therapies can inspire antiviral strategies, as conserved viral enzymes (eg., viral proteases and RNA-dependent RNA polymerases) represent targets of choice. Since 2003, much effort has been expended in the characterization of the SARS-CoV replication/transcription machinery. Until recently, a pure and highly active preparation of SARS-CoV recombinant RNA synthesis machinery was not available, impeding target-based high throughput screening of drug candidates against this viral family. The current Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic revealed a new pathogen whose RNA synthesis machinery is highly (>96% aa identity) homologous to SARS-CoV. This phylogenetic relatedness highlights the potential use of conserved replication enzymes to discover inhibitors against this significant pathogen, which in turn, contributes to scientific preparedness against emerging viruses. Here, we report the use of a purified and highly active SARS-CoV replication/transcription complex (RTC) to set-up a high-throughput screening of Coronavirus RNA synthesis inhibitors. The screening of a small (1,520 compounds) chemical library of FDA-approved drugs demonstrates the robustness of our assay and will allow to speed-up drug repositioning or novel drug discovery against the SARS-CoV-2.

Principle of SARS-CoV RNA synthesis detection by a fluorescence-based high throughput screening assay

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=81 SRC=""FIGDIR/small/192005v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (20K):
org.highwire.dtl.DTLVardef@e8122dorg.highwire.dtl.DTLVardef@18557org.highwire.dtl.DTLVardef@1d95362org.highwire.dtl.DTLVardef@f15222_HPS_FORMAT_FIGEXP  M_FIG C_FIG Highlights- A new SARS-CoV non radioactive RNA polymerase assay is described
- The robotized assay is suitable to identify RdRp inhibitors based on HTS",biochemistry,exact,100,100
medRxiv,10.1101/2020.07.03.20145839,2020-07-04,https://medrxiv.org/cgi/content/short/2020.07.03.20145839,"The Impact of COVID-19 on Adjusted Mortality Risk in Care Homes for Older Adults in Wales, United Kingdom: A retrospective population-based cohort study for mortality in 2016-2020",Joe Hollinghurst; Jane Lyons; Richard Fry; Ashley Akbari; Mike Gravenor; Alan Watkins; Fiona Verity; Ronan A Lyons,Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University,"BackgroundMortality in care homes has had a prominent focus during the COVID-19 outbreak. Multiple and interconnected challenges face the care home sector in the prevention and management of outbreaks of COVID-19, including adequate supply of personal protective equipment, staff shortages, and insufficient or lack of timely COVID-19 testing. Care homes are particularly vulnerable to infectious diseases.

AimTo analyse the mortality of older care home residents in Wales during COVID-19 lockdown and compare this across the population of Wales and the previous 4-years.

Study Design and SettingWe used anonymised Electronic Health Records (EHRs) and administrative data from the Secure Anonymised Information Linkage (SAIL) Databank to create a cross-sectional cohort study. We anonymously linked data for Welsh residents to mortality data up to the 14th June 2020.

MethodsWe calculated survival curves and adjusted Cox proportional hazards models to estimate hazard ratios (HRs) for the risk of mortality. We adjusted hazard ratios for age, gender, social economic status and prior health conditions.

ResultsSurvival curves show an increased proportion of deaths between 23rd March and 14th June 2020 in care homes for older people, with an adjusted HR of 1{middle dot}72 (1{middle dot}55, 1{middle dot}90) compared to 2016. Compared to the general population in 2016-2019, adjusted care home mortality HRs for older adults rose from 2{middle dot}15 (2{middle dot}11,2{middle dot}20) in 2016-2019 to 2{middle dot}94 (2{middle dot}81,3{middle dot}08) in 2020.

ConclusionsThe survival curves and increased HRs show a significantly increased risk of death in the 2020 study periods.",public and global health,exact,100,100
bioRxiv,10.1101/2020.07.01.182709,2020-07-01,https://biorxiv.org/cgi/content/short/2020.07.01.182709,Genetic architecture of host proteins interacting with SARS-CoV-2,Maik Pietzner; Eleanor Wheeler; Julia Carrasco-Zanini; Johannes Raffler; Nicola D. Kerrison; Erin Oerton; Victoria P.W. Auyeung; Chris Finan; Juan P. Casas; Rachel Ostroff; Steve A. Williams; Gabi Kastenmller; Markus Ralser; Eric G. Gamazon; Nicholas J. Wareham; Aroon Dinesh Hingorani; Claudia Langenberg; Rachid El Jaoudi; Chakib Nejjari; Saaid Amzazi; Rachid Mentag; Lahcen Belyamani; Azeddine Ibrahimi; Sahan Bennett; Alain Kohl; Elihu Aranday-Cortes; Lily Tong; Jenna Nichols; Emma C Thomson; - The COVID-19 Genomics UK (COG-UK) consortium; Dennis Wang; Simon Mallal; Thushan I de Silva; Anett Rideg; Ok-Ryul Song; Amy Strange; Charles Swanton; Samra Turajlic; Philip A. Walker; Mary Wu; Caetano Reis e Sousa; - Crick COVID-19 Consortium,"University of Cambridge; University of Cambridge; University of Cambridge; Helmholtz Zentrum Mnchen - German Research Center for Environmental Health (GmbH); University of Cambridge; University of Cambridge; University of Cambridge; University College London; Harvard Medical School; SomaLogic Inc.; SomaLogic Inc.; Helmholtz Zentrum Mnchen - German Research Center for Environmental Health (GmbH); The Francis Crick Institute; Vanderbilt University Medical Center; University of Cambridge; University College London; University of Cambridge; Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, Morocco.; International School of Public Health, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.; Laboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V University in Rabat, Morocco; Biotechnology Unit, Regional Center of Agricultural Research of Rabat, National Institute of Agricultural Research, Rabat, Morocco.; Emergency Department, Military Hospital Mohammed V, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, Morocco.; Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, Morocco.; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; -; Sheffield Bioinformatics Core, Department of Computer Science, The University of Sheffield, Sheffield, UK.; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; The Florey Institute, Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield Teaching Hospitals NHS Fo; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; University College London; University College London Hospitals, NHS Foundation Trust; The Francis Crick Institute; The Royal Marsden Hospital; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; ","Strategies to develop therapeutics for SARS-CoV-2 infection may be informed by experimental identification of viral-host protein interactions in cellular assays and measurement of host response proteins in COVID-19 patients. Identification of genetic variants that influence the level or activity of these proteins in the host could enable rapid  in silico assessment in human genetic studies of their causal relevance as molecular targets for new or repurposed drugs to treat COVID-19. We integrated large-scale genomic and aptamer-based plasma proteomic data from 10,708 individuals to characterize the genetic architecture of 179 host proteins reported to interact with SARS-CoV-2 proteins or to participate in the host response to COVID-19. We identified 220 host DNA sequence variants acting in cis (MAF 0.01-49.9%) and explaining 0.3-70.9% of the variance of 97 of these proteins, including 45 with no previously known protein quantitative trait loci (pQTL) and 38 encoding current drug targets. Systematic characterization of pQTLs across the phenome identified protein-drug-disease links, evidence that putative viral interaction partners such as MARK3 affect immune response, and establish the first link between a recently reported variant for respiratory failure of COVID-19 patients at the ABO locus and hypercoagulation, i.e. maladaptive host response. Our results accelerate the evaluation and prioritization of new drug development programmes and repurposing of trials to prevent, treat or reduce adverse outcomes. Rapid sharing and dynamic and detailed interrogation of results is facilitated through an interactive webserver (https://omicscience.org/apps/covidpgwas/).",genomics,exact,100,100
bioRxiv,10.1101/2020.07.01.182618,2020-07-01,https://biorxiv.org/cgi/content/short/2020.07.01.182618,Early data on the performance of a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow device compared to a nucleocapsid-only device,Christian A. Linares; Felicity Ryan; Samuel E. Moses; Johannes Raffler; Nicola D. Kerrison; Erin Oerton; Victoria P.W. Auyeung; Chris Finan; Juan P. Casas; Rachel Ostroff; Steve A. Williams; Gabi Kastenmller; Markus Ralser; Eric G. Gamazon; Nicholas J. Wareham; Aroon Dinesh Hingorani; Claudia Langenberg; Rachid El Jaoudi; Chakib Nejjari; Saaid Amzazi; Rachid Mentag; Lahcen Belyamani; Azeddine Ibrahimi; Sahan Bennett; Alain Kohl; Elihu Aranday-Cortes; Lily Tong; Jenna Nichols; Emma C Thomson; - The COVID-19 Genomics UK (COG-UK) consortium; Dennis Wang; Simon Mallal; Thushan I de Silva; Anett Rideg; Ok-Ryul Song; Amy Strange; Charles Swanton; Samra Turajlic; Philip A. Walker; Mary Wu; Caetano Reis e Sousa; - Crick COVID-19 Consortium,"Medical Microbiology Service, Pathology Department, East Kent Hospitals University NHS Foundation Trust, Ashford, Kent TN24 0LZ; Medical Microbiology Service, Pathology Department, East Kent Hospitals University NHS Foundation Trust, Ashford, Kent TN24 0LZ; East Kent Hospitals University NHS Foundation Trust; Honorary Senior Lecturer, University of Kent; Helmholtz Zentrum Mnchen - German Research Center for Environmental Health (GmbH); University of Cambridge; University of Cambridge; University of Cambridge; University College London; Harvard Medical School; SomaLogic Inc.; SomaLogic Inc.; Helmholtz Zentrum Mnchen - German Research Center for Environmental Health (GmbH); The Francis Crick Institute; Vanderbilt University Medical Center; University of Cambridge; University College London; University of Cambridge; Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, Morocco.; International School of Public Health, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.; Laboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V University in Rabat, Morocco; Biotechnology Unit, Regional Center of Agricultural Research of Rabat, National Institute of Agricultural Research, Rabat, Morocco.; Emergency Department, Military Hospital Mohammed V, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, Morocco.; Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, Morocco.; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; Centre for Virus Research, The University of Glasgow, Glasgow, UK; -; Sheffield Bioinformatics Core, Department of Computer Science, The University of Sheffield, Sheffield, UK.; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; The Florey Institute, Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield Teaching Hospitals NHS Fo; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; University College London; University College London Hospitals, NHS Foundation Trust; The Francis Crick Institute; The Royal Marsden Hospital; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; ","The authors have withdrawn their manuscript whilst they perform additional experiments to test some of their conclusions further. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.",immunology,exact,100,100
medRxiv,10.1101/2020.06.29.20142448,2020-06-30,https://medrxiv.org/cgi/content/short/2020.06.29.20142448,Using past and current data to estimate potential crisis service use in mental healthcare after the COVID-19 lockdown: South London and Maudsley data,Robert Stewart; Matthew Broadbent; Wee Chian Koh; Mohammad Fathi Alikhan; Sirajul Adli Jamaludin; Wan Wen Patricia Poh; Lin Naing; delphine chretien; marija backovick; Agnes Moisan-Delaunay; flora donati; melanie albert; elsa foucaud; Bettina Mesplees; gregoire benoist; albert fayes; marc duval-arnould; celia cretolle; marina charbit; melodie aubart; Johanne Auriau; matthie lorrot; Dulanjalee Kariyawasam; laura fertita; Gilles Orliaguet; benedicte pigneur; Brigitte Bader-Meunier; coralie briand; julie toubiana; Tiffany Guilleminot; sylvie van der werf; marianne leruez-ville; marc eloit,"King's College London; South London and Maudsley NHS Foundation Trust; Centre for Strategic and Policy Studies; Disease Control Division, Ministry of Health, Brunei Darussalam; Environmental Health Division, Ministry of Health, Brunei Darussalam; Department of Dental Services, Ministry of Health, Brunei Darussalam; Universiti Brunei Darussalam, Brunei; institut pasteur; institut pasteur; cea; institut pasteur; institut pasteur; aphp; institut pasteur; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; aphp; institut pasteur; aphp; institut pasteur; aphp; institut pasteur","The lockdown policy response to the COVID-19 pandemic in the UK has a potentially important impact on provision of mental healthcare with uncertain consequences over the 12 months ahead. Past activity may provide a means to predict future demand. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource at the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for 1.2m residents in south London), we carried out a range of descriptive analyses to inform the Trust on patient groups who might be most likely to require inpatient and home treatment team (HTT) crisis care. We considered the 12 months following UK COVID-19 lockdown policy on 16th March, drawing on comparable findings from previous years, and quantified levels of change in service delivery to those most likely to receive crisis care. For 12-month crisis days from 16th March in 2015-19, we found that most (over 80%) were accounted for by inpatient care (rather than HTT), most (around 75%) were used by patients who were current or recent Trust patients at the commencement of follow-up, and highest numbers were used by patients with a previously recorded schizophreniform disorder diagnosis. For current/recent patients on 16th March there had been substantial reductions in use of inpatient care in the following 31 days in 2020, more than previous years; changes in total non-inpatient contact numbers did not differ in 2020 compared to previous years, although there had been a marked switch from face-to-face to virtual contacts.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.06.28.20141986,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20141986,Protocol for the development and evaluation of a tool for predicting risk of short-term adverse outcomes due to COVID-19 in the general UK population,Julia Hippisley-Cox; Ashley Kieran Clift; Carol AC Coupland; Ruth Keogh; Karla Diaz-Ordaz; Elizabeth Williamson; Ewen Harrison; Andrew Hayward; Harry Hemingway; Peter Horby; Nisha Mehta; Jonathan Kieran Benger; Kamlesh Khunti; David Spiegelhalter; Aziz Sheikh; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"University of Oxford; University of Oxford; University of Nottingham; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Edinburgh; University College London; University College London; University of Oxford; Department of Health and Social Care; NHS Digital; University of Leicester; University of Cambridge; University of Edinburgh; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","IntroductionNovel coronavirus 2019 (COVID-19) has propagated a global pandemic with significant health, economic and social costs. Emerging emergence has suggested that several factors may be associated with increased risk from severe outcomes or death from COVID-19. Clinical risk prediction tools have significant potential to generate individualised assessment of risk and may be useful for population stratification and other use cases.

Methods and analysisWe will use a prospective open cohort study of routinely collected data from 1205 general practices in England in the QResearch database. The primary outcome is COVID-19 mortality (in or out-of-hospital) defined as confirmed or suspected COVID-19 mentioned on the death certificate, or death occurring in a person with SARS-CoV-2 infection between 24th January and 30th April 2020. Our primary outcome in adults is COVID-19 mortality (including out of hospital and in hospital deaths). We will also examine COVID-19 hospitalisation in children. Time-to-event models will be developed in the training data to derive separate risk equations in adults (19-100 years) for males and females for evaluation of risk of each outcome within the 3-month follow-up period (24th January to 30th April 2020), accounting for competing risks. Predictors considered will include age, sex, ethnicity, deprivation, smoking status, alcohol intake, body mass index, pre-existing medical co-morbidities, and concurrent medication. Measures of performance (prediction errors, calibration and discrimination) will be determined in the test data for men and women separately and by ten-year age group. For children, descriptive statistics will be undertaken if there are currently too few serious events to allow development of a risk model. The final model will be externally evaluated in (a) geographically separate practices and (b) other relevant datasets as they become available.

Ethics and disseminationThe project has ethical approval and the results will be submitted for publication in a peer-reviewed journal.

Strengths and limitations of the studyO_LIThe individual-level linkage of general practice, Public Health England testing, Hospital Episode Statistics and Office of National Statistics death register datasets enable a robust and accurate ascertainment of outcomes
C_LIO_LIThe models will be trained and evaluated in population-representative datasets of millions of individuals
C_LIO_LIShielding for clinically extremely vulnerable was advised and in place during the study period, therefore risk predictions influenced by the presence of some  shielding conditions may require careful consideration
C_LI",epidemiology,exact,100,100
medRxiv,10.1101/2020.06.28.20136168,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20136168,SARS-CoV-2 & Pediatric Mental Health: A Review of Recent Evidence,Mir Ibrahim Sajid; Javeria Tariq; Ayesha Akbar Waheed; Dure Najaf; Samira Shabbir Balouch; Sajid Abaidullah; Ewen Harrison; Andrew Hayward; Harry Hemingway; Peter Horby; Nisha Mehta; Jonathan Kieran Benger; Kamlesh Khunti; David Spiegelhalter; Aziz Sheikh; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"The Aga Khan University; The Aga Khan University; The Aga Khan University; The Aga Khan University; King Edward Medical University; King Edward Medical University; University of Edinburgh; University College London; University College London; University of Oxford; Department of Health and Social Care; NHS Digital; University of Leicester; University of Cambridge; University of Edinburgh; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO) and was met with lockdown policies to curb the spread of the disease. This meant that 890 million students in 114 countries would be affected by the closure of their educational institutes, affecting their mental health. Mental health disorders are suggested to have a well-correlated link to suicide, which is the third most leading cause of death worldwide amongst children aged 15-19 years. According to WHO, ""health is a state of complete physical, mental and social wellbeing and not merely the absence of disease."" Hence the isolation brought about by SARS-CoV-2 is postulated to cause anxiety, fear, and depression amongst the pediatric population, due to the loss of socialization and separation from friends. In this systematic review and meta-analysis, we highlight the major mental health issues in children aged 2-18 years, along with their causes, effects, and potential solutions to tackle these problems.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.06.27.20141770,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.27.20141770,Readability of selected governmental and popular health organization websites on Covid-19 public health information: A descriptive analysis,Patricia Moyinoluwa Ojo; Tolulope Omowonuola Okeowo; Ann Mary Thampy; Zubair Kabir; Samira Shabbir Balouch; Sajid Abaidullah; Ewen Harrison; Andrew Hayward; Harry Hemingway; Peter Horby; Nisha Mehta; Jonathan Kieran Benger; Kamlesh Khunti; David Spiegelhalter; Aziz Sheikh; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"University College Cork; University College Cork; University College Cork; University College Cork; King Edward Medical University; King Edward Medical University; University of Edinburgh; University College London; University College London; University of Oxford; Department of Health and Social Care; NHS Digital; University of Leicester; University of Cambridge; University of Edinburgh; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","BackgroundThe U.S. Department of Health & Human Services (USDHHS) recommends that health material be written at or below a sixth-grade reading level to ensure readability. The aim of this study was to examine the readability of international and national health organizations on Covid-19 information in their websites employing a previously validated tool.

MethodsA purposive sample of publicly accessible governmental and popular international health organization websites was selected. The readability of the websites Covid-19 public health information was estimated using the previously validated SMOG readability formula, which determined reading level by correlating the number of polysyllabic words.

ResultsOf the 10 websites included in the analysis, none had Covid-19 public health information at the USDHHSs recommended reading level. The material ranged in reading level at undergraduate level or above.

DiscussionThe findings indicate that the online Covid-19 materials need to be modified in order to reach recommended reading levels. This study can be of practical use to policy makers and public health government officials when designing, modifying, and evaluating Covid-19 materials. We recommend using simple, non-polysyllable words to ensure that Covid-19 public health information materials are written at the recommended reading levels.",public and global health,exact,100,100
medRxiv,10.1101/2020.06.29.20142307,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.29.20142307,Temperature and Humidity Do Not Influence Global COVID-19 Incidence as Inferred from Causal Models,Raghav Awasthi; Aditya Nagori; Pradeep Singh; Ridam Pal; Vineet Joshi; Tavpritesh Sethi; Ewen Harrison; Andrew Hayward; Harry Hemingway; Peter Horby; Nisha Mehta; Jonathan Kieran Benger; Kamlesh Khunti; David Spiegelhalter; Aziz Sheikh; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"IIIT-Delhi; CSIR-Institute of Genomics and Integrative Biology; IIIT-Delhi; IIIT-Delhi; IIIT-Delhi; IIIT-Delhi; University of Edinburgh; University College London; University College London; University of Oxford; Department of Health and Social Care; NHS Digital; University of Leicester; University of Cambridge; University of Edinburgh; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","The relationship between meteorological factors such as temperature and humidity with COVID-19 incidence is still unclear after 6 months of the beginning of the pandemic. Some literature confirms the association of temperature with disease transmission while some oppose the same. This work intends to determine whether there is a causal association between temperature, humidity and Covid-19 cases. Three different causal models were used to capture stochastic, chaotic and symbolic natured time-series data and to provide a robust & unbiased analysis by constructing networks of causal relationships between the variables. Granger-Causality method, Transfer Entropy method & Convergent Cross-Mapping (CCM) was done on data from regions with different temperatures and cases greater than 50,000 as of 13th May 2020. From the Granger-Causality test we found that in only Canada, the United Kingdom, temperature and daily new infections are causally linked. The same results were obtained from Convergent Cross Mapping for India. Again using Granger-Causality test, we found that in Russia only, relative humidity is causally linked to daily new cases. Thus, a Generalized Additive Model with a smoothing spline function was fitted for these countries to understand the directionality. Using the combined results of the said models, we were able to conclude that there is no evidence of a causal association between temperature, humidity and Covid-19 cases.",public and global health,exact,100,100
medRxiv,10.1101/2020.06.28.20142232,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20142232,EVALUATION OF THE ROCHE ELECSYS ANTI-SARS-COV-2 ASSAY.,CS Lau; SP Hoo; SF Yew; SK Ong; LT Lum; PY Heng; JG Tan; MS Wong; TC Aw; Peter Horby; Nisha Mehta; Jonathan Kieran Benger; Kamlesh Khunti; David Spiegelhalter; Aziz Sheikh; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"Changi General Hospital; Changi General Hospital; Changi General Hospital; Sengkang General Hospital; Sengkang General Hospital; Khoo Teck Puat Hospital; Khoo Teck Puat Hospital; Khoo Teck Puat Hospital; Changi General Hospital; University of Oxford; Department of Health and Social Care; NHS Digital; University of Leicester; University of Cambridge; University of Edinburgh; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","BackgroundLittle is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay analysers.

MethodsWe assessed the linearity, precision, and throughput of the Roche anti-SARS-CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction (PCR) positive samples; specificity was determined from 714 coronavirus disease 2019 (COVID-19)-naive samples. We examined cross-reactivity against other antibody positive samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-CoV-2 kinetics.

ResultsThe assay cut-off index (COI) was linear up to 90.7. The inter-assay precision was 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time is 18min and results are available 1 minute later; throughput for 300 samples was 76 minutes. No cross-reactivity was observed with other antibody positive samples; specificity was 100%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and 100% at [&ge;]21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11 subjects in whom serum was available prior to a positive antibody signal (COI [&ge;]1.0) the interval between the last negative and first positive COI (time to ""sero-conversion"") on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to plateau.

ConclusionThe Roche anti-SARS-CoV-2 assay shows excellent performance with minimal cross-reactivity from other viral and confounding antibodies. Antibody development and sero-conversion appears quite early.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.28.20141945,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20141945,"A Robust, Safe and Scalable Magnetic Nanoparticle Workflow for RNA Extraction of Pathogens from Clinical and Environmental Samples",Gerardo Ramos-Mandujano; Rahul Salunke; Sara Mfarrej; Andri Rachmadi; Sharif Hala; Jinna Xu; Fadwa S Alofi; Asim Khogeer; Anwar M Hashem; Naif AM Almontashiri; Afrah Alsomali; Samir Hamdan; Peiying Hong; Arnab Pain; Mo Li; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Infectious Diseases Department, King Fahad Hospital, Madinah, Saudi Arabia; Plan and Research Department, General Directorate of Health Affairs Makkah Region, MOH, Saudi Arabia; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center; King Abdulaziz University, Jeddah, Saudi Arabia; College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia; King Abdullah Medical Complex (KAMC), Jeddah, Saudi Arabia; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","Diagnosis and surveillance of emerging pathogens such as SARS-CoV-2 depend on nucleic acid isolation from clinical and environmental samples. Under normal circumstances, samples would be processed using commercial proprietary reagents in Biosafety 2 (BSL-2) or higher facilities. A pandemic at the scale of COVID-19 has caused a global shortage of proprietary reagents and BSL-2 laboratories to safely perform testing. Therefore, alternative solutions are urgently needed to address these challenges. We developed an open-source method called Magnetic-nanoparticle-Aided Viral RNA Isolation of Contagious Samples (MAVRICS) that is built upon reagents that are either readily available or can be synthesized in any molecular biology laboratory with basic equipment. Unlike conventional methods, MAVRICS works directly in samples inactivated in acid guanidinium thiocyanate-phenol-chloroform (e.g., TRIzol), thus allowing infectious samples to be handled safely without biocontainment facilities. Using 36 COVID-19 patient samples, 2 wastewater samples and 1 human pathogens control sample, we showed that MAVRICS rivals commercial kits in validated diagnostic tests of SARS-CoV-2, influenza viruses, and respiratory syncytial virus. MAVRICS is scalable and thus could become an enabling technology for widespread community testing and wastewater monitoring in the current and future pandemics.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.28.20140475,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20140475,Reliability of serological tests for COVID-19: Comparison of three immunochromatography test kits for SARS-CoV-2 antibodies.,Hidetsugu Fujigaki; Masao Takemura; Michiko Osawa; Aki Sakurai; Kentaro Nakamoto; Koichi Seto; Takashi Fujita; Tadayoshi Hata; Hidehiko Akiyama; Yohei Doi; Kuniaki Saito; Samir Hamdan; Peiying Hong; Arnab Pain; Mo Li; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"Fujita Health University Graduate School of Health Sciences; Fujita Health University Graduate School of Health Sciences; Fujita Health University Hospital; Fujita Health University School of Medicine; Fujita Health University Graduate School of Health Sciences; Fujita Health University; Fujita Health University Hospital; Fujita Health University Hospital; Fujita Health University Graduate School of Health Sciences; Fujita Health University School of Medicine; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","BackgroundSeveral immunochromatographic serological test kits have been developed to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies, but their relative performance and potential clinical utility is unclear.

MethodsThree commercially available serological test kits were evaluated using 99 serum samples collected from 29 patients diagnosed with coronavirus disease 2019 (COVID-19).

ResultsThe IgM antibody-positive rates of the three serological test kits for samples taken at the early stage of the disease (0-6 days after onset) were 19.0%, 23.8%, and 19.0%, respectively. The IgM antibody-positive rates over the entire period were 21.2%, 60.6%, and 15.2%, respectively. The IgG antibody-positive rates for samples taken after 13 days of onset were 100.0%, 97.6%, and 97.6%, respectively.

ConclusionThere were large differences among the results of the three test kits. Only few cases showed positive results for IgM in the early stage of disease and the IgM antibody-positive rates over the entire period were low, suggesting that the kits used in this study were unsuitable for diagnosis of COVID-19. The IgG antibody was positive in almost all samples after 13 days of onset, suggesting that it may be useful for determining infections in the recent past.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.28.20142240,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20142240,Association of BMI and Obesity with Composite poor outcome in COVID-19 adult patients: A Systematic Review and Meta-Analysis,Arto Yuwono Soeroto; Nanny Natalia Soetedjo; Aga Purwiga; Prayudi Santoso; Iceu Dimas Kulsum; Hendarsyah Suryadinata; Ferdy Ferdian; Tadayoshi Hata; Hidehiko Akiyama; Yohei Doi; Kuniaki Saito; Samir Hamdan; Peiying Hong; Arnab Pain; Mo Li; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandu; Division of Endocrine and Metabolism, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandu; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandu; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandu; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandu; Fujita Health University Hospital; Fujita Health University Graduate School of Health Sciences; Fujita Health University School of Medicine; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","AimThis study aimed to evaluate the association between obesity and composite poor outcome in coronavirus disease 2019 (COVID-19) patients.

MethodsWe conducted a systematic literature search from PubMed and Embase database. We included all original research articles in COVID-19 adult patients and obesity based on classification of Body Mass Index (BMI) and composite poor outcome which consist of mortality, morbidity, admission of Intensive Care Unit (ICU), mechanical ventilation, Acute Respiratory Distress Syndrome (ARDS), and severe COVID-19.

ResultsNine studies were included in meta-analysis with 6 studies presented BMI as continuous outcome and 3 studies presented BMI as dichotomous outcome (obese and non-obese). Most studies were conducted in China (55.5%) with remaining studies from French, Germany, and United States (US). COVID-19 patients with composite poor outcome had higher BMI with mean difference 0.55 kg/m2 (95% CI 0.07-1.03, P=0.02). BMI [&ge;]30 (obese) was associated with composite poor outcome with odds ratio 1.89 (95% CI 1.06-3.34, P=0.03). Multivariate meta-regression analysis by including three moderators: age, hypertension, and Diabetes Mellitus type 2 (DM type 2) showed the association between obesity and composite poor outcome was affected by age with regression coefficient =-0.06 and P=0.02. Subgroup analysis was not performed due to the limited number of studies for several outcomes.

ConclusionObesity is a risk factor of composite poor outcome of COVID-19. On the other hand, COVID-19 patients with composite poor outcome have higher BMI. BMI is an important routine procedure that should be assessed in the management of COVID-19 patients and special attention should be given to patients with obesity.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.28.20142190,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20142190,Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City,Daniel Stadlbauer; Jessica Tan; Kaijun Jiang; Matthew Hernandez; Shelcie Fabre; Fatima Amanat; Catherine Teo; Guh Asthagiri Arunkumar; Meagan McMahon; Jeffrey Jhang; Michael Nowak; Viviana Simon; Emilia Sordillo; Harm van Bakel; Florian Krammer; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Mount Sinai Hospital; Icahn School of Medicine; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","By conducting a retrospective, cross-sectional analysis of SARS-CoV-2 seroprevalence in a  sentinel group (enriched for SARS-CoV-2 infections) and a  screening group (representative of the general population) using >5,000 plasma samples from patients at Mount Sinai Hospital in New York City (NYC), we identified seropositive samples as early as in the week ending February 23, 2020. A stark increase in seropositivity in the sentinel group started the week ending March 22 and in the screening group in the week ending March 29. By the week ending April 19, the seroprevalence in the screening group reached 19.3%, which is well below the estimated 67% needed to achieve community immunity to SARS-CoV-2. These data potentially suggest an earlier than previously documented introduction of SARS-CoV-2 into the NYC metropolitan area.

One Sentence SummarySeroprevalence of SARS-CoV-2 in cross-sectional samples from New York City rose from 0% to 19.3% from early February to mid-April.",epidemiology,exact,100,100
medRxiv,10.1101/2020.06.28.20141655,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20141655,Excess mortality and potential undercounting of COVID-19 deaths by demographic group in Ohio,Troy Quast; Ross Andel; Kaijun Jiang; Matthew Hernandez; Shelcie Fabre; Fatima Amanat; Catherine Teo; Guh Asthagiri Arunkumar; Meagan McMahon; Jeffrey Jhang; Michael Nowak; Viviana Simon; Emilia Sordillo; Harm van Bakel; Florian Krammer; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"University of South Florida, College of Public Health; University of South Florida, College of Behavioral and Community Sciences; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Mount Sinai Hospital; Icahn School of Medicine; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","BackgroundThere are significant gaps in our understanding of the mortality effects of COVID-19 due to evolving diagnosis criteria, shortages of testing supplies, and challenges faced by physicians in treating patients in crisis environments. Accurate information on the number of deaths caused by COVID-19 is vital for policy makers and health care providers.

MethodsWe performed a retrospective study of weekly data for Ohio. To estimate expected mortality in 2020 we employed data from 2010 through 2019, adjusted for secular trends and seasonality. We estimated excess mortality as the number of observed deaths less the number of expected deaths. We conducted the analysis for the entire population and by age, gender, and county.

ResultsWe estimated 2,088 (95% CI 1,119-3,119) excess deaths due to natural causes in Ohio from March 15, 2020 through June 6, 2020. While the largest number excess of deaths was observed in the 80+ age group, our estimate of 366 (95% CI 110-655) excess deaths for those between 20 and 49 years of age substantially exceeds the reported number of COVID-19 deaths of 66.

ConclusionsOur methodology addressed some of the challenges of estimating the number of deaths caused by COVID-19. Our finding of excess deaths being considerably greater than the reported number of COVID-19 deaths for those aged 20 to 49 years old suggests that current tracking methods may not capture a significant number of COVID-19 deaths for this group. Further, increases in the infection rates for this cohort may have a greater mortality impact than anticipated.",epidemiology,exact,100,100
medRxiv,10.1101/2020.06.29.20142281,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.29.20142281,Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy,Antonio Rivero-Juarez; Mario Frias; Isabel Machuca; Marina Gallo; Pedro Lopez-Lopez; Angela Camacho; Antonio Rivero; Guh Asthagiri Arunkumar; Meagan McMahon; Jeffrey Jhang; Michael Nowak; Viviana Simon; Emilia Sordillo; Harm van Bakel; Florian Krammer; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"IMIBIC; IMIBIC; IMIBIC; IMIBIC; IMIBIC; IMIBIC; IMIBIC; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Mount Sinai Hospital; Icahn School of Medicine; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","BackgroundRibavirin (RBV) is been used for SARS-CoV-2 infection. This drug is associated with a wide range of side effects, mainly anemia, so its use in patients with potential respiratory affectation could not be appropriate. The evidences of adverse events associated with RBV-use has mainly been derived in the context of hepatitis C (HCV) treatment, however the possible use of RBV in CoVID-19 patients could be limited to 14 days.

MethodsLongitudinal study including HIV/HCV coinfected patients. We evaluate the hemoglobin dynamics and reductions as well as evaluate the development rate of anemia during the first 2 weeks of therapy in HCV infected patients.

Results189 patients were included in the study. The median hemoglobin levels were 14.6 g/dL (IQR: 13.2-15.6 g/dL) and 13.5 g/dL (IQR: 12.3-14.5 g/dL) at weeks 1 and 2 of therapy, respectively. A cumulative number of 27 (14.2%) patients developed anemia (23 grade 1 [12.1%] and 4 grade 2 [2.1%]). We identify a baseline hemoglobin levels of 14 g/dL as the better cut-off to identify those patients with a high chance to develop anemia. Of the 132 patients with baseline hemoglobin level >14 g/dL, 8 developed anemia (6.1%) compared with 19 of 57 (33.3%) with hemoglobin levels lower than 14 g/dL (p < 0.001).

ConclusionsOur study shows valuable information about the early hemoglobin kinetic timing in patients on RBV-therapy, that could be useful to tailor CoVID-19 treatment if RBV use is considered.",toxicology,exact,100,100
medRxiv,10.1101/2020.06.28.20141960,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20141960,Data presented by the UK government as lockdown was eased shows the transmission of COVID-19 had already increased.,Mike Lonergan; Mario Frias; Isabel Machuca; Marina Gallo; Pedro Lopez-Lopez; Angela Camacho; Antonio Rivero; Guh Asthagiri Arunkumar; Meagan McMahon; Jeffrey Jhang; Michael Nowak; Viviana Simon; Emilia Sordillo; Harm van Bakel; Florian Krammer; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"University of Dundee; IMIBIC; IMIBIC; IMIBIC; IMIBIC; IMIBIC; IMIBIC; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Mount Sinai Hospital; Icahn School of Medicine; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","BackgroundCoronavirus disease 2019 (COVID-19) is an international emergency that has been addressed in many countries by changes in and restrictions on behaviour. These are often collectively labelled social distancing and lockdown. On the 23rd June 2020, Boris Johnson, the Prime Minister of the United Kingdom announced substantial easings of restrictions. This paper examines some of the data he presented.

MethodsGeneralised additive models, with negative binomial errors and cyclic term representing day-of-week effects, were fitted to data on the daily numbers of new confirmed cases of COVID-19. Exponential rates for the epidemic were estimated for different periods, and then used to calculate R, the reproduction number, for the disease in different periods.

ResultsAfter an initial stabilisation, the lockdown reduced R to around 0.81 (95% CI: 0.79, 0.82). This value increased to around 0.94 (95% CI 0.89, 0.996) for the fortnight from the 9th June 2020.

ConclusionsOfficial UK data, presented as the easing of the lockdown was announced, shows that R was already more than half way back to 1 at that point. That suggests there was little scope for the announced changes to be implemented without restarting the spread of the disease.",health policy,exact,100,100
medRxiv,10.1101/2020.06.28.20142174,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20142174,COVID-19: Saving lives and livelihoods using population density driven testing,Karim I Budhwani; Henna Budhwani; Ben Podbielski; Marina Gallo; Pedro Lopez-Lopez; Angela Camacho; Antonio Rivero; Guh Asthagiri Arunkumar; Meagan McMahon; Jeffrey Jhang; Michael Nowak; Viviana Simon; Emilia Sordillo; Harm van Bakel; Florian Krammer; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung,"CerFlux, Inc.; University of Alabama at Birmingham (UAB); Protective Life Corp.; IMIBIC; IMIBIC; IMIBIC; IMIBIC; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai Hospital; Mount Sinai Hospital; Icahn School of Medicine; Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine; University of Chicago Medicine","SARS-CoV-2 transmission risk generally increases with proximity of those shedding the virus to those susceptible to infection. Thus, this risk is a function of both number of people and the area which they occupy. However, the latter continues to evade COVID-19 testing policy. Increased testing in areas with lower population density, has the potential to induce a false sense of security even as cases continue to rise sharply overall.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.24.20139048,2020-06-25,https://medrxiv.org/cgi/content/short/2020.06.24.20139048,A geotemporal survey of hospital bed saturation across England during the first wave of the COVID-19 Pandemic,Bilal A Mateen; Harrison Wilde; John m Dennis; Andrew Duncan; Nicholas John Meyrick Thomas; Andrew P McGovern; Spiros Denaxas; Matt J Keeling; Sebastian J Vollmer; Airu Zhu; Jiandong Li; Peidi Ren; Zhihua Ou; Minfeng Xiao; Min Li; Ziqing Deng; Huanzi Zhong; Fuqiang Li; Weijun Chen; Shida Zhu; Wenjing Wang; Yongwei Zhang; Xun Xu; Xin Jin; Jingxian Zhao; Nanshan Zhong; Wenwei Zhang; Jincun Zhao; Junhua Li; Yonghao Xu; Eng Lim Goh; Joachim L. Schultze; - German COVID-19 OMICS Initiative (DeCOI); Shelli Farhadian; Anita Huttner; danielle seilhean; Nicolas RENIER; Kaya Bilguvar; Akiko Iwasaki,"The Alan Turing Institute; University of Warwick; Kings College Hospital NHS Foundation Trust; University of Warwick, Department of Statistics; University of Exeter Medical School; The Alan Turing Institute; Imperial College London, Faculty of Natural Sciences; University of Exeter Medical School; Royal Devon and Exeter NHS Foundation Trust, Diabetes and Endocrinology; University of Exeter Medical School; University College London; University of Warwick; The Alan Turing Institute; University of Warwick, Department of Statistics; First Affiliated Hospital of Guangzhou Medical University; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; BGI; First Affiliated Hospital of Guangzhou Medical University; First Affiliated Hospital of Guangzhou Medical University; BGI; First Affiliated Hospital of Guangzhou Medical University; BGI; First Affiliated Hospital of Guangzhou Medical University; Hewlett Packard Enterprise; PRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases, Bonn, Germany and University of Bonn, Bonn Germany; ; Yale School of Medicine; Yale University School of Medicine; INSERM; INSERM; Yale University; Yale University School of Medicine","BackgroundNon-pharmacological interventions were introduced based on modelling studies which suggested that the English National Health Service (NHS) would be overwhelmed by the COVID-19 pandemic. In this study, we describe the pattern of bed occupancy across England during the first wave of the pandemic, January 31st to June 5th 2020.

MethodsBed availability and occupancy data was extracted from daily reports submitted by all English secondary care providers, between 27-Mar and 5-June. Two thresholds for  safe occupancy were utilized (85% as per Royal College of Emergency Medicine and 92% as per NHS Improvement).

FindingsAt peak availability, there were 2711 additional beds compatible with mechanical ventilation across England, reflecting a 53% increase in capacity, and occupancy never exceeded 62%. A consequence of the repurposing of beds meant that at the trough, there were 8{middle dot}7% (8,508) fewer general and acute (G&A) beds across England, but occupancy never exceeded 72%. The closest to (surge) capacity that any trust in England reached was 99{middle dot}8% for general and acute beds. For beds compatible with mechanical ventilation there were 326 trust-days (3{middle dot}7%) spent above 85% of surge capacity, and 154 trust-days (1{middle dot}8%) spent above 92%. 23 trusts spent a cumulative 81 days at 100% saturation of their surge ventilator bed capacity (median number of days per trust = 1 [range: 1 to 17]). However, only 3 STPs (aggregates of geographically co-located trusts) reached 100% saturation of their mechanical ventilation beds.

InterpretationThroughout the first wave of the pandemic, an adequate supply of all bed-types existed at a national level. Due to an unequal distribution of bed utilization, many trusts spent a significant period operating above  safe-occupancy thresholds, despite substantial capacity in geographically co-located trusts; a key operational issue to address in preparing for a potential second wave.

FundingThis study received no funding.

Research In ContextO_ST_ABSEvidence Before This StudyC_ST_ABSWe identified information sources describing COVID-19 related bed and mechanical ventilator demand modelling, as well as bed occupancy during the first wave of the pandemic by performing regular searches of MedRxiv, PubMed and Google, using the terms  COVID-19,  mechanical ventilators,  bed occupancy,  England,  UK,  demand, and  non-pharmacological interventions (NPIs), until June 20th, 2020. Two UK-specific studies were found that modelled the demand for mechanical ventilators, one of which incorporated sensitivity analysis based on the introduction of NPIs and found that their effects might prevent the healthcare system being overwhelmed. Separately, several news reports were found pertaining to a single hospital that reached ventilator capacity in England during the first wave of the pandemic, however, no single authoritative source was identified detailing impact across all hospital sites in England.

Added Value of This StudyThis national study of hospital-level bed occupancy in England provides unique and timely insight into bed-specific resource utilization during the first wave of the COVID-19 pandemic, nationally, and by specific (geographically defined) health footprints. We found evidence of an unequal distribution of resource utilization across England. Although occupancy of beds compatible with mechanical ventilation never exceeded 62% at the national level, 52 (30%) hospitals across England reached 100% saturation at some point during the first wave of the pandemic. Close examination of the geospatial data revealed that in the vast majority of circumstances there was relief capacity in geographically co-located hospitals. Over the first wave it was theoretically possible to markedly reduce (by 95.1%) the number of hospitals at 100% saturation of their mechanical ventilator bed capacity by redistributing patients to nearby hospitals.

Implications Of All The Available EvidenceNow-casting using routinely collected administrative data presents a robust approach to rapidly evaluate the effectiveness of national policies introduced to prevent a healthcare system being overwhelmed in the context of a pandemic illness. Early investment in operational field hospital and an independent sector network may yield more overtly positive results in the winter, when G&A occupancy-levels regularly exceed 92% in England, however, during the first wave of the pandemic they were under-utilized. Moreover, in the context of the non-pharmacological interventions utilized during the first wave of COVID-19, demand for beds and mechanical ventilators was much lower than initially predicted, but despite this many trust spent a significant period of time operating above  safe-occupancy thresholds. This finding demonstrates that it is vital that future demand (prediction) models reflect the nuances of local variation within a healthcare system. Failure to incorporate such geographical variation can misrepresent the likelihood of surpassing availability thresholds by averaging out over regions with relatively lower demand, and presents a key operational issue for policymakers to address in preparing for a potential second wave.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.06.21.20136853,2020-06-23,https://medrxiv.org/cgi/content/short/2020.06.21.20136853,Modelling the impact of lockdown easing measures on cumulative COVID-19 cases and deaths in England,Hisham Ziauddeen; Naresh Subramaniam; Deepti Gurdasani; Long Chu; James Camac; Talha Chafekar; Ninad Mehendale; Geoffrey Wool; Amy Durkin; Won Hee Oh; Laura Trockman; Janani Vigneswaran; Robert Keskey; Dustin G Shaw; Haley Dugan; Nai Zheng; Mari Cobb; Henry Utset; Jiaolong Wang; Olivia Stovicek; Cindy Bethel; Scott Matushek; Mihai Giurcanu; Kathleen Beavis; Diego diSabato; David Meltzer; Mark Ferguson; John P Kress; Kumaran Shanmugarajah; Jeffrey Matthews; John Fung; Patrick Wilson; John C Alverdy; Jessica Donington,"Dept. of Psychiatry, University of Cambridge, Cambridge, UK; Dept. of Psychiatry, University of Cambridge, Cambridge UK; Queen Mary University of London; Australian National University; University of Melbourne; K. J. Somaiya College of Engineering; K. J. Somaiya College of Engineering; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; Unviversity of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; The University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago","BackgroundAs countries begin to ease the lockdown measures instituted to control the COVID-19 pandemic, there is a risk of a resurgence of the pandemic, and early reports of this are already emerging from some countries. Unlike many other countries, the UK started easing lockdown in England when levels of community transmission were still high, and this could have a major impact on case numbers and deaths. However thus far, the likely impacts of easing restrictions at this point in the pandemic have not been quantified. Using a Bayesian model, we assessed the potential impacts of successive lockdown easing measures in England, focussing on scenarios where the reproductive number (R) remains [&le;]1 in line with the UK governments stated aim.

MethodsWe developed a Bayesian model to infer incident cases and R in England, from incident death data from the Office of National Statistics. We then used this to forecast excess cases and deaths in multiple plausible scenarios in which R increases at one or more time points, compared to a baseline scenario where R remains unchanged by the easing of lockdown.

FindingsThe model inferred an R of 0.752 on the 13th May when England first started easing lockdown. In the most conservative scenario where R increases to 0.80 as lockdown was eased further on 1st June and then remained constant, the model predicts an excess 257 (95% 108-492) deaths and 26,447 (95% CI 11,105-50,549) cumulative cases over 90 days. In the scenario with maximal increases in R (but staying [&le;]1) with successive easing of lockdown, the model predicts 3,174 (95% 1,334-6,060) excess cumulative deaths and 421,310 (95% 177,012-804,811) excess cases.

ResultsWhen levels of transmission are high, even small changes in R with easing of lockdown can have significant impacts on expected cases and deaths, even if R remains [&le;]1. This will have a major impact on population health, tracing systems and health care services in England.. Following an elimination strategy rather than one of maintenance of R below 1 would substantially mitigate the impact of the COVID-19 epidemic within England. This study provides urgently needed information for developing public health policy for the next stages of the pandemic.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.22.20137182,2020-06-23,https://medrxiv.org/cgi/content/short/2020.06.22.20137182,Obesity during the COVID-19 pandemic: cause of high risk or an effect of lockdown? A population-based electronic health record analysis in 1 958 184 individuals.,Michail Katsoulis; Laura Pasea; Alvina Lai; Richard JB Dobson; Spiros Denaxas; Harry Hemingway; Amitava Banerjee; Pippa Corrie; Nicola L Ainsworth; Elise Whitley; Srinivasa Vittal Katikireddi; Richard Quinton; Meredith Redd; Linda A Gallo; Kirsty R Short; Nai Zheng; Mari Cobb; Henry Utset; Jiaolong Wang; Olivia Stovicek; Cindy Bethel; Scott Matushek; Mihai Giurcanu; Kathleen Beavis; Diego diSabato; David Meltzer; Mark Ferguson; John P Kress; Kumaran Shanmugarajah; Jeffrey Matthews; John Fung; Patrick Wilson; John C Alverdy; Jessica Donington,"UCL; University College London; University College London; University College London; University College London; University College London; University College London; Cambridge University Hospitals NHS Foundation Trust; The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust; University of Glasgow; University of Glasgow; University of Newcastle-upon-Tyne and Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia; School of Biomedical Sciences, The University of Queensland, Brisbane, Australia; School of Chemistry and Molecular Biosciences, and School of Public Health, The University of Queensland, Brisbane, Australia; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; The University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago","BackgroundObesity is a modifiable risk factor for coronavirus(COVID-19)-related mortality. We estimated excess mortality in obesity, both ""direct"", through infection, and ""indirect"", through changes in healthcare, and also due to potential increasing obesity during lockdown.

MethodsIn population-based electronic health records for 1 958 638 individuals in England, we estimated 1-year mortality risk(""direct"" and ""indirect"" effects) for obese individuals, incorporating: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)population infection rate, and (iii)relative impact on mortality(relative risk, RR: 1.2, 1.5, 2.0 and 3.0). Using causal inference models, we estimated impact of change in body-mass index(BMI) and physical activity during 3-month lockdown on 1-year incidence for high-risk conditions(cardiovascular diseases, CVD; diabetes; chronic obstructive pulmonary disease, COPD and chronic kidney disease, CKD), accounting for confounders.

FindingsFor severely obese individuals (3.5% at baseline), at 10% population infection rate, we estimated direct impact of 240 and 479 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 383 to 767 excess deaths, assuming 40% and 80% will be affected at RR=1.2. Due to BMI change during the lockdown, we estimated that 97 755 (5.4%: normal weight to overweight, 5.0%: overweight to obese and 1.3%: obese to severely obese) to 434 104 individuals (15%: normal weight to overweight, 15%: overweight to obese and 6%: obese to severely obese) individuals would be at higher risk for COVID-19 over one year.

InterpretationPrevention of obesity and physical activity are at least as important as physical isolation of severely obese individuals during the pandemic.

O_TEXTBOXResearch in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome Open Research for peer-reviewed articles, preprints, and research reports on obesity, excess mortality and change in body-mass index in the coronavirus disease 2019 (COVID-19), using the search terms ""obesity"", ""coronavirus"", ""COVID-19"", and similar terms, and ""mortality"", up to June 15, 2020. We found no prior studies of excess deaths in obese individuals due to COVID-19 pandemic, and no studies of long-term estimates or the relative impact of COVID-19 on mortality. Moreover, there were no studies of change in body-mass index during lockdown periods. Without these data, it is difficult to make specific recommendations in obese people at individual or population level during the pandemic.

Added value of this studyWe estimated excess COVID-19-related mortality in severely obese individuals, targeted in physical distancing and isolation policies in UK government guidance. Assuming 10% infection rate, we estimated a direct impact of 240 to 479 excess deaths in England and indirect effect of 383 to 767 excess deaths. On the other hand, we estimated that between 97 755 and 434 104 individuals may develop high-risk conditions for COVID-19 mortality during a 3-month lockdown due to change in body-mass index and physical activity.

Implications of all the available evidenceThese analyses support COVID-19 and non-COVID-19 impact assessment in policy planning during the pandemic. The implications of distancing and isolation measures on incidence and mortality from chronic diseases, particularly relating to obesity, needs to be considered in clinical practice, public health and research.

C_TEXTBOX",health policy,exact,100,100
medRxiv,10.1101/2020.06.19.20135491,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.19.20135491,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis",- The OpenSAFELY Collaborative; Anna Schultze; Alex J Walker; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Christopher T. Rentsch; Elizabeth J Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William J Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre; A. John Iafrate; Eric S Rosenberg; Jochen Lennerz,"; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital","BackgroundEarly descriptions of the coronavirus outbreak showed a lower prevalence of asthma and COPD than was expected for people diagnosed with COVID-19, leading to speculation that inhaled corticosteroids (ICS) may protect against infection with SARS-CoV-2, and development of serious sequelae. We evaluated the association between ICS and COVID-19 related death using linked electronic health records in the UK.

MethodsWe conducted cohort studies on two groups of people (COPD and asthma) using the OpenSAFELY platform to analyse data from primary care practices linked to national death registrations. People receiving an ICS were compared to those receiving alternative respiratory medications. Our primary outcome was COVID-19 related death.

FindingsWe identified 148,588 people with COPD and 817,973 people with asthma receiving relevant respiratory medications in the four months prior to 01 March 2020. People with COPD receiving ICS were at a greater risk of COVID-19 related death compared to those receiving a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA) (adjusted HR = 1.38, 95% CI = 1.08 - 1.75). People with asthma receiving high dose ICS were at an increased risk of death compared to those receiving a short-acting beta agonist (SABA) only (adjusted HR = 1.52, 95%CI = 1.08 - 2.14); the adjusted HR for those receiving low-medium dose ICS was 1.10 (95% CI = 0.82 - 1.49). Quantitative bias analyses indicated that an unmeasured confounder of only moderate strength of association with exposure and outcome could explain the observed associations in both populations.

InterpretationThese results do not support a major role of ICS in protecting against COVID-19 related deaths. Observed increased risks of COVID-19 related death among people with COPD and asthma receiving ICS can be plausibly explained by unmeasured confounding due to disease severity.

FundingThis work was supported by the Medical Research Council MR/V015737/1.",respiratory medicine,exact,100,100
bioRxiv,10.1101/2020.06.20.163006,2020-06-20,https://biorxiv.org/cgi/content/short/2020.06.20.163006,Transcriptional response of signalling pathways to SARS-CoV-2 infection in normal human bronchial epithelial cells,Enes Ak; Pinar Pir; Alex J Walker; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Christopher T. Rentsch; Elizabeth J Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William J Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre; A. John Iafrate; Eric S Rosenberg; Jochen Lennerz,"Gebze Technical University; Gebze Technical University; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital","SARS-CoV-2 virus, the pathogen that causes Covid-19 disease, emerged in Wuhan region in China in 2019, infected more than 4M people and is responsible for death of at least 300K patients globally as of May 2020. Identification of the cellular response mechanisms to viral infection by SARS-CoV-2 may shed light on progress of the disease, indicate potential drug targets, and make design of new test methods possible.

In this study, we analysed transcriptomic response of normal human bronchial epithelial cells (NHBE) to SARS-CoV-2 infection and compared the response to H1N1 infection. Comparison of transcriptome of NHBE cells 24 hours after mock-infection and SARS-CoV-2 infection demonstrated that most genes that respond to infection were upregulated (320 genes) rather than being downregulated (115 genes).While upregulated genes were enriched in signalling pathways related to virus response, downregulated genes are related to kidney development. We mapped the upregulated genes on KEGG pathways to identify the mechanisms that mediate the response. We identified canonical NF{kappa}B, TNF and IL-17 pathways to be significantly upregulated and to converge to NF{kappa}B pathway via positive feedback loops. Although virus entry protein ACE2 has low expression in NHBE cells, pathogen response pathways are strongly activated within 24 hours of infection. Our results also indicate that immune response system is activated at the early stage of the infection and orchestrated by a crosstalk of signalling pathways. Finally, we compared transcriptomic SARS-CoV-2 response to H1N1 response in NHBE cells to elucidate the virus specificity of the response and virus specific extracellular proteins expressed by NHBE cells.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.06.20.160499,2020-06-20,https://biorxiv.org/cgi/content/short/2020.06.20.160499,Analysis of SARS-CoV-2 specific T-cell receptors in ImmuneCode reveals cross-reactivity to immunodominant Influenza M1 epitope,John-William Sidhom; Alexander S Baras; Alex J Walker; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Christopher T. Rentsch; Elizabeth J Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William J Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre; A. John Iafrate; Eric S Rosenberg; Jochen Lennerz,"Johns Hopkins University School of Medicine; Johns Hopkins University School of Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital","Adaptive Biotechnologies and Microsoft have recently partnered to release ImmuneCode, a database containing SARS-CoV-2 specific T-cell receptors derived through MIRA, a T-cell receptor (TCR) sequencing based sequencing approach to identify antigen-specific TCRs. Herein, we query the extent of cross reactivity between these derived SARS-CoV-2 specific TCRs and other known antigens present in McPas-TCR, a manually curated catalogue of pathology-associated TCRs. We reveal cross reactivity between SARS-CoV-2 specific TCRs and the immunodominant Influenza GILGFVFTL M1 epitope, suggesting the importance of further work in characterizing the implications of prior Influenza exposure or co-exposure to the pathology of SARS-CoV-2 illness.",immunology,exact,100,100
bioRxiv,10.1101/2020.06.20.162560,2020-06-20,https://biorxiv.org/cgi/content/short/2020.06.20.162560,"Multi-Omics and Integrated Network Approach to Unveil Evolutionary Patterns, Mutational Hotspots, Functional Crosstalk and Regulatory Interactions in SARS-CoV-2",Vipin Gupta; Shazia Haider; Mansi Verma; Nirjara Singhvi; Kalaiarasan Ponnusamy; Md. Zubbair Malik; Helianthous Verma; Roshan Kumar; Utkarsh Sood; Princy Hira; Shiva Satija; Rup Lal; Yogendra Singh; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre; A. John Iafrate; Eric S Rosenberg; Jochen Lennerz,"PHIXGEN PVT. LTD; Jaypee Institute of Information Technology, Noida; Sri Venkateswara College, University of Delhi; University of Delhi; Jawaharlal Nehru University; Jawaharlal Nehru University, New Delhi, India.; Ramjas College, University of Delhi; Magadh University, Bodh Gaya, Bihar; The Energy and Resources Institute; Maitreyi College, University of Delhi.; Sri Venkateswara College, University of Delhi; The Energy and Resources Institute; University of Delhi; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital","SARS-CoV-2 pandemic resulted in 92 million cases in a span of one year. The study focuses on understanding population specific variations attributing its high rate of infections in specific geographical regions particularly in USA. Rigorous phylogenomic network analysis of complete SARS-CoV-2 genomes (245) inferred five central clades named a (ancestral), b, c, d and e (subtype e1 & e2). The clade d & e2 were found exclusively comprising of USA. Clades were distinguished by 10 co-mutational combinations in Nsp3, ORF8, Nsp13, S, Nsp12, Nsp2 and Nsp6. Our analysis revealed that only 67.46% of SNP mutations were at amino acid level. T1103P mutation in Nsp3 was predicted to increase protein stability in 238 strains except 6 strains which were marked as ancestral type; whereas co-mutation (P409L & Y446C) in Nsp13 were found in 64 genomes from USA highlighting its 100% co-occurrence. Docking highlighted mutation (D614G) caused reduction in binding of Spike proteins with ACE2, but it also showed better interaction with TMPRSS2 receptor contributing to high transmissibility among USA strains. We also found host proteins, MYO5A, MYO5B, MYO5C had maximum interaction with viral proteins (N, S, M). Thus, blocking the internalization pathway by inhibiting MYO5 proteins which could be an effective target for COVID-19 treatment. The functional annotations of the HPI network were found to be closely associated with hypoxia and thrombotic conditions confirming the vulnerability and severity of infection. We also screened CpG islands in Nsp1 & N conferring ability of SARS-CoV-2 to enter and trigger ZAP activity inside host cell.

ImportanceIn the current study we presented a global view of mutational pattern observed in SARS-CoV-2 virus transmission. This provided a who-infect-whom geographical model since the early pandemic. This is hitherto the most comprehensive comparative genomics analysis of full-length genomes for co-mutations at different geographical regions specially in USA strains. Compositional structural biology results suggested that mutations have balance of contrary forces effect on pathogenicity suggesting only few mutations to effective at translation level but not all. Novel HPI analysis and CpG predictions elucidates the proof of concept of hypoxia and thrombotic conditions in several patients. Thus, the current study focuses the understanding of population specific variations attributing high rate of SARS-CoV-2 infections in specific geographical regions which may eventually be vital for the most severely affected countries and regions for sharp development of custom-made vindication strategies.",microbiology,exact,100,100
medRxiv,10.1101/2020.06.19.20135996,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.19.20135996,The support needs of Australian primary health care nurses during the COVID-19 pandemic,Elizabeth Halcomb; Anna Williams; Christine Ashley; Susan McInnes; Catherine Stephen; Kaara Ray Calma; Sharon James; Roshan Kumar; Utkarsh Sood; Princy Hira; Shiva Satija; Rup Lal; Yogendra Singh; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre; A. John Iafrate; Eric S Rosenberg; Jochen Lennerz,"University of Wollongong; University of Notre Dame, Sydney; University of Wollongong; University of Wollongong; University of Wollongong; University of Wollongong; University of Wollongong; Magadh University, Bodh Gaya, Bihar; The Energy and Resources Institute; Maitreyi College, University of Delhi.; Sri Venkateswara College, University of Delhi; The Energy and Resources Institute; University of Delhi; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital","AimTo identify Australian primary healthcare nurses immediate support needs during the COVID-19 pandemic.

BackgroundCOVID-19 has had widespread implications for primary healthcare nurses. Supporting these nurses capacity to deliver quality care ensures that ongoing health needs can be met.

MethodsPrimary healthcare nurses were recruited to an online survey via social media and professional organisations in April 2020.

ResultsSix-hundred and thirty-seven responses were included in analysis. Participants provided 1213 statements about perceived supports required to provide quality clinical care. From these, seven key categories emerged, namely; personal protective equipment, communication, funding, industrial issues, self-care, workplace factors and valuing nurses.

ConclusionA number of key issues relating to personal health and safety, care quality, and job security need to be addressed to support primary healthcare nurses during the COVID-19 pandemic. Addressing these support issues can assist in retaining nurses and optimising the role of primary healthcare nurses during a pandemic.

Implications for nursing managementResponding to the needs of primary healthcare nurses has the potential to facilitate their role in providing community based healthcare. This knowledge can guide the provision of support for primary healthcare nurses during the current pandemic, as well as informing planning for future health crises.",nursing,exact,100,100
medRxiv,10.1101/2020.06.19.20134908,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.19.20134908,ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank,Chia-Ling Kuo; Luke C Pilling; Janice L Atkins; Jane Masoli; Joao Delgado; George Kuchel; David Melzer; Roshan Kumar; Utkarsh Sood; Princy Hira; Shiva Satija; Rup Lal; Yogendra Singh; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre; A. John Iafrate; Eric S Rosenberg; Jochen Lennerz,"University of Connecticut Health; University of Exeter; University of Exeter; University of Exeter; University of Exeter; University of Connecticut Health; University of Exeter; Magadh University, Bodh Gaya, Bihar; The Energy and Resources Institute; Maitreyi College, University of Delhi.; Sri Venkateswara College, University of Delhi; The Energy and Resources Institute; University of Delhi; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital","We previously reported that the ApoE e4e4 genotype was associated with COVID-19 test positivity (OR=2.31, 95% CI: 1.65 to 3.24, p=1.19x10-6) in the UK Biobank (UKB) cohort, during the epidemic peak in England, from March 16 to April 26, 2020. With more COVID-19 test results (March 16 to May 31, 2020) and mortality data (to April 26, 2020) linked to UKB, we re-evaluated the ApoE e4 allele association with COVID-19 test positivity, and with all-cause mortality following test-confirmed COVID-19. Logistic regression models compared ApoE e4e4 participants (or e3e4s) to e3e3s with adjustment for sex; age on April 26th or age at death; baseline UKB assessment center in England (accounting for geographical differences in viral exposures); genotyping array type; and the top five genetic principal components (accounting for possible population admixture). ApoE e4e4 genotype was associated with increased risks of test positivity (OR=2.24, 95% CI: 1.72 to 2.93, p=3.24x10-9) and of mortality with test-confirmed COVID-19 (OR=4.29, 95% CI: 2.38 to 7.72, p=1.22x10-6), compared to e3e3s. Independent replications are needed to confirm our findings and mechanistic work is needed to understand how ApoE e4e4 results in the marked increase in vulnerability, especially for COVID-19 mortality. These findings also demonstrate that risks for COVID-19 mortality are not simply related to advanced chronological age or the comorbidities commonly seen in aging.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.06.17.20133959,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.17.20133959,A downscaling approach to compare COVID-19 count data from databases aggregated at different spatial scales,Andre Python; Andreas Bender; Marta Blangiardo; Janine B Illian; Ying Lin; Baoli Liu; Tim C D Lucas; Siwei Tan; Yingying Wen; Davit Svanidze; Jianwei Yin; Marinella Turla; Ubaldo Balducci; Sara Mariotto; Sergio Ferrari; Alfonso Ciccone; Fabrizio Fiacco; Alberto Imarisio; Barbara Risi; Alberto Benussi; Emanuele Foca'; Francesca Caccuri; Matilde Leonardi; Roberto Gasparotti; Francesco Castelli; Gianluigi Zanusso; Alessandro Pezzini; Alessandro Padovani; Alberto Fantin; Xueyuan Cao; Lucio Torelli; Antonella Zucchetto; Marcella Montico; Annalisa Casarin; Micaela Romagnoli; Stefano Gasparini; Martina Bonifazi; Pierlanfranco D'Agaro; Alessandro Marcello; Danilo Licastro; Barbara Ruaro; Maria Concetta Volpe; Reba Umberger; Gianfranco Umberto Meduri; Marco Confalonieri,"University of Oxford; LMU Munich; Imperial College London; Glasgow University; Fuzhou University; Oxford University; University of Oxford; Zhejiang University; Zhejiang University; Goettingen University; Zhejiang University; Neurology Unit, ASST Valcamonica, Esine, Brescia, Italy; Neurology Unit, ASST Chiari, Chiari, Italy; Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Department of Neurology and Stroke Unit, Carlo Poma Hospital, ASST Mantova, Mantova, Italy; Neurology Unit, ASST Bergamo Est, Seriate, Italy; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy; University of Brescia; University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy; Microbiology Unit, Department of Molecular and Translational Medicine, University; Neurology, Public Health, Disability Unit - IRCCS Neurology Institute Besta, Milan, Italy; Neuroradiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia and ASST Spedali Civili Hosp; University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy; Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; University of Brescia; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy; Azienda Sanitaria Universitaria Friuli Centrale, Udin, Italy; University of Tennessee, Memphis, USA; University of Trieste; CRO Aviano; CRO Aviano; University of Hertfordshire, Hatfield UK; Hospital of Treviso; University of Ancona; University of Ancona; University of Trieste; ICGEB; Area Science Park, Trieste, Italy; University Hospital of Trieste; University of Trieste; University of Tennessee, Memphis, USA; University of Tennessee, Memphis, USA; University of Trieste","As the COVID-19 pandemic continues to threaten various regions around the world, obtaining accurate and reliable COVID-19 data is crucial for governments and local communities aiming at rigorously assessing the extent and magnitude of the virus spread and deploying efficient interventions. Using data reported between January and February 2020 in China, we compared counts of COVID-19 from near-real time spatially disaggregated data (city-level) with fine-spatial scale predictions from a Bayesian downscaling regression model applied to a reference province-level dataset. The results highlight discrepancies in the counts of coronavirus-infected cases at district level and identify districts that may require further investigation.",epidemiology,exact,100,100
medRxiv,10.1101/2020.06.16.20133322,2020-06-18,https://medrxiv.org/cgi/content/short/2020.06.16.20133322,KNOWLEDGE AND BEHAVIORS RELATED TO THE COVID-19 PANDEMIC IN MALAWI,Jethro Banda; Albert Dube; Sarah Brumfield; Abena Amoah; Amelia Crampin; Georges Reniers; Stphane Helleringer; Sachin Kheterpal; Lynda Lisabeth; Lars G. Fritsche; Bhramar G. Mukherjee; Katarzyna A Ciazyns; Xiaoli Xiong; John AG Briggs; James Nathan; Federica Mescia; Hongyi Zhang; Petros Barmpounakis; Nikos Demeris; Richard Skells; Paul Lyons; John Bradley; Stephen Baker; Jean Pierre Allain; Kenneth GC Smith; Ian Goodfellow; Ravindra K Gupta; Alex G. Richter,"Malawi Epidemiological and Intervention Research Unit; Malawi Epidemiological and Intervention Research Unit; Johns Hopkins University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Johns Hopkins University; University of Michigan; University of Michigan; University of Michigan; University of Michigan; Medical Research Council Laboratory of Molecular Biology, Cambridge; Medical Research Council Laboratory of Molecular Biology; Medical Research Council Laboratory of Molecular Biology; University of Cambridge; University of Cambridge; CUH NHS Trust; Athens University of Economics and Business; Cambridge Clinical Trials Unit-Cancer Theme; Cambridge Clinical Trials Unit-Cancer Theme; University of Cambridge; University of Cambridge; Cambridge University; Diagnostics for the Real World EU Ltd; University of Cambridge; ig299@cam.ac.uk; University of Cambridge; University of Birmingham","BackgroundThere are limited data on knowledge and behaviors related to COVID-19 in African countries.

MethodsBetween April 25th and May 23rd, we contacted 793 individuals aged 18 and older, who previously participated in studies conducted in the Karonga Health and Demographic Surveillance Site in Malawi. During an interview by mobile phone, we ascertained respondents sources of information about COVID-19 and we evaluated their knowledge of the transmission and course/severity of COVID-19. We also asked them to evaluate their own risks of infection and severe illness. Finally, we inquired about the preventive measures they had adopted in response to the pandemic. We described patterns of knowledge and behaviors by area of residence (rural vs. urban).

ResultsWe interviewed 630 respondents (79.5% response rate). Four hundred and eighty-nine respondents resided in rural areas (77.6%) and 141 in urban areas (22.4%). Only one respondent had never heard of COVID-19. Misconceptions about the modes of transmission of SARS-CoV-2, and about the course and severity of COVID-19, were common. For example, 33.2% of respondents believed that the novel coronavirus is also waterborne and 50.6% believed that it is also bloodborne. A large percentage of respondents perceived that there was no risk, or only a small risk, that they would become infected (44.4%), but 72% of respondents expected to be severely ill if they became infected with SARS-CoV-2. Increased hand washing and avoiding crowds were the most reported strategies to prevent the spread of SARS-CoV-2. Use of face masks was more common among urban residents (22.5%) than among rural residents (5.0%).

ConclusionDespite widespread access to information about the COVID-19 pandemic, gaps in knowledge about COVID-19 persist in this population. The adoption of preventive strategies remains limited, possibly due to low perceived risk of infection among a large fraction of the population.

What is already known?O_LISARS-CoV-2 is projected to spread widely in African countries.
C_LIO_LIThere is limited information about what affected populations know about this new health threat, and how they react to it.
C_LI

What are the new findings?O_LIIn a study in Malawi, respondents lacked knowledge about several aspects of the transmission of SARS-CoV-2, and about the course and severity of COVID-19.
C_LIO_LIThese knowledge gaps were larger among residents of rural areas than among urban dwellers.
C_LIO_LIStudy respondents perceived themselves at low risk of infection with SARS-CoV-2, but they over-estimated the likely severity of the disease they would experience if they became infected.
C_LIO_LIMost respondents reported increased frequency of handwashing, but the adoption of other protective behaviors (e.g., social distancing, use of masks) was limited, particularly in rural areas.
C_LI

What do the new findings imply?O_LIAdditional information campaigns are needed to address knowledge gaps and misperceptions about SARS-CoV-2/COVID-19 in Malawi.
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.13.20130419,2020-06-16,https://medrxiv.org/cgi/content/short/2020.06.13.20130419,Mental health service activity during COVID-19 lockdown: South London and Maudsley data on working age community and home treatment team services and mortality from February to mid-May 2020,Robert Stewart; Evangelia Martin; Matthew Broadbent; Cian Brendan McDermott; Robert Jarman,"King's College London; King's College London; South London and Maudsley NHS Foundation Trust; Mater University Hospital; Royal Victoria Infirmary, Newcastle upon Tyne","The lockdown and social distancing policy response to the COVID-19 pandemic in the UK has a potentially important impact on provision of mental healthcare; however, there has been relatively little quantification of this. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource with 24-hourly updates of electronic mental health records data, this paper describes daily caseloads and contact numbers (face-to-face and virtual) for home treatment teams (HTTs) and working age adult community mental health teams (CMHTs) from 1st February to 15th May 2020 at the South London and Maudsley NHS Trust (SLaM), a large mental health service provider for 1.2m residents in south London. In addition daily deaths are described for all current and previous SLaM service users over this period and the same dates in 2019. In summary, comparing periods before and after 16th March 2020 the CMHT sector showed relatively stable caseloads and total contact numbers, but a substantial shift from face-to-face to virtual contacts, while HTTs showed the same changeover but reductions in caseloads and total contacts (although potentially an activity rise again during May). Number of deaths for the two months between 16th March and 15th May were 2.4-fold higher in 2020 than 2019, with 958 excess deaths.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.06.12.20129494,2020-06-14,https://medrxiv.org/cgi/content/short/2020.06.12.20129494,Impact on mental health care and on mental health service users of the COVID-19 pandemic: a mixed methods survey of UK mental health care staff,Sonia Johnson; Christian Dalton-Locke; Norha Vera San Juan; Una Foye; Sian Oram; Alexandra Papamichail; Sabine Landau; Rachel Rowan Olive; Tamar Jeynes; Prisha Shah; Luke Sheridan Rains; Brynmor Lloyd-Evans; Sarah Carr; Helen Killaspy; Steve Gillard; Alan Simpson; - The COVID-19 Mental Health Policy Research Unit Group; Ankit Gupta; Manne Manikumar; Uma Chaudhary; Feiyue Wang; Yuting Yuan; Wendi Wu; Chengcheng Sun; Haorong Lu; Jihong Wu; Xinghuai Sun; Shenghai Zhang; Sunil Kumar Sahu; Haixia Chen; Dongming Fang; Lihua Luo; Yuying Zeng; Yiquan Wu; ZeHua Cui; Qian He; Sanjie Jiang; Xiaoyan Ma; Weimin Feng; Yan Xu; Fang Li; Zhongmin Liu; Lei Chen; Fang Chen; Xin Jin; Wei Qiu; Huanming Yang; Jian Wang; Yan Hua; Yahong Liu; Huan Liu; Xun Xu,"NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; School of Social Policy/ Institute for Mental Health, University of Birmingham, Birmingham, UK; 1.	NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; Population Health Research Institute, St George s, University of London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; ; Bioinformatics Review- nCoV-2019 Drug Development Team; 16.	NIN-TATA Centre for excellence in public health nutrition, ICMR-National Institute of Nutrition, Jamai-Osmania (Post), Hyderabad, Telangana, India; Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-shenzhen; China National Genebank, BGI-Shenzhen, Shenzhen 518120, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; Department of Biochemistry, University of Cambridge, UK; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; College of Veterinary Medicine, Yangzhou University, Yangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Guangdong Provincial Key Laboratory of Silviculture, Protection and Utilization, Guangdong Academy of Forestry, Guangzhou 510520, China; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China","PurposeThe COVID-19 pandemic has potential to disrupt and burden the mental health care system, and to magnify inequalities experienced by mental health service users.

MethodsWe investigated staff reports regarding the impact of the COVID-19 pandemic in its early weeks on mental health care and mental health service users in the UK using a mixed methods online survey. Recruitment channels included professional associations and networks, charities and social media. Quantitative findings were reported with descriptive statistics, and content analysis conducted for qualitative data.

Results2,180 staff from a range of sectors, professions and specialties participated. Immediate infection control concerns were highly salient for inpatient staff, new ways of working for community staff. Multiple rapid adaptations and innovations in response to the crisis were described, especially remote working. This was cautiously welcomed but found successful in only some clinical situations. Staff had specific concerns about many groups of service users, including people whose conditions are exacerbated by pandemic anxieties and social disruptions; people experiencing loneliness, domestic abuse and family conflict; those unable to understand and follow social distancing requirements; and those who cannot engage with remote care.

ConclusionThis overview of staff concerns and experiences in the early COVID-19 pandemic suggests directions for further research and service development: we suggest that how to combine infection control and a therapeutic environment in hospital, and how to achieve effective and targeted tele-health implementation in the community, should be priorities. The limitations of our convenience sample must be noted.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.06.12.20129643,2020-06-14,https://medrxiv.org/cgi/content/short/2020.06.12.20129643,Improving effectiveness of different deep learning-based models for detecting COVID-19 from computed tomography (CT) images,Erdi Acar; Engin AHN; hsan Yilmaz; Una Foye; Sian Oram; Alexandra Papamichail; Sabine Landau; Rachel Rowan Olive; Tamar Jeynes; Prisha Shah; Luke Sheridan Rains; Brynmor Lloyd-Evans; Sarah Carr; Helen Killaspy; Steve Gillard; Alan Simpson; - The COVID-19 Mental Health Policy Research Unit Group; Ankit Gupta; Manne Manikumar; Uma Chaudhary; Feiyue Wang; Yuting Yuan; Wendi Wu; Chengcheng Sun; Haorong Lu; Jihong Wu; Xinghuai Sun; Shenghai Zhang; Sunil Kumar Sahu; Haixia Chen; Dongming Fang; Lihua Luo; Yuying Zeng; Yiquan Wu; ZeHua Cui; Qian He; Sanjie Jiang; Xiaoyan Ma; Weimin Feng; Yan Xu; Fang Li; Zhongmin Liu; Lei Chen; Fang Chen; Xin Jin; Wei Qiu; Huanming Yang; Jian Wang; Yan Hua; Yahong Liu; Huan Liu; Xun Xu,"Canakkale Onsekiz Mart University; Canakkale Onsekiz Mart University; Canakkale Onsekiz Mart University; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; School of Social Policy/ Institute for Mental Health, University of Birmingham, Birmingham, UK; 1.	NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; Population Health Research Institute, St George s, University of London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; ; Bioinformatics Review- nCoV-2019 Drug Development Team; 16.	NIN-TATA Centre for excellence in public health nutrition, ICMR-National Institute of Nutrition, Jamai-Osmania (Post), Hyderabad, Telangana, India; Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-shenzhen; China National Genebank, BGI-Shenzhen, Shenzhen 518120, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; Department of Biochemistry, University of Cambridge, UK; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; College of Veterinary Medicine, Yangzhou University, Yangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Guangdong Provincial Key Laboratory of Silviculture, Protection and Utilization, Guangdong Academy of Forestry, Guangzhou 510520, China; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China","Computerized Tomography (CT) has a prognostic role in the early diagnosis of COVID-19 due to it gives both fast and accurate results. This is very important to help decision making of clinicians for quick isolation and appropriate patient treatment. In this study, we combine methods such as segmentation, data augmentation and the generative adversarial network (GAN) to improve the effectiveness of learning models. We obtain the best performance with 99% accuracy for lung segmentation. Using the above improvements we get the highest rates in terms of accuracy (99.8%), precision (99.8%), recall (99.8%), f1-score (99.8%) and roc acu (99.9979%) with deep learning methods in this paper. Also we compare popular deep learning-based frameworks such as VGG16, VGG19, Xception, ResNet50, ResNet50V2, DenseNet121, DenseNet169, InceptionV3 and InceptionResNetV2 for automatic COVID-19 classification. The DenseNet169 amongst deep convolutional neural networks achieves the best performance with 99.8% accuracy. The second-best learner is InceptionResNetV2 with accuracy of 99.65%. The third-best learner is Xception and InceptionV3 with accuracy of 99.60%.",health informatics,exact,100,100
medRxiv,10.1101/2020.06.12.20129460,2020-06-14,https://medrxiv.org/cgi/content/short/2020.06.12.20129460,Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals,Jian Zhang; Xiaowang Qu; hsan Yilmaz; Una Foye; Sian Oram; Alexandra Papamichail; Sabine Landau; Rachel Rowan Olive; Tamar Jeynes; Prisha Shah; Luke Sheridan Rains; Brynmor Lloyd-Evans; Sarah Carr; Helen Killaspy; Steve Gillard; Alan Simpson; - The COVID-19 Mental Health Policy Research Unit Group; Ankit Gupta; Manne Manikumar; Uma Chaudhary; Feiyue Wang; Yuting Yuan; Wendi Wu; Chengcheng Sun; Haorong Lu; Jihong Wu; Xinghuai Sun; Shenghai Zhang; Sunil Kumar Sahu; Haixia Chen; Dongming Fang; Lihua Luo; Yuying Zeng; Yiquan Wu; ZeHua Cui; Qian He; Sanjie Jiang; Xiaoyan Ma; Weimin Feng; Yan Xu; Fang Li; Zhongmin Liu; Lei Chen; Fang Chen; Xin Jin; Wei Qiu; Huanming Yang; Jian Wang; Yan Hua; Yahong Liu; Huan Liu; Xun Xu,"Translational Medicine Institute, The First Peoples Hospital of Chenzhou, University of South China; Translational Medicine Institute, The First Peoples Hospital of Chenzhou, University of South China; Canakkale Onsekiz Mart University; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; Division of Psychiatry (NIHR Mental Health Policy Research Unit COVID-19 Co-Production Group), University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; School of Social Policy/ Institute for Mental Health, University of Birmingham, Birmingham, UK; 1.	NIHR Mental Health Policy Research Unit, Division of Psychiatry, University College London, London, UK; Population Health Research Institute, St George s, University of London, London, UK; NIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King s College London, London, UK; ; Bioinformatics Review- nCoV-2019 Drug Development Team; 16.	NIN-TATA Centre for excellence in public health nutrition, ICMR-National Institute of Nutrition, Jamai-Osmania (Post), Hyderabad, Telangana, India; Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-shenzhen; China National Genebank, BGI-Shenzhen, Shenzhen 518120, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; Eye and ENT Hospital, College of Medicine, Fudan University, Shanghai, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; Department of Biochemistry, University of Cambridge, UK; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; College of Veterinary Medicine, Yangzhou University, Yangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China; Guangdong Provincial Key Laboratory of Silviculture, Protection and Utilization, Guangdong Academy of Forestry, Guangzhou 510520, China; National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou, China; BGI-Shenzhen, Shenzhen 518083, China; BGI-Shenzhen, Shenzhen 518083, China","Seroconversion appeared early after COVID-19 onset, and convalescent sera therapy benefit some critical patients. However, neutralizing antibody (nAb) in convalescents is largely unknown. We found that 97.01% (65/67) of COVID-19 convalescents maintained IgG antibodies with high binding and avidity to SARS-CoV-2 spike subunits S1 and S2, and 95.52% (64/67) had neutralization activity against SARS-CoV-2 pesudovirus, one month after discharge (median ID50, 2.75; IQR, 2.34-3.08). Some sera exhibited cross-neutralization against SARS-CoV (76.12%), MERS-CoV (17.91%), or both (10.45%). Interestingly, individuals recovered from severe disease (severe group) had nAbs with binding and neutralization titers higher than non-severe group. Severe group appeared a rapid increase of lymphocytes and a high proportion of circulating CXCR3+ Tfh cells. Interestingly, the later were spike-specific and positively correlated with SARS-CoV-2 nAb titers. All subjects had no autoimmunity. Our findings provide novel insights into nAb responses in COVID-19 convalescents and facilitate treatment and vaccine development for SARS-CoV-2 infection.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.10.20127175,2020-06-11,https://medrxiv.org/cgi/content/short/2020.06.10.20127175,Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic.,Amitava Banerjee; Suliang Chen; Laura Pasea; Alvina Lai; Michail Katsoulis; Spiros Denaxas; Vahe Nafilyan; Bryan Williams; Wai Keong Wong; Ameet Bakhai; Kamlesh Khunti; Deenan Pillay; Mahdad Noursadeghi; Honghan Wu; Nilesh Pareek; Daniel Bromage; Theresa Mcdonagh; Jonathan Byrne; James T Teo; Ajay Shah; Ben Humberstone; Liang V Tang; Anoop SV Shah; Andrea Rubboli; Yutao Guo; Yu Hu; Cathie LM Sudlow; Gregory YH Lip; Harry Hemingway; Oliver J Brady; Samuel M. Nicholls; Amilcar Tanuri; Atila Duque Rossi; Carlos Kaue Vieira Braga; Alexandra Lehmkuhl Gerber; Ana Paula Guimaraes; Nelson Gaburo Jr.; Cecilia Salete Alencar; Alessandro Clayton de Souza Ferreira; Cristiano Xavier Lima; Jose Eduardo Levi; Celso Granato; Giula Magalhaes Ferreira; Ronaldo da Silva Francisco Jr.; Fabiana Granja; Marcia Teixeira Garcia; Maria Luiza Moretti; Mauricio Wesley Perroud Jr.; Terezinha Marta Pereira Pinto Castineiras; Carolina Dos Santos Lazari; Sarah C Hill; Andreza Aruska de Souza Santos; Camila Lopes Simeoni; Julia Forato; Andrei Carvalho Sposito; Angelica Zaninelli Schreiber; Magnun Nueldo Nunes Santos; Camila Zolini Sa; Renan Pedra Souza; Luciana Cunha Resende Moreira; Mauro Martins Teixeira; Josy Hubner; Patricia Asfora Falabella Leme; Rennan Garcias Moreira; Mauricio Lacerda Nogueira; - CADDE-Genomic-Network; Neil Ferguson; Silvia Figueiredo Costa; Jose Luiz Proenca-Modena; Ana Tereza Vasconcelos; Samir Bhatt; Philippe Lemey; Chieh-Hsi Wu; Andrew Rambaut; Nick J Loman; Renato Santana Aguiar; Oliver G Pybus; Ester Cerdeira Sabino; Nuno Rodrigues Faria,"University College London; University College London; University College London; University College London; UCL; University College London; Office for National Statistics; UCL; University College London Hospitals NHS Trust; Royal Free Hospitals NHS Trust; University of Leicester; UCL; UCL; UCL; King's College Hospital; Kings College London; Kings College London; Kings London NHS Trust; Kings College Hospital NHS Foundation Trust; King's College London; Office for National Statistics; Huazhong University of Science and Technology, Wuhan, China; University of Edinburgh; Ospedale S. Maria delle Croci, Ravenna, Italy; PLA General Hospital, Beijing, China.; Huazhong University of Science and Technology, Wuhan, China.; University of Edinburgh; University of Liverpool; UCL; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine; Centre for the Mathe; Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.; Departamento de Genetica, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Departamento de Genetica, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Institute for Applied Economic Research (Ipea), Brasilia, Brazil; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; DB Diagnosticos do Brasil, Sao Paulo, Brazil.; Divisao de Laboratorio Central do Hospital das Clinicas, da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto Hermes Pardini, Belo Horizonte, Brazil; Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Simile Instituto de Imunologia Aplicada Ltda, Bel; Laboratorio DASA, Sao Paulo, Brazil.; Laboratorio Fleury, Sao Paulo, Brazil.; Laboratorio de Virologia, Instituto de Ciencias Biomedicas, Universidade Federal de Uberlandia, Uberlandia, Brazil.; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Centro de Estudos da Biodiversidade, Universidade Federal de Roraima, Boa Vista, Brazil.; Divisao de Doencas Infecciosas, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil; Divisao de Doencas Infecciosas, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil; Hospital Estadual Sumare, Universidade Estadual de Campinas, Campinas, Brazil; Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Divisao de Laboratorio Central do Hospital das Clinicas, da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Zoology, Univeristy of Oxford, UK.; University of Oxford, Brazilian Studies Programme, Oxford School of Global and Area Studies; Departamento de Genetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Departamento de Geetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Departamento de Clinica Medica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Patologia Clinica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Patologia Clinica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Departamento de Botanica, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Biologia Celular, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Centro de Saude da Comunidade, Universidade Estadual de Campinas, Campinas, Brazil.; Centro de Laboratorios Multiusuarios, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Sao Paulo, Brazil.; ; Department of Infectious Disease Epidemiology, Imperial College London, UK.; Instituto de Medicina Tropical, Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Departamento de Genetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Department of Infectious Disease Epidemiology, Imperial College London, UK.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.; Mathematical Sciences, University of Southampton, Southampton, UK; Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK; Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Department of Zoology, Univeristy of Oxford, UK.; Instituto de Medicina Tropical, Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom; Department of Zoology, University of Oxford, United Kingdom","BackgroundCardiovascular diseases(CVD) increase mortality risk from coronavirus infection(COVID-19), but there are concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess mortality in specific CVDs, both ""direct"", through infection, and ""indirect"", through changes in healthcare.

MethodsWe used population-based electronic health records from 3,862,012 individuals in England to estimate pre- and post-COVID-19 mortality risk(""direct"" effect) for people with incident and prevalent CVD. We incorporated: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)estimated population COVID-19 prevalence, and (iii)estimated relative impact of COVID-19 on mortality(relative risk, RR: 1.5, 2.0 and 3.0). For ""indirect"" effects, we analysed weekly mortality and emergency department data for England/Wales and monthly hospital data from England(n=2), China(n=5) and Italy(n=1) for CVD referral, diagnosis and treatment until 1 May 2020.

FindingsCVD service activity decreased by 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy and England during the pandemic. In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown, and is still reduced in Italy and England. Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous(peak RR 1.4). For total CVD(incident and prevalent), at 10% population COVID-19 rate, we estimated direct impact of 31,205 and 62,410 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 49932 to 99865 excess deaths.

InterpretationSupply and demand for CVD services have dramatically reduced across countries with potential for substantial, but avoidable, excess mortality during and after the COVID-19 pandemic.

FundingNIHR, HDR UK, Astra Zeneca",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.06.10.20127258,2020-06-11,https://medrxiv.org/cgi/content/short/2020.06.10.20127258,"Knowledge, attitudes, and practices among the general population during COVID-19 outbreak in Iran: A national cross-sectional survey",Edris Kakemam; DJavad Ghoddoosi-Nejad; Zahra Chegini; Khalil Momeni; Hamid Salehinia; Soheil Hassanipour; Hosein Ameri; Morteza Arab-Zozani; Wai Keong Wong; Ameet Bakhai; Kamlesh Khunti; Deenan Pillay; Mahdad Noursadeghi; Honghan Wu; Nilesh Pareek; Daniel Bromage; Theresa Mcdonagh; Jonathan Byrne; James T Teo; Ajay Shah; Ben Humberstone; Liang V Tang; Anoop SV Shah; Andrea Rubboli; Yutao Guo; Yu Hu; Cathie LM Sudlow; Gregory YH Lip; Harry Hemingway; Oliver J Brady; Samuel M. Nicholls; Amilcar Tanuri; Atila Duque Rossi; Carlos Kaue Vieira Braga; Alexandra Lehmkuhl Gerber; Ana Paula Guimaraes; Nelson Gaburo Jr.; Cecilia Salete Alencar; Alessandro Clayton de Souza Ferreira; Cristiano Xavier Lima; Jose Eduardo Levi; Celso Granato; Giula Magalhaes Ferreira; Ronaldo da Silva Francisco Jr.; Fabiana Granja; Marcia Teixeira Garcia; Maria Luiza Moretti; Mauricio Wesley Perroud Jr.; Terezinha Marta Pereira Pinto Castineiras; Carolina Dos Santos Lazari; Sarah C Hill; Andreza Aruska de Souza Santos; Camila Lopes Simeoni; Julia Forato; Andrei Carvalho Sposito; Angelica Zaninelli Schreiber; Magnun Nueldo Nunes Santos; Camila Zolini Sa; Renan Pedra Souza; Luciana Cunha Resende Moreira; Mauro Martins Teixeira; Josy Hubner; Patricia Asfora Falabella Leme; Rennan Garcias Moreira; Mauricio Lacerda Nogueira; - CADDE-Genomic-Network; Neil Ferguson; Silvia Figueiredo Costa; Jose Luiz Proenca-Modena; Ana Tereza Vasconcelos; Samir Bhatt; Philippe Lemey; Chieh-Hsi Wu; Andrew Rambaut; Nick J Loman; Renato Santana Aguiar; Oliver G Pybus; Ester Cerdeira Sabino; Nuno Rodrigues Faria,"Tabriz University of Medical Sciences; Birjand University of Medical Sciences; Qazvin University of Medical Sciences; Ilam University of Medical Sciences; Birjand University of Medical sciences; Guilan University of Medical Sciences; Shahid Sadoughi University of Medical Sciences; Birjand University of Medical Sciences; University College London Hospitals NHS Trust; Royal Free Hospitals NHS Trust; University of Leicester; UCL; UCL; UCL; King's College Hospital; Kings College London; Kings College London; Kings London NHS Trust; Kings College Hospital NHS Foundation Trust; King's College London; Office for National Statistics; Huazhong University of Science and Technology, Wuhan, China; University of Edinburgh; Ospedale S. Maria delle Croci, Ravenna, Italy; PLA General Hospital, Beijing, China.; Huazhong University of Science and Technology, Wuhan, China.; University of Edinburgh; University of Liverpool; UCL; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine; Centre for the Mathe; Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.; Departamento de Genetica, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Departamento de Genetica, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Institute for Applied Economic Research (Ipea), Brasilia, Brazil; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; DB Diagnosticos do Brasil, Sao Paulo, Brazil.; Divisao de Laboratorio Central do Hospital das Clinicas, da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto Hermes Pardini, Belo Horizonte, Brazil; Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Simile Instituto de Imunologia Aplicada Ltda, Bel; Laboratorio DASA, Sao Paulo, Brazil.; Laboratorio Fleury, Sao Paulo, Brazil.; Laboratorio de Virologia, Instituto de Ciencias Biomedicas, Universidade Federal de Uberlandia, Uberlandia, Brazil.; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Centro de Estudos da Biodiversidade, Universidade Federal de Roraima, Boa Vista, Brazil.; Divisao de Doencas Infecciosas, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil; Divisao de Doencas Infecciosas, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil; Hospital Estadual Sumare, Universidade Estadual de Campinas, Campinas, Brazil; Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Divisao de Laboratorio Central do Hospital das Clinicas, da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Zoology, Univeristy of Oxford, UK.; University of Oxford, Brazilian Studies Programme, Oxford School of Global and Area Studies; Departamento de Genetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Departamento de Geetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Departamento de Clinica Medica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Patologia Clinica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Patologia Clinica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Departamento de Botanica, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Biologia Celular, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Centro de Saude da Comunidade, Universidade Estadual de Campinas, Campinas, Brazil.; Centro de Laboratorios Multiusuarios, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Sao Paulo, Brazil.; ; Department of Infectious Disease Epidemiology, Imperial College London, UK.; Instituto de Medicina Tropical, Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Departamento de Genetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Department of Infectious Disease Epidemiology, Imperial College London, UK.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.; Mathematical Sciences, University of Southampton, Southampton, UK; Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK; Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Department of Zoology, Univeristy of Oxford, UK.; Instituto de Medicina Tropical, Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom; Department of Zoology, University of Oxford, United Kingdom","BackgroundCOVID-19, which emerged in December 2019, is the largest pandemic ever to occur. During the early phase, little was known about public awareness relating to Coronavirus disease. This study was designed to determine knowledge, attitudes and practices (KAP) among the Iranian public towards COVID-19.

MethodsA cross-sectional online survey was carried out in Iran from 2 March to 8 April 2020 using a self-administered questionnaire on 1,480 people. COVID-19-related KAP questions were adapted from other internationally validated questionnaires specific to infectious diseases.

ResultsAll participants were aware of COVID-19. When asked unprompted, 80% of respondents could correctly cite fever, difficulty breathing and cough as signs/symptoms of COVID-19. Most of our sample population knew that by staying at home and staying isolated (95.3%, 95 % CI: 94.2-96.3) as well as constant hand washing and using disinfectants (92.5%, 95 % CI: 91.1-93.8) could prevent COVID-19. However, there was also widespread misconceptions such as the belief that COVID-19 can be transmitted by wild animals (58%, 95 % CI: 55.5-60.5) and by air (48.3%, 95 % CI: 45.7-50.8). Unprompted, self-reported actions taken to avoid COVID-19 infection included hand washing with soap and water (95.4%, 95 % CI: 94.3-96.4), avoiding crowded places (93%, 95 % CI: 91.7-94.3), cleaning hands with other disinfectants (80.9 %, 95 % CI: 78.9-82.9), and covering mouths and noses when coughing and sneezing (76.1 %, 95 % CI: 73.9-78.2). The internet and social media (94.5%, 95 % CI: 93.3-95.6) were the main Coronavirus information sources. However, the most trusted information sources on Coronavirus were health and medical professionals (79.3%, 95 % CI: 77.2-81.3). The majority of participants (77.0%, 95 % CI: 74.8-79.1) wanted more information about Coronavirus to be available.

ConclusionOur findings suggest that peoples knowledge and attitude towards COVID-19 at the time of its outbreak was of a high level. Therefore, health systems should use multiple ways, such as mass media, phone applications, electronic, print, and tele-education to increase KAP related to COVID-19.",medical education,exact,100,100
medRxiv,10.1101/2020.06.09.20126722,2020-06-11,https://medrxiv.org/cgi/content/short/2020.06.09.20126722,Work-related and Personal Factors Associated with Mental Well-being during COVID-19 Response: A Survey of Health Care and Other Workers,Bradley A Evanoff; Jaime R Strickland; Ann Marie Dale; Lisa Hayibor; Emily Page; Jennifer G Duncan; Thomas Kannampallil; Diana L Gray; Wai Keong Wong; Ameet Bakhai; Kamlesh Khunti; Deenan Pillay; Mahdad Noursadeghi; Honghan Wu; Nilesh Pareek; Daniel Bromage; Theresa Mcdonagh; Jonathan Byrne; James T Teo; Ajay Shah; Ben Humberstone; Liang V Tang; Anoop SV Shah; Andrea Rubboli; Yutao Guo; Yu Hu; Cathie LM Sudlow; Gregory YH Lip; Harry Hemingway; Oliver J Brady; Samuel M. Nicholls; Amilcar Tanuri; Atila Duque Rossi; Carlos Kaue Vieira Braga; Alexandra Lehmkuhl Gerber; Ana Paula Guimaraes; Nelson Gaburo Jr.; Cecilia Salete Alencar; Alessandro Clayton de Souza Ferreira; Cristiano Xavier Lima; Jose Eduardo Levi; Celso Granato; Giula Magalhaes Ferreira; Ronaldo da Silva Francisco Jr.; Fabiana Granja; Marcia Teixeira Garcia; Maria Luiza Moretti; Mauricio Wesley Perroud Jr.; Terezinha Marta Pereira Pinto Castineiras; Carolina Dos Santos Lazari; Sarah C Hill; Andreza Aruska de Souza Santos; Camila Lopes Simeoni; Julia Forato; Andrei Carvalho Sposito; Angelica Zaninelli Schreiber; Magnun Nueldo Nunes Santos; Camila Zolini Sa; Renan Pedra Souza; Luciana Cunha Resende Moreira; Mauro Martins Teixeira; Josy Hubner; Patricia Asfora Falabella Leme; Rennan Garcias Moreira; Mauricio Lacerda Nogueira; - CADDE-Genomic-Network; Neil Ferguson; Silvia Figueiredo Costa; Jose Luiz Proenca-Modena; Ana Tereza Vasconcelos; Samir Bhatt; Philippe Lemey; Chieh-Hsi Wu; Andrew Rambaut; Nick J Loman; Renato Santana Aguiar; Oliver G Pybus; Ester Cerdeira Sabino; Nuno Rodrigues Faria,"Washington University School of Medicine; Washington University School of Medicine; Washington University School of Medicine; Washington University School of Medicine; Washington University in St. Louis; Washington University School of Medicine; Washington University School of Medicine; Washington University School of Medicine; University College London Hospitals NHS Trust; Royal Free Hospitals NHS Trust; University of Leicester; UCL; UCL; UCL; King's College Hospital; Kings College London; Kings College London; Kings London NHS Trust; Kings College Hospital NHS Foundation Trust; King's College London; Office for National Statistics; Huazhong University of Science and Technology, Wuhan, China; University of Edinburgh; Ospedale S. Maria delle Croci, Ravenna, Italy; PLA General Hospital, Beijing, China.; Huazhong University of Science and Technology, Wuhan, China.; University of Edinburgh; University of Liverpool; UCL; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine; Centre for the Mathe; Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.; Departamento de Genetica, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Departamento de Genetica, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Institute for Applied Economic Research (Ipea), Brasilia, Brazil; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; DB Diagnosticos do Brasil, Sao Paulo, Brazil.; Divisao de Laboratorio Central do Hospital das Clinicas, da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto Hermes Pardini, Belo Horizonte, Brazil; Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Simile Instituto de Imunologia Aplicada Ltda, Bel; Laboratorio DASA, Sao Paulo, Brazil.; Laboratorio Fleury, Sao Paulo, Brazil.; Laboratorio de Virologia, Instituto de Ciencias Biomedicas, Universidade Federal de Uberlandia, Uberlandia, Brazil.; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Centro de Estudos da Biodiversidade, Universidade Federal de Roraima, Boa Vista, Brazil.; Divisao de Doencas Infecciosas, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil; Divisao de Doencas Infecciosas, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil; Hospital Estadual Sumare, Universidade Estadual de Campinas, Campinas, Brazil; Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Divisao de Laboratorio Central do Hospital das Clinicas, da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Zoology, Univeristy of Oxford, UK.; University of Oxford, Brazilian Studies Programme, Oxford School of Global and Area Studies; Departamento de Genetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Departamento de Geetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Departamento de Clinica Medica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Patologia Clinica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Patologia Clinica, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Departamento de Botanica, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Biologia Celular, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Centro de Saude da Comunidade, Universidade Estadual de Campinas, Campinas, Brazil.; Centro de Laboratorios Multiusuarios, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Sao Paulo, Brazil.; ; Department of Infectious Disease Epidemiology, Imperial College London, UK.; Instituto de Medicina Tropical, Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Departamento de Genetica, Evolucao, Microbiologia e Imunologia, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil; Laboratorio de Bioinformatica, Laboratorio Nacional de Computacao Cientifica, Petropolis, Brazil.; Department of Infectious Disease Epidemiology, Imperial College London, UK.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.; Mathematical Sciences, University of Southampton, Southampton, UK; Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK; Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.; Departamento de Genetica, Ecologia e Evolucao, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Department of Zoology, Univeristy of Oxford, UK.; Instituto de Medicina Tropical, Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom; Department of Zoology, University of Oxford, United Kingdom","ObjectiveMeasure the prevalence of stress, anxiety, depression, work-exhaustion, burnout, and decreased well-being among faculty and staff at a university and academic medical center during the SARS-CoV-2 pandemic, and describe work-related and personal factors associated with mental health and well-being.

DesignObservational cohort study conducted between April 17 and May 1, 2020 using a web-based questionnaire.

SettingMedical and main campuses of a university.

ParticipantsAll faculty, staff, and post-doctoral fellows.

ExposuresWork factors including supervisor support and exposure to high-risk clinical settings; personal factors including demographics and family/home stressors.

Main Outcomes and MeasuresStress, anxiety, depression, work exhaustion, burnout, and decreased well-being.

ResultsThere were 5550 respondents (overall response rate of 34.3%). 38% of faculty and 14% of staff (n=915) were providing clinical care, while 57% of faculty and 77% of staff were working from home. The prevalence of anxiety, depression, and work exhaustion were somewhat higher among clinicians than non-clinicians. Among all workers, anxiety, depression, and high work exhaustion were independently associated with community or clinical exposure to COVID-19 [Prevalence Ratios and 95% confidence intervals 1.37(1.09- 1.73), 1.28(1.03 - 1.59), and 1.24(1.13 - 1.36) respectively]. Poor family supportive behaviors by supervisors were also associated with these outcomes [1.40 (1.21 - 1.62), 1.69 (1.48 - 1.92), 1.54 (1.44 - 1.64)]. Age below 40 and a greater number of family/home stressors were also associated with poorer outcomes. Among the subset of clinicians, caring for patients with COVID-19 and work in high-risk clinical settings were additional risk factors.

Conclusions and ImplicationsOur findings suggest that the pandemic has had negative effects on mental health and well-being among both clinical and non-clinical employees. Prevention of exposure to COVID-19 and increased supervisor support are modifiable risk factors that may protect mental health and well-being.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2020.06.08.20120584,2020-06-09,https://medrxiv.org/cgi/content/short/2020.06.08.20120584,SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study,Catherine Houlihan; Nina Vora; Thomas Byrne; Dan Lewer; Judith Heaney; David A Moore; Rebecca Matthews; Sajida Adam; Louise Enfield; Abigail Severn; Angela McBride; Moira Jane Spyer; Rupert Beale; Peter Cherepanov; Kathleen Gaertner; Maryam Shahmanesh; - The SAFER Field Study Team; Kevin Ng; Georgina Cornish; Naomi Walker; Susan Michie; Ed Manley; Fabiana Lorencatto; - The Crick-COVID-Consortium; Richard Gilson; Sonia Gandhi; Steve Gamblin; George Kassiotis; Laura McCoy; Charles Swanton; Andrew Hayward; Eleni Nastouli; Alexandre Fabro; Thais Mauad; Marisa Dolhnikoff; Amaro Duarte-Neto; Paulo Saldiva; Thiago Cunha; Jose Carlos Alves-Filho; Eurico Arruda; Paulo Louzada-Junior; Rene Oliveira; Fernando Cunha,"University College London Hospital; UCL; UCL; University College London; UCL; Francis Crick Institute; UCL; UCL; UCL; UCL; UCL; UCL; Francis Crick Institute; Francis Crick Institute; UCL; UCL; ; Francis Crick Institute; Francis Crick Institute; UCL; UCL; Leeds University; UCL; ; UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; UCL; Francis Crick Institute; UCL; University College London; University of Sao Paulo, Pathology and Legal Medicine, Ribeirao Preto Medical School; University of Sao Paulo, Department Pathology, School of Medicine; University of Sao Paulo, Department Pathology, School of Medicine; University of Sao Paulo, Department Pathology, School of Medicine; University of Sao Paulo, Pathology and Legal Medicine, Ribeirao Preto Medical School; University of Sao Paulo, Center of Research in Inflammatory Diseases (CRID), Department of  Pharmacology, Ribeirao Preto Medical School; University of Sao Paulo, Center of Research in Inflammatory Diseases (CRID), Department of  Pharmacology, Ribeirao Preto Medical School; University of Sao Paulo, Ribeirao Preto Medical School, Virology Research Center, Department of Cell and Molecular Biology, Ribeirao Preto Medical School; University of Sao Paulo, Center of Research in Inflammatory Diseases (CRID), Divisions of Clinical Immunology, Emergency, Infectious Diseases and Intensive Care; University of Sao Paulo, Divisions of Clinical Immunology, Emergency, Infectious Diseases and Intensive Care Unit, Ribeirao Preto Medical School; University of Sao Paulo, Center of Research in Inflammatory Diseases (CRID), Department of  Pharmacology, Ribeirao Preto Medical School","BackgroundAlthough SARS-CoV-2 infection in Healthcare Workers (HCWs) is a public health concern, there is little description of their longitudinal antibody response in the presence or absence of SARS-CoV-2 and symptoms. We followed HCWs in an acute London hospital to measure seroconversion and RNA detection at the peak of the pandemic.

MethodsWe enrolled 200 patient-facing HCWs between 26 March and 8 April 2020 and collected twice-weekly self-administered nose and throat swabs, symptom data and monthly blood samples. Swabs were tested for SARS-CoV-2 by PCR, and serum for antibodies to spike protein by ELISA and flow cytometry.

FindingsDuring the first month, 42/200 (21%) HCWs were PCR positive in at least one nose and throat swab. Only 8/42 HCW (19%) who were PCR positive during the study period had symptoms that met current case definition. Of 181 HCWs who provided enrollment and follow-up blood samples, 82/181 (45.3%) were seropositive. In 33 HCWs who had positive serology at baseline but were PCR negative, 32 remained PCR negative. One HCW had a PCR positive swab six days after enrollment, likely representing waning infection.

ConclusionThe high seropositivity and RNA detection in these front-line HCWs brings policies to protect staff and patients into acute focus. Our findings have implications for planning for the  second wave and for vaccination campaigns in similar settings. The evidence of asymptomatic SARS-CoV-2 infection indicates that asymptomatic HCW surveillance is essential, while our study sets the foundations to answer pertinent questions around the duration of protective immune response and the risk of re-infection.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.08.20125211,2020-06-09,https://medrxiv.org/cgi/content/short/2020.06.08.20125211,Estimating weekly excess mortality at subnational level in Italy during the COVID-19 pandemic,Marta Blangiardo; Michela Cameletti; Monica Pirani; Gianni Corsetti; Marco Battaglini; Gianluca Baio; Natacha Mezquia; Rafael Venegas; Julio Betancourt; Rodolfo Dominguez,"Imperial College London; University of Bergamo; Imperial College London; Italian Statistical Institute; Italian Statistical Institute; University College London; Medical college of Havana. Havana city, Cuba; Medical college of Havana. Havana city, Cuba; Medical college of Villa Clara. Santa Clara city, Cuba; Medical college of Camaguey. Camaguey city, Cuba","ObjectivesTo provide a sub-national analysis of excess mortality during the COVID-19 pandemic in Italy.

DesignPopulation-based on all-cause mortality official data, available as counts by age and sex.

SettingThe 7,904 municipalities in Italy.

ParticipantsAll residents in Italy in the years 2016 to 2020.

Main outcome measuresAll-cause mortality weekly rates for each municipality, based on the first four months of 2016 - 2019. Predicted all-cause weekly deaths and mortality rates at municipality level for 2020, based on the modelled spatio-temporal trends.

ResultsThere was strong evidence of excess mortality for Northern Italy; Lombardia showed higher mortality rates than expected from the end of February, with 23,946 (23,013 to 24,786) total excess deaths. North-West and North-East regions showed higher mortality from the beginning of March, with 6,942 (6,142 to 7,667) and 8,033 (7,061 to 9,044) total excess deaths respectively. After discounting for the number of COVID-19-confirmed deaths, Lombardia still registered 10,197 (9,264 to 11,037) excess deaths, while regions in the North-West and North-East had 2,572 (1,772 to 3,297) and 2,047 (1,075 to 3,058) extra deaths, respectively. We observed marked geographical differences at municipality level. The city of Bergamo (Lombardia) showed the largest percent excess 88.9% (81.9% to 95.2%) at the peak of the pandemic. An excess of 84.2% (73.8% to 93.4%) was also estimated at the same time for the city of Pesaro (Central Italy), in stark contrast with the rest of the region, which does not show evidence of excess deaths.

ConclusionsOur study gives a comprehensive picture of the evolution of all-cause mortality in Italy from 2016 to 2020 and describes the spatio-temporal differences in excess mortality during the COVID-19 pandemic. Our model shows heterogeneous impact of COVID-19, and it can be used to help policy- makers target measures to limit the burden on the health-care system as well as reducing social and economic consequences. Our probabilistic methodology is useful for real-time mortality surveillance, continuously monitoring local temporal trends and flagging where and when mortality rates deviate from the expected range, which might suggest a second wave of the pandemic.",public and global health,exact,100,100
medRxiv,10.1101/2020.06.05.20122226,2020-06-07,https://medrxiv.org/cgi/content/short/2020.06.05.20122226,"Different adiposity measures across sex, age, ethnicity, and COVID-19",Naveed Sattar; Frederick K Ho; Jason MR Gill; Nazim Ghouri; Stuart R Gray; Carlos A Celis-Morales; Srinivasa Vittal Katikireddi; Colin Berry; Jill P Pell; John JV McMurray; Paul Welsh; John Edmunds; Christopher I Jarvis; Karen Austrian,"University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Population Council, Kenya","We examined the link between BMI and risk of a positive test for SARS-CoV-2 and risk of COVID-19-related death among UK Biobank participants. Among 4855 participants tested for SARS-CoV-2 in hospital, 839 were positive and of these 189 died from COVID-19. Poisson models with penalised thin plate splines were run relating exposures of interest to test positivity and case-fatality, adjusting for confounding factors. BMI was associated strongly with positive test, and risk of death related to COVID-19. The gradient of risk in relation to BMI was steeper in those under 70, compared with those aged 70 years or older for COVID-19 related death (Pinteraction=0.03). BMI was more strongly related to test positivity (Pinteraction=0.010) and death (Pinteraction=0.002) in non-whites, compared with whites. These data add support for adiposity being more strongly linked to COVID-19-related deaths in younger people and non-white ethnicities. If future studies confirm causality, lifestyle interventions to improve adiposity status may be important to reduce the risk of COVID-19 in all, but perhaps particularly, non-white communities.",epidemiology,exact,100,100
medRxiv,10.1101/2020.06.05.20123133,2020-06-07,https://medrxiv.org/cgi/content/short/2020.06.05.20123133,Pollen Explains Flu-Like and COVID-19 Seasonality,Martijn J Hoogeveen; Eric CM Van Gorp; Ellen K Hoogeveen; Nazim Ghouri; Stuart R Gray; Carlos A Celis-Morales; Srinivasa Vittal Katikireddi; Colin Berry; Jill P Pell; John JV McMurray; Paul Welsh; John Edmunds; Christopher I Jarvis; Karen Austrian,"Open University Netherlands; Erasmus Medical Center; Jeroen Bosch Ziekenhuis; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Population Council, Kenya","Current models for flu-like epidemics insufficiently explain multi-cycle seasonality. Meteorological factors alone, including the associated behavior, do not predict seasonality, given substantial climate differences between countries that are subject to flu-like epidemics or COVID-19. Pollen is documented to be allergenic, it plays a role in immuno-activation and defense against respiratory viruses, and seems to create a bio-aerosol that lowers the reproduction number of flu-like viruses. Therefore, we hypothesize that pollen may explain the seasonality of flu-like epidemics, including COVID-19, in combination with meteorological variables.

We have tested the Pollen-Flu Seasonality Theory for 2016-2020 flu-like seasons, including COVID-19, in the Netherlands, with its 17.4 million inhabitants. We combined changes in flu-like incidence per 100K/Dutch residents (code: ILI) with pollen concentrations and meteorological data. Finally, a predictive model was tested using pollen and meteorological threshold values, inversely correlated to flu-like incidence.

We found a highly significant inverse correlation of r(224)= -0.41 (p < 0.001) between pollen and changes in flu-like incidence, corrected for the incubation period. The correlation was stronger after taking into account the incubation time. We found that our predictive model has the highest inverse correlation with changes in flu-like incidence of r(222) = -0.48 (p < 0.001) when average thresholds of 610 total pollen grains/m3, 120 allergenic pollen grains/m3, and a solar radiation of 510 J/cm2 are passed. The passing of at least the pollen thresholds, preludes the beginning and end of flu-like seasons. Solar radiation is a co-inhibitor of flu-like incidence, while temperature makes no difference. However, higher relative humidity increases with flu-like incidence.

We conclude that pollen is a predictor of the inverse seasonality of flu-like epidemics, including COVID-19, and that solar radiation is a co-inhibitor.",epidemiology,exact,100,100
medRxiv,10.1101/2020.06.02.20120642,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.02.20120642,Estimating excess visual loss in people with neovascular age-related macular degeneration during the COVID-19 pandemic,Darren S Thomas; Alasdair Warwick; Abraham Olvera-Barrios; Catherine Egan; Roy Schwartz; Sudeshna Patra; Haralabos Eleftheriadis; Anthony P Khawaja; Andrew Lotery; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"Institute of Health Informatics, University College London, London, UK; Institute of Cardiovascular Science, University College London, London, UK & Moorfields Eye Hospital NHS Foundation Trust, London, UK.; Moorfields Eye Hospital NHS Turst & Institute of Ophthalmology UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Health Informatics, University College London, London, UK; Bart's Health NHS Trust, London, UK; King's College Hospital NHS Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Faculty of Medicine, University of Southampton, Southampton, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","ObjectivesTo report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at one year.

DesignRetrospective clinical audit and simulation model.

SettingMultiple UK NHS ophthalmology centres.

ParticipantsData on the reduction in new nAMD referrals was obtained from four NHS Trusts in England comparing April 2020 to April 2019. To estimate the potential impact on one-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20,825 nAMD eyes from 27 NHS Trusts.

Main outcome measuresSimulated mean visual acuity and proportions of eyes with vision [&le;]6/60, [&le;]6/24 and [&ge;]6/12 at one year under four hypothetical scenarios: no treatment delay, 3, 6 and 9-month treatment delays. Estimated additional number of eyes with vision [&le;]6/60 at one year nationally.

ResultsThe number of nAMD referrals at four major eye treatment hospital groups based in England dropped on average by 72% (range 65 to 87%) in April 2020 compared to April 2019. Simulated one-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision [&le;]6/60 from 15.5% (13.2 to 17.9) to 23.3% (20.7 to25.9), and a decrease in the proportion of eyes with vision [&ge;]6/12 (driving vision) from 35.1% (32.1 to 38.1) to 26.4% (23.8 to29.2). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level at the national level for only one month, these simulated results suggest an additional 186-365 eyes with vision [&le;]6/60 at one-year with even a short treatment delay.

ConclusionsWe report a large decrease in nAMD referrals during the first month of COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision [&le;]6/60 and 25% relative decrease in the number of eyes with driving vision at one year.",ophthalmology,exact,100,100
medRxiv,10.1101/2020.06.03.20121608,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.03.20121608,COVID-19 DYNAMICS CONSIDERING THE INFLUENCE OF HOSPITAL INFRASTRUCTURE: AN INVESTIGATION OF BRAZILIAN SCENARIOS,Pedro M.C.L. Pacheco; Marcelo A. Savi; Pedro V. Savi; Catherine Egan; Roy Schwartz; Sudeshna Patra; Haralabos Eleftheriadis; Anthony P Khawaja; Andrew Lotery; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"Centro Federal de Educacao Tecnologica Celso Suckow da Fonseca - CEFET/RJ; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Health Informatics, University College London, London, UK; Bart's Health NHS Trust, London, UK; King's College Hospital NHS Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Faculty of Medicine, University of Southampton, Southampton, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","This paper deals with the mathematical modeling and numerical simulations related to the coronavirus dynamics. A description is developed based on the framework of susceptible-exposed-infectious-removed model. Removed population is split into recovered and death populations allowing a better comprehension of real situations. Besides, total population is reduced based on the number of deaths. Hospital infrastructure is also included into the mathematical description allowing the consideration of collapse scenarios. Initially, a model verification is carried out calibrating system parameters with data from China outbreak that is considered a benchmark due the availability of data for the entire cycle. Afterward, numerical simulations are performed to analyze COVID-19 dynamics in Brazil. Results show several scenarios showing the importance of social isolation. System dynamics has a strong sensitivity to transmission rate showing the importance of numerical simulations to guide public health decision strategies.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.03.20121145,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.03.20121145,"The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children",Itai Dattner; Yair Goldberg; Guy Katriel; Rami Yaari; Nurit Gal; Yoav Miron; Arnona Ziv; Yoram Hamo; Amit Huppert; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"University of Haifa, Israel; Technion - Israel Institute of Technology; ORT Braude College; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","BackgroundOne of the significant unanswered questions about COVID-19 epidemiology relates to the role of children in transmission. In this study we estimate susceptibility and infectivity of children compared to those of adults. Understanding the age-structured transmission dynamics of the outbreak provides precious and timely information to guide epidemic modelling and public health policy.

MethodsData were collected from households in the city of Bnei Brak, Israel, in which all household members were tested for COVID-19 using PCR. To estimate relative transmission parameters in the absence of data on who infected whom, we developed an estimation method based on a discrete stochastic dynamic model of the spread of the epidemic within a household. The model describes the propagation of the disease between household members allowing for susceptibility and infectivity parameters to vary among two age groups. The parameter estimates are obtained by a maximum likelihood method, where the likelihood function is computed based on the stochastic model via simulations.

FindingsInspection of the data reveals that children are less likely to become infected compared to adults (25% of children infected over all households, 44% of adults infected over all households, excluding index cases), and the chances of becoming infected increases with age. An interesting exception is that infants up to age one year are more likely to be infected than children between one and four. Using our modelling approach, we estimate that the susceptibility of children (under 20 years old) is 45% [40%, 55%] of the susceptibility of adults. The infectivity of children was estimated to be 85% [65%, 110%] relative to that of adults.

InterpretationIt is widely observed that the percentage of children within confirmed cases is low. A common explanation is that children who are infected are less likely to develop symptoms than adults, and thus are less likely to be tested. We estimate that children are less susceptible to infection, which is an additional factor explaining their relatively low rate of occurrence within confirmed cases. Moreover, our results indicate that children, when infected, are somewhat less prone to infect others compared to adults; however, this result is not statistically significant.

The resulting estimates of susceptibility and infectivity of children compared to adults are crucial for deciding on appropriate interventions, and for controlling the epidemic outbreak and its progress. These estimates can guide age-dependent public health policy such as school closure and opening. However, while our estimates of childrens susceptibility and infectivity are lower than those of adults within a household, it is important to bear in mind that their role in the spread of COVID-19 outside the household, is also affected by different contact patterns and hygiene habits.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.02.20119883,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.02.20119883,A simplified model for the analysis of COVID-19 evolution during the lockdown period in Italy,Roberto Simeone; Yair Goldberg; Guy Katriel; Rami Yaari; Nurit Gal; Yoav Miron; Arnona Ziv; Yoram Hamo; Amit Huppert; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"None; Technion - Israel Institute of Technology; ORT Braude College; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","A simplified model applied to COVID-19 cases detected and officially published by the italian government [1], seems to fit quite well the time evolution of the disease in Italy during the period feb-24th - may-19th 2020.

The hypothesis behind the model is based on the fact that in the lockdown period the infection cannot be transmitted due to social isolation and, more generally, due to the strong protection measures in place during the observation period. In this case a compartment model is used and the interactions between the different compartments are simplified. The sample of cases detected is intended as a set of individuals susceptible to infection which, after being exposed and undergoing the infection, were isolated ( treated) in such a way they can no longer spread the infection.

The values obtained are to be considered indicative.

The same model has been applied both to the data relating to Italy and to some regions of Italy (Lombardia, Piemonte, Lazio, Campania, Calabria, Sicilia, Sardegna), generally finding a good response and indicatively interesting values (see chap. 5).

The only tuning parameter is the  incubation period{tau} that, together with the calculated growth rate{kappa} of the exponential curve used to approximate the early stage data, in this modelization, are in strong relationship with the compartments transfer rates.

In particular[R] 0 and the numerical value of{kappa} (dimensionless) in this model are linked by the relation:[R] 0 = 1/{kappa}2

Revision HistoryO_ST_ABSRevision # 1C_ST_ABSO_LIErrata corrige in section 1 (Introduction): the equations that summarize the relationship between the parameters were wrong. This revised version contains the correct equations at page 2.
C_LIO_LIThe synchronization criteria is updated. No need to use a threshold different to the one used to determine the growth coefficient. The results are now updated with the synchronization point near to the 20% of the maximum value of the cases detected per day: O_FD O_INLINEFIG[Formula 1]C_INLINEFIGM_FD(1)C_FD
C_LIO_LIModifications in section 4 (Model results for Italy). It is appropriate to use an exponential function instead of a logistic function to find the growth rate in the initial phase. Section 4 and the results are now updated.
C_LIO_LISome non-substantial corrections in the descriptive part.
C_LI

Revision # 2O_LIErrata corrige in the system differential equation 6: in the the derivative of S were reported a wrong additional term N. Now the equation 6 is correct.
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.03.20120576,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.03.20120576,A RELAXATION VIEWPOINT TO COVID-19 INFECTION,Oscar Sotolongo-Costa; Jos Weberszpil; Oscar Sotolongo-Grau; Rami Yaari; Nurit Gal; Yoav Miron; Arnona Ziv; Yoram Hamo; Amit Huppert; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"Ctedra ""Henri Poincar"" de sistemas complejos. Universidad de La Habana. Cuba.; Univ. Federal Rural do Rio de Janeiro-UFRRJ; Alzheimer Research Center and Memory Clinic, Fundacin ACE, Institut Catal de Neurocinciens Aplicades. Spain.; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Gertner Institute for Health Policy and Epidemiology; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","One of the central tools to control the COVID-19 pandemics is the knowledge of its spreading dynamics. Here we develop a fractal model capable of describe this dynamics, in term of daily new cases, and provide quantitative criteria for some predictions. We propose a fractal dynamical model using conformed derivative and fractal time scale. A Burr-XII shaped solution of the fractal-like equation is obtained. The model is tested using data from several countries, showing that a single function is able to describe very different shapes of the outbreak. The diverse behavior of the outbreak on those countries is presented and discussed. Moreover, a criterion to determine the existence of the pandemic peak and a expression to find the time to reach herd immunity are also obtained.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.03.20119867,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.03.20119867,"The psychological effects of COVID-19 on frontline healthcare workers and how they are coping: a web-based, cross-sectional study from Pakistan",Muhammad Salman; Muhammad Hussnain Raza; Zia Ul Mustafa; Tahir Mehmood Khan; Noman Asif; Humera Tahir; Naureen Shehzadi; Khalid Hussain; Amit Huppert; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"The University of Lahore; Faisalabad Institute of Cardiology; District Headquarter Hospital Pakpattan; University of Veterinary and Animal Sciences; University of the Punjab; Lahore Medical and Dental College; University of the Punjab; University of the Punjab; Gertner Institute for Health Policy and Epidemiology; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","BackgroundHigh level stress is expected when crises starts affecting peoples lives and communities which is witnessed in the past epidemics. Infectious diseases outbreaks like the ongoing COVID19 pandemic have negative impact on healthcare workers (HCWs) mental health, which needs to be investigated. Therefore, we aimed to assess the psychological impact of COVID-19 on frontline HCWs and their coping strategies.

MethodsA web-based, cross-sectional study was conducted among HCWs of the Punjab province of Pakistan. The generalized anxiety scale (GAD-7), patient health questionnaire (PHQ-9) and Brief-COPE were used to assess anxiety, depression and coping strategies.

ResultsThe mean age of respondents (N = 398) was 28.67 {+/-} 4.15 years, with majority of medical doctors (52%). The prevalence of anxiety and depression were 21.4% and 21.9%, respectively. There was no significant difference of anxiety and depression scores among doctors, nurses and pharmacists. Females had significantly higher anxiety (p = 0.003) and depression (p = 0.001) scores than males. Moreover, HCWs performing duties in COVID-19 ICU had significantly higher anxiety score than those from isolation wards (p = 0.020) and other departments (p = 0.014). Depression, not anxiety, score were higher among those who did not receive the infection prevention training. Most frequently adopted coping strategy was religious coping (5.98 {+/-} 1.73) followed by acceptance (5.59 {+/-} 1.55) and coping planning (4.91 {+/-} 1.85).

ConclusionA considerable proportion of HCWs are having generalized anxiety and depression during the ongoing COVID-19 pandemic. Our findings call for interventions to mitigate mental health risks in HCWs.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.04.20122069,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.04.20122069,Mechanical ventilation utilization in COVID-19: A systematic review and meta-analysis,Mohammed A Almeshari; Nowaf Y Alobaidi; Mansour Al Asmri; Eyas Alhuthail; Ziyad Alshehri; Farhan Alenezi; Elizabeth Sapey; Dhruv Parekh; Lawrence Ross; Iain Thomson; Declan Devane; Trish Greenhalgh; Samuel Scott; Emery Manirambona; Asif Machhada; Aditi Aggarwal; Lydia Benazaize; Mina Ibrahim; David Kim; Isabel Tol; Elliott H Taylor; Alexandra Knighton; Dorothy Bbaale; Duha Jasim; Heba Alghoul; Henna Reddy; Hibatullah Abuelgasim; Alicia Sigler; Kirandeep Saini; Leenah Abuelgasim; Mario Moran-Romero; Mary Kumarendran; Najlaa Abu Jamie; Omaima Ali; Raghav Sudarshan; Riley Dean; Rumi Kisyova; Sonam Kelzang; Sophie Roche; Tazin Ahsan; Yethrib Mohamed; Andile Maqhawe Dube; Grace Paida Gwini; Rashidah Gwokyala; Robin Brown; Mohammad Rabiul Karim Khan Papon; Zoe Li; Salvador Sun Ruzats; Somy Charuvila; Noel Peter; Khalil Khalidy; Nkosikhona Moyo; Osaid Alser; Arielis Solano; Eduardo Robles-Perez; Aiman Tariq; Mariam Gaddah; Spyros Kolovos; Faith C Muchemwa; Abdullah Saleh; Amanda Gosman; Rafael Pinedo-Villanueva; Anant Jani; Roba Khundkar,"University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Taibah University; King Saud bin Abdulaziz University for Health Sciences; University of Birmingham; University of Birmingham; Children's Hospital of Los Angeles; Medecins Sans Frontieres/Doctors without Borders; National University of Ireland Galway; University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; University of Rwanda, College of Medicine and Health Sciences, Rwanda; North Bristol NHS Trust, Bristol, UK; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; North Bristol NHS Trust, Bristol, UK; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Mbarara University of Science and Technology, Uganda; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Islamic University of Gaza, Palestine; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Shriners Ambulatory Clinic, Tijuana, Mexico; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Department of Plastic Surgery, Hospital General Dr. Manuel Gea Gonzalez, National Autonomous University of Mexico, Mexico City, Mexico; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Palestinian Ministry of Health, Gaza, Palestine; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; University of California San Diego; North Bristol NHS Trust, Bristol; Gelephu Central Regional Referral Hospital, Bhutan; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka, Bangladesh; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Faculty of Medicine, National University of Science and Technology, Bulawayo, Zimbabwe; Faculty of Medicine, National University of Science and Technology, Bulawayo, Zimbabwe; Gulu University faculty of Medicine, Uganda; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka, Bangladesh; Swansea Bay University Health Board, UK; University of Huddersfield, UK; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Gaza; Faculty of Medicine, National University of Science and Technology, Bulawayo, Zimbabwe; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Dominican Republic; Mexican Social Security Institute, Mexico; Jinnah Post Graduate Medical Center, Karachi, Pakistan.; Lancaster University, UK; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford; Parirenyatwa Hospital at the University of Zimbabwe College of Health Sciences; University of Alberta, Canada; University of California San Diego; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford; Oxford University Global Surgery Group, Nuffield Department of Surgical Sciences, University of Oxford","BackgroundIn December 2019, SARS-CoV-2 caused a global pandemic with a viral infection called COVID-19. The disease usually causes respiratory symptoms but in a small proportion of patients can lead to a pneumonitis, Adult Respiratory Distress Syndrome and death. Invasive Mechanical Ventilation (IMV) is considered a life-saving treatment for COVID-19 patients and a huge demand for IMV devices was reported globally. This review aims to provide insight on the initial IMV practises for COVID-19 patients in the initial phase of the pandemic.

MethodsElectronic databases (Embase and MEDLINE) were searched for applicable articles using relevant keywords. The references of included articles were hand searched. Articles that reported the use of IMV in adult COVID-19 patients were included in the review. The NIH quality assessment tool for cohort and cross-sectional studies was used to appraise studies.

Results106 abstracts were identified from the databases search, of which 16 were included. 5 studies were included in the meta-analysis. In total, 9988 patients were included across all studies. The overall cases of COVID-19 requiring IMV ranged from 2-77%. Increased age and pre-existing comorbidities increased the likelihood of IMV requirement. The reported mortality rate in patients receiving IMV ranged between 50-100%. On average, IMV was required and initiated between 10-10.5 days from symptoms onset. When invasively ventilated, COVID-19 patients required IMV for a median of 10-17 days across studies. Little information was provided on ventilatory protocols or management strategies and were inconclusive.

ConclusionIn these initial reporting studies for the first month of the pandemic, patients receiving IMV were older and had more pre-existing co-morbidities than those who did not require IMV. The mortality rate was high in COVID-19 patients who received IMV. Studies are needed to evaluate protocols and modalities of IMV to improve outcomes and identify the populations most likely to benefit from IMV.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.06.01.20116608,2020-06-03,https://medrxiv.org/cgi/content/short/2020.06.01.20116608,Is death from Covid-19 a multistep process?,Neil Pearce; Giovenale Moirano; Milena Maule; Manolis Kogevinas; Xavier Rodo; Deborah Lawlor; Jan Vandenbroucke; Christina Vandenbroucke-Grauls; Fernando P Polack; Adnan Custovic; Andrew D. Badley; Amy W Williams; Gregory J Gores; John D. Halamka; William G. Morice II; Venky Soundararajan; Vincent Enouf; Samuel Alizon; Magnus Evander; Johan Normark; Anders Johansson; Anna K Overby; Mattias Forsell; Karen Bisnauthsing; Geraldine O'Hara; Eithne MacMahon; Rahul Batra; Michael H Malim; Stuart JD Neil; Katie Doores; Jonathan D Edgeworth,"London School of Hygiene and Tropical Medicine; University of Turin, Italy; University of Turin, Italy; ISGlobal; ISGlobal; University of Bristol; Leiden University Medical Center; Amsterdam UMC; Vanderbilt Unversity; Imperial College London; Mayo Clinic, Rochester MN, USA; Mayo Clinic; Mayo Clinic; Mayo Clinic, Rochester MN, USA; Mayo Clinic, Rochester MN, USA; Mayo Clinic Laboratories, Rochester MN, USA; nference, inc., One Main Street, Suite 400, East Arcade, Cambridge, MA 02142, USA; Institut Pasteur; CNRS; Umea University; Umea University; Umea University; Umea University; Umea University; Guy's and St.Thomas' NHS Foundation Trust; Guy's and St.Thomas' NHS Foundation Trust; Guy's and St.Thomas' NHS Foundation Trust; Guy's and St.Thomas' NHS Foundation Trust; King's College London; King's College London; King's College London; King's College London","Covid-19 death has a different relationship with age than is the case for other severe respiratory pathogens. The Covid-19 death rate increases exponentially with age, and the main risk factors are age itself, as well as having underlying conditions such as hypertension, diabetes, cardiovascular disease, severe chronic respiratory disease and cancer. Furthermore, the almost complete lack of deaths in children suggests that infection alone is not sufficient to cause death; rather, one must have gone through a number of changes, either as a result of undefined aspects of aging, or as a result of chronic disease. These characteristics of Covid-19 death are consistent with the multistep model of disease, a model which has primarily been used for cancer, and more recently for amyotrophic lateral sclerosis (ALS). We applied the multi-step model to data on Covid-19 case fatality rates (CFRs) from China, South Korea, Italy, Spain and Japan. In all countries we found that a plot of ln (CFR) against ln (age) was approximately linear with a slope of about 5. As a comparison, we also conducted similar analyses for selected other respiratory diseases. SARS showed a similar log-log age-pattern to that of Covid-19, albeit with a lower slope, whereas seasonal and pandemic influenza showed quite different age-patterns. Thus, death from Covid-19 and SARS appears to follow a distinct age-pattern, consistent with a multistep model of disease that in the case of Covid-19 is probably defined by comorbidities and age producing immune-related susceptibility. Identification of these steps would be potentially important for prevention and therapy for SARS-COV-2 infection.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.31.20118638,2020-06-02,https://medrxiv.org/cgi/content/short/2020.05.31.20118638,Respiratory Failure in Covid19 is associated with increased monocyte expression of complement receptor 3,Rajeev Gupta; Vanya A Gant; Bryan Williams; Tariq Enver; Martha S Medina Acu&ntildea Sr.; Mark J Caulfield; Patricia B Munroe; Nicholas C Harvey; Steffen E Petersen; Miranda Olff; Giacomo Ciusa; Erica Bacca; Carlotta Rogati; Marco Tutone; Giulia Burastero; Alessandro Raimondi; Marianna Menozzi; Erica Franceschini; Gianluca Cuomo; Luca Corradi; Gabriella Orlando; Antonella Santoro; Margherita Di Gaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Riccardo Fantini; Luca Tabb; Ivana Castaniere; Stefano Busani; Enrico Clini; Massimo Girardis; Mario Sarti; Andrea Cossarizza; Cristina Mussini; Federica Mandreoli; Paolo Missier; Giovanni Guaraldi,"UCL Cancer Institute; UCL Hospitals NHS Trust; UCLH NHS Hospitals Foundation Trust; UCL Cancer Institute; National University of Callao; William Harvey Research Institute; William Harvey Research Institute; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; William Harvey Research Institute; Department of Psychiatry, Amsterdam Neuroscience & Public Health, Amsterdam UMC, Amsterdam, The Netherlands; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Respiratory Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Respiratory Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Respiratory Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Anesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Respiratory Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy; Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy; Clinical Microbiology, Ospedale Civile di Baggiovara, Modena, Italy; Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Italy; Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy; Department of Physical, Computer and Mathematical Sciences, University of Modena and Reggio Emilia, Italy; Newcastle University; Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy","A key question in COVID-19 infection is why some previously healthy patients develop severe pulmonary failure and some ultimately die. Initial pulmonary failure does not exhibit classical features of ARDS; hypercoagulability is a common laboratory feature, and pulmonary thrombotic microangiopathy has been reported post mortem1,2,3. Biomarkers cannot robustly identify such patients pre-emptively and no specific interventions exist to mitigate clinical deterioration. Mononuclear phagocytic cells are key immune cells and bind fibrinogen through the CD11b/CD18 dimer CR3, whose activated form can initiate microthrombus formation. Accordingly, we profiled circulating monocyte CD11b/CD18 cell surface density from COVID-19 infected adults who were (i) symptomatic but breathless, (ii) requiring ventilatory support, and (iii) recovering following ICU care for hypoxia.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.27.20083287,2020-06-01,https://medrxiv.org/cgi/content/short/2020.05.27.20083287,Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency,Alvina G Lai; Laura Pasea; Amitava Banerjee; Spiros Denaxas; Michail Katsoulis; Wai Hoong Chang; Bryan Williams; Deenan Pillay; Mahdad Noursadeghi; David Linch; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,"University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge","BackgroundCancer and multiple non-cancer conditions are considered by the Centers for Disease Control and Prevention (CDC) as high risk conditions in the COVID-19 emergency. Professional societies have recommended changes in cancer service provision to minimize COVID-19 risks to cancer patients and health care workers. However, we do not know the extent to which cancer patients, in whom multi-morbidity is common, may be at higher overall risk of mortality as a net result of multiple factors including COVID-19 infection, changes in health services, and socioeconomic factors.

MethodsWe report multi-center, weekly cancer diagnostic referrals and chemotherapy treatments until April 2020 in England and Northern Ireland. We analyzed population-based health records from 3,862,012 adults in England to estimate 1-year mortality in 24 cancer sites and 15 non-cancer comorbidity clusters (40 conditions) recognized by CDC as high-risk. We estimated overall (direct and indirect) effects of COVID-19 emergency on mortality under different Relative Impact of the Emergency (RIE) and different Proportions of the population Affected by the Emergency (PAE). We applied the same model to the US, using Surveillance, Epidemiology, and End Results (SEER) program data.

ResultsWeekly data until April 2020 demonstrate significant falls in admissions for chemotherapy (45-66% reduction) and urgent referrals for early cancer diagnosis (70-89% reduction), compared to pre-emergency levels. Under conservative assumptions of the emergency affecting only people with newly diagnosed cancer (incident cases) at COVID-19 PAE of 40%, and an RIE of 1.5, the model estimated 6,270 excess deaths at 1 year in England and 33,890 excess deaths in the US. In England, the proportion of patients with incident cancer with [&ge;]1 comorbidity was 65.2%. The number of comorbidities was strongly associated with cancer mortality risk. Across a range of model assumptions, and across incident and prevalent cancer cases, 78% of excess deaths occur in cancer patients with Harry [&ge;]1 comorbidity.

ConclusionWe provide the first estimates of potential excess mortality among people with cancer and multimorbidity due to the COVID-19 emergency and demonstrate dramatic changes in cancer services. To better inform prioritization of cancer care and guide policy change, there is an urgent need for weekly data on cause-specific excess mortality, cancer diagnosis and treatment provision and better intelligence on the use of effective treatments for comorbidities.",oncology,exact,100,100
bioRxiv,10.1101/2020.05.28.120998,2020-06-01,https://biorxiv.org/cgi/content/short/2020.05.28.120998,"Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats",Angela Bosco-Lauth; Airn E. Hartwig; Stephanie Porter; Paul Gordy; Mary Nehring; Alex Byas; Sue VandeWoude; Izabela Ragan; Rachel Maison; Richard Bowen; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,"Colorado State University; Colorado State University; Colorado State University; Colorado State University; Colorado State University; Colorado State University; Colorado State University; Colorado State University; Colorado State University; Colorado State University; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge","The pandemic caused by SARS-CoV-2 has reached nearly every country in the world with extraordinary person-to-person transmission. The most likely original source of the virus was spillover from an animal reservoir and subsequent adaptation to humans sometime during the winter of 2019 in Wuhan Province, China. Because of its genetic similarity to SARS-CoV-1, it is likely that this novel virus has a similar host range and receptor specificity. Due to concern for human-pet transmission, we investigated the susceptibility of domestic cats and dogs to infection and potential for infected cats to transmit to naive cats. We report that cats are highly susceptible to subclinical infection, with a prolonged period of oral and nasal viral shedding that is not accompanied by clinical signs, and are capable of direct contact transmission to other cats. These studies confirm that cats are susceptible to productive SARS-CoV-2 infection, but are unlikely to develop clinical disease. Further, we document that cats develop a robust neutralizing antibody response that prevented re-infection to a second viral challenge. Conversely, we found that dogs do not shed virus following infection, but do mount an anti-viral neutralizing antibody response. There is currently no evidence that cats or dogs play a significant role in human exposure; however, reverse zoonosis is possible if infected owners expose their domestic pets during acute infection. Resistance to re-exposure holds promise that a vaccine strategy may protect cats, and by extension humans, to disease susceptibility.",microbiology,exact,100,100
medRxiv,10.1101/2020.05.31.20118687,2020-06-01,https://medrxiv.org/cgi/content/short/2020.05.31.20118687,"Changes in Reproductive Rate of SARS-CoV-2 Due to Non-pharmaceutical Interventions in 1,417 U.S. Counties",Jie Ying Wu; Benjamin D Killeen; Philipp Nikutta; Mareike Thies; Anna Zapaishchykova; Shreya Chakraborty; Mathias Unberath; Izabela Ragan; Rachel Maison; Richard Bowen; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,"Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Colorado State University; Colorado State University; Colorado State University; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge","In response to the rapid spread of the novel coronavirus, SARS-CoV-2, the U.S. has largely delegated implementation of non-pharmaceutical interventions (NPIs) to local governments on the state and county level. This staggered implementation combined with the heterogeneity of the U.S. complicates quantification the effect of NPIs on the reproductive rate of SARS-CoV-2.

We describe a data-driven approach to quantify the effect of NPIs that relies on county-level similarities to specialize a Bayesian mechanistic model based on observed fatalities. Using this approach, we estimate change in reproductive rate, Rt, due to implementation of NPIs in 1,417 U.S. counties.

We estimate that as of May 28th, 2020 1,177 out of the considered 1,417 U.S. counties have reduced the reproductive rate of SARS-CoV-2 to below 1.0. The estimated effect of any individual NPI, however, is different across counties. Stay-at-home orders were estimated as the only effective NPI in metropolitan and urban counties, while advisory NPIs were estimated to be effective in more rural counties. The expected level of infection predicted by the model ranges from 0 to 28.7% and is far from herd immunity even in counties with advanced spread.

Our results suggest that local conditions are pertinent to containment and re-opening decisions.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.01.20100461,2020-06-01,https://medrxiv.org/cgi/content/short/2020.06.01.20100461,"Determining the optimal strategy for reopening schools, work and society in the UK: balancing earlier opening and the impact of test and trace strategies with the risk of occurrence of a secondary COVID-19 pandemic wave",Jasmina Panovska-Griffiths; Cliff Kerr; Robyn Margaret Stuart; Dina Mistry; Daniel Klein; Russell M Viner; Chris Bonell; Izabela Ragan; Rachel Maison; Richard Bowen; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,"UCL; Institute for Disease Modeling; University of Copenhagen; Institute for Disease Modelling; Institute for Disease Modelling; UCL Great Ormond St. Institute of Child Health; London School of Hygiene and Tropical Medicine; Colorado State University; Colorado State University; Colorado State University; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge","BackgroundIn order to slow down the spread of SARS-CoV-2, the virus causing the COVID-19 pandemic, the UK government has imposed strict physical distancing ( lockdown) measures including school  dismissals since 23 March 2020. As evidence is emerging that these measures may have slowed the spread of the pandemic, it is important to assess the impact of any changes in strategy, including scenarios for school reopening and broader relaxation of social distancing. This work uses an individual-based model to predict the impact of a suite of possible strategies to reopen schools in the UK, including that currently proposed by the UK government.

MethodsWe use Covasim, a stochastic agent-based model for transmission of COVID-19, calibrated to the UK epidemic. The model describes individuals contact networks stratified as household, school, work and community layers, and uses demographic and epidemiological data from the UK. We simulate a range of different school reopening strategies with a society-wide relaxation of lockdown measures and in the presence of different non-pharmaceutical interventions, to estimate the number of new infections, cumulative cases and deaths, as well as the effective reproduction number with different strategies. To account for uncertainties within the stochastic simulation, we also simulated different levels of infectiousness of children and young adults under 20 years old compared to older ages.

FindingsWe found that with increased levels of testing of people (between 25% and 72% of symptomatic people tested at some point during an active COVID-19 infection depending on scenarios) and effective contact-tracing and isolation for infected individuals, an epidemic rebound may be prevented across all reopening scenarios, with the effective reproduction number (R) remaining below one and the cumulative number of new infections and deaths significantly lower than they would be if testing did not increase. If UK schools reopen in phases from June 2020, prevention of a second wave would require testing 51% of symptomatic infections, tracing of 40% of their contacts, and isolation of symptomatic and diagnosed cases. However, without such measures, reopening of schools together with gradual relaxing of the lockdown measures are likely to induce a secondary pandemic wave, as are other scenarios for reopening. When infectiousness of <20 year olds was varied from 100% to 50% of that of older ages, our findings remained unchanged.

InterpretationTo prevent a secondary COVID-19 wave, relaxation of social distancing including reopening schools in the UK must be implemented alongside an active large-scale population-wide testing of symptomatic individuals and effective tracing of their contacts, followed by isolation of symptomatic and diagnosed individuals. Such combined measures have a greater likelihood of controlling the transmission of SARS-CoV-2 and preventing a large number of COVID-19 deaths than reopening schools and society with the current level of implementation of testing and isolation of infected individuals.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSSince the onset of COVID-19 pandemic, mathematical modelling has been at the heart of informing decision-making, including the imposing of the lockdown in the UK. As countries are now starting to plan modification of these measures, it is important to assess the impact of different lockdown exit strategies including whether and how to reopen schools and relax other social distancing measures.

Added value of this studyUsing mathematical modelling, we explored the impact of strategies to reopen schools and society in the UK, including that currently proposed by the UK government. We assessed the impact of opening all schools fully or in a phased way with only some school years going back, with a society-wide relaxation of lockdown measures and in the presence of a different levels of implementation of test-trace-isolate strategies. We projected the number of new COVID-19 infections, cumulative cases and deaths, as well as the temporal distribution in the effective reproduction number (R) across different strategies. Our study is the first to provide quantification of the amount of testing and tracing that would be needed to prevent a second wave of COVID-19 in the UK under different reopening scenarios. To account for uncertainties within the stochastic simulation, we also simulated different levels of infectiousness of children and young adults under 20 years old compared to older ages.

Implications of all the available evidenceEvidence to date points to the need for additional testing, contact tracing, and isolation of individuals who have either been diagnosed with COVID-19, or who are considered to be at high risk of carrying infection due to their contact history or symptoms. Our study supports these conclusions and provides additional quantification of the amount of testing and tracing that would be needed to prevent a second wave of COVID-19 in the UK under different lockdown exit strategies. Reopening schools and society alongside active testing of the symptomatic population (between 25% and 72% of people with symptomatic COVID-19 infection depending on scenarios) and with an effective contact-tracing and rapid isolation of symptomatic and diagnosed individuals, will not only prevent a secondary pandemic wave, but is also likely to be able to control the transmission of SARS-CoV-2, via keeping the R value below 1, thus preventing a large number of COVID-19 cases and deaths. However, in the absence of fully implemented large-scale testing, contact-tracing and isolation strategy, plans for reopening schools, including those currently proposed by the UK government, and the associated increase in work and community contacts, are likely to induce a secondary pandemic wave of COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.01.20118885,2020-06-01,https://medrxiv.org/cgi/content/short/2020.06.01.20118885,Modelling testing frequencies required for early detection of a SARS-CoV-2 outbreak on a university campus,Natasha Martin; Robert T Schooley; Victor De Gruttola; Dina Mistry; Daniel Klein; Russell M Viner; Chris Bonell; Izabela Ragan; Rachel Maison; Richard Bowen; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,"University of California San Diego; University of California San Diego; Harvard University; Institute for Disease Modelling; Institute for Disease Modelling; UCL Great Ormond St. Institute of Child Health; London School of Hygiene and Tropical Medicine; Colorado State University; Colorado State University; Colorado State University; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge","BackgroundEarly detection and risk mitigation efforts are essential for averting large outbreaks of SARS-CoV-2. Active surveillance for SARS-CoV-2 can aid in early detection of outbreaks, but the testing frequency required to identify an outbreak at its earliest stage is unknown. We assess what testing frequency is required to detect an outbreak before there are 10 detectable infections.

MethodsA dynamic compartmental transmission model of SARS-CoV-2 was developed to simulate spread among a university community. After introducing a single infection into a fully susceptible population, we calculate the probability of detecting at least one case on each succeeding day with various NAT testing frequencies (daily testing achieving 25%, 50%, 75%, and 100% of the population tested per month) assuming an 85% test sensitivity. A proportion of infected individuals (varied from 1-60%) are assumed to present to health services (HS) for symptomatic testing. We ascertain the expected number of detectable infections in the community when there is a > 90% probability of detecting at least 1 case. Sensitivity analyses examine impact of transmission rates (Rt = 0 = 2, 2.5,3), presentation to HS (1%/5%/30%/60%), and pre-existing immunity (0%/10%)

ResultsAssuming an 85% test sensitivity, identifying an outbreak with 90% probability when the expected number of detectable infections is 9 or fewer requires NAT testing of 100% of the population per month; this result holds for all transmission rates and all levels of presentation at health services we considered. If 1% of infected people present at HS and Rt=0=3, testing 75%/50%/25% per month could identify an outbreak when the expected numbers of detectable infections are 12/17/30 respectively; these numbers decline to 9/11/12 if 30% of infected people present at HS. As proportion of infected individuals present at health services increases, the marginal impact of active surveillance is reduced. Higher transmission rates result in shorter time to detection but also rapidly escalating cases without intervention. Little differences were observed with 10% pre-existing immunity.

ConclusionsWidespread testing of 100% of the campus population every month is required to detect an outbreak when there are fewer than 9 detectable infections for the scenarios examined, but high presentation of symptomatic people at HS can compensate in part for lower levels of testing. Early detection is necessary, but not sufficient, to curtail disease outbreaks; the proposed testing rates would need to be accompanied by case isolation, contact tracing, quarantine, and other risk mitigation and social distancing interventions.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.06.01.20118901,2020-06-01,https://medrxiv.org/cgi/content/short/2020.06.01.20118901,Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials,Yitong WANG; Shuyao Liang; Tingting Qiu; Ru HAN; Monique Dabbous; Anna Nowotarska; Mondher Toumi; Izabela Ragan; Rachel Maison; Richard Bowen; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,"Aix Marseille University; Aix Marseille University; Aix Marseille University; Aix Marseille University; Aix Marseille University; Creativ-Ceutical company; Aix Marseille University; Colorado State University; Colorado State University; Colorado State University; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge","PurposeThis study aims to critically assess the published studies of Chloroquine (CQ) and hydroxychloroquine (HCQ) for the treatment of COVID-19 and provide recommendations for future clinical trials for the COVID-19 pandemic.

MethodA rapid systematic review was conducted by searching the PubMed, Embase, and China National Knowledge Infrastructure databases on April 13, 2020. Three clinical trial registry platforms, including ClinicalTrials.gov, the EU Clinical Trials Register, and the Chinese Clinical Trial Register were also complementarily searched.

ResultsA total of 10 clinical studies were identified, including 3 randomized controlled trials (RCTs), 1 comparative nonrandomized trial, 5 single-arm trials, and 1 interim analysis. The heterogeneity among studies of the baseline disease severity and reported endpoints made a pooled analysis impossible. CQ and HCQ (with or without azithromycin) showed significant therapeutic benefit in terms of virologic clearance rate, improvement in symptoms and imaging findings, time to clinical recovery, and length of hospital stay in 1 RCT, 4 single-arm trials, and the interim analysis, whereas no treatment benefit of CQ or HCQ was observed in the remaining 4 studies. Limitations of the included studies ranged from small sample size, to insufficient information concerning baseline patient characteristics, to potential for selection bias without detailing the rationale for exclusion, and presence of confounding factors.

ConclusionBased on the studies evaluated, there still lacked solid evidence supporting the efficacy and safety of HCQ and CQ as a treatment for COVID-19 with or without azithromycin. This emphasized the importance of robust RCTs investing HCQ/CQ to address the evidence uncertainties.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20106641,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106641,Study Data Element Mapping: Feasibility of Defining Common Data Elements Across COVID-19 Studies,Priscilla Mathewson; Ben Gordon; Kay Snowley; Clara Fennessy; Alastair Denniston; Neil Sebire; Leigh J Sowerby; Claire Hopkins; Sven Saussez; Nataly Espinoza-Suarez; Elizabeth Golembiewski; Percy Soto-Becerra,"University of Birmingham; HDRUK; HDRUK; HDRUK; HDRUK; Great Ormond Street Hospital and ICH London; Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Guy's and St Thomas's Hospitals; University of Mons; Knowledge and Evaluation Research Unit, Mayo Clinic; Knowledge and Evaluation Research Unit, Mayo Clinic; Facultad de Administracion y Salud Publica, Universidad Peruana Cayetano Heredia, Lima, Peru","BackgroundNumerous clinical studies are now underway investigating aspects of COVID-19. The aim of this study was to identify a selection of national and/or multicentre clinical COVID-19 studies in the United Kingdom to examine the feasibility and outcomes of documenting the most frequent data elements common across studies to rapidly inform future study design and demonstrate proof-of-concept for further subject-specific study data element mapping to improve research data management.

Methods25 COVID-19 studies were included. For each, information regarding the specific data elements being collected was recorded. Data elements collated were arbitrarily divided into categories for ease of visualisation. Elements which were most frequently and consistently recorded across studies are presented in relation to their relative commonality.

ResultsAcross the 25 studies, 261 data elements were recorded in total. The most frequently recorded 100 data elements were identified across all studies and are presented with relative frequencies. Categories with the largest numbers of common elements included demographics, admission criteria, medical history and investigations. Mortality and need for specific respiratory support were the most common outcome measures, but with specific studies including a range of other outcome measures.

ConclusionThe findings of this study have demonstrated that it is feasible to collate specific data elements recorded across a range of studies investigating a specific clinical condition in order to identify those elements which are most common among studies. These data may be of value for those establishing new studies and to allow researchers to rapidly identify studies collecting data of potential use hence minimising duplication and increasing data re-use and interoperability",health informatics,exact,100,100
medRxiv,10.1101/2020.05.19.20106799,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106799,Use of inhibitors of the renin angiotensin system and COVID-19 prognosis: a systematic review and meta-analysis,Jessica Barochiner; Rocio Martinez; Kay Snowley; Clara Fennessy; Alastair Denniston; Neil Sebire; Leigh J Sowerby; Claire Hopkins; Sven Saussez; Nataly Espinoza-Suarez; Elizabeth Golembiewski; Percy Soto-Becerra,"Hospital Italiano de Buenos Aires; Hospital Italiano de Buenos Aires; HDRUK; HDRUK; HDRUK; Great Ormond Street Hospital and ICH London; Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Guy's and St Thomas's Hospitals; University of Mons; Knowledge and Evaluation Research Unit, Mayo Clinic; Knowledge and Evaluation Research Unit, Mayo Clinic; Facultad de Administracion y Salud Publica, Universidad Peruana Cayetano Heredia, Lima, Peru","Backgroundcontroversy has arisen in the scientific community on whether the use of renin angiotensin system (RAS) inhibitors in the context of COVID-19 would be of benefit or harmful. A meta-analysis of eligible studies comparing the occurrence of severe and fatal COVID-19 in infected patients who were under treatment with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) vs no treatment or other antihypertensives was conducted.

MethodsPubMed, Google Scholar, the Cochrane Library, MedRxiv and BioRxiv were searched for relevant studies. Fixed-effect models or random-effect models were used depending on the heterogeneity between estimates.

Resultsa total of fifteen studies with 21,614 patients were included. The use of RAS inhibitors was associated with a non-significant 20% decreased risk of the composite outcome (death, admission to intensive care unit, mechanical ventilation requirement or progression to severe or critical pneumonia): RR 0.81 (95%CI: 0.631.04), p=0.10, I2=82%. In a subgroup analysis that included hypertensive subjects only, ACEI/ARB were associated with a 27% significant decrease in the risk of the composite outcome (RR 0.73 (95%CI: 0.56 0.96), p=0.02, I2=65%).

Conclusionthe results of this pooled analysis suggest that the use of ACEI/ARB does not worsen the prognosis, and could even be protective in hypertensive subjects. Patients should continue these drugs during their COVID-19 illness.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20106781,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106781,Hypertension and renin-angiotensin system blockers are not associated with expression of Angiotensin Converting Enzyme 2 (ACE2) in the kidney,Xiao Jiang; James M. Eales; David Scannali; Alicja Nazgiewicz; Priscilla Prestes; Michelle Maier; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Federation University Australia, Ballarat, Victoria, Australia; Federation University Australia, Ballarat, Victoria, Australia; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","Angiotensin converting enzyme 2 (ACE2) is the cellular entry point for severe acute respiratory syndrome coronavirus (SARS-CoV-2) - the cause of COVID-19 disease. It has been hypothesized that use of renin-angiotensin system (RAS) inhibiting medications in patients with hypertension, increases the expression of ACE2 and thereby increases the risk of COVID-19 infection and severe outcomes or death. However, the effect of RAS-inhibition on ACE2 expression in human tissues of key relevance to blood pressure regulation and COVID-19 infection has not previously been reported.

We examined how hypertension, its major metabolic co-phenotypes and antihypertensive medications relate to ACE2 renal expression using information from up to 436 patients whose kidney transcriptomes were characterised by RNA-sequencing. We further validated some of the key observations in other human tissues and/or a controlled experimental model. Our data reveal increasing expression of ACE2 with age in both human lungs and the kidney. We show no association between renal expression of ACE2 and either hypertension or common types of RAS inhibiting drugs. We demonstrate that renal abundance of ACE2 is positively associated with a biochemical index of kidney function and show a strong enrichment for genes responsible for kidney health and disease in ACE2 co-expression analysis.

Collectively, our data indicate that neither hypertension nor antihypertensive treatment are likely to alter individual risk of SARS-CoV-2 infection or influence clinical outcomes in COVID-19 through changes of ACE2 expression. Our data further suggest that in the absence of SARS-CoV-2 infection, kidney ACE2 is most likely nephro-protective but the age-related increase in its expression within lungs and kidneys may be relevant to the risk of SARS-CoV-2 infection.",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.05.19.20106740,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106740,Eruption of COVID-19 like illness in a remote village in Papua (Indonesia),Elco van Burg; Wijnanda van Burg-Verhage; David Scannali; Alicja Nazgiewicz; Priscilla Prestes; Michelle Maier; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Vrije Universiteit Amsterdam; Lentera Papua; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Federation University Australia, Ballarat, Victoria, Australia; Federation University Australia, Ballarat, Victoria, Australia; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","BackgroundThe COVID-19 pandemic is creating significant challenges for healthcare infrastructure for countries of all development and resource levels. Low-and-middle resource countries face even larger challenges, as their resources are stretched and often insufficient under normal circumstances. A village in the Papuan highlands of Indonesia; small, isolated, accessed only by small plane or trekking has experienced an outbreak typical of COVID-19.

Methodology/Principal FindingsThis description was compiled from patient care records by lay healthcare workers in M20 (a pseudonym) during and after an outbreak and from medical doctors responding to online requests for help. We assume that, for reasons given, the outbreak that has been described was COVID-19. The dense social structure of the village resulted in a rapid infection of 90-95% of the population. Physical distancing and isolation measures were used, but probably implemented suboptimal and too late, and their effect on the illness course was unclear. The relatively young population, with a majority of women, probably influenced the impact of the epidemic, resulting in only two deaths so far.

Conclusions/SignificanceThis outbreak pattern of suspected SARS-CoV-2 in a village in the highlands of Papua (Indonesia) presents a unique report of the infection of an entire village population over five weeks. The age distribution, common in Papuan highland villages may have reduced case fatality rate (CFR) in this context and that might be the case in similar remote areas since survival to old age is already very limited and CFR among younger people is lower.

Author summaryA village in the Papuan highlands of Indonesia; small, isolated, accessed only by small plane or trekking has experienced an outbreak typical of COVID-19. The outbreak affected 90-95% of approximately 200 residents between 20 February 2020 and 31 March 2020. Lay health workers, consisting of trained local volunteers, without healthcare facilities and limited medication options reached out for help online and managed with what they had available. Their experience is relevant to others in similar settings. This report describes the village, outbreak, timeline, symptoms and treatments, and outcomes.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.19.20106542,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106542,European lockdowns and the consequences of relaxation during the COVID-19 pandemic,David H Glass; Wijnanda van Burg-Verhage; David Scannali; Alicja Nazgiewicz; Priscilla Prestes; Michelle Maier; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Ulster University; Lentera Papua; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Federation University Australia, Ballarat, Victoria, Australia; Federation University Australia, Ballarat, Victoria, Australia; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","This paper investigates the lockdowns introduced in France, Germany, Italy, Spain, and the UK and also explores the potential consequences of different degrees of relaxation. The analysis employs a two-stage SEIR model with different reproductive numbers pre-and post-lockdown. These parameters are estimated from data on the daily number of confirmed cases in a process that automatically detects the time at which the lockdown became effective. The model is evaluated by considering its predictive accuracy on current data and it is then deployed to explore partial relaxations. The results indicate that the different countries have been successful in reducing the reproductive number to values ranging from 0.67 (95% CI: 0.64 - 0.70) to 0.92 (95% CI: 0.89 - 0.95). Results also suggest that a relaxation of 25% could halt the decline incases in all five countries, while a 50% relaxation could lead to second peaks that are higher and last longer than the earlier peaks in each country. Even though the relaxations so far may have preserved the success of the lockdowns, vigilance is still needed. A relaxation of around 10-15% is recommended if COVID-19 is to continue to decline in all five countries.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.18.20106138,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.18.20106138,Sample Pooling as a Strategy of SARS-COV-2 Nucleic Acid Screening Increases the False-negative Rate,Yichuan Gan; Lingyan Du; Faleti Oluwasijibomi Damola; Jing Huang; Gang Xiao; Xiaoming Lyu; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Department of laboratory medicine,The Third Affiliated Hospital, Southern Medical University; Department of laboratory medicine,The Third Affiliated Hospital, Southern Medical University; Department of laboratory medicine,The Third Affiliated Hospital, Southern Medical University; Department of laboratory medicine,The Third Affiliated Hospital, Southern Medical University; Department of Laboratory Medicine, Third Affiliated Hospital of Southern Medical University; The Third Affiliated Hospital, Southern Medical University; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","BackgroundIdentification of less costly and accurate methods for monitoring novel coronavirus disease 2019 (CoViD-19) transmission has attracted much interest in recent times. Here, we evaluated a pooling method to determine if this could improve screening efficiency and reduce costs while maintaining accuracy in Guangzhou, China.

MethodsWe evaluated 8097 throat swap samples collected from individuals who came for a health check-up or fever clinic in The Third Affiliated Hospital, Southern Medical University between March 4, 2020 and April 26, 2020. Samples were screened for CoViD-19 infection using the WHO-approved quantitative reverse transcription PCR (RT-qPCR) primers. The positive samples were classified into two groups (high or low) based on viral load in accordance with the CT value of COVID-19 RT-qPCR results. Each positive RNA samples were mixed with COVID-19 negative RNA or ddH2O to form RNA pools.

FindingsSamples with high viral load could be detected in pool negative samples (up to 1/1000 dilution fold). In contrast, the detection of RNA sample from positive patients with low viral load in a pool was difficult and not repeatable.

InterpretationOur results show that the COVID-19 viral load significantly influences in pooling efficacy. COVID-19 has distinct viral load profile which depends on the timeline of infection. Thus, application of pooling for infection surveillance may lead to false negatives and hamper infection control efforts.

FundingNational Natural Science Foundation of China; Hong Kong Scholars Program, Natural Science Foundation of Guangdong Province; Science and Technology Program of Guangzhou, China.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSSince it emergence in late 2019, CoViD-19 has dramatically increased the burden healthcare system worldwide. A research letter titled ""Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2"" which was recently published in JAMA journal proposed that sample pooling could be used for SARS-COV-2 community surveillance. Currently, the need for large-scale testing increases the number of 2019-nCOV nucleic acid analysis required for proper policy-making especially as work and normal school resumes. As far as we know, there are many countries and regions in the world, who are beginning to try this strategy for nucleic acid screening of SARS-CoV-2.

Added value of this studyWe carried out a study using pooled samples formed from SARS-COV-2 negative samples and positive samples with high or low viral and assessed detection rate for the positive samples. We found that positive sample with high viral load could be detected in pools in a wide range of dilution folds (ranging from1/2 to 1/50). On the contrary, the sample with low viral load could only be detected in RNA ""pools"" at very low dilution ratio, and the repeatability was unsatisfactory. Our results show the application of the ""pooling"" strategy for large-scale community surveillance requires careful consideration and depends on the viral load of the positive samples.

Implications of all the available evidenceAlthough the number of newly diagnosed cases has been reducing in some parts of the world, the possibility of a second wave of infection has made quick and efficient data gathering essential for policy-making, isolation and treatment of patients. Fast and efficient nucleic acid detection methods are encouraged, but sample pooling as a strategy of SARS-COV-2 nucleic acid screening increased the false-negative rate, especially those with asymptomatic infections have lower viral load. Therefore, the application of the ""pooling"" strategy for large-scale community surveillance requires careful consideration by policy makers.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.19.20106336,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106336,ROBUST COVID-19-RELATED CONDITION CLASSIFICATION NETWORK,Maximiliano Lucius; Martin Belvisi; Carlos Maria Galmarini; Jing Huang; Gang Xiao; Xiaoming Lyu; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Topazium Artificial Intelligence; Topazium Artificial Intelligence; Topazium Artificial Intelligence; Department of laboratory medicine,The Third Affiliated Hospital, Southern Medical University; Department of Laboratory Medicine, Third Affiliated Hospital of Southern Medical University; The Third Affiliated Hospital, Southern Medical University; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","COVID-19 can exponentially precipitate life-threatening emergencies as witnessed during the recent spreading of a novel coronavirus infection which can rapidly evolve into lung collapse and respiratory distress (among other various severe clinical conditions). Our study evaluates the performance of a tailor-designed deep convolutional network on the tasks of early detection and localization of radiological signs associated to COVID-19 on frontal chest X-rays. We also asses the frameworks capacity in differentiating the above-mentioned signs, which are usually confused with the more usual common bacterial and viral pneumonias. Open-source chest X-ray images categorized as Normal, Non-COVID-19 and COVID-19 pneumonias were downloaded from the NIH (n=2,259), RSNA (n=600) and HM Hospitales (n=2,307). Our algorithmic framework was able to precisely detect the images with COVID19-related radiological findings (mean Accuracy: 90.5%; Sensitivity: 80.6%; Specificity: 98.0%), whilst correctly categorizing images deemed as Non-COVID-19 pneumonias (mean Accuracy: 88.4%; Sensitivity: 93.3%; Specificity: 92.0%) and normal chest X-rays (mean Accuracy 92.1%; Sensitivity: 91.8%; Specificity: 94.3%). The associated results show that our AI framework is able to classify COVID-19 accurately, making of it a potential tool to improve the diagnostic performance across primary-care centres and, to grant priority to a subset of algorithmic selected images for urgent follow-on expert review. This would sensibly accelerate diagnosis in remote locations, reduce the bottleneck on specialized centres, and/or help to alleviate the needs on situations of scarcity in the availability of molecular tests.",radiology and imaging,exact,100,100
medRxiv,10.1101/2020.05.19.20107045,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107045,Strict Physical Distancing May Be More Efficient: A Mathematical Argument for Making Lockdowns Count,Scott R Sheffield; Anna York; Nicole A Swartwood; Alyssa Bilinski; Anne Williamson; Meagan C Fitzpatrick; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Massachusetts Institute of Technology; Yale University; Harvard University; Harvard University; Queen Mary University of London; University of Maryland; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","COVID-19 created a global public health and economic emergency. Policymakers acted quickly and decisively to contain the spread of disease through physical distancing measures. However, these measures also impact physical, mental and economic well-being, creating difficult trade-offs. Here we use a simple mathematical model to explore the balance between public health measures and their associated social and economic costs. Across a range of cost-functions and model structures, commitment to intermittent and strict social distancing measures leads to better overall outcomes than temporally consistent implementation of moderate physical distancing measures. With regard to the trade-offs that policymakers may soon face, our results emphasize that economic and health outcomes do not exist in full competition. Compared to consistent moderation, intermittently strict policies can better mitigate the impact of the pandemic on both of these priorities for a range of plausible utility functions.",health policy,exact,100,100
medRxiv,10.1101/2020.05.19.20107144,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107144,A Unique Clade of SARS-CoV-2 Viruses is Associated with Lower Viral Loads in Patient Upper Airways,Ramon Lorenzo-Redondo; Hannah Hyochan Nam; Scott Christopher Roberts; Lacy Marie Simons; Lawrence J Jennings; Chao Qi; Chad J Achenbach; Alan R Hauser; Michael G Ison; Judd F Hultquist; Egon A Ozer; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","BackgroundThe rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID- 19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. Here, we aimed to investigate the phylogenetic characteristics of SARS-CoV-2 infections in Chicago, Illinois and assess their relationship to clinical parameters.

MethodsWe performed whole-genome sequencing of SARS-CoV-2 isolates collected from COVID-19 patients in a Chicago healthcare system in mid-March, 2020. Using these and other publicly available sequences, we performed phylogenetic, phylogeographic, and phylodynamic analyses. Patient data was assessed for correlations between demographic or clinical characteristics and virologic features.

FindingsThe 88 SARS-CoV-2 genome sequences in our study separated into three distinct phylogenetic clades. Clade 1 was most closely related to viral sequences from New York, and showed evidence of rapid expansion across the US, while Clade 3 was most closely related to those in Washington state. Clade 2 was localized primarily to the Chicago area with limited evidence of expansion elsewhere. At the time of diagnosis, patients infected with Clade 1 viruses had significantly higher average viral loads in their upper airways relative to patients infected with Clade 2 viruses, independent of time to symptom onset and disease severity.

InterpretationThese results show that multiple variants of SARS-CoV-2 are circulating in the Chicago area that differ in their relative viral loads in patient upper airways. These data suggest that differences in virus genotype impact viral load and may in turn influence viral transmission and spread.

FundingDixon Family Translational Research Award, Northwestern University Clinical and Translational Sciences Institute (NUCATS), National Institute of Allergy and Infectious Diseases (NIAID)",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20106997,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106997,"Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial",Alexandre B Cavalcanti; Fernando G Zampieri; Luciani CP Azevedo; Regis G Rosa; Alvaro Avezum; Viviane C Veiga; Renato D Lopes; Leticia Kawano-Dourado; Lucas P Damiani; Adriano J Pereira; Ary Serpa Neto; Remo Furtado; Bruno Tomazini; Fernando A Bozza; Israel S Maia; Maicon Falavigna; Thiago C Lisboa; Henrique Fonseca; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"HCor Research Institute, Sao Paulo, Brazil; HCor; Hospital Sirio Libanes Research and Education Institute, Sao Paulo, Brazil; Hospital Moinhos de Vento, Porto Alegre,Brazil; Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil; BP - A Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil; Duke University Medical Center - Duke Clinical Research Institute - Durham, North Carolina, USA.; HCor Research Institute, Sao Paulo, Brazil; HCor Research Institute, Sao Paulo, Brazil; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Intensive Care Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Intensive Care Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Hospital Sirio Libanes Research and Education Institute, Sao Paulo, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Hospital Moinhos de Vento, Porto Alegre, Brazil; HCor Research Institute, Sao Paulo, Brazil; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","IntroductionHydroxychloroquine and its combination with azithromycin have been suggested to improve viral clearance in patients with COVID-19, but its effect on clinical outcomes remains uncertain.

Methods and analysisWe describe the rationale and design of an open-label pragmatic multicentre randomised (concealed) clinical trial of 7 days of hydroxychloroquine (400 mg BID) plus azithromycin (500 mg once daily), hydroxychloroquine 400 mg BID, or standard of care for moderately severe hospitalised patients with suspected or confirmed COVID-19 (in-patients with up to 4L/minute oxygen supply through nasal catheter). Patients are randomised in around 50 recruiting sites and we plan to enrol 630 patients with COVID-19. The primary endpoint is a 7-level ordinal scale measured at 15-days: 1)not hospitalised, without limitations on activities; 2)not hospitalised, with limitations on activities; 3)hospitalised, not using supplementary oxygen; 4)hospitalised, using supplementary oxygen; 5)hospitalised, using high-flow nasal cannula or non-invasive ventilation; 6)hospitalised, on mechanical ventilation; 7)death. Secondary endpoints are the ordinal scale at 7 days, need for mechanical ventilation and rescue therapies during 15 days, need of high-flow nasal cannula or non-invasive ventilation during 15 days, length of hospital stay, in-hospital mortality, thromboembolic events, occurrence of acute kidney injury, and number of days free of respiratory support at 15 days. Secondary safety outcomes include prolongation of QT interval on electrocardiogram, ventricular arrhythmias, and liver toxicity. The main analysis will consider all patients with confirmed COVID-19 in the groups they were randomly assigned.

Ethics and disseminationThis study has been approved by Brazils National Ethic Committee (CONEP) and National Health Surveillance Agency (ANVISA). An independent data monitoring committee will perform interim analyses and evaluate adverse events throughout the trial. Results will be submitted for publication after enrolment and follow-up are complete, as well as presented and reported to local health agencies.

ClinicalTrials.gov identifierNCT04322123

O_LSTStrengths and limitations of this studyC_LSTO_LIPragmatic randomised controlled trial of 7 days of hydroxychloroquine plus azithromycin, hydroxychloroquine or standard of care for moderately severe in-patients with suspected or confirmed COVID-19
C_LIO_LIMulticentre: around 50 recruiting sites in Brazil with planned enrolment of 630 patients (1:1:1)
C_LIO_LIThe primary endpoint is a 7-level ordinal scale ([1] not hospitalised, without limitations on activities; [2] not hospitalised, with limitations on activities; [3] hospitalised, not using supplementary oxygen; [4] hospitalised, using supplementary oxygen; [5] hospitalised, using high-flow nasal cannula or non-invasive ventilation; [6] hospitalised, on mechanical ventilation; [7] death) measured at 15 days.
C_LIO_LIOpen label design (no placebo)
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20106906,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106906,Efficacy and Safety of Hydroxychloroquine and Chloroquine for COVID-19: A systematic review,Sonal Singh; Thomas J Moore; Luciani CP Azevedo; Regis G Rosa; Alvaro Avezum; Viviane C Veiga; Renato D Lopes; Leticia Kawano-Dourado; Lucas P Damiani; Adriano J Pereira; Ary Serpa Neto; Remo Furtado; Bruno Tomazini; Fernando A Bozza; Israel S Maia; Maicon Falavigna; Thiago C Lisboa; Henrique Fonseca; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Department of Family Medicine and Community Health, Meyers Primary Care Institute and Quantitative Health Sciences, University of Massachusetts Medical School, ; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA  and  Department of Epidemiology, The George Washi; Hospital Sirio Libanes Research and Education Institute, Sao Paulo, Brazil; Hospital Moinhos de Vento, Porto Alegre,Brazil; Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil; BP - A Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil; Duke University Medical Center - Duke Clinical Research Institute - Durham, North Carolina, USA.; HCor Research Institute, Sao Paulo, Brazil; HCor Research Institute, Sao Paulo, Brazil; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Intensive Care Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Intensive Care Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Hospital Sirio Libanes Research and Education Institute, Sao Paulo, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Hospital Moinhos de Vento, Porto Alegre, Brazil; HCor Research Institute, Sao Paulo, Brazil; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","BACKGROUNDHydroxychloroquine and chloroquine are widely used to treat hospitalized COVID-19 patients primarily based on antiviral activity in in vitro studies. Our objective was to systematically evaluate their efficacy and safety in hospitalized patients with COVID-19.

METHODSWe systematically reviewed PubMed, ClinicalTrials.gov, and Medrxviv for studies of hydroxychloroquine and chloroquine in COVID-19 hospitalized patients on April 26, 2020. We evaluated the quality of trials and observational studies using the Jadad criteria and Newcastle Ottawa Scale, respectively.

RESULTSAfter a review of 175 citations, we included 5 clinical trials (total of 345 patients), 9 observational studies (n = 2529), and 6 additional studies (n = 775) reporting on the QT interval. Three studies reported treatment benefits including two studies reporting benefit on virologic outcomes, which was statistically significant in one study, and another reported significant improvement on cough symptoms. Three studies reported that treatment was potentially harmful, including an significantly increased risk of mortality in two studies and increased need for respiratory support in another. Eight studies were unable to detect improvements on virologic outcomes (n = 3) or pneumonia or transfer to ICU/death (n = 5). The proportion of participants with critical QTc intervals of [&ge;] 500 ms or an increase of [&ge;] 60 ms from baseline ranged from 8.3% to 36% (n = 8). One clinical trial and six observational studies were of good quality. The remaining studies were of poor quality.

CONCLUSIONSOur systematic review of reported clinical studies did not identify substantial evidence to support the efficacy of hydroxychloroquine or chloroquine in hospitalized COVID-19 patients and raises questions about potential harm from QT prolongation and increased mortality.

O_LSTKey PointsC_LSTO_LIWe conducted a systematic review of the efficacy and safety of hydroxychloroquine and chloroquine among patients hospitalized with COVID-19 and identified 14 studies reporting on clinical or virologic outcomes and 6 additional studies reporting on the QT interval.
C_LIO_LIWe conducted a systematic review of the efficacy and safety of hydroxychloroquine and chloroquine among patients hospitalized with COVID-19 and identified 14 studies reporting on clinical or virologic outcomes and 6 additional studies reporting on the QT interval.
C_LIO_LIHydroxychloroquine or chloroquine improved virologic outcomes in 2 clinical studies and cough in another study.
C_LIO_LIWe conducted a systematic review of the efficacy and safety of hydroxychloroquine and chloroquine among patients hospitalized with COVID-19 and identified 14 studies reporting on clinical or virologic outcomes and 6 additional studies reporting on the QT interval.
C_LIO_LIHydroxychloroquine or chloroquine improved virologic outcomes in 2 clinical studies and cough in another study.
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.23.20111450,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.23.20111450,The Outcome Impact of Early vs Late HFNC Oxygen Therapy in Elderly Patients with COVID-19 and ARDS,Liehua Deng; Shaoqing Lei; Fang Jiang; David A. Lubarsky; Liangqing Zhang; Danyong Liu; Conghua Han; Dunrong Zhou; Zheng Wang; Xiaocong Sun; Yuanli Zhang; Chi Wai Cheung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Department of Critical Care Medicine of affiliated hospital of Guangdong Medical University; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology, The University of Hong Kong; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Critical Care Medicine of Xiantao first people's Hospital of Xiantao City; Department of Critical Care Medicine of people's Hospital of Yangjiang City; Department of Critical Care Medicine of people's Hospital of Maoming City; Department of Critical Care Medicine of affiliated hospital of Guangdong Medical University; Department of Critical Care Medicine of affiliated hospital of Guangdong Medical University; Department of Anesthesiology, The University of Hong Kong; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","Coronavirus disease-2019 (COVID-19) has rapidly spread worldwide. High-flow nasal cannula therapy (HFNC) is a major oxygen supporting therapy for severely ill patients, but information regarding the timing of HFNC application is scarce, especially in elderly patients. We retrospectively analyzed the clinical data of 110 elderly patients ([&ge;]65 years) who received HFNC from Renmin Hospital of Wuhan University, Peoples Hospital of Xiantao City and Chinese Medicine Hospital of Shishou City in Hubei Province, China, and from Affiliated Hospital of Guangdong Medical University, Peoples Hospital of Yangjiang City, Peoples Hospital of Maoming City in Guangdong Province, China.

Of the 110 patients, the median age was 71 years (IQR, 68-78) and 59.1% was male. Thirty-eight patients received HFNC when 200 mmHg < PO2/FiO2 [&le;] 300 mmHg (early HFNC group), and 72 patients received HFNC treatment when 100 mmHg < PaO2/FiO2 [&le;] 200 mmHg (late HFNC group). Compared with the late HFNC group, patients in the early HFNC group had a lower likelihood of developing severe ARDS, longer time from illness onset to severe ARDS and shorter duration of viral shedding after illness onset, as well as shorter lengths of ICU and hospital stay. Twenty-four patients died during hospitalization, of whom 22 deaths (30.6%) were in the late HFNC group and 2(5.3%) in the early HFNC group. It is concluded that the Prognosis was better in severely ill elderly patients with COVID-19 receiving early compared to late HFNC. This suggests HFNC could be considered early in this disease process.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.21.20107003,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.21.20107003,Renin-angiotensin-aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID-19: a systematic review and meta-analysis,Anna Ssentongo; Paddy Ssentongo; Emily S. Heilbrunn; Alain Lekoubou; Ping Du; Duanping Liao; John S Oh; Vernon M. Chinchilli; Zheng Wang; Xiaocong Sun; Yuanli Zhang; Chi Wai Cheung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Penn State University; Penn State University; Penn State University; Penn State University; Penn State University; Penn State University; Penn State University; Penn State University; Department of Critical Care Medicine of people's Hospital of Maoming City; Department of Critical Care Medicine of affiliated hospital of Guangdong Medical University; Department of Critical Care Medicine of affiliated hospital of Guangdong Medical University; Department of Anesthesiology, The University of Hong Kong; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","ObjectiveThe association between renin-angiotensin-aldosterone (RAAS) inhibitors and Coronavirus diseases 2019 (COVID-19) mortality is unclear. We aimed to explore the association of RAAS inhibitors, including angiotensin-converting inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) with COVID-19 mortality in patients with hypertension.

MethodsMEDLINE, SCOPUS, OVID, and Cochrane Library were searched for the period of January 1, 2020 to May 20, 2020. Studies reporting the association of RAAS inhibitors (ACEi and ARBs) and mortality in patients with hypertension, hospitalized for COVID-19 were extracted. Two reviewers independently extracted appropriate data of interest and assessed the risk of bias. All analyses were performed using random-effects models on log-transformed risk ratio estimates, and heterogeneity was quantified.

ResultsData were collected on 2,065,805 individuals (mean age, 58.73 years; 53.4% male). Patients with hypertension taking RAAS inhibitors were 35% less likely to die from COVID-19 compared to patients with hypertension not taking RAAS inhibitors (pooled RR= 0.65, 95% Confidence Intervals (CI): 0.45-0.94). To explore the association of COVID-19 and specific classes of RAAS inhibitors, we conducted a subgroup analysis of ARBs and ACEi separately from studies that provided them. Pooled risk ratio estimates from ARBs and ACEi showed a lower but not significant risk of death from COVID-19 (RR=0.93, 95% CI: 0.70-1.22) and ACEi (RR=0.65, 95% CI: 0.32-1.30).

ConclusionsIn this meta-analysis, it was discovered that taking RAAS inhibitors, significantly decreased the risk of COVID-19 mortality in patients with hypertension. This indicates a potential protective role that RAAS-inhibitors may have in COVID-19 patients with hypertension.

Key QuestionsO_ST_ABSWhat is already known about this subject?C_ST_ABSSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the recent coronavirus disease 2019 (COVID-19) pandemic, interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2 (ACE2). Recent studies have questioned whether RAAS inhibitors are safe in patients with COVID-19. However, observational studies involving patients hospitalized with COVID-19 that report the association of RAAS-inhibitors and COVID-19 severity or death have yielded conflicting findings.

What does this study add?This systematic review and meta-analysis discovered that RAAS inhibitors reduced the risk of mortality by 35% in patients with hypertension hospitalized for COVID-19 (RR= 0.65, 95% CI 0.45-0.94).

How might this impact clinical practice?Patients taking RAAS-inhibitors to manage their hypertension should continue to do as per current treatment guidelines.",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.05.19.20107219,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107219,"Transmission of SARS-CoV-2 in Georgia, USA, 2020",Kamalich Muniz-Rodriguez; Gerardo Chowell; Jessica Smith Schwind; Randall Ford; Sylvia K. Ofori; Chigozie A. Ogwara; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia State University School of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","In 2020, SARS-CoV-2 impacted Georgia, USA. Georgia announced state-wide shelter-in-place on April 2 and partially lifted restrictions on April 27. We analyzed daily incidence of confirmed COVID-19 cases by reporting date, March 2-June 14, in Georgia, Metro Atlanta, and Dougherty County and estimate the time-varying reproduction number, Rt, using R package EpiEstim. The median Rt estimate in Georgia dropped from between 2 and 4 in mid-March, to <2 in late March, and around 1 from mid-April to mid-June. Regarding Metro Atlanta, Rt fluctuated above 1.5 in March and around 1 since April. In Dougherty County, the median Rt declined from around 2 in late March to 0.32 on April 26. In Spring 2020, SARS-CoV-2 transmission in Georgia declined likely because of social distancing measures. However, as restrictions were relaxed in late April, community transmission continued with Rt fluctuating around 1 across Georgia, Metro Atlanta, and Dougherty County as of mid-June.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.20.20107169,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.20.20107169,Quantitative modeling and analysis show country-specific quarantine measures can circumvent COVID19 infection spread post lockdown,Uddipan Sarma; Bhaswar Ghosh; Jessica Smith Schwind; Randall Ford; Sylvia K. Ofori; Chigozie A. Ogwara; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Vantage Research; International Institute of Information Technology; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","The COVID19 outbreak, which started in Wuhan, is now spread across 200+ countries with over 6 million reported infections and a death toll over 350 thousand. In response, and primarily in the absence of a vaccine, many countries have implemented lockdown to ensure social distancing and started rigorously quarantining the infected subjects. In this study, we attempt to identify the most potent component(s) in the system that can be manipulated via human intervention. Firstly, analysis of the metadata for 93 countries showed a reduction in the estimated reproduction number (a month post-infection) is correlated to the testing rate in a country. To systematically study the dynamics of infection we next built epidemic models for 23 different countries and calibrated the confirmed, recovered, and dead population trajectories in the model to the respective data from WHO. The countries chosen either had the infection peak long crossed; peak recently reached but still with significant daily infection, or, infection peak is yet to arrive. Our model successfully fits data from all 23 countries and provides us with incubation time, transmission rate, quarantine, recovery, and death rates for each country. With further analysis, we found infection spread towards a much larger second wave can be controlled via a rigorous increase in the quarantine rates that, we show, can be tailored in a country-specific manner; for instance, we found the USA or Spain might require a 10 fold increase in testing/ quarantine rates compared to India to control the second wave post lockdown. Our data-driven modeling and analysis thus pave a way to understand and manipulate the infection dynamics during and post lockdown phases in various countries. The findings can also be used to strategize the testing and quarantine processes to manipulate the spread of the disease in the future.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.19.20107094,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107094,Ethnic and regional variation in hospital mortality from COVID-19 in Brazil,Pedro Otavio Baqui; Ioana Bica; Valerio Marra; Ari Ercole; Mihaela Van Der Schaar; Chigozie A. Ogwara; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Federal University of Espirito Santo; University of Oxford; The Alan Turing Institute; Federal University of Espirito Santo; University of Cambridge; The Alan Turing Institute; University of Cambridge; University of California Los Angeles; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","BackgroundThe COVID-19 pandemic is quickly spreading throughout Brazil, which is rapidly ascending the ranking of countries with the highest number of cases and deaths. A particularly unstable federal regime and fragile socioeconomic situation is likely to have contributed to the impact of the disease. Amid this crisis there is substantial concern in the possible socioeconomic, geopolitical and ethnic inequity of the impact of COVID-19 on the countrys particularly diverse population.

MethodsWe performed a cross-sectional observational study of COVID-19 hospital mortality using observational data from the SIVEP-Gripe dataset. We present descriptive statistics to quantify the COVID-19 pandemic in Brazil. We assess the importance of regional factors such as education, income and health either on a state-by-state basis or by splitting Brazil into a North and a Central-South region. Mixed-effects survival analysis was used to estimate the effects of ethnicity and comorbidity at an individual level in the context of regional variation.

FindingsOur results show that, compared to branco comparators, hospitalised pardo and preto Brazilians have significantly higher risk of mortality, with hazard ratios and 95% CI of 1.47 (1.33-1.58) and 1.32 (1.15-1.52), respectively. In particular, pardo ethnicity was the second most important risk factor (after age). We also found that hospitalised Brazilians in North regions tend to have more comorbidities than in the Central-South, with similar proportions between the various ethnic groups. Finally, we found that states in the North have a higher hazard ratio as compared to the Central-South, and that Rio de Janeiro obtained one of the highest hazard ratios, similar to the ones of the more underdeveloped Pernambuco and Amazonas.

InterpretationOur results can be interpreted according to the interplay of two independent, but correlated, effects: i) mortality by COVID-19 increases going North (vertical effect), ii) mortality increases for the pardo and preto population (horizontal effect). We speculate that the vertical effect is driven by increasing levels of comorbidity in Northern regions where levels of socioeconomic development are lower, whereas the horizontal effect may be related to lower levels of healthcare access or availability (including intensive care) for pardo and preto Brazilians. For most states the vertical and horizontal effects are correlated giving a larger cumulative mortality. However, Rio de Janeiro was found to be an outlier to this trend: It has an ethnicity composition (horizontal effect) similar to the states in the North region, despite high levels of socioeconomic development (vertical effect). Our analysis motivates an urgent effort on the part of Brazilian authorities to consider how the national response to COVID-19 can better protect pardo and preto Brazilians as well as the population of poorer states from their higher death risk from SARS-CoV-2 infection.

FundingNone.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.19.20107227,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107227,Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports,Isaac V Cohen; Tigran Makunts; Talar Moumedjian; Masara Issa; Ruben Abagyan; Chigozie A. Ogwara; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Clinical Pharmacology and Therapeutics (CPT) Postdoctoral Training Program, University of California San Francisco, San Francisco, California, United States; Oak Ridge Institute of Science and Education (ORISE), Clinical Pharmacology and Machine Learning fellowship at the Center for Drug Evaluation and Research, Unit; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organizations List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to the risk of drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.",pharmacology and therapeutics,exact,100,100
medRxiv,10.1101/2020.05.19.20107532,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107532,COVID-19 Datasets: A Survey and Future Challenges,Junaid Shuja; Eisa Alanazi; Waleed Alasmary; Abdulaziz Alashaikh; Ruben Abagyan; Chigozie A. Ogwara; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Umm Al-Qura University; Umm Al-Qura University; Umm Al-Qura University; University of Jeddah; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","AO_SCPLOWBSTRACTC_SCPLOWIn December 2019, a novel virus named COVID-19 emerged in the city of Wuhan, China. In early 2020, the COVID-19 virus spread in all continents of the world except Antarctica causing widespread infections and deaths due to its contagious characteristics and no medically proven treatment. The COVID-19 pandemic has been termed as the most consequential global crisis after the World Wars. The first line of defense against the COVID-19 spread are the non-pharmaceutical measures like social distancing and personal hygiene. The great pandemic affecting billions of lives economically and socially has motivated the scientific community to come up with solutions based on computer-aided digital technologies for diagnosis, prevention, and estimation of COVID-19. Some of these efforts focus on statistical and Artificial Intelligence-based analysis of the available data concerning COVID-19. All of these scientific efforts necessitate that the data brought to service for the analysis should be open source to promote the extension, validation, and collaboration of the work in the fight against the global pandemic. Our survey is motivated by the open source efforts that can be mainly categorized as (a) COVID-19 diagnosis from CT scans, X-ray images, and cough sounds, (b) COVID-19 case reporting, transmission estimation, and prognosis from epidemiological, demographic, and mobility data, (c) COVID-19 emotional and sentiment analysis from social media, and (d) knowledge-based discovery and semantic analysis from the collection of scholarly articles covering COVID-19. We survey and compare research works in these directions that are accompanied by open source data and code. Future research directions for data-driven COVID-19 research are also debated. We hope that the article will provide the scientific community with an initiative to start open source extensible and transparent research in the collective fight against the COVID-19 pandemic.",public and global health,exact,100,100
medRxiv,10.1101/2020.05.24.20107193,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.24.20107193,Using HoloLens to reduce staff exposure to aerosol generating procedures during a global pandemic,John J Cafferkey; Dominic OP Hampson; Clare Ross; Angad S Kooner; Guy FJ Martin; James M Kinross; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"Imperial College Healthcare NHS Trust; Division of Respiratory Medicine, Imperial College Healthcare NHS Trust, London UK; Division of Respiratory Medicine, Imperial College Healthcare NHS Trust, London UK; Cutrale Perioperative and Ageing Research Group, Department of Bioengineering, Imperial College London; Department of Surgery and Cancer, Imperial College London, London UK; Department of Surgery and Cancer, Imperial College London, London UK; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","RATIONALECOVID-19 poses a unique challenge; caring for patients with a novel, infectious disease whilst protecting staff. Some interventions used to give oxygen therapy are aerosol generating procedures. Staff delivering such interventions require PPE and are exposed to a significant viral load resulting in sick days and even death. We aim to reduce this risk using an augmented-reality communication device: The HoloLens by Microsoft.

OBJECTIVESIn a tertiary centre in London we aim to implement HoloLens technology, allowing other medical staff to remotely join the consulting clinician when in a high-risk patient area delivering oxygen therapy. The study primary outcome was to reduce the exposure to staff and demonstrate non-inferiority staff satisfaction when compared to not using the device. Our secondary outcome was to reduce extrapolated PPE costs when using the device.

METHODSOur study was conducted in March and April 2020, within a respiratory unit delivering aerosolising oxygen therapies (High flow nasal oxygen, Continuous positive airway pressure and non-invasive ventilation) to patients with suspected or confirmed COVID-19 infection.

MEASUREMENTSSelf-reported questionnaires to assess satisfaction in key areas of patient care. An infrared people counting device was also used to assess staff in and out of the unit.

MAIN RESULTSMean self-reported time in the high-risk zone was less when using HoloLens (2.69 hours) compared to usual practice (3.96 hours) although this difference was not statistically significant (p = 0.3657). HoloLens showed non-inferiority when compared to usual practice in staff satisfaction score for all domains. Furthermore, mean staff satisfaction score encouragingly improved when using HoloLens. Self-reported PPE counts from this study showed 12 staff members changing PPE 25.8 times per shift, almost double the 13.5 times in the HoloLens count.

CONCLUSIONSWe have demonstrated HoloLens can reduce the number of staff exposed to aerosol generating areas in a novel infectious disease. Our results show it did not impair communication, medical staff availability or end of life care. HoloLens technology may also reduce the use of PPE, which has equipment availability and cost benefits. This study provides grounding for further use of the HoloLens device by bringing a bedside experience to experts remote to the situation.",respiratory medicine,exact,100,100
medRxiv,10.1101/2020.05.19.20107102,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20107102,"COVID-19: A Chronological Review of the Neurological Repercussions - What do We Know by May, 2020?",Paulo Afonso Mei; Laura Loeb; Clare Ross; Angad S Kooner; Guy FJ Martin; James M Kinross; Margaret R. Davies; Terrence Jacobs; Chi-Hin Cheung; Logan T. Cowan; Andrew R. Hansen; Isaac Chun-Hai Fung; Sheng Wang; Zhong-yuan Xia; Richard L Applegate II; Hong Liu; Jing Tang; Zhengyuan Xia; Flavia R Machado; Otavio Berwanger; COALITION COVID-19 Brazil I Investigators; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski; Marta S Oliveira; Timothy Peto; Rutger J Ploeg; Jeremy Ratcliff; David J Roberts; Justine Rudkin; Rebecca A Russell; Gavin Screaton; Malcolm G Semple; Donal T Skelly; Peter Simmonds; Nicole Stoesser; Lance Turtle; Sue Wareing; Maria Zambon,"So Leopoldo Mandic College; So Leopoldo Mandic College; Division of Respiratory Medicine, Imperial College Healthcare NHS Trust, London UK; Cutrale Perioperative and Ageing Research Group, Department of Bioengineering, Imperial College London; Department of Surgery and Cancer, Imperial College London, London UK; Department of Surgery and Cancer, Imperial College London, London UK; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Independent Researcher; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Georgia Southern University Jiann-Ping Hsu College of Public Health; Department of Anesthesiology, Guangdong provincial people Hospital, Guangdong Academy of Medical Sciences; Department of Anesthesiology, Renmin Hospital of Wuhan University; Department of Anesthesiology and Pain Medicine, University of California Davis Health; Department of Anesthesiology and Pain Medicine, University of California Davis Health; The Department of Anesthesiology, Affiliated hospital of Guangdong Medical University; Department of Anesthesiology, University of Hong Kong; Brazilian Research in Intensive Care Network (BRICNet), Sao Paulo, Brazil.; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK; NHSBT, Oxford; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of; NHSBT, Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NHSBT, Oxford; Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK. Big Data Institute, University of Oxford, OX3 7LF, UK; University of Oxford; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool, L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK; Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Nuffield Department of Medicine, University of Oxford, OX3 9DU, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Faculty of Health and Life Sciences, University of Liverpool,  L69 3BX, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK; Public Health England, Colindale, London, NW9 5EQ, UK","IntroductionDespite the new SARS-CoV-2 (COVID-19) be the seventh of the coronavirus family viruses known to cause human disease, little is known about potential symptoms and syndromes secondary to the compromise of the central and peripheral nervous systems. We reviewed neurological manifestations due to the new coronavirus, thus far published in the literature, as well as guidelines issued by sub-specialties in Neurology, to tackle the disease.

Methodswe searched medical databases, such as PubMed, PubMed Central, LILACS and Google scholar for papers (case reports, short letters, case series, etc) describing neurological symptoms in patients with confirmed or suspect COVID-19 diagnosis and also searched webpages of associations and organizations that deal with neurological disorders.

Resultswe describe briefly each article considered for this review. Forty-one papers were found associating neurological conditions and COVID-19. Cases are divided by disease groups and, within each disease group, results are listed in chronological order or publication date. We also discuss briefly recommendations for neurological patients, according to disease group.

ConclusionAlthough there is evidence of neurological manifestations with previous coronaviruses, COVID-19 is assuring a volume of published papers not seen before for other coronavirus infections. Most neurological cases are not life-threatening, but 10 to 20% of cases will require hospitalization and are in risk for sequelae and death. Although a lot of data coming from these papers is amassing, researchers must bear in mind that many papers currently published are not yet peer-reviewed, and thus are prone to further corrections.",neurology,exact,100,100
medRxiv,10.1101/2020.05.20.20108126,2020-05-24,https://medrxiv.org/cgi/content/short/2020.05.20.20108126,Susceptibility to and transmission of COVID-19 amongst children and adolescents compared with adults: a systematic review and meta-analysis,Russell M Viner; Oliver T Mytton; Chris Bonell; G.J. Melendez-Torres; Joseph L Ward; Lee Hudson; Claire Waddington; James Thomas; Simon Russell; Fiona van der Klis; Archana Koiral; Shamez Ladhani; Jasmina Panovska-Griffiths; Nicholas G Davies; Robert Booy; Rosalind Eggo; Tim Frenzel; Monique Reijers; Wouter Hoefsloot; Anton S.M. Dofferhoff; Angle P.M. Kerckhoffs; Marc J.T. Blaauw; Karin Veerman; Coen Maas; Arjan H. Schoneveld; Imo E. Hoefer; Lennie P.G. Derde; Loek Willems; Erik Toonen; Marcel van Deuren; Jos W.M. van der Meer; Reinout van Crevel; Evangelos J. Giamarellos-Bourboulis; Leo A.B. Joosten; Michel M. van den Heuvel; Jacobien Hoogerwerf; Quirijn de Mast; Peter Pickkers; Mihai G. Netea,"UCL Great Ormond St. Institute of Child Health; University of Cambridge; London School of Hygiene and Tropical Medicine; College of Medicine and Health, University of Exeter, UK; UCL Great Ormond St. Institute of Child Health; UCL Great Ormond St. Institute of Child Health; Addenbrookes Hospital, Cambridge; UCL Institute of Education; UCL Great Ormond St. Institute of Child Health; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; University of Sydney; Public Health England; UCL; London School of Hygiene and Tropical Medicine; University of Sydney; London School of Hygiene and Tropical Medicine; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Canisius Wilhelmina Hospital; Jeroen Bosch Hospital; Bernhoven Hospital; Sint Maartenskliniek; University Medical Center Utrecht; University Medical Center Utrecht; University Medical Center Utrecht; University Medical Center Utrecht; Hycult Biotechnology; Hycult Biotechnology; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; National and Kapodistrian University of Athens; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center and University of Bonn","ImportanceThe degree to which children and young people are infected by and transmit the SARS-CoV-2 virus is unclear. The role of children and young people in transmission of SARS-CoV-2 is dependent on susceptibility, symptoms, viral load, social contact patterns and behaviour.

ObjectiveWe undertook a rapid systematic review to address the question ""What is the susceptibility to and transmission of SARS-CoV-2 by children and adolescents compared with adults?""

Data sourcesWe searched PubMed and medRxiv up to 28 July 2020 and identified 13,926 studies, with additional studies identified through handsearching of cited references and professional contacts.

Study SelectionWe included studies which provided data on the prevalence of SARS-CoV-2 in children and young people (<20 years) compared with adults derived from contact-tracing or population-screening. We excluded single household studies.

Data extraction and SynthesisWe followed PRISMA guidelines for abstracting data, independently by 2 reviewers. Quality was assessed using a critical appraisal checklist for prevalence studies. Random effects meta-analysis was undertaken.

Main OutcomesSecondary infection rate (contact-tracing studies) or prevalence or seroprevalence (population-screening studies) amongst children and young people compared with adults.

Results32 studies met inclusion criteria; 18 contact-tracing and 14 population-screening. The pooled odds ratio of being an infected contact in children compared with adults was 0.56 (0.37, 0.85) with substantial heterogeneity (95%). Three school contact tracing studies found minimal transmission by child or teacher index cases. Findings from population-screening studies were heterogenous and were not suitable for meta-analysis. The majority of studies were consistent with lower seroprevalence in children compared with adults, although seroprevalence in adolescents appeared similar to adults.

ConclusionsThere is preliminary evidence that children and young people have lower susceptibility to SARS-CoV-2, with a 43% lower odds of being an infected contact. There is weak evidence that children and young people play a lesser role in transmission of SARS-CoV-2 at a population level. Our study provides no information on the infectivity of children.

Key pointsO_ST_ABSQuestionC_ST_ABSWhat is the evidence on the susceptibility and transmission of children and young people to SARS-CoV-2 in comparison with adults?

FindingsIn this systematic review and meta-analysis, children and young people under 18-20 years had an 435 lower odds of secondary infection of with SARS-CoV-2 compared to adults 20 years plus, a significant difference. This finding was most marked in children under 12-14 years. Data were insufficient to conclude whether transmission of SARS-CoV-2 by children is lower than by adults.

MeaningWe found preliminary evidence that children have a lower susceptibility for SARS-CoV-2 infection compared with adults, although data for adolescents is less clear. The role that children and young people play in transmission of this pandemic remains unclear.",public and global health,exact,100,100
bioRxiv,10.1101/2020.05.23.111385,2020-05-24,https://biorxiv.org/cgi/content/short/2020.05.23.111385,COVIDep: A web-based platform for real-time reporting of vaccine target recommendations for SARS-CoV-2,Syed Faraz Ahmed; Ahmed A. Quadeer; Matthew R. McKay; G.J. Melendez-Torres; Joseph L Ward; Lee Hudson; Claire Waddington; James Thomas; Simon Russell; Fiona van der Klis; Archana Koiral; Shamez Ladhani; Jasmina Panovska-Griffiths; Nicholas G Davies; Robert Booy; Rosalind Eggo; Tim Frenzel; Monique Reijers; Wouter Hoefsloot; Anton S.M. Dofferhoff; Angle P.M. Kerckhoffs; Marc J.T. Blaauw; Karin Veerman; Coen Maas; Arjan H. Schoneveld; Imo E. Hoefer; Lennie P.G. Derde; Loek Willems; Erik Toonen; Marcel van Deuren; Jos W.M. van der Meer; Reinout van Crevel; Evangelos J. Giamarellos-Bourboulis; Leo A.B. Joosten; Michel M. van den Heuvel; Jacobien Hoogerwerf; Quirijn de Mast; Peter Pickkers; Mihai G. Netea,"The Hong Kong University of Science and Technology; The Hong Kong University of Science and Technology; The Hong Kong University of Science and Technology; College of Medicine and Health, University of Exeter, UK; UCL Great Ormond St. Institute of Child Health; UCL Great Ormond St. Institute of Child Health; Addenbrookes Hospital, Cambridge; UCL Institute of Education; UCL Great Ormond St. Institute of Child Health; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; University of Sydney; Public Health England; UCL; London School of Hygiene and Tropical Medicine; University of Sydney; London School of Hygiene and Tropical Medicine; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Canisius Wilhelmina Hospital; Jeroen Bosch Hospital; Bernhoven Hospital; Sint Maartenskliniek; University Medical Center Utrecht; University Medical Center Utrecht; University Medical Center Utrecht; University Medical Center Utrecht; Hycult Biotechnology; Hycult Biotechnology; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; National and Kapodistrian University of Athens; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center; Radboud University Medical Center and University of Bonn","We introduce COVIDep (https://COVIDep.ust.hk), a web-based platform that provides immune target recommendations for guiding SARS-CoV-2 vaccine development. COVIDep implements a protocol that pools together publicly-available genetic data for SARS-CoV-2 and epitope data for SARS-CoV to identify B cell and T cell epitopes that present potential immune targets for SARS-CoV-2. Correspondences between outputs of COVIDep and immune responses recorded in COVID-19 patients and preclinical vaccine trials are also indicated. The platform is user-friendly, flexible, and based on up-to-date data. It may help guide vaccine designs and associated experimental studies for SARS-CoV-2.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.05.20.20108183,2020-05-23,https://medrxiv.org/cgi/content/short/2020.05.20.20108183,A Rapid Review of the Asymptomatic Proportion of PCR-Confirmed SARS-CoV-2 Infections in Community Settings,Sarah Beale; Andrew Hayward; Laura Shallcross; Robert W Aldridge; Ellen Fragaszy; gezhi xu; wenjun cao; John Cleland; John Forbes; Jason MR Gill; Claire Hastie; Frederick K Ho; Bhautesh D Jani; Daniel F Mackay; Barbara I Nicholl; Naveed I Sattar; Paul I Welsh; Jill P Pell; Srinivasa Vittal Katikireddi; Evangelia Demou,"University College London; University College London; University College London; University College London; University College London; Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College; Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow; University of Glasgow","BackgroundUp to 80% of active SARS-CoV-2 infections are proposed to be asymptomatic based on cross-sectional studies. However, accurate estimates of the asymptomatic proportion require systematic detection and follow-up to differentiate between truly asymptomatic and pre-symptomatic cases. We conducted a rapid review and meta-analysis of current evidence regarding the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections based on methodologically-appropriate studies in community settings.

MethodsWe searched Medline and EMBASE for peer-reviewed articles, and BioRxiv and MedRxiv for pre-prints published prior to 05/05/2020. We included studies based in community settings that involved systematic PCR testing on participants and follow-up symptom monitoring regardless of symptom status. We extracted data on study characteristics, frequencies of PCR-confirmed infections by symptom status, and (if available) cycle threshold values and/or duration of viral shedding by symptom status. We computed estimates of the asymptomatic proportion and 95% confidence intervals for each study and overall using random effect meta-analysis.

FindingsWe screened 270 studies and included 6. The pooled estimate for the asymptomatic proportion of SARS-CoV-2 infections was 11% (95% CI 4%-18%). Estimates of baseline viral load appeared to be similar for asymptomatic and symptomatic cases based on available data in three studies, though detailed reporting of cycle threshold values and natural history of viral shedding by symptom status was limited.

InterpretationThe asymptomatic proportion of SARS-CoV-2 infections is relatively low when estimated from methodologically-appropriate studies. Further investigation into the degree and duration of infectiousness for asymptomatic infections is warranted.

FundingMedical Research Council",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.18.20086157,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.18.20086157,COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis,Nicola L Boddington; Andre Charlett; Suzanne Elgohari; Jemma L Walker; Helen Mcdonald; Chloe Byers; Laura Coughlan; Tatiana Garcia Vilaplana; Rosie Whillock; Mary Sinnathamby; Nikolaos Panagiotopoulos; Louise Letley; Pauline MacDonald; Roberto Vivancos; Obaghe Edeghere; Joseph Shingleton; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"ObjectivesFollowing detection of the first virologically-confirmed cases of COVID-19 in Great Britain, an enhanced surveillance study was initiated by Public Health England to describe the clinical presentation, course of disease and underlying health conditions associated with infection of the first few hundred cases.

MethodsInformation was collected on the first COVID-19 cases according to the First Few X WHO protocol. Case-control analyses of the sensitivity, specificity and predictive value of symptoms and underlying health conditions associated with infection were conducted. Point prevalences of underlying health conditions among the UK general population were presented.

FindingsThe majority of FF100 cases were imported (51.4%), of which the majority had recent travel to Italy (71.4%). 24.7% were secondary cases acquired mainly through household contact (40.4%). Children had lower odds of COVID-19 infection compared with the general population.

The clinical presentation of cases was dominated by cough, fever and fatigue. Non-linear relationships with age were observed for fever, and sensitivity and specificity of symptoms varied by age.

Conditions associated with higher odds of COVID-19 infection (after adjusting for age and sex) were chronic heart disease, immunosuppression and multimorbidity.

ConclusionThis study presents the first epidemiological and clinical summary of COVID-19 cases in Great Britain. The FFX study design enabled systematic data collection. The study characterized underlying health conditions associated with infection and set relative risks in context with population prevalence estimates. It also provides important evidence for generating case definitions to support public health risk assessment, clinical triage and diagnostic algorithms.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.18.20102509,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.18.20102509,"Low blood sodium increases risk and severity of COVID-19: a systematic review, meta-analysis and retrospective cohort study",Yi Luo; Yirong Li; Jiapei Dai; Jemma L Walker; Helen Mcdonald; Chloe Byers; Laura Coughlan; Tatiana Garcia Vilaplana; Rosie Whillock; Mary Sinnathamby; Nikolaos Panagiotopoulos; Louise Letley; Pauline MacDonald; Roberto Vivancos; Obaghe Edeghere; Joseph Shingleton; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; South-Central University for Nationalities; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","BackgroundNovel coronavirus (SARS-CoV-2) infects human lung tissue cells through angiotensin-converting enzyme-2 (ACE2), and the body sodium is an important factor for regulating the expression of ACE2. Through a systematic review, meta-analysis and retrospective cohort study, we found that the low blood sodium population may significantly increase the risk and severity of SARS-CoV-2 infection.

MethodsWe extracted the data of serum sodium concentrations of patients with COVID-19 on admission from the articles published between Jan 1 and April 28, 2020, and analyzed the relationship between the serum sodium concentrations and the illness severity of patients. Then we used a cohort of 244 patients with COVID-19 for a retrospective analysis.

ResultsWe identified 36 studies, one of which comprised 2736 patients.The mean serum sodium concentration in patients with COVID-19 was 138.6 mmol/L, which was much lower than the median level in population (142.0). The mean serum sodium concentration in severe/critical patients (137.0) was significantly lower than those in mild and moderate patients (140.8 and 138.7, respectively). Such findings were confirmed in a retrospective cohort study, of which the mean serum sodium concentration in all patients was 137.5 mmol/L, and the significant differences were found between the mild (139.2) and moderate (137.2) patients, and the mild and severe/critical (136.6) patients. Interestingly, such changes were not obvious in the serum chlorine and potassium concentrations.

ConclusionsThe low sodium state of patients with COVID-19 may not be the consequence of virus infection, but could be a physiological state possibly caused by living habits such as low salt diet and during aging process, which may result in ACE2 overexpression, and increase the risk and severity of COVID-19. These findings may provide a new idea for the prevention and treatment of COVID-19.",pharmacology and therapeutics,exact,100,100
medRxiv,10.1101/2020.05.17.20101915,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20101915,Factors Contributing to Healthcare Professional Burnout During the COVID-19 Pandemic: A Rapid Turnaround Global Survey,Luca Alfredo Morgantini; Ushasi Naha; Heng Wang; Simone Francavilla; Omer Acar; Jose M Flores; Simone Crivellaro; Daniel Moreira; Michael Abern; Martin Eklund; Hari Vigneswaran; Stevan M Weine; Pauline MacDonald; Roberto Vivancos; Obaghe Edeghere; Joseph Shingleton; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; Karolinska Institute; Karolinska Institute; University of Illinois at Chicago; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"BackgroundHealthcare professionals (HCPs) on the front lines against COVID-19 may face increased workload, and stress. Understanding HCPs risk for burnout is critical to supporting HCPs and maintaining the quality of healthcare during the pandemic.

MethodsTo assess exposure, perceptions, workload, and possible burnout of HCPs during the COVID-19 pandemic we conducted a cross-sectional survey. The main outcomes and measures were HCPs self-assessment of burnout and other experiences and attitudes associated with working during the COVID-19 pandemic.

FindingsA total of 2,707 HCPs from 60 countries participated in this study. Fifty-one percent of HCPs reported burnout. Burnout was associated with work impacting household activities (RR=1{middle dot}57, 95% CI=1{middle dot}39-1{middle dot}78, P<0{middle dot}001), feeling pushed beyond training (RR=1{middle dot}32, 95% CI=1{middle dot}20-1{middle dot}47, P<0{middle dot}001), exposure to COVID-19 patients (RR=1{middle dot}18, 95% CI=1{middle dot}05-1{middle dot}32, P=0{middle dot}005), making life prioritizing decisions (RR=1{middle dot}16, 95% CI=1{middle dot}02-1{middle dot}31, P=0{middle dot}03). Adequate personal protective equipment (PPE) was protective against burnout (RR=0{middle dot}88, 95% CI=0{middle dot}79-0{middle dot}97, P=0{middle dot}01). Burnout was higher in high-income countries (HICs) compared to low- and middle-income countries (LMICs) (RR=1{middle dot}18; 95% CI=1{middle dot}02-1{middle dot}36, P=0{middle dot}018).

InterpretationBurnout is prevalent at higher than previously reported rates among HCPs working during the COVID-19 pandemic and is related to high workload, job stress, and time pressure, and limited organizational support. Current and future burnout among HCPs could be mitigated by actions from healthcare institutions and other governmental and non-governmental stakeholders aimed at potentially modifiable factors, including providing additional training, organizational support, support for family, PPE, and mental health resources.

FundingN/A",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.05.19.20103168,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20103168,Multifocal transient cortical brain lesions: a consistent MRI finding in neuro-COVID-19 patients,Nicoletta Anzalone; Antonella Castellano; Roberta Scotti; Anna Mara Scandroglio; Massimo Filippi; Fabio Ciceri; Moreno Tresoldi; Andrea Falini; Michael Abern; Martin Eklund; Hari Vigneswaran; Stevan M Weine; Pauline MacDonald; Roberto Vivancos; Obaghe Edeghere; Joseph Shingleton; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Neurology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Hematology and Stem Cell Transplantation, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Unit of General Medicine and Advanced Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; University of Illinois at Chicago; Karolinska Institute; Karolinska Institute; University of Illinois at Chicago; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","We report four cases of subacute encephalopathy occurring in patients with SARS-CoV-2 infection. All patients have been intubated in the first week from onset of ARDS and presented neurological signs of agitation and spatial disorientation after weaning from mechanical ventilation. The MRI picture and the clinical features are described. MRI lesions characteristics are unusual but demonstrate a highly consistent pattern through all the four patients with similar neurological symptoms. They do not fulfill any typical criteria for a definite neuroradiological entity. Their predominantly parieto-occipital distribution recalls posterior reversible encephalopathy syndrome (PRES), although the prevalent cortical involvement and diffusion MRI pattern are not typical of PRES. We speculate that this pattern may be related to a possible transient dysregulation of vasomotor reactivity.",radiology and imaging,exact,100,100
medRxiv,10.1101/2020.05.17.20104562,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20104562,COVID 19 in Bangladesh: Assumption of possible infection and death,Sadik Hasan Shuvo; Antonella Castellano; Roberta Scotti; Anna Mara Scandroglio; Massimo Filippi; Fabio Ciceri; Moreno Tresoldi; Andrea Falini; Michael Abern; Martin Eklund; Hari Vigneswaran; Stevan M Weine; Pauline MacDonald; Roberto Vivancos; Obaghe Edeghere; Joseph Shingleton; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Jatiya Kabi Kazi Nazrul Islam University; Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Neurology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Department of Hematology and Stem Cell Transplantation, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; Unit of General Medicine and Advanced Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy; University of Illinois at Chicago; Karolinska Institute; Karolinska Institute; University of Illinois at Chicago; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","It is a painful job to predict the death of people. But sometimes it is important to predict the future and concern the government. A furious future is waiting for Bangladesh.

ObjectiveObjective of the study is to assume the number of positive case and death till 30th December, 2020 in Bangladesh.

Study designThis study was designed with systematic review and data analysis.

MethodThe study was completed by analyzing data available on website. First COVID 19 case in Bangladesh was identified on 8th March. Analyzing the data increasing rate/common ratio of infection and death has been identified. Then this common ratio has been used in the formula of multiplication series (at decreasing rate). Data of China, Iran, Italy and the USA was also analyzed to assume how the death and case number increased. Social issues of Bangladesh were also analyzed. Considering all these the assumption was made.

ResultIt has been assumed that by the 43rd week (on 30th December, 2020) of first identification the total case can be 15640747 and total death can be 638769 by 30 December, 2020. As this is an assumption this can be true, partially true or false. But the base of assumption is strong enough so the possibility of being true or nearly true is higher.

Policy SuggestionGovernment should choose properly one between two options. Either government should declare curfew or let people lead normal life for the purpose of herd immunity. A very weak lockdown for a long time doesnt make any sense.",health policy,exact,100,100
medRxiv,10.1101/2020.05.17.20104604,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20104604,Characterization of Patients Who Return to Hospital Following Discharge from Hospitalization For COVID-19,Sulaiman Somani; Felix Richter; Valentin Fuster; Jessica De Freitas; Nidhi Naik; Keith Sigel; Mount Sinai Covid Informatics Center (MSCIC); Erwin P. Boettinger; Matthew A. Levin; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; ; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"BackgroundData on patients with coronavirus disease 2019 (COVID-19) who return to hospital after discharge are scarce. Characterization of these patients may inform post-hospitalization care.

Methods and FindingsRetrospective cohort study of patients with confirmed SARS-CoV-2 discharged alive from five hospitals in New York City with index hospitalization between February 27th-April 12th, 2020, with follow-up of [&ge;]14 days. Significance was defined as P<0.05 after multiplying P by 125 study-wide comparisons. Of 2,864 discharged patients, 103 (3.6%) returned for emergency care after a median of 4.5 days, with 56 requiring inpatient readmission. The most common reason for return was respiratory distress (50%). Compared to patients who did not return, among those who returned there was a higher proportion of COPD (6.8% vs 2.9%) and hypertension (36% vs 22.1%). Patients who returned also had a shorter median length of stay (LOS) during index hospitalization (4.5 [2.9,9.1] vs. 6.7 [3.5, 11.5] days; Padjusted=0.006), and were less likely to have required intensive care on index hospitalization (5.8% vs 19%; Padjusted=0.001). A trend towards association between absence of in-hospital anticoagulation on index admission and return to hospital was also observed (20.9% vs 30.9%, Padjusted=0.064). On readmission, rates of intensive care and death were 5.8% and 3.6%, respectively.

ConclusionsReturn to hospital after admission for COVID-19 was infrequent within 14 days of discharge. The most common cause for return was respiratory distress. Patients who returned had higher proportion of COPD and hypertension with shorter LOS on index hospitalization, and a trend towards lower rates of in-hospital treatment-dose anticoagulation. Future studies should focus on whether these comorbid conditions, longer LOS and anticoagulation are associated with reduced readmissions.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.05.17.20104547,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20104547,Meteorological Conditions and Covid-19 in Large U.S. Cities,Hisato Takagi; Toshiki Kuno; Yujiro v; Hiroki Ueyama; Takuya Matsushiro; Yosuke Hari; Tomo Ando; Erwin P. Boettinger; Matthew A. Levin; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Shizuoka Medical Center, Shizuoka, Japan; Kitasato University, School of Medicine, Sagamihara, Japan; Mount Sinai Beth Israel Medical Center, New York, NY, USA; Easton Hospital, Easton, PA, USA; Mount Sinai Beth Israel Medical Center, New York, NY, USA; Shizuoka Medical Center, Shizuoka, Japan; Kitasato University, School of Medicine, Sagamihara, Japan; Shizuoka Medical Center, Shizuoka, Japan; Kitasato University, School of Medicine, Sagamihara, Japan; New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","To determine whether prevalence of Coronavirus disease 2019 (Covid-19) is modulated by meteorological conditions, we herein conducted meta-regression of data in large U.S. cities. We selected 33 large U.S. cities with a population of >500,000. The integrated numbers of confirmed Covid-19 cases in the country to which the city belongs on 14 May 2020, the estimated population in 2019 in the country, and monthly meteorological conditions at the city for 4 months (from January to April 2020) were obtained. Meteorological conditions consisted of mean temperature (F), total precipitation (inch), mean wind speed (MPH), mean sky cover, and mean relative humidity (%). Monthly data for 4 months were averaged or integrated. The Covid-19 prevalence was defined as the integrated number of Covid-19 cases divided by the population. Random-effects meta-regression was performed by means of OpenMetaAnalyst. In a meta-regression graph, Covid-19 prevalence (plotted as the logarithm transformed prevalence on the y-axis) was depicted as a function of a given factor (plotted as a meteorological datum on the x-axis). A slope of the meta-regression line was significantly negative (coefficient, -0.069; P < 0.001) for the mean temperature and significantly positive for the mean wind speed (coefficient, 0.174; P = 0.027) and the sky cover (coefficient, 2.220; P = 0.023). In conclusion, lower temperature and higher wind speed/sky cover may be associated with higher Covid-19 prevalence, which should be confirmed by further epidemiological researches adjusting for various risk and protective factors (in addition to meteorological conditions) of Covid-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.18.20103697,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.18.20103697,Comparative Efficacy and Safety of Pharmacological Managements for Hospitalized COVID-19 Patients: Protocol for Systematic Review and Trade-Off Network Meta-Analysis.,Min Seo Kim; Won Jun Kim; Min Ho An; Hiroki Ueyama; Takuya Matsushiro; Yosuke Hari; Tomo Ando; Erwin P. Boettinger; Matthew A. Levin; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Korea University, College of Medicine and Director of Cheongsan Public Health Center, Wando, Republic of Korea; Korea University College of Medicine and Gangneung Prison Medical Department, Ministry of Justice, Republic of Korea.; Ajou University, School of Medicine and Director of So Ahn Public Health Center, Wando, Republic of Korea; Mount Sinai Beth Israel Medical Center, New York, NY, USA; Shizuoka Medical Center, Shizuoka, Japan; Kitasato University, School of Medicine, Sagamihara, Japan; Shizuoka Medical Center, Shizuoka, Japan; Kitasato University, School of Medicine, Sagamihara, Japan; New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","Coronavirus-Disease 2019 (COVID-19) is the clinical disease caused by the SARS-CoV-2 virus, the infectious agent causing the ongoing pandemic that has impacted the lives of hundreds of millions of people in almost every nation worldwide. It is a potentially fatal disease to many vulnerable patients including the elderly and those with chronic illnesses; but because this virus is a novel one, there are no firmly established treatment protocols. Many treatment methods are being investigated worldwide, and scientific conclusions drawn from these endeavors are crucial for healthcare professionals in combating this disease. In this network meta-analysis, we focus specifically on the pharmacologic agents that have been investigated for the treatment of COVID-19 and aim to produce a comprehensive picture of the evidence from current data in order to produce relevant insights on the comparative efficacy and safety profiles of various pharmacologic agents against COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20103036,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20103036,Clinical predictors of COVID-19 mortality,Arjun S. Yadaw; Yan-chak Li; Sonali Bose; Ravi Iyengar; Supinda Bunyavanich; Gaurav Pandey; Tomo Ando; Erwin P. Boettinger; Matthew A. Levin; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has affected over millions of individuals and caused hundreds of thousands of deaths worldwide.

It can be difficult to accurately predict mortality among COVID-19 patients presenting with a spectrum of complications, hindering the prognostication and management of the disease.

MethodsWe applied machine learning techniques to clinical data from a large cohort of 5,051 COVID-19 patients treated at the Mount Sinai Health System in New

York City, the global COVID-19 epicenter, to predict mortality. Predictors were designed to classify patients into Deceased or Alive mortality classes and were evaluated in terms of the area under the receiver operating characteristic (ROC) curve (AUC score).

FindingsUsing a development cohort (n=3,841) and a systematic machine learning framework, we identified a COVID-19 mortality predictor that demonstrated high accuracy (AUC=0{middle dot}91) when applied to test sets of retrospective (n= 961) and prospective (n=249) patients. This mortality predictor was based on five clinical features: age, minimum O2 saturation during encounter, type of patient encounter (inpatient vs. various types of outpatient and telehealth encounters), hydroxychloroquine use, and maximum body temperature.

InterpretationAn accurate and parsimonious COVID-19 mortality predictor based on five features may have utility in clinical settings to guide the management and prognostication of patients affected by this disease.

FundingThis work was funded by the National Institutes of Health.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20101469,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20101469,Effect of Heat inactivation on Real-Time Reverse Transcription PCR of the SARS-COV-2 Detection,yanxia liu; zhengan cao; mei chen; Yan zhong; yuhao luo; gang shi; Hongxia Xiang; Jianping Luo; Hongwei Zhou; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Zhujiang Hospital, Southern Medical University; Zhuzhou center for Disease Control and Prevention; Zhuzhou center for Disease Control and Prevention; Zhuzhou center for Disease Control and Prevention; Zhuzhou center for Disease Control and Prevention; Zhuzhou center for Disease Control and Prevention; Zhuzhou center for Disease Control and Prevention; Zhuzhou center for Disease Control and Prevention; Zhujiang Hospital, Southern Medical University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","Real-time reverse transcription PCR (rRT-PCR) is commonly used to diagnose SARS-CoV-2 infection. Heat inactivation prior to nucleic acid isolation may allow safe testing, while the effects of heat inactivation on SARS-CoV-2 rRT-PCR detection result need to be determined. 14 positive nasopharyngeal swab specimens were inactivated at 56{degrees}C for 30min, 56{degrees}C for 60min, 60{degrees}C for 30min, 60{degrees}C for 75min, and 100{degrees}C for 10min, then were detected by rRT-PCR. All 14 heat treated samples remained positive. Another 2 positive nasopharyngeal swab specimens were inactivated at 100{degrees}C for 10min, 100{degrees}C for 30min, and 100{degrees}C for 60min, after which the samples were isolated and detected by rRT-PCR. The range of threshold cycle (Ct) values observed when detecting ORF1a/b was 27.228-34.011 in heat-treated samples, while 25.281-34.861 in unheated samples, and the range of threshold cycle (Ct) values observed at the time of detecting N was 25.777-33.351 in heat-treated samples, while 24.1615-35.433 in unheated samples, on basis of which it showed no statistical difference otherwise a good correlation of Ct values between the heat-inactivated samples and the untreated samples. However, the 2 samples inactivated at 100{degrees}C 30min, 100{degrees}C 60min turned into negative. Heat inactivation at 56{degrees}C for 30min, 56{degrees}C for 60min, 60{degrees}C for 30min, 60{degrees}C for 75min, and 100{degrees}C for 10min shall not affect the detection results of Real-Time Reverse Transcription PCR of the SARS-COV2. Furthermore, it is recommended to inactive nasopharyngeal swab specimens 10min at 100{degrees}C before RNA extraction in consideration of efficiency and reliable results.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20103150,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20103150,Detection of SARS-CoV-2 from raw patient samples by coupled high temperature reverse transcription and amplification,Johannes W.P. Kuiper; Timo Baade; Marcel Kremer; Ramon Kranaster; Linda Irmisch; Marcus Schuchmann; Johannes Zander; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,University of Konstanz; University of Konstanz; Labor Brunner Konstanz; myPOLS; Klinikum Konstanz; Klinikum Konstanz; Labor Brunner Konstanz; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"The SARS-CoV-2 beta coronavirus is spreading globally with unprecedented consequences for modern societies. The early detection of infected individuals is a prerequisite for all strategies aiming to contain the virus. Currently, purification of RNA from patient samples followed by RT-PCR is the gold standard to assess the presence of this single-strand RNA virus. However, these procedures are time consuming, require continuous supply of specialized reagents, and are prohibitively expensive in resource-poor settings. Here, we report an improved nucleic-acid-based approach to detect SARS-CoV-2, which alleviates the need to purify RNA, reduces handling steps, minimizes costs, and allows evaluation by non-specialized equipment. The use of unprocessed swap samples and the ability to detect as little as three viral genome equivalents is enabled by employing a heat-stable RNA- and DNA-dependent DNA polymerase, which performs the double task of stringent reverse transcription of RNA at elevated temperatures as well as PCR amplification of a SARS-CoV-2 specific target gene. As results are obtained within 2 hours and can be read-out by a hand-held LED-screen, this novel protocol will be of particular importance for large-scale virus surveillance in economically constrained settings.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.17.20101063,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20101063,Hospital-acquired infective endocarditis during Covid-19 pandemic,Antonio Ramos-Martinez; Ana Fernndez-Cruz; Fernando Dominguez; Alberto Forteza; Marta Cobo; Isabel Sanchez-Romero; Angel asensio; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,HU Puerta de Hierro-Majadahonda; HU Puerta de Hierro-Majadahonda; HU Puerta de Hierro-Majadahonda; HUY Puerta de Hierro-Majadahinda; HU Puerta de Hierrro-Majadahonda; HU Puerta de Hierro-Majadahonda; HU Puerta deHierro-Majadahonda; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"BackgroundThe COVID pandemic has had a major impact on healthcare in hospitals, including the diagnosis and treatment of infections. Hospital-acquired infective endocarditis (HAIE) is a severe complication of medical procedures that has shown a progressive increase in recent years.

Objectivesto determine whether the incidence of HAIE during the first two months of the epidemic (March-April 2020) was higher than previously observed and to describe the clinical characteristics of these cases. The probability of studied event (HAIE) during the studied period was calculate by Poisson distribution.

ResultsFour cases of HAIE were diagnosed in our institution during the study period. The incidence of HAIE during the study period was 2/patient-month and 0.25/patient-month during the previous 5 years (p=0.024). Two cases appeared during admission for COVID-19 with pulmonary involvement treated with methylprednisolone and tocilizumab. The other two cases were admitted to the hospital during the epidemic. All cases underwent central venous and urinary catheterization during admission. The etiology of HAIE was Enterococcus faecalis (2 cases), Staphylococcus aureus and Candida albicans (one case each). A source of infection was identified in three cases (central venous catheter, peripheral venous catheter, sternal wound infection, respectively). One patient was operated on. There were no fatalities during the first 30 days of follow-up.

ConclusionsThe incidence of HAIE during COVID-19 pandemic in our institution was higher than usual. In order to reduce the risk of this serious infection, optimal catheter care, appropriate use of corticosteroids and interleukin antagonists and early treatment of every local infection should be prioritized during coronavirus outbreaks.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.19.20104596,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20104596,Susceptibility-adjusted herd immunity threshold model and potential R0 distribution fitting the observed Covid-19 data in Stockholm,Paul V Brennan; Luke Paul Brennan; Fernando Dominguez; Alberto Forteza; Marta Cobo; Isabel Sanchez-Romero; Angel asensio; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,University College London; University College London; HU Puerta de Hierro-Majadahonda; HUY Puerta de Hierro-Majadahinda; HU Puerta de Hierrro-Majadahonda; HU Puerta de Hierro-Majadahonda; HU Puerta deHierro-Majadahonda; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"The reproduction number, R0, is commonly used, and sometimes misused, in conjunction with the classic Kermack and McKindrick theory based on the assumption of homogeneity, in order to estimate herd immunity threshold (HIT). This provides a crude first estimate of HIT, with more elaborate modelling required to arrive at a more realistic value. Early estimates of HIT for Covid-19 were based on this simplistic homogeneous approach, yielding high HIT values that have since been revised downwards with more sophisticated network modelling taking account of R0 heterogeneity and with reference to the low HIT found from serological sampling in Stockholm County. The aim of this paper is to describe a simple model in which host susceptibility is directly linked to the heterogeneous R0 distribution, to shed further light on the mechanisms involved and to arrive at a bimodal R0 distribution consistent with the Covid-19 HIT observed in Stockholm County.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.17.20104554,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20104554,The true case fatality of COVID19: An analytical solution,Syamantak Khan; Luke Paul Brennan; Fernando Dominguez; Alberto Forteza; Marta Cobo; Isabel Sanchez-Romero; Angel asensio; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,Stanford University; University College London; HU Puerta de Hierro-Majadahonda; HUY Puerta de Hierro-Majadahinda; HU Puerta de Hierrro-Majadahonda; HU Puerta de Hierro-Majadahonda; HU Puerta deHierro-Majadahonda; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"The exact risk of dying from COVID-19 has remained elusive and a topic of debate. In this study, the observed case fatality rates of 46 different countries are hypothesized to be dependent on their testing rates. An analytical test to this hypothesis suggests that the case fatality rate of COVID-19 could be consistent to a certain degree across all countries and states. The current global fatality rate is estimated to be around 1% and expected to converge between 1-3% when the pandemic ends. This model can be helpful to estimate the true infection rate for individual countries.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.19.20103788,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20103788,"Prevalence of Mental Health Problems During Virus Epidemics in the General Public, Health Care Workers and Survivors: A Rapid Review of the Evidence",Simeon J Zuercher Jr.; Philipp Kerksieck Jr.; Christine Adamus Jr.; Christian Burr Jr.; Anja I Lehmann Jr.; Flavia K Huber Jr.; Dirk Richter Sr.; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; Epidemiology, Biostatistics and Prevention Institute, Public and Organizational Health, University of Zurich, Zurich, Switzerland; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; Epidemiology, Biostatistics and Prevention Institute, Public and Organizational Health, University of Zurich, Zurich, Switzerland; University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","BackgroundThe swift spread of SARS-CoV-2 provides a challenge worldwide. As a consequence of restrictive public health measures like isolation, quarantine, and community containment, the provision of mental health services is a major challenge. Evidence from past virus epidemics and the current SARS-CoV-2 outbreak indicate high prevalence rates of mental health problems (MHP) as short- and long-term consequences. However, a broader picture of MHP among different populations is still lacking.

MethodsWe conducted a rapid review on MHP prevalence rates published since 2000, during and after epidemics, including the general public, health care workers, and survivors. Any quantitative articles reporting on MHP rates were included. Out of 2855 articles screened, a total of 74 were included in this review.

ResultsMost original studies on MHP were conducted in China in the context of SARS-CoV-1, and reported on anxiety, depression, post-traumatic stress symptoms/disorder, general psychiatric morbidity, and psychological symptoms. The MHP rates across studies, populations, and epidemics vary substantially. While some studies show high and persistent rates of MHP in populations directly affected by isolation, quarantine, threat of infection, infection, or life-threatening symptoms (e.g. health care workers), other studies report minor effects. Furthermore, even less affected populations (e.g. distant to epidemic epicenter, no contact history with suspected or confirmed cases) can show high rates of MHP.

DiscussionMHP vary largely across countries and risk-groups in reviewed studies. The results call attention to potentially high MHP during epidemics. Individuals affected directly by an epidemic might be at a higher risk of short or even long-term mental health impairments. This study delivers insights stemming from a wide range of psychiatric instruments and questionnaires. The results call for the use of validated and standardized instruments, reference norms, and pre-post measurements to better understand the magnitude of the MHP during and after the epidemics. Nevertheless, emerging MHP should be considered during epidemics including the provision of access to mental health care to mitigate potential mental impairments.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.05.16.20104422,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.16.20104422,Contributions of Latin American researchers in the understanding the novel coronavirus outbreak: A literature review,Karen Y Fiesco-Sepulveda; Luis Miguel Serrano-Bermudez; Christine Adamus Jr.; Christian Burr Jr.; Anja I Lehmann Jr.; Flavia K Huber Jr.; Dirk Richter Sr.; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Epidemiology Program, Faculty of Health Sciences, Universidad Surcolombiana, Neiva, Colombia.; Bioprocesses and Bioprospecting Group, Universidad Nacional de Colombia, Bogota D.C., Colombia.; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; Epidemiology, Biostatistics and Prevention Institute, Public and Organizational Health, University of Zurich, Zurich, Switzerland; University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","This paper aimed to give the visibility of Latin American researchers contributions to the comprehension of COVID-19; our method was a literature review. Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus, SARS-CoV-2, and its disease COVID-19. Therefore, in less than four months, researchers have published a significant number of articles related to this novel virus. For instance, a search focused on the Scopus database on April 10, 2020, showed 1224 documents published by authors with 1797 affiliations from 80 countries. 25.4%, 24.0%, and 12.6% of these national affiliations were from China, Europe, and the USA, respectively, making these regions leaders in COVID-19 research. In the case of Latin America, on April 10, 2020, we searched different databases, such as Scopus, PubMed, and Web of Science, finding that the contribution of this region was 2.7{+/-}0.6% of the total publications found. In other words, we found 153 publications related to COVID-19 with at least one Latin American researcher. We summarized and processed the information from these 153 publications, finding active participation in topics like medical, social, and environmental considerations, bioinformatics, and epidemiology.",public and global health,exact,100,100
medRxiv,10.1101/2020.05.17.20104588,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.17.20104588,"COVID 19: Real-time Forecasts of Confirmed Cases, Active Cases, and Health Infrastructure Requirements for India and its Majorly Affected States using the ARIMA model.",Rishabh Tyagi; Mahadev Bramhankar; Mohit Pandey; Kishore M; Anja I Lehmann Jr.; Flavia K Huber Jr.; Dirk Richter Sr.; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"International Institute for Population Sciences; International Institute For population Sciences, Mumbai; IIPS; IIPS; Epidemiology, Biostatistics and Prevention Institute, Public and Organizational Health, University of Zurich, Zurich, Switzerland; University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","BackgroundCOVID-19 is an emerging infectious disease which has been declared a Pandemic by the World Health Organization (WHO) on 11th March 2020. The Indian public health care system is already overstretched, and this pandemic is making things even worse. That is why forecasting cases for India is necessary to meet the future demands of the health infrastructure caused due to COVID-19.

ObjectiveOur study forecasts the confirmed and active cases for COVID-19 until July mid, using time series Autoregressive Integrated Moving Average (ARIMA) model. Additionally, we estimated the number of isolation beds, Intensive Care Unit (ICU) beds and ventilators required for the growing number of COVID-19 patients.

MethodsWe used ARIMA model for forecasting confirmed and active cases till the 15th July. We used time-series data of COVID-19 cases in India from 14th March to 22nd May. We estimated the requirements for ICU beds as 10%, ventilators as 5% and isolation beds as 85% of the active cases forecasted using the ARIMA model.

ResultsOur forecasts indicate that India will have an estimated 7,47,772 confirmed cases (95% CI: 493943, 1001601) and 296,472 active cases (95% CI:196820, 396125) by 15th July. While Maharashtra will be the most affected state, having the highest number of active and confirmed cases, Punjab is expected to have an estimated 115 active cases by 15th July. India needs to prepare 2,52,001 isolation beds (95% CI: 167297, 336706), 29,647 ICU beds (95% CI: 19682, 39612), and 14,824 ventilator beds (95% CI: 9841, 19806).

ConclusionOur forecasts show an alarming situation for India, and Maharashtra in particular. The actual numbers can go higher than our estimated numbers as India has a limited testing facility and coverage.",public and global health,exact,100,100
medRxiv,10.1101/2020.05.19.20099309,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.19.20099309,"Evaluating epidemiological scenarios of isolation and further releases considering protection actions to control transmission of CoViD-19 in Sao Paulo State, Brazil.",Hyun Mo Yang; Luis Pedro Pedro Lombardi Junior; Fbio Fernandes Morato Castro; Ariana Campos Yang; Anja I Lehmann Jr.; Flavia K Huber Jr.; Dirk Richter Sr.; Andreas Marx; Christof R Hauck; Zahi Fayad; Allan C. Just; Alexander Charney; Shan Zhao; Benjamin S. Glicksberg; Anuradha Lala; Girish Nadkarni; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,"Institute of Mathematics, Statistics and Scientific Computation - UNICAMP; State University of Campinas; Hospital das Clnicas da Faculdade de Medicina da Universidade de So Paulo; Hospital das Clnicas da Faculdade de Medicina da Universidade Estadual de So Paulo; Epidemiology, Biostatistics and Prevention Institute, Public and Organizational Health, University of Zurich, Zurich, Switzerland; University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland; Center for Psychiatric Rehabilitation, University Hospital for Mental Health (UPD), Bern, Switzerland and University Hospital of Psychiatry and Psychotherapy, U; University of Konstanz; University of Konstanz; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England","Sao Paulo State registered the first case of CoViD-19 on 26 February, the first death due to CoViD-19 on 16 March, and implemented the isolation of the population in non-essential activities on 24 March, which is programmed to end on 1 June. A mathematical model considering young (below 60 years old) and elder (above 60 years) subpopulations was formulated based on the natural history of CoViD-19 to study the transmission of the new coronavirus in Sao Paulo State, Brazil. This deterministic model used the data collected in Sao Paulo State to estimate the model parameters and to evaluate the effects of herd protection, that is, isolation and personal and collective protective measures. Based on the estimated parameters, we evaluated the scenarios of three releases divided in equal proportions elapsed by 14 days between releases, but beginning in three different times (the first release occurring on 1 and 23 June, and 6 July). We concluded that these three strategies of release are equivalent (little difference) in reducing the number of severe CoViD-19 if social behaviour does not change. However, if protective measures as using face mask and hygiene (washing hands, for instance) and social distancing could be massively disseminated in the population to decrease the transmission of CoViD-19 by 80%, we concluded that the health care system may not collapse with release.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.13.20100495,2020-05-19,https://medrxiv.org/cgi/content/short/2020.05.13.20100495,Risk factors for adverse clinical outcomes in patients with COVID-19: A systematic review and meta-analysis,Vanesa Bellou; Ioanna Tzoulaki; Evangelos Evangelou; Lazaros Belbasis; Richard Capstick; Gabriella Marchitelli; Ang Li; Andrew Barr; Alsafi Eid; Sajeel Ahmed; Dalvir Bajwa; Omer Mohammed; Neil Alderson; Clare Lendrem; Dennis Lendrem; COVID-19 Control Group; COVID-19 Clinical Group; Lucia Pareja-Cebrian; Andrew Welch; Joanne Field; Brendan A.I. Payne; Yusri Taha; David A. Price; Christopher Gibbins; Matthias L. Schmid; Ewan Hunter; Christopher J.A. Duncan; Kate Bailey; Richard Dillon; Matthew Streetly; Anna Rigg; Richard Sullivan; Saoirse Dolly; Mieke Van Hemelrijck; Jocelyn Dachary; Fabien Brulport; Adrian Gonzalez; Olivier Dehaene; Jean-Baptiste Schiratti; Kathryn Schutte; Jean-Christophe Pesquet; Hugues Talbot; Elodie Pronier; Gilles Wainrib; Thomas Clozel; Fabrice Barlesi; Marie-France Bellin; Michael G. B. Blum,"University of Ioannina Medical School; University of Ioannina Medical School; University of Ioannina Medical School; University of Ioannina Medical School; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; NIHR In Vitro Diagnostics Cooperative, Newcastle University, UK; National Institute of Health Research (NIHR) Biomedical Research Centre, Newcastle University, UK; ; ; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, UK; Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; Guy's and St. Thomas NHS Foundation Trust; King's College London; Guy's and St. Thomas NHS Foundation Trust; King's College London; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Centre de Vision Numrique, Universit Paris-Saclay, CentraleSuplec, Inria, 91190 Gif-sur-Yvette, France; Centre de Vision Numrique, Universit Paris-Saclay, CentraleSuplec, Inria, 91190 Gif-sur-Yvette, France; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Owkin Lab, Owkin, Inc. New York, NY USA; Dpartement d'Oncologie Mdicale, Gustave Roussy, Universit Paris-Saclay, Villejuif, F-94805, France; Radiology Department, Hpital de Bictre, AP-HP, Universit Paris Saclay, Le Kremlin-Bictre, France; Owkin Lab, Owkin, Inc. New York, NY USA","ImportanceCOVID-19 is a clinically heterogeneous disease of varying severity and prognosis. Clinical characteristics that impact disease course could offer guidance for clinical decision making and future research endeavors and unveil disease pathways.

ObjectiveTo examine risk factors associated with adverse clinical outcomes in patients with COVID-19.

Data sourcesWe performed a systematic review in PubMed from January 1 until April 19, 2020.

Study selectionObservational studies that examined the association of any clinical characteristic with an adverse clinical outcome were considered eligible. We scrutinized studies for potential overlap.

Data extraction and synthesisInformation on the effect of clinical factors on clinical endpoints of patients with COVID-19 was independently extracted by two researchers. When an effect size was not reported, crude odds ratios were calculated based on the available information from the eligible articles. Study-specific effect sizes from non-overlapping studies were synthesized applying the random-effects model.

Main outcome and measureThe examined outcomes were severity and progression of disease, admission to ICU, need for mechanical ventilation, mortality, or a composite outcome.

ResultsWe identified 88 eligible articles, and we performed a total of 256 meta-analyses on the association of 98 unique risk factors with five clinical outcomes. Seven meta-analyses presented the strongest epidemiological evidence in terms of statistical significance (P-value <0.005), between-study heterogeneity (I2 <50%), sample size (more than 1000 COVID-19 patients), 95% prediction interval excluded the null value, and absence of small-study effects. Elevated C-reactive protein (OR, 6.46; 95% CI, 4.85 - 8.60), decreased lymphocyte count (OR, 4.16; 95% CI, 3.17 - 5.45), cerebrovascular disease (OR, 2.84; 95% CI, 1.55 - 5.20), chronic obstructive pulmonary disease (OR, 4.44; 95% CI, 2.46 - 8.02), diabetes mellitus (OR, 2.04; 95% CI, 1.54 - 2.70), hemoptysis (OR, 7.03; 95% CI, 4.57 - 10.81), and male sex (OR, 1.51; 95% CI, 1.30 - 1.75) were associated with risk of severe COVID-19.

Conclusions and relevanceOur results highlight factors that could be useful for prognostic model building, help guide patients selection for randomized clinical trials, as well as provide alternative treatment targets by shedding light to disease pathophysiology.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.11.20098269,2020-05-18,https://medrxiv.org/cgi/content/short/2020.05.11.20098269,Accessibility and allocation of public parks and gardens during COVID-19 social distancing in England and Wales,Niloofar Shoari; Majid Ezzati; Jill Baumgartner; Diego Malacarne; Daniela Fecht; Varshini Vasudevaraja; Douglas Allison; Lawrence H. Lin; Tatyana Gindin; Michael Astudillo; Diane Yang; Mandakolathur Murali; A. John Iafrate; George Jour; Paolo Cotzia; Matija Snuderl,Imperial College London; Imperial College London; McGill University; Imperial College London; Imperial College London; NYU Langone Health; NYU Langone Health; NYU Langone Health; NYU Langone Health; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; NYU Langone Health; NYU Langone Health; NYU Langone Health,"Visiting parks and gardens may attenuate the adverse physical and mental health impacts of social distancing implemented to reduce the spread of COVID-19. We quantified access to public parks and gardens in urban areas of England and Wales, and the potential for park crowdedness during periods of high use. We combined data from the Office for National Statistics and Ordnance Survey to quantify (i) the number of parks within 500 and 1,000 metres of urban postcodes (i.e., availability), (ii) the distance of postcodes to the nearest park (i.e., accessibility), and (iii) per-capita space in each park for people living within 1,000m. We examined how these measures vary by city and share of homes that are flats. Around 25.4 million people can access public parks or gardens within a ten-minute walk, while 3.8 million residents live farther away; of these 21% are children and 13% are elderly. Areas with a higher share of flats on average are closer to a park but people living in these areas are potentially less able to meet social distancing requirements while in parks during periods of high use. Cities in England and Wales can provide residents with access to green space that enables outdoor exercise and play during social distancing. Cities aiming to facilitate social distancing while keeping public green spaces open might require implementing measures such as dedicated park times for different age groups or entry allocation systems that, combined with smartphone apps or drones, can monitor and manage the total number of people using the park.",public and global health,exact,100,100
medRxiv,10.1101/2020.05.08.20095687,2020-05-14,https://medrxiv.org/cgi/content/short/2020.05.08.20095687,Rapid implementation of real-time SARS-CoV-2 sequencing to investigate healthcare-associated COVID-19 infections,Luke W Meredith; William L Hamilton; Ben Warne; Charlotte J Houldcroft; Myra Hosmillo; Aminu Jahun; Martin D Curran; Surendra Parmar; Laura Caller; Sarah L Caddy; Fahad A Khokhar; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","BackgroundThe burden and impact of healthcare-associated COVID-19 infections is unknown. We aimed to examine the utility of rapid sequencing of SARS-CoV-2 combined with detailed epidemiological analysis to investigate healthcare-associated COVID-19 infections and to inform infection control measures.

MethodsWe set up rapid viral sequencing of SARS-CoV-2 from PCR-positive diagnostic samples using nanopore sequencing, enabling sample-to-sequence in less than 24 hours. We established a rapid review and reporting system with integration of genomic and epidemiological data to investigate suspected cases of healthcare-associated COVID-19.

ResultsBetween 13 March and 24 April 2020 we collected clinical data and samples from 5191 COVID-19 patients in the East of England. We sequenced 1000 samples, producing 747 complete viral genomes. We conducted combined epidemiological and genomic analysis of 299 patients at our hospital and identified 26 genomic clusters involving 114 patients. 66 cases (57.9%) had a strong epidemiological link and 15 cases (13.2%) had a plausible epidemiological link. These results were fed back to clinical, infection control and hospital management teams, resulting in infection control interventions and informing patient safety reporting.

ConclusionsWe established real-time genomic surveillance of SARS-CoV-2 in a UK hospital and demonstrated the benefit of combined genomic and epidemiological analysis for the investigation of healthcare-associated COVID-19 infections. This approach enabled us to detect cryptic transmission events and identify opportunities to target infection control interventions to reduce further healthcare-associated infections.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.11.20097964,2020-05-14,https://medrxiv.org/cgi/content/short/2020.05.11.20097964,Patterns of COVID-19 related excess mortality in the municipalities of Northern Italy,Dino Gibertoni; Kadjo Yves Cedric Adja; Davide Golinelli; Chiara Reno; Luca Regazzi; Maria Pia Fantini; Martin D Curran; Surendra Parmar; Laura Caller; Sarah L Caddy; Fahad A Khokhar; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Alma Mater Studiorum - University of Bologna; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","The Coronavirus Disease 2019 (COVID-19) spatial distribution in Italy is inhomogeneous, because of its ways of spreading from the initial hotspots. The impact of COVID-19 on mortality has been described at the regional level, while less is known about mortality in demographic subgroups within municipalities.

We aimed to describe the excess mortality (EM) due to COVID-19 in the three most affected Italian regions, by estimating EM in subgroups defined by gender and age classes within each municipality from February 23 to March 31, 2020.

EM varied widely among municipalities even within the same region; it was similar between genders for the [&ge;]75 age group, while in the other age groups it was higher in males. Thus, nearby municipalities may show a different mortality burden despite being under common regional health policies, possibly as a result of policies adopted both at the regional and at the municipality level.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.11.20098087,2020-05-14,https://medrxiv.org/cgi/content/short/2020.05.11.20098087,Monitoring and Tracking the Evolution of a Viral Epidemic Through Nonlinear Kalman Filtering: Application to the Covid-19 Case,Antonio Gomez-Exposito; Jose A. Rosendo-Macias; Miguel A. Gonzalez-Cagigal; Chiara Reno; Luca Regazzi; Maria Pia Fantini; Martin D Curran; Surendra Parmar; Laura Caller; Sarah L Caddy; Fahad A Khokhar; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"University of Seville; University of Seville; University of Seville; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Alma Mater Studiorum - University of Bologna; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","This work presents a novel methodology for systematically processing the time series that report the number of positive, recovered and deceased cases from a viral epidemic, such as Covid-19. The main objective is to unveil the evolution of the number of real infected people, and consequently to predict the peak of the epidemic and subsequent evolution. For this purpose, an original nonlinear model relating the raw data with the time-varying geometric ratio of infected people is elaborated, and a Kalman Filter is used to estimate the involved state variables. A hypothetical simulated case is used to show the adequacy and limitations of the proposed method. Then, several countries, including China, South Korea, Italy, Spain, UK and the USA, are tested to illustrate its behavior when real-life data are processed. The results obtained clearly show the beneficial effect of the social distancing measures adopted worldwide, confirming that the Covid-19 epidemic peak is left behind in those countries where the outbreak started earlier, and anticipating when the peak will take place in the remaining countries.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.11.20098145,2020-05-14,https://medrxiv.org/cgi/content/short/2020.05.11.20098145,Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico,Maria Fernanda Carrillo-Vega; Guillermo Salinas-Escudero; Carmen Garcia-Pea; Luis Miguel Gutierrez-Robledo; Lorena Parra-Rodriguez; Maria Pia Fantini; Martin D Curran; Surendra Parmar; Laura Caller; Sarah L Caddy; Fahad A Khokhar; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Instituto Nacional de Geriatria; Hospital Infantil de Mexico Federico Gomez; Instituto Nacional de Geriatria; Instituto Nacional de Geriatria; Instituto Nacional de Geriatria; Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","BackgroundWith its high prevalence of chronic non-degenerative diseases, it is suspected that in Mexico there is a high risk of fatal complications from COVID-19. The present study aims to estimate the risk factors for hospitalisation and death in the Mexican population infected by SARS-CoV-2.

Methods and FindingsWe used the publicly available data released by the Epidemiological Surveillance System for Viral Respiratory Diseases of the Mexican Ministry of Health (Secretaria de Salud, SS). All records of positive SARS-CoV-2 cases were included. Two multiple logistic regression models were fitted to estimate the association between the hospitalisation and mortality, with other covariables. Data on 10,544 individuals (57.68% men), with mean age 46.47{+/-}15.62, were analysed. Men were about 1.54 times as likely to be hospitalized than women (p<0.001, 95% C.I. 1.37-1.74); individuals aged 50-74 and [&ge;]74 years were more likely to be hospitalized than people from 25-49 years (OR 2.05, p<0.001, 95% C.I. 1.81-2.32, and OR 23.84, p<0.001, 95% C.I. 2.90-5.15, respectively). People with hypertension, obesity, and diabetes were more likely to be hospitalised than people without these morbidities (p<0.01). Men had more risk of death in comparison to women (OR=1.53, p<0.001, 95% C.I. 1.30-1.81) and individuals aged 50-74 and [&ge;]75 years were more likely to die than people from 25-49 years (OR 1.96, p<0.001, 95% C.I. 1.63-2.34, and OR 3.74, p<0.001, 95% C.I. 2.80-4.98, respectively). Hypertension, obesity, and diabetes presented in combination, provided a higher risk of dying in comparison to not having these diseases (OR=2.10; p<0.001, 95% C.I. 1.50-2.93). Hospitalisation, intubation and pneumonia conferred a higher risk of dying (OR 5.02, p<0.001, 95% C.I. 3.88-6.50; OR 4.27, p<0.001, 95% C.I. 3.26-5.59, and OR=2.57; p<0.001, 95% C.I. 2.11-3.13, respectively). The main limitation of our study is the lack of information on mild (asymptomatic) or moderate cases of COVID-19.

ConclusionsThe present study points out that in Mexico, where an important proportion of the population develops two or more chronic conditions simultaneously, high mortality is a sever outcome for those infected by SARS-CoV-2.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.05.13.092478,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.13.092478,Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota,Fabrizio Chiodo; Sven C.M Bruijns; Ernesto Rodriguez; R.J. Eveline Li; Antonio Molinaro; Alba Silipo; Flaviana Di Lorenzo; Dagmar Garcia-Rivera; Yury Valdes-Balbin; Vicente Verez-Bencomo; Yvette van Kooyk; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam UMC, Vrije Universiteit Amsterdam; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Finlay Vaccine Institute; Finlay Vaccine Institute; Finlay Vaccine Institute; Amsterdam UMC, Vrije Universiteit Amsterdam; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","The immediate call for translational research in the field of coronavirus disease (COVID-19) pandemic, needs new and unexplored angles to support and contribute to this important worldwide health problem. The aim of this study is to better understand the pathogenic mechanisms underlying COVID-19, deciphering the carbohydrate-mediated interactions of the SARS-CoV-2 spike protein. We studied the carbohydrate-binding receptors that could be important for viral entry and for immune-modulatory responses, and we studied the interactions of the spike protein with the host lung microbiota. Exploring solid-phase immunoassays, we evaluated the interactions between the SARS-CoV-2 spike protein and a library of 12 different human carbohydrate-binding proteins (C-type lectins and Siglecs) involved in binding, triggering and modulation of innate and adaptive immune-responses. We revealed a specific binding of the SARS-CoV-2 spike protein to the receptors DC-SIGN, MGL, Siglec-9 and Siglec-10 that are all expressed on myeloid immune cells. In addition, because the lung microbiota can promote or modulate viral infection, we studied the interactions between the SARS-CoV-2 spike protein and a library of Streptococcus pneumoniae capsular polysaccharides, as well as other bacterial glyco-conjugates. We show specific binding of the spike protein to different S. pneumoniae capsular polysaccharides (serotypes 19F and 23F but not to serotype 14). Moreover we demonstrated a specific binding of SARS-CoV-2 spike protein to the lipopolysaccharide from the opportunistic human pathogen Pseudomonas aeruginosa, one of the leading cause of acute nosocomial infections and pneumonia. Interestingly, we identified rhamnosylated epitopes as one of the discriminating structures in lung microbiota to bind SARS-CoV-2 spike protein. In conclusion, we revealed novel ACE2-independent carbohydrate-mediated interactions with immune modulating lectins expressed on myeloid cells, as well as host lung microbiota glyco-conjugates. Our results identified new molecular pathways using host lectins and signalling, that may contribute to viral infection and subsequent immune exacerbation. Moreover we identified specific rhamnosylated epitopes in lung microbiota to bind SARS-CoV-2, providing a hypothetical link between the presence of specific lung microbiota and SARS-CoV-2 infection and severity.",immunology,exact,100,100
bioRxiv,10.1101/2020.05.14.095661,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.14.095661,Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication,Kevin Klann; Denisa Bojkova; Georg Tascher; Sandra Ciesek; Christian Muench; Jindrich Cinatl; Flaviana Di Lorenzo; Dagmar Garcia-Rivera; Yury Valdes-Balbin; Vicente Verez-Bencomo; Yvette van Kooyk; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany; Institute of Medical Virology, University Hospital Frankfurt, Frankfurt am Main, Germany; Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany; Institute of Medical Virology, University Hospital Frankfurt, Frankfurt am Main, Germany; German Centre for Infection Research (DZIF), External partner site Fra; Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany; Frankfurt Cancer Institute, Frankfurt am Main, Germany; Cardio; Institute of Medical Virology, University Hospital Frankfurt, Frankfurt am Main, Germany; University of Naples Federico II; Finlay Vaccine Institute; Finlay Vaccine Institute; Finlay Vaccine Institute; Amsterdam UMC, Vrije Universiteit Amsterdam; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","SARS-CoV-2 infections are rapidly spreading around the globe. The rapid development of therapies is of major importance. However, our lack of understanding of the molecular processes and host cell signaling events underlying SARS-CoV-2 infection hinder therapy development. We employed a SARS-CoV-2 infection system in permissible human cells to study signaling changes by phospho-proteomics. We identified viral protein phosphorylation and defined phosphorylation-driven host cell signaling changes upon infection. Growth factor receptor (GFR) signaling and downstream pathways were activated. Drug-protein network analyses revealed GFR signaling as key pathway targetable by approved drugs. Inhibition of GFR downstream signaling by five compounds prevented SARS-CoV-2 replication in cells, assessed by cytopathic effect, viral dsRNA production, and viral RNA release into the supernatant. This study describes host cell signaling events upon SARS-CoV-2 infection and reveals GFR signaling as central pathway essential for SARS-CoV-2 replication. It provides with novel strategies for COVID-19 treatment.",systems biology,exact,100,100
bioRxiv,10.1101/2020.05.13.094839,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.13.094839,Patient DNA cross-reactivity of CDC SARS-nCoV2 extraction control leads to potential false negative results,Adam P Rosebrock; Denisa Bojkova; Georg Tascher; Sandra Ciesek; Christian Muench; Jindrich Cinatl; Flaviana Di Lorenzo; Dagmar Garcia-Rivera; Yury Valdes-Balbin; Vicente Verez-Bencomo; Yvette van Kooyk; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Stony Brook Medicine; Institute of Medical Virology, University Hospital Frankfurt, Frankfurt am Main, Germany; Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany; Institute of Medical Virology, University Hospital Frankfurt, Frankfurt am Main, Germany; German Centre for Infection Research (DZIF), External partner site Fra; Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany; Frankfurt Cancer Institute, Frankfurt am Main, Germany; Cardio; Institute of Medical Virology, University Hospital Frankfurt, Frankfurt am Main, Germany; University of Naples Federico II; Finlay Vaccine Institute; Finlay Vaccine Institute; Finlay Vaccine Institute; Amsterdam UMC, Vrije Universiteit Amsterdam; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","Testing for RNA viruses such as SARS-CoV-2 requires careful handling of inherently labile RNA during sample collection, clinical processing, and molecular analysis. Tests must include fail-safe controls that affirmatively report the presence of intact RNA and demonstrate success of all steps of the assay. A result of ""no virus signal"" is insufficient for clinical interpretation: controls must also say ""The reaction worked as intended and would have found virus if present."" Unfortunately, a widely used test specified by the US Centers for Disease Control and Prevention (CDC) incorporates a control that does not perform as intended and claimed. Detecting SARS-CoV-2 with this assay requires both intact RNA and successful reverse transcription. The CDC-specified control does not require either of these, due to its inability to differentiate human genomic DNA from reverse-transcribed RNA. Patient DNA is copurified from nasopharyngeal swabs during clinically-approved RNA extraction and is sufficient to return an ""extraction control success"" signal using the CDC design. As such, this assay fails-unsafe: truly positive patient samples return a false-negative result of ""no virus detected, control succeeded"" following any of several readily-encountered mishaps. This problem affects tens-of-millions of patients worth of shipped assays, but many of these flawed reagents have not yet been used. There is an opportunity to improve this important diagnostic tool. As demonstrated here, a re-designed transcript-specific control correctly monitors sample collection, extraction, reverse transcription, and qPCR detection. This approach can be rapidly implemented and will help reduce truly positive patients from being incorrectly given the all-clear.

One Sentence SummaryA widely-used COVID-19 diagnostic is mis-designed and generates false-negative results, dangerously confusing ""No"" with ""Dont know"" - but its fixable",molecular biology,exact,100,100
bioRxiv,10.1101/2020.05.13.093088,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.13.093088,Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody,Wei Li; Aleksandra Drelich; David R Martinez; Lisa E Gralinski; Chuan Chen; Zehua Sun; Alexandra Schfer; Sarah R Leist; Xianglei Liu; Doncho V Zhelev; Liyong Zhang; Eric L Peterson; Alex Conard; John W Mellors; Chien-Te Tseng; Ralph S Baric; Dimiter S Dimitrov; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"University of Pittsburgh; University of Texas Medical Branch at Galveston; University of North Carolina; Universitty of North Carolina; University of Pittsburgh; University of Pittsburgh; University of North Carolina at Chapel Hill; University of North Carolina; University of Pittsburgh; University of Pittsburgh; University of Pittsburgh; Abound Bio; Abound Bio; University of Pittsburgh; University of Texas Medical Branch at Galveston; University of North Carolina at Chapel Hill; University of Pittsburgh; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We identified panels of fully human monoclonal antibodies (mAbs) from eight large phage-displayed Fab, scFv and VH libraries by panning against the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. One high affinity mAb, IgG1 ab1, specifically neutralized replication competent SARS-CoV-2 with exceptional potency as measured by two different assays. There was no enhancement of pseudovirus infection in cells expressing Fc{gamma} receptors at any concentration. It competed with human angiotensin-converting enzyme 2 (hACE2) for binding to RBD suggesting a competitive mechanism of virus neutralization. IgG1 ab1 potently neutralized mouse ACE2 adapted SARS-CoV-2 in wild type BALB/c mice and native virus in hACE2 expressing transgenic mice. The ab1 sequence has relatively low number of somatic mutations indicating that ab1-like antibodies could be quickly elicited during natural SARS-CoV-2 infection or by RBD-based vaccines. IgG1 ab1 does not have developability liabilities, and thus has potential for therapy and prophylaxis of SARS-CoV-2 infections. The rapid identification (within 6 days) of potent mAbs shows the value of large antibody libraries for response to public health threats from emerging microbes.",microbiology,exact,100,100
bioRxiv,10.1101/2020.05.13.092536,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.13.092536,Network Analysis and Transcriptome Profiling Identify Autophagic and Mitochondrial Dysfunctions in SARS-CoV-2 Infection,Komudi Singh; Yun-Ching Chen; Jennifer T. Judy; Fayaz Seifuddin; Ilker Tunc; Mehdi Pirooznia; Alexandra Schfer; Sarah R Leist; Xianglei Liu; Doncho V Zhelev; Liyong Zhang; Eric L Peterson; Alex Conard; John W Mellors; Chien-Te Tseng; Ralph S Baric; Dimiter S Dimitrov; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; University of North Carolina at Chapel Hill; University of North Carolina; University of Pittsburgh; University of Pittsburgh; University of Pittsburgh; Abound Bio; Abound Bio; University of Pittsburgh; University of Texas Medical Branch at Galveston; University of North Carolina at Chapel Hill; University of Pittsburgh; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","Analyzing host transcriptional changes in response to SARS-CoV-2 infection will help delineate biological processes underlying viral pathogenesis. Comparison of expression profiles of lung cell lines A549 (infected with either SARS-CoV-2 (with ACE2 expression)) or Influenza A virus (IAV)) and Calu3 (infected with SARS-CoV-2 or MERS-CoV) revealed upregulation of the antiviral interferon signaling in all three viral infections. However, perturbations in inflammatory, mitochondrial, and autophagy processes were specifically observed in SARS-CoV-2 infected cells. Validation of findings from cell line data revealed perturbations in autophagy and mitochondrial processes in the infected human nasopharyngeal samples. Specifically, downregulation of mTOR expression, mitochondrial ribosomal, mitochondrial complex I, and lysosome acidification genes were concurrently observed in both infected cell lines and human datasets. Furthermore, SARS-CoV-2 infection impedes autophagic flux by upregulating GSK3B in lung cell lines, or by downregulating autophagy genes, SNAP29 and lysosome acidification genes in human samples, contributing to increased viral replication. Therefore, drugs targeting lysosome acidification or autophagic flux could be tested as intervention strategies. Additionally, downregulation of MTFP1 (in cell lines) or SOCS6 (in human samples) results in hyperfused mitochondria and impede proper interferon response. Coexpression networks analysis identifies correlated clusters of genes annotated to inflammation and mitochondrial processes that are misregulated in SARS-CoV-2 infected cells. Finally, comparison of age stratified human gene expression data revealed impaired upregulation of chemokines, interferon stimulated and tripartite motif genes that are critical for antiviral signaling. Together, this analysis has revealed specific aspects of autophagic and mitochondrial function that are uniquely perturbed in SARS-CoV-2 infection.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.05.14.056085,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.14.056085,Evolutionary Dynamics And Geographic Dispersal Of Beta Coronaviruses In African Bats,Babatunde Olanrewaju Motayo; Olukune Oluwapamilerin Oluwasemowo; Paul Akiniyi Akinduti; Fayaz Seifuddin; Ilker Tunc; Mehdi Pirooznia; Alexandra Schfer; Sarah R Leist; Xianglei Liu; Doncho V Zhelev; Liyong Zhang; Eric L Peterson; Alex Conard; John W Mellors; Chien-Te Tseng; Ralph S Baric; Dimiter S Dimitrov; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Federal Medical Center, Abeokuta; Dept of Virology, College of Medicine, University of Ibadan, Nigeria; Covenant University; National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; National Heart Lung and Blood Institute, National Institutes of Health; University of North Carolina at Chapel Hill; University of North Carolina; University of Pittsburgh; University of Pittsburgh; University of Pittsburgh; Abound Bio; Abound Bio; University of Pittsburgh; University of Texas Medical Branch at Galveston; University of North Carolina at Chapel Hill; University of Pittsburgh; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","Bats have been shown to serve as reservoir host of various viral agents including coronaviruses. They have also been associated with the novel coronavirus SARS-CoV-2. This has made them an all important agent for CoV evolution and transmission. Our objective in this study was to investigate the dispersal, phylogenomics and evolution of betacoronavirus ({beta}CoV) among African bats. We retrieved sequence data from established databases such as GenBank and Virus Pathogen Resource, covering the partial RNA dependent RNA polymerase (RdRP) gene of Bat coronaviruses from eight African, three Asian, five European, two South American countries and Australia. We analyzed for Phylogeographic information relating to genetic diversity and evolutionary dynamics. Our study revealed that majority of the African strains fell within Norbecovirus subgenera, with an Evolutionary rate of 1.301 x 10-3, HPD (1.064 x 10-3 - 1.434 x 10-3) subs/site/year. The African strains diversified into three main subgenera, Norbecovirus, Hibecovirus and Marbecovirus. The time to most common recent ancestor for Norbecovirus strains was 1968, and 2010, for the African Marbecovirus strains. There was evidence of inter species transmission of Norbecovirus among bats in Cameroun and DRC. Phlylogeography showed that there were inter-continental spread of Bt-CoV from Europe, China and Hong Kong into Central and Southern Africa, highlighting the possibility of long distance transmission. Our study has elucidated the possible evolutionary origins of {beta}CoV among African bats, we therefore advocate for broader studies of whole genome sequences of BtCoV to further understand the drivers for their emergence and zoonotic spillovers into human population.",microbiology,exact,100,100
bioRxiv,10.1101/2020.05.13.094714,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.13.094714,ACE2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors,Zofia Wicik; Ceren Eyileten; Daniel Jakubik; Sergio N Simoes; David C Martins Jr.; Rodrigo Pavao; Jolanta M Siller-Matula; Marek Postula; Xianglei Liu; Doncho V Zhelev; Liyong Zhang; Eric L Peterson; Alex Conard; John W Mellors; Chien-Te Tseng; Ralph S Baric; Dimiter S Dimitrov; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"Centro de Matematica, Computacao e Cognicao, Universidade Federal do ABC, Sao Paulo, Brazil; Department of Experimental and Clinical Pharmacology, Medical Unive; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland; Federal Institute of Education, Science and Technology of Espirito Santo, Serra, ES, Brazil; Centro de Matematica, Computacao e Cognicao, Universidade Federal do ABC, Sao Paulo, Brazil; Centro de Matematica, Computacao e Cognicao, Universidade Federal do ABC, Sao Paulo, Brazil; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, CEPT, Warsaw, Poland; Department of Internal Medicine II, Division of Cardio; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland; University of Pittsburgh; University of Pittsburgh; University of Pittsburgh; Abound Bio; Abound Bio; University of Pittsburgh; University of Texas Medical Branch at Galveston; University of North Carolina at Chapel Hill; University of Pittsburgh; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","(1) BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) is associated with adverse outcomes in patients with cardiovascular disease (CVD). The aim of the study was to characterize the interaction between SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2) functional networks with a focus on CVD.;

(2) MethodsUsing the network medicine approach and publicly available datasets, we investigated ACE2 tissue expression and described ACE2 interaction networks which could be affected by SARS-CoV-2 infection in the heart, lungs and nervous system. We compared them with changes in ACE-2 networks following SARS-CoV-2 infection by analyzing public data of stem cell-derived cardiomyocytes (hiPSC-CMs). This analysis was performed using the NERI algorithm, which integrates protein-protein interaction with co-expression networks. We also performed miRNA-target predictions to identify which ones regulate ACE2-related networks and could play a role in the COVID19 outcome. Finally, we performed enrichment analysis for identifying the main COVID-19 risk groups.

(3) ResultsWe found similar ACE2 expression confidence levels in respiratory and cardiovascular systems, supporting that heart tissue is a potential target of SARS-CoV-2. Analysis of ACE2 interaction networks in infected hiPSC-CMs identified multiple hub genes with corrupted signalling which can be responsible for cardiovascular symptoms. The most affected genes were EGFR, FN1, TP53, HSP90AA1, and APP, while the most affected interactions were associated with MAST2 and CALM1. Enrichment analysis revealed multiple diseases associated with the interaction networks of ACE2, especially cancerous diseases, obesity, hypertensive disease, Alzheimers disease, non-insulin-dependent diabetes mellitus, and congestive heart failure. Among affected ACE2-network components connected with SARS-Cov-2 interactome, we identified AGT, CAT, DPP4, CCL2, TFRC and CAV1, associated with cardiovascular risk factors. We described for the first time miRNAs which were common regulators of ACE2 networks and virus-related proteins in all analyzed datasets. The top miRNAs were miR-27a-3p, miR-26b-5p, miR-10b-5p, miR-302c-5p, hsa-miR-587, hsa-miR-1305, hsa-miR-200b-3p, hsa-miR-124-3p, and hsa-miR-16-5p.;

(4) ConclusionOur study provides a complete mechanistic framework for investigating the ACE2 network which was validated by expression data. This framework predicted risk groups, including the established ones, thus providing reliable novel information regarding the complexity of signalling pathways affected by SARS-CoV-2. It also identified miR which could be used in personalized diagnosis in COVID-19.",genomics,exact,100,100
bioRxiv,10.1101/2020.05.14.093583,2020-05-14,https://biorxiv.org/cgi/content/short/2020.05.14.093583,Exosomes Facilitate Transmission of SARS-CoV-2 Genome into Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes,Youjeong Kwon; Sarath Babu Nukala; Shubhi Srivastava; Hiroe Miyamoto; Nur Izzah Ismail; Jalees Rehman; Sang-Bing Ong; Won Hee Lee; Sang-Ging Ong; Doncho V Zhelev; Liyong Zhang; Eric L Peterson; Alex Conard; John W Mellors; Chien-Te Tseng; Ralph S Baric; Dimiter S Dimitrov; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis,"University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; University of Illinois at Chicago; Chinese University of Hong Kong (CUHK), Hong Kong SAR; University of Illinois at Chicago; Chinese University of Hong Kong (CUHK), Hong Kong SAR; University of Arizona College of Medicine - Phoenix; University of Illinois at Chicago; University of Pittsburgh; University of Pittsburgh; Abound Bio; Abound Bio; University of Pittsburgh; University of Texas Medical Branch at Galveston; University of North Carolina at Chapel Hill; University of Pittsburgh; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Departments of Microbiology and Immunology, The Univers; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Adimab LLC, Lebanon, NH 03766, USA; UCL Great Ormond Street Hospital Centre for Rheumatology Research; UCL Great Ormond Street Institute for Child Health; Division of Medicine, UCL; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Division of Infection and Immunity, University College London; Francis Crick Institute; University College London Hospitals NHS Trust; Department of Population, Policy and Practice, Great Ormond Street Institute for Child Health, University College; Francis Crick Institute; Department of Medicine, Imperial College London","ABSTRACTThe novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a worldwide pandemic. Early data suggest that the prevalence and severity of COVID-19 appear to be higher among patients with underlying cardiovascular risk factors. Despite the expression of angiotensin-converting enzyme 2 (ACE2), a functional receptor for SARS-CoV-2 infection, in cardiomyocytes, there has been no conclusive evidence of direct viral infection although the presence of inflammation and viral genome within the hearts of COVID-19 patients have been reported. Here we transduced A549 lung epithelial cells with lentivirus overexpressing selected genes of the SARS-CoV-2. We then isolated extracellular vesicles (EVs) from the supernatant of A549 cells and detected the presence of viral RNA within the purified EVs. Importantly, we observed that human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were able to actively uptake these EVs and viral genes were subsequently detected in the cardiomyocytes. Accordingly, uptake of EVs containing viral genes led to an upregulation of inflammation-related genes in hiPSC-CMs. Thus, our findings indicate that SARS-CoV-2 RNA-containing EVs represent an indirect route of viral RNA entry into cardiomyocytes.Competing Interest StatementThe authors have declared no competing interest.View Full Text",cell biology,exact,100,100
bioRxiv,10.1101/2020.05.11.089409,2020-05-13,https://biorxiv.org/cgi/content/short/2020.05.11.089409,An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets,Daniel Ward; Matthew Higgins; Jody Phelan; Martin L. Hibberd; Susana Campino; Taane G Clark; Jordan Van Wyk; Timothy Grant Evans; Chad Wiggins; John RA Shepherd; Robert Rea; Emily Whelan; Andrew Clayburn; Matthew Spiegel; Patrick Johnson; Elizabeth Lesser; Sarah Baker; Kathryn Larson; Juan Ripoll Sanz; Kylie Andersen; David Hodge; Katie Kunze; Matthew Buras; Matthew Vogt; Vitaly Herasevich; Joshua Dennis; Riley Regimbal; Philippe Bauer; Janis Blair; Camille van Buskirk; Jeffrey Winters; James Stubbs; Nigel Paneth; Arturo Casadevall,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Waterloo; McGill University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Michigan State University; Johns Hopkins University,"BackgroundThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has a major global health and socio-economic burden. It has instigated the mobilisation of resources into the development of control tools, such as diagnostics and vaccines. The poor performance of some diagnostic serological tools has emphasised the need for up to date immune-informatic analyses to inform the selection of viable targets for further study. This requires the integration and analysis of genetic and immunological data for SARS-CoV-2 and its homology with other human coronavirus species to understand cross-reactivity.

MethodsWe have developed an online ""immuno-analytics"" resource to facilitate SARS-CoV-2 research, combining an extensive B/T-cell epitope mapping and prediction meta-analysis, and human CoV sequence homology mapping and protein database annotation, with an updated variant database and geospatial tracking for >7,800 non-synonymous mutation positions derived from >150,000 whole genome sequences. To demonstrate its utility, we present an integrated analysis of SARS-CoV-2 spike and nucleocapsid proteins, both being vaccine and serological diagnostic targets, including an analysis of changes in relevant mutation frequencies over time.

ResultsOur analysis reveals that the nucleocapsid protein in its native form appears to be a sub-optimal target for use in serological diagnostic platforms. The most frequent mutations were the spike protein D614G and nsp12 L314P, which were common (>86%) across all the geographical regions. Some mutations in the spike protein (e.g. A222V and L18F) have increased in frequency in Europe during the latter half of 2020, detected using our automated algorithms. The tool also suggests that orf3a proteins may be a suitable alternative target for diagnostic serologic assays in a post-vaccine surveillance setting.

ConclusionsThe immuno-analytics tool can be accessed online (http://genomics.lshtm.ac.uk/immuno) and will serve as a useful resource for biological discovery and surveillance in the fight against SARS-CoV-2. Further, the tool may be adapted to inform on biological targets in future outbreaks, including potential emerging human coronaviruses that spill over from animal hosts.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.05.08.20094474,2020-05-12,https://medrxiv.org/cgi/content/short/2020.05.08.20094474,"The Association of Social Distancing, Population Density, and Temperature with the SARS-CoV-2 Instantaneous Reproduction Number in Counties Across the United States",David Rubin; Jing Huang; Brian T Fisher; Antonio Gasparrini; Vicky Tam; Lihai Song; Xi Wang; Jason Kaufman; Kate Fitzpatrick; Arushi Jain; Heather Griffis; Koby Crammer; Gregory Tasian; Didier RAOULT; Michel Drancourt; Kirsten Verheul; Niels van der Velde; Alex van der Kooi; Jelle van Schooten; Marielle van Breemen; Tom Bijl; Kwinten Sliepen; Aafke Aartse; Ronald Derking; Ilja Bontjer; Neeltje Kootstra; Joost Wiersinga; Gestur Vidarsson; Bart Haagmans; Andrew Ward; Godelieve de Bree; Rogier Sanders; Marit van Gils,"Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania; Perelman School of Medicine at the University of Pennsylvania; London School of Hygiene and Tropical Medicine; Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania; Children's Hospital of Philadelphia; CHOP; Children's Hospital of Philadelphia; The Technion, Haifa, Israel; The Children's Hospital of Philadelphia; IHU; Aix Marseille Universite-IHU Mediterranee Infection; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Sanquin Research; Erasmus Medical Center; Scripps Research; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC","ImportanceThe Covid-19 pandemic has been marked by considerable heterogeneity in outbreaks across the United States. Local factors that may be associated with variation in SARS-CoV-2 transmission have not been well studied.

ObjectiveTo examine the association of county-level factors with variation in the SARS-CoV-2 reproduction number over time.

DesignObservational study

Setting211 counties in 46 states and the District of Columbia between February 25, 2020 and April 23, 2020.

ParticipantsResidents within the counties (55% of the US population)

ExposuresSocial distancing as measured by percent change in visits to non-essential businesses, population density, lagged daily wet bulb temperatures.

Main Outcomes and MeasuresThe instantaneous reproduction number (Rt) which is the estimated number of cases generated by one case at a given time during the pandemic.

ResultsMedian case incidence was 1185 cases and fatality rate was 43.7 deaths per 100,000 people for the top decile of 21 counties, nearly ten times the incidence and fatality rate in the lowest density quartile. Average Rt in the first two weeks was 5.7 (SD 2.5) in the top decile, compared to 3.1 (SD 1.2) in the lowest quartile. In multivariable analysis, a 50% decrease in visits to non-essential businesses was associated with a 57% decrease in Rt (95% confidence interval, 56% to 58%). Cumulative temperature effects over 4 to 10 days prior to case incidence were nonlinear; relative Rt decreased as temperatures warmed above 32{degrees}F to 53{degrees}F, which was the point of minimum Rt, then increased between 53{degrees}F and 66{degrees}F, at which point Rt began to decrease. At 55{degrees}F, and with a 70% reduction in visits to non-essential business, 96% of counties were estimated to fall below a threshold Rt of 1.0, including 86% of counties among the top density decile and 98% of counties in the lowest density quartile.

Conclusions and RelevanceSocial distancing, lower population density, and temperate weather change were associated with a decreased SARS-Co-V-2 Rt in counties across the United States. These relationships can inform selective public policy planning in communities during the SARS-CoV-2 pandemic.

Key PointsO_ST_ABSQuestionC_ST_ABSHow is the instantaneous reproduction number (Rt) of SARS-CoV-2 influenced by local area effects of social distancing, wet bulb temperature, and population density in counties across the United States?

FindingsSocial distancing, temperate weather, and lower population density were associated with a decrease in Rt. Of these county-specific factors, social distancing appeared to be the most significant in reducing SARS-CoV-2 transmission.

MeaningRt varies significantly across counties. The relationship between Rt and county-specific factors can inform policies to reduce SARS-CoV-2 transmission in selective and heterogeneous communities.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.07.20094789,2020-05-12,https://medrxiv.org/cgi/content/short/2020.05.07.20094789,Quantitative COVID-19 infectiousness estimate correlating with viral shedding and culturability suggests 68% pre-symptomatic transmissions,Meher K Prakash; Jing Huang; Brian T Fisher; Antonio Gasparrini; Vicky Tam; Lihai Song; Xi Wang; Jason Kaufman; Kate Fitzpatrick; Arushi Jain; Heather Griffis; Koby Crammer; Gregory Tasian; Didier RAOULT; Michel Drancourt; Kirsten Verheul; Niels van der Velde; Alex van der Kooi; Jelle van Schooten; Marielle van Breemen; Tom Bijl; Kwinten Sliepen; Aafke Aartse; Ronald Derking; Ilja Bontjer; Neeltje Kootstra; Joost Wiersinga; Gestur Vidarsson; Bart Haagmans; Andrew Ward; Godelieve de Bree; Rogier Sanders; Marit van Gils,"Jawaharlal Nehru Centre for Advanced Scientific Research; Perelman School of Medicine at the University of Pennsylvania; Perelman School of Medicine at the University of Pennsylvania; London School of Hygiene and Tropical Medicine; Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania; Children's Hospital of Philadelphia; CHOP; Children's Hospital of Philadelphia; The Technion, Haifa, Israel; The Children's Hospital of Philadelphia; IHU; Aix Marseille Universite-IHU Mediterranee Infection; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC; Sanquin Research; Erasmus Medical Center; Scripps Research; Amsterdam UMC; Amsterdam UMC; Amsterdam UMC","A person clinically diagnosed with COVID 19 can infect others for several days before and after the onset of symptoms. At the epidemiological level, this information on how infectious someone is lies embedded implicitly in the serial interval data. Other clinical indicators of infectiousness based on the temporal kinetics of the viral shedding from the nasopharyngeal swabs and sputum show the former decaying weeks sooner than the latter. In this work, we attempt to provide a better quantitative estimate for the temporal infectiousness profile using serial interval data from a combined 1251 individuals reported in the literature. We show that the infectiousness profile which we calculate correlates well with the viral shedding kinetics from nasopharyngeal swabs ({rho}=0.97, p=0.00) and culturability ({rho}=0.83, p=0.01). The profile suggests that a 68.4% (95% CI: 67.0-69.7%) of the infections are caused by infections before the symptoms appear, which is a much stronger pre-symptomatic influence than what was predicted in the literature 44% (95% CI: 25-69%) using serial data from 77 individuals.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.05.20092296,2020-05-09,https://medrxiv.org/cgi/content/short/2020.05.05.20092296,Ethnicity and risk of death in patients hospitalised for COVID-19 infection: an observational cohort study in an urban catchment area,Elizabeth Sapey; Suzy Gallier; Chris Mainey; Peter Nightingale; David McNulty; Hannah Crothers; Felicity Evison; Katharine Reeves; Domenico Pagano; Alastair K Denniston; Krishnarajah Nirantharakumar; Peter Diggle; Simon Ball; Alvaro Nagib Atallah,University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS FoundationTrust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University of Lancaster; University Hospitals Birmingham NHS Foundation Trust; Universidade Federal de Sao Paulo/Cochrane Brazil,"ObjectivesTo determine if specific ethnic groups are at higher risk of mortality from COVID19 infection.

DesignRetrospective cohort study

SettingUniversity Hospitals Birmingham NHS Foundation Trust (UHB) in Birmingham, UK

ParticipantsPatients with confirmed SARS-CoV-2 infection requiring admission to UHB between 10th March 2020 and 17th April 2020

ExposureEthnicity

Main outcome measuresStandardised Admission Ratio (SAR) and Standardised Mortality Ratio (SMR) for each ethnicity was calculated using observed sex-specific age distributions of COVID-19 admissions/deaths and 2011 census data for Birmingham/Solihull. Hazard Ratio (aHR) for mortality was estimated for each ethnic group with white population as reference group, using Cox proportional hazards model adjusting for age, sex, social deprivation and co-morbidities, and propensity score matching.

Results2217 patients admitted to UHB with a proven diagnosis of COVID-19 were included. 58.2% were male, 69.5% White and the majority (80.2%) had co-morbidities. 18.5% were of South Asian ethnicity, and these patients were more likely to be younger (median age 61 years vs.77 years), have no co-morbidities (27.8% vs. 16.6%) but a higher prevalence of diabetes mellitus (48.0% vs 28.2%) than White patients. SAR and SMR suggested more admissions and deaths in South Asian patients than would be predicted. South Asian patients were also more likely to present with severe disease despite no delay in presentation since symptom onset. South Asian ethnicity was associated with an increased risk of death; both by Cox regression (Hazard Ratio 1.66 (95%CI 1.32 - 2.10)) after adjusting for age, sex, deprivation and comorbidities and by propensity score matching, (Hazard ratio 1.68 (1.33-2.13), using the same factors but categorising ethnicity into South Asian or not.

ConclusionsCurrent evidence suggests those of South Asian ethnicity may be at risk of worse COVID-19 outcomes, further studies need to establish the underlying mechanistic pathways.

Research in contextO_ST_ABSEvidence beforeC_ST_ABSPublished studies of the evolving COVID-19 pandemic have suggested risk factors for the most severe manifestations of the disease, including increasing age, male sex and co-morbidities, especially hypertension, cardiovascular disease and diabetes. There have been observations suggesting poorer outcomes for patients of some ethnicities, and understanding this has become a global priority.

Added valueAlthough still an emerging picture, initial data from our multi-ethnic cohort suggests there are more admissions from South Asian patients than would be expected based on our population, these patients are admitted with a worse severity of COVID19 related respiratory compromise without a significant delay in presentation and experience a higher level of mortality even when differences in age, sex, deprivation and key comorbidities were taken into account. This was consistently shown using different statistical methods.

ImplicationsSouth Asian ethnicity may form another  at risk population from COVID-19. However, further studies are needed to better understand the underlying reasons, in particular any modifiable factors to improve outcomes as well as to refine our understanding and communication around non-modifiable risk factors.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.06.20092999,2020-05-07,https://medrxiv.org/cgi/content/short/2020.05.06.20092999,OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.,- The OpenSAFELY Collaborative; Elizabeth Williamson; Alex J Walker; Krishnan J Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I Mcdonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard T Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen Evans; Liam Smeeth; Ben Goldacre,; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ICNARC; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundEstablishing who is at risk from a novel rapidly arising cause of death, and why, requires a new approach to epidemiological research with very large datasets and timely data. Working on behalf of NHS England we therefore set out to deliver a secure and pseudonymised analytics platform inside the data centre of a major primary care electronic health records vendor establishing coverage across detailed primary care records for a substantial proportion of all patients in England. The following results are preliminary.

Data sourcesPrimary care electronic health records managed by the electronic health record vendor TPP, pseudonymously linked to patient-level data from the COVID-19 Patient Notification System (CPNS) for death of hospital inpatients with confirmed COVID-19, using the new OpenSAFELY platform.

Population17,425,445 adults.

Time period1st Feb 2020 to 25th April 2020.

Primary outcomeDeath in hospital among people with confirmed COVID-19.

MethodsCohort study analysed by Cox-regression to generate hazard ratios: age and sex adjusted, and multiply adjusted for co-variates selected prospectively on the basis of clinical interest and prior findings.

ResultsThere were 5683 deaths attributed to COVID-19. In summary after full adjustment, death from COVID-19 was strongly associated with: being male (hazard ratio 1.99, 95%CI 1.88-2.10); older age and deprivation (both with a strong gradient); uncontrolled diabetes (HR 2.36 95% CI 2.18-2.56); severe asthma (HR 1.25 CI 1.08-1.44); and various other prior medical conditions. Compared to people with ethnicity recorded as white, black people were at higher risk of death, with only partial attenuation in hazard ratios from the fully adjusted model (age-sex adjusted HR 2.17 95% CI 1.84-2.57; fully adjusted HR 1.71 95% CI 1.44-2.02); with similar findings for Asian people (age-sex adjusted HR 1.95 95% CI 1.73-2.18; fully adjusted HR 1.62 95% CI 1.431.82).

ConclusionsWe have quantified a range of clinical risk factors for death from COVID-19, some of which were not previously well characterised, in the largest cohort study conducted by any country to date. People from Asian and black groups are at markedly increased risk of in-hospital death from COVID-19, and contrary to some prior speculation this is only partially attributable to pre-existing clinical risk factors or deprivation; further research into the drivers of this association is therefore urgently required. Deprivation is also a major risk factor with, again, little of the excess risk explained by co-morbidity or other risk factors. The findings for clinical risk factors are concordant with policies in the UK for protecting those at highest risk. Our OpenSAFELY platform is rapidly adding further NHS patients records; we will update and extend these results regularly.",epidemiology,exact,100,100
medRxiv,10.1101/2020.05.01.20053413,2020-05-07,https://medrxiv.org/cgi/content/short/2020.05.01.20053413,Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study,Guangyao Wu; Pei Yang; Henry C. Woodruff; Xiangang Rao; Julien Guiot; Anne-Noelle Frix; Michel Moutschen; Renaud Louis; Jiawei Li; Jing Li; Chenggong Yan; Dan Du; Shengchao Zhao; Yi Ding; Bin Liu; Wenwu Sun; Fabrizio Albarello; Vincenzo Schinina; Emanuele Nicastri; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"Maastricht university; The Central Hospital of Wuhan; Maastricht University; The Central Hospital of Huangshi; CHU of Liege; CHU of Liege; CHU of Liege; CHU of Liege; China Resources Wuhan Iron and Steel Hospital; The Central Hospital of Shaoyang; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; The Central Hospital of Wuhan; The Central Hospital of Wuhan; The Central Hospital of Wuhan; IRCCS, Lazzaro Spallanzani, Via Portuense; IRCCS, Lazzaro Spallanzani, Via Portuense; IRCCS, Lazzaro Spallanzani, Via Portuense; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Key pointsO_ST_ABSQuestionC_ST_ABSHow do nomograms and machine-learning algorithms of severity risk prediction and triage of COVID-19 patients at hospital admission perform?

FindingsThis model was prospectively validated on six test datasets comprising of 426 patients and yielded AUCs ranging from 0.816 to 0.976, accuracies ranging from 70.8% to 93.8%, sensitivities ranging from 83.7% to 100%, and specificities ranging from 41.0% to 95.7%. The cut-off probability values for low, medium, and high-risk groups were 0.072 and 0.244.

MeaningThe findings of this study suggest that our models performs well for the diagnosis and prediction of progression to severe or critical illness of COVID-19 patients and could be used for triage of COVID-19 patients at hospital admission.

IMPORTANCEThe outbreak of the coronavirus disease 2019 (COVID-19) has globally strained medical resources and caused significant mortality for severely and critically ill patients. However, the availability of validated nomograms and the machine-learning model to predict severity risk and triage of affected patients is limited.

OBJECTIVETo develop and validate nomograms and machine-learning models for severity risk assessment and triage for COVID-19 patients at hospital admission.

DESIGN, SETTING, AND PARTICIPANTSA retrospective cohort of 299 consecutively hospitalized COVID-19 patients at The Central Hospital of Wuhan, China, from December 23, 2019, to February 13, 2020, was used to train and validate the models. Six cohorts with 426 patients from eight centers in China, Italy, and Belgium, from February 20, 2020, to March 21, 2020, were used to prospectively validate the models.

MAIN OUTCOME AND MEASURESThe main outcome was the onset of severe or critical illness during hospitalization. Model performances were quantified using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.

RESULTSOf the 299 hospitalized COVID-19 patients in the retrospective cohort, the median age was 50 years ((interquartile range, 35.5-63.0; range, 20-94 years) and 137 (45.8%) were men. Of the 426 hospitalized COVID-19 patients in the prospective cohorts, the median age was 62.0 years ((interquartile range, 50.0-72.0; range, 19-94 years) and 236 (55.4%) were men. The model was prospectively validated on six cohorts yielding AUCs ranging from 0.816 to 0.976, with accuracies ranging from 70.8% to 93.8%, sensitivities ranging from 83.7% to 100%, and specificities ranging from 41.0% to 95.7%. The cut-off values of the low, medium, and high-risk probabilities were 0.072 and 0.244. The developed online calculators can be found at https://covid19risk.ai/.

CONCLUSION AND RELEVANCEThe machine learning models, nomograms, and online calculators might be useful for the prediction of onset of severe and critical illness among COVID-19 patients and triage at hospital admission. Further prospective research and clinical feedback are necessary to evaluate the clinical usefulness of this model and to determine whether these models can help optimize medical resources and reduce mortality rates compared with current clinical practices.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.01.20087239,2020-05-07,https://medrxiv.org/cgi/content/short/2020.05.01.20087239,Immune alterations during SARS-CoV-2-related acute respiratory distress syndrome,Lila Bouadma; Aurelie Wiedemann; Juliette Patrier; Mathieu Surenaud; Paul-Henri Wicky; Emile Foucat; Jean-Luc Diehl; Boris P Hejblum; Fabrice Sinnah; Etienne de Montmollin; Christine Lacabaratz; Rodolphe Thiebaut; Jean-Francois Timsit; Yves Levy; Bin Liu; Wenwu Sun; Fabrizio Albarello; Vincenzo Schinina; Emanuele Nicastri; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"APHP-Hopital Bichat; Vaccine research Institute; APHP-Hopital Bichat; Vaccine Research Institute; APHP-Hopital Bichat; VAccine Research Institute; APHP-Hopital Georges Pompidou; Univ Bordeaux; APHP-Hopital Bichat; APHP-Hopital Bichat; Vaccine Research Insitute; Univ Bordeaux; APHP-Hopital Bichat; VAccine Research Institute; The Central Hospital of Wuhan; The Central Hospital of Wuhan; IRCCS, Lazzaro Spallanzani, Via Portuense; IRCCS, Lazzaro Spallanzani, Via Portuense; IRCCS, Lazzaro Spallanzani, Via Portuense; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2-3 fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-secreting cells, a 15-fold increase in {gamma}{delta} T-cell and proliferating NK-cell populations, and the total disappearance of monocytes, suggesting lung trafficking. In the serum, waves of a proinflammatory cytokine storm, Th1 and Th2 activation, and markers of T-cell exhaustion, apoptosis, cell cytotoxicity, and endothelial activation were observed until the fatal outcome. This case underscores the need for well-designed studies to investigate complementary approaches to control viral replication, the source of the hyperinflammatory status, and immunomodulation to target the pathophysiological response.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.05.01.20088054,2020-05-07,https://medrxiv.org/cgi/content/short/2020.05.01.20088054,The landscape of host genetic factors involved in infection to common viruses and SARS-CoV-2,Linda Kachuri; Stephen S Francis; Maike Morrison; George Wendt; Yohan Boss; Taylor B Cavazos; Sara R Rashkin; Elad Ziv; John S Witte; Etienne de Montmollin; Christine Lacabaratz; Rodolphe Thiebaut; Jean-Francois Timsit; Yves Levy; Bin Liu; Wenwu Sun; Fabrizio Albarello; Vincenzo Schinina; Emanuele Nicastri; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"University of California, San Francisco; University of California, San Francisco; The University of Texas at Austin; University of California San Francisco; Laval University; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; APHP-Hopital Bichat; Vaccine Research Insitute; Univ Bordeaux; APHP-Hopital Bichat; VAccine Research Institute; The Central Hospital of Wuhan; The Central Hospital of Wuhan; IRCCS, Lazzaro Spallanzani, Via Portuense; IRCCS, Lazzaro Spallanzani, Via Portuense; IRCCS, Lazzaro Spallanzani, Via Portuense; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","IntroductionHumans and viruses have co-evolved for millennia resulting in a complex host genetic architecture. Understanding the genetic mechanisms of immune response to viral infection provides insight into disease etiology and informs public health interventions.

MethodsWe conducted a comprehensive study linking germline genetic variation and gene expression with antibody response to 28 antigens for 16 viruses using serological data from 7924 participants in the UK Biobank cohort. Using test results from 2010 UK Biobank subjects, we also investigated genetic determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

ResultsSignals in human leukocyte antigen (HLA) class II region dominated the landscape of viral antibody response, with 40 independent loci and 14 independent classical alleles, 7 of which exhibited pleiotropic effects across viral families. Genome-wide association analyses discovered 7 novel genetic loci associated with viral antibody response (P<5.0x10-8), including FUT2 (19q13.33) for human polyomavirus BK (BKV), STING1 (5q31.2) for Merkel cell polyomavirus (MCV), as well as CXCR5 (11q23.3) and TBKBP1 (17q21.32) for human herpesvirus 7. Transcriptome-wide association analyses identified 114 genes associated with response to viral infection, 12 outside of the HLA region, including ECSCR: P=5.0x10-15 (MCV), NTN5: P=1.1x10-9 (BKV), and P2RY13: P=1.1x10-8 (Epstein-Barr virus nuclear antigen). We also demonstrated pleiotropy between viral response genes and complex diseases, such as C4A expression in varicella zoster virus and schizophrenia. Finally, our analyses of SARS-CoV-2 revealed the first genome-wide significant infection susceptibility signal in EHF, an epithelial-specific transcriptional repressor implicated in airway disease. Targeted analyses of expression quantitative trait loci suggest a possible role for tissue-specific ACE2 expression in modifying SARS-CoV-2 susceptibility.

ConclusionsOur study confirms the importance of the HLA region in host response to viral infection and elucidates novel genetic determinants of host-virus interaction. Our results may have implications for complex disease etiology and COVID-19.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.05.06.081497,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.06.081497,A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures,Kenneth H. Dinnon III; Sarah R. Leist; Alexandra Schafer; Caitlin E. Edwards; David R. Martinez; Stephanie A. Montgomery; Ande West; Boyd L. Yount Jr.; Yixuan J. Hou; Lily E. Adams; Kendra L. Gully; Ariane J. Brown; Emily Huang; Matthew D. Bryant; Ingrid C. Choong; Jeffrey S. Glenn; Lisa E. Gralinski; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Eiger BioPharmaceuticals; Eiger BioPharmaceuticals; Stanford University; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Coronaviruses are prone to emergence into new host species most recently evidenced by SARS-CoV-2, the causative agent of the COVID-19 pandemic. Small animal models that recapitulate SARS-CoV-2 disease are desperately needed to rapidly evaluate medical countermeasures (MCMs). SARS-CoV-2 cannot infect wildtype laboratory mice due to inefficient interactions between the viral spike (S) protein and the murine ortholog of the human receptor, ACE2. We used reverse genetics to remodel the S and mACE2 binding interface resulting in a recombinant virus (SARS-CoV-2 MA) that could utilize mACE2 for entry. SARS-CoV-2 MA replicated in both the upper and lower airways of both young adult and aged BALB/c mice. Importantly, disease was more severe in aged mice, and showed more clinically relevant phenotypes than those seen in hACE2 transgenic mice. We then demonstrated the utility of this model through vaccine challenge studies in immune competent mice with native expression of mACE2. Lastly, we show that clinical candidate interferon (IFN) lambda-1a can potently inhibit SARS-CoV-2 replication in primary human airway epithelial cells in vitro, and both prophylactic and therapeutic administration diminished replication in mice. Our mouse-adapted SARS-CoV-2 model demonstrates age-related disease pathogenesis and supports the clinical use of IFN lambda-1a treatment in human COVID-19 infections.",microbiology,exact,100,100
bioRxiv,10.1101/2020.05.07.077016,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.07.077016,The SARS-CoV-2-like virus found in captive pangolins from Guangdong should be better sequenced.,Kenneth H. Dinnon III; Sarah R. Leist; Alexandra Schafer; Caitlin E. Edwards; David R. Martinez; Stephanie A. Montgomery; Ande West; Boyd L. Yount Jr.; Yixuan J. Hou; Lily E. Adams; Kendra L. Gully; Ariane J. Brown; Emily Huang; Matthew D. Bryant; Ingrid C. Choong; Jeffrey S. Glenn; Lisa E. Gralinski; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Eiger BioPharmaceuticals; Eiger BioPharmaceuticals; Stanford University; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins (Manis javanica) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3. These viruses belong to two lineages: one from Guangdong (GD/P) and the other from Guangxi (GX/P). The GD/P viruses are particularly intriguing as the amino-acid sequence of the receptor binding domain of the spike protein is very similar to that of the human SARS-CoV-2 virus (97.4%)2. This characteristic suggests that GD/P viruses are capable of binding human ACE2 receptor and may therefore be able to mediate infection of human cells. Whereas all six GX/P genomes were deposited as annotated sequences in GenBank, none of the two GD/P genomes assembled in previous studies2,3 are currently available. To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS-CoV-2-like viruses detected in five captive pangolins from Guangdong. I found the genome assemblies of GD/P virus of poor quality, having high levels of missing data. Additionally, unexpected reads in the Illumina sequencing data were identified. The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus. In the four other GD/P datasets1 many mitochondrial reads from pangolin were identified, as well as from three other species, namely, human, mouse and tiger. Importantly, I only identified three polymorphic nucleotide sites between the five GD/P sequences. Such low levels of polymorphism may reasonably be accounted for by sequencing errors alone, thus raising the possibility that the five pangolins seized in Guangdong in March 2019 were infected by the same virus strain, most probably during their captivity.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.05.06.081968,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.06.081968,Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle,Clarisse Salgado-Benvindo; Melissa Thaler; Ali Tas; Natacha S. Ogando; Peter J Bredenbeek; Dennis Ninaber; Ying Wang; Pieter Hiemstra; Eric J. Snijder; Martijn J. van Hemert; Kendra L. Gully; Ariane J. Brown; Emily Huang; Matthew D. Bryant; Ingrid C. Choong; Jeffrey S. Glenn; Lisa E. Gralinski; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; Leiden University Medical Center; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Eiger BioPharmaceuticals; Eiger BioPharmaceuticals; Stanford University; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","The SARS-CoV-2 pandemic that originated from Wuhan, China, in December 2019 has impacted public health, society and economy and the daily lives of billions of people in an unprecedented manner. There are currently no specific registered antiviral drugs to treat or prevent SARS-CoV-2 infections. Therefore, drug repurposing would be the fastest route to provide at least a temporary solution while better, more specific drugs are being developed. Here we demonstrate that the antiparasitic drug suramin inhibits SARS-CoV-2 replication, protecting Vero E6 cells with an EC50 of [~]20 {micro}M, which is well below the maximum attainable level in human serum. Suramin also decreased the viral load by 2-3 logs when Vero E6 cells or cells of a human lung epithelial cell line (Calu-3) were treated. Time of addition and plaque reduction assays showed that suramin acts on early steps of the replication cycle, possibly preventing entry of the virus. In a primary human airway epithelial cell culture model, suramin also inhibited the progression of infection. The results of our preclinical study warrant further investigation and suggest it is worth evaluating whether suramin provides any benefit for COVID-19 patients, which obviously requires well-designed, properly controlled randomized clinical trials.",microbiology,exact,100,100
bioRxiv,10.1101/2020.05.06.079830,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.06.079830,Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles,Lisha Zha; Hongxin Zhao; Mona O Mohsen; Liang Hong; Yuhang Zhou; Zehua Li; Chuankai Yao; Hongquan Chen; Xuelan Liu; Xinyue Chang; Jie Zhang; Dong Li; Ke Wu; Monique Vogel; Martin F Bachmann; Junfeng Wang; Lisa E. Gralinski; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"International Immunology Centre, Anhui Agricultural University, Hefei, China; High Magnetic Field Laboratory, CAS, 350 Shushan Hu Road, Hefei, Anhui, China; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland; Department of BioMedical Research, University of Bern, Bern; International Immunology Centre, Anhui Agricultural University, Hefei, China; Shandong H&Z lifescience Gmbh, Yantai, China; International Immunology centre, Anhui agricultural University; Shandong H&Z lifescience Gmbh, Yantai, China; International Immunology Centre, Anhui Agricultural University, Hefei, China; International Immunology Centre, Anhui Agricultural University, Hefei, China; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, ; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland; Department of BioMedical Research, University of Bern, Bern; Beijing key laboratory of monoclonal antibody research and development, Beijing, China; Beijing key laboratory of monoclonal antibody research and development, Beijing, China; Institute of Risk Analysis, Prediction and Management, Academy of Interdisciplinary and Advanced Studies, Southern University of Science and Technology, Shenzhe; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland; Department of BioMedical Research, University of Bern, Bern; International Immunology Centre, Anhui Agricultural University, Hefei, China; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, ; High Magnetic Field Laboratory, CAS, 350 Shushan Hu Road, Hefei, Anhui, China; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","The recently ermerging disease COVID-19 is caused by the new SARS-CoV-2 virus first detected in the city of Wuhan, China. From there it has been rapidly spreading inside and outside China. With initial death rates around 4%, COVID-19 patients at longer distances from Wuhan showed reduced mortality as was previously observed for the SARS coronavirus. However, the new coronavirus spreads more strongly, as it sheds long before onset of symptoms or may be transmitted by people without symptoms. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here we demonstrate that recombinantly expressed receptor binding domain (RBD) of the spike protein homologous to SARS binds to ACE2, the viral receptor. Higly repetitive display of RBD on immunologically optimized virus-like particles derived from cucumber mosaic virus resulted in a vaccine candidate (RBD-CuMVTT) that induced high levels of specific antibodies in mice which were able to block binding of spike protein to ACE2 and potently neutralized the SARS-CoV-2 virus in vitro.",immunology,exact,100,100
bioRxiv,10.1101/2020.05.06.074039,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.06.074039,The heterogeneous landscape and early evolution of pathogen-associated CpG and UpA dinucleotides in SARS CoV-2,Andrea Di Gioacchino; Petr Sulc; Anastassia V Komarova; Benjamin D Greenbaum; Remi Monasson; Simona Cocco; Chuankai Yao; Hongquan Chen; Xuelan Liu; Xinyue Chang; Jie Zhang; Dong Li; Ke Wu; Monique Vogel; Martin F Bachmann; Junfeng Wang; Lisa E. Gralinski; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"Ecole Normale Superieure, PSL and CNRS; Arizona State University; Institut Pasteur; Memorial Sloan Kettering Cancer Center; Ecole Normale Superieure, PSL and CNRS; Ecole Normale Superieure, PSL and CNRS; Shandong H&Z lifescience Gmbh, Yantai, China; International Immunology Centre, Anhui Agricultural University, Hefei, China; International Immunology Centre, Anhui Agricultural University, Hefei, China; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, ; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland; Department of BioMedical Research, University of Bern, Bern; Beijing key laboratory of monoclonal antibody research and development, Beijing, China; Beijing key laboratory of monoclonal antibody research and development, Beijing, China; Institute of Risk Analysis, Prediction and Management, Academy of Interdisciplinary and Advanced Studies, Southern University of Science and Technology, Shenzhe; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland; Department of BioMedical Research, University of Bern, Bern; International Immunology Centre, Anhui Agricultural University, Hefei, China; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, ; High Magnetic Field Laboratory, CAS, 350 Shushan Hu Road, Hefei, Anhui, China; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","COVID-19 can lead to acute respiratory syndrome, which can be due to dysregulated immune signaling. We analyze the distribution of CpG dinucleotides, a pathogen-associated molecular pattern, in the SARS-CoV-2 genome. We find that the CpG content, which we characterize by a force parameter that accounts for statistical constraints acting on the genome at the nucleotidic and amino-acid levels, is, on average, low compared to other pathogenic betacoronaviruses. However, the CpG force widely fluctuates along the genome, with a particularly low value, comparable to the circulating seasonal HKU1, in the spike coding region and a greater value, comparable to SARS and MERS, in the highly expressed nucleocapside coding region (N ORF), whose transcripts are relatively abundant in the cytoplasm of infected cells and present in the 3UTRs of all subgenomic RNA. This dual nature of CpG content could confer to SARS-CoV-2 the ability to avoid triggering pattern recognition receptors upon entry, while eliciting a stronger response during replication. We then investigate the evolution of synonymous mutations since the outbreak of the COVID-19 pandemic, finding a signature of CpG loss in regions with a greater CpG force. Sequence motifs preceding the CpG-loss-associated loci in the N ORF match recently identified binding patterns of the Zinc finger Anti-viral Protein. Using a model of the viral gene evolution under human host pressure, we find that synonymous mutations seem driven in the SARS-CoV-2 genome, and particularly in the N ORF, by the viral codon bias, the transition-transversion bias and the pressure to lower CpG content.",genomics,exact,100,100
bioRxiv,10.1101/2020.05.07.082487,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.07.082487,COVID-19: Viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection.,Francesco Messina; Emanuela Giombini; Chiara Agrati; Francesco Vairo; Tommaso Ascoli Bartoli; Samir Al Moghazi; Mauro Piancentini; Markus Maeurer; Alimuddin Zumla; Maria R. Capobianchi; Francesco Nicola Lauria; Giuseppe Ippolito; Ke Wu; Monique Vogel; Martin F Bachmann; Junfeng Wang; Lisa E. Gralinski; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"National Instritute for Infectious Diseases ""L. Spallanzani"" - IRCCS; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; Department of Biology, University of Rome ""Tor Vergata,"" Rome, Italy.; Champalimaud Centre for the Unknown, Lisbon, Portugal; I. Medizinische Klinik Johannes Gutenberg-Universitat, University of Mainz, 55131 Mainz, Germany.; Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centr; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS, Rome, Italy.; Institute of Risk Analysis, Prediction and Management, Academy of Interdisciplinary and Advanced Studies, Southern University of Science and Technology, Shenzhe; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland; Department of BioMedical Research, University of Bern, Bern; International Immunology Centre, Anhui Agricultural University, Hefei, China; Department of Rheumatology, Immunology and Allergology, University Hospital Bern, ; High Magnetic Field Laboratory, CAS, 350 Shushan Hu Road, Hefei, Anhui, China; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundEpidemiological, virological and pathogenetic characteristics of SARS-CoV-2 infection are under evaluation. A better understanding of the pathophysiology associated with COVID-19 is crucial to improve treatment modalities and to develop effective prevention strategies. Transcriptomic and proteomic data on the host response against SARS-CoV-2 still have anecdotic character; currently available data from other coronavirus infections are therefore a key source of information.

MethodsWe investigated selected molecular aspects of three human coronavirus (HCoV) infections, namely SARS-CoV, MERS-CoV and HCoV-229E, through a network based-approach. A functional analysis of HCoV-host interactome was carried out in order to provide a theoretic host-pathogen interaction model for HCoV infections and in order to translate the results in prediction for SARS-CoV-2 pathogenesis.

The 3D model of S-glycoprotein of SARS-CoV-2 was compared to the structure of the corresponding SARS-CoV, HCoV-229E and MERS-CoV S-glycoprotein. SARS-CoV, MERS-CoV, HCoV-229E and the host interactome were inferred through published protein-protein interactions (PPI) as well as gene co-expression, triggered by HCoV S-glycoprotein in host cells.

ResultsAlthough the amino acid sequences of the S-glycoprotein were found to be different between the various HCoV, the structures showed high similarity, but the best 3D structural overlap shared by SARS-CoV and SARS-CoV-2, consistent with the shared ACE2 predicted receptor. The host interactome, linked to the S-glycoprotein of SARS-CoV and MERS-CoV, mainly highlighted innate immunity pathway components, such as Toll Like receptors, cytokines and chemokines.

ConclusionsIn this paper, we developed a network-based model with the aim to define molecular aspects of pathogenic phenotypes in HCoV infections. The resulting pattern may facilitate the process of structure-guided pharmaceutical and diagnostic research with the prospect to identify potential new biological targets.",bioinformatics,exact,100,100
bioRxiv,10.1101/2020.05.07.082909,2020-05-07,https://biorxiv.org/cgi/content/short/2020.05.07.082909,The coding capacity of SARS-CoV-2,Yaara Finkel; Orel Mizrahi; Aharon Nachshon; Shira Weingarten-Gabbay; David Morgenstern; Yfat Yahalom-Ronen; Hadas Tamir; Hagit Achdout; Dana Stein; Ofir Israeli; Adi Beth-Din; Sharon Melamed; Shay Weiss; Tomer Isrealy; Nir Paran; Michal Schwartz; Noam Stern-Ginossar; Timothy P. Sheahan; Ralph S. Baric; Mariaelena Occhipinti; Giovanni Barisione; Emanuela Barisione; Iva Halilaj; Yuanliang Xie; Xiang Wang; Pierre Lovinfosse; Jianlin Wu; Philippe Lambin; Stephen Evans; Liam Smeeth; Ben Goldacre,"Department of Molecular Genetics, Weizmann Institute of Science; Department of Molecular Genetics, Weizmann Institute of Science; Department of Molecular Genetics, Weizmann Institute of Science; Broad Institute of MIT and Harvard, Cambridge, Department of Organismal and Evolutionary Biology, Harvard University, Cambridge; de Botton Institute for Protein Profiling, The Nancy and Stephen Grand Israel National Center for Personalised Medicine, Weizmann Institute of Science; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona; Department of Molecular Genetics, Weizmann Institute of Science; Department of Molecular Genetics, Weizmann Institute of Science; University of North Carolina at Chapel Hill; University of North Carolina at Chapel Hill; Clinical and Experimental Sciences ""Mario Serio"", University of Florence; IRCCS Ospedale Policlinico San Martino; IRCCS Ospedale Policlinico San Martino; Maastricht University; The Central Hospital of Wuhan; The Central Hospital of Wuhan; CHU of Liege; Affiliated Zhongshan Hospital of Dalian University; Maastricht University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing Coronavirus disease 19 (COVID-19) pandemic 1,2. In order to understand SARS-CoV-2 pathogenicity and antigenic potential, and to develop diagnostic and therapeutic tools, it is essential to portray the full repertoire of its expressed proteins. The SARS-CoV-2 coding capacity map is currently based on computational predictions and relies on homology to other coronaviruses. Since coronaviruses differ in their protein array, especially in the variety of accessory proteins, it is crucial to characterize the specific collection of SARS-CoV-2 proteins in an unbiased and open-ended manner. Utilizing a suite of ribosome profiling techniques 3-8, we present a high-resolution map of the SARS-CoV-2 coding regions, allowing us to accurately quantify the expression of canonical viral open reading frames (ORF)s and to identify 23 novel unannotated viral translated ORFs. These ORFs include upstream ORFs (uORFs) that are likely playing a regulatory role, several in-frame internal ORFs lying within existing ORFs, resulting in N-terminally truncated products, as well as internal out-of-frame ORFs, which generate novel polypeptides. We further show that viral mRNAs are not translated more efficiently than host mRNAs; rather, virus translation dominates host translation due to high levels of viral transcripts. Overall, our work reveals the full coding capacity of SARS-CoV-2 genome, providing a rich resource, which will form the basis of future functional studies and diagnostic efforts.",microbiology,exact,100,100
medRxiv,10.1101/2020.05.02.20078642,2020-05-06,https://medrxiv.org/cgi/content/short/2020.05.02.20078642,Impact of ethnicity on outcome of severe COVID-19 infection. Data from an ethnically diverse UK tertiary centre,James T Teo; Daniel Bean; Rebecca Bendayan; Richard Dobson; Ajay Shah; Jack Kamm; Lucy M Li; Charles Y Chiu; Jennifer M Babick; Margaret C Fang; Yumiko Abe-Jones; Narges Alipanah; Francisco N Alvarez; Olga B Botvinnik; Jennifer M Davis; Gloria D Castenada; CLIAHub Consortium; Rand M Dadasovich; Xianding Deng; Joseph L DeRisi; Angela M Detweiler; Scot Federman; John R Haliburton; Samantha L Hao; Andrew D Kerkhoff; Renuka Kumar; Katherine Malcolm; Sabrina A Mann; Sandra P Martinez; Rupa Marya; Eran Mick; Lusajo L Mwakibete; Nader Najafi; Michael J Peluso; Maira S Phelps; Angela O Pisco; Kalani Ratnasiri; Luis A Rubio; Anna B Sellas; Kyla D Sherwood; Jonathan Sheu; Natasha Spottiswoode; Michelle Tan; Guixa Yu; Kirsten N Kangelaris; Charles Langelier,Kings College Hospital NHS Foundation Trust; King's College London; King's College London; Kings College London; King's College London; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; UCSF; UCSF; UCSF; UCSF; UCSF; UCSF; Chan Zuckerberg Biohub; UCSF; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; UCSF; UCSF; UCSF; Chan Zuckerberg Biohub; UCSF; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; UCSF; Chan Zuckerberg Biohub; UCSF; Chan Zuckerberg Biohub; UCSF; UCSF; UCSF; Chan Zuckerberg Biohub; UCSF; UCSF; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Stanford; UCSF; Chan Zuckerberg Biohub; UCSF; Chan Zuckerberg Initiative; UCSF; Chan Zuckerberg Biohub; UCSF; UCSF; University of California San Francisco,"During the current COVID-19 pandemic, it has been suggested that BAME background patients may be disproportionately affected compared to White but few detailed data are available. We took advantage of near real-time hospital data access and analysis pipelines to look at the impact of ethnicity in 1200 consecutive patients admitted between 1st March 2020 and 12th May 2020 to Kings College Hospital NHS Trust in London (UK).

Our key findings are firstly that BAME patients are significantly younger and have different co-morbidity profiles than White individuals. Secondly, there is no significant independent effect of ethnicity on severe outcomes (death or ITU admission) within 14-days of symptom onset, after adjustment for age, sex and comorbidities.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.04.28.20083170,2020-05-05,https://medrxiv.org/cgi/content/short/2020.04.28.20083170,Quantifying and mitigating the impact of the COVID-19 pandemic on outcomes in colorectal cancer,Amit Sud; Michael Jones; John Broggio; Stephen Scott; Chey Loveday; Bethany Torr; Alice Garrett; David L. Nicol; Shaman Jhanji; Stephen A. Boyce; Matthew Williams; Georgios Lyratzopoulos; Claire Barry; Elio Riboli; Emma Kipps; Ethna McFerran; Mark Lawler; David C. Muller; Muti Abulafi; Richard Houlston; Clare Ann Turnbull,"Institute of Cancer Research; Institute of Cancer Research; Public Health England; RM Partners, West London Cancer Alliance; Institute of Cancer Research; Institute of Cancer Research; Institute of Cancer Research; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Imperial College; University College London; RM Partners, West London Cancer Alliance; Imperial College London; Royal Marsden NHS Foundation Trust; Queen's University Belfast; Queen's University Belfast; Imperial College London; Croydon Health Services NHS Trust, on behalf of RMP NICE FIT Steering Group; Institute of Cancer Research; Institute of Cancer Research","BackgroundThe COVID-19 pandemic has caused disruption across cancer pathways for diagnosis and treatment. In England, 32% of colorectal cancer (CRC) is diagnosed via urgent symptomatic referral from primary care, the ""2-week-wait"" (2WW) pathway. Access to routine endoscopy is likely to be a critical bottleneck causing delays in CRC management due to chronic limitation in capacity, acute competition for physician time, and safety concerns.

MethodsWe used age-specific, stage-specific 10 year CRC survival for England 2007-2017 and 2WW CRC cases volumes. We used per-day hazard ratios of CRC survival generated from observational studies of CRC diagnosis-to-treatment interval to model the effect of different durations of per-patient delay. We utilised data from a large London observational study of faecal immunochemical testing (FIT) in symptomatic patients to model FIT-triage to mitigate delay to colonoscopy.

FindingsModest delays result in significant reduction in survival from CRC with a 4-month delay resulting across age groups in [&ge;]20% reduction in survival in Stage 3 disease and in total over a year, 1,419 attributable deaths across the 11,266 CRC patients diagnosed via the 2WW pathway. FIT triage of >10 ug Hb/g would salvage 1,292/1,419 of the attributable deaths and reduce colonoscopy requirements by >80%. Diagnostic colonoscopy offers net survival in all age groups, providing nosocomial COVID-19 infection rates are kept low (<2{middle dot}5%).

InterpretationTo avoid significant numbers of avoidable deaths from CRC, normal diagnostic and surgical throughput must be maintained. An accrued backlog of cases will present to primary care following release of lockdown, supranormal endoscopy capacity will be required to manage this without undue delays. FIT-triage of symptomatic cases provides a rational approach by which to avoid patient delay and mitigate pressure on capacity in endoscopy. This would also reduce exposure to nosocomial COVID-19 infection, relevant in particular to older patient groups.

FundingBreast Cancer Now, Cancer Research UK, Bobby Moore Fund for Cancer Research, National Institute for Health Research (NIHR).",oncology,exact,100,100
medRxiv,10.1101/2020.05.04.20082081,2020-05-05,https://medrxiv.org/cgi/content/short/2020.05.04.20082081,ai-corona: Radiologist-Assistant Deep Learning Framework for COVID-19 Diagnosis in Chest CT Scans,Mehdi Yousefzadeh; Parsa Esfahanian; Seyed Mohammad Sadegh Movahed; Saeid Gorgin; Reza Lashgari; Dara Rahmati; Arda Kiani; Shahram Kahkouee; Seyed Alireza Nadji; Sara Haseli; Meisam Hoseinyazdi; Jafar Roshandel; Negar Bandegani; Abbas Danesh; Mehrdad Bakhshayesh Karam; Atefeh Abedini; Mark Lawler; David C. Muller; Muti Abulafi; Richard Houlston; Clare Ann Turnbull,"Institute for Research in Fundamental Sciences (IPM); Institute for Research in Fundamental Sciences (IPM); Shahid Beheshti University; Iranian Research Organization for Science and Technology (IROST); Institute for Research in Fundamental Sciences (IPM); Shahid Beheshti University; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; Shiraz University of Medical Sciences; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; Queen's University Belfast; Imperial College London; Croydon Health Services NHS Trust, on behalf of RMP NICE FIT Steering Group; Institute of Cancer Research; Institute of Cancer Research","BackgroundWith the global outbreak of COVID-19 epidemic since early 2020, there has been considerable attention on CT-based diagnosis as an effective and reliable method. Recently, the advent of deep learning in medical diagnosis has been well proven. Convolutional Neural Networks (CNN) can be used to detect the COVID-19 infection imaging features in a chest CT scan. We introduce ai-corona, a radiologist-assistant deep learning framework for COVID-19 infection diagnosis using the chest CT scans.

MethodOur dataset comprises 2121 cases of axial spiral chest CT scans in three classes; COVID-19 abnormal, non COVID-19 abnormal, and normal, from which 1764 cases were used for training and 357 cases for validation. The training set was annotated using the reports of two experienced radiologists. The COVID-19 abnormal class validation set was annotated using the general consensus of a collective of criteria that indicate COVID-19 infection. Moreover, the validation sets for the non COVID-19 abnormal and the normal classes were annotated by a different experienced radiologist. ai-corona constitutes a CNN-based feature extractor conjoined with an average pooling and a fully-connected layer to classify a given chest CT scan into the three aforementioned classes.

ResultsWe compare the diagnosis performance of ai-corona, radiologists, and model-assisted radiologists for six combinations of distinguishing between the three mentioned classes, including COVID-19 abnormal vs. others, COVID-19 abnormal vs. normal, COVID-19 abnormal vs. non COVID-19 abnormal, non COVID-19 abnormal vs. others, normal vs. others, and normal vs. abnormal. ai-corona achieves an AUC score of 0.989 (95% CI: 0.984, 0.994), 0.997 (95% CI: 0.995, 0.999), 0.986 (95% CI: 0.981, 0.991), 0.959 (95% CI: 0.944, 0.974), 0.978 (95% CI: 0.968, 0.988), and 0.961 (95% CI: 0.951, 0.971) in each combination, respectively. By employing Bayesian statistics to calculate the accuracies at a 95% confidence interval, ai-corona surpasses the radiologists in distinguishing between the COVID-19 abnormal class and the other two classes (especially the non COVID-19 abnormal class). Our results show that radiologists diagnosis performance improves when incorporating ai-coronas prediction. In addition, we also show that RT-PCRs diagnosis has a much lower sensitivity compared to all the other methods.

Conclusionai-corona is a radiologist-assistant deep learning framework for fast and accurate COVID-19 diagnosis in chest CT scans. Our results ascertain that our framework, as a reliable detection tool, also improves experts diagnosis performance and helps especially in diagnosing non-typical COVID-19 cases or non COVID-19 abnormal cases that manifest COVID-19 imaging features in chest CT scan. Our framework is available at: ai-corona.com",health informatics,exact,100,100
medRxiv,10.1101/2020.04.28.20083675,2020-05-05,https://medrxiv.org/cgi/content/short/2020.04.28.20083675,BRAZIL IS PROJECTED TO BE THE NEXT GLOBAL COVID-19 PANDEMIC EPICENTER,Pedro de Lemos Menezes; David M. Garner; Vitor E Valenti; Saeid Gorgin; Reza Lashgari; Dara Rahmati; Arda Kiani; Shahram Kahkouee; Seyed Alireza Nadji; Sara Haseli; Meisam Hoseinyazdi; Jafar Roshandel; Negar Bandegani; Abbas Danesh; Mehrdad Bakhshayesh Karam; Atefeh Abedini; Mark Lawler; David C. Muller; Muti Abulafi; Richard Houlston; Clare Ann Turnbull,"University of Health Sciences of Alagoas, AL, Brazil; Cardiorespiratory Research Group, Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Camp; SaoPaulo State University, UNESP, Marilia, SP, Brazil.; Iranian Research Organization for Science and Technology (IROST); Institute for Research in Fundamental Sciences (IPM); Shahid Beheshti University; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; Shiraz University of Medical Sciences; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; Queen's University Belfast; Imperial College London; Croydon Health Services NHS Trust, on behalf of RMP NICE FIT Steering Group; Institute of Cancer Research; Institute of Cancer Research","Coronavirus disease 2019 (COVID-19) is a disease triggered by SARS-CoV-2 infection, which is related in the most recent pandemic situation, significantly affecting health and economic systems. In this study we assessed the death rate associated to COVID-19 in Brazil and the United States of America (USA) to estimate the probability of Brazil becoming the next pandemic epicenter. We equated data between Brazil and USA obtained through the Worldometer website (www.worldometer.info). Epidemic curves from Brazil and USA were associated and regression analysis was undertaken to predict the Brazilian death rate regarding COVID-19 in June. In view of data from April 9th 2020, death rates in Brazil follow a similar exponential increase to USA (r=0.999; p<0.001), estimating 64,310 deaths by June 9th 2020. In brief, our results demonstrated that Brazil follows an analogous progression of COVID-19 deaths cases when compared to USA, signifying that Brazil could be the next global epicenter of COVID-19. We highlight public strategies to decrease the COVID-19 outbreak.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.04.28.20083956,2020-05-05,https://medrxiv.org/cgi/content/short/2020.04.28.20083956,Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative,yunying zhou; Fengyan Pei; Li Wang; Huailong Zhao; Huanjie Li; Mingyu Ji; Weihua Yang; Qingxi Wang; Qianqian Zhao; Yunshan Wang; Meisam Hoseinyazdi; Jafar Roshandel; Negar Bandegani; Abbas Danesh; Mehrdad Bakhshayesh Karam; Atefeh Abedini; Mark Lawler; David C. Muller; Muti Abulafi; Richard Houlston; Clare Ann Turnbull,"Jinan Central Hospital, Cheeloo College of Medicine, Shandong University; Jinan Central Hospital Affiliated to Shandong University; inan Infectious Disease Hospital, Shandong University; Jinan Center for Disease Control and Prevention; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong University; Shiraz University of Medical Sciences; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences and Health Services; Queen's University Belfast; Imperial College London; Croydon Health Services NHS Trust, on behalf of RMP NICE FIT Steering Group; Institute of Cancer Research; Institute of Cancer Research","An ongoing outbreak of pneumonia associated with SARS-CoV-2 has now been confirmed globally. In absence of effective vaccines, infection prevention and control through diagnostic testing and quarantine is critical. Early detection and differential diagnosis of respiratory infections increases the chances for successful control of COVID-19 disease. The nucleic acid RT-PCR test is regarded as the current standard for molecular diagnosis with high sensitivity. However, the highest specificity confirmation target ORF1ab gene is considered to be less sensitive than other targets in clinical application. In addition, a large amount of recent evidence indicates that the initial missed diagnosis of asymptomatic patients with SARS-CoV-2 and discharged patients with ""re-examination positive"" may be due to low viral load, and the ability of rapid mutation of coronavirus also increases the rate of false negative results. We aimed to evaluate the sensitivity of different nucleic acid detection kits so as to make recommendations for the selection of validation kit, and amplify the suspicious result to be reportable positive by means of simple continuous amplification, which is of great significance for the prevention and control of the current epidemic and the discharge criteria of low viral load patients.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.24.20078006,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078006,Supplementing the National Early Warning Score (NEWS2) for anticipating early deterioration among patients with COVID-19 infection,Ewan Carr; Rebecca Bendayan; Daniel Bean; Matthew Stammers; Wenjuan Wang; Huayu Zhang; Thomas Searle; Zeljko Kraljevic; Anthony Shek; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"King's College London; King's College London; King's College London; Clinical Informatics Research Unit, University of Southampton; King's College London; University of Edinburgh; King's College London; King's College London; King's College London; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","ObjectivesTo evaluate the National Early Warning Score (NEWS2), currently recommended in the UK for risk-stratification of severe COVID-19 outcomes, and subsequently identify and validate a minimal set of common parameters taken at hospital admission that improve the score.

DesignRetrospective observational cohort with internal and multi-hospital external validation.

SettingSecondary care.

InterventionsNot applicable.

ParticipantsMain outcome measures

ResultsTraining and temporal external validation cohorts comprised 1464 patients admitted to Kings College Hospital NHS Foundation Trust (KCH) with COVID-19 disease from 1st March to 30th April 2020. External validation cohorts included 3869 patients from two UK NHS Trusts (Guys and St Thomas Hospitals, GSTT and University Hospitals Southampton, UHS) and two hospitals in Wuhan, China (Wuhan Sixth Hospital and Taikang Tongji Hospital).

The primary outcome was patient status at 14 days after symptom onset categorised as severe disease (transferred to intensive care unit or death). Age, physiological measures, blood biomarkers, sex, ethnicity and comorbidities (hypertension, diabetes, cardiovascular, respiratory and kidney diseases) were included.

ConclusionsNEWS2 score on admission was a weak predictor of severe COVID-19 infection (AUC = 0.628). Adding age and common blood tests (CRP, neutrophil count, estimated GFR and albumin) provided substantial improvements to a risk stratification model, particularly in relation to sensitivity, but performance was only moderate (AUC = 0.753). Improvement over NEWS2 remained robust and generalisable in GSTT (AUC = 0.817), UHS (AUC = 0.835) and Wuhan hospitals (AUC = 0.918).

Adding age and a minimal set of blood parameters to NEWS2 improves the detection of patients likely to develop severe COVID-19 outcomes. This finding was replicated across NHS and non-UK hospitals. Adding a few common parameters to a pre-existing acuity score allows rapid and easy implementation of this risk-scoring system.

KO_SCPLOWEYC_SCPLOW MO_SCPLOWESSAGESC_SCPLOWO_LIThe National Early Warning Score (NEWS2), currently recommended for severe COVID-19 disease in the UK shows overall poor discrimination for severe outcomes (transfer to ICU or death). It can be improved by the addition of a small number of blood and physiological parameters routinely measured at hospital admission.
C_LIO_LIThe addition of age and a minimal set of common blood tests (C-reactive protein, neutrophil count, estimated GFR and albumin) provided substantial improvements in a risk stratification model.
C_LIO_LIAlthough predictive performance varied from hospital to hospital, the improvement over NEWS2 alone was consistent across different patient cohorts.
C_LIO_LIThe proposed addition of a limited number of dichotomised parameters is easily derived from a pre-existing acuity score would be substantially easier to implement in a short-time scale compared to novel high-dimensional risk-scoring systems.
C_LI",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.24.20077933,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20077933,Comprehensive Investigation and Isolation have Effectively Suppressed the Spread of COVID-19,Yubo Huang; Weidong Zhang; Daniel Bean; Matthew Stammers; Wenjuan Wang; Huayu Zhang; Thomas Searle; Zeljko Kraljevic; Anthony Shek; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Shanghai Jiao Tong university; Shanghai Jiaotong University; King's College London; Clinical Informatics Research Unit, University of Southampton; King's College London; University of Edinburgh; King's College London; King's College London; King's College London; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","The outbreak of COVID-19 since Dec. 2019 has caused severe life and economic damage worldwide, many countries are trapped by medical resource constraints or absence of targeted therapeutics, and therefore the implement of systemic policies to block this pandemic should be prioritized. Based on the transmission mechanisms and physicochemical properties of betacoron-aviruses, we construct a fine-grained transmission dynamics model (ICRD) to forecast the crucial information of public concern, therein using dynamical coefficients to quantify the impact of the implement time and intensity of containment policies on the spread of epidemic. We find that the comprehensive investigation policy for susceptible population and the quarantine for suspected cases eminently contribute to reduce casualties during the phase of the dramatic increase of diagnosed cases. Statistic evidences strongly suggest that society should take such forceful public health interventions to cut the infection channels in the initial stage until the pandemic is interrupted.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.25.20077842,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.25.20077842,The values of coagulation function in COVID-19 patients,Xin Jin; Yongwei Duan; Tengfei Bao; Junjuan Gu; Yawen Chen; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","ObjectiveTo investigate the blood coagulation function in COVID-19 patients, and the correlation between coagulopathy and disease severity.

MethodsWe retrospectively collected 147 clinically diagnosed COVID-19 patients at Wuhan Leishenshan Hospital of Hubei, China. We analyzed the coagulation function in COVID-19 patients through the data including thrombin-antithrombin complex (TAT), 2-plasmininhibitor-plasmin Complex (PIC), thrombomodulin (TM), t-PA/PAI-1 Complex (t-PAIC), prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), D-Dimer (DD), and platelet (PLT).

ResultThe levels of TAT, PIC, TM, t-PAIC, PT, INR, FIB, and DD in COVID-19 patients were higher than health controls (p<0.05), and also higher in the patients with thrombotic disease than without thrombotic disease (p<0.05). Whats more, the patients with thrombotic disease had a higher case-fatality (p<0.05). TAT, PIC, TM, t-PAIC, PT, INR, APTT, FIB, DD, and PLT were also found correlated with disease severity. Meanwhile, we found that there were significant difference in TAT, TM, t-PAIC, PT, INR, APTT, DD, and PLT in the death and survival group. Further using univariate and multivariate logistic regression analysis also found that t-PAIC and DD were independent risk factors for death in patients and are excellent predicting the mortality risk of COVID-19.

ConclusionThe coagulation systems in COVID-19 patients are inordinate, and dynamic monitoring of them, might be a key in the control of COVID-19 death.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.24.20078105,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078105,A Nationwide Survey of UK cardiac surgeons view on clinical decision making during the COVID-19 pandemic,Umberto Benedetto; Andrew Goodwin; Simon Kendall; Rakesh Uppal; Enoch Akowuah; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Bristol Heart Institute, University Hospitals bristol NHS Foundation Trust; South Tees Hospitals NHS Trust; South Tees Hospitals NHS Trust; Barts Health NHS Turst; South Tees Hospitals NHS Trust; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","BackgroundNo firm recommendations are currently available to guide decision making for patients requiring cardiac surgery during the COVID-19 pandemic. Systematic appraisal of national expert consensus can be used to generate interim recommendations until data from clinical observations will become available. Hence, we aimed to collect and quantitatively appraise nationwide UK senior surgeons opinion on clinical decision making for patients requiring cardiac surgery during the COVID-19 pandemic.

MethodsWe mailed a web-based questionnaire to all consultant cardiac surgeons through the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS) mailing list on the 17th April 2020 and we pre-determined to close the survey on the 21st April 2020. This survey was primarily designed to gather information on UK surgeons opinion using 12 items. Strong consensus was predefined as an opinion shared by at least 60% of responding consultants.

ResultsA total of 86 consultant surgeons undertook the survey. All UK cardiac units were represented by at least one consultant. Strong consensus was achieved for the following key questions:1) before hospital admission every patient should receive nasopharyngeal swab, PCR and chest CT; 2) the use of full PPE should to be adopted in every case by the theatre team regardless patients COVID-19 status; 3) the risk of COVID-19 exposure for patients undergoing heart surgery should be considered moderate to high and likely to increase mortality if it occurs; 4) cardiac procedure should be decided based on ad-hoc multidisciplinary team discussion for every patient. The majority believed that both aortic and mitral surgery should be considered in selected cases. The role of CABG surgery during the pandemic was more controversial.

ConclusionsIn the current unprecedented scenario, the present survey provides information for generating interim recommendations until data from clinical observations will become available.

Perspective statementSystematic appraisal of national expert consensus can be used to generate interim recommendations for patients undergoing cardiac surgery during COVID-19 pandemic until data from clinical observations will become available.

Central messageNo firm recommendations are currently available to guide decision making for patients requiring cardiac surgery during the pandemic. This can translate into significant variability in clinical practice and patients outcomes across cardiac units. Systematic appraisal of national expert consensus can represent a rapid and efficient instrument to provide support to heath policy makers and other stakeholders in generating interim recommendations until data from clinical observations will become available.",cardiovascular medicine,exact,100,100
medRxiv,10.1101/2020.04.22.20075093,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.22.20075093,COVID-19 containment policies through time may cost more lives at metapopulation level,Konstans Wells; Miguel Lurgi; Simon Kendall; Rakesh Uppal; Enoch Akowuah; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Swansea University; Swansea University; South Tees Hospitals NHS Trust; Barts Health NHS Turst; South Tees Hospitals NHS Trust; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","The rapid and pandemic spread of COVID-19 has led to unprecedented containment policies in response to overloaded health care systems. Disease mitigation strategies require informed decision-making to ensure a balance between the protection of the vulnerable from disease and the maintenance of global economies. We show that temporally restricted containment efforts, that have the potential to flatten epidemic curves, can result in wider disease spread and larger epidemic sizes in metapopulations. Longer-term rewiring of metapopulation networks or the enforcement of feasible long-term measures that decrease disease transmissions appear to be more efficient than temporarily restricted intensive mitigation strategies (e.g. short-term mass quarantine). Our results may inform balanced containment strategies for short-term disease spread mitigation in response to overloaded health care systems and longer-term epidemiological sizes.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078345,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078345,"No Detectable Surge in SARS-CoV-2 Transmission due to the April 7, 2020 Wisconsin Election",Kathy Leung; Joseph T Wu; Kuang Xu; Lawrence M Wein; Enoch Akowuah; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"The University of Hong Kong; The University of Hong Kong; Stanford University; Stanford Unversity; South Tees Hospitals NHS Trust; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","We analyze confirmed cases and new hospitalizations in Wisconsin in the weeks surrounding the April 7, 2020 election, and find no evidence of a surge in SARS-CoV-2 transmission.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078402,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078402,A Statistical Analysis Of CoV-19 Positive Test Frequency Data Indicates A Need For Greater Attention To CoV-19 Test Quality And Pre-Wuhan Cov-19 Prevalence,James L Sherley; Joseph T Wu; Kuang Xu; Lawrence M Wein; Enoch Akowuah; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Asymmetrex LLC; The University of Hong Kong; Stanford University; Stanford Unversity; South Tees Hospitals NHS Trust; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","Increased attention to analysis of SARS-CoV-2 (CoV-19) positive test frequency data is essential for achievement of better knowledge of the natural history of the virus in human populations, improved accuracy of CoV-19 epidemiological data, and development of public response policies that are better crafted to address the current CoV-19-induced global crisis. A statistical analysis of currently available positive test frequency data reveals a surprisingly uniform relationship between the number of CoV-19 test performed and the number of positive tests obtained. The uniformity is particularly striking for United States CoV-19 test data. Such observations warrant closer evaluation of other factors, besides virus spread, that may also contribute to the nature of the coronavirus pandemic. These include indigenous CoV-19 and the quality of CoV-19 testing.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078279,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078279,COVID-19 data analysis and modeling in Palestine,Ines Abdeljaoued-Tej; Joseph T Wu; Kuang Xu; Lawrence M Wein; Enoch Akowuah; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"BIMS Laboratory, LR16IPT09, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia; The University of Hong Kong; Stanford University; Stanford Unversity; South Tees Hospitals NHS Trust; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","We estimate an actual number of infected cases in Palestine based on the 18-day effect from infection to death. We find that the number of cases in April 22 varies between 506 and 2 026 infected cases. We also focus on the reproductive number in Palestine based on population dynamics with two SEIR models. Dataset is from 5 March to 22 April 2020. With a transmission rate equal to 4.55 10-6, on May 22, the simulations predict 11 014 total infected cases in the optimistic scenario and 113 171 in the worst one. The crest of the pandemic is from 22 to 27 May 2020. The reproductive number [R]0 is equal to 1.54 for a fixed fraction of 0.6 of symptomatic cases that are reported and for a removal rate of 7. Palestinian COVID-19 mortality number is equal to 6 per million. It is small compared to countries neighboring Palestine. The infected number is equal to 88.4 per million, which is less than most of its neighbors. The basic reproduction number is still greater than 1. Changes to the transmission rate (over time) would be advisable, to fall [R]0 below the critical threshold.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078030,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078030,Modelling the impact of control measures against the COVID-19 pandemic in Viet Nam,Thu Anh Nguyen; Quoc Cuong Nguyen; Anh Thi Kim Le; Huyen Nguyen Nguyen; Thao Thi Huong Nguyen; Yuanyuan Li; Shi Mao; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Sydney School of Medicine, The Faculty of Medicine and Health, The University of Sydney, Australia; Save the Children International, Vientiane, Laos; Hanoi University of Public Health, Hanoi, Vietnam; National Hospital for Tropical Diseases, Vietnam; Strategic Consultancy Company, Hanoi, Vietnam; Department of Laboratory Medicine, Wuhan hospital of traditional Chinese Medicine,Hubei,China; Department of Laboratory Medicine, Wuhan Third Hospital; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","ObjectivesHealth care system of many countries are facing a surging burden of COVID-19. Although Vietnam has successfully controlled the COVID-19 pandemic to date, there is a sign of initial community transmission. An estimate of possible scenarios to prepare health resources in the future is needed. We used modelling methods to estimate impacts of mitigation measures on the COVID-19 pandemic in Vietnam.

MethodsSEIR model built in the COVIDSIM1.1 tool was adopted using available data for estimation. The herd immunization scenario was with no intervention implemented. Other scenarios consisted of isolation and social distancing at different levels (25%, 50%, 75% and 10%, 20%, 30%, respectively). Outcomes include epidemic apex, daily new and cumulative cases, deaths, hospitalized patients and ICU beds needed.

ResultsBy April 8, 2020, there would be 465 infected cases with COVID-19 in Viet Nam, of those 50% were detected. Cumulatively, there would be 1,400 cases and 30 deaths by end of 2020, if 75% of cases was detected and isolated, and 30% of social distancing could be maintained.

The most effective intervention scenario is the detection and isolation of 75% infected cases and reduction of 10% social contacts. This will require an expansion of testing capacity at health facilities and in the community, posing a challenge to identify high-risk groups to prioritized testing.

ConclusionsIn a localized epidemic setting, the expansion of testing should be the key measure to control the epidemic. Social distancing plays a significant role to prevent further transmission to the community.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078303,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078303,Concentration-dependent mortality of chloroquine in overdose,James A Watson; Joel Tarning; Richard M Hoglund; Frederic J Baud; Bruno Megarbane; Jean-Luc Clemessy; Nicholas J White; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Mahidol Oxford Tropical Medicine Research Unit; Mahidol Oxford Research Unit; Mahidol Oxford Tropical Medicine Research Unit; Assistance Publique - Hopitaux de Paris; Universite de Paris; Clinique du Sport; Mahidol Oxford Tropical Medicine Research Unit; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment. Although generally safe they are potentially lethal in overdose. In-vitro data suggest that high concentrations and thus high doses are needed for COVID-19 infections, but as yet there is no convincing evidence they are clinically effective. Bayesian regression models were fitted to survival outcomes and electrocardiograph QRS durations from 302 prospectively studied French patients who had taken intentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunteers who took 620 mg base chloroquine single doses. Whole blood concentrations of 13.5 mol/L (95% credible interval 10.1-17.7) were associated with 1% mortality. Prolongation of ventricular depolarisation is concentration-dependent with a QRS duration >150 msec independently highly predictive of mortality. Pharmacokinetic modelling combined with these lethality data predicts that the majority of chloroquine regimens trialled in COVID-19 should not cause serious cardiovascular toxicity.",pharmacology and therapeutics,exact,100,100
bioRxiv,10.1101/2020.04.27.065383,2020-04-29,https://biorxiv.org/cgi/content/short/2020.04.27.065383,In silico analysis of RT-qPCR designs recommended by WHO for detection of SARS-CoV-2 and a commercial kit validated following UNE/EN ISO 17025:2005 and two reference laboratories,Antonio J Martinez-Murcia; Gema Bru; Aaron Navarro; Patricia Ros-Trraga; Adrin Garca-Sirera; Laura Prez; Nicholas J White; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Universidad Miguel Hernndez; Genetic Analysis Strategies S.L.; Universidad Miguel Hernndez; Genetic Analysis Strategies S.L.; Genetic Analysis Strategies S.L.; genetic PCR solutions; Mahidol Oxford Tropical Medicine Research Unit; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","BackgroundThe Corona Virus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has become a serious infectious disease affecting human health worldwide and rapidly declared a pandemic by WHO. Early, several RT-qPCR were designed by using only the first SARS-CoV-2 genome sequence.

ObjectivesA few days later, when additional SARS-CoV-2 genome were retrieved, the kit GPS CoVID-19 dtec-RT-qPCR Test was designed to provide a highly specific detection method and commercially available worldwide. The kit was validated following criteria recommended by the UNE/EN ISO 17025:2005 and ISO/IEC 15189:2012.

MethodsThe present study approached the in silico specificity of the GPS CoVID-19 dtec-RT-qPCR Test and RT-qPCR designs currently published. The empirical validation parameters specificity (inclusivity/exclusivity), quantitative phase analysis (10-106 copies), reliability (repeatability/reproducibility) and sensitivity (detection/quantification limits) were evaluated for a minimum of 10-15 assays. Diagnostic validation was achieved by two independent reference laboratories, the Instituto de Salud Carlos III (ISCIII), (Madrid, Spain) and the Public Health England (PHE; Colindale, London, UK).

ResultsThe GPS RT-qPCR primers and probe showed the highest number of mismatches with the closet related non-SARS-CoV-2 coronavirus, including some indels. The kits passed all parameters of validation with strict acceptance criteria. Results from reference laboratories 100% correlated with these obtained by suing reference methods and received an evaluation with 100% of diagnostic sensitivity and specificity.

ConclusionsThe GPS CoVID-19 dtec-RT-qPCR Test, available with full analytical and diagnostic validation, represents a case of efficient transfer of technology being successfully used since the pandemic was declared. The analysis suggested the GPS CoVID-19 dtec-RT-qPCR Test is the more exclusive by far.",genetics,exact,100,100
medRxiv,10.1101/2020.04.24.20078824,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078824,"Estimating COVID-19 Antibody Seroprevalence in Santa Clara County, California. A re-analysis of Bendavid et al.",Stephen T Bennett; Mark Steyvers; Aaron Navarro; Patricia Ros-Trraga; Adrin Garca-Sirera; Laura Prez; Nicholas J White; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"University of California, Irvine; University of California, Irvine; Universidad Miguel Hernndez; Genetic Analysis Strategies S.L.; Genetic Analysis Strategies S.L.; genetic PCR solutions; Mahidol Oxford Tropical Medicine Research Unit; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","AO_SCPLOWBSTRACTC_SCPLOWA recent study by Bendavid et al. claimed that the rate of infection of COVID-19 in Santa Clara county was between 2.49% and 4.16%, 50-85 times higher than the number of officially confirmed cases. The statistical methodology used in that study overestimates of rate of infection given the available data. We jointly estimate the sensitivity and specificity of the test kit along with rate of infection with a simple Bayesian model, arriving at lower estimates of the rate of COVID-19 in Santa Clara county. Re-analyzing their data, we find that the rate of infection was likely between 0.27% and 3.21%.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078808,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078808,Reacting to outbreaks at neighboring localities,Ceyhun Eksin; Martial Ndeffo-Mbah; Joshua S Weitz; Patricia Ros-Trraga; Adrin Garca-Sirera; Laura Prez; Nicholas J White; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Texas A&M; Texas A&M; Georgia Institute of Technology; Genetic Analysis Strategies S.L.; Genetic Analysis Strategies S.L.; genetic PCR solutions; Mahidol Oxford Tropical Medicine Research Unit; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","We study the dynamics of epidemics in a networked metapopulation model. In each subpopulation, representing a locality, disease propagates according to a modified susceptible-exposed-infected-recovered (SEIR) dynamics. We assume that individuals reduce their number of contacts as a function of the weighted sum of cumulative number of cases within the locality and in neighboring localities. We also assume that susceptible and exposed (pre-symptomatic and infectious) individuals can travel between localities. To investigate the combined effects of mobility and contact reduction on disease progression within interconnected localities, we consider a scenario with two localities where disease originates in one and is exported to the neighboring locality via travel of undetected pre-symptomatic individuals. We establish a lower bound on the outbreak size at the origin as a function of the speed of spread. We associate the behavior change at the disease-importing locality due to the outbreak size at the origin with the level of preparedness of the locality. Using the lower bound on the outbreak size at the origin, we establish an upper bound on the outbreak size at the importing locality as a function of the speed of spread and the level of preparedness for low mobility regimes. We show the accuracy of the bounds in determining critical levels of preparedness that stop the disease from becoming endemic at neighboring localities. Finally, we show how the benefit of preparedness diminishes under high mobility rates. Our results highlight the importance of preparedness at localities where cases are beginning to rise, and demonstrate the benefits of increase in contact reduction by considering the outbreaks in neighboring localities with severe, rather than weak, outbreaks.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.24.20078493,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078493,Forecast analysis of the epidemics trend of COVID-19 in the United States by a generalized fractional-order SEIR model,Conghui Xu; Yongguang Yu; YangQuan Chen; Zhenzhen Lu; Adrin Garca-Sirera; Laura Prez; Nicholas J White; Yongfeng Chen; Wen Xie; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"Beijing Jiao Tong University; Beijing Jiao Tong University; University of California Merced; Beijing Jiao Tong University; Genetic Analysis Strategies S.L.; genetic PCR solutions; Mahidol Oxford Tropical Medicine Research Unit; Medical management department, Zhongnan Hospital of Wuhan University; Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","In this paper, a generalized fractional-order SEIR model is proposed, denoted by SEIQRP model, which has a basic guiding significance for the prediction of the possible outbreak of infectious diseases like COVID-19 and other insect diseases in the future. Firstly, some qualitative properties of the model are analyzed. The basic reproduction number R0 is derived. When R0 < 1, the disease-free equilibrium point is unique and locally asymptotically stable. When R0 > 1, the endemic equilibrium point is also unique. Furthermore, some conditions are established to ensure the local asymptotic stability of disease-free and endemic equilibrium points. The trend of COVID-19 spread in the United States is predicted. Considering the influence of the individual behavior and government mitigation measurement, a modified SEIQRP model is proposed, defined as SEIQRPD model. According to the real data of the United States, it is found that our improved model has a better prediction ability for the epidemic trend in the next two weeks. Hence, the epidemic trend of the United States in the next two weeks is investigated, and the peak of isolated cases are predicted. The modified SEIQRP model successfully capture the development process of COVID-19, which provides an important reference for understanding the trend of the outbreak.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.04.28.066977,2020-04-29,https://biorxiv.org/cgi/content/short/2020.04.28.066977,"Controlling the SARS-CoV-2 outbreak, insights from large scale whole genome sequences generated across the world",Jody Phelan; Wouter Deelder; Daniel Ward; Susana Campino; Martin L Hibberd; Taane G Clark; Zhao-Hua Lin; Yin-Qi Zeng; Da-Yu Wu; Ming Tang; Di Xu; Zonghua Liu; Ying-Cheng Lai; Angela Mo; Greg Gibson; John McLauchlan; Eleanor Barnes; John Kenneth Baillie; Sarah Teichmann; Alex Mentzer; John Todd; Julian Knight; Holm Uhlig; Paul Klenerman; Tang Chi Thuong; Guy Thwaites; Le Van Tan; Luca Borroni; Patrick Gerber; Ross Venook; Peter Baek MD; Nitin Arora M.D.; Philip Wagner MD; Roberto Miki MD; Jocelyne Kohn MD; David Kohn Bitran MD; John Pearson MD; Cristian Muniz Herrera MD; Manu Prakash,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; East China Normal University; East China Normal University; East China Normal University; East China Normal University; Fudan University; East China Normal University; Arizona State University - Tempe Campus; Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, USA; Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, USA; MRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, University of Glasgow, Glasgow, G61 1qh,; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK; Genetics and Genomics, Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK.; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton Cambridge, CB10 1SA UK; Wellcome Centre for Human Genetics, Roosevelt Dr, Headington, Oxford OX3 7BN; Wellcome Centre for Human Genetics, Roosevelt Dr, Headington, Oxford OX3 7BN; Wellcome Centre for Human Genetics, Roosevelt Dr, Headington, Oxford OX3 7BN; Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford OX3 9DU, UK; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK; Department of Health, Ho Chi Minh City, Vietnam; OUCRU; OUCRU; Italy; EPFL; Stanford University; US. Anesthesia Partners Texas, Dallas, USA; University of Alabama at Birmingham, Birmingham USA; Hospital for Special Surgery, New York City, USA; Miki & Alfonso Hand & Upper Extremity Center, Miami, USA; Instituto de Oftalmologia, Ophthalmologist, Santiago, Chile; Instituto de Oftalmologia, Ophthalmologist, Santiago, Chile; University of Utah; Santiago, Chile; Stanford University","BackgroundSARS-CoV-2 most likely evolved from a bat beta-coronavirus and started infecting humans in December 2019. Since then it has rapidly infected people around the world, with more than 4.5 million confirmed cases by the middle of May 2020. Early genome sequencing of the virus has enabled the development of molecular diagnostics and the commencement of therapy and vaccine development. The analysis of the early sequences showed relatively few evolutionary selection pressures. However, with the rapid worldwide expansion into diverse human populations, significant genetic variations are becoming increasingly likely. The current limitations on social movement between countries also offers the opportunity for these viral variants to become distinct strains with potential implications for diagnostics, therapies and vaccines.

MethodsWe used the current sequencing archives (NCBI and GISAID) to investigate 15,487 whole genomes, looking for evidence of strain diversification and selective pressure.

ResultsWe used 6,294 SNPs to build a phylogenetic tree of SARS-CoV-2 diversity and noted strong evidence for the existence of two major clades and six sub-clades, unevenly distributed across the world. We also noted that convergent evolution has potentially occurred across several locations in the genome, showing selection pressures, including on the spike glycoprotein where we noted a potentially critical mutation that could affect its binding to the ACE2 receptor. We also report on mutations that could prevent current molecular diagnostics from detecting some of the sub-clades.

ConclusionThe worldwide whole genome sequencing effort is revealing the challenge of developing SARS-CoV-2 containment tools suitable for everyone and the need for data to be continually evaluated to ensure accuracy in outbreak estimations.",genomics,exact,100,100
bioRxiv,10.1101/2020.04.29.067983,2020-04-29,https://biorxiv.org/cgi/content/short/2020.04.29.067983,Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection,Shufeng Liu; Christopher Lien; Prabhuanand Selveraj; Tony Wang; Martin L Hibberd; Taane G Clark; Zhao-Hua Lin; Yin-Qi Zeng; Da-Yu Wu; Ming Tang; Di Xu; Zonghua Liu; Ying-Cheng Lai; Angela Mo; Greg Gibson; John McLauchlan; Eleanor Barnes; John Kenneth Baillie; Sarah Teichmann; Alex Mentzer; John Todd; Julian Knight; Holm Uhlig; Paul Klenerman; Tang Chi Thuong; Guy Thwaites; Le Van Tan; Luca Borroni; Patrick Gerber; Ross Venook; Peter Baek MD; Nitin Arora M.D.; Philip Wagner MD; Roberto Miki MD; Jocelyne Kohn MD; David Kohn Bitran MD; John Pearson MD; Cristian Muniz Herrera MD; Manu Prakash,"US FDA; US FDA; US FDA; US FDA; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; East China Normal University; East China Normal University; East China Normal University; East China Normal University; Fudan University; East China Normal University; Arizona State University - Tempe Campus; Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, USA; Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, USA; MRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, University of Glasgow, Glasgow, G61 1qh,; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK; Genetics and Genomics, Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK.; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton Cambridge, CB10 1SA UK; Wellcome Centre for Human Genetics, Roosevelt Dr, Headington, Oxford OX3 7BN; Wellcome Centre for Human Genetics, Roosevelt Dr, Headington, Oxford OX3 7BN; Wellcome Centre for Human Genetics, Roosevelt Dr, Headington, Oxford OX3 7BN; Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford OX3 9DU, UK; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK; Department of Health, Ho Chi Minh City, Vietnam; OUCRU; OUCRU; Italy; EPFL; Stanford University; US. Anesthesia Partners Texas, Dallas, USA; University of Alabama at Birmingham, Birmingham USA; Hospital for Special Surgery, New York City, USA; Miki & Alfonso Hand & Upper Extremity Center, Miami, USA; Instituto de Oftalmologia, Ophthalmologist, Santiago, Chile; Instituto de Oftalmologia, Ophthalmologist, Santiago, Chile; University of Utah; Santiago, Chile; Stanford University","The global pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) has prompted multiple clinical trials to jumpstart search for anti-SARS-CoV-2 therapies from existing drugs, including those with reported in vitro efficacies as well as those ones that are not known to inhibit SARS-CoV-2, such as ritonavir/lopinavir and favilavir. Here we report that after screening 19 antiviral drugs that are either in clinical trials or with proposed activity against SARS-CoV-2, remdesivir was the most effective. Chloroquine only effectively protected virus-induced cytopathic effect at around 30 {micro}M with a therapeutic index of 1.5. Our findings also suggest that velpatasvir, ledipasvir, ritonavir, litonavir, lopinavir, favilavir, sofosbuvir, danoprevir, and pocapavir do not have direct antiviral effect.",microbiology,exact,100,100
medRxiv,10.1101/2020.04.21.20074732,2020-04-26,https://medrxiv.org/cgi/content/short/2020.04.21.20074732,Forecasting the impact of the first wave of the COVID-19 pandemic on hospital demand and deaths for the USA and European Economic Area countries,IHME COVID-19 health service utilization forecasting team; Christopher JL Murray; Zhiwen Zhao; Dhananjay Kalbande; B. N. Chaudhari; Thomas Monks; Jianbing Shen; Ling Shao; Naveed Sattar; Jill Pell; Srinivasa Vittal Katikireddi,"; Institute for Health Metrics and Evaluation; Beijing Normal University; Bharatiya Vidya Bhavan's Sardar Patel Institute of Technology; Bharatiya Vidya Bhavan's Sardar Patel Institute of Technology; University of Exeter; Inception Institute of Artificial Intelligence, Abu Dhabi, UAE; Inception Institute of Artificial Intelligence, Abu Dhabi, UAE; University of Glasgow; University of Glasgow; University of Glasgow","BackgroundHospitals need to plan for the surge in demand in each state or region in the United States and the European Economic Area (EEA) due to the COVID-19 pandemic. Planners need forecasts of the most likely trajectory in the coming weeks and will want to plan for the higher values in the range of those forecasts. To date, forecasts of what is most likely to occur in the weeks ahead are not available for states in the USA or for all countries in the EEA.

MethodsThis study used data on confirmed COVID-19 deaths by day from local and national government websites and WHO. Data on hospital capacity and utilisation and observed COVID-19 utilisation data from select locations were obtained from publicly available sources and direct contributions of data from select local governments. We develop a mixed effects non-linear regression framework to estimate the trajectory of the cumulative and daily death rate as a function of the implementation of social distancing measures, supported by additional evidence from mobile phone data. An extended mixture model was used in data rich settings to capture asymmetric daily death patterns. Health service needs were forecast using a micro-simulation model that estimates hospital admissions, ICU admissions, length of stay, and ventilator need using available data on clinical practices in COVID-19 patients. We assume that those jurisdictions that have not implemented school closures, non-essential business closures, and stay at home orders will do so within twenty-one days.

FindingsCompared to licensed capacity and average annual occupancy rates, excess demand in the USA from COVID-19 at the estimated peak of the epidemic (the end of the second week of April) is predicted to be 9,079 (95% UI 253-61,937) total beds and 9,356 (3,526-29,714) ICU beds. At the peak of the epidemic, ventilator use is predicted to be 16,545 (8,083-41,991). The corresponding numbers for EEA countries are 120,080 (119,183-121,107), 32,291 (32,157- 32,425) and 28,973 (28,868-29,085) at a peak of April 6. The date of peak daily deaths varies from March 30 through May 12 by state in the USA and March 27 through May 4 by country in the EEA. We estimate that through the end of July, there will be 60,308 (34,063-140,381) deaths from COVID-19 in the USA and 143,088 (101,131-253,163) deaths in the EEA. Deaths from COVID-19 are estimated to drop below 0.3 per million between May 4 and June 29 by state in the USA and between May 4 and July 13 by country in the EEA. Timing of the peak need for hospital resource requirements varies considerably across states in the USA and across regions of Europe.

InterpretationIn addition to a large number of deaths from COVID-19, the epidemic will place a load on health system resources well beyond the current capacity of hospitals in the USA and EEA to manage, especially for ICU care and ventilator use. These estimates can help inform the development and implementation of strategies to mitigate this gap, including reducing non-COVID-19 demand for services and temporarily increasing system capacity. The estimated excess demand on hospital systems is predicated on the enactment of social distancing measures within three weeks in all locations that have not done so already and maintenance of these measures throughout the epidemic, emphasising the importance of implementing, enforcing, and maintaining these measures to mitigate hospital system overload and prevent deaths.

FundingBill & Melinda Gates Foundation and the state of Washington",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.22.20072124,2020-04-24,https://medrxiv.org/cgi/content/short/2020.04.22.20072124,"Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV-2 infection, are heritable",Frances MK Williams; Maxim Freydin; Massimo Mangino; Simon Couvreur; Alessia Visconti; Ruth CE Bowyer; Caroline I Le Roy; Mario Falchi; Carole Sudre; Richard Davies; Christopher Hammond; Cristina Menni; Claire Steves; Tim Spector; Stephen Scott; Paul D.P. Pharoah; Charles Swanton; Christopher Abbosh; Matthew Williams; Georgios Lyratzopoulos; Richard Houlston; Clare Turnbull,"King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Ltd; King's College London; King's College London; King's College London; King's College London; RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust; University of Cambridge; The Francis Crick Institute; University College London Cancer Institute; The Francis Crick Institute; University College London Cancer Institute; Imperial College Healthcare NHS Trust; Imperial College London; National Cancer Registration and Analysis Service, Public Health England; University College London; Institute of Cancer Research; Institute of Cancer Research","Susceptibility to infection such as SARS-CoV-2 may be influenced by host genotype. TwinsUK volunteers (n=2633) completing the C-19 Covid symptom tracker app allowed classical twin studies of covid-19 symptoms including predicted covid-19, a symptom-based algorithm predicting true infection derived in app users tested for SARS-CoV-2. We found heritability for fever = 41 (95% confidence intervals 12-70)%; anosmia 47 (27-67)%; delirium 49 (24-75)%; and predicted covid-19 gave heritability = 50 (29-70)%.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.04.18.20070656,2020-04-24,https://medrxiv.org/cgi/content/short/2020.04.18.20070656,A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19,Yongshent Huang; Xiaoyu Lyu; Dan Li; Yujun Wang; Lin Wang; Wenbin Zou; Yingxin Wei; Xiaowei Wu; Carole Sudre; Richard Davies; Christopher Hammond; Cristina Menni; Claire Steves; Tim Spector; Stephen Scott; Paul D.P. Pharoah; Charles Swanton; Christopher Abbosh; Matthew Williams; Georgios Lyratzopoulos; Richard Houlston; Clare Turnbull,"School of Basic Medicine Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; Department of Endocrinology, the Central Hospital of Wuhan , Tongji Medical College, Huazhong University of Science and Technology; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scie; Department of Critical care medicine, the Central Hospital of Wuhan , Tongji Medical College, Huazhong University of Science and Technology; School of Basic Medicine Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology; King's College London; Zoe Global Ltd; King's College London; King's College London; King's College London; King's College London; RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust; University of Cambridge; The Francis Crick Institute; University College London Cancer Institute; The Francis Crick Institute; University College London Cancer Institute; Imperial College Healthcare NHS Trust; Imperial College London; National Cancer Registration and Analysis Service, Public Health England; University College London; Institute of Cancer Research; Institute of Cancer Research","BACKGROUNDCoronavirus Disease 2019 (COVID-19) has recently become a public emergency and a worldwide pandemic. The clinical symptoms of severe and non-severe patients vary, and the case-fatality rate (CFR) in severe COVID-19 patients is very high. However, the information on the risk factors associated with the severity of COVID-19 and of their prognostic potential is limited.

METHODSIn this retrospective study, the clinical characteristics, laboratory findings, treatment and outcome data were collected and analyzed from 223 COVID-19 patients stratified into 125 non-severe patients and 98 severe patients. In addition, a pooled large-scale meta-analysis of 1646 cases was performed.

RESULTSWe found that the age, gender and comorbidities are the common risk factors associated with the severity of COVID-19. For the diagnosis markers, we found that the levels of D-dimer, C-reactive protein (CRP), lactate dehydrogenase (LDH), procalcitonin (PCT) were significantly higher in severe group compared with the non-severe group on admission (D-Dimer: 87.3% vs. 35.3%, P<0.001; CRP, 65.1% vs. 13.5%, P<0.001; LDH: 83.9% vs. 22.2%, P<0.001; PCT: 35.1% vs. 2.2%, P<0.001), while the levels of aspartate aminotransferase (ASP) and creatinine kinase (CK) were only mildly increased. We also made a large scale meta-analysis of 1646 cases combined with 4 related literatures, and further confirmed the relationship between the COVID-19 severity and these risk factors. Moreover, we tracked dynamic changes during the process of COVID-19, and found CRP, D-dimer, LDH, PCT kept in high levels in severe patient. Among all these markers, D-dimer increased remarkably in severe patients and mostly related with the case-fatality rate (CFR). We found adjuvant antithrombotic treatment in some severe patients achieved good therapeutic effect in the cohort.

CONCLUSIONSThe diagnosis markers CRP, D-dimer, LDH and PCT are associated with severity of COVID-19. Among these markers, D-dimer is sensitive for both severity and CFR of COVID-19. Treatment with heparin or other anticoagulants may be beneficial for COVID-19 patients.

FundingThis study was supported by funding from the National Key Research and Development Program of China (2016YFC1302203); Beijing Nova Program (grant number: xx2018040).

Role of the funding sourceThe funding listed above supports this study, but had no role in the design and conduct of the study.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.19.20071357,2020-04-24,https://medrxiv.org/cgi/content/short/2020.04.19.20071357,Immune defects and cardiovascular risk in X chromosome monosomy mosaicism mediated by loss of chromosome Y. A risk factor for SARS-CoV-2 vulnerability in elderly men?,Luis A Perez-Jurado; Alejandro Caceres; Tonu Esko; Juan R Gonzalez; Lin Wang; Wenbin Zou; Yingxin Wei; Xiaowei Wu; Carole Sudre; Richard Davies; Christopher Hammond; Cristina Menni; Claire Steves; Tim Spector; Stephen Scott; Paul D.P. Pharoah; Charles Swanton; Christopher Abbosh; Matthew Williams; Georgios Lyratzopoulos; Richard Houlston; Clare Turnbull,"Genetics Unit, Universitat Pompeu Fabra, Hospital del Mar Research Institute (IMIM); ISGlobal; EGCUT; Barcelona Institute for Global Health; School of Basic Medicine Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology; King's College London; Zoe Global Ltd; King's College London; King's College London; King's College London; King's College London; RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust; University of Cambridge; The Francis Crick Institute; University College London Cancer Institute; The Francis Crick Institute; University College London Cancer Institute; Imperial College Healthcare NHS Trust; Imperial College London; National Cancer Registration and Analysis Service, Public Health England; University College London; Institute of Cancer Research; Institute of Cancer Research","The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) has an estimated overall case fatality ratio of 1.38% in China, being 53% higher in males and increasing exponentially with age. Mosaicism for X chromosome monosomy (XCM) shows a similar increase in aging population mostly driven by loss of chromosome Y in males (LOY), and is associated with a raise in all-cause mortality. Using comparative transcriptomic data, we have defined that XCM/LOY is associated with abnormal peripheral blood cell counts with decreased progenitor cells and multiple biomarkers of immune system dysfunction, pro-coagulation activity and increased cardiovascular risk. Several differentially down-regulated genes in XCM/LOY individuals are involved in the initial immune response to SARS-CoV-2 (OR of enrichment=7.23, p=1.5x10-7), mainly interferon-induced genes that code for inhibitors of viral processes. Thus, our data suggest that XCM mosaicism underlies at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential relevance for modulating prognosis and therapeutic response, we propose that evaluation of LOY and XCM by currently established methods should be implemented as biomarkers in infected patients, including currently ongoing clinical trials with different medications and vaccines for COVID-19. Testing for LOY/XCM at large scale among elderly people may also be helpful to identify still unexposed people who may be especially vulnerable to severe Covid-19 disease.",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.04.21.20073049,2020-04-24,https://medrxiv.org/cgi/content/short/2020.04.21.20073049,What can trends in hospital deaths from COVID-19 tell us about the progress and peak of the pandemic? An analysis of death counts from England announced up to 20 April 2020,David A Leon; Christopher I Jarvis; Anne M Johnson; Liam Smeeth; Vladimir M Shkolnikov; Claudia Gambarrutta-Malfatti; Eduardo Vargas-Baquero; Scott Solomon; Pardeep Singh Jhund; Milad Sanginabadi; Talat Mokhtari Azad; Leila Aghaghazvini; Sara Ghaderkhani; Tahereh Poordast; Alieh Pourdast; Pershang Nazemi,"London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; London School of Hygiene & Tropical Medicine; Max Planck Institute for Demographic Research; National Hospital for Paraplegics; National Hospital for Paraplegics; Division of Cardiovascular Medicine, Brigham and Women's Hospital; University of Glasgow; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Shiraz University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences","BackgroundReporting of daily hospital COVID-19 deaths in the UK are promoted by the government and scientific advisers alike as a key metric for assessing the progress in the control of the epidemic. These data, however, have certain limitations, among which one of the most significant concerns the fact that the daily totals span deaths that have occurred between 1 and 10 days or more in the past.

Data and methodsWe obtained daily data published published by NHS England up to and including April 25 in the form of Excel spreadsheets in which deaths counts are presented by date of death according to age and region. Simple descriptive analyses were conducted and presented in graphical and tabular form which were aimed at illustrating the biases inherent in focussing on daily counts regardless of when the deaths occurred. We then looked at how a less biased picture could be obtained by looking at trends in death counts stratifying by individual period of delay in days between occurrence of death and when the death was included in the daily announcement.

FindingsThe number of hospital COVID-19 deaths announced daily overestimates the maximum number of deaths actually occurring so far in the epidemic in the UK, and also obscures the pattern of decline in deaths. Taking account of reporting delays suggests that for England as a whole a peak in hospital COVID-19 deaths may have been reached on April 8 with a subsequent gradual decline suggested. The same peak is also seen among those aged 60-79 and 80+, although there is slightly shallower decline in the oldest age group (80+ years). Among those aged 40-59 years a later peak on April 11 is evident. London shows a peak on April 8 and a clearer and steeper pattern of subsequent decline compared to England as a whole.

InterpretationAnalyses of mortality trends must take account of delay, and in communication with the public more emphasis should be placed on looking at trends based on deaths that occurred 5 or more days prior to the announcement day. The slightly weaker decline seen at age 80+ may reflect increased hospitalisation of people from care homes, whereas the later peak under the age of 60 years may reflect the higher proportions at these younger ages being admitted to critical care resulting in an extension of life of several days.

Competing interestsAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years other than LS who reported grants from Wellcome, MRC, NIHR, GSK, BHF, Diabetes UK all outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work other than LS who is a Trustee of the British Heart Foundation and AJM who is a member of the Royal Society Delve Committee.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.18.20064774,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.18.20064774,"How many are at increased risk of severe COVID-19 disease? Rapid global, regional and national estimates for 2020",Andrew Clark; Mark Jit; Charlotte Warren-Gash; Bruce Guthrie; Harry HX Wang; Stewart W Mercer; Colin Sanderson; Martin McKee; Christopher Troeger; Kanyin I Ong; Francesco Checchi; Pablo Perel; Sarah Joseph; Hamish P Gibbs; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel,LSHTM; London School of Hygiene & Tropical Medicine; LSHTM; Edinburgh University; Sun Yat-Sen University; Edinburgh University; LSHTM; LSHTM; University of Washington; University of Washington; LSHTM; LSHTM; IAVI; LSHTM; UCL; ; London School of Hygiene & Tropical Medicine; Miltenyi Biotec GmbH; Miltenyi Biotec GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; JPT Petide Technologies GmbH; JPT Peptide Technologies GmbH; JPT Peptide Technologies GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Max Planck Institute for Molecular Genetics; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin,"BackgroundThe risk of severe COVID-19 disease is known to be higher in older individuals and those with underlying health conditions. Understanding the number of individuals at increased risk of severe COVID-19 illness, and how this varies between countries may inform the design of possible strategies to shield those at highest risk.

MethodsWe estimated the number of individuals at increased risk of severe COVID-19 disease by age (5-year age groups), sex and country (n=188) based on prevalence data from the Global Burden of Disease (GBD) study for 2017 and United Nations population estimates for 2020. We also calculated the number of individuals without an underlying condition that could be considered at-risk because of their age, using thresholds from 50-70 years. The list of underlying conditions relevant to COVID-19 disease was determined by mapping conditions listed in GBD to the guidelines published by WHO and public health agencies in the UK and US. We analysed data from two large multimorbidity studies to determine appropriate adjustment factors for clustering and multimorbidity.

ResultsWe estimate that 1.7 (1.0 - 2.4) billion individuals (22% [15-28%] of the global population) are at increased risk of severe COVID-19 disease. The share of the population at increased risk ranges from 16% in Africa to 31% in Europe. Chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes and chronic respiratory disease (CRD) were the most prevalent conditions in males and females aged 50+ years. African countries with a high prevalence of HIV/AIDS and Island countries with a high prevalence of diabetes, also had a high share of the population at increased risk. The prevalence of multimorbidity (>1 underlying conditions) was three times higher in Europe than in Africa (10% vs 3%).

ConclusionBased on current guidelines and prevalence data from GBD, we estimate that one in five individuals worldwide has a condition that is on the list of those at increased risk of severe COVID-19 disease. However, for many of these individuals the underlying condition will be undiagnosed or not severe enough to be captured in health systems, and in some cases the increase in risk may be quite modest. There is an urgent need for robust analyses of the risks associated with different underlying conditions so that countries can identify the highest risk groups and develop targeted shielding policies to mitigate the effects of the COVID-19 pandemic.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSAs the COVID-19 pandemic evolves, countries are considering policies of  shielding the most vulnerable, but there is currently very limited evidence on the number of individuals that might need to be shielded. Guidelines on who is currently believed to be at increased risk of severe COVID-19 illness have been published online by the WHO and public health agencies in the UK and US. We searched PubMed (""Risk factors"" AND ""COVID-19"") without language restrictions, from database inception until April 5, 2020, and identified 62 studies published between Feb 15, 2020 and March 20, 2020. Evidence from China, Italy and the USA indicates that older individuals, males and those with underlying conditions, such as CVD, diabetes and CRD, are at greater risk of severe COVID-19 illness and death.

Added value of this studyThis study combines evidence from large international databases and new analysis of large multimorbidity studies to inform policymakers about the number of individuals that may be at increased risk of severe COVID-19 illness in different countries. We developed a tool for rapid assessments of the number and percentage of country populations that would need to be targeted under different shielding policies.

Implications of all the available evidenceQuantifying how many and who is at increased risk of severe COVID-19 illness is critical to help countries design more effective interventions to protect vulnerable individuals and reduce pressure on health systems. This information can also inform a broader assessment of the health, social and economic implications of shielding various groups.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.17.20059535,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.17.20059535,"Modeling projections for COVID-19 pandemic by combining epidemiological, statistical, and neural network approaches",Steffen Uhlig; Kapil Nichani; Carsten Uhlig; Kirsten Simon; Harry HX Wang; Stewart W Mercer; Colin Sanderson; Martin McKee; Christopher Troeger; Kanyin I Ong; Francesco Checchi; Pablo Perel; Sarah Joseph; Hamish P Gibbs; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel,QuoData GmbH; QuoData GmbH; Akees GmbH; QuoData GmbH; Sun Yat-Sen University; Edinburgh University; LSHTM; LSHTM; University of Washington; University of Washington; LSHTM; LSHTM; IAVI; LSHTM; UCL; ; London School of Hygiene & Tropical Medicine; Miltenyi Biotec GmbH; Miltenyi Biotec GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; JPT Petide Technologies GmbH; JPT Peptide Technologies GmbH; JPT Peptide Technologies GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Max Planck Institute for Molecular Genetics; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin,"As the number of people affected by COVID-19 disease caused by the novel coronavirus SARS-CoV-2 ebbs and flows in different national and sub-national regions across the world, it is evident that our lifestyle and socio-economic trajectories will have to be adapted and adjusted to the changing scenarios. Novel forecasting tools and frameworks provide an arguable advantage to facilitate this adapting and adjusting process, by promoting efficient resource management at individual and institutional levels. Based on deterministic compartment models we propose an empirical top-down modeling approach to provide epidemic forecasts and risk calculations for (local) outbreaks. We use neural networks to develop leading indicators based on available data for different regions. These indicators are not only used to assess the risk of a (new) outbreak or to determine the effectiveness of a measure at an early stage, but also in parametric models to determine an effective forecast, along with the associated uncertainty. Based on initial results, we show the performance of such an approach and its robustness against inherent disturbances in epidemiological surveillance data. We foresee such a statistical framework to drive web-based automatic platforms to democratize the dissemination of prognosis results.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.16.20067975,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.16.20067975,LONG-TERM CLINICAL OUTCOMES IN SURVIVORS OF CORONAVIRUS OUTBREAKS AFTER HOSPITALISATION OR ICU ADMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FOLLOW-UP STUDIES,Hassaan Ahmed; Kajal Patel; Darren Greenwood; Stephen Halpin; Penny Lewthwaite; Abayomi Salawu; Lorna Eyre; Andrew Breen; Anthony Jones; Manoj Sivan; Francesco Checchi; Pablo Perel; Sarah Joseph; Hamish P Gibbs; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel,University of Manchester; University of Manchester; University of Leeds; University of Leeds; Leeds Teaching Hospitals NHS Trust; Hull University Teaching Hospitals NHS Trust; Leeds Teaching Hospitals NHS Trust; Leeds Teaching Hospitals NHS Trust; University of Manchester; University of Leeds; LSHTM; LSHTM; IAVI; LSHTM; UCL; ; London School of Hygiene & Tropical Medicine; Miltenyi Biotec GmbH; Miltenyi Biotec GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; JPT Petide Technologies GmbH; JPT Peptide Technologies GmbH; JPT Peptide Technologies GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Max Planck Institute for Molecular Genetics; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin,"ObjectiveTo determine the long-term clinical problems in adult survivors of coronavirus (CoV) infection [Coronavirus disease 2019 (COVID-19), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)] after hospitalisation or Intensive Care Unit (ICU) admission.

DesignSystematic review and meta-analysis of the literature.

Data sourcesOvid MEDLINE, EMBASE, CINAHL Plus and PsycINFO were searched using the strategy: (Coronavirus OR Coronavirus Infections OR COVID OR SARS virus OR Severe acute respiratory syndrome OR MERS OR Middle east respiratory syndrome) AND (Follow-up OR Follow-up studies OR Prevalence). Original studies reporting the clinical outcomes of adult survivors of coronavirus outbreaks two months after discharge or three months after admission were included. The quality of the studies was assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2009 Level of Evidence Tool. Meta-analysis was conducted to derive pooled estimates of prevalence and severity for different outcomes at time points up to 6 months follow-up and beyond 6 months follow-up.

ResultsThe search yielded 1169 studies of which 28 were included in this review. There were 15 Level 1b, 8 Level 2b, 2 Level 3b and 3 Level 4 studies by OCEBM grading. Pooled analysis of studies revealed that complications commonly observed were impaired diffusing capacity for carbon monoxide (DLCO) [prevalence of 27.26%, 95% CI 14.87 to 44.57] and reduced exercise capacity [(6-minute walking distance (6MWD) mean 461m, 95% CI 449.66 to 472.71] at 6 months with limited improvement beyond 6 months. Coronavirus survivors had considerable prevalence of psychological disorders such as post-traumatic stress disorder (PTSD) [38.80%, CI 30.93 to 47.31], depression [33.20%, CI 19.80 to 50.02] and anxiety [30.04%, CI 10.44 to 61.26) beyond 6 months. These complications were accompanied by low Short Form 36 (SF-36) scores at 6 months and beyond indicating reduced quality of life which is present long-term.

ConclusionsThe long term clinical problems in survivors of CoV infections (SARS and MERS) after hospitalisation or Intensive Care Unit (ICU) admission include respiratory dysfunction, reduced exercise capacity, psychological problems such as PTSD, depression and anxiety, and reduced quality of life. Critical care, rehabilitation and mental health services should anticipate a high prevalence of these problems following COVID-19 and ensure their adequate and timely management with the aim of restoring premorbid quality of life.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.18.20070367,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.18.20070367,Utah-Stanford Ventilator (Vent4US): Developing a rapidlyscalable ventilator for COVID-19 patients with ARDS,Hongquan Li; Ethan Li; Deepak Krishnamurthy; Patrick Kolbay; Beca Chacin; Soeren Hoehne; Jim Cybulski; Lara Brewer; Tomasz Petelenz; Joseph Orr; Derek Sakata; Thomas Clardy; Kai Kuck; Manu Prakash; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel,"Stanford University; Stanford University; Stanford University; University of Utah; University of Utah; University of Utah; Foldscope Instruments; University of Utah; University of Utah; University of Utah; University of Utah; CKC Medical, Utah; University of Utah; Stanford University; UCL; ; London School of Hygiene & Tropical Medicine; Miltenyi Biotec GmbH; Miltenyi Biotec GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; JPT Petide Technologies GmbH; JPT Peptide Technologies GmbH; JPT Peptide Technologies GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Max Planck Institute for Molecular Genetics; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin","We describe a minimum, rapidly scalable ventilator designed for COVID-19 patients with ARDS. Our design philosophy is not only to try to address potential ventilator shortages, but also to account for uncertainties in the supply chains of parts commonly used in traditional ventilators. To do so we employ a modular design approach and broadly explore taking advantage of parts from non-traditional supply chains. In our current prototype, we demonstrate volume control with assist control on a test lung and present a linear actuator-driven pinch valve-based implementation for both pressure control and volume control with decelerating inspiratory flow. We estimate the component cost of the system to be around $500. We publish our draft design documents and current implementation which is open and accessible in the hope that broadening the community globally will accelerate arriving at a solution and that peer review will improve the final design.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.04.16.20067991,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.16.20067991,The Contribution of Age Structure to the Number of Deaths from Covid-19 in the UK by Geographical Units,Hill Kulu; Peter Dorey; Deepak Krishnamurthy; Patrick Kolbay; Beca Chacin; Soeren Hoehne; Jim Cybulski; Lara Brewer; Tomasz Petelenz; Joseph Orr; Derek Sakata; Thomas Clardy; Kai Kuck; Manu Prakash; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel,"University of St Andrews; University of St Andrews; Stanford University; University of Utah; University of Utah; University of Utah; Foldscope Instruments; University of Utah; University of Utah; University of Utah; University of Utah; CKC Medical, Utah; University of Utah; Stanford University; UCL; ; London School of Hygiene & Tropical Medicine; Miltenyi Biotec GmbH; Miltenyi Biotec GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; JPT Petide Technologies GmbH; JPT Peptide Technologies GmbH; JPT Peptide Technologies GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Max Planck Institute for Molecular Genetics; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin","This study investigates the contribution of population age structure to mortality from Covid-19 in the UK by geographical units. We project death rates at various spatial scales by applying data on age-specific fatality rates to the areas population by age and sex. Our analysis shows a significant variation in the projected death rates between the constituent countries of the UK, between its regions and within regions. First, Scotland and Wales have higher projected fatality levels from Covid-19 than England, whereas Northern Ireland has lower rate. Second, the infection fatality rates are projected to be substantially higher in small towns and rural areas than those in large urban areas. Third, our analysis shows that within urban regions there are also  pockets of high projected death rates. Overall, the areas with high and low fatality rates tend to cluster because of the high residential separation of different population age-groups in the UK. Our analysis also reveals that the Welsh-, Gaelic- and Cornish-speaking communities with relatively old populations are likely to experience heavy population losses if the virus spreads widely across the UK.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.16.20067884,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.16.20067884,"""No test is better than a bad test"": Impact of diagnostic uncertainty in mass testing on the spread of Covid-19",Nicholas Gray; Dominic Calleja; Alexander Wimbush; Enrique Miralles-Dolz; Ander Gray; Marco De-Angelis; Elfride Derrer-Merk; Bright Uchenna Oparaji; Vladimir Stepanov; Louis Clearkin; Scott Ferson; Thomas Clardy; Kai Kuck; Manu Prakash; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel,"University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; Wirral & Liverpool University Teaching Hospitals; University of Liverpool; CKC Medical, Utah; University of Utah; Stanford University; UCL; ; London School of Hygiene & Tropical Medicine; Miltenyi Biotec GmbH; Miltenyi Biotec GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; JPT Petide Technologies GmbH; JPT Peptide Technologies GmbH; JPT Peptide Technologies GmbH; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin; Max Planck Institute for Molecular Genetics; Charite Universitaetsmedizin Berlin; Charite Universitaetsmedizin Berlin","Testing is viewed as a critical aspect of any strategy to tackle epidemics. Much of the dialogue around testing has concentrated on how countries can scale up capacity, but the uncertainty in testing has not received nearly as much attention beyond asking if a test is accurate enough to be used. Even for highly accurate tests, false positives and false negatives will accumulate as mass testing strategies are employed under pressure, and these misdiagnoses could have major implications on the ability of governments to suppress the virus. The present analysis uses a modified SIR model to understand the implication and magnitude of misdiagnosis in the context of ending lockdown measures. The results indicate that increased testing capacity alone will not provide a solution to lockdown measures. The progression of the epidemic and peak infections is shown to depend heavily on test characteristics, test targeting, and prevalence of the infection. Antibody based immunity passports are rejected as a solution to ending lockdown, as they can put the population at risk if poorly targeted. Similarly, mass screening for active viral infection may only be beneficial if it can be sufficiently well targeted, otherwise reliance on this approach for protection of the population can again put them at risk. A well targeted active viral test combined with a slow release rate is a viable strategy for continuous suppression of the virus.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.14.20065417,2020-04-17,https://medrxiv.org/cgi/content/short/2020.04.14.20065417,Clinical academic research in the time of Corona: a simulation study in England and a call for action,Amitava Banerjee; Michail Katsoulis; Alvina G Lai; Laura Pasea; Thomas A Treibel; Charlotte Manisty; Spiros Denaxas; Giovanni Quarta; Harry Hemingway; Joao Cavalcante; Mahdad Nousardeghi; James C Moon; Ramy Arnaout; Zhengxiu Luo Sr.; Enmei Liu Sr.; Xiaohui Wang Jr.; Yaolong Chen Sr.; Fabienne Gas; Laurent Bellanger; Jean Armengaud,"University College London; University College London; University College London; University College London; University College London; University College London; University College London; Ospedale Papa Giovanni XXIII, Bergamo, Italy; University College London; Minneapolis Heart Institute, Minneapolis, Minnesota. USA; University College London; University College London; Beth Israel Deaconess Medical Center; Department of Respiratory Medicine, Childrens Hospital of Chongqing Medical University; Department of Respiratory Medicine, Childrens Hospital of Chongqing Medical University; School of Public Health, Lanzhou University; Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University; CEA; CEA; CEA","BackgroundCoronavirus (COVID-19) poses health system challenges in every country. As with any public health emergency, a major component of the global response is timely, effective science. However, particular factors specific to COVID-19 must be overcome to ensure that research efforts are optimised. We aimed to model the impact of COVID-19 on the clinical academic response in the UK, and to provide recommendations for COVID-related research.

MethodsWe constructed a simple stochastic model to determine clinical academic capacity in the UK in four policy approaches to COVID-19 with differing population infection rates: ""Italy model"" (6%), ""mitigation"" (10%), ""relaxed mitigation"" (40%) and ""do-nothing"" (80%) scenarios. The ability to conduct research in the COVID-19 climate is affected by the following key factors: (i) infection growth rate and population infection rate (from UK COVID-19 statistics and WHO); (ii) strain on the healthcare system (from published model); and (iii) availability of clinical academic staff with appropriate skillsets affected by frontline clinical activity and sickness (from UK statistics).

FindingsIn ""Italy model"", ""mitigation"", ""relaxed mitigation"" and ""do-nothing"" scenarios, from 5 March 2020 the duration (days) and peak infection rates (%) are 95(2.4%), 115(2.5%), 240(5.3%) and 240(16.7%) respectively. Near complete attrition of academia (87% reduction, <400 clinical academics) occurs 35 days after pandemic start for 11, 34, 62, 76 days respectively - with no clinical academics at all for 37 days in the ""do-nothing"" scenario. Restoration of normal academic workforce (80% of normal capacity) takes 11,12, 30 and 26 weeks respectively.

InterpretationPandemic COVID-19 crushes the science needed at system level. National policies mitigate, but the academic community needs to adapt. We highlight six key strategies: radical prioritisation (eg 3-4 research ideas per institution), deep resourcing, non-standard leadership (repurposing of key non-frontline teams), rationalisation (profoundly simple approaches), careful site selection (eg protected sites with large academic backup) and complete suspension of academic competition with collaborative approaches.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.04.15.20066019,2020-04-17,https://medrxiv.org/cgi/content/short/2020.04.15.20066019,Forecasting Hospital Staff Availability During The COVID-19 Epidemic,Chloe N Schooling; Norbert Gyenge; Visakan Kadirkamanathan; James J.P. Alix; Thomas A Treibel; Charlotte Manisty; Spiros Denaxas; Giovanni Quarta; Harry Hemingway; Joao Cavalcante; Mahdad Nousardeghi; James C Moon; Ramy Arnaout; Zhengxiu Luo Sr.; Enmei Liu Sr.; Xiaohui Wang Jr.; Yaolong Chen Sr.; Fabienne Gas; Laurent Bellanger; Jean Armengaud,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University College London; University College London; University College London; Ospedale Papa Giovanni XXIII, Bergamo, Italy; University College London; Minneapolis Heart Institute, Minneapolis, Minnesota. USA; University College London; University College London; Beth Israel Deaconess Medical Center; Department of Respiratory Medicine, Childrens Hospital of Chongqing Medical University; Department of Respiratory Medicine, Childrens Hospital of Chongqing Medical University; School of Public Health, Lanzhou University; Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University; CEA; CEA; CEA","The COVID-19 pandemic poses two challenges to healthcare providers. Firstly, a high number of patients require hospital admission. Second, a high number of healthcare staff are either falling ill with the infection, or self-isolating. This poses significant problems for the staffing of busy hospital departments. We have created a simple model which allows users to stress test their rota. The model provides plots of staff availability over time using either a constant infection rate, or a changing infection rate fitted to population-based infection curves. It allows users to gauge the extent and timing of dips in staff availability. The basic constant infection rate model is available within an on-line web application (https://covid19.shef.ac.uk). As for any model, our work is imperfect. However, it allows a range of infection rates to be simulated quickly across different work patterns. We hope it will be useful to those planning staff deployment and will stimulate debate on the most effective patterns of work during the COVID-19 epidemic.",health systems and quality improvement,exact,100,100
medRxiv,10.1101/2020.04.09.20059865,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059865,Forecasting the scale of the COVID-19 epidemic in Kenya,Samuel P C Brand; Rabia Aziza; Ivy K Kombe; Charles N Agoti; Joe Hilton; Kat S Rock; Andrea Parisi; D James Nokes; Matt Keeling; Edwine Barasa; Meiling Zhang; Gaojing Qu; Wufeng Fan; Hongming Lin; Desheng Li; Bin Pei,"University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme; Kenya Medical Research Institute, Wellcome Trust Research Programme; University of Warwick; University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme and University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital","BackgroundThe first COVID-19 case in Kenya was confirmed on March 13th, 2020. Here, we provide forecasts for the potential incidence rate, and magnitude, of a COVID-19 epidemic in Kenya based on the observed growth rate and age distribution of confirmed COVID-19 cases observed in China, whilst accounting for the demographic and geographic dissimilarities between China and Kenya.

MethodsWe developed a modelling framework to simulate SARS-CoV-2 transmission in Kenya, KenyaCoV. KenyaCoV was used to simulate SARS-CoV-2 transmission both within, and between, different Kenyan regions and age groups. KenyaCoV was parameterized using a combination of human mobility data between the defined regions, the recent 2019 Kenyan census, and estimates of age group social interaction rates specific to Kenya. Key epidemiological characteristics such as the basic reproductive number and the age-specific rate of developing COVID-19 symptoms after infection with SARS-CoV-2, were adapted for the Kenyan setting from a combination of published estimates and analysis of the age distribution of cases observed in the Chinese outbreak.

ResultsWe find that if person-to-person transmission becomes established within Kenya, identifying the role of subclinical, and therefore largely undetected, infected individuals is critical to predicting and containing a very significant epidemic. Depending on the transmission scenario our reproductive number estimates for Kenya range from 1.78 (95% CI 1.44 -2.14) to 3.46 (95% CI 2.81-4.17). In scenarios where asymptomatic infected individuals are transmitting significantly, we expect a rapidly growing epidemic which cannot be contained only by case isolation. In these scenarios, there is potential for a very high percentage of the population becoming infected (median estimates: >80% over six months), and a significant epidemic of symptomatic COVID-19 cases. Exceptional social distancing measures can slow transmission, flattening the epidemic curve, but the risk of epidemic rebound after lifting restrictions is predicted to be high.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.09.20059832,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059832,Standardization and Age-Distribution of COVID-19: Implications for Variability in Case Fatality and Outbreak Identification,David Fisman; Amy Greer; Ashleigh Tuite; Charles N Agoti; Joe Hilton; Kat S Rock; Andrea Parisi; D James Nokes; Matt Keeling; Edwine Barasa; Meiling Zhang; Gaojing Qu; Wufeng Fan; Hongming Lin; Desheng Li; Bin Pei,"University of Toronto; University of Guelph; University of Toronto; Kenya Medical Research Institute, Wellcome Trust Research Programme; University of Warwick; University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme and University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital","BackgroundEpidemiological data from the COVID-19 pandemic has demonstrated variability in attack rates by age, and country-to-country variability in case fatality ratio (CFR).

ObjectiveTo use direct and indirect standardization for insights into the impact of age-specific under-reporting on between-country variability in CFR, and apparent size of COVID-19 epidemics.

DesignPost-hoc secondary data analysis (""case studies""), and mathematical modeling.

SettingChina, global.

InterventionsNone.

MeasurementsData were extracted from a sentinel epidemiological study by the Chinese Center for Disease Control (CCDC) that describes attack rates and CFR for COVID-19 in China prior to February 12, 2020. Standardized morbidity ratios (SMR) were used to impute missing cases and adjust CFR. Age-specific attack rates and CFR were applied to different countries with differing age structures (Italy, Japan, Indonesia, and Egypt), in order to generate estimates for CFR, apparent epidemic size, and time to outbreak recognition for identical age-specific attack rates.

ResultsSMR demonstrated that 50-70% of cases were likely missed during the Chinese epidemic. Adjustment for under-recognition of younger cases decreased CFR from 2.4% to 0.8% (assuming 50% case ascertainment in older individuals). Standardizing the Chinese epidemic to countries with older populations (Italy, and Japan) resulted in larger apparent epidemic sizes, higher CFR and earlier outbreak recognition. The opposite effect was demonstrated for countries with younger populations (Indonesia, and Egypt).

LimitationsSecondary data analysis based on a single country at an early stage of the COVID-19 pandemic, with no attempt to incorporate second order effects (ICU saturation) on CFR.

ConclusionDirect and indirect standardization are simple tools that provide key insights into between-country variation in the apparent size and severity of COVID-19 epidemics.

FundingThe research was supported by a grant to DNF from the Canadian Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.09.20059659,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059659,"How do environmental, economic and health factors influence regional vulnerability to COVID-19?",Pejman Tahmasebi; Salome M.S. Shokri-Kuehni; Muhammad Sahimi; Nima Shokri; Joe Hilton; Kat S Rock; Andrea Parisi; D James Nokes; Matt Keeling; Edwine Barasa; Meiling Zhang; Gaojing Qu; Wufeng Fan; Hongming Lin; Desheng Li; Bin Pei,"University of Wyoming; Imperial College London; University of Southern California; The University of Manchester; University of Warwick; University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme and University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital","We have studied the correlations between twelve environmental, economic and health variables, by carrying out a statistical analysis of the fatality rate of COVID-19 in 14 countries. Our statistical analysis indicates that, among the 12 variables, the diabetes percentage of the total population and the extent of the population ages 65 and older in each country are correlated most strongly with the total number of deaths in them. Although the strength of the correlations between the variables and the total ND may change as the ongoing pandemic evolves, the study highlights the importance of integrating regional-specific variables in the modelling efforts aimed at projecting how the spread of the virus may influence different parts of the world.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.09.20059683,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059683,Case- fatality rate in COVID- 19 patients: A meta-analysis of publicly accessible database,Souvik Maitra; Mansij Biswas; Sulagna Bhattacharjee; Nima Shokri; Joe Hilton; Kat S Rock; Andrea Parisi; D James Nokes; Matt Keeling; Edwine Barasa; Meiling Zhang; Gaojing Qu; Wufeng Fan; Hongming Lin; Desheng Li; Bin Pei,"All India Institute of Medical Sciences, New Delhi; Boehringer Ingelheim; All India Institute of Medical Sciences, New Delhi; The University of Manchester; University of Warwick; University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme and University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital; Xiangyang No.1 Peoples Hospital","A novel coronavirus was reported in Wuhan, China in December 2019 to cause severe acute respiratory symptoms (COVID-19). In this meta-analysis, we estimated case fatality rate from COVID-19 infection by random effect meta-analysis model with country level data. Publicly accessible web database WorldOMeter (https://www.worldometers.info/coronavirus/) was accessed on 24th March 2020 GMT and reported total number of cases, total death, active cases and seriously ill/ critically ill patients were retrieved. Primary outcome of this meta-analysis was case fatality rate defined by total number of deaths divided by total number of diagnosed cases. Pooled case fatality rate (95% CI) was 1.78 (1.34-2.22) %. Between country heterogeneity was 0.018 (p<0.0001). Pooled estimate of composite poor outcome (95% CI) was 4.06 (3.24-4.88) % at that point of time after exclusion of countries reported small number of cases. Pooled mortality rate (95% CI) was 33.97 (27.44-40.49) % amongst closed cases (where patients have recovered or died) with. Meta regression analysis identified statistically significant association between health expenditure and case fatality rate (p=0.0017).",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.04.10.20059121,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.10.20059121,"ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study",Dipender Gill; Marios Arvanitis; Paul Carter; Ana I Hernandez Cordero; Brian Jo; Ville Karhunen; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Imperial College London; Johns Hopkins University; University of Cambridge; The University of British Columbia Center for Heart Lung Innovation; Lewis Sigler Institute for Integrative Biology; Imperial College London; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","ObjectivesTo use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 gene expression and circulating ACE2 levels.

DesignTwo-sample Mendelian randomization (MR) analysis.

SettingSummary-level genetic association data.

ParticipantsParticipants were predominantly of European ancestry. Variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors (body mass index, chronic obstructive pulmonary disease, lifetime smoking index, low-density lipoprotein cholesterol, systolic blood pressure and type 2 diabetes mellitus) were selected from publicly available genome-wide association study data (sample sizes ranging from 188,577 to 898,130 participants). Genetic association estimates for lung expression of ACE2 and TMPRSS2 were obtained from the Gene-Tissue Expression (GTEx) project (515 participants) and the Lung eQTL Consortium (1,038 participants). Genetic association estimates for circulating plasma ACE2 levels were obtained from the INTERVAL study (4,947 participants).

Main outcomes and measuresLung ACE2 and TMPRSS2 expression and plasma ACE2 levels.

ResultsThere were no association of genetically proxied ACE inhibition with any of the outcomes considered here. There was evidence of a positive association of genetic liability to type 2 diabetes mellitus with lung ACE2 gene expression in GTEx (p = 4x10-4) and with circulating plasma ACE2 levels in INTERVAL (p = 0.03), but not with lung ACE2 expression in the Lung eQTL Consortium study (p = 0.68). There were no associations between genetically predicted levels of the other cardiometabolic traits with the outcomes.

ConclusionsThis study does not provide evidence to support that ACE inhibitor antihypertensive drugs affect lung ACE2 and TMPRSS2 expression or plasma ACE2 levels. In the current COVID-19 pandemic, our findings do not support a change in ACE inhibitor medication use without clinical justification.

Summary boxesO_ST_ABSWhat is already known on this topicC_ST_ABSO_LISevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic.
C_LIO_LISerine protease TMPRSS2 is involved in priming the SARS-CoV-2 spike protein for cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor.
C_LIO_LIExpression of ACE2 and TMPRSS2 in the lung epithelium might have implications for risk of SARS-CoV-2 infection and severity of COVID-19.
C_LI

What this study addsO_LIWe used human genetic variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 expression and circulating ACE2 levels.
C_LIO_LIOur findings do not support the hypothesis that ACE inhibitors have effects on ACE2 expression.
C_LIO_LIWe found some support for an association of genetic liability to type 2 diabetes mellitus with higher lung ACE2 expression and plasma ACE2 levels, but evidence was inconsistent across studies.
C_LI",genetic and genomic medicine,exact,100,100
medRxiv,10.1101/2020.04.10.20061192,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.10.20061192,COVID-19 most vulnerable Mexican cities lack the public health infrastructure to face the pandemic: a new temporally-explicit model,Wesley Dattilo Sr.; Alcides Castro e Silva; Roger Guevara Sr.; Ian MacGregor-Fors; Servio Pontes Ribeiro; Ville Karhunen; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Instituto de Ecologia AC; Universidade Federal de Ouro Preto; Instituto de Ecologia AC; Instituto de Ecologia AC; Universidade Federal de Ouro Preto; Imperial College London; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","Recently, a wide array of epidemiological models have been developed to guide public health actors in containing the rapid dissemination of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cause of COVID-19. Despite their usefulness, many epidemiological models recently developed to understand the spread of SARS-CoV-2 and infection rates of COVID-19 fall short as they ignore human mobility, limiting our understanding of the spread of the disease, together with the vulnerability of population centers in a broad scale. We developed a new temporally-explicit model and simulated several social distancing scenarios to predict the vulnerability to COVID-19 of 50 Mexican cities that are interconnected by their air transportation network. Additionally, we assessed the sufficiency of the public health infrastructure in the focal cities to face the pandemic over time. Based on our model, we show that the most important cities within the Mexican air transportation network are the most vulnerable to COVID-19, with all assessed public health infrastructure being insufficient to face the modeled scenario for the pandemic after 100 days. Despite these alarming findings, our results show that social distancing could dramatically decrease the total number of infected people (77% drop-off for the 45% distancing scenario when contrasted with no distancing), flattening the growth of infection rate. Thus, we consider that this study provides useful information that may help decision-makers to timely implement health policies to anticipate and lessen the impact of the current pandemic in Mexico.

Significance StatementWe used a new temporally-explicit model focused on air transportation networks to predict the vulnerability of 50 focal Mexican cities to COVID-19. We found that most vulnerable cities lack of the required public health infrastructure (i.e., number of inpatient and intensive care unit beds) to face this new pandemic, overloading in all cases after 100 days. However, our results show that a 45% social distancing scenario can reduce the number of infected people by up to 78.7%, flattening the growth rate of people with COVID-19 before infection rates soar exponentially countrywide.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.09.20060103,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20060103,Acceptance and preference for COVID-19 vaccination in health-care workers (HCWs),Chuanxi Fu; Zheng Wei; Sen Pei; Shunping Li; Xiaohui Sun; Ping Liu; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University; Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University; Mailman School of Public Health, Columbia University; NHC Key Laboratory of Health Economics and Policy Research, Shandong University;School of Health Care Management, Shandong University; Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University; NHC Key Laboratory of Health Economics and Policy Research, Shandong University;School of Health Care Management, Shandong University; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The objective of the present study is to reveal the acceptance and preference for the 2019 novel coronavirus disease (COVID-19) vaccination in health-care workers (HCWs). We performed an internet-based, region-stratified survey among 352 HCWs and 189 individuals in the general population enrolled on March 17th and 18th 2020 from 26 Chinese provinces. The HCWs developed a more in-depth understanding of SARS-Coronavirus-2 infection and showed a higher tolerance to the future vaccination than the general population. 76.4% of HCWs (vs. 72.5% in the general) showed their willingness to receive vaccination. Potential benefits from COVID-19 outbreak such as seeking influenza (65.3%) or pneumonia (55.7%) vaccination can be gained in HCWs. To estimate the relative effects of attributes influencing vaccination choice in the discrete choice experiment, 7 attributes (3 disease-relevant, 3 vaccine-relevant, and 1 of social acceptance) were identified as key determinants. Among them, disease trend (odds ratio, OR: 4.367 (95%CI, 3.721-5.126) for seasonal epidemic, OR: 3.069 (2.612-3.605) for persistent epidemic, with reference to disappearance in summer), social contacts decisions (0.398: 0.339-0.467 for refusal, 0.414: 0.353-0.487 for neutral, with reference to acceptance) and high possibility of being infected (2.076: 1.776-2.425 for infection probability of 30%+) were significantly associated with increased probability of choosing vaccination in the HCWs. In contrast, for the general population, vaccine safety and social contacts decisions were the most important predictors. For COVID-19 vaccination, education in HCWs should be taken as a priority, and further benefits of its recommendation to the general public will also be anticipated.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.13.20060269,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.13.20060269,Sequential Vaccination for Containing Epidemics,Guy Tennenholtz; Constantine Caramanis; Shie Mannor; Shunping Li; Xiaohui Sun; Ping Liu; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Technion Institute of Technology; University of Texas at Austin; Technion - Israel Institute of Technology; NHC Key Laboratory of Health Economics and Policy Research, Shandong University;School of Health Care Management, Shandong University; Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University; NHC Key Laboratory of Health Economics and Policy Research, Shandong University;School of Health Care Management, Shandong University; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The dynamics of infectious diseases spread is crucial in determining their risk and offering ways to contain them. We study sequential vaccination of individuals in networks, where there is a limit on the number of individuals that can be vaccinated every day. Effective allocation of vaccine will play a critical role in preventing the spread and reducing the effects of a future pandemic. We derive methods for calculating upper and lower bounds of the expected number of infected individuals, as well as provide estimates on the number of vaccinations that is needed for containment. We calculate these explicitly on trees, d-dimensional grids, and Erd[o]s Renyi graphs. Finally, we construct a time-dependent budget allocation strategy and demonstrate its superiority over constant budget allocation on real networks following first acquaintance vaccination. Our results provide a principled approach to assess the needed vaccination rate given the social graph topology.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.09.20059881,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059881,Next weeks of SARS-CoV-2: Projection model to predict time evolution scenarios of accumulated cases in Spain,TONI MONLEON-GETINO Sr.; Jaume Canela-Soler; Shie Mannor; Shunping Li; Xiaohui Sun; Ping Liu; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"UNIVERSITY OF BARCELONA; University of Barcelona; Technion - Israel Institute of Technology; NHC Key Laboratory of Health Economics and Policy Research, Shandong University;School of Health Care Management, Shandong University; Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University; NHC Key Laboratory of Health Economics and Policy Research, Shandong University;School of Health Care Management, Shandong University; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","Background and objectivesSARS-CoV-2 is a new type of coronavirus that can affect people and causes respiratory disease, COVID-19. It is affecting the entire planet and we focus in Spain, where the first case was detected at the end of January 2020 and in recent weeks it has increased in many cases. We need predictive models in order to be efficient and take actions. The general goal of this work is present a new model of SARS-CoV-2 to predict different scenarios of accumulated cases in Spain.

Material and methodsIn this short report is used a model proposed previously, based on a parametric model Weibull and in a the library BDSbiost3 developed in R to infer and predict different scenarios of the evolution of SARS-CoV-2 for the accumulated cases in Spain after the spread that affects Spain detected at the end of January of this year.

ResultsIn the analyses presented, projective curves have been generated for the evolution of accumulated cases in which they reach about 4,000 cases or about 15,000 cases, for which the lines of the day in which the value for 90 will be reached can be seen vertically 90, 95 and 99% of the asymptote (maximum number of cases, from that day they will begin to descend or remain the same), that is why the vertical lines would indicate the brake of the disease. For the worst-case scenario, it takes 118, 126 or 142 days to reach the maximum number of cases (n = 15,000) to reach 90, 95 and 99% of the asymptote (maximum number of cases), respectively. This means translated in a time scale that in the worst case the virus will not stop its progress, in Spain, until summer 2020, hopefully before.

Comments and conclusionsThis model could be used to plan the resources and see if the policies or means dedicated to the virus are slowing the progress of the virus or it is necessary to implement others that are more effective, and can also validate a method for future outbreaks of diseases such as these.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.08.20058842,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.08.20058842,"The Epidemiological Implications of Incarceration Dynamics in Jails for Community, Corrections Officer, and Incarcerated Population Risks from COVID-19",Eric Lofgren; Kristian Lum; Aaron Horowitz; Brooke Madubuonwu; Kellen Myers; Nina Fefferman; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Washington State University; University of Pennsylvania; American Civil Liberties Union; American Civil Liberties Union; Tusculum University; University of Tennessee; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","COVID-19 is challenging many societal institutions, including our criminal justice systems. Some have proposed or enacted (e.g. the State of New Jersey) reductions in the jail and/or prison populations. We present a mathematical model to explore the epidemiological impact of such interventions in jails and contrast them with the consequences of maintaining unaltered practices. We consider infection risk and likely in-custody deaths, and estimate how within-jail dynamics lead to spill-over risks, not only affecting incarcerated people, but increasing exposure, infection, and death rates for both corrections officers, and the broader community beyond the justice system. We show that, given a typical jail-community dynamic, operating in a business-as-usual way will result in significant and rapid loss of life. Large scale reductions in arrest and speeding of releases are likely to save the lives of incarcerated people, jail staff, and the community at large.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.09.20059824,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059824,Recovery Ratios Reliably Anticipate COVID-19 Pandemic Progression,Dan Valeriu Nicolau; Alexander Hasson; Mona Bafadhel; Brooke Madubuonwu; Kellen Myers; Nina Fefferman; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Queensland University of Technology; Queensland University of Technology; University of Oxford; American Civil Liberties Union; Tusculum University; University of Tennessee; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The COVID-19 pandemic is placing unprecedented demands on healthcare systems worldwide and exacting a massive humanitarian toll. This makes the development of accurate predictive models imperative, not just for understanding the course of the pandemic but more importantly for gaining insight into the efficacy of public health measures and planning accordingly. Epidemiological models are forced to make assumptions about many unknowns and therefore can be unreliable. Here, taking an empirical approach, we report a 20-30 day lag between the peak of confirmed to recovered cases and the peak of daily deaths in each country, independent of the epoch of that country in its pandemic cycle. This analysis is expected to be largely independent of the proportion of the population being tested and therefore should aid in planning around the timing and easing of public health measures. Our data also suggests broad predictions for the number of fatalities, generally somewhat lower than most other models. Finally, our model suggests that the world as a whole is shortly to enter a recovery phase, at least as far as the first pandemic wave is concerned.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.09.20057802,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20057802,COVID-19 pandemic and lockdown measures impact on mental health among the general population in Italy. An N=18147 web-based survey.,Rodolfo Rossi; Valentina Socci; Dalila Talevi; Sonia Mensi; Cinzia Niolu; Francesca Pacitti; Antinisca Di Marco; Alessandro Rossi; Alberto Siracusano; Giorgio Di Lorenzo; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"University of Rome Tor Vergata; University of L'Aquila; University of L'Aquila; Policlinico Gemelli Foundation; University ofRome Tor Vergata; University of L'Aquila; University of L'Aquila; University of L'Aquila; University of Rome Tor Vergata; University of Rome Tor Vergata; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","BackgroundThe psychological impact of the COronaVIrus Disease 2019 (COVID-19) outbreak and lockdown measures on the Italian population are unknown.

The current study assesses rates of mental health outcomes in the Italian general population three to four weeks into lockdown measures and explores the impact of COVID-19 related potential risk factors.

MethodsA web-based survey spread throughout the internet between March 27th and April 6th 2020. 18147 individuals completed the questionnaire, 79.6% women.

Selected outcomes were post-traumatic stress symptoms (PTSS), depression, anxiety, insomnia, perceived stress and adjustment disorder symptoms (ADS). Seemingly unrelated logistic regression analysis was performed to identify COVID-19 related risk factors.

ResultsRespondents endorsing PTSS, depression, anxiety, insomnia, high perceived stress and adjustment disorder were 6604 (37%), 3084 (17.3%), 3700 (20.8%), 1301 (7.3%), 3895 (21.8%) and 4092 (22.9%), respectively. Being woman and younger age were associated with all of the selected outcomes. Quarantine was associated with PTSS, anxiety and ADS. Any recent COVID-related stressful life event was associated with all the selected outcomes. Discontinued working activity due to the COVID-19 was associated with all the selected outcomes, except for ADS; working more than usual was associated with PTSS, Perceived stress and ADS. Having a loved one deceased by COVID-19 was associated with PTSS, depression, perceived stress and insomnia.

ConclusionWe found high rates of negative mental health outcomes in the Italian general population three weeks into the COVID-19 lockdown measures and different COVID-19 related risk factors. These findings warrant further monitoring on the Italian populations mental health.",psychiatry and clinical psychology,exact,100,100
medRxiv,10.1101/2020.04.09.20060137,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20060137,An effect assessment of Airborne particulate matter pollution on COVID-19: A multi-city Study in China,Bo Wang; Jiangtao Liu; Shihua Fu; Xiaocheng Xu; Lanyu Li; Yueling Ma; Ji Zhou; Jinxi Yao; Xingrong Liu; Xiuxia Zhang; Xiaotao He; Jun Yan; Yanjun Shi; Xiaowei Ren; Jingping Niu; Bin Luo; Kai zhang; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Shanghai Meteorological Bureau; Gansu Provincial Centre for Diseases Prevention and Control; Lanzhou University; Lanzhou University of Technology; Lanzhou University; The First Hospital of Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; The University of Texas Health Science Center at Houston; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","ObjectiveCoronavirus disease 2019 (COVID-19) is a serious infectious disease, which has caused great number of deaths and health problems worldwide. This study aims to examine the effects of airborne particulate matter (PM) pollution on COVID-19 across China.

MethodsIn this study, we obtained confirmed cases of COVID-19, the data of airborne ambient PM with aerodynamic diameter [&le;] 2.5 m (PM2.5) and [&le;] 10 m (PM10), ambient temperature (AT), absolute humidity (AH) and migration scale index (MSI) in 72 cities of China (excluded Wuhan city) on a daily basis, each of which confirmed more than 50 cases from January 20th to March 2nd, 2020. We applied a two-stage analysis. Generalized additive models with quasi-Poisson distribution was first fitted to estimate city-specific effects of PM10 and PM2.5 on daily confirmed COVID-19 cases while controlling AT, AH and MSI. Then, we used meta-analysis to generate the pooled effect estimates from city-specific results.

ResultsDuring the study period, there were a total of 24 939 COVID-19 cases, most of which were reported in Hubei Province. In our meta-analysis, we found each 10 g/m3 increase in concentration of PM2.5 and PM10 in single day lag (from lag 0 to lag 7 and lag 14) were positively associated with confirmed cases of COVID-19, not including PM10 at lag 5, lag 6 and lag 7, and PM2.5 at lag 5, lag 6. Similar trend was also found in different cumulative lag days (from lag 01 to lag 07 and lag 014). The effects of PM2.5 and PM10 on daily COVID-19 confirmed cases are statistically significant for three cumulative lag periods over 3, 7 and 14 days with the greatest effect over 14 days. The estimated RRs of which were 1.64 (95% CIs: 1.47, 1.82) and 1.47 (95% CIs: 1.34, 1.61) with each 10 g/m3 increase in concentrations of PM2.5 and PM10, respectively. In addition, we found that the effects of PM2.5 on daily confirmed cases were greater than PM10 in all included lag days.

ConclusionsThis nationwide study suggests that airborne PM pollution likely increases the risk of getting COVID-19 in China.",occupational and environmental health,exact,100,100
bioRxiv,10.1101/2020.04.05.026633,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.05.026633,ACE 2 Coding Variants: A Potential X-linked Risk Factor for COVID-19 Disease,William T Gibson; Daniel M Evans; Shihua Fu; Xiaocheng Xu; Lanyu Li; Yueling Ma; Ji Zhou; Jinxi Yao; Xingrong Liu; Xiuxia Zhang; Xiaotao He; Jun Yan; Yanjun Shi; Xiaowei Ren; Jingping Niu; Bin Luo; Kai zhang; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"University of British Columbia; Centre for Applied Neurogenetics, University of British Columbia, Vancouver, Canada; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Shanghai Meteorological Bureau; Gansu Provincial Centre for Diseases Prevention and Control; Lanzhou University; Lanzhou University of Technology; Lanzhou University; The First Hospital of Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; The University of Texas Health Science Center at Houston; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","Viral genetic variants are widely known to influence disease progression among infected humans. Given the recent and rapid emergence of pandemic SARS-CoV-2 infection, the cause of COVID-19 disease, viral protein variants have attracted research interest. However, little has yet been written about genetic risk factors among human hosts. Human genetic variation has proven to affect disease progression and outcome for important diseases such as HIV infection and malaria infestation. The fact that the human ACE2 protein is encoded on the X chromosome means that males who carry rare ACE2 coding variants will express those variants in all ACE2-expressing cells, whereas females will typically express those variants in a mosaic distribution determined by early X-inactivation events. This sex-based difference in ACE2 expression has unique implications for epidemiological studies designed to assess host genetic factors influencing progression from asymptomatic SARS-coV-2 infection to COVID-19. Here we present theoretical modelling of rare ACE2 coding variants documented to occur naturally in several human superpopulations and subpopulations, and show that rare variants predicted to affect the binding of ACE2 to the SARS-CoV-2 spike protein exist in people. Though the rs4646116 (p.Lys26Arg) allele is found in 1 in 70 Ashkenazi Jewish males, and in 1 in 172 non-Finnish European males, this allele is found at higher frequencies in females. Furthermore, the class of missense ACE2 alleles predicted to affect SARS-CoV-2 binding are found in aggregate among 1.43% and 2.16% of Ashkenazi males and females, respectively, as well as in 0.58% and 1.24% of European males and females outside of Finland. These alleles are rarer in other population groups, and almost absent from East Asians genotyped to date.

Though we are aware that full genome-wide and exome-wide sequencing studies may ultimately be required to assess human genetic susceptibility to SARS-CoV-2 fully, we argue on the basis of strong prior probabilities that genotyping of this class of alleles is justified in cases of atypical SARS-CoV-2 diseases, such as asymptomatic super-spreaders (if any are identified), and in neonatal/paediatric-onset COVID-19 disease. Even relatively rare susceptibility factors (1% or fewer carriers) may become quantitatively important in the context of hundreds of thousands of infections. A small number of asymptomatic carriers, or a small number of super-spreaders, or a small segment of the population that is disproportionately likely to require intensive care, can magnify the medical, social and economic impacts of a pandemic of this size. The speed of the pandemic and the large number of affected cases worldwide justify efforts to identify all possible risk factors for adverse outcomes, including efforts to identify genetic susceptibility factors in human hosts.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.04.09.20059857,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059857,Implementation of a Novel Remote Physician SBRT Coverage Process during the Coronavirus Pandemic,Alex T Price; Lauren E Henke; Borna Maraghechi; Taeho Kim; Matthew B Spraker; Geoffrey D Hugo; Clifford G Robinson; Nels C Knutson; Xingrong Liu; Xiuxia Zhang; Xiaotao He; Jun Yan; Yanjun Shi; Xiaowei Ren; Jingping Niu; Bin Luo; Kai zhang; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Lanzhou University; Lanzhou University of Technology; Lanzhou University; The First Hospital of Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; The University of Texas Health Science Center at Houston; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","INTRODUCTIONDuring the COVID-19 pandemic, alternative methods of care are needed to reduce the relative risk of transmission in departments. Also needed is the ability to provide vital radiation oncological care if radiation oncologists (RO) are reallocated to other departments. We implemented a novel remote RO SBRT coverage practice, requiring it to be reliable, of high audio and visual quality, timely, and the same level of specialty care as our current in-person treatment coverage practice.

METHODSAll observed failure modes were recorded during implementation over the first 15 sequential fractions. The time from CBCT to treatment was calculated before and after implementation to determine timeliness of remote coverage. Image quality metrics were calculated between the imaging console screen and the ROs shared screen. Comfort levels with audio/visual communication as well as overall comfort in comparison to in-person RO coverage was evaluated using Likert scale surveys after treatment.

RESULTSRemote RO SBRT coverage was successfully implemented in 14/15 fractions with 3 observed process failures that were all corrected before treatment. Average times of pre-treatment coverage before and after implementation were 8.74 and 8.51min, respectively. The cross correlation between the imaging console screen and ROs shared screen was r=0.96 and lag was 0.05s. The average value for all survey questions was above 4.5, approaching in-person RO coverage comfort levels.

CONCLUSIONSOur novel method of remote RO SBRT coverage permits reduced personnel and patient interactions surrounding RT procedures. This may help to reduce transmission of COVID-19 in our department and provides a means for SBRT coverage if ROs are reallocated to other areas of the hospital for COVID-19 support.",oncology,exact,100,100
bioRxiv,10.1101/2020.04.06.027698,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.06.027698,Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations,Lourdes Ortiz-Fernandez; Amr H Sawalha; Borna Maraghechi; Taeho Kim; Matthew B Spraker; Geoffrey D Hugo; Clifford G Robinson; Nels C Knutson; Xingrong Liu; Xiuxia Zhang; Xiaotao He; Jun Yan; Yanjun Shi; Xiaowei Ren; Jingping Niu; Bin Luo; Kai zhang; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"University of Pittsburgh; University of Pittsburgh; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Lanzhou University; Lanzhou University of Technology; Lanzhou University; The First Hospital of Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; The University of Texas Health Science Center at Houston; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The entry of SARS-CoV-2 into host cells is dependent upon angiotensin-converting enzyme 2 (ACE2), which serves as a functional attachment receptor for the viral spike glycoprotein, and the serine protease TMPRSS2 which allows fusion of the viral and host cell membranes. We devised a quantitative measure to estimate genetic determinants of ACE2 and TMPRSS2 expression and applied this measure to >2,500 individuals. Our data show significant variability in genetic determinants of ACE2 and TMPRSS2 expression among individuals and between populations, and demonstrate a genetic predisposition for lower expression levels of both key viral entry genes in African populations. These data suggest that genetic factors might lead to lower susceptibility for SARS-CoV-2 infection in African populations and that host genetics might help explain inter-individual variability in disease susceptibility and severity of COVID-19.",genomics,exact,100,100
medRxiv,10.1101/2020.04.10.20060301,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.10.20060301,Should contact bans be lifted in Germany? A quantitative prediction of its effects,Jean Roch Donsimoni; Ren Glawion; Bodo Plachter; Constantin Weiser; Klaus Wlde; Geoffrey D Hugo; Clifford G Robinson; Nels C Knutson; Xingrong Liu; Xiuxia Zhang; Xiaotao He; Jun Yan; Yanjun Shi; Xiaowei Ren; Jingping Niu; Bin Luo; Kai zhang; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Johannes Gutenberg-Universitt; Universitt Hamburg; Johannes Gutenberg-Universitt; Johannes Gutenberg-Universitt; Johannes Gutenberg-Universitt; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Washington University in St Louis School of Medicine; Lanzhou University; Lanzhou University of Technology; Lanzhou University; The First Hospital of Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; The University of Texas Health Science Center at Houston; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","Many countries consider the lifting of restrictions of social contacts (RSC). We quantify the effects of RSC for Germany. We initially employ a purely statistical approach to predicting prevalence of COVID19 if RSC were upheld after April 20. We employ these findings and feed them into our theoretical model. We find that the peak of the number of sick individuals would be reached already mid April. The number of sick individuals would fall below 1,000 at the beginning of July. When restrictions are lifted completely on April 20, the number of sick should rise quickly again from around April 27. A balance between economic and individual costs of RSC and public health objectives consists in lifting RSC for activities that have high economic benefits but low health costs. In the absence of large-scale representative testing of CoV-2 infections, these activities can most easily be identified if federal states of Germany adopted exit strategies that differ across states.",health economics,exact,100,100
bioRxiv,10.1101/2020.04.13.038687,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.13.038687,"Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro",Haixia Su; Sheng Yao; Wenfeng Zhao; Minjun Li; Jia Liu; Weijuan Shang; Hang Xie; Changqiang Ke; Meina Gao; Kunqian Yu; Hong Liu; Jingshan Shen; Wei Tang; Leike Zhang; Jianping Zuo; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Shanghai Institute of Materia Medica; Shanghai Institute of Materia Medica; Shanghai Institute of Materia Medica; Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Wuhan Institute of Virology, Chinese Academy of Sciences; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","Human infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause coronavirus disease 19 (COVID-19) and there is currently no cure. The 3C-like protease (3CLpro), a highly conserved protease indispensable for replication of coronaviruses, is a promising target for development of broad-spectrum antiviral drugs. To advance the speed of drug discovery and development, we investigated the inhibition of SARS-CoV-2 3CLpro by natural products derived from Chinese traditional medicines. Baicalin and baicalein were identified as the first non-covalent, non-peptidomimetic inhibitors of SARS-CoV-2 3CLpro and exhibited potent antiviral activities in a cell-based system. Remarkably, the binding mode of baicalein with SARS-CoV-2 3CLpro determined by X-ray protein crystallography is distinctly different from those of known inhibitors. Baicalein is perfectly ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues, the crucial S1/S2 subsites and the oxyanion loop, acting as a ""shield"" in front of the catalytic dyad to prevent the peptide substrate approaching the active site. The simple chemical structure, unique mode of action, and potent antiviral activities in vitro, coupled with the favorable safety data from clinical trials, emphasize that baicalein provides a great opportunity for the development of critically needed anti-coronaviral drugs.",molecular biology,exact,100,100
medRxiv,10.1101/2020.04.09.20059154,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059154,"COVID-19 pandemic in the African continent: forecasts of cumulative cases, new infections, and mortality",Tom Achoki; Uzma Alam; Lawrence Were; Tesfaye Gebremedhin; Flavia Senkubuge; Abaleng Lesego; Shuangzhe Liu; Richard Wamai; Yohannes Kinfu; Kunqian Yu; Hong Liu; Jingshan Shen; Wei Tang; Leike Zhang; Jianping Zuo; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"School of Health Systems and Public Health, University of Pretoria, South Africa; Africa Institute for Health Policy Foundation, Kenya; Department of Health Sciences & Department of Global Health, Boston University, Boston, MA.; Department of Economics, Faculty of Business, Government and Law, University of Canberra.; School of Health Systems and Public Health, University of Pretoria, South Africa; Kudu Communications - Health Services; Faculty of Science and Technology, University of Canberra; Department of Cultures, Societies and Global Studies, and Integrated Initiative for Global Health, Northeastern University; Faculty of Health, University of Canberra, Australia; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Wuhan Institute of Virology, Chinese Academy of Sciences; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","BackgroundThe epidemiology of COVID-19 remains speculative in Africa. To the best of our knowledge, no study, using robust methodology provides its trajectory for the region or accounts for local context. This paper is the first systematic attempt to provide prevalence, incidence, and mortality estimates across Africa.

MethodsCaseloads and incidence forecasts are from a co-variate-based instrumental variable regression model. Fatality rates from Italy and China were applied to generate mortality estimates after making relevant health system and population-level characteristics related adjustments between each of the African countries.

ResultsBy June 30 2020, around 16.3 million people in Africa will contract COVID-19 (95% CI 718,403 to 98,358,799). Northern and Eastern Africa will be the most and least affected areas. Cumulative cases by June 30 are expected to reach around 2.9 million (95% CI 465,028 to 18,286,358) in Southern Africa, 2.8 million (95% CI 517,489 to 15,056,314) in Western Africa, and 1.2 million (95% CI 229,111 to 6,138,692) in Central Africa. Incidence for the month of April 2020 is expected to be highest in Djibouti, 32.8 per 1000 (95% CI 6.25 to 171.77), while Morocco will experience among the highest fatalities (1,045 deaths, 95% CI 167 to 6,547).

ConclusionLess urbanized countries with low levels of socio-economic development (hence least connected to the world), are likely to register lower and slower transmissions at the early stages of an epidemic. However, the same enabling factors that worked for their benefit can hinder interventions that have lessened the impact of COVID-19 elsewhere.",health policy,exact,100,100
bioRxiv,10.1101/2020.04.12.038216,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.12.038216,Detection of spreader nodes and ranking of interacting edges in Human-SARS-CoV protein interaction network,Sovan Saha; Piyali Chatterjee; Subhadip Basu; Mita Nasipuri; Flavia Senkubuge; Abaleng Lesego; Shuangzhe Liu; Richard Wamai; Yohannes Kinfu; Kunqian Yu; Hong Liu; Jingshan Shen; Wei Tang; Leike Zhang; Jianping Zuo; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Dr. Sudhir Chandra Sur Degree Engineering College; Netaji Subhash Engineering College; Jadavpur University; Jadavpur University; School of Health Systems and Public Health, University of Pretoria, South Africa; Kudu Communications - Health Services; Faculty of Science and Technology, University of Canberra; Department of Cultures, Societies and Global Studies, and Integrated Initiative for Global Health, Northeastern University; Faculty of Health, University of Canberra, Australia; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Wuhan Institute of Virology, Chinese Academy of Sciences; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The entire world has recently witnessed the commencement of coronavirus disease 19 (COVID-19) pandemic. It is caused by a novel coronavirus (n-CoV) generally distinguished as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It has exploited human vulnerabilities to coronavirus outbreak. SARS-CoV-2 promotes fatal chronic respiratory disease followed by multiple organ failure which ultimately puts an end to human life. No proven vaccine for n-CoV is available till date in spite of significant research efforts worldwide. International Committee on Taxonomy of Viruses (ICTV) has reached to a consensus that the virus SARS-CoV-2 is highly genetically similar to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) outbreak of 2003. It has been reported that SARS-CoV has [~]89% genetic similarities with n-CoV. With this hypothesis, the current work focuses on the identification of spreader nodes in SARS-CoV protein interaction network. Various network characteristics like edge ratio, neighborhood density and node weight have been explored for defining a new feature spreadability index by virtue of which spreader nodes and edges are identified. The selected top spreader nodes having high spreadability index have been also validated by Susceptible-Infected-Susceptible (SIS) disease model. Initially, the proposed method is applied on a synthetic protein interaction network followed by SARS-CoV-human protein interaction network. Hence, key spreader nodes and edges (ranked edges) are unmasked in SARS-CoV proteins and its connected level 1 and level 2 human proteins. The new network attribute spreadability index along with generated SIS values of selected top spreader nodes when compared with the other network centrality based methodologies like Degree centrality (DC), Closeness centrality (CC), Local average centrality (LAC) and Betweeness centrality (BC) is found to perform relatively better than the existing-state-of-art.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.04.09.20058651,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20058651,Scaling diagnostics in times of COVID-19: Rapid prototyping of 3D-printed water circulators for Loop-mediated Isothermal Amplification (LAMP) and detection of SARS-CoV-2 virus,Everardo Gonzalez-Gonzalez; Itzel Montserrat Lara-Mayorga; Iram Pablo Rodriguez-Sanchez; Felipe Yee-de Leon; Andres Garcia-Rubio; Carlos Ezio Garciamendez-Mijares; Gilberto Emilio Guerra-Alvarez; German Garcia-Martinez; Juan Andres Aguayo-Hernandez; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Tecnologico de Monterrey; Tecnologico de Monterrey; Universidad Autonoma de Nuevo Leon; Delee, Corp.; Tecnologico de Monterrey; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","By the third week of June 2020, more than 8,500,000 positive cases of COVID-19 and more than 450,000 deaths had been officially reported worldwide. The COVID-19 pandemic arrived in Latin America, India, and Africa--territories in which the mounted infrastructure for diagnosis is greatly underdeveloped. Here, we demonstrate the combined use of a three-dimensional (3D)-printed incubation chamber for commercial Eppendorf PCR tubes, and a colorimetric embodiment of a loop-mediated isothermal amplification (LAMP) reaction scheme for the detection of SARS-CoV-2 nucleic acids. We used this strategy to detect and amplify SARS-CoV-2 genetic sequences using a set of in-house designed initiators that target regions encoding the N protein. We were able to detect and amplify SARS-CoV-2 nucleic acids in the range of 62 to 2 x 105 DNA copies by this straightforward method. Using synthetic SARS-CoV-2 samples and a limited number of RNA extracts from patients, we also demonstrate that colorimetric LAMP is a quantitative method comparable in diagnostic performance to RT-qPCR. We envision that LAMP may greatly enhance the capabilities for COVID-19 testing in situations where RT-qPCR is not feasible or is unavailable. Moreover, the portability, ease of use, and reproducibility of this strategy make it a reliable alternative for deployment of point-of-care SARS-CoV-2 detection efforts during the pandemics.",infectious diseases,exact,100,100
bioRxiv,10.1101/2020.04.13.039198,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.13.039198,"Identification of potential vaccine candidates against SARS-CoV-2, A step forward to fight novel coronavirus 2019-nCoV: A Reverse Vaccinology Approach",Ekta Gupta; Rupesh Kumar Mishra; Ravi Ranjan Kumar Niraj; Felipe Yee-de Leon; Andres Garcia-Rubio; Carlos Ezio Garciamendez-Mijares; Gilberto Emilio Guerra-Alvarez; German Garcia-Martinez; Juan Andres Aguayo-Hernandez; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Dr. B. Lal Institute of Biotechnology, Jaipur; Amity University Rajasthan, Jaipur; Amity University Rajasthan, Jaipur; Delee, Corp.; Tecnologico de Monterrey; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The recent Coronavirus Disease 2019 (COVID-19) causes an immense health crisis to global public health. The COVID-19 is the etiologic agent of a recently arose disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Presently, there is no vaccine available against this emerged viral disease. Therefore, it is indeed a need of the hour to develop an effectual and safe vaccine against this decidedly pandemic disease. In the current study, we collected SARS-CoV-2 genome which is prominent in India against human host, further more using reverse vaccinology here we claim effective vaccine candidates that can be mile stone in battle against COVID19. This novel study divulged one promising antigenic peptide GVYFASTEK from surface glycoprotein (protein accession no. - QIA98583.1) of SARS-CoV-2, which was predicated to be interacted with MHC alleles and showed up to 90% conservancy and high value of antigenicity. Subsequently, the molecular docking and simulation studies were verified molecular interaction of this prime antigenic peptide with the residues of HLA-A*11-01 allele for MHC Class I. After vigorous analysis, this peptide was predicted to be suitable epitope which is capable to induce the strong cell-mediated immune response against the SARS-CoV-2. Consequences from the current study could facilitate selecting SARS-CoV-2 epitopes for vaccine production pipelines in the immediate future. This novel research will certainly pave the way for a fast, reliable and virtuous platform to provide timely countermeasure of this dangerous pandemic disease, COVID-19.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.04.09.20059451,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059451,Comparison of different exit scenarios from the lock-down for COVID-19 epidemic in the UK and assessing uncertainty of the predictions,Anatoly Zhigljavsky; Roger Whitaker; Ivan Fesenko; Yakov Kremnitzer; Jack Noonan; Carlos Ezio Garciamendez-Mijares; Gilberto Emilio Guerra-Alvarez; German Garcia-Martinez; Juan Andres Aguayo-Hernandez; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Cardiff University; Cardiff University; University of Nottingham; University of Oxford; Cardiff University; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","We model further development of the COVID-19 epidemic in the UK given the current data and assuming different scenarios of handling the epidemic. In this research, we further extend the stochastic model suggested in [1] and incorporate in it all available to us knowledge about parameters characterising the behaviour of the virus and the illness induced by it. The models we use are flexible, comprehensive, fast to run and allow us to incorporate the following: O_LItime-dependent strategies of handling the epidemic;
C_LIO_LIspatial heterogeneity of the population and heterogeneity of development of epidemic in different areas;
C_LIO_LIspecial characteristics of particular groups of people, especially people with specific medical pre-histories and elderly.
C_LI

Standard epidemiological models such as SIR and many of its modifications are not flexible enough and hence are not precise enough in the studies that requires the use of the features above. Decision-makers get serious benefits from using better and more flexible models as they can avoid of nuanced lock-downs, better plan the exit strategy based on local population data, different stages of the epidemic in different areas, making specific recommendations to specific groups of people; all this resulting in a lesser impact on economy, improved forecasts of regional demand upon NHS allowing for intelligent resource allocation.

In this work, we investigate the sensitivity of the model to all its parameters while considering several realistic scenarios of what is likely to happen with the dynamics of the epidemic after the lock-down, which has started on March 23, is lifted.

The main findings from this research are the following O_LIvery little gain, in terms of the projected hospital bed occupancy and expected numbers of death, of continuing the lock-down beyond April 13, provided the isolation of older and vulnerable people continues and the public carries on some level of isolation in the next 2-3 months, see Section 3.1;
C_LIO_LIin agreement with [1], isolation of the group of vulnerable people during the next 2-3 months should be one of the main priorities, see Section 3.2;
C_LIO_LIit is of high importance that the whole population carries on some level of isolation in the next 2-3 months, see Section 3.5;
C_LIO_LIthe timing of the current lock-down seems to be very sensible in areas like London where the epidemic has started to pick up by March 23; in such areas the second wave of epidemic is not expected, see figures in Sections 2.2 and 3;
C_LIO_LIthe epidemic should almost completely finish in July, no global second wave should be expected, except areas where the first wave is almost absent, see Section 3.4.
C_LI",epidemiology,exact,100,100
bioRxiv,10.1101/2020.04.13.039792,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.13.039792,Improving COVID-19 Testing Efficiency using Guided Agglomerative Sampling,Fayyaz Minhas; Dimitris Grammatopoulos; Lawrence Young; Imran Amin; David Snead; Neil Anderson; Asa Ben-Hur; Nasir Rajpoot; Juan Andres Aguayo-Hernandez; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"University of Warwick; University of Warwick; University of Warwick; National Institute ofBiotechnology and Genetic Engineering, Pakistan.; Institute of Precision Diagnostics and Translational Medicine, Department of Pathology, University Hospitals Coventry & Warwickshire, Coventry, UK.; Institute of Precision Diagnostics and Translational Medicine, Department of Pathology, University Hospitals Coventry & Warwickshire, Coventry, UK.; Department of Computer Science, Colorado State University, USA.; Department of Computer Science, University of Warwick, Coventry, UK; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","One of the challenges in the current COVID-19 crisis is the time and cost of performing tests especially for large-scale population surveillance. Since, the probability of testing positive in large population studies is expected to be small (<15%), therefore, most of the test outcomes will be negative. Here, we propose the use of agglomerative sampling which can prune out multiple negative cases in a single test by intelligently combining samples from different individuals. The proposed scheme builds on the assumption that samples from the population may not be independent of each other. Our simulation results show that the proposed sampling strategy can significantly increase testing capacity under resource constraints: on average, a saving of ~40% tests can be expected assuming a positive test probability of 10% across the given samples. The proposed scheme can also be used in conjunction with heuristic or Machine Learning guided clustering for improving the efficiency of large-scale testing further. The code for generating the simulation results for this work is available here: https://github.com/foxtrotmike/AS.",bioinformatics,exact,100,100
medRxiv,10.1101/2020.04.10.20060459,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.10.20060459,Global COVID-19 transmission rate is influenced by precipitation seasonality and the speed of climate temperature warming,Katsumi Chiyomaru; Kazuhiro Takemoto; Lawrence Young; Imran Amin; David Snead; Neil Anderson; Asa Ben-Hur; Nasir Rajpoot; Juan Andres Aguayo-Hernandez; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Kyushu Institute of Technology; Kyushu Institute of Technology; University of Warwick; National Institute ofBiotechnology and Genetic Engineering, Pakistan.; Institute of Precision Diagnostics and Translational Medicine, Department of Pathology, University Hospitals Coventry & Warwickshire, Coventry, UK.; Institute of Precision Diagnostics and Translational Medicine, Department of Pathology, University Hospitals Coventry & Warwickshire, Coventry, UK.; Department of Computer Science, Colorado State University, USA.; Department of Computer Science, University of Warwick, Coventry, UK; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The novel coronavirus disease 2019 (COVID-19) became a rapidly spreading worldwide epidemic; thus, it is a global priority to reduce the speed of the epidemic spreading. Several studies predicted that high temperature and humidity could reduce COVID-19 transmission. However, exceptions exist to this observation, further thorough examinations are thus needed for their confirmation. In this study, therefore, we used a global dataset of COVID-19 cases and global climate databases and comprehensively investigated how climate parameters could contribute to the growth rate of COVID-19 cases while statistically controlling for potential confounding effects using spatial analysis. We also confirmed that the growth rate decreased with the temperature; however, the growth rate was affected by precipitation seasonality and warming velocity rather than temperature. In particular, a lower growth rate was observed for a higher precipitation seasonality and lower warming velocity. These effects were independent of population density, human life quality, and travel restrictions. The results indicate that the temperature effect is less important compared to these intrinsic climate characteristics, which might thus be useful for explaining the exceptions. However, the contributions of the climate parameters to the growth rate were moderate; rather, the contribution of travel restrictions in each country was more significant. Although our findings are preliminary owing to data-analysis limitations, they may be helpful when predicting COVID-19 transmission.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.04.12.038554,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.12.038554,The origin and underlying driving forces of the SARS-CoV-2 outbreak,Shu-Miaw Chaw; Jui-Hung Tai; Shi-Lun Chen; Chia-Hung Hsieh; Sui-Yuan Chang; Shiou-Hwei Yeh; Wei-Shiung Yang; Pei-Jer Chen; Hurng-Yi Wang; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Biodiversity Research Center, Academia Sinica; Biodiversity Research Center, Academia Sinica; Department of Life Science, National Taiwan Normal University; Department of Forestry and Nature Conservation, Chinese Culture University; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University; Department of Microbiology, College of Medicine, National Taiwan University; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","The spread of SARS-CoV-2 since December 2019 has become a pandemic and impacted many aspects of human society. Here, we analyzed genetic variation of SARS-CoV-2 and its related coronavirus and found the evidence of intergenomic recombination. After correction for mutational bias, analysis of 137 SARS-CoV-2 genomes as of 2/23/2020 revealed the excess of low frequency mutations on both synonymous and nonsynonymous sites which is consistent with recent origin of the virus. In contrast to adaptive evolution previously reported for SARS-CoV in its brief epidemic in 2003, our analysis of SARS-CoV-2 genomes shows signs of relaxation of selection. The sequence similarity of the spike receptor binding domain between SARS-CoV-2 and a sequence from pangolin is probably due to an ancient intergenomic introgression. Therefore, SARS-CoV-2 might have cryptically circulated within humans for years before being recently noticed. Data from the early outbreak and hospital archives are needed to trace its evolutionary path and reveal critical steps required for effective spreading. Two mutations, 84S in orf8 protein and 251V in orf3 protein, occurred coincidentally with human intervention. The 84S first appeared on 1/5/2020 and reached a plateau around 1/23/2020, the lockdown of Wuhan. 251V emerged on 1/21/2020 and rapidly increased its frequency. Thus, the roles of these mutations on infectivity need to be elucidated. Genetic diversity of SARS-CoV-2 collected from China was two time higher than those derived from the rest of the world. In addition, in network analysis, haplotypes collected from Wuhan city were at interior and have more mutational connections, both of which are consistent with the observation that the outbreak of cov-19 was originated from China.

SUMMARYIn contrast to adaptive evolution previously reported for SARS-CoV in its brief epidemic, our analysis of SARS-CoV-2 genomes shows signs of relaxation of selection. The sequence similarity of the spike receptor binding domain between SARS-CoV-2 and a sequence from pangolin is probably due to an ancient intergenomic introgression. Therefore, SARS-CoV-2 might have cryptically circulated within humans for years before being recently noticed. Data from the early outbreak and hospital archives are needed to trace its evolutionary path and reveal critical steps required for effective spreading. Two mutations, 84S in orf8 protein and 251V in orf3 protein, occurred coincidentally with human intervention. The 84S first appeared on 1/5/2020 and reached a plateau around 1/23/2020, the lockdown of Wuhan. 251V emerged on 1/21/2020 and rapidly increased its frequency. Thus, the roles of these mutations on infectivity need to be elucidated.",evolutionary biology,exact,100,100
medRxiv,10.1101/2020.04.11.20061432,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.11.20061432,Application of COVID-19 pneumonia diffusion data to predict epidemic situation,Zhenguo Wu; Jui-Hung Tai; Shi-Lun Chen; Chia-Hung Hsieh; Sui-Yuan Chang; Shiou-Hwei Yeh; Wei-Shiung Yang; Pei-Jer Chen; Hurng-Yi Wang; Eduardo Marquez-Garcia; Yu-Shrike Zhang; Sergio Omar Martinez-Chapa; Joaquin Zuiga; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Hualiang Jiang; Fang Bai; Yan Wu; Yang Ye; Yechun Xu; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Xi'an Jioatong University; Biodiversity Research Center, Academia Sinica; Department of Life Science, National Taiwan Normal University; Department of Forestry and Nature Conservation, Chinese Culture University; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University; Department of Microbiology, College of Medicine, National Taiwan University; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Division of Engineering in Medicine, Harvard Medical School; Tecnologico de Monterrey; Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas; Tecnologico de Monterrey; Tecnologico de Monterrey; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Shanghai Institute of Materia Medica Chinese Academy of Sciences; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","ObjectiveTo evaluate novel coronavirus pneumonia cases by establishing the mathematical model of the number of confirmed cases daily, and to assess the current situation and development of the epidemic situation, so as to provide a digital basis for decision-making.

MethodsThe number of newly confirmed covid-19 cases per day was taken as the research object, and the seven-day average value (M) and the sequential value (R) of M were calculated to study the occurrence and development of covid-19 epidemic through the analysis of charts and data.

ResultsM reflected the current situation of epidemic development; R reflected the current level of infection and the trend of epidemic development.

ConclusionThe current data can be used to evaluate the number of people who have been infected, and when R < 1, the peak of epidemic can be predicted.

PrefaceIn December 2019, a number of cases of pneumonia with unknown causes were found in some hospitals in Wuhan, Hubei province, China. On 11 March 2020, the director-general of the world health organization (WHO), Tedros Adhanom Ghebreyesus, announced that based on the assessment, WHO believes that the current outbreak of COVID-19 can be called a global pandemic. By early April 2020, there were more than one million confirmed cases worldwide.

COVID-19 has developed from sporadic cases to pandemic in a short period of 3 months. The analysis and research of its infectious data will help to prevent and control the next stage of epidemic prevention and other infectious diseases in the future.

In this paper, COVID-19 rounded average of seven days (M), and Ms ring ratio (R) are used to predict the current potential patients data, and the relative state of epidemic prevention and control is judged through the graphic features and characteristic data, so as to provide evidence for the prevention and control decisions.",epidemiology,exact,100,100
bioRxiv,10.1101/2020.04.12.037580,2020-04-14,https://biorxiv.org/cgi/content/short/2020.04.12.037580,Single Nucleus Multiomic Profiling Reveals Age-Dynamic Regulation of Host Genes Associated with SARS-CoV-2 Infection,Allen Wang; Joshua A Chiou; Olivier B Poirion; Justin Buchanan; Michael J Valdez; Jamie M Verheyden; Xiaomeng Hou; Jacklyn M Newsome; Parul Kudtarkar; Dina A Faddah; Kai Zhang; Randee E Young; Justinn Barr; Ravi Misra; Heidie Huyck; Lisa Rogers; Cory Poole; Gloria Pryhuber; Kyle J Gaulton; Sebastian Preissl; Xin Sun; - NHLBI LungMap Consortium; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; Vertex Phamaceuticals; University of California San Diego; University of California San Diego; University of California San Diego; University of Rochester Medical Center; University of Rochester Medical Center; University of Rochester Medical Center; University of Rochester Medical Center; University of Rochester Medical Center; University of California San Diego; University of California San Diego; University of California San Diego; -; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge,"Respiratory failure is the leading cause of COVID-19 death and disproportionately impacts adults more than children. Here, we present a large-scale snATAC-seq dataset (90,980 nuclei) of the human lung, generated in parallel with snRNA-seq (46,500 nuclei), from healthy donors of ~30 weeks, ~3 years and ~30 years of age. Focusing on genes implicated in SARS-CoV-2 cell entry, we observed an increase in the proportion of alveolar epithelial cells expressing ACE2 and TMPRSS2 in adult compared to young lungs. Consistent with expression dynamics, 10 chromatin peaks linked to TMPRSS2 exhibited significantly increased activity with age and harbored IRF and STAT binding sites. Furthermore, we identified 14 common sequence variants in age-increasing peaks with predicted regulatory function, including several associated with respiratory traits and TMPRSS2 expression. Our findings reveal a plausible contributor to why children are more resistant to COVID-19 and provide an epigenomic basis for transferring this resistance to older populations.",genomics,exact,100,100
medRxiv,10.1101/2020.04.10.20060442,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.10.20060442,Possibilities of exponential or Sigmoid growth of Covid19 data in different states of India,SUPRIYA MONDAL; Sabyasachi Ghosh; Olivier B Poirion; Justin Buchanan; Michael J Valdez; Jamie M Verheyden; Xiaomeng Hou; Jacklyn M Newsome; Parul Kudtarkar; Dina A Faddah; Kai Zhang; Randee E Young; Justinn Barr; Ravi Misra; Heidie Huyck; Lisa Rogers; Cory Poole; Gloria Pryhuber; Kyle J Gaulton; Sebastian Preissl; Xin Sun; - NHLBI LungMap Consortium; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,Aadarsh Nursing Institute; IIT Bhilai; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; University of California San Diego; Vertex Phamaceuticals; University of California San Diego; University of California San Diego; University of California San Diego; University of Rochester Medical Center; University of Rochester Medical Center; University of Rochester Medical Center; University of Rochester Medical Center; University of Rochester Medical Center; University of California San Diego; University of California San Diego; University of California San Diego; -; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge,"We have attempted to understand existing covid19 data of India, where growth of total and new cases with time in different states are kept as focal points. Identifying the last trend of exponential growth, mainly noticed in month of March, we have zoomed in its disaster possibilities by straight forward extrapolation of exponential growth. As a hopeful extrapolation, the existing data might be considered low time-axis values of Sigmoid-type function, whose growth might be saturated to values of 104 or 105. To fulfill this expectation, a turning from increasing to decreasing trend in new case data should be noticed around April-May, which definitely demand extension of present lock-down with additional interventions.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.07.20056788,2020-04-11,https://medrxiv.org/cgi/content/short/2020.04.07.20056788,Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust,Daniel Bean; Zeljko Kraljevic; Thomas Searle; Rebecca Bendayan; Andrew Pickles; Amos Folarin; Lukasz Roguski; Kawsar Noor; Anthony Shek; Rosita Zakeri; Ajay Shah; James Teo; Richard JB Dobson; Nancy Francoeur; Betsaida Salom Melo; Irina Oussenko; Gintaras Deikus; Juan Soto; Shwetha Hara Sridhar; Ying-Chih Wang; Kathryn Twyman; Andrew Kasarskis; Deena Rose Altman; Melissa Smith; Robert Sebra; Judith Aberg; Florian Krammer; Adolfo Garcia-Sarstre; Marta Luksza; Gopi Patel; Alberto Paniz-Mondolfi; Melissa Gitman; Emilia Mia Sordillo; Viviana Simon; Harm van Bakel,King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; University College London; University College London; King's College London; King's College London; King's College London; King's College Hospital; Kings College London; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai,"AimsThe SARS-Cov2 virus binds to the ACE2 receptor for cell entry. It has been suggested that ACE-inhibitors (ACEi) and Angiotensin-2 Blockers (ARB), which are commonly used in patients with hypertension or diabetes and may raise ACE2 levels, could increase the risk of severe COVID19 infection.

Methods and ResultsWe evaluated this hypothesis in a consecutive cohort of 1200 acute inpatients with COVID19 at two hospitals with a multi-ethnic catchment population in London (UK). The mean age was 68{+/-}17 years (57% male) and 74% of patients had at least 1 comorbidity. 415 patients (34.6%) reached the primary endpoint of death or transfer to a critical care unit for organ support within 21-days of symptom onset. 399 patients (33.3 %) were taking ACEi or ARB. Patients on ACEi/ARB were significantly older and had more comorbidities. The odds ratio (OR) for the primary endpoint in patients on ACEi and ARB, after adjustment for age, sex and co-morbidities, was 0.63 (CI 0.47-0.84, p<0.01).

ConclusionsThere was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB. A trend towards a beneficial effect of ACEi/ARB requires further evaluation in larger meta-analyses and randomised clinical trials.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.05.20048421,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.05.20048421,Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection,Cristina Menni; Ana Valdes; Maxim B Freydin; Sajaysurya Ganesh; Julia El-Sayed Moustafa; Alessia Visconti; Pirro Hysi; Ruth C E Bowyer; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"King's College London; NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham; King's College London; Zoe Global limited; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","ImportanceA strategy for preventing further spread of the ongoing COVID-19 epidemic is to detect infections and isolate infected individuals without the need of extensive bio-specimen testing.

ObjectivesHere we investigate the prevalence of loss of smell and taste among COVID-19 diagnosed individuals and we identify the combination of symptoms, besides loss of smell and taste, most likely to correspond to a positive COVID-19 diagnosis in non-severe cases.

DesignCommunity survey.

Setting and ParticipantsSubscribers of RADAR COVID-19, an app that was launched for use among the UK general population asking about COVID-19 symptoms.

Main ExposureLoss of smell and taste.

Main Outcome MeasuresCOVID-19.

ResultsBetween 24 and 29 March 2020, 1,573,103 individuals reported their symptoms via the app; 26% reported suffering from one or more symptoms of COVID-19. Of those, n=1702 reported having had a RT-PCR COVID-19 test and gave full report on symptoms including loss of smell and taste; 579 were positive and 1123 negative. In this subset, we find that loss of smell and taste were present in 59% of COVID-19 positive individuals compared to 18% of those negative to the test, yielding an odds ratio (OR) of COVID-19 diagnosis of OR[95%CI]=6.59[5.25; 8.27], P= 1.90x10-59. We also find that a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhoea, abdominal pain and loss of appetite is predictive of COVID-19 positive test with sensitivity 0.54[0.44; 0.63], specificity 0.86[0.80; 0.90], ROC-AUC 0.77[0.72; 0.82] in the test set, and cross-validation ROC-AUC 0.75[0.72; 0.77]. When applied to the 410,598 individuals reporting symptoms but not formally tested, our model predicted that 13.06%[12.97%;13.15] of these might have been already infected by the virus.

Conclusions and RelevanceOur study suggests that loss of taste and smell is a strong predictor of having been infected by the COVID-19 virus. Also, the combination of symptoms that could be used to identify and isolate individuals includes anosmia, fever, persistent cough, diarrhoea, fatigue, abdominal pain and loss of appetite. This is particularly relevant to healthcare and other key workers in constant contact with the public who have not yet been tested for COVID-19.

Key pointsO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIThe spread of COVID-19 can be reduced by identifying and isolating infected individuals but it is not possible to test everyone and priority has been given in most countries to individuals presenting symptoms of the disease.
C_LIO_LICOVID-19 symptoms, such as fever, cough, aches, fatigue are common in many other viral infections
C_LIO_LIThere is therefore a need to identify symptom combinations that can rightly pinpoint to infected individuals
C_LI

What this study addsO_LIAmong individuals showing symptoms severe enough to be given a COVID-19 RT-PCR test in the UK the prevalence of loss of smell (anosmia) was 3-fold higher (59%) in those positive to the test than among those negative to the test (18%).
C_LIO_LIWe developed a mathematical model combining symptoms to predict individuals likely to be COVID-19 positive and applied this to over 400,000 individuals in the general population presenting some of the COVID-19 symptoms.
C_LIO_LIWe find that [~]13% of those presenting symptoms are likely to have or have had a COVID-19 infection. The proportion was slightly higher in women than in men but is comparable in all age groups, and corresponds to 3.4% of those who filled the app report.
C_LI",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.06.20052159,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.06.20052159,Efficient and Practical Sample Pooling High-Throughput PCR Diagnosis of COVID-19,Haran Shani-Narkiss; Omri David Gilday; Nadav Yayon; Itamar Daniel Landau; Julia El-Sayed Moustafa; Alessia Visconti; Pirro Hysi; Ruth C E Bowyer; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"Center for Brain Sciences, Hebrew University of Jerusalem; Center for Brain Sciences, Hebrew University of Jerusalem; Center for Brain Sciences, Hebrew University of Jerusalem; Center for Brain Sciences, Hebrew University of Jerusalem; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","In the global effort to combat the COVID-19 pandemic, governments and public health agencies are striving to rapidly increase the volume and rate of diagnostic testing. The most common form of testing today employs Polymerase Chain Reaction in order to identify the presence of viral RNA in individual patient samples one by one. This process has become one of the most significant bottlenecks to increased testing, especially due to reported shortages in the chemical reagents needed in the PCR reaction.

Recent technical advances have enabled High-Throughput PCR, in which multiple samples are pooled into one tube. Such methods can be highly efficient, saving large amounts of time and reagents. However, their efficiency is highly dependent on the frequency of positive samples, which varies significantly across regions and even within regions as testing criterion and conditions change.

Here, we present two possible optimized pooling strategies for diagnostic SARS-CoV-2 testing on large scales, both addressing dynamic conditions. In the first, we employ a simple information-theoretic heuristic to derive a highly efficient re-pooling protocol: an estimate of the target frequency determines the initial pool size, and any subsequent pools found positive are re-pooled at half-size and tested again. In the range of very rare target (<0.05), this approach can reduce the number of necessary tests dramatically, for example, achieving a reduction by a factor of 50 for a target frequency of 0.001. The second method is a simpler approach of optimized one-time pooling followed by individual tests on positive pools. We show that this approach is just as efficient for moderate target-product frequencies (0.05<0.2), for example, achieving a two-fold in the number of when the frequency of positive samples is 0.07.

These strategies require little investment, and they offer a significant reduction in the amount of materials, equipment and time needed to test large numbers of samples. We show that both these pooling strategies are roughly comparable to the absolute upper-bound efficiency given by Shannons source coding theorem. We compare our strategies to the naive way of testing and to alternative matrix-pooling methods. Most importantly, we offer straightforward, practical pooling instructions for laboratories that perform large scale PCR assays to diagnose SARS-CoV-2 viral particles. These two pooling strategies may offer ways to alleviate the bottleneck currently preventing massive expansion of SARS-CoV-2 testing around the world.",public and global health,exact,100,100
medRxiv,10.1101/2020.04.04.20052241,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.04.20052241,A Systematic Meta-Analysis of CT Features of COVID-19: Lessons from Radiology,Vasantha Kumar Venugopal; Vidur Mahajan; Sriram Rajan; Vikash Kumar Agarwal; Ruchika Rajan; Salsabeel Syed; Harsh Mahajan; Ruth C E Bowyer; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"CARING, Mahajan Imaging; CARING, Mahajan Imaging; CARING, Mahajan Imaging; Mahajan Imaging; Teleradiology Consultant; Mahajan Imaging; CARING, Mahajan Imaging; King's College London; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","1.Several studies have been published in the past few months describing the CT features of Coronavirus Disease 2019 (COVID-19). There is a great degree of heterogeneity in the study designs, lesion descriptors used and conclusions derived. In our systematic analysis and meta-review, we have attempted to homogenize the reported features and provide a comprehensive view of the disease pattern and progression in different clinical stages. After an extensive literature search, we short-listed and reviewed 49 studies including over 4145 patients with 3615 RT-PCR positive cases of COVID-19 disease. We have found that there is a good agreement among these studies that diffuse bilateral ground-glass opacities (GGOs) is the most common finding at all stages of the disease followed by consolidations and mixed density lesions. 78% of patients with RT-PCR confirmed COVID-19 infections had either ground-glass opacities, consolidation or both. Inter-lobular septal thickening was also found to be a common feature in many patients in advanced stages. The progression of these initial patchy GGOs and consolidations to diffuse lesions with septal thickening, air bronchograms in the advanced stages, to either diffuse ""white-out"" lungs needing ICU admissions or finally resolving completely without or with residual fibrotic strips was also found to be congruent among multiple studies. Prominent juxta- lesional pulmonary vessels, pleural effusion and lymphadenopathy in RT-PCR proven cases were found to have poor clinical prognosis. Additionally, we noted wide variation in terminology used to describe lesions across studies and suggest the use of standardized lexicons to describe findings related to diseases of vital importance.",radiology and imaging,exact,100,100
medRxiv,10.1101/2020.04.02.20048793,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.02.20048793,A globally available COVID-19 - Template for clinical imaging studies,Gabriel Alexander Salg; Maria Katharina Ganten; Matthias Baumhauer; Claus Peter Heussel; Jens Kleesiek; Salsabeel Syed; Harsh Mahajan; Ruth C E Bowyer; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"University Hospital Heidelberg, Department of Surgery, New Technologies and Data Science, Heidelberg, Germany; Mint Medical GmbH, Heidelberg, Germany; Mint Medical GmbH, Heidelberg, Germany; University Hospital Heidelberg, Department of Diagnostic and Interventional Radiology, Heidelberg, Germany; German Cancer Research Center (DKFZ), Department of Radiology, Computational Radiology, Heidelberg, Germany; Mahajan Imaging; CARING, Mahajan Imaging; King's College London; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","BackgroundThe pandemic spread of COVID-19 has caused worldwide implications on societies and economies. Chest computed tomography (CT) has been found to support both, current diagnostic and disease monitoring. A joint approach to collect, analyze and share clinical and imaging information about COVID-19 in the highest quality possible is urgently needed.

MethodsAn evidence-based reporting template was developed for assessing COVID-19 pneumonia using an FDA-approved medical software. The annotation of qualitative and quantitative findings including radiomics features is performed directly on primary imaging data. For data collection, secondary information from the patient history and clinical data such as symptoms and comorbidities are queried.

ResultsLicense-royalty free, cloud-based web platform and on-premise deployments are offered. Hospitals can upload, assess, report and if pseudonymized share their COVID-19 cases. The aggregation of radiomics in correlation with rt-PCR, patient history, clinical and radiological findings, systematically documented in a single database, will lead to optimized diagnosis, risk stratification and response evaluation. A customizable analytics dashboard allows the explorative real-time data analysis of imaging features and clinical information.

ConclusionsThe COVID-19-Template is based on a systematic, computer-assisted and context-guided approach to collect, analyze and share data. Epidemiological and clinical studies for therapies and vaccine candidates can be implemented in compliance with high data quality, integrity and traceability.

An additional explanation video of the COVID-19-Template video is provided via:http://cloud1.mint-medical.de/downloads/player/index.html?v=Covid19StandardizedAssessmentWeb

HighlightsO_LIDynamic evidence-based electronic case report form (eCRF) for COVID-19 including documentation of primary imaging data, secondary clinical data and patient history including radiomics features
C_LIO_LIComputer-assisted, context-guided reporting approach based on FDA approved medical product software package available free of charge
C_LIO_LIData quality, traceability, integrity in open-access web platform
C_LIO_LICustomizable analytics dashboard for explorative real-time data analysis of imaging features and clinical information
C_LIO_LIHuman and machine-readable data export for clinical trials
C_LI",radiology and imaging,exact,100,100
medRxiv,10.1101/2020.04.01.20050443,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.01.20050443,Can N95 respirators be reused after disinfection? And for how many times?,Lei Liao; Wang Xiao; Mervin Zhao; Xuanze Yu; Haotian Wang; Qiqi Wang; Steven Chu; Yi Cui; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"4C Air, inc.; 4C Air, Inc.; 4C Air, Inc.; 4C Air, Inc.; 4C Air, Inc.; 4C Air, Inc.; Stanford University; Stanford University; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","The Coronavirus Disease 2019 (COVID-19) pandemic has led to a major shortage of N95 respirators, which are essential to protecting healthcare professionals and the general public who may come into contact with the virus. Thus, it is essential to determine how we can reuse respirators and other personal protection in these urgent times. We investigated multiple commonly used and easily deployable, scalable disinfection schemes on media with particle filtration efficiency of 95%. Among these, heating ([&le;]85 {degrees}C) under various humidities ([&le;]100% RH) was the most promising, nondestructive method for the preservation of filtration properties in meltblown fabrics as well as N95-grade respirators. Heating can be applied up to 50 cycles (85 {degrees}C, 30% RH) without observation in the degradation of meltblown filtration performance. Ultraviolet (UV) irradiation was a secondary choice which was able to withstand 10 cycles of treatment and showed small degradation by 20 cycles. However, UV can also potentially impact the material strength and fit of respirators. Finally, treatments involving liquids and vapors require caution, as steam, alcohol, and household bleach may all lead to degradation of the filtration efficiency, leaving the user vulnerable to the viral aerosols.",occupational and environmental health,exact,100,100
medRxiv,10.1101/2020.04.05.20053983,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.05.20053983,Clinical characteristics of COVID-19 infection in pregnant women: a systematic review and meta-analysis,Sina Arabi; Golnaz Vaseghi; Zahra Heidari; Laleh Shariati; Bahareh Amin; Harunor Rashid; Shaghayegh Haghjooy Javanmard; Yi Cui; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.; Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.; Cardiac Rehabilitation Research Center, Cardiovascular Research Institute and Department of Biostatistics and Epidemiology, Isfahan University of Medical Scienc; Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.; Cellular and Molecular Research Center, Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.; National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead, Sydney, Australia.; Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.; Stanford University; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","BackgroundOn December 2019, Novel coronavirus disease (COVID-19) was detected in Wuhan, China, and then spread around the world. There is little information about effects of COVID-19 on Pregnant women and newborns as a sensitive population. The current study is a systemic review and Meta-analysis to measure the risks and determine the presentations of COVID-19 in pregnant women and newborn.

Methodsonline data bases were searched on march 20. Heterogeneity of the included studies was assessed using the Cochran Q test and Higgins I2 statistic and expressed as percentage. All data were analyzed with 95% confidence intervals.

ResultsA total of 7 studies involving 50 participants with Positive test of COVID-19 were enrolled. Mean age of pregnant women was 30.57 years old and the Mean Gestational age was 36.9 weeks. Other variables such as Apgar score, birth weight, Sign and symptoms, Complications and Laboratory data were Analyzed.

ConclusionOur findings showed same clinical characteristics in pregnant women as in non-pregnant adults, with the main symptoms being cough and fever. No vertical transmission was seen and all patients delivered healthy neonates. Our findings would be of great help to the decision making process, regarding the management of pregnant women diagnosed with COVID-19.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.02.20051284,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.02.20051284,Building an International Consortium for Tracking Coronavirus Health Status,Eran Segal; Feng Zhang; Xihong Lin; Gary King; Ophir Shalem; Smadar Shilo; William E. Allen; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Weizmann Institute of Science; Howard Hughes Medical Institute, Core Member, Broad Institute of MIT and Harvard, United States; Departments of Biostatistics and Statistics, Harvard T.H. Chan School of Public Health; Albert J. Weatherhead III University, Institute for Quantitative Social Science, Harvard University; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Society of Fellows, Harvard University, United States; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","Information is the most potent protective weapon we have to combat a pandemic, at both the individual and global level. For individuals, information can help us make personal decisions and provide a sense of security. For the global community, information can inform policy decisions and offer critical insights into the epidemic of COVID-19 disease. Fully leveraging the power of information, however, requires large amounts of data and access to it. To achieve this, we are making steps to form an international consortium, Coronavirus Census Collective (CCC, coronaviruscensuscollective.org), that will serve as a hub for integrating information from multiple data sources that can be utilized to understand, monitor, predict, and combat global pandemics. These sources may include self-reported health status through surveys (including mobile apps), results of diagnostic laboratory tests, and other static and real-time geospatial data. This collective effort to track and share information will be invaluable in predicting hotspots of disease outbreak, identifying which factors control the rate of spreading, informing immediate policy decisions, evaluating the effectiveness of measures taken by health organizations on pandemic control, and providing critical insight on the etiology of COVID-19. It will also help individuals stay informed on this rapidly evolving situation and contribute to other global efforts to slow the spread of disease.

In the past few weeks, several initiatives across the globe have surfaced to use daily self-reported symptoms as a means to track disease spread, predict outbreak locations, guide population measures and help in the allocation of healthcare resources. The aim of this paper is to put out a call to standardize these efforts and spark a collaborative effort to maximize the global gain while protecting participant privacy.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.01.20049478,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.01.20049478,Differential COVID-19-attributable mortality and BCG vaccine use in countries,Anita Shet; Debashree Ray; Neelika Malavige; Mathuram Santosham; Naor Bar-Zeev; Smadar Shilo; William E. Allen; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Johns Hopkins Bloomberg School of Public Health, USA; Johns Hopkins Bloomberg School of Public Health, USA; University of Sri Jayewardenepura, Sri Lanka; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Society of Fellows, Harvard University, United States; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","While mortality attributable to COVID-19 has devastated global health systems and economies, striking regional differences have been observed. The Bacille Calmette Guerin (BCG) vaccine has previously been shown to have non-specific protective effects on infections, as well as long-term efficacy against tuberculosis. Using publicly available data we built a simple log-linear regression model to assess the association of BCG use and COVID-19-attributable mortality per 1 million population after adjusting for confounders including country economic status (GDP per capita), and proportion of elderly among the population. The timing of country entry into the pandemic epidemiological trajectory was aligned by plotting time since the 100th reported case. Countries with economies classified as lower-middle-income, upper-middle-income and high-income countries (LMIC, UMIC, HIC) had median crude COVID-19 log-mortality of 0.4 (Interquartile Range (IQR) 0.1, 0.4), 0.7 (IQR 0.2, 2.2) and 5.5 (IQR 1.6, 13.9), respectively. COVID-19-attributable mortality among BCG-using countries was 5.8 times lower [95% CI 1.8-19.0] than in non BCG-using countries. Notwithstanding limitations due to testing constraints in LMICs, case ascertainment bias and a plausible rise of cases as countries progress along the epidemiological trajectory, these analyses provide intriguing observations that urgently warrant mobilization of resources for prospective randomized interventional studies and institution of systematic disease surveillance, particularly in LMICs.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.01.20049528,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.01.20049528,Facemasks and similar barriers to prevent respiratory illness such asCOVID-19: A rapid systematic review,Julii Suzanne Brainard; Natalia Jones; Iain Lake; Lee Hooper; Paul Hunter; Smadar Shilo; William E. Allen; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Norwich Medical School, University of East Anglia; School of Environmental Sciences, University of East Anglia; School of Environmental Science, University of East Anglia; Norwich Medical School, University of East Anglia; Norwich Medical School, University of East Anglia; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Society of Fellows, Harvard University, United States; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","The current pandemic of COVID-19 has lead to conflicting opinions on whether wearing facemasks outside of health care facilities protects against the infection. To better understand the value of wearing facemasks we undertook a rapid systematic review of existing scientific evidence about development of respiratory illness, linked to use of facemasks in community settings.

MethodsWe included all study designs. There were 31 eligible studies (including 12 RCTs). Narrative synthesis and random-effects meta-analysis of attack rates for primary and secondary prevention in 28 studies were performed. Results were reported by design, setting and type of face barrier in primary prevention, and by who wore the facemask (index patient or well contacts) in secondary prevention trials. The preferred outcome was influenza-like illness (ILI) but similar outcomes were pooled with ILI when ILI was unavailable. GRADE quality assessment was based on RCTs with support from observational studies.

ResultsWhere specific information was available, most studies reported about use of medical grade (surgical paper masks). In 3 RCTs, wearing a facemask may very slightly reduce the odds of developing ILI/respiratory symptoms, by around 6% (OR 0.94, 95% CI 0.75 to 1.19, I 29%, low-certainty evidence). Greater effectiveness was suggested by observational studies. When both house-mates and an infected household member wore facemasks the odds of further household members becoming ill may be modestly reduced by around 19% (OR 0.81, 95%CI 0.48 to 1.37, I 45%, 5 RCTs, low certainty evidence). The protective effect was very small if only the well person (OR 0.93, 95% CI 0.68 to 1.28, I 11%, 2 RCTs, low uncertainty evidence) or the infected person wore the facemask (very low certainty evidence).

DiscussionBased on the RCTs we would conclude that wearing facemasks can be very slightly protective against primary infection from casual community contact, and modestly protective against household infections when both infected and uninfected members wear facemasks. However, the RCTs often suffered from poor compliance and controls using facemasks. Across observational studies the evidence in favour of wearing facemasks was stronger. We expect RCTs to under-estimate the protective effect and observational studies to exaggerate it. The evidence is not sufficiently strong to support widespread use of facemasks as a protective measure against COVID-19. However, there is enough evidence to support the use of facemasks for short periods of time by particularly vulnerable individuals when in transient higher risk situations. Further high quality trials are needed to assess when wearing a facemask in the community is most likely to be protective.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.02.20049189,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.02.20049189,Optimal COVID-19 epidemic control until vaccine deployment,Ramses Djidjou-Demasse; Yannis Michalakis; Marc Choisy; Mircea T. Sofonea; Samuel Alizon; Smadar Shilo; William E. Allen; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"The French National Research Institute for Development (IRD); CNRS; IRD; Univ. Montpellier; CNRS; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Society of Fellows, Harvard University, United States; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","Since Dec 2019, the COVID-19 epidemic has spread over the globe creating one of the greatest pandemics ever witnessed. This epidemic wave will only begin to roll back once a critical proportion of the population is immunised, either by mounting natural immunity following infection, or by vaccination. The latter option can minimise the cost in terms of human lives but it requires to wait until a safe and efficient vaccine is developed, a period estimated to last at least 18 months. In this work, we use optimal control theory to explore the best strategy to implement while waiting for the vaccine. We seek a solution minimizing deaths and costs due to the implementation of the control strategy itself. We find that such a solution leads to an increasing level of control with a maximum reached near the 16th month of the epidemics and a steady decrease until vaccine deployment. The average containment level is approximately 50% during the 25-months period for vaccine deployment. This strategy strongly out-performs others with constant or cycling allocations of the same amount of resources to control the outbreak. This work opens new perspectives to mitigate the effects of the ongoing COVID-19 pandemics, and be used as a proof-of-concept in using mathematical modelling techniques to enlighten decision making and public health management in the early times of an outbreak.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.02.20051086,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.02.20051086,Projection of COVID-19 Pandemic in Uganda,Fulgensia Kamugisha Mbabazi; Yannis Michalakis; Marc Choisy; Mircea T. Sofonea; Samuel Alizon; Smadar Shilo; William E. Allen; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Busitema University, Tororo, Uganda; CNRS; IRD; Univ. Montpellier; CNRS; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Society of Fellows, Harvard University, United States; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","COVID-19 (Corona Virus) is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-COV-2). The virus that was first discovered in China Wuhan Province about 3 months ago (first cases were reported in Wuhan on December 31st 2019) has spread world wide. The six (6) top countries (excluding China) most affected so far include; USA, Italy, Spain, Germany, France and Iran. With Italy showing the highest death toll.

In Uganda where it was discovered on 19/3/2020 with one (01) case has just in nine (9) days, increased to thirty (30) infected individuals. This model is a wake up call over the rate at which COVID-19 is likely to spread throughout the country. Thus it is a guide for policymakers and planners to benchmark on for solutions to this deadly virus.",infectious diseases,exact,100,100
medRxiv,10.1101/2020.04.03.20049080,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.03.20049080,No indications for overt innate immune suppression in critically ill COVID-19 patients,Matthijs Kox; Tim Frenzel; Jeroen Schouten; Frank van de Veerdonk; Hans J.P.M. Koenen; Peter Pickkers; RCI-COVID-19 study group; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Radboud university medical centre; Radboud university medical center; Radboud university medical center; Radboud university medical center; Radboud university medical center; Radboud university medical center; ; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","At the end of March 2020, there were in excess of 800.000 confirmed cases of coronavirus disease 2019 (COVID-19) worldwide. Several reports suggest that, in severe cases, COVID-19 may cause a hyperinflammatory ""cytokine storm"". However, unlike SARS-CoV infection, high levels of anti-inflammatory mediators have also been reported in COVID-19 patients. One study reported that 16% of COVID-19 patients who died developed secondary infection, which might indicate an immune-suppressed state. We explored kinetics of mHLA-DR expression, the most widely used marker of innate immune suppression in critically ill patients, in COVID-19 patients admitted to the ICU.

Twenty-four confirmed COVID-19 patients were included, of which 75% was male and 79% had comorbidities. All patients were mechanically ventilated and exhibited large high levels of inflammatory parameters such as CRP and PCT. mHLA-DR expression levels were mostly within the normal range of 15000-45000 mAb/cell and showed no change over time. COVID-19 patients displayed notably higher mHLA-DR expression levels compared with bacterial septic shock patients. None of the COVID-19 patients developed a secondary infection.

In conclusion, despite a pronounced inflammatory response, mHLA-DR expression kinetics indicate no overt innate immune suppression in COVID-19 patients. These data signify that innate immune suppression as a negative feedback mechanism following PAMP-induced inflammation appears not to be present in COVID-19.",intensive care and critical care medicine,exact,100,100
medRxiv,10.1101/2020.03.31.20049197,2020-04-06,https://medrxiv.org/cgi/content/short/2020.03.31.20049197,Aerosol-spread during chest compressions in a cadaver model,Matthias Ott; Alfio Milazzo; Stefan Liebau; Christina Jaki; Tobias Schilling; Alexander Krohn; Johannes Heymer; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Institute of Neuroanatomy & Developmental Biology INDB, Eberhard Karls University Tuebingen; Institute of Neuroanatomy & Developmental Biology INDB, Eberhard Karls University Tuebingen; Klinikum Stuttgart, Simulation Center STUPS; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","ObjectiveTo evaluate aerosol-spread in cardiopulmonary resuscitation (CPR) using different methods of airway management. Knowledge about aerosol-spread is vital during the SARS-CoV-2-Pandemic.

MethodsTo evaluate feasibility we nebulized ultraviolet sensitive detergents into the artificial airway of a resuscitation dummy and performed CPR. The spread of the visualized aerosol was documented by a camera. In a second approach we applied nebulized detergents into human cadavers by an endotracheal tube and detected aerosol-spread during chest compressions the same way. We did recordings with undergoing compression-only-CPR, with a surgical mask and with an inserted laryngeal tube with and without a connected airway filter.

ResultsMost aerosol-spread at the direction of the provider was visualized during compression-only-CPR. The use of a surgical mask deflected the spread. Inserting a laryngeal tube connected to an airway filter lead to a remarkable reduction of aerosol-spread.

ConclusionThe early insertion of a laryngeal tube connected to an airway filter before starting chest compression may be good for two things - the treatment of hypoxemia as the likeliest cause of cardiac arrest and for staff protection during CPR.",emergency medicine,exact,100,100
medRxiv,10.1101/2020.04.03.20049734,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.03.20049734,Monitoring Italian COVID-19 spread by an adaptive SEIRD model,Elena Loli Piccolomiini; Fabiana Zama; Stefan Liebau; Christina Jaki; Tobias Schilling; Alexander Krohn; Johannes Heymer; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"University of Bologna; University of Bologna; Institute of Neuroanatomy & Developmental Biology INDB, Eberhard Karls University Tuebingen; Klinikum Stuttgart, Simulation Center STUPS; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","Due to the recent diffusion of COVID-19 outbreak, the scientific community is making efforts in analysing models for understanding the present situation and predicting future scenarios. In this paper, we propose a Susceptible-Infected-Exposed-Recovered-Dead (SEIRD) differential model [Weitz J. S. and Dushoff J., Scientific reports, 2015] for the analysis and forecast of the COVID-19 spread in Italian regions, using the data from the Italian Protezione Civile from February 24th 2020. In this study, we investigate an adaptation of SEIRD that takes into account the actual policies of the Italian government, consisting of modelling the infection rate as a time-dependent function (SEIRD(rm)). Preliminary results on Lombardia and Emilia-Romagna regions confirm that SEIRD(rm) fits the data more accurately than the original SEIRD model with constant rate infection parameter. Moreover, the increased flexibility in the choice of the infection rate function makes it possible to better control the predictions due to the lockdown policy.",epidemiology,exact,100,100
medRxiv,10.1101/2020.03.31.20049387,2020-04-06,https://medrxiv.org/cgi/content/short/2020.03.31.20049387,The impacts of diagnostic capability and prevention measures on transmission dynamics of COVID-19 in Wuhan,Jingbo LIANG; Hsiang-Yu Yuan; Lindsey Wu; Dirk Udo Pfeiffer; Tobias Schilling; Alexander Krohn; Johannes Heymer; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China; Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, United Kingdom; Centre for Applied One Health Research and Policy Advice, City University of Hong Kong, Hong Kong, China; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","BackgroundAlthough by late February 2020 the COVID-19 epidemic was effectively controlled in Wuhan, China, the virus has since spread around the world and been declared a pandemic on March 11. Estimating the effects of interventions, such as transportation restrictions and quarantine measures, on the early COVID-19 transmission dynamics in Wuhan is critical for guiding future virus containment strategies. Since the exact number of COVID-19 infected cases is unknown, the number of documented cases was used by many disease transmission models to infer epidemiological parameters. However, this means that it would not be possible to adequately estimate epidemiological parameters and the effects of intervention measures, because the percentage of all infected cases that were documented changed during the first 2 months of the epidemic as a consequence of a gradually increasing diagnostic capability.

MethodsTo overcome the limitations, we constructed a stochastic susceptible-exposed-infected-quarantined-recovered (SEIQR) model, accounting for intervention measures and temporal changes in the proportion of new documented infections out of total new infections, to characterize the transmission dynamics of COVID-19 in Wuhan across different stages of the outbreak. Pre-symptomatic transmission was taken into account in our model, and all epidemiological parameters were estimated using Particle Markov-chain Monte Carlo (PMCMC) method.

ResultsOur model captured the local Wuhan epidemic pattern as a two-peak transmission dynamics, with one peak on February 4 and the other on February 12, 2020. The impact of intervention measures determined the timing of the first peak, leading to an 86% drop in the Re from 3.23 (95% CI, 2.22 to 4.20) to 0.45 (95% CI, 0.20 to 0.69). An improved diagnostic capability led to the second peak and a higher proportion of documented infections. Our estimated proportion of new documented infections out of the total new infections increased from 11% (95% CI 1% - 43%) to 28% (95% CI 4% - 62%) after January 26 when more detection kits were released. After the introduction of a new diagnostic criterion (case definition) on February 12, a higher proportion of daily infected cases were documented (49% (95% CI 7% - 79%)).",epidemiology,exact,100,100
medRxiv,10.1101/2020.03.31.20049452,2020-04-06,https://medrxiv.org/cgi/content/short/2020.03.31.20049452,A Covid-19 case mortality rate without time delay systematics,Richard Lieu; Siobhan Quenby; Ally Bi-zhu Jiang; Dirk Udo Pfeiffer; Tobias Schilling; Alexander Krohn; Johannes Heymer; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"University of Alabama; Division of Reproductive Health, Warwick Medical School, The University of Warwick, UK; Shenzhen RAK wireless Technology Co., Ltd., China; Centre for Applied One Health Research and Policy Advice, City University of Hong Kong, Hong Kong, China; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","Concerning the two approaches to the Covid-19 case mortality rate published in the literature, namely computing the ratio of (a) the daily number of deaths to a time delayed daily number of confirmed infections; and (b) the cumulative number of deaths to confirmed infections up to a certain time, both numbers having been acquired in the middle of an outbreak, it is shown that each suffers from systematic error of a different source. We further show that in the absence of detailed knowledge of the time delay distribution of (a), the true case mortality rate is obtained by pursuing method (b) at the end of the outbreak when the fate of every case has decisively been rendered. The approach is then employed to calculate the mean case mortality rate of 13 regions of China where every case has already been resolved. This leads to a mean rate of 0.527 {+/-} 0.001 %.",epidemiology,exact,100,100
medRxiv,10.1101/2020.04.01.20049684,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.01.20049684,COVID19-Tracker: A shiny app to produce comprehensive data visualization for SARS-CoV-2 epidemic in Spain,Aurelio Tobias; Joan Valls; Pau Satorra; Cristian Tebe; Tobias Schilling; Alexander Krohn; Johannes Heymer; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective); Duncan MacCannell; Gregory L Armstrong; Geoffrey S Baird; Helen Y Chu; Jay Shendure; Keith R Jerome,"Spanish Council for Scientific Research (CSIC); Universitat Autonoma de Barcelona (UAB); Institut Investigacio Biomedica de Bellvitge (IDIBELL); Institut Investigacio Biomedica de Bellvitge (IDIBELL); Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Klinikum Stuttgart, Department of interdisciplinary emergency and intensive care medicine; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Washington; University of Washington; University of Washington; University of Washington","Data visualization is an essential tool for exploring and communicating findings in medical research, especially in epidemiological surveillance. The COVID19-Tracker web application systematically produces daily updated data visualization and analysis of the SARS-CoV-2 epidemic in Spain. It collects automatically daily data on COVID-19 diagnosed cases, and mortality from February 24th, 2020 onwards. Several analyses have been developed to visualize data trends and estimating short-term projections; to estimate the case fatality rate; to assess the effect of the lockdown measures on the trends of incident data; to estimate infection time and the basic reproduction number; and to analyse the excess of mortality. The application may help for a better understanding of the SARS-CoV-2 epidemic data in Spain.",public and global health,exact,100,100
medRxiv,10.1101/2020.03.30.20047217,2020-03-30,https://medrxiv.org/cgi/content/short/2020.03.30.20047217,"Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - Face masks, eye protection and person distancing: systematic review and meta-analysis",Tom Jefferson; Mark Jones; Lubna A Al Ansari; Ghada Bawazeer; Elaine Beller; Justin Clark; John Conly; Chris Del Mar; Elisabeth Dooley; Eliana Ferroni; Paul Glasziou; Tammy Hoffman; Sarah Thorning; Mieke Van Driel; Claudio Pagani; Elena Reutskaja; Federico Raimondi Slepoi; Lingfang Zhao; Junli Liu; Huailong Zhao; Yue Liu; Weihong Yang; Jing Peng; Xiaoyu Chen; Ping Li; Yaoning Liu; Yonghong Xie; Jibo Song; Lu Zhang; Qingjun Ma; Xiuwu Bian; Wei Chen; Xuan Liu; Qing Mao; Cheng Cao,"University of Oxford; Bond University, Australia; Kind Saud University, Saudi Arabia; King Saud, University, Saudi Arabia; Bond University, Australia; Bond University, Australia; Department of Medicine, Microbiology, Immunology & Infectious Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services , Calgary,; Bond University, Australia; Bond University, Australia; Regione Veneto, Italy; Bond University, Australia; Bond University, Australia; Bond University, Australia; Primary Care Clinical Unit, Faculty of Medicine, University of Queensland, Australia; Data Rebel Consulting; IESE Business School; City of Rome; The 940th Hospital; Beijing Institute of Biotechnology; Beijing Institute of Biotechnology; Beijing Institute of Biotechnology; Beijing Institute of Biotechnology; First Affiliated Hospital, Army Medical University; Department of Anesthesiology, General Hospital of Northern Theater Command; Beijing Institute of Biotechnology; Beijing Institute of Biotechnology; Department of Respiratory Disease, the Second Affiliated Hospital of Air Force Military Medical University; The 960th Hospital; The 940th Hospital; Beijing Institute of Biotechnology; First Affiliated Hospital, Army Medical University; Beijing Institute of Biotechnology; Beijing Institute of Biotechnology; First Affiliated Hospital, Army Medical University; Beijing Institute of Biotechnology","OBJECTIVETo examine the effectiveness of eye protection, face masks, or person distancing on interrupting or reducing the spread of respiratory viruses.

DESIGNUpdate of a Cochrane review that included a meta-analysis of observational studies during the SARS outbreak of 2003.

DATA SOURCESEligible trials from the previous review; search of Cochrane Central Register of Controlled Trials, PubMed, Embase and CINAHL from October 2010 up to 1 April 2020; and forwardand backward citation analysis.

DATA SELECTIONRandomised and cluster-randomised trials of people of any age, testing the use ofeye protection, face masks, or person distancing against standard practice, or a similar physical barrier. Outcomes included any acute respiratory illness and its related consequences.

DATA EXTRACTION AND ANALYSISSix authors independently assessed risk of bias using the Cochrane tool and extracted data. We used a generalised inverse variance method for pooling using a random-effects model and reported results with risk ratios and 95% Confidence Intervals (CI).

RESULTSWe included 15 randomised trials investigating the effect of masks (14 trials) in healthcare workers and the general population and of quarantine (1 trial). We found no trials testing eye protection. Compared to no masks there was no reduction of influenza-like illness (ILI) cases (Risk Ratio 0.93, 95%CI 0.83 to 1.05) or influenza (Risk Ratio 0.84, 95%CI 0.61-1.17) for masks in the general population, nor in healthcare workers (Risk Ratio 0.37, 95%CI 0.05 to 2.50). There was no difference between surgical masks and N95 respirators: for ILI (Risk Ratio 0.83, 95%CI 0.63 to 1.08), for influenza (Risk Ratio 1.02, 95%CI 0.73 to 1.43). Harms were poorly reported and limited to discomfort with lower compliance. The only trial testing quarantining workers with household ILI contacts found a reduction in ILI cases, but increased risk of quarantined workers contracting influenza. All trials were conducted during seasonal ILI activity.

CONCLUSIONSMost included trials had poor design, reporting and sparse events. There was insufficient evidence to provide a recommendation on the use of facial barriers without other measures. We found insufficient evidence for a difference between surgical masks and N95 respirators and limited evidence to support effectiveness of quarantine. Based on observational evidence from the previous SARS epidemic included in the previous version of our Cochrane review we recommend the use of masks combined with other measures.",public and global health,exact,100,100
